Document ID,Sentence #,Word,Tag
PMC10640930_447,7520,Of,O
PMC10640930_447,7520,the,O
PMC10640930_447,7520,two,O
PMC10640930_447,7520,anti,O
PMC10640930_447,7520,-,O
PMC10640930_447,7520,breast,B-Disease
PMC10640930_447,7520,cancer,I-Disease
PMC10640930_447,7520,drugs,O
PMC10640930_447,7520,",",O
PMC10640930_447,7520,tamoxifen,B-Drug
PMC10640930_447,7520,showed,O
PMC10640930_447,7520,IC,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,number,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,=,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,number,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,microM,O
PMC10640930_447,7520,to,O
PMC10640930_447,7520,BC,O
PMC10640930_447,7520,-,O
PMC10640930_447,7520,M,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,number,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,cells,O
PMC10640930_447,7520,and,O
PMC10640930_447,7520,paclitaxel,O
PMC10640930_447,7520,had,O
PMC10640930_447,7520,much,O
PMC10640930_447,7520,less,O
PMC10640930_447,7520,sensitivity,O
PMC10640930_447,7520,than,O
PMC10640930_447,7520,AZ,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,number,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,_,O
PMC10640930_447,7520,0,O
PMC10874940_502,7521,So,O
PMC10874940_502,7521,far,O
PMC10874940_502,7521,there,O
PMC10874940_502,7521,is,O
PMC10874940_502,7521,no,O
PMC10874940_502,7521,evidence,O
PMC10874940_502,7521,that,O
PMC10874940_502,7521,topiramate,B-Drug
PMC10874940_502,7521,has,O
PMC10874940_502,7521,anti,O
PMC10874940_502,7521,-,O
PMC10874940_502,7521,manic,B-Symptom
PMC10874940_502,7521,effect,O
PMC10874940_502,7521,and,O
PMC10874940_502,7521,it,O
PMC10874940_502,7521,should,O
PMC10874940_502,7521,not,O
PMC10874940_502,7521,be,O
PMC10874940_502,7521,used,O
PMC10874940_502,7521,as,O
PMC10874940_502,7521,monotherapy,O
PMC10874940_502,7521,0,O
PMC11878860_182,7522,Further,O
PMC11878860_182,7522,randomized,O
PMC11878860_182,7522,control,O
PMC11878860_182,7522,trials,O
PMC11878860_182,7522,are,O
PMC11878860_182,7522,required,O
PMC11878860_182,7522,to,O
PMC11878860_182,7522,asses,O
PMC11878860_182,7522,the,O
PMC11878860_182,7522,full,O
PMC11878860_182,7522,benefits,O
PMC11878860_182,7522,of,O
PMC11878860_182,7522,Montelukast,B-Drug
PMC11878860_182,7522,therapy,O
PMC11878860_182,7522,in,O
PMC11878860_182,7522,the,O
PMC11878860_182,7522,whole,O
PMC11878860_182,7522,spectrum,O
PMC11878860_182,7522,of,O
PMC11878860_182,7522,eosinophilic,O
PMC11878860_182,7522,gastrointestinal,O
PMC11878860_182,7522,disorders,O
PMC11878860_182,7522,0,O
PMC13511740_562,7523,Effectiveness,O
PMC13511740_562,7523,of,O
PMC13511740_562,7523,sertraline,B-Drug
PMC13511740_562,7523,in,O
PMC13511740_562,7523,treatment,O
PMC13511740_562,7523,of,O
PMC13511740_562,7523,depression,B-Disease
PMC13511740_562,7523,in,O
PMC13511740_562,7523,a,O
PMC13511740_562,7523,consecutive,O
PMC13511740_562,7523,sample,O
PMC13511740_562,7523,of,O
PMC13511740_562,7523,patients,O
PMC13511740_562,7523,with,O
PMC13511740_562,7523,acute,O
PMC13511740_562,7523,myocardial,O
PMC13511740_562,7523,infarction,O
PMC13511740_562,7523,:,O
PMC13511740_562,7523,six,O
PMC13511740_562,7523,month,O
PMC13511740_562,7523,prospective,O
PMC13511740_562,7523,study,O
PMC13511740_562,7523,on,O
PMC13511740_562,7523,outcome,O
PMC13511740_562,7523,0,O
PMC14135520_641,7524,BACKGROUND,O
PMC14135520_641,7524,:,O
PMC14135520_641,7524,Chorea,O
PMC14135520_641,7524,in,O
PMC14135520_641,7524,Huntington,B-Disease
PMC14135520_641,7524,',I-Disease
PMC14135520_641,7524,s,I-Disease
PMC14135520_641,7524,Disease,I-Disease
PMC14135520_641,7524,(,O
PMC14135520_641,7524,HD,O
PMC14135520_641,7524,),O
PMC14135520_641,7524,is,O
PMC14135520_641,7524,usually,O
PMC14135520_641,7524,treated,O
PMC14135520_641,7524,with,O
PMC14135520_641,7524,antidopaminergic,O
PMC14135520_641,7524,neuroleptics,O
PMC14135520_641,7524,like,O
PMC14135520_641,7524,haloperidol,O
PMC14135520_641,7524,",",O
PMC14135520_641,7524,olanzapine,B-Drug
PMC14135520_641,7524,and,O
PMC14135520_641,7524,tiaprid,O
PMC14135520_641,7524,or,O
PMC14135520_641,7524,dopamine,O
PMC14135520_641,7524,depleting,O
PMC14135520_641,7524,drugs,O
PMC14135520_641,7524,like,O
PMC14135520_641,7524,tetrabenazine,O
PMC14135520_641,7524,0,O
PMC14357460_816,7525,The,O
PMC14357460_816,7525,study,O
PMC14357460_816,7525,subjects,O
PMC14357460_816,7525,were,O
PMC14357460_816,7525,outpatients,O
PMC14357460_816,7525,with,O
PMC14357460_816,7525,serious,O
PMC14357460_816,7525,mental,O
PMC14357460_816,7525,disorders,O
PMC14357460_816,7525,treated,O
PMC14357460_816,7525,with,O
PMC14357460_816,7525,SGA,O
PMC14357460_816,7525,(,O
PMC14357460_816,7525,clozapine,O
PMC14357460_816,7525,",",O
PMC14357460_816,7525,olanzapine,B-Drug
PMC14357460_816,7525,",",O
PMC14357460_816,7525,risperidone,O
PMC14357460_816,7525,",",O
PMC14357460_816,7525,quetiapine,B-Drug
PMC14357460_816,7525,),O
PMC14357460_816,7525,0,O
PMC14486960_559,7526,SSRIs,O
PMC14486960_559,7526,have,O
PMC14486960_559,7526,a,O
PMC14486960_559,7526,cardiovascular,O
PMC14486960_559,7526,safety,O
PMC14486960_559,7526,profile,O
PMC14486960_559,7526,superior,O
PMC14486960_559,7526,to,O
PMC14486960_559,7526,that,O
PMC14486960_559,7526,of,O
PMC14486960_559,7526,tricyclic,O
PMC14486960_559,7526,antidepressants,O
PMC14486960_559,7526,for,O
PMC14486960_559,7526,patients,O
PMC14486960_559,7526,with,O
PMC14486960_559,7526,cardiovascular,O
PMC14486960_559,7526,disease,O
PMC14486960_559,7526,;,O
PMC14486960_559,7526,fluvoxamine,B-Drug
PMC14486960_559,7526,is,O
PMC14486960_559,7526,safe,O
PMC14486960_559,7526,in,O
PMC14486960_559,7526,patients,O
PMC14486960_559,7526,with,O
PMC14486960_559,7526,cardiovascular,B-Disease
PMC14486960_559,7526,disease,I-Disease
PMC14486960_559,7526,and,O
PMC14486960_559,7526,in,O
PMC14486960_559,7526,the,O
PMC14486960_559,7526,elderly,O
PMC14486960_559,7526,0,O
PMC14569700_883,7527,RESULTS,O
PMC14569700_883,7527,:,O
PMC14569700_883,7527,EBC,O
PMC14569700_883,7527,cysLTs,O
PMC14569700_883,7527,were,O
PMC14569700_883,7527,significantly,O
PMC14569700_883,7527,lower,O
PMC14569700_883,7527,in,O
PMC14569700_883,7527,asthmatic,B-Disease
PMC14569700_883,7527,children,O
PMC14569700_883,7527,who,O
PMC14569700_883,7527,were,O
PMC14569700_883,7527,treated,O
PMC14569700_883,7527,with,O
PMC14569700_883,7527,montelukast,B-Drug
PMC14569700_883,7527,than,O
PMC14569700_883,7527,in,O
PMC14569700_883,7527,those,O
PMC14569700_883,7527,who,O
PMC14569700_883,7527,were,O
PMC14569700_883,7527,not,O
PMC14569700_883,7527,(,O
PMC14569700_883,7527,median,O
PMC14569700_883,7527,(,O
PMC14569700_883,7527,interquartile,O
PMC14569700_883,7527,range,O
PMC14569700_883,7527,),O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,number,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,(,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,number,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,_,O
PMC14569700_883,7527,0,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,number,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,),O
PMC14569700_883,7528,versus,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,number,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,(,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,number,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,_,O
PMC14569700_883,7528,0,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,number,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,),O
PMC14569700_883,7529,pg,O
PMC14569700_883,7529,/,O
PMC14569700_883,7529,ml,O
PMC14569700_883,7529,",",O
PMC14569700_883,7529,p,O
PMC14569700_883,7529,=,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,number,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,_,O
PMC14569700_883,7529,),O
PMC14569700_883,7529,0,O
PMC14629920_218,7530,METHODS,O
PMC14629920_218,7530,:,O
PMC14629920_218,7530,From,O
PMC14629920_218,7530,a,O
PMC14629920_218,7530,large,O
PMC14629920_218,7530,claims,O
PMC14629920_218,7530,database,O
PMC14629920_218,7530,we,O
PMC14629920_218,7530,retrospectively,O
PMC14629920_218,7530,identified,O
PMC14629920_218,7530,individuals,O
PMC14629920_218,7530,age,O
PMC14629920_218,7530,_,O
PMC14629920_218,7530,_,O
PMC14629920_218,7530,number,O
PMC14629920_218,7530,_,O
PMC14629920_218,7530,_,O
PMC14629920_218,7530,or,O
PMC14629920_218,7530,older,O
PMC14629920_218,7530,who,O
PMC14629920_218,7530,were,O
PMC14629920_218,7530,diagnosed,O
PMC14629920_218,7530,with,O
PMC14629920_218,7530,ADHD,B-Disease
PMC14629920_218,7530,and,O
PMC14629920_218,7530,who,O
PMC14629920_218,7530,received,O
PMC14629920_218,7530,either,O
PMC14629920_218,7530,once,O
PMC14629920_218,7530,daily,O
PMC14629920_218,7530,",",O
PMC14629920_218,7530,extended,O
PMC14629920_218,7530,-,O
PMC14629920_218,7530,release,O
PMC14629920_218,7530,oral,O
PMC14629920_218,7530,system,O
PMC14629920_218,7530,methylphenidate,O
PMC14629920_218,7530,(,O
PMC14629920_218,7530,OROS,O
PMC14629920_218,7530,MPH,O
PMC14629920_218,7530,),O
PMC14629920_218,7530,(,O
PMC14629920_218,7530,e,O
PMC14629920_218,7530,0,O
PMC14629920_218,7531,g,O
PMC14629920_218,7531,0,O
PMC14629920_218,7532,",",O
PMC14629920_218,7532,Concerta,B-Drug
PMC14629920_218,7532,),O
PMC14629920_218,7532,or,O
PMC14629920_218,7532,three,O
PMC14629920_218,7532,-,O
PMC14629920_218,7532,times,O
PMC14629920_218,7532,daily,O
PMC14629920_218,7532,immediate,O
PMC14629920_218,7532,-,O
PMC14629920_218,7532,release,O
PMC14629920_218,7532,generic,O
PMC14629920_218,7532,methylphenidate,B-Drug
PMC14629920_218,7532,(,O
PMC14629920_218,7532,TID,O
PMC14629920_218,7532,MPH,O
PMC14629920_218,7532,),O
PMC14629920_218,7532,0,O
PMC14798030_665,7533,CONCLUSION,O
PMC14798030_665,7533,:,O
PMC14798030_665,7533,The,O
PMC14798030_665,7533,present,O
PMC14798030_665,7533,case,O
PMC14798030_665,7533,report,O
PMC14798030_665,7533,of,O
PMC14798030_665,7533,topiramate,B-Drug
PMC14798030_665,7533,',O
PMC14798030_665,7533,s,O
PMC14798030_665,7533,effect,O
PMC14798030_665,7533,on,O
PMC14798030_665,7533,comorbid,O
PMC14798030_665,7533,obesity,O
PMC14798030_665,7533,and,O
PMC14798030_665,7533,nonparaphilic,O
PMC14798030_665,7533,addiction,O
PMC14798030_665,7533,could,O
PMC14798030_665,7533,be,O
PMC14798030_665,7533,interpreted,O
PMC14798030_665,7533,as,O
PMC14798030_665,7533,a,O
PMC14798030_665,7533,further,O
PMC14798030_665,7533,indication,O
PMC14798030_665,7533,that,O
PMC14798030_665,7533,topiramate,O
PMC14798030_665,7533,acts,O
PMC14798030_665,7533,on,O
PMC14798030_665,7533,the,O
PMC14798030_665,7533,common,O
PMC14798030_665,7533,pathway,O
PMC14798030_665,7533,underlying,O
PMC14798030_665,7533,conditioned,O
PMC14798030_665,7533,behaviors,O
PMC14798030_665,7533,and,O
PMC14798030_665,7533,seems,O
PMC14798030_665,7533,to,O
PMC14798030_665,7533,be,O
PMC14798030_665,7533,a,O
PMC14798030_665,7533,treatment,O
PMC14798030_665,7533,of,O
PMC14798030_665,7533,behavioral,O
PMC14798030_665,7533,disorders,O
PMC14798030_665,7533,associated,O
PMC14798030_665,7533,with,O
PMC14798030_665,7533,environmental,O
PMC14798030_665,7533,cues,O
PMC14798030_665,7533,0,O
PMC1494500_370,7534,Intravenous,O
PMC1494500_370,7534,immunoglobulin,O
PMC1494500_370,7534,in,O
PMC1494500_370,7534,the,O
PMC1494500_370,7534,treatment,O
PMC1494500_370,7534,of,O
PMC1494500_370,7534,primary,O
PMC1494500_370,7534,trigeminal,O
PMC1494500_370,7534,neuralgia,O
PMC1494500_370,7534,refractory,O
PMC1494500_370,7534,to,O
PMC1494500_370,7534,carbamazepine,B-Drug
PMC1494500_370,7534,:,O
PMC1494500_370,7534,a,O
PMC1494500_370,7534,study,O
PMC1494500_370,7534,protocol,O
PMC1494500_370,7534,[,O
PMC1494500_370,7534,ISRCTN,O
PMC1494500_370,7534,_,O
PMC1494500_370,7534,_,O
PMC1494500_370,7534,number,O
PMC1494500_370,7534,_,O
PMC1494500_370,7534,_,O
PMC1494500_370,7534,],O
PMC1494500_370,7534,0,O
PMC1654180_734,7535,The,O
PMC1654180_734,7535,aim,O
PMC1654180_734,7535,of,O
PMC1654180_734,7535,this,O
PMC1654180_734,7535,trial,O
PMC1654180_734,7535,was,O
PMC1654180_734,7535,to,O
PMC1654180_734,7535,evaluate,O
PMC1654180_734,7535,the,O
PMC1654180_734,7535,effect,O
PMC1654180_734,7535,of,O
PMC1654180_734,7535,the,O
PMC1654180_734,7535,antidepressant,O
PMC1654180_734,7535,paroxetine,B-Drug
PMC1654180_734,7535,on,O
PMC1654180_734,7535,metabolic,O
PMC1654180_734,7535,control,O
PMC1654180_734,7535,",",O
PMC1654180_734,7535,quality,O
PMC1654180_734,7535,of,O
PMC1654180_734,7535,life,O
PMC1654180_734,7535,and,O
PMC1654180_734,7535,mental,O
PMC1654180_734,7535,well,O
PMC1654180_734,7535,-,O
PMC1654180_734,7535,being,O
PMC1654180_734,7535,in,O
PMC1654180_734,7535,mildly,O
PMC1654180_734,7535,depressed,B-Disease
PMC1654180_734,7535,women,O
PMC1654180_734,7535,with,O
PMC1654180_734,7535,type,O
PMC1654180_734,7535,_,O
PMC1654180_734,7535,_,O
PMC1654180_734,7535,number,O
PMC1654180_734,7535,_,O
PMC1654180_734,7535,_,O
PMC1654180_734,7535,diabetes,O
PMC1654180_734,7535,0,O
PMC1838650_657,7536,Diarrhea,B-Symptom
PMC1838650_657,7536,resolved,O
PMC1838650_657,7536,within,O
PMC1838650_657,7536,_,O
PMC1838650_657,7536,_,O
PMC1838650_657,7536,number,O
PMC1838650_657,7536,_,O
PMC1838650_657,7536,_,O
PMC1838650_657,7536,hours,O
PMC1838650_657,7536,of,O
PMC1838650_657,7536,initiation,O
PMC1838650_657,7536,of,O
PMC1838650_657,7536,ciprofloxacin,B-Drug
PMC1838650_657,7536,0,O
PMC18517050_31,7537,BACKGROUND,O
PMC18517050_31,7537,:,O
PMC18517050_31,7537,Clinical,O
PMC18517050_31,7537,trials,O
PMC18517050_31,7537,assessing,O
PMC18517050_31,7537,efficacy,O
PMC18517050_31,7537,and,O
PMC18517050_31,7537,safety,O
PMC18517050_31,7537,of,O
PMC18517050_31,7537,Intramuscular,O
PMC18517050_31,7537,(,O
PMC18517050_31,7537,IM,O
PMC18517050_31,7537,),O
PMC18517050_31,7537,Olanzapine,B-Drug
PMC18517050_31,7537,in,O
PMC18517050_31,7537,acute,B-Disease
PMC18517050_31,7537,schizophrenia,I-Disease
PMC18517050_31,7537,and,O
PMC18517050_31,7537,acute,B-Disease
PMC18517050_31,7537,mania,I-Disease
PMC18517050_31,7537,have,O
PMC18517050_31,7537,previously,O
PMC18517050_31,7537,been,O
PMC18517050_31,7537,undertaken,O
PMC18517050_31,7537,in,O
PMC18517050_31,7537,studies,O
PMC18517050_31,7537,required,O
PMC18517050_31,7537,for,O
PMC18517050_31,7537,drug,O
PMC18517050_31,7537,registration,O
PMC18517050_31,7537,in,O
PMC18517050_31,7537,patients,O
PMC18517050_31,7537,who,O
PMC18517050_31,7537,were,O
PMC18517050_31,7537,required,O
PMC18517050_31,7537,to,O
PMC18517050_31,7537,give,O
PMC18517050_31,7537,informed,O
PMC18517050_31,7537,consent,O
PMC18517050_31,7537,0,O
PMC18911980_472,7538,Oral,O
PMC18911980_472,7538,melphalan,B-Drug
PMC18911980_472,7538,and,O
PMC18911980_472,7538,prednisone,B-Drug
PMC18911980_472,7538,remain,O
PMC18911980_472,7538,an,O
PMC18911980_472,7538,effective,O
PMC18911980_472,7538,and,O
PMC18911980_472,7538,tolerable,O
PMC18911980_472,7538,treatment,O
PMC18911980_472,7538,for,O
PMC18911980_472,7538,patients,O
PMC18911980_472,7538,with,O
PMC18911980_472,7538,multiple,B-Disease
PMC18911980_472,7538,myeloma,I-Disease
PMC18911980_472,7538,0,O
PMC18995130_74,7539,Pilot,O
PMC18995130_74,7539,study,O
PMC18995130_74,7539,of,O
PMC18995130_74,7539,fluvoxamine,B-Drug
PMC18995130_74,7539,treatment,O
PMC18995130_74,7539,for,O
PMC18995130_74,7539,climacteric,B-Symptom
PMC18995130_74,7539,symptoms,O
PMC18995130_74,7539,in,O
PMC18995130_74,7539,Japanese,O
PMC18995130_74,7539,women,O
PMC18995130_74,7539,0,O
PMC19140730_806,7540,The,O
PMC19140730_806,7540,study,O
PMC19140730_806,7540,indicates,O
PMC19140730_806,7540,that,O
PMC19140730_806,7540,in,O
PMC19140730_806,7540,pragmatic,O
PMC19140730_806,7540,circumstances,O
PMC19140730_806,7540,any,O
PMC19140730_806,7540,possible,O
PMC19140730_806,7540,benefit,O
PMC19140730_806,7540,from,O
PMC19140730_806,7540,administration,O
PMC19140730_806,7540,of,O
PMC19140730_806,7540,paroxetine,B-Drug
PMC19140730_806,7540,in,O
PMC19140730_806,7540,diabetic,B-Disease
PMC19140730_806,7540,patients,O
PMC19140730_806,7540,with,O
PMC19140730_806,7540,sub,O
PMC19140730_806,7540,-,O
PMC19140730_806,7540,threshold,O
PMC19140730_806,7540,depression,B-Disease
PMC19140730_806,7540,is,O
PMC19140730_806,7540,likely,O
PMC19140730_806,7540,to,O
PMC19140730_806,7540,be,O
PMC19140730_806,7540,modest,O
PMC19140730_806,7540,and,O
PMC19140730_806,7540,of,O
PMC19140730_806,7540,short,O
PMC19140730_806,7540,duration,O
PMC19140730_806,7540,0,O
PMC19363140_732,7541,A,O
PMC19363140_732,7541,review,O
PMC19363140_732,7541,of,O
PMC19363140_732,7541,the,O
PMC19363140_732,7541,literature,O
PMC19363140_732,7541,undoubtedly,O
PMC19363140_732,7541,establishes,O
PMC19363140_732,7541,montelukast,B-Drug
PMC19363140_732,7541,as,O
PMC19363140_732,7541,a,O
PMC19363140_732,7541,viable,O
PMC19363140_732,7541,alternative,O
PMC19363140_732,7541,for,O
PMC19363140_732,7541,the,O
PMC19363140_732,7541,treatment,O
PMC19363140_732,7541,of,O
PMC19363140_732,7541,seasonal,O
PMC19363140_732,7541,allergic,O
PMC19363140_732,7541,rhinitis,O
PMC19363140_732,7541,0,O
PMC19687390_1000,7542,Repeat,O
PMC19687390_1000,7542,administration,O
PMC19687390_1000,7542,of,O
PMC19687390_1000,7542,high,O
PMC19687390_1000,7542,dose,O
PMC19687390_1000,7542,melphalan,B-Drug
PMC19687390_1000,7542,in,O
PMC19687390_1000,7542,relapsed,O
PMC19687390_1000,7542,myeloma,O
PMC19687390_1000,7542,0,O
PMC19770200_918,7543,Response,O
PMC19770200_918,7543,to,O
PMC19770200_918,7543,aminoglutethimide,O
PMC19770200_918,7543,and,O
PMC19770200_918,7543,cortisone,B-Drug
PMC19770200_918,7543,acetate,O
PMC19770200_918,7543,in,O
PMC19770200_918,7543,advanced,B-Disease
PMC19770200_918,7543,prostatic,I-Disease
PMC19770200_918,7543,cancer,I-Disease
PMC19770200_918,7543,0,O
PMC19770940_554,7544,The,O
PMC19770940_554,7544,effects,O
PMC19770940_554,7544,of,O
PMC19770940_554,7544,the,O
PMC19770940_554,7544,administration,O
PMC19770940_554,7544,of,O
PMC19770940_554,7544,tamoxifen,B-Drug
PMC19770940_554,7544,",",O
PMC19770940_554,7544,ethynyloestradiol,O
PMC19770940_554,7544,",",O
PMC19770940_554,7544,and,O
PMC19770940_554,7544,prednisolone,O
PMC19770940_554,7544,on,O
PMC19770940_554,7544,the,O
PMC19770940_554,7544,activities,O
PMC19770940_554,7544,of,O
PMC19770940_554,7544,certain,O
PMC19770940_554,7544,enzymes,O
PMC19770940_554,7544,of,O
PMC19770940_554,7544,carbohydrate,O
PMC19770940_554,7544,metabolism,O
PMC19770940_554,7544,in,O
PMC19770940_554,7544,primary,O
PMC19770940_554,7544,human,O
PMC19770940_554,7544,breast,B-Disease
PMC19770940_554,7544,carcinomas,I-Disease
PMC19770940_554,7544,in,O
PMC19770940_554,7544,vivo,O
PMC19770940_554,7544,0,O
PMC19771020_413,7545,In,O
PMC19771020_413,7545,the,O
PMC19771020_413,7545,Medical,O
PMC19771020_413,7545,Research,O
PMC19771020_413,7545,Council,O
PMC19771020_413,7545,',O
PMC19771020_413,7545,s,O
PMC19771020_413,7545,IVth,O
PMC19771020_413,7545,trial,O
PMC19771020_413,7545,in,O
PMC19771020_413,7545,Myelomatosis,B-Disease
PMC19771020_413,7545,the,O
PMC19771020_413,7545,possible,O
PMC19771020_413,7545,benefit,O
PMC19771020_413,7545,of,O
PMC19771020_413,7545,adding,O
PMC19771020_413,7545,vincristine,O
PMC19771020_413,7545,to,O
PMC19771020_413,7545,first,O
PMC19771020_413,7545,line,O
PMC19771020_413,7545,treatment,O
PMC19771020_413,7545,with,O
PMC19771020_413,7545,intermittent,O
PMC19771020_413,7545,melphalan,B-Drug
PMC19771020_413,7545,and,O
PMC19771020_413,7545,prednisone,B-Drug
PMC19771020_413,7545,has,O
PMC19771020_413,7545,been,O
PMC19771020_413,7545,assessed,O
PMC19771020_413,7545,0,O
PMC19772810_29,7546,Verapamil,O
PMC19772810_29,7546,also,O
PMC19772810_29,7546,increased,O
PMC19772810_29,7546,the,O
PMC19772810_29,7546,area,O
PMC19772810_29,7546,under,O
PMC19772810_29,7546,the,O
PMC19772810_29,7546,blood,O
PMC19772810_29,7546,concentration,O
PMC19772810_29,7546,time,O
PMC19772810_29,7546,curve,O
PMC19772810_29,7546,and,O
PMC19772810_29,7546,the,O
PMC19772810_29,7546,gastrointestinal,B-Symptom
PMC19772810_29,7546,toxicity,I-Symptom
PMC19772810_29,7546,of,O
PMC19772810_29,7546,melphalan,B-Drug
PMC19772810_29,7546,0,O
PMC20012220_991,7547,AIs,O
PMC20012220_991,7547,decrease,O
PMC20012220_991,7547,the,O
PMC20012220_991,7547,risks,O
PMC20012220_991,7547,of,O
PMC20012220_991,7547,thromboembolic,B-Symptom
PMC20012220_991,7547,and,I-Symptom
PMC20012220_991,7547,cerebrovascular,I-Symptom
PMC20012220_991,7547,events,I-Symptom
PMC20012220_991,7547,compared,O
PMC20012220_991,7547,with,O
PMC20012220_991,7547,tamoxifen,B-Drug
PMC20012220_991,7547,",",O
PMC20012220_991,7547,and,O
PMC20012220_991,7547,the,O
PMC20012220_991,7547,overall,O
PMC20012220_991,7547,rate,O
PMC20012220_991,7547,of,O
PMC20012220_991,7547,cardiovascular,O
PMC20012220_991,7547,events,O
PMC20012220_991,7547,in,O
PMC20012220_991,7547,patients,O
PMC20012220_991,7547,treated,O
PMC20012220_991,7547,with,O
PMC20012220_991,7547,AIs,O
PMC20012220_991,7547,is,O
PMC20012220_991,7547,within,O
PMC20012220_991,7547,the,O
PMC20012220_991,7547,range,O
PMC20012220_991,7547,seen,O
PMC20012220_991,7547,in,O
PMC20012220_991,7547,age,O
PMC20012220_991,7547,-,O
PMC20012220_991,7547,matched,O
PMC20012220_991,7547,",",O
PMC20012220_991,7547,non,O
PMC20012220_991,7547,-,O
PMC20012220_991,7547,breast,O
PMC20012220_991,7547,-,O
PMC20012220_991,7547,cancer,O
PMC20012220_991,7547,populations,O
PMC20012220_991,7547,0,O
PMC20017310_708,7548,A,O
PMC20017310_708,7548,comparison,O
PMC20017310_708,7548,of,O
PMC20017310_708,7548,the,O
PMC20017310_708,7548,incidence,O
PMC20017310_708,7548,of,O
PMC20017310_708,7548,the,O
PMC20017310_708,7548,myelodysplastic,B-Disease
PMC20017310_708,7548,syndrome,I-Disease
PMC20017310_708,7548,and,O
PMC20017310_708,7548,acute,O
PMC20017310_708,7548,myeloid,B-Disease
PMC20017310_708,7548,leukaemia,I-Disease
PMC20017310_708,7548,following,O
PMC20017310_708,7548,melphalan,B-Drug
PMC20017310_708,7548,and,O
PMC20017310_708,7548,cyclophosphamide,O
PMC20017310_708,7548,treatment,O
PMC20017310_708,7548,for,O
PMC20017310_708,7548,myelomatosis,B-Disease
PMC20017310_708,7548,0,O
PMC20088130_273,7549,Specific,O
PMC20088130_273,7549,substances,O
PMC20088130_273,7549,binding,O
PMC20088130_273,7549,[,O
PMC20088130_273,7549,(,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,number,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,),O
PMC20088130_273,7549,H,O
PMC20088130_273,7549,],O
PMC20088130_273,7549,-,O
PMC20088130_273,7549,triamcinolone,B-Drug
PMC20088130_273,7549,acetonide,O
PMC20088130_273,7549,have,O
PMC20088130_273,7549,been,O
PMC20088130_273,7549,demonstrated,O
PMC20088130_273,7549,in,O
PMC20088130_273,7549,the,O
PMC20088130_273,7549,cytoplasmic,O
PMC20088130_273,7549,fraction,O
PMC20088130_273,7549,of,O
PMC20088130_273,7549,the,O
PMC20088130_273,7549,R,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,number,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,_,O
PMC20088130_273,7549,AC,O
PMC20088130_273,7549,mammary,B-Disease
PMC20088130_273,7549,carcinoma,I-Disease
PMC20088130_273,7549,using,O
PMC20088130_273,7549,sucrose,O
PMC20088130_273,7549,gradient,O
PMC20088130_273,7549,centrifugation,O
PMC20088130_273,7549,0,O
PMC20092100_234,7550,The,O
PMC20092100_234,7550,treatment,O
PMC20092100_234,7550,response,O
PMC20092100_234,7550,in,O
PMC20092100_234,7550,each,O
PMC20092100_234,7550,group,O
PMC20092100_234,7550,was,O
PMC20092100_234,7550,different,O
PMC20092100_234,7550,:,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,%,O
PMC20092100_234,7550,of,O
PMC20092100_234,7550,patients,O
PMC20092100_234,7550,with,O
PMC20092100_234,7550,ALL,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,/,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,achieved,O
PMC20092100_234,7550,complete,O
PMC20092100_234,7550,remission,O
PMC20092100_234,7550,with,O
PMC20092100_234,7550,prednisone,B-Drug
PMC20092100_234,7550,",",O
PMC20092100_234,7550,vincristine,O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,other,O
PMC20092100_234,7550,drugs,O
PMC20092100_234,7550,in,O
PMC20092100_234,7550,standard,O
PMC20092100_234,7550,use,O
PMC20092100_234,7550,in,O
PMC20092100_234,7550,childhood,O
PMC20092100_234,7550,ALL,O
PMC20092100_234,7550,;,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,%,O
PMC20092100_234,7550,of,O
PMC20092100_234,7550,patients,O
PMC20092100_234,7550,with,O
PMC20092100_234,7550,AML,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,/,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,achieved,O
PMC20092100_234,7550,complete,O
PMC20092100_234,7550,remission,O
PMC20092100_234,7550,with,O
PMC20092100_234,7550,cytosine,O
PMC20092100_234,7550,arabinoside,O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,daunorubicin,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,patients,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,",",O
PMC20092100_234,7550,or,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,-,O
PMC20092100_234,7550,thioguanine,O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,cyclophosphamide,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,patients,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,",",O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,-,O
PMC20092100_234,7550,thioguanine,O
PMC20092100_234,7550,",",O
PMC20092100_234,7550,cyclophosphamide,O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,Adriamycin,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,patient,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,",",O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,cytosine,O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,Adriamycin,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,patient,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,;,O
PMC20092100_234,7550,only,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,out,O
PMC20092100_234,7550,of,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,patients,O
PMC20092100_234,7550,(,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,number,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,_,O
PMC20092100_234,7550,%,O
PMC20092100_234,7550,),O
PMC20092100_234,7550,with,O
PMC20092100_234,7550,acute,O
PMC20092100_234,7550,undifferentiated,O
PMC20092100_234,7550,leukaemia,O
PMC20092100_234,7550,achieved,O
PMC20092100_234,7550,complete,O
PMC20092100_234,7550,remission,O
PMC20092100_234,7550,using,O
PMC20092100_234,7550,cytosine,O
PMC20092100_234,7550,and,O
PMC20092100_234,7550,daunorubicin,O
PMC20092100_234,7550,after,O
PMC20092100_234,7550,an,O
PMC20092100_234,7550,initial,O
PMC20092100_234,7550,trial,O
PMC20092100_234,7550,of,O
PMC20092100_234,7550,prednisone,B-Drug
PMC20092100_234,7550,and,O
PMC20092100_234,7550,vincristine,O
PMC20092100_234,7550,had,O
PMC20092100_234,7550,failed,O
PMC20092100_234,7550,0,O
PMC20108780_494,7551,We,O
PMC20108780_494,7551,measured,O
PMC20108780_494,7551,the,O
PMC20108780_494,7551,effect,O
PMC20108780_494,7551,of,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,number,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,standard,O
PMC20108780_494,7551,(,O
PMC20108780_494,7551,Adriamycin,O
PMC20108780_494,7551,",",O
PMC20108780_494,7551,BCNU,O
PMC20108780_494,7551,",",O
PMC20108780_494,7551,DTIC,O
PMC20108780_494,7551,",",O
PMC20108780_494,7551,melphalan,B-Drug
PMC20108780_494,7551,",",O
PMC20108780_494,7551,vinblastine,O
PMC20108780_494,7551,",",O
PMC20108780_494,7551,actinomycin,O
PMC20108780_494,7551,D,O
PMC20108780_494,7551,),O
PMC20108780_494,7551,and,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,number,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,Phase,O
PMC20108780_494,7551,II,O
PMC20108780_494,7551,agents,O
PMC20108780_494,7551,(,O
PMC20108780_494,7551,cis,O
PMC20108780_494,7551,-,O
PMC20108780_494,7551,platinum,O
PMC20108780_494,7551,",",O
PMC20108780_494,7551,vindesine,O
PMC20108780_494,7551,",",O
PMC20108780_494,7551,AMSA,O
PMC20108780_494,7551,),O
PMC20108780_494,7551,on,O
PMC20108780_494,7551,melanoma,O
PMC20108780_494,7551,colony,O
PMC20108780_494,7551,-,O
PMC20108780_494,7551,forming,O
PMC20108780_494,7551,units,O
PMC20108780_494,7551,(,O
PMC20108780_494,7551,CFU,O
PMC20108780_494,7551,),O
PMC20108780_494,7551,in,O
PMC20108780_494,7551,soft,O
PMC20108780_494,7551,agar,O
PMC20108780_494,7551,from,O
PMC20108780_494,7551,biopsies,O
PMC20108780_494,7551,of,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,number,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,_,O
PMC20108780_494,7551,patients,O
PMC20108780_494,7551,with,O
PMC20108780_494,7551,metastatic,O
PMC20108780_494,7551,melanoma,B-Disease
PMC20108780_494,7551,0,O
PMC20109540_295,7552,A,O
PMC20109540_295,7552,group,O
PMC20109540_295,7552,of,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,number,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,children,O
PMC20109540_295,7552,with,O
PMC20109540_295,7552,advanced,O
PMC20109540_295,7552,neuroblastoma,B-Disease
PMC20109540_295,7552,(,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,number,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,Stage,O
PMC20109540_295,7552,IV,O
PMC20109540_295,7552,and,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,number,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,Stage,O
PMC20109540_295,7552,II,O
PMC20109540_295,7552,),O
PMC20109540_295,7552,",",O
PMC20109540_295,7552,selected,O
PMC20109540_295,7552,by,O
PMC20109540_295,7552,their,O
PMC20109540_295,7552,initial,O
PMC20109540_295,7552,response,O
PMC20109540_295,7552,to,O
PMC20109540_295,7552,chemotherapy,O
PMC20109540_295,7552,with,O
PMC20109540_295,7552,pulsed,O
PMC20109540_295,7552,cyclophosphamide,O
PMC20109540_295,7552,/,O
PMC20109540_295,7552,vincristine,O
PMC20109540_295,7552,/,O
PMC20109540_295,7552,Adriamycin,O
PMC20109540_295,7552,(,O
PMC20109540_295,7552,CVA,O
PMC20109540_295,7552,),O
PMC20109540_295,7552,",",O
PMC20109540_295,7552,were,O
PMC20109540_295,7552,given,O
PMC20109540_295,7552,consolidation,O
PMC20109540_295,7552,therapy,O
PMC20109540_295,7552,with,O
PMC20109540_295,7552,high,O
PMC20109540_295,7552,-,O
PMC20109540_295,7552,dose,O
PMC20109540_295,7552,melphalan,B-Drug
PMC20109540_295,7552,(,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,number,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,mg,O
PMC20109540_295,7552,/,O
PMC20109540_295,7552,m,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,number,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,_,O
PMC20109540_295,7552,),O
PMC20109540_295,7552,and,O
PMC20109540_295,7552,then,O
PMC20109540_295,7552,surgical,O
PMC20109540_295,7552,removal,O
PMC20109540_295,7552,of,O
PMC20109540_295,7552,residual,O
PMC20109540_295,7552,disease,O
PMC20109540_295,7552,0,O
PMC20109660_593,7553,The,O
PMC20109660_593,7553,in,O
PMC20109660_593,7553,vivo,O
PMC20109660_593,7553,response,O
PMC20109660_593,7553,of,O
PMC20109660_593,7553,B,O
PMC20109660_593,7553,_,O
PMC20109660_593,7553,_,O
PMC20109660_593,7553,number,O
PMC20109660_593,7553,_,O
PMC20109660_593,7553,_,O
PMC20109660_593,7553,melanoma,B-Disease
PMC20109660_593,7553,and,O
PMC20109660_593,7553,Lewis,O
PMC20109660_593,7553,lung,B-Disease
PMC20109660_593,7553,carcinoma,I-Disease
PMC20109660_593,7553,to,O
PMC20109660_593,7553,combinations,O
PMC20109660_593,7553,of,O
PMC20109660_593,7553,hyperthermia,O
PMC20109660_593,7553,and,O
PMC20109660_593,7553,graded,O
PMC20109660_593,7553,doses,O
PMC20109660_593,7553,of,O
PMC20109660_593,7553,CCNU,O
PMC20109660_593,7553,or,O
PMC20109660_593,7553,Melphalan,B-Drug
PMC20109660_593,7553,was,O
PMC20109660_593,7553,studied,O
PMC20109660_593,7553,0,O
PMC20335130_857,7554,Docetaxel,B-Drug
PMC20335130_857,7554,(,O
PMC20335130_857,7554,Taxotere,B-Drug
PMC20335130_857,7554,),O
PMC20335130_857,7554,",",O
PMC20335130_857,7554,a,O
PMC20335130_857,7554,new,O
PMC20335130_857,7554,semisynthetic,O
PMC20335130_857,7554,taxoid,O
PMC20335130_857,7554,",",O
PMC20335130_857,7554,is,O
PMC20335130_857,7554,a,O
PMC20335130_857,7554,potentially,O
PMC20335130_857,7554,important,O
PMC20335130_857,7554,chemotherapeutic,O
PMC20335130_857,7554,agent,O
PMC20335130_857,7554,for,O
PMC20335130_857,7554,the,O
PMC20335130_857,7554,treatment,O
PMC20335130_857,7554,of,O
PMC20335130_857,7554,cancer,B-Disease
PMC20335130_857,7554,0,O
PMC20337060_878,7555,It,O
PMC20337060_878,7555,is,O
PMC20337060_878,7555,concluded,O
PMC20337060_878,7555,that,O
PMC20337060_878,7555,PS,O
PMC20337060_878,7555,_,O
PMC20337060_878,7555,_,O
PMC20337060_878,7555,number,O
PMC20337060_878,7555,_,O
PMC20337060_878,7555,_,O
PMC20337060_878,7555,status,O
PMC20337060_878,7555,may,O
PMC20337060_878,7555,be,O
PMC20337060_878,7555,used,O
PMC20337060_878,7555,as,O
PMC20337060_878,7555,a,O
PMC20337060_878,7555,parameter,O
PMC20337060_878,7555,",",O
PMC20337060_878,7555,additional,O
PMC20337060_878,7555,to,O
PMC20337060_878,7555,ER,O
PMC20337060_878,7555,and,O
PMC20337060_878,7555,PgR,O
PMC20337060_878,7555,",",O
PMC20337060_878,7555,for,O
PMC20337060_878,7555,better,O
PMC20337060_878,7555,refinement,O
PMC20337060_878,7555,of,O
PMC20337060_878,7555,prediction,O
PMC20337060_878,7555,of,O
PMC20337060_878,7555,response,O
PMC20337060_878,7555,to,O
PMC20337060_878,7555,tamoxifen,B-Drug
PMC20337060_878,7555,treatment,O
PMC20337060_878,7555,in,O
PMC20337060_878,7555,advanced,B-Disease
PMC20337060_878,7555,breast,I-Disease
PMC20337060_878,7555,cancer,I-Disease
PMC20337060_878,7555,patients,O
PMC20337060_878,7555,especially,O
PMC20337060_878,7555,with,O
PMC20337060_878,7555,intermediate,O
PMC20337060_878,7555,ER,O
PMC20337060_878,7555,/,O
PMC20337060_878,7555,PgR,O
PMC20337060_878,7555,levels,O
PMC20337060_878,7555,in,O
PMC20337060_878,7555,their,O
PMC20337060_878,7555,primary,O
PMC20337060_878,7555,tumour,O
PMC20337060_878,7555,0,O
PMC20456910_695,7556,METHODS,O
PMC20456910_695,7556,:,O
PMC20456910_695,7556,Optic,O
PMC20456910_695,7556,nerve,O
PMC20456910_695,7556,head,O
PMC20456910_695,7556,(,O
PMC20456910_695,7556,ONH,O
PMC20456910_695,7556,),O
PMC20456910_695,7556,topography,O
PMC20456910_695,7556,was,O
PMC20456910_695,7556,measured,O
PMC20456910_695,7556,using,O
PMC20456910_695,7556,a,O
PMC20456910_695,7556,commercially,O
PMC20456910_695,7556,available,O
PMC20456910_695,7556,",",O
PMC20456910_695,7556,confocal,O
PMC20456910_695,7556,scanning,O
PMC20456910_695,7556,laser,O
PMC20456910_695,7556,ophthalmoscope,O
PMC20456910_695,7556,for,O
PMC20456910_695,7556,three,O
PMC20456910_695,7556,populations,O
PMC20456910_695,7556,of,O
PMC20456910_695,7556,amenorrheic,O
PMC20456910_695,7556,women,O
PMC20456910_695,7556,ages,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,years,O
PMC20456910_695,7556,:,O
PMC20456910_695,7556,subjects,O
PMC20456910_695,7556,using,O
PMC20456910_695,7556,(,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,),O
PMC20456910_695,7556,tamoxifen,B-Drug
PMC20456910_695,7556,(,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,mg,O
PMC20456910_695,7556,/,O
PMC20456910_695,7556,day,O
PMC20456910_695,7556,),O
PMC20456910_695,7556,or,O
PMC20456910_695,7556,(,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,),O
PMC20456910_695,7556,anastrozole,O
PMC20456910_695,7556,(,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,mg,O
PMC20456910_695,7556,/,O
PMC20456910_695,7556,day,O
PMC20456910_695,7556,),O
PMC20456910_695,7556,for,O
PMC20456910_695,7556,<,O
PMC20456910_695,7556,or,O
PMC20456910_695,7556,=,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,years,O
PMC20456910_695,7556,as,O
PMC20456910_695,7556,adjuvant,O
PMC20456910_695,7556,therapy,O
PMC20456910_695,7556,after,O
PMC20456910_695,7556,successful,O
PMC20456910_695,7556,primary,O
PMC20456910_695,7556,treatment,O
PMC20456910_695,7556,for,O
PMC20456910_695,7556,breast,B-Disease
PMC20456910_695,7556,cancer,I-Disease
PMC20456910_695,7556,",",O
PMC20456910_695,7556,and,O
PMC20456910_695,7556,(,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,number,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,_,O
PMC20456910_695,7556,),O
PMC20456910_695,7556,control,O
PMC20456910_695,7556,subjects,O
PMC20456910_695,7556,with,O
PMC20456910_695,7556,no,O
PMC20456910_695,7556,breast,O
PMC20456910_695,7556,cancer,O
PMC20456910_695,7556,histories,O
PMC20456910_695,7556,and,O
PMC20456910_695,7556,not,O
PMC20456910_695,7556,using,O
PMC20456910_695,7556,any,O
PMC20456910_695,7556,hormonal,O
PMC20456910_695,7556,medication,O
PMC20456910_695,7556,0,O
PMC20627500_2,7557,Preliminary,O
PMC20627500_2,7557,results,O
PMC20627500_2,7557,in,O
PMC20627500_2,7557,premenopausal,O
PMC20627500_2,7557,women,O
PMC20627500_2,7557,with,O
PMC20627500_2,7557,early,O
PMC20627500_2,7557,breast,B-Disease
PMC20627500_2,7557,cancer,I-Disease
PMC20627500_2,7557,indicate,O
PMC20627500_2,7557,that,O
PMC20627500_2,7557,endocrine,O
PMC20627500_2,7557,treatment,O
PMC20627500_2,7557,with,O
PMC20627500_2,7557,goserelin,O
PMC20627500_2,7557,plus,O
PMC20627500_2,7557,tamoxifen,B-Drug
PMC20627500_2,7557,may,O
PMC20627500_2,7557,be,O
PMC20627500_2,7557,as,O
PMC20627500_2,7557,effective,O
PMC20627500_2,7557,as,O
PMC20627500_2,7557,standard,O
PMC20627500_2,7557,combination,O
PMC20627500_2,7557,chemotherapy,O
PMC20627500_2,7557,(,O
PMC20627500_2,7557,cyclophosphamide,O
PMC20627500_2,7557,-,O
PMC20627500_2,7557,methotrexate,O
PMC20627500_2,7557,_,O
PMC20627500_2,7557,_,O
PMC20627500_2,7557,number,O
PMC20627500_2,7557,_,O
PMC20627500_2,7557,_,O
PMC20627500_2,7557,-,O
PMC20627500_2,7557,fluorouracil,O
PMC20627500_2,7557,),O
PMC20627500_2,7557,",",O
PMC20627500_2,7557,but,O
PMC20627500_2,7557,has,O
PMC20627500_2,7557,significantly,O
PMC20627500_2,7557,less,O
PMC20627500_2,7557,acute,O
PMC20627500_2,7557,toxicity,O
PMC20627500_2,7557,0,O
PMC20785850_242,7558,OBJECTIVE,O
PMC20785850_242,7558,:,O
PMC20785850_242,7558,To,O
PMC20785850_242,7558,assess,O
PMC20785850_242,7558,the,O
PMC20785850_242,7558,long,O
PMC20785850_242,7558,-,O
PMC20785850_242,7558,term,O
PMC20785850_242,7558,response,O
PMC20785850_242,7558,to,O
PMC20785850_242,7558,add,O
PMC20785850_242,7558,-,O
PMC20785850_242,7558,on,O
PMC20785850_242,7558,quetiapine,B-Drug
PMC20785850_242,7558,therapy,O
PMC20785850_242,7558,in,O
PMC20785850_242,7558,patients,O
PMC20785850_242,7558,with,O
PMC20785850_242,7558,bipolar,B-Disease
PMC20785850_242,7558,I,I-Disease
PMC20785850_242,7558,disorder,I-Disease
PMC20785850_242,7558,who,O
PMC20785850_242,7558,were,O
PMC20785850_242,7558,not,O
PMC20785850_242,7558,adequately,O
PMC20785850_242,7558,responding,O
PMC20785850_242,7558,to,O
PMC20785850_242,7558,standard,O
PMC20785850_242,7558,medications,O
PMC20785850_242,7558,0,O
PMC20890600_417,7559,Both,O
PMC20890600_417,7559,first,O
PMC20890600_417,7559,and,O
PMC20890600_417,7559,second,O
PMC20890600_417,7559,generation,O
PMC20890600_417,7559,antipsychotics,O
PMC20890600_417,7559,are,O
PMC20890600_417,7559,widely,O
PMC20890600_417,7559,used,O
PMC20890600_417,7559,and,O
PMC20890600_417,7559,the,O
PMC20890600_417,7559,FDA,O
PMC20890600_417,7559,has,O
PMC20890600_417,7559,approved,O
PMC20890600_417,7559,olanzapine,B-Drug
PMC20890600_417,7559,",",O
PMC20890600_417,7559,risperidone,O
PMC20890600_417,7559,",",O
PMC20890600_417,7559,quetiapine,B-Drug
PMC20890600_417,7559,",",O
PMC20890600_417,7559,ziprasidone,B-Drug
PMC20890600_417,7559,and,O
PMC20890600_417,7559,aripiprazole,O
PMC20890600_417,7559,for,O
PMC20890600_417,7559,the,O
PMC20890600_417,7559,treatment,O
PMC20890600_417,7559,of,O
PMC20890600_417,7559,acute,O
PMC20890600_417,7559,mania,O
PMC20890600_417,7559,0,O
PMC20890600_740,7560,Lamotrigine,B-Drug
PMC20890600_740,7560,may,O
PMC20890600_740,7560,be,O
PMC20890600_740,7560,effective,O
PMC20890600_740,7560,in,O
PMC20890600_740,7560,the,O
PMC20890600_740,7560,treatment,O
PMC20890600_740,7560,of,O
PMC20890600_740,7560,depression,B-Disease
PMC20890600_740,7560,but,O
PMC20890600_740,7560,not,O
PMC20890600_740,7560,mania,O
PMC20890600_740,7560,0,O
PMC21361150_308,7561,Collateral,O
PMC21361150_308,7561,studies,O
PMC21361150_308,7561,have,O
PMC21361150_308,7561,shown,O
PMC21361150_308,7561,that,O
PMC21361150_308,7561,the,O
PMC21361150_308,7561,doses,O
PMC21361150_308,7561,of,O
PMC21361150_308,7561,cortisone,B-Drug
PMC21361150_308,7561,which,O
PMC21361150_308,7561,produced,O
PMC21361150_308,7561,the,O
PMC21361150_308,7561,reactions,O
PMC21361150_308,7561,described,O
PMC21361150_308,7561,above,O
PMC21361150_308,7561,also,O
PMC21361150_308,7561,evoked,O
PMC21361150_308,7561,a,O
PMC21361150_308,7561,lymphopenia,B-Symptom
PMC21361150_308,7561,",",O
PMC21361150_308,7561,marked,O
PMC21361150_308,7561,reductions,O
PMC21361150_308,7561,in,O
PMC21361150_308,7561,the,O
PMC21361150_308,7561,sizes,O
PMC21361150_308,7561,of,O
PMC21361150_308,7561,the,O
PMC21361150_308,7561,axillary,O
PMC21361150_308,7561,and,O
PMC21361150_308,7561,inguinal,O
PMC21361150_308,7561,lymph,O
PMC21361150_308,7561,nodes,O
PMC21361150_308,7561,and,O
PMC21361150_308,7561,spleen,O
PMC21361150_308,7561,",",O
PMC21361150_308,7561,and,O
PMC21361150_308,7561,striking,O
PMC21361150_308,7561,histological,O
PMC21361150_308,7561,changes,O
PMC21361150_308,7561,in,O
PMC21361150_308,7561,the,O
PMC21361150_308,7561,latter,O
PMC21361150_308,7561,organ,O
PMC21361150_308,7561,0,O
PMC21361750_246,7562,Cortisone,B-Drug
PMC21361750_246,7562,enhanced,O
PMC21361750_246,7562,the,O
PMC21361750_246,7562,lethal,O
PMC21361750_246,7562,effect,O
PMC21361750_246,7562,of,O
PMC21361750_246,7562,a,O
PMC21361750_246,7562,single,O
PMC21361750_246,7562,",",O
PMC21361750_246,7562,large,O
PMC21361750_246,7562,dose,O
PMC21361750_246,7562,of,O
PMC21361750_246,7562,meningococcal,O
PMC21361750_246,7562,toxin,O
PMC21361750_246,7562,",",O
PMC21361750_246,7562,as,O
PMC21361750_246,7562,well,O
PMC21361750_246,7562,as,O
PMC21361750_246,7562,causing,O
PMC21361750_246,7562,bilateral,B-Symptom
PMC21361750_246,7562,renal,I-Symptom
PMC21361750_246,7562,cortical,I-Symptom
PMC21361750_246,7562,necrosis,I-Symptom
PMC21361750_246,7562,0,O
PMC21364750_626,7563,Studies,O
PMC21364750_626,7563,on,O
PMC21364750_626,7563,the,O
PMC21364750_626,7563,antipyretic,O
PMC21364750_626,7563,action,O
PMC21364750_626,7563,of,O
PMC21364750_626,7563,cortisone,B-Drug
PMC21364750_626,7563,in,O
PMC21364750_626,7563,pyrogen,O
PMC21364750_626,7563,-,O
PMC21364750_626,7563,induced,O
PMC21364750_626,7563,fever,B-Symptom
PMC21364750_626,7563,0,O
PMC21377330_493,7564,It,O
PMC21377330_493,7564,can,O
PMC21377330_493,7564,be,O
PMC21377330_493,7564,evoked,O
PMC21377330_493,7564,into,O
PMC21377330_493,7564,the,O
PMC21377330_493,7564,active,O
PMC21377330_493,7564,disease,O
PMC21377330_493,7564,",",O
PMC21377330_493,7564,pseudotuberculosis,B-Disease
PMC21377330_493,7564,",",O
PMC21377330_493,7564,by,O
PMC21377330_493,7564,a,O
PMC21377330_493,7564,single,O
PMC21377330_493,7564,injection,O
PMC21377330_493,7564,of,O
PMC21377330_493,7564,_,O
PMC21377330_493,7564,_,O
PMC21377330_493,7564,number,O
PMC21377330_493,7564,_,O
PMC21377330_493,7564,_,O
PMC21377330_493,7564,mg,O
PMC21377330_493,7564,of,O
PMC21377330_493,7564,cortisone,B-Drug
PMC21377330_493,7564,0,O
PMC21704500_537,7565,This,O
PMC21704500_537,7565,report,O
PMC21704500_537,7565,describes,O
PMC21704500_537,7565,a,O
PMC21704500_537,7565,patient,O
PMC21704500_537,7565,suffering,O
PMC21704500_537,7565,from,O
PMC21704500_537,7565,panic,O
PMC21704500_537,7565,disorder,O
PMC21704500_537,7565,who,O
PMC21704500_537,7565,developed,O
PMC21704500_537,7565,repeated,O
PMC21704500_537,7565,suicidal,B-Symptom
PMC21704500_537,7565,ideation,I-Symptom
PMC21704500_537,7565,specifically,O
PMC21704500_537,7565,due,O
PMC21704500_537,7565,to,O
PMC21704500_537,7565,the,O
PMC21704500_537,7565,treatment,O
PMC21704500_537,7565,with,O
PMC21704500_537,7565,Venlafaxine,B-Drug
PMC21704500_537,7565,0,O
PMC21947330_802,7566,CONCLUSION,O
PMC21947330_802,7566,:,O
PMC21947330_802,7566,For,O
PMC21947330_802,7566,patients,O
PMC21947330_802,7566,with,O
PMC21947330_802,7566,partial,B-Symptom
PMC21947330_802,7566,onset,I-Symptom
PMC21947330_802,7566,seizures,I-Symptom
PMC21947330_802,7566,",",O
PMC21947330_802,7566,results,O
PMC21947330_802,7566,favour,O
PMC21947330_802,7566,carbamazepine,B-Drug
PMC21947330_802,7566,",",O
PMC21947330_802,7566,oxcarbazepine,O
PMC21947330_802,7566,and,O
PMC21947330_802,7566,lamotrigine,B-Drug
PMC21947330_802,7566,0,O
PMC22040240_592,7567,Rikkunshi,O
PMC22040240_592,7567,-,O
PMC22040240_592,7567,to,O
PMC22040240_592,7567,attenuates,O
PMC22040240_592,7567,adverse,O
PMC22040240_592,7567,gastrointestinal,B-Symptom
PMC22040240_592,7567,symptoms,I-Symptom
PMC22040240_592,7567,induced,O
PMC22040240_592,7567,by,O
PMC22040240_592,7567,fluvoxamine,B-Drug
PMC22040240_592,7567,0,O
PMC22459320_574,7568,Status,O
PMC22459320_574,7568,on,O
PMC22459320_574,7568,prescribing,O
PMC22459320_574,7568,of,O
PMC22459320_574,7568,asthma,O
PMC22459320_574,7568,medication,O
PMC22459320_574,7568,(,O
PMC22459320_574,7568,at,O
PMC22459320_574,7568,least,O
PMC22459320_574,7568,one,O
PMC22459320_574,7568,prescription,O
PMC22459320_574,7568,for,O
PMC22459320_574,7568,beta,O
PMC22459320_574,7568,_,O
PMC22459320_574,7568,_,O
PMC22459320_574,7568,number,O
PMC22459320_574,7568,_,O
PMC22459320_574,7568,_,O
PMC22459320_574,7568,-,O
PMC22459320_574,7568,agonists,O
PMC22459320_574,7568,",",O
PMC22459320_574,7568,inhaled,O
PMC22459320_574,7568,corticosteroids,O
PMC22459320_574,7568,",",O
PMC22459320_574,7568,cromones,O
PMC22459320_574,7568,or,O
PMC22459320_574,7568,montelukast,B-Drug
PMC22459320_574,7568,),O
PMC22459320_574,7568,and,O
PMC22459320_574,7568,doctor,O
PMC22459320_574,7568,-,O
PMC22459320_574,7568,diagnosed,O
PMC22459320_574,7568,asthma,B-Disease
PMC22459320_574,7568,(,O
PMC22459320_574,7568,coded,O
PMC22459320_574,7568,according,O
PMC22459320_574,7568,to,O
PMC22459320_574,7568,the,O
PMC22459320_574,7568,International,O
PMC22459320_574,7568,Classification,O
PMC22459320_574,7568,of,O
PMC22459320_574,7568,Primary,O
PMC22459320_574,7568,Care,O
PMC22459320_574,7568,),O
PMC22459320_574,7568,was,O
PMC22459320_574,7568,determined,O
PMC22459320_574,7568,0,O
PMC22467000_1020,7569,A,O
PMC22467000_1020,7569,randomized,O
PMC22467000_1020,7569,trial,O
PMC22467000_1020,7569,of,O
PMC22467000_1020,7569,maintenance,O
PMC22467000_1020,7569,versus,O
PMC22467000_1020,7569,no,O
PMC22467000_1020,7569,maintenance,O
PMC22467000_1020,7569,melphalan,B-Drug
PMC22467000_1020,7569,and,O
PMC22467000_1020,7569,prednisone,B-Drug
PMC22467000_1020,7569,in,O
PMC22467000_1020,7569,responding,O
PMC22467000_1020,7569,multiple,B-Disease
PMC22467000_1020,7569,myeloma,I-Disease
PMC22467000_1020,7569,patients,O
PMC22467000_1020,7569,0,O
PMC22467000_56,7570,In,O
PMC22467000_56,7570,order,O
PMC22467000_56,7570,to,O
PMC22467000_56,7570,assess,O
PMC22467000_56,7570,the,O
PMC22467000_56,7570,role,O
PMC22467000_56,7570,of,O
PMC22467000_56,7570,maintenance,O
PMC22467000_56,7570,melphalan,B-Drug
PMC22467000_56,7570,and,O
PMC22467000_56,7570,prednisone,B-Drug
PMC22467000_56,7570,(,O
PMC22467000_56,7570,MP,O
PMC22467000_56,7570,),O
PMC22467000_56,7570,in,O
PMC22467000_56,7570,responding,O
PMC22467000_56,7570,multiple,B-Disease
PMC22467000_56,7570,myeloma,I-Disease
PMC22467000_56,7570,patients,O
PMC22467000_56,7570,",",O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,number,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,eligible,O
PMC22467000_56,7570,patients,O
PMC22467000_56,7570,who,O
PMC22467000_56,7570,responded,O
PMC22467000_56,7570,to,O
PMC22467000_56,7570,initial,O
PMC22467000_56,7570,MP,O
PMC22467000_56,7570,with,O
PMC22467000_56,7570,stabilization,O
PMC22467000_56,7570,for,O
PMC22467000_56,7570,at,O
PMC22467000_56,7570,least,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,number,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,_,O
PMC22467000_56,7570,months,O
PMC22467000_56,7570,were,O
PMC22467000_56,7570,randomized,O
PMC22467000_56,7570,to,O
PMC22467000_56,7570,either,O
PMC22467000_56,7570,stop,O
PMC22467000_56,7570,treatment,O
PMC22467000_56,7570,and,O
PMC22467000_56,7570,resume,O
PMC22467000_56,7570,therapy,O
PMC22467000_56,7570,at,O
PMC22467000_56,7570,relapse,O
PMC22467000_56,7570,or,O
PMC22467000_56,7570,to,O
PMC22467000_56,7570,continue,O
PMC22467000_56,7570,MP,O
PMC22467000_56,7570,until,O
PMC22467000_56,7570,relapse,O
PMC22467000_56,7570,0,O
PMC22495980_854,7571,CONCLUSION,O
PMC22495980_854,7571,:,O
PMC22495980_854,7571,Intraocular,B-Symptom
PMC22495980_854,7571,pressures,I-Symptom
PMC22495980_854,7571,and,O
PMC22495980_854,7571,anterior,O
PMC22495980_854,7571,chamber,O
PMC22495980_854,7571,depth,O
PMC22495980_854,7571,were,O
PMC22495980_854,7571,normalized,O
PMC22495980_854,7571,after,O
PMC22495980_854,7571,discontinuation,O
PMC22495980_854,7571,of,O
PMC22495980_854,7571,topiramate,B-Drug
PMC22495980_854,7571,and,O
PMC22495980_854,7571,initiation,O
PMC22495980_854,7571,of,O
PMC22495980_854,7571,antiglaucoma,O
PMC22495980_854,7571,therapy,O
PMC22495980_854,7571,0,O
PMC23501450_249,7572,Review,O
PMC23501450_249,7572,of,O
PMC23501450_249,7572,duloxetine,B-Drug
PMC23501450_249,7572,in,O
PMC23501450_249,7572,the,O
PMC23501450_249,7572,management,O
PMC23501450_249,7572,of,O
PMC23501450_249,7572,diabetic,O
PMC23501450_249,7572,peripheral,O
PMC23501450_249,7572,neuropathic,O
PMC23501450_249,7572,pain,O
PMC23501450_249,7572,0,O
PMC23501450_457,7573,Duloxetine,B-Drug
PMC23501450_457,7573,is,O
PMC23501450_457,7573,a,O
PMC23501450_457,7573,balanced,O
PMC23501450_457,7573,selective,O
PMC23501450_457,7573,serotonin,O
PMC23501450_457,7573,norepinephrine,O
PMC23501450_457,7573,reuptake,O
PMC23501450_457,7573,inhibitor,O
PMC23501450_457,7573,(,O
PMC23501450_457,7573,SNRI,O
PMC23501450_457,7573,),O
PMC23501450_457,7573,which,O
PMC23501450_457,7573,",",O
PMC23501450_457,7573,in,O
PMC23501450_457,7573,_,O
PMC23501450_457,7573,_,O
PMC23501450_457,7573,number,O
PMC23501450_457,7573,_,O
PMC23501450_457,7573,_,O
PMC23501450_457,7573,",",O
PMC23501450_457,7573,became,O
PMC23501450_457,7573,the,O
PMC23501450_457,7573,first,O
PMC23501450_457,7573,agent,O
PMC23501450_457,7573,to,O
PMC23501450_457,7573,receive,O
PMC23501450_457,7573,regulatory,O
PMC23501450_457,7573,approval,O
PMC23501450_457,7573,for,O
PMC23501450_457,7573,the,O
PMC23501450_457,7573,treatment,O
PMC23501450_457,7573,of,O
PMC23501450_457,7573,painful,O
PMC23501450_457,7573,diabetic,O
PMC23501450_457,7573,neuropathy,O
PMC23501450_457,7573,in,O
PMC23501450_457,7573,the,O
PMC23501450_457,7573,US,O
PMC23501450_457,7573,0,O
PMC23501450_821,7574,Results,O
PMC23501450_821,7574,from,O
PMC23501450_821,7574,controlled,O
PMC23501450_821,7574,clinical,O
PMC23501450_821,7574,trials,O
PMC23501450_821,7574,reveal,O
PMC23501450_821,7574,that,O
PMC23501450_821,7574,duloxetine,B-Drug
PMC23501450_821,7574,administered,O
PMC23501450_821,7574,at,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,number,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,mg,O
PMC23501450_821,7574,qd,O
PMC23501450_821,7574,or,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,number,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,_,O
PMC23501450_821,7574,mg,O
PMC23501450_821,7574,bid,O
PMC23501450_821,7574,is,O
PMC23501450_821,7574,efficacious,O
PMC23501450_821,7574,in,O
PMC23501450_821,7574,treating,O
PMC23501450_821,7574,diabetic,O
PMC23501450_821,7574,neuropathic,O
PMC23501450_821,7574,pain,O
PMC23501450_821,7574,relative,O
PMC23501450_821,7574,to,O
PMC23501450_821,7574,placebo,O
PMC23501450_821,7574,0,O
PMC23611120_54,7575,In,O
PMC23611120_54,7575,all,O
PMC23611120_54,7575,",",O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,number,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,patients,O
PMC23611120_54,7575,with,O
PMC23611120_54,7575,IHC,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,number,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,_,O
PMC23611120_54,7575,+,O
PMC23611120_54,7575,primary,O
PMC23611120_54,7575,breast,B-Disease
PMC23611120_54,7575,cancer,I-Disease
PMC23611120_54,7575,were,O
PMC23611120_54,7575,treated,O
PMC23611120_54,7575,with,O
PMC23611120_54,7575,trastuzumab,O
PMC23611120_54,7575,plus,O
PMC23611120_54,7575,docetaxel,B-Drug
PMC23611120_54,7575,0,O
PMC23613220_838,7576,Docetaxel,B-Drug
PMC23613220_838,7576,induces,O
PMC23613220_838,7576,apoptosis,O
PMC23613220_838,7576,in,O
PMC23613220_838,7576,hormone,O
PMC23613220_838,7576,refractory,O
PMC23613220_838,7576,prostate,B-Disease
PMC23613220_838,7576,carcinomas,I-Disease
PMC23613220_838,7576,during,O
PMC23613220_838,7576,multiple,O
PMC23613220_838,7576,treatment,O
PMC23613220_838,7576,cycles,O
PMC23613220_838,7576,0,O
PMC23618040_938,7577,In,O
PMC23618040_938,7577,all,O
PMC23618040_938,7577,",",O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,patients,O
PMC23618040_938,7577,with,O
PMC23618040_938,7577,advanced,O
PMC23618040_938,7577,disease,O
PMC23618040_938,7577,(,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,squamous,B-Disease
PMC23618040_938,7577,cell,I-Disease
PMC23618040_938,7577,carcinoma,I-Disease
PMC23618040_938,7577,and,O
PMC23618040_938,7577,seven,O
PMC23618040_938,7577,adenocarcinoma,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,received,O
PMC23618040_938,7577,oral,O
PMC23618040_938,7577,capecitabine,O
PMC23618040_938,7577,(,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,mg,O
PMC23618040_938,7577,m,O
PMC23618040_938,7577,(,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,twice,O
PMC23618040_938,7577,daily,O
PMC23618040_938,7577,on,O
PMC23618040_938,7577,days,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,plus,O
PMC23618040_938,7577,intravenous,O
PMC23618040_938,7577,docetaxel,B-Drug
PMC23618040_938,7577,(,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,mg,O
PMC23618040_938,7577,m,O
PMC23618040_938,7577,(,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,on,O
PMC23618040_938,7577,day,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,every,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,weeks,O
PMC23618040_938,7577,as,O
PMC23618040_938,7577,first,O
PMC23618040_938,7577,-,O
PMC23618040_938,7577,(,O
PMC23618040_938,7577,n,O
PMC23618040_938,7577,=,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,or,O
PMC23618040_938,7577,second,O
PMC23618040_938,7577,-,O
PMC23618040_938,7577,line,O
PMC23618040_938,7577,(,O
PMC23618040_938,7577,n,O
PMC23618040_938,7577,=,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,number,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,_,O
PMC23618040_938,7577,),O
PMC23618040_938,7577,therapy,O
PMC23618040_938,7577,0,O
PMC23618810_778,7578,The,O
PMC23618810_778,7578,purpose,O
PMC23618810_778,7578,of,O
PMC23618810_778,7578,the,O
PMC23618810_778,7578,study,O
PMC23618810_778,7578,was,O
PMC23618810_778,7578,to,O
PMC23618810_778,7578,investigate,O
PMC23618810_778,7578,the,O
PMC23618810_778,7578,toxicity,O
PMC23618810_778,7578,and,O
PMC23618810_778,7578,efficacy,O
PMC23618810_778,7578,of,O
PMC23618810_778,7578,the,O
PMC23618810_778,7578,combination,O
PMC23618810_778,7578,of,O
PMC23618810_778,7578,gemcitabine,O
PMC23618810_778,7578,and,O
PMC23618810_778,7578,docetaxel,B-Drug
PMC23618810_778,7578,in,O
PMC23618810_778,7578,untreated,O
PMC23618810_778,7578,advanced,B-Disease
PMC23618810_778,7578,urothelial,I-Disease
PMC23618810_778,7578,carcinoma,I-Disease
PMC23618810_778,7578,0,O
PMC23623410_309,7579,Docetaxel,B-Drug
PMC23623410_309,7579,has,O
PMC23623410_309,7579,been,O
PMC23623410_309,7579,reported,O
PMC23623410_309,7579,to,O
PMC23623410_309,7579,show,O
PMC23623410_309,7579,promising,O
PMC23623410_309,7579,anti,O
PMC23623410_309,7579,-,O
PMC23623410_309,7579,tumour,O
PMC23623410_309,7579,activity,O
PMC23623410_309,7579,in,O
PMC23623410_309,7579,pancreatic,B-Disease
PMC23623410_309,7579,ductal,I-Disease
PMC23623410_309,7579,cancer,I-Disease
PMC23623410_309,7579,(,O
PMC23623410_309,7579,PC,O
PMC23623410_309,7579,),O
PMC23623410_309,7579,0,O
PMC23623410_755,7580,Cooperative,O
PMC23623410_755,7580,Group,O
PMC23623410_755,7580,of,O
PMC23623410_755,7580,Docetaxel,B-Drug
PMC23623410_755,7580,for,O
PMC23623410_755,7580,Pancreatic,B-Disease
PMC23623410_755,7580,Cancer,I-Disease
PMC23623410_755,7580,in,O
PMC23623410_755,7580,Japan,O
PMC23623410_755,7580,0,O
PMC23628210_586,7581,Ovarian,O
PMC23628210_586,7581,cysts,O
PMC23628210_586,7581,in,O
PMC23628210_586,7581,women,O
PMC23628210_586,7581,receiving,O
PMC23628210_586,7581,tamoxifen,B-Drug
PMC23628210_586,7581,for,O
PMC23628210_586,7581,breast,B-Disease
PMC23628210_586,7581,cancer,I-Disease
PMC23628210_586,7581,0,O
PMC23760660_124,7582,Montelukast,B-Drug
PMC23760660_124,7582,:,O
PMC23760660_124,7582,its,O
PMC23760660_124,7582,role,O
PMC23760660_124,7582,in,O
PMC23760660_124,7582,the,O
PMC23760660_124,7582,treatment,O
PMC23760660_124,7582,of,O
PMC23760660_124,7582,childhood,O
PMC23760660_124,7582,asthma,B-Disease
PMC23760660_124,7582,0,O
PMC23760660_931,7583,For,O
PMC23760660_931,7583,treatment,O
PMC23760660_931,7583,of,O
PMC23760660_931,7583,chronic,B-Disease
PMC23760660_931,7583,asthma,I-Disease
PMC23760660_931,7583,",",O
PMC23760660_931,7583,montelukast,B-Drug
PMC23760660_931,7583,is,O
PMC23760660_931,7583,administered,O
PMC23760660_931,7583,once,O
PMC23760660_931,7583,daily,O
PMC23760660_931,7583,to,O
PMC23760660_931,7583,adults,O
PMC23760660_931,7583,as,O
PMC23760660_931,7583,a,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,number,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,-,O
PMC23760660_931,7583,mg,O
PMC23760660_931,7583,film,O
PMC23760660_931,7583,-,O
PMC23760660_931,7583,coated,O
PMC23760660_931,7583,tablet,O
PMC23760660_931,7583,",",O
PMC23760660_931,7583,to,O
PMC23760660_931,7583,children,O
PMC23760660_931,7583,aged,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,number,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,years,O
PMC23760660_931,7583,as,O
PMC23760660_931,7583,a,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,number,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,-,O
PMC23760660_931,7583,mg,O
PMC23760660_931,7583,chewable,O
PMC23760660_931,7583,tablet,O
PMC23760660_931,7583,",",O
PMC23760660_931,7583,and,O
PMC23760660_931,7583,to,O
PMC23760660_931,7583,children,O
PMC23760660_931,7583,aged,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,number,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,years,O
PMC23760660_931,7583,as,O
PMC23760660_931,7583,a,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,number,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,_,O
PMC23760660_931,7583,-,O
PMC23760660_931,7583,mg,O
PMC23760660_931,7583,chewable,O
PMC23760660_931,7583,tablet,O
PMC23760660_931,7583,form,O
PMC23760660_931,7583,0,O
PMC23912940_216,7584,METHODS,O
PMC23912940_216,7584,:,O
PMC23912940_216,7584,Secondary,O
PMC23912940_216,7584,analysis,O
PMC23912940_216,7584,of,O
PMC23912940_216,7584,stress,O
PMC23912940_216,7584,hemoconcentration,O
PMC23912940_216,7584,was,O
PMC23912940_216,7584,performed,O
PMC23912940_216,7584,on,O
PMC23912940_216,7584,data,O
PMC23912940_216,7584,from,O
PMC23912940_216,7584,controls,O
PMC23912940_216,7584,and,O
PMC23912940_216,7584,subjects,O
PMC23912940_216,7584,with,O
PMC23912940_216,7584,mild,O
PMC23912940_216,7584,to,O
PMC23912940_216,7584,moderate,O
PMC23912940_216,7584,MDD,B-Disease
PMC23912940_216,7584,participating,O
PMC23912940_216,7584,in,O
PMC23912940_216,7584,an,O
PMC23912940_216,7584,ongoing,O
PMC23912940_216,7584,pharmacogenetic,O
PMC23912940_216,7584,study,O
PMC23912940_216,7584,of,O
PMC23912940_216,7584,antidepressant,O
PMC23912940_216,7584,treatment,O
PMC23912940_216,7584,response,O
PMC23912940_216,7584,to,O
PMC23912940_216,7584,desipramine,O
PMC23912940_216,7584,or,O
PMC23912940_216,7584,fluoxetine,B-Drug
PMC23912940_216,7584,0,O
PMC24089160_248,7585,One,O
PMC24089160_248,7585,hundred,O
PMC24089160_248,7585,and,O
PMC24089160_248,7585,seventy,O
PMC24089160_248,7585,-,O
PMC24089160_248,7585,six,O
PMC24089160_248,7585,metastatic,O
PMC24089160_248,7585,breast,B-Disease
PMC24089160_248,7585,cancer,I-Disease
PMC24089160_248,7585,patients,O
PMC24089160_248,7585,were,O
PMC24089160_248,7585,randomised,O
PMC24089160_248,7585,to,O
PMC24089160_248,7585,receive,O
PMC24089160_248,7585,docetaxel,B-Drug
PMC24089160_248,7585,(,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,mg,O
PMC24089160_248,7585,m,O
PMC24089160_248,7585,(,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,),O
PMC24089160_248,7585,),O
PMC24089160_248,7585,every,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,weeks,O
PMC24089160_248,7585,or,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,-,O
PMC24089160_248,7585,fluorouracil,O
PMC24089160_248,7585,+,O
PMC24089160_248,7585,vinorelbine,O
PMC24089160_248,7585,:,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,-,O
PMC24089160_248,7585,fluorouracil,O
PMC24089160_248,7585,(,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,mg,O
PMC24089160_248,7585,m,O
PMC24089160_248,7585,(,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,),O
PMC24089160_248,7585,per,O
PMC24089160_248,7585,day,O
PMC24089160_248,7585,continuous,O
PMC24089160_248,7585,infusion,O
PMC24089160_248,7585,),O
PMC24089160_248,7585,D,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,plus,O
PMC24089160_248,7585,vinorelbine,O
PMC24089160_248,7585,(,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,mg,O
PMC24089160_248,7585,m,O
PMC24089160_248,7585,(,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,),O
PMC24089160_248,7585,),O
PMC24089160_248,7585,D,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,and,O
PMC24089160_248,7585,D,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,of,O
PMC24089160_248,7585,each,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,number,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,_,O
PMC24089160_248,7585,-,O
PMC24089160_248,7585,week,O
PMC24089160_248,7585,cycle,O
PMC24089160_248,7585,0,O
PMC24098260_271,7586,The,O
PMC24098260_271,7586,main,O
PMC24098260_271,7586,aim,O
PMC24098260_271,7586,of,O
PMC24098260_271,7586,our,O
PMC24098260_271,7586,study,O
PMC24098260_271,7586,was,O
PMC24098260_271,7586,to,O
PMC24098260_271,7586,assess,O
PMC24098260_271,7586,the,O
PMC24098260_271,7586,effects,O
PMC24098260_271,7586,of,O
PMC24098260_271,7586,adjuvant,O
PMC24098260_271,7586,tamoxifen,B-Drug
PMC24098260_271,7586,and,O
PMC24098260_271,7586,polychemotherapy,O
PMC24098260_271,7586,on,O
PMC24098260_271,7586,breast,B-Disease
PMC24098260_271,7586,cancer,I-Disease
PMC24098260_271,7586,mortality,O
PMC24098260_271,7586,",",O
PMC24098260_271,7586,compared,O
PMC24098260_271,7586,to,O
PMC24098260_271,7586,the,O
PMC24098260_271,7586,effects,O
PMC24098260_271,7586,of,O
PMC24098260_271,7586,the,O
PMC24098260_271,7586,mammography,O
PMC24098260_271,7586,screening,O
PMC24098260_271,7586,programme,O
PMC24098260_271,7586,0,O
PMC24099420_558,7587,Phase,O
PMC24099420_558,7587,II,O
PMC24099420_558,7587,multicentre,O
PMC24099420_558,7587,randomised,O
PMC24099420_558,7587,study,O
PMC24099420_558,7587,of,O
PMC24099420_558,7587,docetaxel,B-Drug
PMC24099420_558,7587,plus,O
PMC24099420_558,7587,epirubicin,O
PMC24099420_558,7587,vs,O
PMC24099420_558,7587,_,O
PMC24099420_558,7587,_,O
PMC24099420_558,7587,number,O
PMC24099420_558,7587,_,O
PMC24099420_558,7587,_,O
PMC24099420_558,7587,-,O
PMC24099420_558,7587,fluorouracil,O
PMC24099420_558,7587,plus,O
PMC24099420_558,7587,epirubicin,O
PMC24099420_558,7587,and,O
PMC24099420_558,7587,cyclophosphamide,O
PMC24099420_558,7587,in,O
PMC24099420_558,7587,metastatic,O
PMC24099420_558,7587,breast,B-Disease
PMC24099420_558,7587,cancer,I-Disease
PMC24099420_558,7587,0,O
PMC24132020_899,7588,At,O
PMC24132020_899,7588,the,O
PMC24132020_899,7588,suggestion,O
PMC24132020_899,7588,of,O
PMC24132020_899,7588,Professor,O
PMC24132020_899,7588,Stan,O
PMC24132020_899,7588,Kutcher,O
PMC24132020_899,7588,(,O
PMC24132020_899,7588,chair,O
PMC24132020_899,7588,),O
PMC24132020_899,7588,and,O
PMC24132020_899,7588,as,O
PMC24132020_899,7588,part,O
PMC24132020_899,7588,of,O
PMC24132020_899,7588,an,O
PMC24132020_899,7588,ongoing,O
PMC24132020_899,7588,commitment,O
PMC24132020_899,7588,to,O
PMC24132020_899,7588,provide,O
PMC24132020_899,7588,independent,O
PMC24132020_899,7588,education,O
PMC24132020_899,7588,pertaining,O
PMC24132020_899,7588,to,O
PMC24132020_899,7588,the,O
PMC24132020_899,7588,utility,O
PMC24132020_899,7588,of,O
PMC24132020_899,7588,new,O
PMC24132020_899,7588,psychotropic,O
PMC24132020_899,7588,compounds,O
PMC24132020_899,7588,to,O
PMC24132020_899,7588,health,O
PMC24132020_899,7588,professionals,O
PMC24132020_899,7588,",",O
PMC24132020_899,7588,a,O
PMC24132020_899,7588,panel,O
PMC24132020_899,7588,of,O
PMC24132020_899,7588,Canadian,O
PMC24132020_899,7588,experts,O
PMC24132020_899,7588,in,O
PMC24132020_899,7588,the,O
PMC24132020_899,7588,treatment,O
PMC24132020_899,7588,of,O
PMC24132020_899,7588,schizophrenia,B-Disease
PMC24132020_899,7588,spectrum,O
PMC24132020_899,7588,disorders,O
PMC24132020_899,7588,was,O
PMC24132020_899,7588,convened,O
PMC24132020_899,7588,to,O
PMC24132020_899,7588,provide,O
PMC24132020_899,7588,consensus,O
PMC24132020_899,7588,suggestions,O
PMC24132020_899,7588,for,O
PMC24132020_899,7588,the,O
PMC24132020_899,7588,appropriate,O
PMC24132020_899,7588,clinical,O
PMC24132020_899,7588,use,O
PMC24132020_899,7588,of,O
PMC24132020_899,7588,ziprasidone,B-Drug
PMC24132020_899,7588,0,O
PMC24241170_106,7589,Several,O
PMC24241170_106,7589,well,O
PMC24241170_106,7589,controlled,O
PMC24241170_106,7589,studies,O
PMC24241170_106,7589,have,O
PMC24241170_106,7589,confirmed,O
PMC24241170_106,7589,the,O
PMC24241170_106,7589,efficacy,O
PMC24241170_106,7589,of,O
PMC24241170_106,7589,fluvoxamine,B-Drug
PMC24241170_106,7589,in,O
PMC24241170_106,7589,children,O
PMC24241170_106,7589,and,O
PMC24241170_106,7589,adolescents,O
PMC24241170_106,7589,with,O
PMC24241170_106,7589,OCD,B-Disease
PMC24241170_106,7589,",",O
PMC24241170_106,7589,SAD,B-Disease
PMC24241170_106,7589,",",O
PMC24241170_106,7589,and,O
PMC24241170_106,7589,other,O
PMC24241170_106,7589,anxiety,B-Disease
PMC24241170_106,7589,disorders,I-Disease
PMC24241170_106,7589,",",O
PMC24241170_106,7589,and,O
PMC24241170_106,7589,it,O
PMC24241170_106,7589,was,O
PMC24241170_106,7589,the,O
PMC24241170_106,7589,first,O
PMC24241170_106,7589,SSRI,O
PMC24241170_106,7589,to,O
PMC24241170_106,7589,be,O
PMC24241170_106,7589,registered,O
PMC24241170_106,7589,for,O
PMC24241170_106,7589,the,O
PMC24241170_106,7589,treatment,O
PMC24241170_106,7589,of,O
PMC24241170_106,7589,OCD,B-Disease
PMC24241170_106,7589,in,O
PMC24241170_106,7589,children,O
PMC24241170_106,7589,0,O
PMC24241170_550,7590,Fluvoxamine,B-Drug
PMC24241170_550,7590,does,O
PMC24241170_550,7590,not,O
PMC24241170_550,7590,cause,O
PMC24241170_550,7590,sedation,B-Symptom
PMC24241170_550,7590,or,O
PMC24241170_550,7590,cognitive,B-Symptom
PMC24241170_550,7590,impairment,I-Symptom
PMC24241170_550,7590,and,O
PMC24241170_550,7590,is,O
PMC24241170_550,7590,associated,O
PMC24241170_550,7590,with,O
PMC24241170_550,7590,a,O
PMC24241170_550,7590,low,O
PMC24241170_550,7590,risk,O
PMC24241170_550,7590,of,O
PMC24241170_550,7590,sexual,B-Symptom
PMC24241170_550,7590,dysfunction,I-Symptom
PMC24241170_550,7590,",",O
PMC24241170_550,7590,suicidality,B-Symptom
PMC24241170_550,7590,",",O
PMC24241170_550,7590,and,O
PMC24241170_550,7590,withdrawal,B-Symptom
PMC24241170_550,7590,reactions,I-Symptom
PMC24241170_550,7590,0,O
PMC24241170_852,7591,Fluvoxamine,B-Drug
PMC24241170_852,7591,in,O
PMC24241170_852,7591,the,O
PMC24241170_852,7591,treatment,O
PMC24241170_852,7591,of,O
PMC24241170_852,7591,anxiety,B-Disease
PMC24241170_852,7591,disorders,I-Disease
PMC24241170_852,7591,0,O
PMC24241170_9,7592,Fluvoxamine,B-Drug
PMC24241170_9,7592,is,O
PMC24241170_9,7592,a,O
PMC24241170_9,7592,selective,O
PMC24241170_9,7592,-,O
PMC24241170_9,7592,serotonin,O
PMC24241170_9,7592,reuptake,O
PMC24241170_9,7592,inhibitor,O
PMC24241170_9,7592,(,O
PMC24241170_9,7592,SSRI,O
PMC24241170_9,7592,),O
PMC24241170_9,7592,that,O
PMC24241170_9,7592,has,O
PMC24241170_9,7592,proved,O
PMC24241170_9,7592,effective,O
PMC24241170_9,7592,in,O
PMC24241170_9,7592,large,O
PMC24241170_9,7592,double,O
PMC24241170_9,7592,-,O
PMC24241170_9,7592,blind,O
PMC24241170_9,7592,",",O
PMC24241170_9,7592,randomized,O
PMC24241170_9,7592,",",O
PMC24241170_9,7592,controlled,O
PMC24241170_9,7592,trials,O
PMC24241170_9,7592,involving,O
PMC24241170_9,7592,patients,O
PMC24241170_9,7592,with,O
PMC24241170_9,7592,social,O
PMC24241170_9,7592,anxiety,B-Disease
PMC24241170_9,7592,disorder,I-Disease
PMC24241170_9,7592,(,O
PMC24241170_9,7592,SAD,B-Disease
PMC24241170_9,7592,),O
PMC24241170_9,7592,",",O
PMC24241170_9,7592,obsessive,B-Disease
PMC24241170_9,7592,-,I-Disease
PMC24241170_9,7592,compulsive,I-Disease
PMC24241170_9,7592,disorder,I-Disease
PMC24241170_9,7592,(,O
PMC24241170_9,7592,OCD,B-Disease
PMC24241170_9,7592,),O
PMC24241170_9,7592,",",O
PMC24241170_9,7592,and,O
PMC24241170_9,7592,panic,B-Disease
PMC24241170_9,7592,disorder,I-Disease
PMC24241170_9,7592,0,O
PMC24241250_663,7593,This,O
PMC24241250_663,7593,report,O
PMC24241250_663,7593,is,O
PMC24241250_663,7593,the,O
PMC24241250_663,7593,first,O
PMC24241250_663,7593,to,O
PMC24241250_663,7593,describe,O
PMC24241250_663,7593,the,O
PMC24241250_663,7593,use,O
PMC24241250_663,7593,of,O
PMC24241250_663,7593,milnacipran,O
PMC24241250_663,7593,and,O
PMC24241250_663,7593,olanzapine,B-Drug
PMC24241250_663,7593,in,O
PMC24241250_663,7593,combination,O
PMC24241250_663,7593,in,O
PMC24241250_663,7593,the,O
PMC24241250_663,7593,treatment,O
PMC24241250_663,7593,of,O
PMC24241250_663,7593,delusional,O
PMC24241250_663,7593,depression,B-Disease
PMC24241250_663,7593,0,O
PMC24531130_581,7594,We,O
PMC24531130_581,7594,are,O
PMC24531130_581,7594,reporting,O
PMC24531130_581,7594,two,O
PMC24531130_581,7594,cases,O
PMC24531130_581,7594,of,O
PMC24531130_581,7594,suicidal,B-Symptom
PMC24531130_581,7594,attempt,I-Symptom
PMC24531130_581,7594,that,O
PMC24531130_581,7594,occurred,O
PMC24531130_581,7594,concomitantly,O
PMC24531130_581,7594,with,O
PMC24531130_581,7594,the,O
PMC24531130_581,7594,use,O
PMC24531130_581,7594,of,O
PMC24531130_581,7594,Duloxetine,B-Drug
PMC24531130_581,7594,0,O
PMC24916160_442,7595,CASE,O
PMC24916160_442,7595,PRESENTATION,O
PMC24916160_442,7595,:,O
PMC24916160_442,7595,A,O
PMC24916160_442,7595,_,O
PMC24916160_442,7595,_,O
PMC24916160_442,7595,number,O
PMC24916160_442,7595,_,O
PMC24916160_442,7595,_,O
PMC24916160_442,7595,-,O
PMC24916160_442,7595,year,O
PMC24916160_442,7595,-,O
PMC24916160_442,7595,old,O
PMC24916160_442,7595,man,O
PMC24916160_442,7595,with,O
PMC24916160_442,7595,a,O
PMC24916160_442,7595,six,O
PMC24916160_442,7595,-,O
PMC24916160_442,7595,week,O
PMC24916160_442,7595,history,O
PMC24916160_442,7595,of,O
PMC24916160_442,7595,fever,B-Symptom
PMC24916160_442,7595,",",O
PMC24916160_442,7595,initially,O
PMC24916160_442,7595,treated,O
PMC24916160_442,7595,as,O
PMC24916160_442,7595,pneumonia,B-Disease
PMC24916160_442,7595,and,O
PMC24916160_442,7595,sinusitis,O
PMC24916160_442,7595,with,O
PMC24916160_442,7595,levofloxacin,B-Drug
PMC24916160_442,7595,",",O
PMC24916160_442,7595,was,O
PMC24916160_442,7595,admitted,O
PMC24916160_442,7595,to,O
PMC24916160_442,7595,the,O
PMC24916160_442,7595,hospital,O
PMC24916160_442,7595,with,O
PMC24916160_442,7595,a,O
PMC24916160_442,7595,new,O
PMC24916160_442,7595,onset,O
PMC24916160_442,7595,of,O
PMC24916160_442,7595,a,O
PMC24916160_442,7595,heart,B-Symptom
PMC24916160_442,7595,murmur,I-Symptom
PMC24916160_442,7595,0,O
PMC24969810_691,7596,An,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,number,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,-,O
PMC24969810_691,7596,year,O
PMC24969810_691,7596,-,O
PMC24969810_691,7596,old,O
PMC24969810_691,7596,obese,O
PMC24969810_691,7596,man,O
PMC24969810_691,7596,with,O
PMC24969810_691,7596,a,O
PMC24969810_691,7596,body,O
PMC24969810_691,7596,mass,O
PMC24969810_691,7596,index,O
PMC24969810_691,7596,of,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,number,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,_,O
PMC24969810_691,7596,",",O
PMC24969810_691,7596,diagnosed,O
PMC24969810_691,7596,with,O
PMC24969810_691,7596,attention,B-Disease
PMC24969810_691,7596,-,I-Disease
PMC24969810_691,7596,deficit,I-Disease
PMC24969810_691,7596,hyperactivity,I-Disease
PMC24969810_691,7596,disorder,I-Disease
PMC24969810_691,7596,and,O
PMC24969810_691,7596,treated,O
PMC24969810_691,7596,with,O
PMC24969810_691,7596,methylphenidate,B-Drug
PMC24969810_691,7596,(,O
PMC24969810_691,7596,Concerta,B-Drug
PMC24969810_691,7596,),O
PMC24969810_691,7596,was,O
PMC24969810_691,7596,acutely,O
PMC24969810_691,7596,admitted,O
PMC24969810_691,7596,to,O
PMC24969810_691,7596,hospital,O
PMC24969810_691,7596,with,O
PMC24969810_691,7596,hypoxia,B-Symptom
PMC24969810_691,7596,and,O
PMC24969810_691,7596,dyspnoea,B-Symptom
PMC24969810_691,7596,0,O
PMC24969810_912,7597,The,O
PMC24969810_912,7597,investigation,O
PMC24969810_912,7597,concluded,O
PMC24969810_912,7597,with,O
PMC24969810_912,7597,a,O
PMC24969810_912,7597,probable,O
PMC24969810_912,7597,relationship,O
PMC24969810_912,7597,between,O
PMC24969810_912,7597,his,O
PMC24969810_912,7597,cardiomyopathy,O
PMC24969810_912,7597,and,O
PMC24969810_912,7597,the,O
PMC24969810_912,7597,use,O
PMC24969810_912,7597,of,O
PMC24969810_912,7597,methylphenidate,B-Drug
PMC24969810_912,7597,(,O
PMC24969810_912,7597,Concerta,B-Drug
PMC24969810_912,7597,),O
PMC24969810_912,7597,0,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,number,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,patients,O
PMC25158960_871,7598,with,O
PMC25158960_871,7598,a,O
PMC25158960_871,7598,DSM,O
PMC25158960_871,7598,IV,O
PMC25158960_871,7598,diagnosis,O
PMC25158960_871,7598,of,O
PMC25158960_871,7598,dysphoric,O
PMC25158960_871,7598,mania,O
PMC25158960_871,7598,were,O
PMC25158960_871,7598,randomized,O
PMC25158960_871,7598,to,O
PMC25158960_871,7598,three,O
PMC25158960_871,7598,groups,O
PMC25158960_871,7598,comprising,O
PMC25158960_871,7598,gapbapentin,O
PMC25158960_871,7598,",",O
PMC25158960_871,7598,lamotrogine,B-Drug
PMC25158960_871,7598,or,O
PMC25158960_871,7598,carbamazepine,B-Drug
PMC25158960_871,7598,and,O
PMC25158960_871,7598,followed,O
PMC25158960_871,7598,for,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,number,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,_,O
PMC25158960_871,7598,weeks,O
PMC25158960_871,7598,0,O
PMC25159250_192,7599,Further,O
PMC25159250_192,7599,studies,O
PMC25159250_192,7599,are,O
PMC25159250_192,7599,needed,O
PMC25159250_192,7599,to,O
PMC25159250_192,7599,more,O
PMC25159250_192,7599,fully,O
PMC25159250_192,7599,investigate,O
PMC25159250_192,7599,dose,O
PMC25159250_192,7599,-,O
PMC25159250_192,7599,response,O
PMC25159250_192,7599,relationships,O
PMC25159250_192,7599,and,O
PMC25159250_192,7599,comparing,O
PMC25159250_192,7599,quetiapine,B-Drug
PMC25159250_192,7599,monotherapy,O
PMC25159250_192,7599,to,O
PMC25159250_192,7599,other,O
PMC25159250_192,7599,mood,O
PMC25159250_192,7599,stabilizers,O
PMC25159250_192,7599,(,O
PMC25159250_192,7599,lithium,O
PMC25159250_192,7599,",",O
PMC25159250_192,7599,valproate,O
PMC25159250_192,7599,",",O
PMC25159250_192,7599,and,O
PMC25159250_192,7599,lamotrigine,O
PMC25159250_192,7599,),O
PMC25159250_192,7599,in,O
PMC25159250_192,7599,bipolar,B-Disease
PMC25159250_192,7599,depression,I-Disease
PMC25159250_192,7599,",",O
PMC25159250_192,7599,both,O
PMC25159250_192,7599,singly,O
PMC25159250_192,7599,and,O
PMC25159250_192,7599,in,O
PMC25159250_192,7599,combination,O
PMC25159250_192,7599,0,O
PMC25159250_693,7600,Pooling,O
PMC25159250_693,7600,the,O
PMC25159250_693,7600,two,O
PMC25159250_693,7600,studies,O
PMC25159250_693,7600,",",O
PMC25159250_693,7600,quetiapine,B-Drug
PMC25159250_693,7600,was,O
PMC25159250_693,7600,effective,O
PMC25159250_693,7600,for,O
PMC25159250_693,7600,both,O
PMC25159250_693,7600,bipolar,B-Disease
PMC25159250_693,7600,I,I-Disease
PMC25159250_693,7600,and,O
PMC25159250_693,7600,bipolar,B-Disease
PMC25159250_693,7600,II,I-Disease
PMC25159250_693,7600,depressions,I-Disease
PMC25159250_693,7600,and,O
PMC25159250_693,7600,for,O
PMC25159250_693,7600,patients,O
PMC25159250_693,7600,with,O
PMC25159250_693,7600,(,O
PMC25159250_693,7600,and,O
PMC25159250_693,7600,without,O
PMC25159250_693,7600,),O
PMC25159250_693,7600,a,O
PMC25159250_693,7600,history,O
PMC25159250_693,7600,of,O
PMC25159250_693,7600,rapid,O
PMC25159250_693,7600,cycling,O
PMC25159250_693,7600,0,O
PMC25265400_810,7601,So,O
PMC25265400_810,7601,far,O
PMC25265400_810,7601,",",O
PMC25265400_810,7601,numerous,O
PMC25265400_810,7601,drugs,O
PMC25265400_810,7601,such,O
PMC25265400_810,7601,as,O
PMC25265400_810,7601,sulfonamides,O
PMC25265400_810,7601,",",O
PMC25265400_810,7601,phenobarbital,O
PMC25265400_810,7601,",",O
PMC25265400_810,7601,sulfasalazine,O
PMC25265400_810,7601,",",O
PMC25265400_810,7601,carbamazepine,B-Drug
PMC25265400_810,7601,",",O
PMC25265400_810,7601,and,O
PMC25265400_810,7601,phenytoin,O
PMC25265400_810,7601,have,O
PMC25265400_810,7601,been,O
PMC25265400_810,7601,reported,O
PMC25265400_810,7601,to,O
PMC25265400_810,7601,cause,O
PMC25265400_810,7601,the,O
PMC25265400_810,7601,DRESS,O
PMC25265400_810,7601,syndrome,O
PMC25265400_810,7601,0,O
PMC25293420_428,7602,The,O
PMC25293420_428,7602,results,O
PMC25293420_428,7602,for,O
PMC25293420_428,7602,duloxetine,B-Drug
PMC25293420_428,7602,are,O
PMC25293420_428,7602,compared,O
PMC25293420_428,7602,with,O
PMC25293420_428,7602,published,O
PMC25293420_428,7602,data,O
PMC25293420_428,7602,for,O
PMC25293420_428,7602,other,O
PMC25293420_428,7602,antidepressants,O
PMC25293420_428,7602,in,O
PMC25293420_428,7602,neuropathic,B-Symptom
PMC25293420_428,7602,pain,I-Symptom
PMC25293420_428,7602,0,O
PMC25293420_477,7603,Comparing,O
PMC25293420_477,7603,duloxetine,B-Drug
PMC25293420_477,7603,with,O
PMC25293420_477,7603,antidepressants,O
PMC25293420_477,7603,for,O
PMC25293420_477,7603,pain,B-Symptom
PMC25293420_477,7603,relief,O
PMC25293420_477,7603,in,O
PMC25293420_477,7603,DPN,O
PMC25293420_477,7603,shows,O
PMC25293420_477,7603,inadequacies,O
PMC25293420_477,7603,in,O
PMC25293420_477,7603,the,O
PMC25293420_477,7603,evidence,O
PMC25293420_477,7603,for,O
PMC25293420_477,7603,efficacy,O
PMC25293420_477,7603,of,O
PMC25293420_477,7603,antidepressants,O
PMC25293420_477,7603,",",O
PMC25293420_477,7603,which,O
PMC25293420_477,7603,are,O
PMC25293420_477,7603,currently,O
PMC25293420_477,7603,recommended,O
PMC25293420_477,7603,in,O
PMC25293420_477,7603,PDN,O
PMC25293420_477,7603,care,O
PMC25293420_477,7603,pathways,O
PMC25293420_477,7603,0,O
PMC25563450_199,7604,CONCLUSION,O
PMC25563450_199,7604,:,O
PMC25563450_199,7604,Duloxetine,B-Drug
PMC25563450_199,7604,may,O
PMC25563450_199,7604,be,O
PMC25563450_199,7604,a,O
PMC25563450_199,7604,useful,O
PMC25563450_199,7604,treatment,O
PMC25563450_199,7604,option,O
PMC25563450_199,7604,in,O
PMC25563450_199,7604,patients,O
PMC25563450_199,7604,with,O
PMC25563450_199,7604,chronic,O
PMC25563450_199,7604,tennis,O
PMC25563450_199,7604,elbow,O
PMC25563450_199,7604,",",O
PMC25563450_199,7604,even,O
PMC25563450_199,7604,those,O
PMC25563450_199,7604,who,O
PMC25563450_199,7604,have,O
PMC25563450_199,7604,failed,O
PMC25563450_199,7604,conventional,O
PMC25563450_199,7604,medical,O
PMC25563450_199,7604,",",O
PMC25563450_199,7604,physiotherapeutic,O
PMC25563450_199,7604,",",O
PMC25563450_199,7604,surgical,O
PMC25563450_199,7604,",",O
PMC25563450_199,7604,and,O
PMC25563450_199,7604,other,O
PMC25563450_199,7604,forms,O
PMC25563450_199,7604,of,O
PMC25563450_199,7604,management,O
PMC25563450_199,7604,0,O
PMC25563450_804,7605,Duloxetine,B-Drug
PMC25563450_804,7605,in,O
PMC25563450_804,7605,treatment,O
PMC25563450_804,7605,of,O
PMC25563450_804,7605,refractory,O
PMC25563450_804,7605,chronic,O
PMC25563450_804,7605,tennis,O
PMC25563450_804,7605,elbow,O
PMC25563450_804,7605,:,O
PMC25563450_804,7605,two,O
PMC25563450_804,7605,case,O
PMC25563450_804,7605,reports,O
PMC25563450_804,7605,0,O
PMC25569750_81,7606,Triamcinolone,B-Drug
PMC25569750_81,7606,acetonide,O
PMC25569750_81,7606,(,O
PMC25569750_81,7606,TA,O
PMC25569750_81,7606,),O
PMC25569750_81,7606,and,O
PMC25569750_81,7606,anecortave,O
PMC25569750_81,7606,acetate,O
PMC25569750_81,7606,(,O
PMC25569750_81,7606,AA,O
PMC25569750_81,7606,),O
PMC25569750_81,7606,can,O
PMC25569750_81,7606,be,O
PMC25569750_81,7606,used,O
PMC25569750_81,7606,to,O
PMC25569750_81,7606,treat,O
PMC25569750_81,7606,radiation,O
PMC25569750_81,7606,retinopathy,B-Symptom
PMC25569750_81,7606,0,O
PMC25665550_77,7607,Early,O
PMC25665550_77,7607,evaluation,O
PMC25665550_77,7607,of,O
PMC25665550_77,7607,patient,O
PMC25665550_77,7607,risk,O
PMC25665550_77,7607,for,O
PMC25665550_77,7607,substantial,O
PMC25665550_77,7607,weight,O
PMC25665550_77,7607,gain,O
PMC25665550_77,7607,during,O
PMC25665550_77,7607,olanzapine,B-Drug
PMC25665550_77,7607,treatment,O
PMC25665550_77,7607,for,O
PMC25665550_77,7607,schizophrenia,B-Disease
PMC25665550_77,7607,",",O
PMC25665550_77,7607,schizophreniform,B-Disease
PMC25665550_77,7607,",",O
PMC25665550_77,7607,or,O
PMC25665550_77,7607,schizoaffective,B-Disease
PMC25665550_77,7607,disorder,I-Disease
PMC25665550_77,7607,0,O
PMC25665630_116,7608,Following,O
PMC25665630_116,7608,localized,O
PMC25665630_116,7608,radiotherapy,O
PMC25665630_116,7608,and,O
PMC25665630_116,7608,five,O
PMC25665630_116,7608,courses,O
PMC25665630_116,7608,of,O
PMC25665630_116,7608,melphalan,B-Drug
PMC25665630_116,7608,and,O
PMC25665630_116,7608,prednisolone,O
PMC25665630_116,7608,",",O
PMC25665630_116,7608,the,O
PMC25665630_116,7608,patient,O
PMC25665630_116,7608,achieved,O
PMC25665630_116,7608,partial,O
PMC25665630_116,7608,remission,O
PMC25665630_116,7608,of,O
PMC25665630_116,7608,her,O
PMC25665630_116,7608,myeloma,B-Disease
PMC25665630_116,7608,0,O
PMC25699220_1021,7609,CONCLUSION,O
PMC25699220_1021,7609,:,O
PMC25699220_1021,7609,Our,O
PMC25699220_1021,7609,results,O
PMC25699220_1021,7609,indicate,O
PMC25699220_1021,7609,that,O
PMC25699220_1021,7609,both,O
PMC25699220_1021,7609,memantine,O
PMC25699220_1021,7609,and,O
PMC25699220_1021,7609,escitalopram,O
PMC25699220_1021,7609,are,O
PMC25699220_1021,7609,useful,O
PMC25699220_1021,7609,adjunct,O
PMC25699220_1021,7609,medications,O
PMC25699220_1021,7609,for,O
PMC25699220_1021,7609,the,O
PMC25699220_1021,7609,treatment,O
PMC25699220_1021,7609,of,O
PMC25699220_1021,7609,alcohol,O
PMC25699220_1021,7609,dependence,O
PMC25699220_1021,7609,co,O
PMC25699220_1021,7609,-,O
PMC25699220_1021,7609,morbid,O
PMC25699220_1021,7609,with,O
PMC25699220_1021,7609,major,B-Disease
PMC25699220_1021,7609,depression,I-Disease
PMC25699220_1021,7609,0,O
PMC25818220_1027,7610,XeNA,O
PMC25818220_1027,7610,:,O
PMC25818220_1027,7610,capecitabine,O
PMC25818220_1027,7610,plus,O
PMC25818220_1027,7610,docetaxel,B-Drug
PMC25818220_1027,7610,",",O
PMC25818220_1027,7610,with,O
PMC25818220_1027,7610,or,O
PMC25818220_1027,7610,without,O
PMC25818220_1027,7610,trastuzumab,O
PMC25818220_1027,7610,",",O
PMC25818220_1027,7610,as,O
PMC25818220_1027,7610,preoperative,O
PMC25818220_1027,7610,therapy,O
PMC25818220_1027,7610,for,O
PMC25818220_1027,7610,early,O
PMC25818220_1027,7610,breast,B-Disease
PMC25818220_1027,7610,cancer,I-Disease
PMC25818220_1027,7610,0,O
PMC25818220_112,7611,Capecitabine,O
PMC25818220_112,7611,plus,O
PMC25818220_112,7611,docetaxel,B-Drug
PMC25818220_112,7611,(,O
PMC25818220_112,7611,XT,O
PMC25818220_112,7611,),O
PMC25818220_112,7611,and,O
PMC25818220_112,7611,trastuzumab,O
PMC25818220_112,7611,with,O
PMC25818220_112,7611,XT,O
PMC25818220_112,7611,(,O
PMC25818220_112,7611,HXT,O
PMC25818220_112,7611,),O
PMC25818220_112,7611,are,O
PMC25818220_112,7611,promising,O
PMC25818220_112,7611,non,O
PMC25818220_112,7611,-,O
PMC25818220_112,7611,anthracycline,O
PMC25818220_112,7611,regimens,O
PMC25818220_112,7611,for,O
PMC25818220_112,7611,the,O
PMC25818220_112,7611,preoperative,O
PMC25818220_112,7611,treatment,O
PMC25818220_112,7611,of,O
PMC25818220_112,7611,women,O
PMC25818220_112,7611,with,O
PMC25818220_112,7611,HER,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,number,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,-,O
PMC25818220_112,7611,negative,O
PMC25818220_112,7611,and,O
PMC25818220_112,7611,HER,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,number,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,_,O
PMC25818220_112,7611,-,O
PMC25818220_112,7611,positive,O
PMC25818220_112,7611,breast,B-Disease
PMC25818220_112,7611,cancer,I-Disease
PMC25818220_112,7611,",",O
PMC25818220_112,7611,respectively,O
PMC25818220_112,7611,0,O
PMC25839640_552,7612,Before,O
PMC25839640_552,7612,schizophrenia,O
PMC25839640_552,7612,onset,O
PMC25839640_552,7612,his,O
PMC25839640_552,7612,cognitive,O
PMC25839640_552,7612,functioning,O
PMC25839640_552,7612,was,O
PMC25839640_552,7612,poor,O
PMC25839640_552,7612,and,O
PMC25839640_552,7612,he,O
PMC25839640_552,7612,could,O
PMC25839640_552,7612,not,O
PMC25839640_552,7612,attend,O
PMC25839640_552,7612,regular,O
PMC25839640_552,7612,courses,O
PMC25839640_552,7612,to,O
PMC25839640_552,7612,reach,O
PMC25839640_552,7612,his,O
PMC25839640_552,7612,high,O
PMC25839640_552,7612,school,O
PMC25839640_552,7612,degree,O
PMC25839640_552,7612,;,O
PMC25839640_552,7612,he,O
PMC25839640_552,7612,started,O
PMC25839640_552,7612,but,O
PMC25839640_552,7612,was,O
PMC25839640_552,7612,not,O
PMC25839640_552,7612,able,O
PMC25839640_552,7612,to,O
PMC25839640_552,7612,attend,O
PMC25839640_552,7612,the,O
PMC25839640_552,7612,University,O
PMC25839640_552,7612,courses,O
PMC25839640_552,7612,for,O
PMC25839640_552,7612,several,O
PMC25839640_552,7612,years,O
PMC25839640_552,7612,0,O
PMC25839640_552,7613,After,O
PMC25839640_552,7613,schizophrenia,B-Disease
PMC25839640_552,7613,onset,O
PMC25839640_552,7613,",",O
PMC25839640_552,7613,he,O
PMC25839640_552,7613,was,O
PMC25839640_552,7613,treated,O
PMC25839640_552,7613,",",O
PMC25839640_552,7613,in,O
PMC25839640_552,7613,sequence,O
PMC25839640_552,7613,",",O
PMC25839640_552,7613,with,O
PMC25839640_552,7613,olanzapine,B-Drug
PMC25839640_552,7613,",",O
PMC25839640_552,7613,amisulpride,O
PMC25839640_552,7613,and,O
PMC25839640_552,7613,aripiprazole,O
PMC25839640_552,7613,0,O
PMC25839940_456,7614,BACKGROUND,O
PMC25839940_456,7614,:,O
PMC25839940_456,7614,Docetaxel,B-Drug
PMC25839940_456,7614,and,O
PMC25839940_456,7614,gemcitabine,O
PMC25839940_456,7614,combinations,O
PMC25839940_456,7614,have,O
PMC25839940_456,7614,proven,O
PMC25839940_456,7614,active,O
PMC25839940_456,7614,for,O
PMC25839940_456,7614,the,O
PMC25839940_456,7614,treatment,O
PMC25839940_456,7614,of,O
PMC25839940_456,7614,non,B-Disease
PMC25839940_456,7614,-,I-Disease
PMC25839940_456,7614,small,I-Disease
PMC25839940_456,7614,cell,I-Disease
PMC25839940_456,7614,lung,I-Disease
PMC25839940_456,7614,cancer,I-Disease
PMC25839940_456,7614,(,I-Disease
PMC25839940_456,7614,NSCLC,I-Disease
PMC25839940_456,7614,),O
PMC25839940_456,7614,0,O
PMC25961150_617,7615,INTRODUCTION,O
PMC25961150_617,7615,:,O
PMC25961150_617,7615,Antiepileptic,O
PMC25961150_617,7615,drug,O
PMC25961150_617,7615,induced,O
PMC25961150_617,7615,hypersensitivity,O
PMC25961150_617,7615,syndrome,O
PMC25961150_617,7615,is,O
PMC25961150_617,7615,a,O
PMC25961150_617,7615,rare,O
PMC25961150_617,7615,side,O
PMC25961150_617,7615,effect,O
PMC25961150_617,7615,of,O
PMC25961150_617,7615,some,O
PMC25961150_617,7615,of,O
PMC25961150_617,7615,the,O
PMC25961150_617,7615,first,O
PMC25961150_617,7615,line,O
PMC25961150_617,7615,anticonvulsive,O
PMC25961150_617,7615,drugs,O
PMC25961150_617,7615,such,O
PMC25961150_617,7615,as,O
PMC25961150_617,7615,carbamazepine,B-Drug
PMC25961150_617,7615,and,O
PMC25961150_617,7615,other,O
PMC25961150_617,7615,aromatic,O
PMC25961150_617,7615,agents,O
PMC25961150_617,7615,0,O
PMC26038250_747,7616,The,O
PMC26038250_747,7616,effects,O
PMC26038250_747,7616,of,O
PMC26038250_747,7616,cortisone,B-Drug
PMC26038250_747,7616,and,O
PMC26038250_747,7616,chemical,O
PMC26038250_747,7616,inflammation,O
PMC26038250_747,7616,on,O
PMC26038250_747,7616,experimental,O
PMC26038250_747,7616,mucormycosis,O
PMC26038250_747,7616,(,O
PMC26038250_747,7616,Rhizopus,O
PMC26038250_747,7616,oryzae,O
PMC26038250_747,7616,infection,O
PMC26038250_747,7616,),O
PMC26038250_747,7616,0,O
PMC26145240_228,7617,A,O
PMC26145240_228,7617,candidate,O
PMC26145240_228,7617,molecular,O
PMC26145240_228,7617,signature,O
PMC26145240_228,7617,associated,O
PMC26145240_228,7617,with,O
PMC26145240_228,7617,tamoxifen,B-Drug
PMC26145240_228,7617,failure,O
PMC26145240_228,7617,in,O
PMC26145240_228,7617,primary,O
PMC26145240_228,7617,breast,B-Disease
PMC26145240_228,7617,cancer,I-Disease
PMC26145240_228,7617,0,O
PMC26211350_461,7618,Due,O
PMC26211350_461,7618,to,O
PMC26211350_461,7618,the,O
PMC26211350_461,7618,toxicity,O
PMC26211350_461,7618,of,O
PMC26211350_461,7618,cyclophosphamide,O
PMC26211350_461,7618,",",O
PMC26211350_461,7618,her,O
PMC26211350_461,7618,relatively,O
PMC26211350_461,7618,mild,O
PMC26211350_461,7618,disease,B-Disease
PMC26211350_461,7618,sparing,O
PMC26211350_461,7618,the,O
PMC26211350_461,7618,kidneys,O
PMC26211350_461,7618,and,O
PMC26211350_461,7618,the,O
PMC26211350_461,7618,underlying,O
PMC26211350_461,7618,rheumatoid,B-Disease
PMC26211350_461,7618,arthritis,I-Disease
PMC26211350_461,7618,",",O
PMC26211350_461,7618,weekly,O
PMC26211350_461,7618,methotrexate,O
PMC26211350_461,7618,was,O
PMC26211350_461,7618,started,O
PMC26211350_461,7618,and,O
PMC26211350_461,7618,low,O
PMC26211350_461,7618,dose,O
PMC26211350_461,7618,prednisone,B-Drug
PMC26211350_461,7618,was,O
PMC26211350_461,7618,continued,O
PMC26211350_461,7618,0,O
PMC26213850_334,7619,Double,O
PMC26213850_334,7619,-,O
PMC26213850_334,7619,blind,O
PMC26213850_334,7619,",",O
PMC26213850_334,7619,randomized,O
PMC26213850_334,7619,trial,O
PMC26213850_334,7619,comparing,O
PMC26213850_334,7619,efficacy,O
PMC26213850_334,7619,and,O
PMC26213850_334,7619,safety,O
PMC26213850_334,7619,of,O
PMC26213850_334,7619,continuing,O
PMC26213850_334,7619,olanzapine,B-Drug
PMC26213850_334,7619,versus,O
PMC26213850_334,7619,switching,O
PMC26213850_334,7619,to,O
PMC26213850_334,7619,quetiapine,B-Drug
PMC26213850_334,7619,in,O
PMC26213850_334,7619,overweight,O
PMC26213850_334,7619,or,O
PMC26213850_334,7619,obese,O
PMC26213850_334,7619,patients,O
PMC26213850_334,7619,with,O
PMC26213850_334,7619,schizophrenia,B-Disease
PMC26213850_334,7619,or,O
PMC26213850_334,7619,schizoaffective,B-Disease
PMC26213850_334,7619,disorder,I-Disease
PMC26213850_334,7619,0,O
PMC26213850_868,7620,We,O
PMC26213850_868,7620,examined,O
PMC26213850_868,7620,the,O
PMC26213850_868,7620,potential,O
PMC26213850_868,7620,risks,O
PMC26213850_868,7620,and,O
PMC26213850_868,7620,benefits,O
PMC26213850_868,7620,of,O
PMC26213850_868,7620,switching,O
PMC26213850_868,7620,from,O
PMC26213850_868,7620,olanzapine,B-Drug
PMC26213850_868,7620,to,O
PMC26213850_868,7620,quetiapine,B-Drug
PMC26213850_868,7620,in,O
PMC26213850_868,7620,mentally,O
PMC26213850_868,7620,stable,O
PMC26213850_868,7620,",",O
PMC26213850_868,7620,obese,O
PMC26213850_868,7620,",",O
PMC26213850_868,7620,or,O
PMC26213850_868,7620,overweight,O
PMC26213850_868,7620,patients,O
PMC26213850_868,7620,with,O
PMC26213850_868,7620,schizophrenia,B-Disease
PMC26213850_868,7620,or,O
PMC26213850_868,7620,schizoaffective,B-Disease
PMC26213850_868,7620,disorder,I-Disease
PMC26213850_868,7620,0,O
PMC26280260_726,7621,PURPOSE,O
PMC26280260_726,7621,:,O
PMC26280260_726,7621,To,O
PMC26280260_726,7621,compare,O
PMC26280260_726,7621,the,O
PMC26280260_726,7621,efficacy,O
PMC26280260_726,7621,of,O
PMC26280260_726,7621,posterior,O
PMC26280260_726,7621,sub,O
PMC26280260_726,7621,-,O
PMC26280260_726,7621,Tenon,O
PMC26280260_726,7621,',O
PMC26280260_726,7621,s,O
PMC26280260_726,7621,capsule,O
PMC26280260_726,7621,triamcinolone,B-Drug
PMC26280260_726,7621,acetonide,O
PMC26280260_726,7621,injection,O
PMC26280260_726,7621,combined,O
PMC26280260_726,7621,with,O
PMC26280260_726,7621,modified,O
PMC26280260_726,7621,grid,O
PMC26280260_726,7621,macular,O
PMC26280260_726,7621,photocoagulation,O
PMC26280260_726,7621,(,O
PMC26280260_726,7621,PSTI,O
PMC26280260_726,7621,+,O
PMC26280260_726,7621,MP,O
PMC26280260_726,7621,),O
PMC26280260_726,7621,with,O
PMC26280260_726,7621,intravitreal,O
PMC26280260_726,7621,triamcinolone,B-Drug
PMC26280260_726,7621,acetonide,O
PMC26280260_726,7621,(,O
PMC26280260_726,7621,IVTA,O
PMC26280260_726,7621,),O
PMC26280260_726,7621,injection,O
PMC26280260_726,7621,in,O
PMC26280260_726,7621,the,O
PMC26280260_726,7621,treatment,O
PMC26280260_726,7621,of,O
PMC26280260_726,7621,diffuse,O
PMC26280260_726,7621,diabetic,O
PMC26280260_726,7621,macular,O
PMC26280260_726,7621,edema,O
PMC26280260_726,7621,(,O
PMC26280260_726,7621,DME,O
PMC26280260_726,7621,),O
PMC26280260_726,7621,0,O
PMC26296840_147,7622,PURPOSE,O
PMC26296840_147,7622,:,O
PMC26296840_147,7622,To,O
PMC26296840_147,7622,evaluate,O
PMC26296840_147,7622,therapeutic,O
PMC26296840_147,7622,effects,O
PMC26296840_147,7622,and,O
PMC26296840_147,7622,usefulness,O
PMC26296840_147,7622,of,O
PMC26296840_147,7622,a,O
PMC26296840_147,7622,combination,O
PMC26296840_147,7622,treatment,O
PMC26296840_147,7622,of,O
PMC26296840_147,7622,intravitreal,O
PMC26296840_147,7622,injection,O
PMC26296840_147,7622,of,O
PMC26296840_147,7622,triamcinolone,B-Drug
PMC26296840_147,7622,acetonide,O
PMC26296840_147,7622,(,O
PMC26296840_147,7622,IVTA,O
PMC26296840_147,7622,),O
PMC26296840_147,7622,and,O
PMC26296840_147,7622,panretinal,O
PMC26296840_147,7622,photocoagulation,O
PMC26296840_147,7622,(,O
PMC26296840_147,7622,PRP,O
PMC26296840_147,7622,),O
PMC26296840_147,7622,in,O
PMC26296840_147,7622,patients,O
PMC26296840_147,7622,with,O
PMC26296840_147,7622,clinically,O
PMC26296840_147,7622,significant,O
PMC26296840_147,7622,macular,O
PMC26296840_147,7622,edema,O
PMC26296840_147,7622,secondary,O
PMC26296840_147,7622,to,O
PMC26296840_147,7622,proliferative,O
PMC26296840_147,7622,diabetic,O
PMC26296840_147,7622,retinopathy,O
PMC26296840_147,7622,(,O
PMC26296840_147,7622,PDR,O
PMC26296840_147,7622,),O
PMC26296840_147,7622,0,O
PMC26296840_337,7623,Laser,O
PMC26296840_337,7623,photocoagulation,O
PMC26296840_337,7623,combined,O
PMC26296840_337,7623,with,O
PMC26296840_337,7623,intravitreal,O
PMC26296840_337,7623,triamcinolone,B-Drug
PMC26296840_337,7623,acetonide,O
PMC26296840_337,7623,injection,O
PMC26296840_337,7623,in,O
PMC26296840_337,7623,proliferative,O
PMC26296840_337,7623,diabetic,O
PMC26296840_337,7623,retinopathy,O
PMC26296840_337,7623,with,O
PMC26296840_337,7623,macular,O
PMC26296840_337,7623,edema,O
PMC26296840_337,7623,0,O
PMC26296940_597,7624,Early,O
PMC26296940_597,7624,versus,O
PMC26296940_597,7624,late,O
PMC26296940_597,7624,intravitreal,O
PMC26296940_597,7624,triamcinolone,B-Drug
PMC26296940_597,7624,acetonide,O
PMC26296940_597,7624,for,O
PMC26296940_597,7624,macular,O
PMC26296940_597,7624,edema,O
PMC26296940_597,7624,associated,O
PMC26296940_597,7624,with,O
PMC26296940_597,7624,branch,O
PMC26296940_597,7624,retinal,O
PMC26296940_597,7624,vein,O
PMC26296940_597,7624,occlusion,O
PMC26296940_597,7624,0,O
PMC26361720_524,7625,Three,O
PMC26361720_524,7625,patients,O
PMC26361720_524,7625,had,O
PMC26361720_524,7625,resolution,O
PMC26361720_524,7625,of,O
PMC26361720_524,7625,canaliculitis,O
PMC26361720_524,7625,on,O
PMC26361720_524,7625,combination,O
PMC26361720_524,7625,broad,O
PMC26361720_524,7625,-,O
PMC26361720_524,7625,spectrum,O
PMC26361720_524,7625,topical,O
PMC26361720_524,7625,antibiotic,O
PMC26361720_524,7625,therapy,O
PMC26361720_524,7625,using,O
PMC26361720_524,7625,ciprofloxacin,B-Drug
PMC26361720_524,7625,and,O
PMC26361720_524,7625,fortified,O
PMC26361720_524,7625,cefazolin,O
PMC26361720_524,7625,0,O
PMC26372580_111,7626,Both,O
PMC26372580_111,7626,topiramate,B-Drug
PMC26372580_111,7626,and,O
PMC26372580_111,7626,citalopram,B-Drug
PMC26372580_111,7626,have,O
PMC26372580_111,7626,been,O
PMC26372580_111,7626,related,O
PMC26372580_111,7626,to,O
PMC26372580_111,7626,the,O
PMC26372580_111,7626,increase,B-Symptom
PMC26372580_111,7626,of,I-Symptom
PMC26372580_111,7626,intraocular,I-Symptom
PMC26372580_111,7626,pressure,I-Symptom
PMC26372580_111,7626,and,O
PMC26372580_111,7626,the,O
PMC26372580_111,7626,development,O
PMC26372580_111,7626,of,O
PMC26372580_111,7626,glaucoma,B-Disease
PMC26372580_111,7626,0,O
PMC26372580_138,7627,We,O
PMC26372580_138,7627,recommend,O
PMC26372580_138,7627,to,O
PMC26372580_138,7627,pay,O
PMC26372580_138,7627,particular,O
PMC26372580_138,7627,attention,O
PMC26372580_138,7627,in,O
PMC26372580_138,7627,prescribing,O
PMC26372580_138,7627,of,O
PMC26372580_138,7627,topiramate,B-Drug
PMC26372580_138,7627,in,O
PMC26372580_138,7627,migraine,O
PMC26372580_138,7627,patients,O
PMC26372580_138,7627,who,O
PMC26372580_138,7627,are,O
PMC26372580_138,7627,already,O
PMC26372580_138,7627,under,O
PMC26372580_138,7627,treatment,O
PMC26372580_138,7627,with,O
PMC26372580_138,7627,citalopram,B-Drug
PMC26372580_138,7627,or,O
PMC26372580_138,7627,other,O
PMC26372580_138,7627,antidepressants,O
PMC26372580_138,7627,with,O
PMC26372580_138,7627,a,O
PMC26372580_138,7627,similar,O
PMC26372580_138,7627,mechanisms,O
PMC26372580_138,7627,of,O
PMC26372580_138,7627,action,O
PMC26372580_138,7627,0,O
PMC26372580_526,7628,Topiramate,B-Drug
PMC26372580_526,7628,-,O
PMC26372580_526,7628,associated,O
PMC26372580_526,7628,acute,B-Disease
PMC26372580_526,7628,glaucoma,I-Disease
PMC26372580_526,7628,in,O
PMC26372580_526,7628,a,O
PMC26372580_526,7628,migraine,O
PMC26372580_526,7628,patient,O
PMC26372580_526,7628,receiving,O
PMC26372580_526,7628,concomitant,O
PMC26372580_526,7628,citalopram,B-Drug
PMC26372580_526,7628,therapy,O
PMC26372580_526,7628,:,O
PMC26372580_526,7628,a,O
PMC26372580_526,7628,case,O
PMC26372580_526,7628,-,O
PMC26372580_526,7628,report,O
PMC26372580_526,7628,0,O
PMC26372580_539,7629,We,O
PMC26372580_539,7629,can,O
PMC26372580_539,7629,',O
PMC26372580_539,7629,t,O
PMC26372580_539,7629,exclude,O
PMC26372580_539,7629,that,O
PMC26372580_539,7629,in,O
PMC26372580_539,7629,this,O
PMC26372580_539,7629,patient,O
PMC26372580_539,7629,citalopram,B-Drug
PMC26372580_539,7629,caused,O
PMC26372580_539,7629,an,O
PMC26372580_539,7629,increase,B-Symptom
PMC26372580_539,7629,of,I-Symptom
PMC26372580_539,7629,the,I-Symptom
PMC26372580_539,7629,ocular,I-Symptom
PMC26372580_539,7629,pressure,I-Symptom
PMC26372580_539,7629,in,O
PMC26372580_539,7629,dose,O
PMC26372580_539,7629,-,O
PMC26372580_539,7629,dependent,O
PMC26372580_539,7629,manner,O
PMC26372580_539,7629,",",O
PMC26372580_539,7629,facilitating,O
PMC26372580_539,7629,topiramate,B-Drug
PMC26372580_539,7629,-,O
PMC26372580_539,7629,induced,O
PMC26372580_539,7629,glaucoma,B-Disease
PMC26372580_539,7629,0,O
PMC26431130_191,7630,Currently,O
PMC26431130_191,7630,the,O
PMC26431130_191,7630,two,O
PMC26431130_191,7630,drugs,O
PMC26431130_191,7630,that,O
PMC26431130_191,7630,are,O
PMC26431130_191,7630,approved,O
PMC26431130_191,7630,by,O
PMC26431130_191,7630,the,O
PMC26431130_191,7630,United,O
PMC26431130_191,7630,States,O
PMC26431130_191,7630,Food,O
PMC26431130_191,7630,and,O
PMC26431130_191,7630,Drug,O
PMC26431130_191,7630,Administration,O
PMC26431130_191,7630,(,O
PMC26431130_191,7630,FDA,O
PMC26431130_191,7630,),O
PMC26431130_191,7630,for,O
PMC26431130_191,7630,the,O
PMC26431130_191,7630,management,O
PMC26431130_191,7630,of,O
PMC26431130_191,7630,fibromyalgia,B-Disease
PMC26431130_191,7630,are,O
PMC26431130_191,7630,pregabalin,O
PMC26431130_191,7630,and,O
PMC26431130_191,7630,duloxetine,B-Drug
PMC26431130_191,7630,0,O
PMC26442920_87,7631,Thirteen,O
PMC26442920_87,7631,patients,O
PMC26442920_87,7631,were,O
PMC26442920_87,7631,able,O
PMC26442920_87,7631,to,O
PMC26442920_87,7631,be,O
PMC26442920_87,7631,maintained,O
PMC26442920_87,7631,without,O
PMC26442920_87,7631,relapse,O
PMC26442920_87,7631,or,O
PMC26442920_87,7631,recurrence,O
PMC26442920_87,7631,in,O
PMC26442920_87,7631,good,O
PMC26442920_87,7631,quality,O
PMC26442920_87,7631,remission,O
PMC26442920_87,7631,on,O
PMC26442920_87,7631,quetiapine,B-Drug
PMC26442920_87,7631,monotherapy,O
PMC26442920_87,7631,",",O
PMC26442920_87,7631,while,O
PMC26442920_87,7631,_,O
PMC26442920_87,7631,_,O
PMC26442920_87,7631,number,O
PMC26442920_87,7631,_,O
PMC26442920_87,7631,_,O
PMC26442920_87,7631,patients,O
PMC26442920_87,7631,required,O
PMC26442920_87,7631,additional,O
PMC26442920_87,7631,medication,O
PMC26442920_87,7631,to,O
PMC26442920_87,7631,treat,O
PMC26442920_87,7631,impairing,O
PMC26442920_87,7631,residual,O
PMC26442920_87,7631,depressive,B-Symptom
PMC26442920_87,7631,and,I-Symptom
PMC26442920_87,7631,/,I-Symptom
PMC26442920_87,7631,or,I-Symptom
PMC26442920_87,7631,anxiety,I-Symptom
PMC26442920_87,7631,symptoms,I-Symptom
PMC26442920_87,7631,0,O
PMC26453970_274,7632,OBJECTIVE,O
PMC26453970_274,7632,:,O
PMC26453970_274,7632,This,O
PMC26453970_274,7632,analysis,O
PMC26453970_274,7632,of,O
PMC26453970_274,7632,data,O
PMC26453970_274,7632,from,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,number,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,double,O
PMC26453970_274,7632,-,O
PMC26453970_274,7632,blind,O
PMC26453970_274,7632,",",O
PMC26453970_274,7632,placebo,O
PMC26453970_274,7632,-,O
PMC26453970_274,7632,controlled,O
PMC26453970_274,7632,clinical,O
PMC26453970_274,7632,studies,O
PMC26453970_274,7632,of,O
PMC26453970_274,7632,venlafaxine,B-Drug
PMC26453970_274,7632,in,O
PMC26453970_274,7632,adult,O
PMC26453970_274,7632,patients,O
PMC26453970_274,7632,with,O
PMC26453970_274,7632,major,O
PMC26453970_274,7632,depressive,B-Disease
PMC26453970_274,7632,disorder,I-Disease
PMC26453970_274,7632,was,O
PMC26453970_274,7632,aimed,O
PMC26453970_274,7632,at,O
PMC26453970_274,7632,assessing,O
PMC26453970_274,7632,correlations,O
PMC26453970_274,7632,among,O
PMC26453970_274,7632,these,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,number,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,_,O
PMC26453970_274,7632,scales,O
PMC26453970_274,7632,0,O
PMC26466470_981,7633,Quetiapine,B-Drug
PMC26466470_981,7633,has,O
PMC26466470_981,7633,demonstrated,O
PMC26466470_981,7633,efficacy,O
PMC26466470_981,7633,in,O
PMC26466470_981,7633,schizophrenia,B-Disease
PMC26466470_981,7633,",",O
PMC26466470_981,7633,bipolar,B-Disease
PMC26466470_981,7633,disorder,I-Disease
PMC26466470_981,7633,and,O
PMC26466470_981,7633,in,O
PMC26466470_981,7633,the,O
PMC26466470_981,7633,treatment,O
PMC26466470_981,7633,of,O
PMC26466470_981,7633,specific,O
PMC26466470_981,7633,symptom,O
PMC26466470_981,7633,clusters,O
PMC26466470_981,7633,such,O
PMC26466470_981,7633,as,O
PMC26466470_981,7633,agitation,B-Symptom
PMC26466470_981,7633,and,O
PMC26466470_981,7633,sleep,O
PMC26466470_981,7633,problems,O
PMC26466470_981,7633,in,O
PMC26466470_981,7633,mood,O
PMC26466470_981,7633,disorders,O
PMC26466470_981,7633,0,O
PMC26490650_289,7634,Ninety,O
PMC26490650_289,7634,adult,O
PMC26490650_289,7634,male,O
PMC26490650_289,7634,prisoners,O
PMC26490650_289,7634,requesting,O
PMC26490650_289,7634,an,O
PMC26490650_289,7634,opiate,O
PMC26490650_289,7634,detoxification,O
PMC26490650_289,7634,were,O
PMC26490650_289,7634,randomised,O
PMC26490650_289,7634,to,O
PMC26490650_289,7634,receive,O
PMC26490650_289,7634,either,O
PMC26490650_289,7634,daily,O
PMC26490650_289,7634,sublingual,O
PMC26490650_289,7634,buprenorphine,B-Drug
PMC26490650_289,7634,or,O
PMC26490650_289,7634,daily,O
PMC26490650_289,7634,oral,O
PMC26490650_289,7634,dihydrocodeine,O
PMC26490650_289,7634,",",O
PMC26490650_289,7634,given,O
PMC26490650_289,7634,in,O
PMC26490650_289,7634,the,O
PMC26490650_289,7634,context,O
PMC26490650_289,7634,of,O
PMC26490650_289,7634,routine,O
PMC26490650_289,7634,care,O
PMC26490650_289,7634,0,O
PMC26547980_134,7635,This,O
PMC26547980_134,7635,has,O
PMC26547980_134,7635,clinical,O
PMC26547980_134,7635,relevance,O
PMC26547980_134,7635,as,O
PMC26547980_134,7635,DLB,O
PMC26547980_134,7635,patients,O
PMC26547980_134,7635,may,O
PMC26547980_134,7635,be,O
PMC26547980_134,7635,particularly,O
PMC26547980_134,7635,sensitive,O
PMC26547980_134,7635,to,O
PMC26547980_134,7635,antipsychotics,O
PMC26547980_134,7635,and,O
PMC26547980_134,7635,even,O
PMC26547980_134,7635,the,O
PMC26547980_134,7635,effectiveness,O
PMC26547980_134,7635,of,O
PMC26547980_134,7635,atypical,O
PMC26547980_134,7635,neuroleptics,O
PMC26547980_134,7635,such,O
PMC26547980_134,7635,as,O
PMC26547980_134,7635,quetiapine,B-Drug
PMC26547980_134,7635,for,O
PMC26547980_134,7635,the,O
PMC26547980_134,7635,treatment,O
PMC26547980_134,7635,of,O
PMC26547980_134,7635,agitation,B-Symptom
PMC26547980_134,7635,and,O
PMC26547980_134,7635,hallucinations,B-Symptom
PMC26547980_134,7635,has,O
PMC26547980_134,7635,been,O
PMC26547980_134,7635,questioned,O
PMC26547980_134,7635,by,O
PMC26547980_134,7635,double,O
PMC26547980_134,7635,-,O
PMC26547980_134,7635,blind,O
PMC26547980_134,7635,",",O
PMC26547980_134,7635,placebo,O
PMC26547980_134,7635,-,O
PMC26547980_134,7635,controlled,O
PMC26547980_134,7635,",",O
PMC26547980_134,7635,randomized,O
PMC26547980_134,7635,studies,O
PMC26547980_134,7635,0,O
PMC26550870_411,7636,The,O
PMC26550870_411,7636,role,O
PMC26550870_411,7636,of,O
PMC26550870_411,7636,lamotrigine,B-Drug
PMC26550870_411,7636,in,O
PMC26550870_411,7636,the,O
PMC26550870_411,7636,management,O
PMC26550870_411,7636,of,O
PMC26550870_411,7636,bipolar,B-Disease
PMC26550870_411,7636,disorder,I-Disease
PMC26550870_411,7636,0,O
PMC26557470_935,7637,The,O
PMC26557470_935,7637,effect,O
PMC26557470_935,7637,of,O
PMC26557470_935,7637,an,O
PMC26557470_935,7637,intravitreal,O
PMC26557470_935,7637,triamcinolone,B-Drug
PMC26557470_935,7637,acetonide,O
PMC26557470_935,7637,injection,O
PMC26557470_935,7637,for,O
PMC26557470_935,7637,acute,O
PMC26557470_935,7637,nonarteritic,O
PMC26557470_935,7637,anterior,O
PMC26557470_935,7637,ischemic,O
PMC26557470_935,7637,optic,O
PMC26557470_935,7637,neuropathy,O
PMC26557470_935,7637,0,O
PMC26563090_867,7638,To,O
PMC26563090_867,7638,investigate,O
PMC26563090_867,7638,the,O
PMC26563090_867,7638,antidepressant,O
PMC26563090_867,7638,effect,O
PMC26563090_867,7638,of,O
PMC26563090_867,7638,high,O
PMC26563090_867,7638,-,O
PMC26563090_867,7638,dose,O
PMC26563090_867,7638,milnacipran,O
PMC26563090_867,7638,",",O
PMC26563090_867,7638,we,O
PMC26563090_867,7638,retrospectively,O
PMC26563090_867,7638,compared,O
PMC26563090_867,7638,three,O
PMC26563090_867,7638,groups,O
PMC26563090_867,7638,of,O
PMC26563090_867,7638,inpatients,O
PMC26563090_867,7638,with,O
PMC26563090_867,7638,major,B-Disease
PMC26563090_867,7638,depression,I-Disease
PMC26563090_867,7638,;,O
PMC26563090_867,7638,those,O
PMC26563090_867,7638,who,O
PMC26563090_867,7638,were,O
PMC26563090_867,7638,given,O
PMC26563090_867,7638,milnacipran,O
PMC26563090_867,7638,>,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,number,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,mg,O
PMC26563090_867,7638,/,O
PMC26563090_867,7638,day,O
PMC26563090_867,7638,(,O
PMC26563090_867,7638,high,O
PMC26563090_867,7638,-,O
PMC26563090_867,7638,dose,O
PMC26563090_867,7638,milnacipran,O
PMC26563090_867,7638,group,O
PMC26563090_867,7638,),O
PMC26563090_867,7638,",",O
PMC26563090_867,7638,those,O
PMC26563090_867,7638,treated,O
PMC26563090_867,7638,with,O
PMC26563090_867,7638,milnacipran,O
PMC26563090_867,7638,at,O
PMC26563090_867,7638,maximum,O
PMC26563090_867,7638,doses,O
PMC26563090_867,7638,of,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,number,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,mg,O
PMC26563090_867,7638,/,O
PMC26563090_867,7638,day,O
PMC26563090_867,7638,(,O
PMC26563090_867,7638,standard,O
PMC26563090_867,7638,-,O
PMC26563090_867,7638,dose,O
PMC26563090_867,7638,milnacipran,O
PMC26563090_867,7638,group,O
PMC26563090_867,7638,),O
PMC26563090_867,7638,",",O
PMC26563090_867,7638,and,O
PMC26563090_867,7638,those,O
PMC26563090_867,7638,treated,O
PMC26563090_867,7638,with,O
PMC26563090_867,7638,paroxetine,B-Drug
PMC26563090_867,7638,at,O
PMC26563090_867,7638,maximum,O
PMC26563090_867,7638,doses,O
PMC26563090_867,7638,of,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,number,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,_,O
PMC26563090_867,7638,mg,O
PMC26563090_867,7638,/,O
PMC26563090_867,7638,day,O
PMC26563090_867,7638,(,O
PMC26563090_867,7638,paroxetine,O
PMC26563090_867,7638,group,O
PMC26563090_867,7638,),O
PMC26563090_867,7638,0,O
PMC26563230_297,7639,Topiramate,B-Drug
PMC26563230_297,7639,in,O
PMC26563230_297,7639,the,O
PMC26563230_297,7639,treatment,O
PMC26563230_297,7639,of,O
PMC26563230_297,7639,partial,B-Disease
PMC26563230_297,7639,and,I-Disease
PMC26563230_297,7639,generalized,I-Disease
PMC26563230_297,7639,epilepsy,I-Disease
PMC26563230_297,7639,0,O
PMC26563240_318,7640,Ziprasidone,B-Drug
PMC26563240_318,7640,in,O
PMC26563240_318,7640,the,O
PMC26563240_318,7640,treatment,O
PMC26563240_318,7640,of,O
PMC26563240_318,7640,mania,B-Symptom
PMC26563240_318,7640,in,O
PMC26563240_318,7640,bipolar,B-Disease
PMC26563240_318,7640,disorder,I-Disease
PMC26563240_318,7640,0,O
PMC26563240_666,7641,The,O
PMC26563240_666,7641,emergence,O
PMC26563240_666,7641,of,O
PMC26563240_666,7641,mania,B-Symptom
PMC26563240_666,7641,in,O
PMC26563240_666,7641,patients,O
PMC26563240_666,7641,taking,O
PMC26563240_666,7641,ziprasidone,B-Drug
PMC26563240_666,7641,is,O
PMC26563240_666,7641,another,O
PMC26563240_666,7641,topic,O
PMC26563240_666,7641,for,O
PMC26563240_666,7641,further,O
PMC26563240_666,7641,study,O
PMC26563240_666,7641,0,O
PMC26563240_705,7642,Unstudied,O
PMC26563240_705,7642,areas,O
PMC26563240_705,7642,of,O
PMC26563240_705,7642,particular,O
PMC26563240_705,7642,importance,O
PMC26563240_705,7642,include,O
PMC26563240_705,7642,the,O
PMC26563240_705,7642,efficacy,O
PMC26563240_705,7642,and,O
PMC26563240_705,7642,safety,O
PMC26563240_705,7642,of,O
PMC26563240_705,7642,ziprasidone,B-Drug
PMC26563240_705,7642,in,O
PMC26563240_705,7642,the,O
PMC26563240_705,7642,treatment,O
PMC26563240_705,7642,of,O
PMC26563240_705,7642,bipolar,B-Disease
PMC26563240_705,7642,depression,I-Disease
PMC26563240_705,7642,and,O
PMC26563240_705,7642,relapse,O
PMC26563240_705,7642,prevention,O
PMC26563240_705,7642,of,O
PMC26563240_705,7642,mania,B-Symptom
PMC26563240_705,7642,as,O
PMC26563240_705,7642,",",O
PMC26563240_705,7642,well,O
PMC26563240_705,7642,as,O
PMC26563240_705,7642,in,O
PMC26563240_705,7642,the,O
PMC26563240_705,7642,subpopulations,O
PMC26563240_705,7642,of,O
PMC26563240_705,7642,pregnant,O
PMC26563240_705,7642,women,O
PMC26563240_705,7642,",",O
PMC26563240_705,7642,the,O
PMC26563240_705,7642,elderly,O
PMC26563240_705,7642,and,O
PMC26563240_705,7642,pediatric,O
PMC26563240_705,7642,patients,O
PMC26563240_705,7642,0,O
PMC26563240_787,7643,Currently,O
PMC26563240_787,7643,",",O
PMC26563240_787,7643,ziprasidone,B-Drug
PMC26563240_787,7643,is,O
PMC26563240_787,7643,approved,O
PMC26563240_787,7643,by,O
PMC26563240_787,7643,the,O
PMC26563240_787,7643,US,O
PMC26563240_787,7643,Food,O
PMC26563240_787,7643,and,O
PMC26563240_787,7643,Drug,O
PMC26563240_787,7643,Administration,O
PMC26563240_787,7643,for,O
PMC26563240_787,7643,the,O
PMC26563240_787,7643,acute,O
PMC26563240_787,7643,treatment,O
PMC26563240_787,7643,of,O
PMC26563240_787,7643,psychosis,O
PMC26563240_787,7643,in,O
PMC26563240_787,7643,schizophrenia,B-Disease
PMC26563240_787,7643,and,O
PMC26563240_787,7643,mania,B-Symptom
PMC26563240_787,7643,in,O
PMC26563240_787,7643,bipolar,B-Disease
PMC26563240_787,7643,disorder,I-Disease
PMC26563240_787,7643,0,O
PMC26635370_949,7644,Meta,O
PMC26635370_949,7644,-,O
PMC26635370_949,7644,analysis,O
PMC26635370_949,7644,of,O
PMC26635370_949,7644,duloxetine,B-Drug
PMC26635370_949,7644,vs,O
PMC26635370_949,7644,0,O
PMC26635370_949,7645,pregabalin,O
PMC26635370_949,7645,and,O
PMC26635370_949,7645,gabapentin,O
PMC26635370_949,7645,in,O
PMC26635370_949,7645,the,O
PMC26635370_949,7645,treatment,O
PMC26635370_949,7645,of,O
PMC26635370_949,7645,diabetic,O
PMC26635370_949,7645,peripheral,O
PMC26635370_949,7645,neuropathic,O
PMC26635370_949,7645,pain,O
PMC26635370_949,7645,0,O
PMC26635480_102,7646,CONCLUSION,O
PMC26635480_102,7646,:,O
PMC26635480_102,7646,In,O
PMC26635480_102,7646,this,O
PMC26635480_102,7646,study,O
PMC26635480_102,7646,",",O
PMC26635480_102,7646,IM,O
PMC26635480_102,7646,ziprasidone,B-Drug
PMC26635480_102,7646,appeared,O
PMC26635480_102,7646,effective,O
PMC26635480_102,7646,",",O
PMC26635480_102,7646,well,O
PMC26635480_102,7646,tolerated,O
PMC26635480_102,7646,",",O
PMC26635480_102,7646,and,O
PMC26635480_102,7646,similar,O
PMC26635480_102,7646,in,O
PMC26635480_102,7646,clinical,O
PMC26635480_102,7646,profile,O
PMC26635480_102,7646,to,O
PMC26635480_102,7646,combined,O
PMC26635480_102,7646,conventional,O
PMC26635480_102,7646,IM,O
PMC26635480_102,7646,medications,O
PMC26635480_102,7646,for,O
PMC26635480_102,7646,treating,O
PMC26635480_102,7646,severe,O
PMC26635480_102,7646,agitation,B-Symptom
PMC26635480_102,7646,in,O
PMC26635480_102,7646,adolescents,O
PMC26635480_102,7646,0,O
PMC26635480_45,7647,Conventional,O
PMC26635480_45,7647,intramuscular,O
PMC26635480_45,7647,sedatives,O
PMC26635480_45,7647,versus,O
PMC26635480_45,7647,ziprasidone,B-Drug
PMC26635480_45,7647,for,O
PMC26635480_45,7647,severe,O
PMC26635480_45,7647,agitation,B-Symptom
PMC26635480_45,7647,in,O
PMC26635480_45,7647,adolescents,O
PMC26635480_45,7647,:,O
PMC26635480_45,7647,case,O
PMC26635480_45,7647,-,O
PMC26635480_45,7647,control,O
PMC26635480_45,7647,study,O
PMC26635480_45,7647,0,O
PMC26635480_538,7648,No,O
PMC26635480_538,7648,changes,O
PMC26635480_538,7648,in,O
PMC26635480_538,7648,blood,O
PMC26635480_538,7648,pressure,O
PMC26635480_538,7648,were,O
PMC26635480_538,7648,found,O
PMC26635480_538,7648,",",O
PMC26635480_538,7648,but,O
PMC26635480_538,7648,pulse,B-Symptom
PMC26635480_538,7648,decreased,I-Symptom
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,number,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,+,O
PMC26635480_538,7648,/,O
PMC26635480_538,7648,-,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,number,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,for,O
PMC26635480_538,7648,haloperidol,O
PMC26635480_538,7648,with,O
PMC26635480_538,7648,lorazepam,O
PMC26635480_538,7648,and,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,number,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,+,O
PMC26635480_538,7648,/,O
PMC26635480_538,7648,-,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,number,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,_,O
PMC26635480_538,7648,for,O
PMC26635480_538,7648,ziprasidone,B-Drug
PMC26635480_538,7648,(,O
PMC26635480_538,7648,P,O
PMC26635480_538,7648,=,O
PMC26635480_538,7648,NS,O
PMC26635480_538,7648,),O
PMC26635480_538,7648,0,O
PMC26702970_743,7649,METHODS,O
PMC26702970_743,7649,:,O
PMC26702970_743,7649,This,O
PMC26702970_743,7649,was,O
PMC26702970_743,7649,a,O
PMC26702970_743,7649,post,O
PMC26702970_743,7649,-,O
PMC26702970_743,7649,hoc,O
PMC26702970_743,7649,analysis,O
PMC26702970_743,7649,using,O
PMC26702970_743,7649,data,O
PMC26702970_743,7649,from,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,double,O
PMC26702970_743,7649,-,O
PMC26702970_743,7649,blind,O
PMC26702970_743,7649,",",O
PMC26702970_743,7649,randomized,O
PMC26702970_743,7649,",",O
PMC26702970_743,7649,comparative,O
PMC26702970_743,7649,trials,O
PMC26702970_743,7649,of,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,or,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,weeks,O
PMC26702970_743,7649,duration,O
PMC26702970_743,7649,in,O
PMC26702970_743,7649,which,O
PMC26702970_743,7649,olanzapine,O
PMC26702970_743,7649,was,O
PMC26702970_743,7649,compared,O
PMC26702970_743,7649,to,O
PMC26702970_743,7649,risperidone,O
PMC26702970_743,7649,(,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,study,O
PMC26702970_743,7649,;,O
PMC26702970_743,7649,N,O
PMC26702970_743,7649,=,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,),O
PMC26702970_743,7649,",",O
PMC26702970_743,7649,quetiapine,B-Drug
PMC26702970_743,7649,(,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,study,O
PMC26702970_743,7649,;,O
PMC26702970_743,7649,N,O
PMC26702970_743,7649,=,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,),O
PMC26702970_743,7649,",",O
PMC26702970_743,7649,ziprasidone,B-Drug
PMC26702970_743,7649,(,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,studies,O
PMC26702970_743,7649,;,O
PMC26702970_743,7649,N,O
PMC26702970_743,7649,=,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,and,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,),O
PMC26702970_743,7649,or,O
PMC26702970_743,7649,aripiprazole,O
PMC26702970_743,7649,(,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,study,O
PMC26702970_743,7649,;,O
PMC26702970_743,7649,N,O
PMC26702970_743,7649,=,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,number,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,_,O
PMC26702970_743,7649,),O
PMC26702970_743,7649,for,O
PMC26702970_743,7649,treatment,O
PMC26702970_743,7649,of,O
PMC26702970_743,7649,schizophrenia,B-Disease
PMC26702970_743,7649,0,O
PMC26717270_198,7650,Carbamazepine,B-Drug
PMC26717270_198,7650,(,O
PMC26717270_198,7650,CBZ,B-Drug
PMC26717270_198,7650,),O
PMC26717270_198,7650,has,O
PMC26717270_198,7650,long,O
PMC26717270_198,7650,been,O
PMC26717270_198,7650,a,O
PMC26717270_198,7650,therapeutic,O
PMC26717270_198,7650,option,O
PMC26717270_198,7650,for,O
PMC26717270_198,7650,bipolar,B-Disease
PMC26717270_198,7650,disorder,I-Disease
PMC26717270_198,7650,0,O
PMC26719480_678,7651,The,O
PMC26719480_678,7651,serotonin,O
PMC26719480_678,7651,and,O
PMC26719480_678,7651,norepinephrine,O
PMC26719480_678,7651,reuptake,O
PMC26719480_678,7651,inhibitors,O
PMC26719480_678,7651,(,O
PMC26719480_678,7651,SNRIs,O
PMC26719480_678,7651,),O
PMC26719480_678,7651,",",O
PMC26719480_678,7651,duloxetine,B-Drug
PMC26719480_678,7651,and,O
PMC26719480_678,7651,milnacipran,O
PMC26719480_678,7651,",",O
PMC26719480_678,7651,on,O
PMC26719480_678,7651,the,O
PMC26719480_678,7651,other,O
PMC26719480_678,7651,hand,O
PMC26719480_678,7651,",",O
PMC26719480_678,7651,have,O
PMC26719480_678,7651,been,O
PMC26719480_678,7651,shown,O
PMC26719480_678,7651,in,O
PMC26719480_678,7651,placebo,O
PMC26719480_678,7651,-,O
PMC26719480_678,7651,controlled,O
PMC26719480_678,7651,trials,O
PMC26719480_678,7651,to,O
PMC26719480_678,7651,offer,O
PMC26719480_678,7651,significant,O
PMC26719480_678,7651,relief,O
PMC26719480_678,7651,to,O
PMC26719480_678,7651,patients,O
PMC26719480_678,7651,suffering,O
PMC26719480_678,7651,from,O
PMC26719480_678,7651,fibromyalgia,B-Disease
PMC26719480_678,7651,0,O
PMC26719540_555,7652,Psychopharmacology,O
PMC26719540_555,7652,of,O
PMC26719540_555,7652,topiramate,B-Drug
PMC26719540_555,7652,:,O
PMC26719540_555,7652,from,O
PMC26719540_555,7652,epilepsy,B-Disease
PMC26719540_555,7652,to,O
PMC26719540_555,7652,bipolar,B-Disease
PMC26719540_555,7652,disorder,I-Disease
PMC26719540_555,7652,0,O
PMC26719580_650,7653,Dexmethylphenidate,B-Drug
PMC26719580_650,7653,hydrochloride,O
PMC26719580_650,7653,in,O
PMC26719580_650,7653,the,O
PMC26719580_650,7653,treatment,O
PMC26719580_650,7653,of,O
PMC26719580_650,7653,attention,B-Disease
PMC26719580_650,7653,deficit,I-Disease
PMC26719580_650,7653,hyperactivity,I-Disease
PMC26719580_650,7653,disorder,I-Disease
PMC26719580_650,7653,0,O
PMC26797200_925,7654,This,O
PMC26797200_925,7654,study,O
PMC26797200_925,7654,compares,O
PMC26797200_925,7654,the,O
PMC26797200_925,7654,cost,O
PMC26797200_925,7654,-,O
PMC26797200_925,7654,effectiveness,O
PMC26797200_925,7654,of,O
PMC26797200_925,7654,oral,O
PMC26797200_925,7654,olanzapine,B-Drug
PMC26797200_925,7654,",",O
PMC26797200_925,7654,oral,O
PMC26797200_925,7654,risperidone,O
PMC26797200_925,7654,(,O
PMC26797200_925,7654,at,O
PMC26797200_925,7654,generic,O
PMC26797200_925,7654,cost,O
PMC26797200_925,7654,",",O
PMC26797200_925,7654,primary,O
PMC26797200_925,7654,comparator,O
PMC26797200_925,7654,),O
PMC26797200_925,7654,",",O
PMC26797200_925,7654,quetiapine,B-Drug
PMC26797200_925,7654,",",O
PMC26797200_925,7654,ziprasidone,B-Drug
PMC26797200_925,7654,",",O
PMC26797200_925,7654,and,O
PMC26797200_925,7654,aripiprazole,O
PMC26797200_925,7654,in,O
PMC26797200_925,7654,the,O
PMC26797200_925,7654,treatment,O
PMC26797200_925,7654,of,O
PMC26797200_925,7654,patients,O
PMC26797200_925,7654,with,O
PMC26797200_925,7654,schizophrenia,B-Disease
PMC26797200_925,7654,from,O
PMC26797200_925,7654,the,O
PMC26797200_925,7654,perspective,O
PMC26797200_925,7654,of,O
PMC26797200_925,7654,third,O
PMC26797200_925,7654,-,O
PMC26797200_925,7654,party,O
PMC26797200_925,7654,payers,O
PMC26797200_925,7654,in,O
PMC26797200_925,7654,the,O
PMC26797200_925,7654,U,O
PMC26797200_925,7654,0,O
PMC26797200_925,7655,S,O
PMC26797200_925,7655,0,O
PMC26797200_925,7656,health,O
PMC26797200_925,7656,care,O
PMC26797200_925,7656,system,O
PMC26797200_925,7656,0,O
PMC26852220_95,7657,In,O
PMC26852220_95,7657,this,O
PMC26852220_95,7657,review,O
PMC26852220_95,7657,we,O
PMC26852220_95,7657,explore,O
PMC26852220_95,7657,the,O
PMC26852220_95,7657,pharmacology,O
PMC26852220_95,7657,of,O
PMC26852220_95,7657,duloxetine,B-Drug
PMC26852220_95,7657,in,O
PMC26852220_95,7657,the,O
PMC26852220_95,7657,nervous,O
PMC26852220_95,7657,system,O
PMC26852220_95,7657,and,O
PMC26852220_95,7657,lower,O
PMC26852220_95,7657,urinary,O
PMC26852220_95,7657,tract,O
PMC26852220_95,7657,",",O
PMC26852220_95,7657,and,O
PMC26852220_95,7657,the,O
PMC26852220_95,7657,evidence,O
PMC26852220_95,7657,for,O
PMC26852220_95,7657,its,O
PMC26852220_95,7657,use,O
PMC26852220_95,7657,in,O
PMC26852220_95,7657,the,O
PMC26852220_95,7657,management,O
PMC26852220_95,7657,of,O
PMC26852220_95,7657,women,O
PMC26852220_95,7657,with,O
PMC26852220_95,7657,urinary,O
PMC26852220_95,7657,incontinence,O
PMC26852220_95,7657,0,O
PMC26858050_620,7658,BACKGROUND,O
PMC26858050_620,7658,:,O
PMC26858050_620,7658,We,O
PMC26858050_620,7658,have,O
PMC26858050_620,7658,previously,O
PMC26858050_620,7658,demonstrated,O
PMC26858050_620,7658,the,O
PMC26858050_620,7658,clinical,O
PMC26858050_620,7658,efficacy,O
PMC26858050_620,7658,of,O
PMC26858050_620,7658,montelukast,B-Drug
PMC26858050_620,7658,in,O
PMC26858050_620,7658,a,O
PMC26858050_620,7658,randomized,O
PMC26858050_620,7658,double,O
PMC26858050_620,7658,-,O
PMC26858050_620,7658,blind,O
PMC26858050_620,7658,controlled,O
PMC26858050_620,7658,cross,O
PMC26858050_620,7658,-,O
PMC26858050_620,7658,over,O
PMC26858050_620,7658,trial,O
PMC26858050_620,7658,in,O
PMC26858050_620,7658,patients,O
PMC26858050_620,7658,with,O
PMC26858050_620,7658,dyspepsia,B-Symptom
PMC26858050_620,7658,in,O
PMC26858050_620,7658,association,O
PMC26858050_620,7658,with,O
PMC26858050_620,7658,duodenal,B-Symptom
PMC26858050_620,7658,eosinophilia,I-Symptom
PMC26858050_620,7658,0,O
PMC26868470_715,7659,Neurotoxic,O
PMC26868470_715,7659,syndrome,O
PMC26868470_715,7659,developed,O
PMC26868470_715,7659,after,O
PMC26868470_715,7659,taking,O
PMC26868470_715,7659,sertraline,B-Drug
PMC26868470_715,7659,and,O
PMC26868470_715,7659,risperidone,O
PMC26868470_715,7659,0,O
PMC26868570_39,7660,A,O
PMC26868570_39,7660,case,O
PMC26868570_39,7660,of,O
PMC26868570_39,7660,lamotrigine,B-Drug
PMC26868570_39,7660,-,O
PMC26868570_39,7660,induced,O
PMC26868570_39,7660,excessive,O
PMC26868570_39,7660,involuntary,O
PMC26868570_39,7660,eye,B-Symptom
PMC26868570_39,7660,blinking,I-Symptom
PMC26868570_39,7660,0,O
PMC26869350_27,7661,BACKGROUND,O
PMC26869350_27,7661,AND,O
PMC26869350_27,7661,PURPOSE,O
PMC26869350_27,7661,:,O
PMC26869350_27,7661,This,O
PMC26869350_27,7661,study,O
PMC26869350_27,7661,compared,O
PMC26869350_27,7661,the,O
PMC26869350_27,7661,cognitive,O
PMC26869350_27,7661,effects,O
PMC26869350_27,7661,of,O
PMC26869350_27,7661,_,O
PMC26869350_27,7661,_,O
PMC26869350_27,7661,number,O
PMC26869350_27,7661,_,O
PMC26869350_27,7661,_,O
PMC26869350_27,7661,year,O
PMC26869350_27,7661,of,O
PMC26869350_27,7661,treatment,O
PMC26869350_27,7661,with,O
PMC26869350_27,7661,lamotrigine,B-Drug
PMC26869350_27,7661,(,O
PMC26869350_27,7661,LTG,O
PMC26869350_27,7661,),O
PMC26869350_27,7661,and,O
PMC26869350_27,7661,oxcarbazepine,O
PMC26869350_27,7661,(,O
PMC26869350_27,7661,OXC,O
PMC26869350_27,7661,),O
PMC26869350_27,7661,in,O
PMC26869350_27,7661,epilepsy,B-Disease
PMC26869350_27,7661,patients,O
PMC26869350_27,7661,0,O
PMC26879280_387,7662,Topiramate,B-Drug
PMC26879280_387,7662,induced,O
PMC26879280_387,7662,acute,O
PMC26879280_387,7662,angle,O
PMC26879280_387,7662,closure,O
PMC26879280_387,7662,glaucoma,O
PMC26879280_387,7662,0,O
PMC26898600_865,7663,Pharmacological,O
PMC26898600_865,7663,therapy,O
PMC26898600_865,7663,consists,O
PMC26898600_865,7663,of,O
PMC26898600_865,7663,the,O
PMC26898600_865,7663,recommended,O
PMC26898600_865,7663,pharmacological,O
PMC26898600_865,7663,treatment,O
PMC26898600_865,7663,for,O
PMC26898600_865,7663,fibromyalgia,B-Disease
PMC26898600_865,7663,:,O
PMC26898600_865,7663,pregabalin,O
PMC26898600_865,7663,(,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,number,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,mg,O
PMC26898600_865,7663,/,O
PMC26898600_865,7663,day,O
PMC26898600_865,7663,),O
PMC26898600_865,7663,",",O
PMC26898600_865,7663,with,O
PMC26898600_865,7663,duloxetine,B-Drug
PMC26898600_865,7663,(,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,number,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,_,O
PMC26898600_865,7663,mg,O
PMC26898600_865,7663,/,O
PMC26898600_865,7663,day,O
PMC26898600_865,7663,),O
PMC26898600_865,7663,added,O
PMC26898600_865,7663,where,O
PMC26898600_865,7663,there,O
PMC26898600_865,7663,is,O
PMC26898600_865,7663,a,O
PMC26898600_865,7663,comorbid,O
PMC26898600_865,7663,depression,B-Disease
PMC26898600_865,7663,),O
PMC26898600_865,7663,0,O
PMC26904910_110,7664,In,O
PMC26904910_110,7664,summary,O
PMC26904910_110,7664,",",O
PMC26904910_110,7664,comparative,O
PMC26904910_110,7664,proteomics,O
PMC26904910_110,7664,performed,O
PMC26904910_110,7664,on,O
PMC26904910_110,7664,laser,O
PMC26904910_110,7664,capture,O
PMC26904910_110,7664,microdissection,O
PMC26904910_110,7664,-,O
PMC26904910_110,7664,derived,O
PMC26904910_110,7664,breast,O
PMC26904910_110,7664,tumor,O
PMC26904910_110,7664,cells,O
PMC26904910_110,7664,using,O
PMC26904910_110,7664,nano,O
PMC26904910_110,7664,-,O
PMC26904910_110,7664,LC,O
PMC26904910_110,7664,-,O
PMC26904910_110,7664,FTICR,O
PMC26904910_110,7664,MS,O
PMC26904910_110,7664,technology,O
PMC26904910_110,7664,revealed,O
PMC26904910_110,7664,a,O
PMC26904910_110,7664,set,O
PMC26904910_110,7664,of,O
PMC26904910_110,7664,putative,O
PMC26904910_110,7664,biomarkers,O
PMC26904910_110,7664,associated,O
PMC26904910_110,7664,with,O
PMC26904910_110,7664,tamoxifen,B-Drug
PMC26904910_110,7664,therapy,O
PMC26904910_110,7664,resistance,O
PMC26904910_110,7664,in,O
PMC26904910_110,7664,recurrent,O
PMC26904910_110,7664,breast,B-Disease
PMC26904910_110,7664,cancer,I-Disease
PMC26904910_110,7664,0,O
PMC26931170_381,7665,To,O
PMC26931170_381,7665,date,O
PMC26931170_381,7665,",",O
PMC26931170_381,7665,however,O
PMC26931170_381,7665,",",O
PMC26931170_381,7665,there,O
PMC26931170_381,7665,is,O
PMC26931170_381,7665,no,O
PMC26931170_381,7665,information,O
PMC26931170_381,7665,available,O
PMC26931170_381,7665,regarding,O
PMC26931170_381,7665,the,O
PMC26931170_381,7665,antiulcer,B-Symptom
PMC26931170_381,7665,activity,I-Symptom
PMC26931170_381,7665,for,O
PMC26931170_381,7665,a,O
PMC26931170_381,7665,similar,O
PMC26931170_381,7665,antidepressant,O
PMC26931170_381,7665,",",O
PMC26931170_381,7665,fluvoxamine,B-Drug
PMC26931170_381,7665,0,O
PMC26940250_67,7666,The,O
PMC26940250_67,7666,patient,O
PMC26940250_67,7666,was,O
PMC26940250_67,7666,treated,O
PMC26940250_67,7666,with,O
PMC26940250_67,7666,topical,O
PMC26940250_67,7666,prednisolone,O
PMC26940250_67,7666,acetate,O
PMC26940250_67,7666,_,O
PMC26940250_67,7666,_,O
PMC26940250_67,7666,number,O
PMC26940250_67,7666,_,O
PMC26940250_67,7666,_,O
PMC26940250_67,7666,%,O
PMC26940250_67,7666,and,O
PMC26940250_67,7666,oral,O
PMC26940250_67,7666,prednisone,B-Drug
PMC26940250_67,7666,with,O
PMC26940250_67,7666,marked,O
PMC26940250_67,7666,improvement,O
PMC26940250_67,7666,in,O
PMC26940250_67,7666,inflammation,B-Symptom
PMC26940250_67,7666,0,O
PMC26945980_977,7667,METHODS,O
PMC26945980_977,7667,:,O
PMC26945980_977,7667,This,O
PMC26945980_977,7667,retrospective,O
PMC26945980_977,7667,consecutive,O
PMC26945980_977,7667,non,O
PMC26945980_977,7667,-,O
PMC26945980_977,7667,comparative,O
PMC26945980_977,7667,case,O
PMC26945980_977,7667,series,O
PMC26945980_977,7667,study,O
PMC26945980_977,7667,included,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,number,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,patients,O
PMC26945980_977,7667,(,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,number,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,eyes,O
PMC26945980_977,7667,),O
PMC26945980_977,7667,(,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,number,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,male,O
PMC26945980_977,7667,",",O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,number,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,female,O
PMC26945980_977,7667,",",O
PMC26945980_977,7667,mean,O
PMC26945980_977,7667,age,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,number,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,_,O
PMC26945980_977,7667,0,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,number,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,;,O
PMC26945980_977,7668,range,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,number,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,-,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,number,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,years,O
PMC26945980_977,7668,),O
PMC26945980_977,7668,with,O
PMC26945980_977,7668,progressive,O
PMC26945980_977,7668,exudative,O
PMC26945980_977,7668,ARMD,O
PMC26945980_977,7668,(,O
PMC26945980_977,7668,n,O
PMC26945980_977,7668,=,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,number,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,eyes,O
PMC26945980_977,7668,),O
PMC26945980_977,7668,or,O
PMC26945980_977,7668,diffuse,O
PMC26945980_977,7668,diabetic,O
PMC26945980_977,7668,macular,O
PMC26945980_977,7668,oedema,O
PMC26945980_977,7668,(,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,number,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,eyes,O
PMC26945980_977,7668,),O
PMC26945980_977,7668,",",O
PMC26945980_977,7668,who,O
PMC26945980_977,7668,received,O
PMC26945980_977,7668,one,O
PMC26945980_977,7668,or,O
PMC26945980_977,7668,more,O
PMC26945980_977,7668,intravitreal,O
PMC26945980_977,7668,injection,O
PMC26945980_977,7668,(,O
PMC26945980_977,7668,s,O
PMC26945980_977,7668,),O
PMC26945980_977,7668,of,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,number,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,_,O
PMC26945980_977,7668,mg,O
PMC26945980_977,7668,triamcinolone,B-Drug
PMC26945980_977,7668,acetonide,O
PMC26945980_977,7668,0,O
PMC26952130_730,7669,Differential,O
PMC26952130_730,7669,clinical,O
PMC26952130_730,7669,effects,O
PMC26952130_730,7669,of,O
PMC26952130_730,7669,fluvoxamine,B-Drug
PMC26952130_730,7669,by,O
PMC26952130_730,7669,the,O
PMC26952130_730,7669,effect,O
PMC26952130_730,7669,of,O
PMC26952130_730,7669,age,O
PMC26952130_730,7669,in,O
PMC26952130_730,7669,Japanese,O
PMC26952130_730,7669,female,O
PMC26952130_730,7669,major,B-Disease
PMC26952130_730,7669,depressive,I-Disease
PMC26952130_730,7669,patients,O
PMC26952130_730,7669,0,O
PMC26952210_769,7670,Risperidone,O
PMC26952210_769,7670,has,O
PMC26952210_769,7670,higher,O
PMC26952210_769,7670,antipsychotic,O
PMC26952210_769,7670,efficacy,O
PMC26952210_769,7670,and,O
PMC26952210_769,7670,tolerability,O
PMC26952210_769,7670,compared,O
PMC26952210_769,7670,with,O
PMC26952210_769,7670,haloperidol,O
PMC26952210_769,7670,-,O
PMC26952210_769,7670,sertraline,B-Drug
PMC26952210_769,7670,combination,O
PMC26952210_769,7670,for,O
PMC26952210_769,7670,the,O
PMC26952210_769,7670,acute,O
PMC26952210_769,7670,treatment,O
PMC26952210_769,7670,of,O
PMC26952210_769,7670,schizoaffective,B-Disease
PMC26952210_769,7670,disorder,I-Disease
PMC26952210_769,7670,",",O
PMC26952210_769,7670,depressed,B-Disease
PMC26952210_769,7670,type,O
PMC26952210_769,7670,0,O
PMC26952260_236,7671,A,O
PMC26952260_236,7671,literature,O
PMC26952260_236,7671,search,O
PMC26952260_236,7671,performed,O
PMC26952260_236,7671,using,O
PMC26952260_236,7671,PubMed,O
PMC26952260_236,7671,with,O
PMC26952260_236,7671,the,O
PMC26952260_236,7671,keywords,O
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,duloxetine,B-Drug
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,",",O
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,gad,O
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,",",O
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,generalized,B-Disease
PMC26952260_236,7671,anxiety,I-Disease
PMC26952260_236,7671,disorder,I-Disease
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,",",O
PMC26952260_236,7671,and,O
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,venlafaxine,B-Drug
PMC26952260_236,7671,XR,O
PMC26952260_236,7671,"""",O
PMC26952260_236,7671,yielded,O
PMC26952260_236,7671,_,O
PMC26952260_236,7671,_,O
PMC26952260_236,7671,number,O
PMC26952260_236,7671,_,O
PMC26952260_236,7671,_,O
PMC26952260_236,7671,articles,O
PMC26952260_236,7671,0,O
PMC26989020_988,7672,This,O
PMC26989020_988,7672,_,O
PMC26989020_988,7672,_,O
PMC26989020_988,7672,number,O
PMC26989020_988,7672,_,O
PMC26989020_988,7672,_,O
PMC26989020_988,7672,-,O
PMC26989020_988,7672,week,O
PMC26989020_988,7672,randomized,O
PMC26989020_988,7672,",",O
PMC26989020_988,7672,double,O
PMC26989020_988,7672,-,O
PMC26989020_988,7672,blind,O
PMC26989020_988,7672,",",O
PMC26989020_988,7672,placebo,O
PMC26989020_988,7672,-,O
PMC26989020_988,7672,controlled,O
PMC26989020_988,7672,clinical,O
PMC26989020_988,7672,trial,O
PMC26989020_988,7672,will,O
PMC26989020_988,7672,compare,O
PMC26989020_988,7672,the,O
PMC26989020_988,7672,efficacy,O
PMC26989020_988,7672,of,O
PMC26989020_988,7672,topiramate,B-Drug
PMC26989020_988,7672,with,O
PMC26989020_988,7672,placebo,O
PMC26989020_988,7672,and,O
PMC26989020_988,7672,study,O
PMC26989020_988,7672,the,O
PMC26989020_988,7672,tolerability,O
PMC26989020_988,7672,of,O
PMC26989020_988,7672,topiramate,B-Drug
PMC26989020_988,7672,in,O
PMC26989020_988,7672,the,O
PMC26989020_988,7672,treatment,O
PMC26989020_988,7672,of,O
PMC26989020_988,7672,PTSD,B-Disease
PMC26989020_988,7672,0,O
PMC26995400_426,7673,We,O
PMC26995400_426,7673,therefore,O
PMC26995400_426,7673,assessed,O
PMC26995400_426,7673,the,O
PMC26995400_426,7673,effects,O
PMC26995400_426,7673,of,O
PMC26995400_426,7673,commonly,O
PMC26995400_426,7673,-,O
PMC26995400_426,7673,prescribed,O
PMC26995400_426,7673,medications,O
PMC26995400_426,7673,for,O
PMC26995400_426,7673,the,O
PMC26995400_426,7673,treatment,O
PMC26995400_426,7673,of,O
PMC26995400_426,7673,insomnia,B-Symptom
PMC26995400_426,7673,(,O
PMC26995400_426,7673,trazodone,B-Drug
PMC26995400_426,7673,and,O
PMC26995400_426,7673,the,O
PMC26995400_426,7673,non,O
PMC26995400_426,7673,-,O
PMC26995400_426,7673,benzodiazepine,O
PMC26995400_426,7673,GABA,O
PMC26995400_426,7673,(,O
PMC26995400_426,7673,A,O
PMC26995400_426,7673,),O
PMC26995400_426,7673,receptor,O
PMC26995400_426,7673,agonists,O
PMC26995400_426,7673,zaleplon,O
PMC26995400_426,7673,and,O
PMC26995400_426,7673,eszopiclone,O
PMC26995400_426,7673,),O
PMC26995400_426,7673,in,O
PMC26995400_426,7673,a,O
PMC26995400_426,7673,canonical,O
PMC26995400_426,7673,model,O
PMC26995400_426,7673,of,O
PMC26995400_426,7673,sleep,O
PMC26995400_426,7673,-,O
PMC26995400_426,7673,dependent,O
PMC26995400_426,7673,",",O
PMC26995400_426,7673,in,O
PMC26995400_426,7673,vivo,O
PMC26995400_426,7673,synaptic,O
PMC26995400_426,7673,plasticity,O
PMC26995400_426,7673,in,O
PMC26995400_426,7673,the,O
PMC26995400_426,7673,primary,O
PMC26995400_426,7673,visual,O
PMC26995400_426,7673,cortex,O
PMC26995400_426,7673,(,O
PMC26995400_426,7673,V,O
PMC26995400_426,7673,_,O
PMC26995400_426,7673,_,O
PMC26995400_426,7673,number,O
PMC26995400_426,7673,_,O
PMC26995400_426,7673,_,O
PMC26995400_426,7673,),O
PMC26995400_426,7673,known,O
PMC26995400_426,7673,as,O
PMC26995400_426,7673,ocular,O
PMC26995400_426,7673,dominance,O
PMC26995400_426,7673,plasticity,O
PMC26995400_426,7673,0,O
PMC26996040_848,7674,CONCLUSION,O
PMC26996040_848,7674,:,O
PMC26996040_848,7674,Our,O
PMC26996040_848,7674,results,O
PMC26996040_848,7674,show,O
PMC26996040_848,7674,",",O
PMC26996040_848,7674,for,O
PMC26996040_848,7674,the,O
PMC26996040_848,7674,first,O
PMC26996040_848,7674,time,O
PMC26996040_848,7674,",",O
PMC26996040_848,7674,that,O
PMC26996040_848,7674,d,O
PMC26996040_848,7674,-,O
PMC26996040_848,7674,limonene,O
PMC26996040_848,7674,enhanced,O
PMC26996040_848,7674,the,O
PMC26996040_848,7674,antitumor,O
PMC26996040_848,7674,effect,O
PMC26996040_848,7674,of,O
PMC26996040_848,7674,docetaxel,B-Drug
PMC26996040_848,7674,against,O
PMC26996040_848,7674,prostate,B-Disease
PMC26996040_848,7674,cancer,I-Disease
PMC26996040_848,7674,cells,O
PMC26996040_848,7674,without,O
PMC26996040_848,7674,being,O
PMC26996040_848,7674,toxic,O
PMC26996040_848,7674,to,O
PMC26996040_848,7674,normal,O
PMC26996040_848,7674,prostate,O
PMC26996040_848,7674,epithelial,O
PMC26996040_848,7674,cells,O
PMC26996040_848,7674,0,O
PMC26996550_841,7675,The,O
PMC26996550_841,7675,pharmacodynamic,O
PMC26996550_841,7675,properties,O
PMC26996550_841,7675,of,O
PMC26996550_841,7675,fluvoxamine,B-Drug
PMC26996550_841,7675,maleate,O
PMC26996550_841,7675,include,O
PMC26996550_841,7675,the,O
PMC26996550_841,7675,modulation,O
PMC26996550_841,7675,of,O
PMC26996550_841,7675,different,O
PMC26996550_841,7675,populations,O
PMC26996550_841,7675,of,O
PMC26996550_841,7675,serotonergic,O
PMC26996550_841,7675,",",O
PMC26996550_841,7675,dopaminergic,O
PMC26996550_841,7675,",",O
PMC26996550_841,7675,and,O
PMC26996550_841,7675,sigma,O
PMC26996550_841,7675,receptors,O
PMC26996550_841,7675,and,O
PMC26996550_841,7675,/,O
PMC26996550_841,7675,or,O
PMC26996550_841,7675,transporters,O
PMC26996550_841,7675,",",O
PMC26996550_841,7675,a,O
PMC26996550_841,7675,complex,O
PMC26996550_841,7675,pattern,O
PMC26996550_841,7675,of,O
PMC26996550_841,7675,activity,O
PMC26996550_841,7675,that,O
PMC26996550_841,7675,may,O
PMC26996550_841,7675,account,O
PMC26996550_841,7675,for,O
PMC26996550_841,7675,its,O
PMC26996550_841,7675,efficacy,O
PMC26996550_841,7675,in,O
PMC26996550_841,7675,the,O
PMC26996550_841,7675,treatment,O
PMC26996550_841,7675,of,O
PMC26996550_841,7675,obsessive,B-Disease
PMC26996550_841,7675,-,I-Disease
PMC26996550_841,7675,compulsive,I-Disease
PMC26996550_841,7675,disorder,I-Disease
PMC26996550_841,7675,(,O
PMC26996550_841,7675,OCD,B-Disease
PMC26996550_841,7675,),O
PMC26996550_841,7675,0,O
PMC26996570_175,7676,A,O
PMC26996570_175,7676,randomized,O
PMC26996570_175,7676,controlled,O
PMC26996570_175,7676,trial,O
PMC26996570_175,7676,of,O
PMC26996570_175,7676,quetiapine,B-Drug
PMC26996570_175,7676,for,O
PMC26996570_175,7676,psychosis,B-Symptom
PMC26996570_175,7676,in,O
PMC26996570_175,7676,Parkinson,B-Disease
PMC26996570_175,7676,',I-Disease
PMC26996570_175,7676,s,I-Disease
PMC26996570_175,7676,disease,I-Disease
PMC26996570_175,7676,0,O
PMC27041740_19,7677,TRIAL,O
PMC27041740_19,7677,REGISTRATION,O
PMC27041740_19,7677,:,O
PMC27041740_19,7677,Official,O
PMC27041740_19,7677,Title,O
PMC27041740_19,7677,:,O
PMC27041740_19,7677,A,O
PMC27041740_19,7677,Phase,O
PMC27041740_19,7677,IIb,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Randomized,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Double,O
PMC27041740_19,7677,-,O
PMC27041740_19,7677,Blind,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Multi,O
PMC27041740_19,7677,-,O
PMC27041740_19,7677,Center,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Placebo,O
PMC27041740_19,7677,-,O
PMC27041740_19,7677,Controlled,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Dose,O
PMC27041740_19,7677,-,O
PMC27041740_19,7677,Optimization,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Cross,O
PMC27041740_19,7677,-,O
PMC27041740_19,7677,Over,O
PMC27041740_19,7677,",",O
PMC27041740_19,7677,Analog,O
PMC27041740_19,7677,Classroom,O
PMC27041740_19,7677,Study,O
PMC27041740_19,7677,to,O
PMC27041740_19,7677,Assess,O
PMC27041740_19,7677,the,O
PMC27041740_19,7677,Time,O
PMC27041740_19,7677,of,O
PMC27041740_19,7677,Onset,O
PMC27041740_19,7677,of,O
PMC27041740_19,7677,Vyvanse,B-Drug
PMC27041740_19,7677,(,O
PMC27041740_19,7677,Lisdexamfetamine,B-Drug
PMC27041740_19,7677,Dimesylate,I-Drug
PMC27041740_19,7677,),O
PMC27041740_19,7677,in,O
PMC27041740_19,7677,Pediatric,O
PMC27041740_19,7677,Subjects,O
PMC27041740_19,7677,Aged,O
PMC27041740_19,7677,_,O
PMC27041740_19,7677,_,O
PMC27041740_19,7677,number,O
PMC27041740_19,7677,_,O
PMC27041740_19,7677,_,O
PMC27041740_19,7677,With,O
PMC27041740_19,7677,Attention,B-Disease
PMC27041740_19,7677,-,I-Disease
PMC27041740_19,7677,Deficit,I-Disease
PMC27041740_19,7677,/,I-Disease
PMC27041740_19,7677,Hyperactivity,I-Disease
PMC27041740_19,7677,Disorder,I-Disease
PMC27041740_19,7677,0,O
PMC27041740_359,7678,A,O
PMC27041740_359,7678,_,O
PMC27041740_359,7678,_,O
PMC27041740_359,7678,number,O
PMC27041740_359,7678,_,O
PMC27041740_359,7678,_,O
PMC27041740_359,7678,-,O
PMC27041740_359,7678,hour,O
PMC27041740_359,7678,laboratory,O
PMC27041740_359,7678,school,O
PMC27041740_359,7678,study,O
PMC27041740_359,7678,of,O
PMC27041740_359,7678,lisdexamfetamine,B-Drug
PMC27041740_359,7678,dimesylate,I-Drug
PMC27041740_359,7678,in,O
PMC27041740_359,7678,school,O
PMC27041740_359,7678,-,O
PMC27041740_359,7678,aged,O
PMC27041740_359,7678,children,O
PMC27041740_359,7678,with,O
PMC27041740_359,7678,attention,B-Disease
PMC27041740_359,7678,-,I-Disease
PMC27041740_359,7678,deficit,I-Disease
PMC27041740_359,7678,/,I-Disease
PMC27041740_359,7678,hyperactivity,I-Disease
PMC27041740_359,7678,disorder,I-Disease
PMC27041740_359,7678,0,O
PMC27041740_83,7679,BACKGROUND,O
PMC27041740_83,7679,:,O
PMC27041740_83,7679,Lisdexamfetamine,B-Drug
PMC27041740_83,7679,dimesylate,I-Drug
PMC27041740_83,7679,(,O
PMC27041740_83,7679,LDX,B-Drug
PMC27041740_83,7679,),O
PMC27041740_83,7679,is,O
PMC27041740_83,7679,indicated,O
PMC27041740_83,7679,for,O
PMC27041740_83,7679,the,O
PMC27041740_83,7679,treatment,O
PMC27041740_83,7679,of,O
PMC27041740_83,7679,attention,B-Disease
PMC27041740_83,7679,-,I-Disease
PMC27041740_83,7679,deficit,I-Disease
PMC27041740_83,7679,/,I-Disease
PMC27041740_83,7679,hyperactivity,I-Disease
PMC27041740_83,7679,disorder,I-Disease
PMC27041740_83,7679,(,I-Disease
PMC27041740_83,7679,ADHD,I-Disease
PMC27041740_83,7679,),O
PMC27041740_83,7679,in,O
PMC27041740_83,7679,children,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,number,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,to,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,number,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,_,O
PMC27041740_83,7679,years,O
PMC27041740_83,7679,of,O
PMC27041740_83,7679,age,O
PMC27041740_83,7679,and,O
PMC27041740_83,7679,in,O
PMC27041740_83,7679,adults,O
PMC27041740_83,7679,0,O
PMC27109730_950,7680,RESULTS,O
PMC27109730_950,7680,:,O
PMC27109730_950,7680,After,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,weeks,O
PMC27109730_950,7680,",",O
PMC27109730_950,7680,systolic,B-Symptom
PMC27109730_950,7680,blood,I-Symptom
PMC27109730_950,7680,pressure,I-Symptom
PMC27109730_950,7680,(,O
PMC27109730_950,7680,SBP,O
PMC27109730_950,7680,),O
PMC27109730_950,7680,decreased,O
PMC27109730_950,7680,from,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,+,O
PMC27109730_950,7680,/,O
PMC27109730_950,7680,-,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,to,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,+,O
PMC27109730_950,7680,/,O
PMC27109730_950,7680,-,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,with,O
PMC27109730_950,7680,irbesartan,O
PMC27109730_950,7680,and,O
PMC27109730_950,7680,to,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,+,O
PMC27109730_950,7680,/,O
PMC27109730_950,7680,-,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,number,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,_,O
PMC27109730_950,7680,mmHg,O
PMC27109730_950,7680,with,O
PMC27109730_950,7680,lisinopril,B-Drug
PMC27109730_950,7680,0,O
PMC27142870_127,7681,Given,O
PMC27142870_127,7681,its,O
PMC27142870_127,7681,potential,O
PMC27142870_127,7681,role,O
PMC27142870_127,7681,in,O
PMC27142870_127,7681,stabilizing,O
PMC27142870_127,7681,mood,O
PMC27142870_127,7681,and,O
PMC27142870_127,7681,reducing,O
PMC27142870_127,7681,impulse,O
PMC27142870_127,7681,control,O
PMC27142870_127,7681,problems,O
PMC27142870_127,7681,and,O
PMC27142870_127,7681,weight,O
PMC27142870_127,7681,",",O
PMC27142870_127,7681,topiramate,B-Drug
PMC27142870_127,7681,has,O
PMC27142870_127,7681,been,O
PMC27142870_127,7681,proposed,O
PMC27142870_127,7681,as,O
PMC27142870_127,7681,a,O
PMC27142870_127,7681,treatment,O
PMC27142870_127,7681,for,O
PMC27142870_127,7681,obese,O
PMC27142870_127,7681,patients,O
PMC27142870_127,7681,with,O
PMC27142870_127,7681,binge,O
PMC27142870_127,7681,eating,O
PMC27142870_127,7681,disorder,O
PMC27142870_127,7681,(,O
PMC27142870_127,7681,BED,O
PMC27142870_127,7681,),O
PMC27142870_127,7681,0,O
PMC27154020_1036,7682,METHODS,O
PMC27154020_1036,7682,/,O
PMC27154020_1036,7682,DESIGN,O
PMC27154020_1036,7682,:,O
PMC27154020_1036,7682,This,O
PMC27154020_1036,7682,study,O
PMC27154020_1036,7682,uses,O
PMC27154020_1036,7682,randomised,O
PMC27154020_1036,7682,controlled,O
PMC27154020_1036,7682,trial,O
PMC27154020_1036,7682,methodology,O
PMC27154020_1036,7682,to,O
PMC27154020_1036,7682,compare,O
PMC27154020_1036,7682,the,O
PMC27154020_1036,7682,open,O
PMC27154020_1036,7682,use,O
PMC27154020_1036,7682,of,O
PMC27154020_1036,7682,buprenorphine,B-Drug
PMC27154020_1036,7682,and,O
PMC27154020_1036,7682,methadone,O
PMC27154020_1036,7682,for,O
PMC27154020_1036,7682,opiate,B-Symptom
PMC27154020_1036,7682,detoxification,I-Symptom
PMC27154020_1036,7682,",",O
PMC27154020_1036,7682,given,O
PMC27154020_1036,7682,in,O
PMC27154020_1036,7682,the,O
PMC27154020_1036,7682,context,O
PMC27154020_1036,7682,of,O
PMC27154020_1036,7682,routine,O
PMC27154020_1036,7682,care,O
PMC27154020_1036,7682,",",O
PMC27154020_1036,7682,within,O
PMC27154020_1036,7682,three,O
PMC27154020_1036,7682,UK,O
PMC27154020_1036,7682,prisons,O
PMC27154020_1036,7682,0,O
PMC27165030_348,7683,METHODS,O
PMC27165030_348,7683,:,O
PMC27165030_348,7683,In,O
PMC27165030_348,7683,this,O
PMC27165030_348,7683,open,O
PMC27165030_348,7683,-,O
PMC27165030_348,7683,label,O
PMC27165030_348,7683,",",O
PMC27165030_348,7683,randomized,O
PMC27165030_348,7683,",",O
PMC27165030_348,7683,parallel,O
PMC27165030_348,7683,-,O
PMC27165030_348,7683,group,O
PMC27165030_348,7683,study,O
PMC27165030_348,7683,",",O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,postmenopausal,O
PMC27165030_348,7683,patients,O
PMC27165030_348,7683,with,O
PMC27165030_348,7683,operable,O
PMC27165030_348,7683,breast,B-Disease
PMC27165030_348,7683,cancer,I-Disease
PMC27165030_348,7683,",",O
PMC27165030_348,7683,who,O
PMC27165030_348,7683,had,O
PMC27165030_348,7683,been,O
PMC27165030_348,7683,treated,O
PMC27165030_348,7683,with,O
PMC27165030_348,7683,tamoxifen,B-Drug
PMC27165030_348,7683,for,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,to,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,years,O
PMC27165030_348,7683,",",O
PMC27165030_348,7683,were,O
PMC27165030_348,7683,randomized,O
PMC27165030_348,7683,to,O
PMC27165030_348,7683,either,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,additional,O
PMC27165030_348,7683,years,O
PMC27165030_348,7683,of,O
PMC27165030_348,7683,exemestane,O
PMC27165030_348,7683,(,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,mg,O
PMC27165030_348,7683,/,O
PMC27165030_348,7683,day,O
PMC27165030_348,7683,;,O
PMC27165030_348,7683,n,O
PMC27165030_348,7683,=,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,),O
PMC27165030_348,7683,or,O
PMC27165030_348,7683,observation,O
PMC27165030_348,7683,only,O
PMC27165030_348,7683,(,O
PMC27165030_348,7683,n,O
PMC27165030_348,7683,=,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,number,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,_,O
PMC27165030_348,7683,),O
PMC27165030_348,7683,0,O
PMC27196520_560,7684,BACKGROUND,O
PMC27196520_560,7684,:,O
PMC27196520_560,7684,There,O
PMC27196520_560,7684,is,O
PMC27196520_560,7684,substantial,O
PMC27196520_560,7684,evidence,O
PMC27196520_560,7684,that,O
PMC27196520_560,7684,methylphenidate,B-Drug
PMC27196520_560,7684,(,O
PMC27196520_560,7684,MPH,O
PMC27196520_560,7684,;,O
PMC27196520_560,7684,Ritalin,B-Drug
PMC27196520_560,7684,),O
PMC27196520_560,7684,",",O
PMC27196520_560,7684,is,O
PMC27196520_560,7684,being,O
PMC27196520_560,7684,used,O
PMC27196520_560,7684,by,O
PMC27196520_560,7684,healthy,O
PMC27196520_560,7684,university,O
PMC27196520_560,7684,students,O
PMC27196520_560,7684,for,O
PMC27196520_560,7684,non,O
PMC27196520_560,7684,-,O
PMC27196520_560,7684,medical,O
PMC27196520_560,7684,motives,O
PMC27196520_560,7684,such,O
PMC27196520_560,7684,as,O
PMC27196520_560,7684,the,O
PMC27196520_560,7684,improvement,B-Symptom
PMC27196520_560,7684,of,I-Symptom
PMC27196520_560,7684,concentration,I-Symptom
PMC27196520_560,7684,",",O
PMC27196520_560,7684,alertness,B-Symptom
PMC27196520_560,7684,",",O
PMC27196520_560,7684,and,O
PMC27196520_560,7684,academic,O
PMC27196520_560,7684,performance,O
PMC27196520_560,7684,0,O
PMC27211390_1007,7685,The,O
PMC27211390_1007,7685,data,O
PMC27211390_1007,7685,provided,O
PMC27211390_1007,7685,here,O
PMC27211390_1007,7685,summarize,O
PMC27211390_1007,7685,short,O
PMC27211390_1007,7685,-,O
PMC27211390_1007,7685,and,O
PMC27211390_1007,7685,long,O
PMC27211390_1007,7685,-,O
PMC27211390_1007,7685,term,O
PMC27211390_1007,7685,safety,O
PMC27211390_1007,7685,from,O
PMC27211390_1007,7685,five,O
PMC27211390_1007,7685,clinical,O
PMC27211390_1007,7685,studies,O
PMC27211390_1007,7685,in,O
PMC27211390_1007,7685,patients,O
PMC27211390_1007,7685,treated,O
PMC27211390_1007,7685,with,O
PMC27211390_1007,7685,duloxetine,B-Drug
PMC27211390_1007,7685,for,O
PMC27211390_1007,7685,fibromyalgia,B-Disease
PMC27211390_1007,7685,0,O
PMC27211390_709,7686,The,O
PMC27211390_709,7686,purpose,O
PMC27211390_709,7686,of,O
PMC27211390_709,7686,this,O
PMC27211390_709,7686,report,O
PMC27211390_709,7686,is,O
PMC27211390_709,7686,to,O
PMC27211390_709,7686,describe,O
PMC27211390_709,7686,the,O
PMC27211390_709,7686,overall,O
PMC27211390_709,7686,safety,O
PMC27211390_709,7686,profile,O
PMC27211390_709,7686,of,O
PMC27211390_709,7686,both,O
PMC27211390_709,7686,short,O
PMC27211390_709,7686,-,O
PMC27211390_709,7686,and,O
PMC27211390_709,7686,longer,O
PMC27211390_709,7686,-,O
PMC27211390_709,7686,term,O
PMC27211390_709,7686,duloxetine,B-Drug
PMC27211390_709,7686,treatment,O
PMC27211390_709,7686,of,O
PMC27211390_709,7686,fibromyalgia,B-Disease
PMC27211390_709,7686,0,O
PMC27299080_845,7687,Drug,O
PMC27299080_845,7687,rash,B-Symptom
PMC27299080_845,7687,with,I-Symptom
PMC27299080_845,7687,eosinophilia,I-Symptom
PMC27299080_845,7687,and,I-Symptom
PMC27299080_845,7687,systemic,I-Symptom
PMC27299080_845,7687,symptoms,I-Symptom
PMC27299080_845,7687,(,B-Symptom
PMC27299080_845,7687,DRESS,I-Symptom
PMC27299080_845,7687,),I-Symptom
PMC27299080_845,7687,syndrome,I-Symptom
PMC27299080_845,7687,associated,O
PMC27299080_845,7687,with,O
PMC27299080_845,7687,anticonvulsant,O
PMC27299080_845,7687,drugs,O
PMC27299080_845,7687,is,O
PMC27299080_845,7687,a,O
PMC27299080_845,7687,rare,O
PMC27299080_845,7687,but,O
PMC27299080_845,7687,potentially,O
PMC27299080_845,7687,life,O
PMC27299080_845,7687,-,O
PMC27299080_845,7687,threatening,O
PMC27299080_845,7687,disease,O
PMC27299080_845,7687,that,O
PMC27299080_845,7687,occurs,O
PMC27299080_845,7687,in,O
PMC27299080_845,7687,response,O
PMC27299080_845,7687,to,O
PMC27299080_845,7687,arene,O
PMC27299080_845,7687,oxide,O
PMC27299080_845,7687,producing,O
PMC27299080_845,7687,anticonvulsant,O
PMC27299080_845,7687,such,O
PMC27299080_845,7687,as,O
PMC27299080_845,7687,phenytoin,O
PMC27299080_845,7687,and,O
PMC27299080_845,7687,carbamazepine,B-Drug
PMC27299080_845,7687,0,O
PMC27299080_901,7688,However,O
PMC27299080_901,7688,",",O
PMC27299080_901,7688,there,O
PMC27299080_901,7688,has,O
PMC27299080_901,7688,been,O
PMC27299080_901,7688,few,O
PMC27299080_901,7688,data,O
PMC27299080_901,7688,describing,O
PMC27299080_901,7688,the,O
PMC27299080_901,7688,development,O
PMC27299080_901,7688,of,O
PMC27299080_901,7688,DRESS,B-Symptom
PMC27299080_901,7688,syndrome,I-Symptom
PMC27299080_901,7688,after,O
PMC27299080_901,7688,switching,O
PMC27299080_901,7688,medication,O
PMC27299080_901,7688,from,O
PMC27299080_901,7688,previously,O
PMC27299080_901,7688,well,O
PMC27299080_901,7688,-,O
PMC27299080_901,7688,tolerated,O
PMC27299080_901,7688,phenytoin,O
PMC27299080_901,7688,to,O
PMC27299080_901,7688,carbamazepine,B-Drug
PMC27299080_901,7688,",",O
PMC27299080_901,7688,and,O
PMC27299080_901,7688,the,O
PMC27299080_901,7688,induction,O
PMC27299080_901,7688,of,O
PMC27299080_901,7688,hypersensitivity,O
PMC27299080_901,7688,to,O
PMC27299080_901,7688,phenytoin,O
PMC27299080_901,7688,by,O
PMC27299080_901,7688,DRESS,B-Symptom
PMC27299080_901,7688,to,O
PMC27299080_901,7688,carbamazepine,B-Drug
PMC27299080_901,7688,0,O
PMC27310360_441,7689,Complete,O
PMC27310360_441,7689,pathological,O
PMC27310360_441,7689,response,O
PMC27310360_441,7689,in,O
PMC27310360_441,7689,a,O
PMC27310360_441,7689,patient,O
PMC27310360_441,7689,with,O
PMC27310360_441,7689,multiple,O
PMC27310360_441,7689,liver,O
PMC27310360_441,7689,metastases,O
PMC27310360_441,7689,from,O
PMC27310360_441,7689,colon,B-Disease
PMC27310360_441,7689,cancer,I-Disease
PMC27310360_441,7689,treated,O
PMC27310360_441,7689,with,O
PMC27310360_441,7689,Folfox,O
PMC27310360_441,7689,_,O
PMC27310360_441,7689,_,O
PMC27310360_441,7689,number,O
PMC27310360_441,7689,_,O
PMC27310360_441,7689,_,O
PMC27310360_441,7689,chemotherapy,O
PMC27310360_441,7689,plus,O
PMC27310360_441,7689,bevacizumab,B-Drug
PMC27310360_441,7689,:,O
PMC27310360_441,7689,a,O
PMC27310360_441,7689,case,O
PMC27310360_441,7689,report,O
PMC27310360_441,7689,0,O
PMC27317510_547,7690,Rationale,O
PMC27317510_547,7690,and,O
PMC27317510_547,7690,design,O
PMC27317510_547,7690,of,O
PMC27317510_547,7690,the,O
PMC27317510_547,7690,participant,O
PMC27317510_547,7690,",",O
PMC27317510_547,7690,investigator,O
PMC27317510_547,7690,",",O
PMC27317510_547,7690,observer,O
PMC27317510_547,7690,",",O
PMC27317510_547,7690,and,O
PMC27317510_547,7690,data,O
PMC27317510_547,7690,-,O
PMC27317510_547,7690,analyst,O
PMC27317510_547,7690,-,O
PMC27317510_547,7690,blinded,O
PMC27317510_547,7690,randomized,O
PMC27317510_547,7690,AGENDA,O
PMC27317510_547,7690,trial,O
PMC27317510_547,7690,on,O
PMC27317510_547,7690,associations,O
PMC27317510_547,7690,between,O
PMC27317510_547,7690,gene,O
PMC27317510_547,7690,-,O
PMC27317510_547,7690,polymorphisms,O
PMC27317510_547,7690,",",O
PMC27317510_547,7690,endophenotypes,O
PMC27317510_547,7690,for,O
PMC27317510_547,7690,depression,O
PMC27317510_547,7690,and,O
PMC27317510_547,7690,antidepressive,O
PMC27317510_547,7690,intervention,O
PMC27317510_547,7690,:,O
PMC27317510_547,7690,the,O
PMC27317510_547,7690,effect,O
PMC27317510_547,7690,of,O
PMC27317510_547,7690,escitalopram,O
PMC27317510_547,7690,versus,O
PMC27317510_547,7690,placebo,O
PMC27317510_547,7690,on,O
PMC27317510_547,7690,the,O
PMC27317510_547,7690,combined,O
PMC27317510_547,7690,dexamethasone,O
PMC27317510_547,7690,-,O
PMC27317510_547,7690,corticotrophine,O
PMC27317510_547,7690,releasing,O
PMC27317510_547,7690,hormone,O
PMC27317510_547,7690,test,O
PMC27317510_547,7690,and,O
PMC27317510_547,7690,other,O
PMC27317510_547,7690,potential,O
PMC27317510_547,7690,endophenotypes,O
PMC27317510_547,7690,in,O
PMC27317510_547,7690,healthy,O
PMC27317510_547,7690,first,O
PMC27317510_547,7690,-,O
PMC27317510_547,7690,degree,O
PMC27317510_547,7690,relatives,O
PMC27317510_547,7690,of,O
PMC27317510_547,7690,persons,O
PMC27317510_547,7690,with,O
PMC27317510_547,7690,depression,B-Disease
PMC27317510_547,7690,0,O
PMC27320090_173,7691,Methylphenidate,B-Drug
PMC27320090_173,7691,hydrochloride,O
PMC27320090_173,7691,",",O
PMC27320090_173,7691,a,O
PMC27320090_173,7691,stimulant,O
PMC27320090_173,7691,that,O
PMC27320090_173,7691,acts,O
PMC27320090_173,7691,through,O
PMC27320090_173,7691,the,O
PMC27320090_173,7691,dopaminergic,O
PMC27320090_173,7691,and,O
PMC27320090_173,7691,adrenergic,O
PMC27320090_173,7691,pathways,O
PMC27320090_173,7691,",",O
PMC27320090_173,7691,has,O
PMC27320090_173,7691,shown,O
PMC27320090_173,7691,more,O
PMC27320090_173,7691,than,O
PMC27320090_173,7691,_,O
PMC27320090_173,7691,_,O
PMC27320090_173,7691,number,O
PMC27320090_173,7691,_,O
PMC27320090_173,7691,_,O
PMC27320090_173,7691,%,O
PMC27320090_173,7691,efficacy,O
PMC27320090_173,7691,in,O
PMC27320090_173,7691,controlling,O
PMC27320090_173,7691,the,O
PMC27320090_173,7691,symptoms,O
PMC27320090_173,7691,of,O
PMC27320090_173,7691,adult,O
PMC27320090_173,7691,ADHD,B-Disease
PMC27320090_173,7691,0,O
PMC27320090_371,7692,Management,O
PMC27320090_371,7692,of,O
PMC27320090_371,7692,attention,B-Disease
PMC27320090_371,7692,-,I-Disease
PMC27320090_371,7692,deficit,I-Disease
PMC27320090_371,7692,hyperactivity,I-Disease
PMC27320090_371,7692,disorder,I-Disease
PMC27320090_371,7692,in,O
PMC27320090_371,7692,adults,O
PMC27320090_371,7692,:,O
PMC27320090_371,7692,focus,O
PMC27320090_371,7692,on,O
PMC27320090_371,7692,methylphenidate,B-Drug
PMC27320090_371,7692,hydrochloride,I-Drug
PMC27320090_371,7692,0,O
PMC27320930_146,7693,Asthma,B-Disease
PMC27320930_146,7693,control,O
PMC27320930_146,7693,and,O
PMC27320930_146,7693,patient,O
PMC27320930_146,7693,perception,O
PMC27320930_146,7693,were,O
PMC27320930_146,7693,assessed,O
PMC27320930_146,7693,prior,O
PMC27320930_146,7693,to,O
PMC27320930_146,7693,",",O
PMC27320930_146,7693,and,O
PMC27320930_146,7693,_,O
PMC27320930_146,7693,_,O
PMC27320930_146,7693,number,O
PMC27320930_146,7693,_,O
PMC27320930_146,7693,_,O
PMC27320930_146,7693,weeks,O
PMC27320930_146,7693,after,O
PMC27320930_146,7693,",",O
PMC27320930_146,7693,the,O
PMC27320930_146,7693,introduction,O
PMC27320930_146,7693,of,O
PMC27320930_146,7693,Montelukast,B-Drug
PMC27320930_146,7693,",",O
PMC27320930_146,7693,and,O
PMC27320930_146,7693,the,O
PMC27320930_146,7693,pre,O
PMC27320930_146,7693,-,O
PMC27320930_146,7693,introduction,O
PMC27320930_146,7693,and,O
PMC27320930_146,7693,post,O
PMC27320930_146,7693,-,O
PMC27320930_146,7693,introduction,O
PMC27320930_146,7693,results,O
PMC27320930_146,7693,were,O
PMC27320930_146,7693,compared,O
PMC27320930_146,7693,0,O
PMC27326260_294,7694,Effect,O
PMC27326260_294,7694,of,O
PMC27326260_294,7694,lisdexamfetamine,B-Drug
PMC27326260_294,7694,dimesylate,I-Drug
PMC27326260_294,7694,on,O
PMC27326260_294,7694,sleep,O
PMC27326260_294,7694,in,O
PMC27326260_294,7694,adults,O
PMC27326260_294,7694,with,O
PMC27326260_294,7694,attention,B-Disease
PMC27326260_294,7694,-,I-Disease
PMC27326260_294,7694,deficit,I-Disease
PMC27326260_294,7694,/,I-Disease
PMC27326260_294,7694,hyperactivity,I-Disease
PMC27326260_294,7694,disorder,I-Disease
PMC27326260_294,7694,0,O
PMC27326260_63,7695,This,O
PMC27326260_63,7695,analysis,O
PMC27326260_63,7695,aimed,O
PMC27326260_63,7695,to,O
PMC27326260_63,7695,evaluate,O
PMC27326260_63,7695,the,O
PMC27326260_63,7695,impact,O
PMC27326260_63,7695,of,O
PMC27326260_63,7695,lisdexamfetamine,B-Drug
PMC27326260_63,7695,dimesylate,I-Drug
PMC27326260_63,7695,(,O
PMC27326260_63,7695,LDX,B-Drug
PMC27326260_63,7695,),O
PMC27326260_63,7695,on,O
PMC27326260_63,7695,sleep,B-Symptom
PMC27326260_63,7695,quality,O
PMC27326260_63,7695,in,O
PMC27326260_63,7695,adults,O
PMC27326260_63,7695,with,O
PMC27326260_63,7695,ADHD,B-Disease
PMC27326260_63,7695,0,O
PMC27383680_683,7696,A,O
PMC27383680_683,7696,comparative,O
PMC27383680_683,7696,study,O
PMC27383680_683,7696,of,O
PMC27383680_683,7696,oxidative,O
PMC27383680_683,7696,stress,O
PMC27383680_683,7696,and,O
PMC27383680_683,7696,interrelationship,O
PMC27383680_683,7696,of,O
PMC27383680_683,7696,important,O
PMC27383680_683,7696,antioxidants,O
PMC27383680_683,7696,in,O
PMC27383680_683,7696,haloperidol,O
PMC27383680_683,7696,and,O
PMC27383680_683,7696,olanzapine,B-Drug
PMC27383680_683,7696,treated,O
PMC27383680_683,7696,patients,O
PMC27383680_683,7696,suffering,O
PMC27383680_683,7696,from,O
PMC27383680_683,7696,schizophrenia,B-Disease
PMC27383680_683,7696,0,O
PMC27384180_576,7697,Serotonin,O
PMC27384180_576,7697,syndrome,O
PMC27384180_576,7697,associated,O
PMC27384180_576,7697,with,O
PMC27384180_576,7697,sertraline,B-Drug
PMC27384180_576,7697,",",O
PMC27384180_576,7697,trazodone,B-Drug
PMC27384180_576,7697,and,O
PMC27384180_576,7697,tramadol,O
PMC27384180_576,7697,abuse,O
PMC27384180_576,7697,0,O
PMC27401270_374,7698,Co,O
PMC27401270_374,7698,-,O
PMC27401270_374,7698,administration,O
PMC27401270_374,7698,of,O
PMC27401270_374,7698,aripiprazole,O
PMC27401270_374,7698,and,O
PMC27401270_374,7698,topiramate,B-Drug
PMC27401270_374,7698,produced,O
PMC27401270_374,7698,a,O
PMC27401270_374,7698,significant,O
PMC27401270_374,7698,improvement,O
PMC27401270_374,7698,of,O
PMC27401270_374,7698,all,O
PMC27401270_374,7698,psychopathological,O
PMC27401270_374,7698,dimensions,O
PMC27401270_374,7698,",",O
PMC27401270_374,7698,obsessive,B-Symptom
PMC27401270_374,7698,-,I-Symptom
PMC27401270_374,7698,compulsive,I-Symptom
PMC27401270_374,7698,symptoms,I-Symptom
PMC27401270_374,7698,",",O
PMC27401270_374,7698,and,O
PMC27401270_374,7698,eating,O
PMC27401270_374,7698,disorder,O
PMC27401270_374,7698,0,O
PMC27401270_395,7699,Treatment,O
PMC27401270_395,7699,with,O
PMC27401270_395,7699,aripiprazole,O
PMC27401270_395,7699,and,O
PMC27401270_395,7699,topiramate,B-Drug
PMC27401270_395,7699,in,O
PMC27401270_395,7699,an,O
PMC27401270_395,7699,obese,O
PMC27401270_395,7699,subject,O
PMC27401270_395,7699,with,O
PMC27401270_395,7699,borderline,O
PMC27401270_395,7699,personality,B-Disease
PMC27401270_395,7699,disorder,I-Disease
PMC27401270_395,7699,",",O
PMC27401270_395,7699,obsessive,B-Symptom
PMC27401270_395,7699,-,I-Symptom
PMC27401270_395,7699,compulsive,I-Symptom
PMC27401270_395,7699,symptoms,I-Symptom
PMC27401270_395,7699,and,O
PMC27401270_395,7699,bulimia,B-Disease
PMC27401270_395,7699,nervosa,I-Disease
PMC27401270_395,7699,:,O
PMC27401270_395,7699,a,O
PMC27401270_395,7699,case,O
PMC27401270_395,7699,report,O
PMC27401270_395,7699,0,O
PMC27401430_767,7700,We,O
PMC27401430_767,7700,report,O
PMC27401430_767,7700,a,O
PMC27401430_767,7700,case,O
PMC27401430_767,7700,of,O
PMC27401430_767,7700,angioedema,O
PMC27401430_767,7700,following,O
PMC27401430_767,7700,the,O
PMC27401430_767,7700,use,O
PMC27401430_767,7700,of,O
PMC27401430_767,7700,lisinopril,B-Drug
PMC27401430_767,7700,0,O
PMC27401980_219,7701,This,O
PMC27401980_219,7701,article,O
PMC27401980_219,7701,describes,O
PMC27401980_219,7701,a,O
PMC27401980_219,7701,case,O
PMC27401980_219,7701,of,O
PMC27401980_219,7701,topiramate,B-Drug
PMC27401980_219,7701,induced,O
PMC27401980_219,7701,acute,O
PMC27401980_219,7701,transient,O
PMC27401980_219,7701,myopia,O
PMC27401980_219,7701,0,O
PMC27401980_489,7702,CASE,O
PMC27401980_489,7702,PRESENTATION,O
PMC27401980_489,7702,:,O
PMC27401980_489,7702,A,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,number,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,-,O
PMC27401980_489,7702,year,O
PMC27401980_489,7702,-,O
PMC27401980_489,7702,old,O
PMC27401980_489,7702,female,O
PMC27401980_489,7702,complained,O
PMC27401980_489,7702,of,O
PMC27401980_489,7702,sudden,O
PMC27401980_489,7702,onset,O
PMC27401980_489,7702,of,O
PMC27401980_489,7702,blurred,B-Symptom
PMC27401980_489,7702,vision,I-Symptom
PMC27401980_489,7702,",",O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,number,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,_,O
PMC27401980_489,7702,days,O
PMC27401980_489,7702,prior,O
PMC27401980_489,7702,to,O
PMC27401980_489,7702,this,O
PMC27401980_489,7702,she,O
PMC27401980_489,7702,had,O
PMC27401980_489,7702,commenced,O
PMC27401980_489,7702,topiramate,B-Drug
PMC27401980_489,7702,therapy,O
PMC27401980_489,7702,for,O
PMC27401980_489,7702,migraine,O
PMC27401980_489,7702,prophylaxis,O
PMC27401980_489,7702,0,O
PMC27499250_968,7703,CONCLUSION,O
PMC27499250_968,7703,:,O
PMC27499250_968,7703,There,O
PMC27499250_968,7703,is,O
PMC27499250_968,7703,an,O
PMC27499250_968,7703,increased,O
PMC27499250_968,7703,prevalence,O
PMC27499250_968,7703,of,O
PMC27499250_968,7703,septal,O
PMC27499250_968,7703,heart,O
PMC27499250_968,7703,defects,O
PMC27499250_968,7703,among,O
PMC27499250_968,7703,children,O
PMC27499250_968,7703,whose,O
PMC27499250_968,7703,mothers,O
PMC27499250_968,7703,were,O
PMC27499250_968,7703,prescribed,O
PMC27499250_968,7703,an,O
PMC27499250_968,7703,SSRI,O
PMC27499250_968,7703,in,O
PMC27499250_968,7703,early,O
PMC27499250_968,7703,pregnancy,O
PMC27499250_968,7703,",",O
PMC27499250_968,7703,particularly,O
PMC27499250_968,7703,sertraline,B-Drug
PMC27499250_968,7703,and,O
PMC27499250_968,7703,citalopram,B-Drug
PMC27499250_968,7703,0,O
PMC27506190_774,7704,Docetaxel,B-Drug
PMC27506190_774,7704,:,O
PMC27506190_774,7704,an,O
PMC27506190_774,7704,alternative,O
PMC27506190_774,7704,taxane,O
PMC27506190_774,7704,in,O
PMC27506190_774,7704,ovarian,B-Disease
PMC27506190_774,7704,cancer,I-Disease
PMC27506190_774,7704,0,O
PMC27610470_257,7705,Serotonin,O
PMC27610470_257,7705,reuptake,O
PMC27610470_257,7705,inhibitor,O
PMC27610470_257,7705,and,O
PMC27610470_257,7705,fluvoxamine,B-Drug
PMC27610470_257,7705,-,O
PMC27610470_257,7705,induced,O
PMC27610470_257,7705,severe,O
PMC27610470_257,7705,hyponatremia,B-Symptom
PMC27610470_257,7705,in,O
PMC27610470_257,7705,a,O
PMC27610470_257,7705,_,O
PMC27610470_257,7705,_,O
PMC27610470_257,7705,number,O
PMC27610470_257,7705,_,O
PMC27610470_257,7705,_,O
PMC27610470_257,7705,-,O
PMC27610470_257,7705,year,O
PMC27610470_257,7705,-,O
PMC27610470_257,7705,old,O
PMC27610470_257,7705,man,O
PMC27610470_257,7705,0,O
PMC27618650_733,7706,The,O
PMC27618650_733,7706,second,O
PMC27618650_733,7706,goal,O
PMC27618650_733,7706,was,O
PMC27618650_733,7706,to,O
PMC27618650_733,7706,evaluate,O
PMC27618650_733,7706,the,O
PMC27618650_733,7706,impact,O
PMC27618650_733,7706,of,O
PMC27618650_733,7706,olanzapine,B-Drug
PMC27618650_733,7706,on,O
PMC27618650_733,7706,quality,O
PMC27618650_733,7706,of,O
PMC27618650_733,7706,life,O
PMC27618650_733,7706,(,O
PMC27618650_733,7706,QoL,O
PMC27618650_733,7706,),O
PMC27618650_733,7706,of,O
PMC27618650_733,7706,cancer,O
PMC27618650_733,7706,patients,O
PMC27618650_733,7706,during,O
PMC27618650_733,7706,the,O
PMC27618650_733,7706,period,O
PMC27618650_733,7706,of,O
PMC27618650_733,7706,chemotherapy,O
PMC27618650_733,7706,0,O
PMC27633170_269,7707,OBJECTIVES,O
PMC27633170_269,7707,:,O
PMC27633170_269,7707,The,O
PMC27633170_269,7707,aim,O
PMC27633170_269,7707,of,O
PMC27633170_269,7707,this,O
PMC27633170_269,7707,study,O
PMC27633170_269,7707,is,O
PMC27633170_269,7707,to,O
PMC27633170_269,7707,evaluate,O
PMC27633170_269,7707,the,O
PMC27633170_269,7707,clinical,O
PMC27633170_269,7707,changes,O
PMC27633170_269,7707,and,O
PMC27633170_269,7707,the,O
PMC27633170_269,7707,levels,O
PMC27633170_269,7707,of,O
PMC27633170_269,7707,interferon,O
PMC27633170_269,7707,-,O
PMC27633170_269,7707,gamma,O
PMC27633170_269,7707,(,O
PMC27633170_269,7707,IFN,O
PMC27633170_269,7707,-,O
PMC27633170_269,7707,gamma,O
PMC27633170_269,7707,),O
PMC27633170_269,7707,and,O
PMC27633170_269,7707,interleukin,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,number,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,(,O
PMC27633170_269,7707,IL,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,number,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,_,O
PMC27633170_269,7707,),O
PMC27633170_269,7707,in,O
PMC27633170_269,7707,nasal,O
PMC27633170_269,7707,lavage,O
PMC27633170_269,7707,fluid,O
PMC27633170_269,7707,from,O
PMC27633170_269,7707,children,O
PMC27633170_269,7707,with,O
PMC27633170_269,7707,allergic,O
PMC27633170_269,7707,rhinitis,O
PMC27633170_269,7707,after,O
PMC27633170_269,7707,different,O
PMC27633170_269,7707,types,O
PMC27633170_269,7707,of,O
PMC27633170_269,7707,pharmacologic,O
PMC27633170_269,7707,treatment,O
PMC27633170_269,7707,(,O
PMC27633170_269,7707,mometasone,O
PMC27633170_269,7707,",",O
PMC27633170_269,7707,montelukast,B-Drug
PMC27633170_269,7707,",",O
PMC27633170_269,7707,or,O
PMC27633170_269,7707,desloratadine,O
PMC27633170_269,7707,),O
PMC27633170_269,7707,0,O
PMC27693310_314,7708,After,O
PMC27693310_314,7708,diagnosis,O
PMC27693310_314,7708,of,O
PMC27693310_314,7708,warm,O
PMC27693310_314,7708,autoimmune,B-Symptom
PMC27693310_314,7708,hemolytic,I-Symptom
PMC27693310_314,7708,anemia,I-Symptom
PMC27693310_314,7708,",",O
PMC27693310_314,7708,the,O
PMC27693310_314,7708,patient,O
PMC27693310_314,7708,was,O
PMC27693310_314,7708,started,O
PMC27693310_314,7708,on,O
PMC27693310_314,7708,prednisone,B-Drug
PMC27693310_314,7708,_,O
PMC27693310_314,7708,_,O
PMC27693310_314,7708,number,O
PMC27693310_314,7708,_,O
PMC27693310_314,7708,_,O
PMC27693310_314,7708,mg,O
PMC27693310_314,7708,/,O
PMC27693310_314,7708,kg,O
PMC27693310_314,7708,with,O
PMC27693310_314,7708,rapid,O
PMC27693310_314,7708,improvement,O
PMC27693310_314,7708,in,O
PMC27693310_314,7708,his,O
PMC27693310_314,7708,anemia,B-Symptom
PMC27693310_314,7708,and,O
PMC27693310_314,7708,jaundice,B-Symptom
PMC27693310_314,7708,0,O
PMC27703780_823,7709,Comparison,O
PMC27703780_823,7709,of,O
PMC27703780_823,7709,prescriber,O
PMC27703780_823,7709,evaluations,O
PMC27703780_823,7709,and,O
PMC27703780_823,7709,patient,O
PMC27703780_823,7709,-,O
PMC27703780_823,7709,directed,O
PMC27703780_823,7709,self,O
PMC27703780_823,7709,-,O
PMC27703780_823,7709,reports,O
PMC27703780_823,7709,in,O
PMC27703780_823,7709,office,O
PMC27703780_823,7709,-,O
PMC27703780_823,7709,based,O
PMC27703780_823,7709,practice,O
PMC27703780_823,7709,for,O
PMC27703780_823,7709,buprenorphine,B-Drug
PMC27703780_823,7709,treatment,O
PMC27703780_823,7709,of,O
PMC27703780_823,7709,opiate,O
PMC27703780_823,7709,-,O
PMC27703780_823,7709,dependent,O
PMC27703780_823,7709,individuals,O
PMC27703780_823,7709,in,O
PMC27703780_823,7709,France,O
PMC27703780_823,7709,",",O
PMC27703780_823,7709,_,O
PMC27703780_823,7709,_,O
PMC27703780_823,7709,number,O
PMC27703780_823,7709,_,O
PMC27703780_823,7709,_,O
PMC27703780_823,7709,0,O
PMC27711720_729,7710,Fluoxetine,B-Drug
PMC27711720_729,7710,(,O
PMC27711720_729,7710,Prozac,B-Drug
PMC27711720_729,7710,),O
PMC27711720_729,7710,is,O
PMC27711720_729,7710,the,O
PMC27711720_729,7710,first,O
PMC27711720_729,7710,approved,O
PMC27711720_729,7710,SSRI,O
PMC27711720_729,7710,for,O
PMC27711720_729,7710,the,O
PMC27711720_729,7710,treatment,O
PMC27711720_729,7710,of,O
PMC27711720_729,7710,depression,B-Disease
PMC27711720_729,7710,in,O
PMC27711720_729,7710,this,O
PMC27711720_729,7710,population,O
PMC27711720_729,7710,0,O
PMC27793460_49,7711,The,O
PMC27793460_49,7711,melphalan,B-Drug
PMC27793460_49,7711,-,O
PMC27793460_49,7711,prednisone,B-Drug
PMC27793460_49,7711,regimen,O
PMC27793460_49,7711,has,O
PMC27793460_49,7711,been,O
PMC27793460_49,7711,considered,O
PMC27793460_49,7711,as,O
PMC27793460_49,7711,standard,O
PMC27793460_49,7711,therapy,O
PMC27793460_49,7711,for,O
PMC27793460_49,7711,patients,O
PMC27793460_49,7711,with,O
PMC27793460_49,7711,multiple,B-Disease
PMC27793460_49,7711,myeloma,I-Disease
PMC27793460_49,7711,(,I-Disease
PMC27793460_49,7711,MM,I-Disease
PMC27793460_49,7711,),O
PMC27793460_49,7711,for,O
PMC27793460_49,7711,many,O
PMC27793460_49,7711,years,O
PMC27793460_49,7711,0,O
PMC27829680_860,7712,Depressed,B-Disease
PMC27829680_860,7712,subjects,I-Disease
PMC27829680_860,7712,with,O
PMC27829680_860,7712,A,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,number,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,C,O
PMC27829680_860,7712,levels,O
PMC27829680_860,7712,>,O
PMC27829680_860,7712,or,O
PMC27829680_860,7712,=,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,number,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,_,O
PMC27829680_860,7712,%,O
PMC27829680_860,7712,were,O
PMC27829680_860,7712,randomly,O
PMC27829680_860,7712,assigned,O
PMC27829680_860,7712,to,O
PMC27829680_860,7712,receive,O
PMC27829680_860,7712,either,O
PMC27829680_860,7712,sertraline,B-Drug
PMC27829680_860,7712,or,O
PMC27829680_860,7712,placebo,O
PMC27829680_860,7712,0,O
PMC27830980_507,7713,CASE,O
PMC27830980_507,7713,PRESENTATION,O
PMC27830980_507,7713,:,O
PMC27830980_507,7713,A,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,number,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,-,O
PMC27830980_507,7713,year,O
PMC27830980_507,7713,-,O
PMC27830980_507,7713,old,O
PMC27830980_507,7713,Caucasian,O
PMC27830980_507,7713,woman,O
PMC27830980_507,7713,was,O
PMC27830980_507,7713,referred,O
PMC27830980_507,7713,by,O
PMC27830980_507,7713,her,O
PMC27830980_507,7713,dentist,O
PMC27830980_507,7713,to,O
PMC27830980_507,7713,our,O
PMC27830980_507,7713,outpatient,O
PMC27830980_507,7713,clinic,O
PMC27830980_507,7713,with,O
PMC27830980_507,7713,a,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,number,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,_,O
PMC27830980_507,7713,-,O
PMC27830980_507,7713,week,O
PMC27830980_507,7713,history,O
PMC27830980_507,7713,of,O
PMC27830980_507,7713,an,O
PMC27830980_507,7713,oral,O
PMC27830980_507,7713,ulceration,O
PMC27830980_507,7713,after,O
PMC27830980_507,7713,using,O
PMC27830980_507,7713,an,O
PMC27830980_507,7713,antidepressant,O
PMC27830980_507,7713,(,O
PMC27830980_507,7713,sertraline,B-Drug
PMC27830980_507,7713,hydrochloride,O
PMC27830980_507,7713,),O
PMC27830980_507,7713,0,O
PMC27831080_427,7714,The,O
PMC27831080_427,7714,patient,O
PMC27831080_427,7714,underwent,O
PMC27831080_427,7714,phacoemulsification,O
PMC27831080_427,7714,of,O
PMC27831080_427,7714,the,O
PMC27831080_427,7714,cataract,O
PMC27831080_427,7714,in,O
PMC27831080_427,7714,the,O
PMC27831080_427,7714,right,O
PMC27831080_427,7714,eye,O
PMC27831080_427,7714,",",O
PMC27831080_427,7714,intraocular,O
PMC27831080_427,7714,lens,O
PMC27831080_427,7714,implantation,O
PMC27831080_427,7714,and,O
PMC27831080_427,7714,intravitreal,O
PMC27831080_427,7714,injections,O
PMC27831080_427,7714,of,O
PMC27831080_427,7714,_,O
PMC27831080_427,7714,_,O
PMC27831080_427,7714,number,O
PMC27831080_427,7714,_,O
PMC27831080_427,7714,_,O
PMC27831080_427,7714,mg,O
PMC27831080_427,7714,triamcinolone,B-Drug
PMC27831080_427,7714,acetonide,O
PMC27831080_427,7714,0,O
PMC27844650_516,7715,A,O
PMC27844650_516,7715,total,O
PMC27844650_516,7715,of,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,number,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,community,O
PMC27844650_516,7715,eligible,O
PMC27844650_516,7715,individuals,O
PMC27844650_516,7715,(,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,number,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,years,O
PMC27844650_516,7715,or,O
PMC27844650_516,7715,older,O
PMC27844650_516,7715,),O
PMC27844650_516,7715,with,O
PMC27844650_516,7715,hypertension,B-Symptom
PMC27844650_516,7715,and,O
PMC27844650_516,7715,early,O
PMC27844650_516,7715,cognitive,B-Symptom
PMC27844650_516,7715,impairment,I-Symptom
PMC27844650_516,7715,are,O
PMC27844650_516,7715,being,O
PMC27844650_516,7715,recruited,O
PMC27844650_516,7715,from,O
PMC27844650_516,7715,the,O
PMC27844650_516,7715,greater,O
PMC27844650_516,7715,Boston,O
PMC27844650_516,7715,area,O
PMC27844650_516,7715,and,O
PMC27844650_516,7715,randomized,O
PMC27844650_516,7715,to,O
PMC27844650_516,7715,lisinopril,B-Drug
PMC27844650_516,7715,",",O
PMC27844650_516,7715,candesartan,O
PMC27844650_516,7715,",",O
PMC27844650_516,7715,or,O
PMC27844650_516,7715,hydrochlorothiazide,O
PMC27844650_516,7715,(,O
PMC27844650_516,7715,"""",O
PMC27844650_516,7715,active,O
PMC27844650_516,7715,control,O
PMC27844650_516,7715,"""",O
PMC27844650_516,7715,),O
PMC27844650_516,7715,for,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,number,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,_,O
PMC27844650_516,7715,months,O
PMC27844650_516,7715,0,O
PMC27899490_24,7716,METHODS,O
PMC27899490_24,7716,:,O
PMC27899490_24,7716,This,O
PMC27899490_24,7716,retrospective,O
PMC27899490_24,7716,study,O
PMC27899490_24,7716,included,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,eyes,O
PMC27899490_24,7716,of,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,patients,O
PMC27899490_24,7716,who,O
PMC27899490_24,7716,received,O
PMC27899490_24,7716,a,O
PMC27899490_24,7716,single,O
PMC27899490_24,7716,injection,O
PMC27899490_24,7716,of,O
PMC27899490_24,7716,intravitreal,O
PMC27899490_24,7716,bevacizumab,B-Drug
PMC27899490_24,7716,(,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,mg,O
PMC27899490_24,7716,/,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,mL,O
PMC27899490_24,7716,",",O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,eyes,O
PMC27899490_24,7716,),O
PMC27899490_24,7716,or,O
PMC27899490_24,7716,triamcinolone,B-Drug
PMC27899490_24,7716,acetonide,O
PMC27899490_24,7716,(,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,mg,O
PMC27899490_24,7716,/,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,mL,O
PMC27899490_24,7716,",",O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,eyes,O
PMC27899490_24,7716,),O
PMC27899490_24,7716,as,O
PMC27899490_24,7716,the,O
PMC27899490_24,7716,only,O
PMC27899490_24,7716,treatment,O
PMC27899490_24,7716,for,O
PMC27899490_24,7716,macular,O
PMC27899490_24,7716,edema,O
PMC27899490_24,7716,secondary,O
PMC27899490_24,7716,to,O
PMC27899490_24,7716,branch,O
PMC27899490_24,7716,retinal,B-Symptom
PMC27899490_24,7716,vein,I-Symptom
PMC27899490_24,7716,occlusion,I-Symptom
PMC27899490_24,7716,;,O
PMC27899490_24,7716,all,O
PMC27899490_24,7716,patients,O
PMC27899490_24,7716,had,O
PMC27899490_24,7716,a,O
PMC27899490_24,7716,post,O
PMC27899490_24,7716,-,O
PMC27899490_24,7716,injection,O
PMC27899490_24,7716,follow,O
PMC27899490_24,7716,-,O
PMC27899490_24,7716,up,O
PMC27899490_24,7716,duration,O
PMC27899490_24,7716,of,O
PMC27899490_24,7716,>,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,number,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,_,O
PMC27899490_24,7716,weeks,O
PMC27899490_24,7716,0,O
PMC27899490_53,7717,PURPOSE,O
PMC27899490_53,7717,:,O
PMC27899490_53,7717,To,O
PMC27899490_53,7717,compare,O
PMC27899490_53,7717,the,O
PMC27899490_53,7717,effects,O
PMC27899490_53,7717,of,O
PMC27899490_53,7717,intravitreal,O
PMC27899490_53,7717,bevacizumab,B-Drug
PMC27899490_53,7717,to,O
PMC27899490_53,7717,those,O
PMC27899490_53,7717,of,O
PMC27899490_53,7717,triamcinolone,B-Drug
PMC27899490_53,7717,acetonide,O
PMC27899490_53,7717,injection,O
PMC27899490_53,7717,for,O
PMC27899490_53,7717,the,O
PMC27899490_53,7717,treatment,O
PMC27899490_53,7717,of,O
PMC27899490_53,7717,macular,O
PMC27899490_53,7717,edema,O
PMC27899490_53,7717,secondary,O
PMC27899490_53,7717,to,O
PMC27899490_53,7717,branch,O
PMC27899490_53,7717,retinal,B-Symptom
PMC27899490_53,7717,vein,I-Symptom
PMC27899490_53,7717,occlusion,I-Symptom
PMC27899490_53,7717,0,O
PMC27926250_1008,7718,We,O
PMC27926250_1008,7718,wish,O
PMC27926250_1008,7718,to,O
PMC27926250_1008,7718,report,O
PMC27926250_1008,7718,another,O
PMC27926250_1008,7718,case,O
PMC27926250_1008,7718,of,O
PMC27926250_1008,7718,TD,O
PMC27926250_1008,7718,",",O
PMC27926250_1008,7718,in,O
PMC27926250_1008,7718,a,O
PMC27926250_1008,7718,male,O
PMC27926250_1008,7718,patient,O
PMC27926250_1008,7718,with,O
PMC27926250_1008,7718,schizophrenia,O
PMC27926250_1008,7718,",",O
PMC27926250_1008,7718,which,O
PMC27926250_1008,7718,developed,O
PMC27926250_1008,7718,after,O
PMC27926250_1008,7718,_,O
PMC27926250_1008,7718,_,O
PMC27926250_1008,7718,number,O
PMC27926250_1008,7718,_,O
PMC27926250_1008,7718,_,O
PMC27926250_1008,7718,months,O
PMC27926250_1008,7718,of,O
PMC27926250_1008,7718,treatment,O
PMC27926250_1008,7718,with,O
PMC27926250_1008,7718,olanzapine,B-Drug
PMC27926250_1008,7718,0,O
PMC27977870_193,7719,CONCLUSION,O
PMC27977870_193,7719,:,O
PMC27977870_193,7719,Prescription,O
PMC27977870_193,7719,drug,O
PMC27977870_193,7719,utilization,O
PMC27977870_193,7719,is,O
PMC27977870_193,7719,much,O
PMC27977870_193,7719,greater,O
PMC27977870_193,7719,in,O
PMC27977870_193,7719,Spanish,O
PMC27977870_193,7719,children,O
PMC27977870_193,7719,than,O
PMC27977870_193,7719,in,O
PMC27977870_193,7719,immigrant,O
PMC27977870_193,7719,children,O
PMC27977870_193,7719,",",O
PMC27977870_193,7719,particularly,O
PMC27977870_193,7719,with,O
PMC27977870_193,7719,reference,O
PMC27977870_193,7719,to,O
PMC27977870_193,7719,bronchodilators,O
PMC27977870_193,7719,(,O
PMC27977870_193,7719,montelukast,B-Drug
PMC27977870_193,7719,and,O
PMC27977870_193,7719,terbutaline,O
PMC27977870_193,7719,),O
PMC27977870_193,7719,and,O
PMC27977870_193,7719,attention,B-Disease
PMC27977870_193,7719,-,I-Disease
PMC27977870_193,7719,disorder,I-Disease
PMC27977870_193,7719,hyperactivity,I-Disease
PMC27977870_193,7719,drugs,O
PMC27977870_193,7719,such,O
PMC27977870_193,7719,as,O
PMC27977870_193,7719,methylphenidate,B-Drug
PMC27977870_193,7719,0,O
PMC28015870_312,7720,Update,O
PMC28015870_312,7720,on,O
PMC28015870_312,7720,the,O
PMC28015870_312,7720,management,O
PMC28015870_312,7720,of,O
PMC28015870_312,7720,attention,B-Disease
PMC28015870_312,7720,-,I-Disease
PMC28015870_312,7720,deficit,I-Disease
PMC28015870_312,7720,/,I-Disease
PMC28015870_312,7720,hyperactivity,I-Disease
PMC28015870_312,7720,disorder,I-Disease
PMC28015870_312,7720,in,O
PMC28015870_312,7720,children,O
PMC28015870_312,7720,and,O
PMC28015870_312,7720,adults,O
PMC28015870_312,7720,:,O
PMC28015870_312,7720,patient,O
PMC28015870_312,7720,considerations,O
PMC28015870_312,7720,and,O
PMC28015870_312,7720,the,O
PMC28015870_312,7720,role,O
PMC28015870_312,7720,of,O
PMC28015870_312,7720,lisdexamfetamine,B-Drug
PMC28015870_312,7720,0,O
PMC28023730_1001,7721,AIMS,O
PMC28023730_1001,7721,:,O
PMC28023730_1001,7721,To,O
PMC28023730_1001,7721,determine,O
PMC28023730_1001,7721,and,O
PMC28023730_1001,7721,compare,O
PMC28023730_1001,7721,the,O
PMC28023730_1001,7721,frequency,O
PMC28023730_1001,7721,of,O
PMC28023730_1001,7721,sexual,O
PMC28023730_1001,7721,dysfunction,O
PMC28023730_1001,7721,associated,O
PMC28023730_1001,7721,with,O
PMC28023730_1001,7721,risperidone,O
PMC28023730_1001,7721,",",O
PMC28023730_1001,7721,olanzapine,B-Drug
PMC28023730_1001,7721,",",O
PMC28023730_1001,7721,and,O
PMC28023730_1001,7721,quetiapine,B-Drug
PMC28023730_1001,7721,",",O
PMC28023730_1001,7721,among,O
PMC28023730_1001,7721,patients,O
PMC28023730_1001,7721,with,O
PMC28023730_1001,7721,clinically,O
PMC28023730_1001,7721,stable,O
PMC28023730_1001,7721,schizophrenia,B-Disease
PMC28023730_1001,7721,0,O
PMC28023820_632,7722,Here,O
PMC28023820_632,7722,is,O
PMC28023820_632,7722,a,O
PMC28023820_632,7722,case,O
PMC28023820_632,7722,report,O
PMC28023820_632,7722,where,O
PMC28023820_632,7722,a,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,number,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,year,O
PMC28023820_632,7722,-,O
PMC28023820_632,7722,old,O
PMC28023820_632,7722,male,O
PMC28023820_632,7722,with,O
PMC28023820_632,7722,social,O
PMC28023820_632,7722,phobia,O
PMC28023820_632,7722,developed,O
PMC28023820_632,7722,delusions,O
PMC28023820_632,7722,of,O
PMC28023820_632,7722,persecution,O
PMC28023820_632,7722,on,O
PMC28023820_632,7722,two,O
PMC28023820_632,7722,occasions,O
PMC28023820_632,7722,when,O
PMC28023820_632,7722,he,O
PMC28023820_632,7722,was,O
PMC28023820_632,7722,put,O
PMC28023820_632,7722,on,O
PMC28023820_632,7722,venlafaxine,B-Drug
PMC28023820_632,7722,_,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,number,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,_,O
PMC28023820_632,7722,mg,O
PMC28023820_632,7722,/,O
PMC28023820_632,7722,day,O
PMC28023820_632,7722,",",O
PMC28023820_632,7722,which,O
PMC28023820_632,7722,responded,O
PMC28023820_632,7722,to,O
PMC28023820_632,7722,withdrawal,B-Symptom
PMC28023820_632,7722,of,O
PMC28023820_632,7722,venlafaxine,B-Drug
PMC28023820_632,7722,and,O
PMC28023820_632,7722,a,O
PMC28023820_632,7722,short,O
PMC28023820_632,7722,course,O
PMC28023820_632,7722,of,O
PMC28023820_632,7722,antipsychotics,O
PMC28023820_632,7722,0,O
PMC28037750_458,7723,Fluvoxamine,B-Drug
PMC28037750_458,7723,monotherapy,O
PMC28037750_458,7723,for,O
PMC28037750_458,7723,psychotic,B-Disease
PMC28037750_458,7723,depression,I-Disease
PMC28037750_458,7723,:,O
PMC28037750_458,7723,the,O
PMC28037750_458,7723,potential,O
PMC28037750_458,7723,role,O
PMC28037750_458,7723,of,O
PMC28037750_458,7723,sigma,O
PMC28037750_458,7723,_,O
PMC28037750_458,7723,_,O
PMC28037750_458,7723,number,O
PMC28037750_458,7723,_,O
PMC28037750_458,7723,_,O
PMC28037750_458,7723,receptors,O
PMC28037750_458,7723,0,O
PMC28037750_514,7724,RESULTS,O
PMC28037750_514,7724,:,O
PMC28037750_514,7724,The,O
PMC28037750_514,7724,scores,O
PMC28037750_514,7724,on,O
PMC28037750_514,7724,the,O
PMC28037750_514,7724,Hamilton,O
PMC28037750_514,7724,Depression,O
PMC28037750_514,7724,(,O
PMC28037750_514,7724,HAM,O
PMC28037750_514,7724,-,O
PMC28037750_514,7724,D,O
PMC28037750_514,7724,),O
PMC28037750_514,7724,scale,O
PMC28037750_514,7724,and,O
PMC28037750_514,7724,the,O
PMC28037750_514,7724,Brief,O
PMC28037750_514,7724,Psychiatric,O
PMC28037750_514,7724,Rating,O
PMC28037750_514,7724,Scale,O
PMC28037750_514,7724,(,O
PMC28037750_514,7724,BPRS,O
PMC28037750_514,7724,),O
PMC28037750_514,7724,in,O
PMC28037750_514,7724,the,O
PMC28037750_514,7724,five,O
PMC28037750_514,7724,patients,O
PMC28037750_514,7724,with,O
PMC28037750_514,7724,psychotic,B-Disease
PMC28037750_514,7724,depression,I-Disease
PMC28037750_514,7724,were,O
PMC28037750_514,7724,reduced,O
PMC28037750_514,7724,after,O
PMC28037750_514,7724,fluvoxamine,B-Drug
PMC28037750_514,7724,monotherapy,O
PMC28037750_514,7724,0,O
PMC28037750_719,7725,METHODS,O
PMC28037750_719,7725,:,O
PMC28037750_719,7725,We,O
PMC28037750_719,7725,report,O
PMC28037750_719,7725,five,O
PMC28037750_719,7725,cases,O
PMC28037750_719,7725,where,O
PMC28037750_719,7725,fluvoxamine,B-Drug
PMC28037750_719,7725,monotherapy,O
PMC28037750_719,7725,was,O
PMC28037750_719,7725,effective,O
PMC28037750_719,7725,in,O
PMC28037750_719,7725,the,O
PMC28037750_719,7725,patients,O
PMC28037750_719,7725,with,O
PMC28037750_719,7725,psychotic,B-Disease
PMC28037750_719,7725,depression,I-Disease
PMC28037750_719,7725,0,O
PMC28040570_150,7726,Since,O
PMC28040570_150,7726,approvement,O
PMC28040570_150,7726,several,O
PMC28040570_150,7726,case,O
PMC28040570_150,7726,reports,O
PMC28040570_150,7726,about,O
PMC28040570_150,7726,intoxication,O
PMC28040570_150,7726,with,O
PMC28040570_150,7726,quetiapine,B-Drug
PMC28040570_150,7726,were,O
PMC28040570_150,7726,linked,O
PMC28040570_150,7726,mainly,O
PMC28040570_150,7726,with,O
PMC28040570_150,7726,tachycardia,B-Symptom
PMC28040570_150,7726,",",O
PMC28040570_150,7726,QT,B-Symptom
PMC28040570_150,7726,(,I-Symptom
PMC28040570_150,7726,c,I-Symptom
PMC28040570_150,7726,),I-Symptom
PMC28040570_150,7726,-,I-Symptom
PMC28040570_150,7726,prolongation,I-Symptom
PMC28040570_150,7726,",",O
PMC28040570_150,7726,somnolence,B-Symptom
PMC28040570_150,7726,",",O
PMC28040570_150,7726,and,O
PMC28040570_150,7726,hyperglycemia,B-Symptom
PMC28040570_150,7726,0,O
PMC28157990_943,7727,Neuroactive,O
PMC28157990_943,7727,steroids,O
PMC28157990_943,7727,after,O
PMC28157990_943,7727,estrogen,O
PMC28157990_943,7727,exposure,O
PMC28157990_943,7727,in,O
PMC28157990_943,7727,depressed,B-Disease
PMC28157990_943,7727,postmenopausal,O
PMC28157990_943,7727,women,O
PMC28157990_943,7727,treated,O
PMC28157990_943,7727,with,O
PMC28157990_943,7727,sertraline,B-Drug
PMC28157990_943,7727,and,O
PMC28157990_943,7727,asymptomatic,O
PMC28157990_943,7727,postmenopausal,O
PMC28157990_943,7727,women,O
PMC28157990_943,7727,0,O
PMC28162490_800,7728,The,O
PMC28162490_800,7728,objective,O
PMC28162490_800,7728,of,O
PMC28162490_800,7728,the,O
PMC28162490_800,7728,present,O
PMC28162490_800,7728,study,O
PMC28162490_800,7728,was,O
PMC28162490_800,7728,to,O
PMC28162490_800,7728,describe,O
PMC28162490_800,7728,a,O
PMC28162490_800,7728,new,O
PMC28162490_800,7728,model,O
PMC28162490_800,7728,of,O
PMC28162490_800,7728,the,O
PMC28162490_800,7728,cost,O
PMC28162490_800,7728,-,O
PMC28162490_800,7728,effectiveness,O
PMC28162490_800,7728,of,O
PMC28162490_800,7728,treatment,O
PMC28162490_800,7728,of,O
PMC28162490_800,7728,generalized,B-Disease
PMC28162490_800,7728,anxiety,I-Disease
PMC28162490_800,7728,disorder,I-Disease
PMC28162490_800,7728,(,O
PMC28162490_800,7728,GAD,O
PMC28162490_800,7728,),O
PMC28162490_800,7728,and,O
PMC28162490_800,7728,its,O
PMC28162490_800,7728,application,O
PMC28162490_800,7728,to,O
PMC28162490_800,7728,a,O
PMC28162490_800,7728,comparison,O
PMC28162490_800,7728,of,O
PMC28162490_800,7728,pregabalin,O
PMC28162490_800,7728,versus,O
PMC28162490_800,7728,venlafaxine,B-Drug
PMC28162490_800,7728,extended,O
PMC28162490_800,7728,-,O
PMC28162490_800,7728,release,O
PMC28162490_800,7728,(,O
PMC28162490_800,7728,XR,O
PMC28162490_800,7728,),O
PMC28162490_800,7728,from,O
PMC28162490_800,7728,a,O
PMC28162490_800,7728,Spanish,O
PMC28162490_800,7728,healthcare,O
PMC28162490_800,7728,perspective,O
PMC28162490_800,7728,0,O
PMC28170470_159,7729,CONCLUSIONS,O
PMC28170470_159,7729,:,O
PMC28170470_159,7729,In,O
PMC28170470_159,7729,this,O
PMC28170470_159,7729,large,O
PMC28170470_159,7729,",",O
PMC28170470_159,7729,population,O
PMC28170470_159,7729,based,O
PMC28170470_159,7729,study,O
PMC28170470_159,7729,",",O
PMC28170470_159,7729,the,O
PMC28170470_159,7729,use,O
PMC28170470_159,7729,of,O
PMC28170470_159,7729,venlafaxine,B-Drug
PMC28170470_159,7729,was,O
PMC28170470_159,7729,not,O
PMC28170470_159,7729,associated,O
PMC28170470_159,7729,with,O
PMC28170470_159,7729,an,O
PMC28170470_159,7729,excess,O
PMC28170470_159,7729,risk,O
PMC28170470_159,7729,of,O
PMC28170470_159,7729,sudden,O
PMC28170470_159,7729,cardiac,O
PMC28170470_159,7729,death,O
PMC28170470_159,7729,or,O
PMC28170470_159,7729,near,O
PMC28170470_159,7729,death,O
PMC28170470_159,7729,compared,O
PMC28170470_159,7729,with,O
PMC28170470_159,7729,fluoxetine,B-Drug
PMC28170470_159,7729,",",O
PMC28170470_159,7729,dosulepin,O
PMC28170470_159,7729,",",O
PMC28170470_159,7729,or,O
PMC28170470_159,7729,citalopram,B-Drug
PMC28170470_159,7729,",",O
PMC28170470_159,7729,in,O
PMC28170470_159,7729,patients,O
PMC28170470_159,7729,with,O
PMC28170470_159,7729,depression,B-Disease
PMC28170470_159,7729,or,O
PMC28170470_159,7729,anxiety,B-Symptom
PMC28170470_159,7729,0,O
PMC28170470_528,7730,OBJECTIVE,O
PMC28170470_528,7730,:,O
PMC28170470_528,7730,To,O
PMC28170470_528,7730,assess,O
PMC28170470_528,7730,whether,O
PMC28170470_528,7730,use,O
PMC28170470_528,7730,of,O
PMC28170470_528,7730,the,O
PMC28170470_528,7730,antidepressant,O
PMC28170470_528,7730,venlafaxine,B-Drug
PMC28170470_528,7730,is,O
PMC28170470_528,7730,associated,O
PMC28170470_528,7730,with,O
PMC28170470_528,7730,an,O
PMC28170470_528,7730,increased,O
PMC28170470_528,7730,risk,O
PMC28170470_528,7730,of,O
PMC28170470_528,7730,sudden,O
PMC28170470_528,7730,cardiac,O
PMC28170470_528,7730,death,O
PMC28170470_528,7730,or,O
PMC28170470_528,7730,near,O
PMC28170470_528,7730,death,O
PMC28170470_528,7730,compared,O
PMC28170470_528,7730,with,O
PMC28170470_528,7730,other,O
PMC28170470_528,7730,commonly,O
PMC28170470_528,7730,used,O
PMC28170470_528,7730,antidepressants,O
PMC28170470_528,7730,0,O
PMC28177540_782,7731,CONCLUSION,O
PMC28177540_782,7731,:,O
PMC28177540_782,7731,Paroxetine,B-Drug
PMC28177540_782,7731,use,O
PMC28177540_782,7731,during,O
PMC28177540_782,7731,tamoxifen,B-Drug
PMC28177540_782,7731,treatment,O
PMC28177540_782,7731,is,O
PMC28177540_782,7731,associated,O
PMC28177540_782,7731,with,O
PMC28177540_782,7731,an,O
PMC28177540_782,7731,increased,B-Disease
PMC28177540_782,7731,risk,I-Disease
PMC28177540_782,7731,of,I-Disease
PMC28177540_782,7731,death,I-Disease
PMC28177540_782,7731,from,I-Disease
PMC28177540_782,7731,breast,I-Disease
PMC28177540_782,7731,cancer,I-Disease
PMC28177540_782,7731,",",O
PMC28177540_782,7731,supporting,O
PMC28177540_782,7731,the,O
PMC28177540_782,7731,hypothesis,O
PMC28177540_782,7731,that,O
PMC28177540_782,7731,paroxetine,O
PMC28177540_782,7731,can,O
PMC28177540_782,7731,reduce,O
PMC28177540_782,7731,or,O
PMC28177540_782,7731,abolish,O
PMC28177540_782,7731,the,O
PMC28177540_782,7731,benefit,O
PMC28177540_782,7731,of,O
PMC28177540_782,7731,tamoxifen,B-Drug
PMC28177540_782,7731,in,O
PMC28177540_782,7731,women,O
PMC28177540_782,7731,with,O
PMC28177540_782,7731,breast,B-Disease
PMC28177540_782,7731,cancer,I-Disease
PMC28177540_782,7731,0,O
PMC28192370_55,7732,METHODS,O
PMC28192370_55,7732,:,O
PMC28192370_55,7732,We,O
PMC28192370_55,7732,report,O
PMC28192370_55,7732,on,O
PMC28192370_55,7732,two,O
PMC28192370_55,7732,cases,O
PMC28192370_55,7732,in,O
PMC28192370_55,7732,which,O
PMC28192370_55,7732,monotherapy,O
PMC28192370_55,7732,of,O
PMC28192370_55,7732,the,O
PMC28192370_55,7732,selective,O
PMC28192370_55,7732,serotonin,O
PMC28192370_55,7732,reuptake,O
PMC28192370_55,7732,inhibitor,O
PMC28192370_55,7732,and,O
PMC28192370_55,7732,sigma,O
PMC28192370_55,7732,_,O
PMC28192370_55,7732,_,O
PMC28192370_55,7732,number,O
PMC28192370_55,7732,_,O
PMC28192370_55,7732,_,O
PMC28192370_55,7732,receptor,O
PMC28192370_55,7732,agonist,O
PMC28192370_55,7732,fluvoxamine,B-Drug
PMC28192370_55,7732,was,O
PMC28192370_55,7732,effective,O
PMC28192370_55,7732,in,O
PMC28192370_55,7732,ameliorating,O
PMC28192370_55,7732,the,O
PMC28192370_55,7732,delirium,B-Symptom
PMC28192370_55,7732,of,O
PMC28192370_55,7732,patients,O
PMC28192370_55,7732,with,O
PMC28192370_55,7732,Alzheimer,B-Disease
PMC28192370_55,7732,',I-Disease
PMC28192370_55,7732,s,I-Disease
PMC28192370_55,7732,disease,I-Disease
PMC28192370_55,7732,0,O
PMC28192370_638,7733,RESULTS,O
PMC28192370_638,7733,:,O
PMC28192370_638,7733,Delirium,O
PMC28192370_638,7733,Rating,O
PMC28192370_638,7733,Scale,O
PMC28192370_638,7733,(,O
PMC28192370_638,7733,DRS,O
PMC28192370_638,7733,),O
PMC28192370_638,7733,scores,O
PMC28192370_638,7733,in,O
PMC28192370_638,7733,the,O
PMC28192370_638,7733,two,O
PMC28192370_638,7733,patients,O
PMC28192370_638,7733,with,O
PMC28192370_638,7733,Alzheimer,B-Disease
PMC28192370_638,7733,',I-Disease
PMC28192370_638,7733,s,I-Disease
PMC28192370_638,7733,disease,I-Disease
PMC28192370_638,7733,decreased,O
PMC28192370_638,7733,after,O
PMC28192370_638,7733,fluvoxamine,B-Drug
PMC28192370_638,7733,monotherapy,O
PMC28192370_638,7733,0,O
PMC28192370_793,7734,Sigma,O
PMC28192370_793,7734,_,O
PMC28192370_793,7734,_,O
PMC28192370_793,7734,number,O
PMC28192370_793,7734,_,O
PMC28192370_793,7734,_,O
PMC28192370_793,7734,receptor,O
PMC28192370_793,7734,agonist,O
PMC28192370_793,7734,fluvoxamine,B-Drug
PMC28192370_793,7734,for,O
PMC28192370_793,7734,delirium,B-Symptom
PMC28192370_793,7734,in,O
PMC28192370_793,7734,patients,O
PMC28192370_793,7734,with,O
PMC28192370_793,7734,Alzheimer,B-Disease
PMC28192370_793,7734,',I-Disease
PMC28192370_793,7734,s,I-Disease
PMC28192370_793,7734,disease,I-Disease
PMC28192370_793,7734,0,O
PMC28192370_874,7735,CONCLUSION,O
PMC28192370_874,7735,:,O
PMC28192370_874,7735,Doctors,O
PMC28192370_874,7735,should,O
PMC28192370_874,7735,consider,O
PMC28192370_874,7735,that,O
PMC28192370_874,7735,fluvoxamine,B-Drug
PMC28192370_874,7735,could,O
PMC28192370_874,7735,be,O
PMC28192370_874,7735,an,O
PMC28192370_874,7735,alternative,O
PMC28192370_874,7735,approach,O
PMC28192370_874,7735,in,O
PMC28192370_874,7735,treating,O
PMC28192370_874,7735,delirium,O
PMC28192370_874,7735,in,O
PMC28192370_874,7735,patients,O
PMC28192370_874,7735,with,O
PMC28192370_874,7735,Alzheimer,B-Disease
PMC28192370_874,7735,',I-Disease
PMC28192370_874,7735,s,I-Disease
PMC28192370_874,7735,disease,I-Disease
PMC28192370_874,7735,because,O
PMC28192370_874,7735,of,O
PMC28192370_874,7735,the,O
PMC28192370_874,7735,risk,O
PMC28192370_874,7735,of,O
PMC28192370_874,7735,extrapyramidal,O
PMC28192370_874,7735,side,O
PMC28192370_874,7735,effects,O
PMC28192370_874,7735,by,O
PMC28192370_874,7735,antipsychotic,O
PMC28192370_874,7735,drugs,O
PMC28192370_874,7735,0,O
PMC28200280_421,7736,BACKGROUND,O
PMC28200280_421,7736,:,O
PMC28200280_421,7736,We,O
PMC28200280_421,7736,present,O
PMC28200280_421,7736,the,O
PMC28200280_421,7736,case,O
PMC28200280_421,7736,of,O
PMC28200280_421,7736,a,O
PMC28200280_421,7736,_,O
PMC28200280_421,7736,_,O
PMC28200280_421,7736,number,O
PMC28200280_421,7736,_,O
PMC28200280_421,7736,_,O
PMC28200280_421,7736,-,O
PMC28200280_421,7736,year,O
PMC28200280_421,7736,-,O
PMC28200280_421,7736,old,O
PMC28200280_421,7736,woman,O
PMC28200280_421,7736,with,O
PMC28200280_421,7736,depression,B-Disease
PMC28200280_421,7736,who,O
PMC28200280_421,7736,developed,O
PMC28200280_421,7736,extrapyramidal,B-Symptom
PMC28200280_421,7736,symptoms,I-Symptom
PMC28200280_421,7736,(,O
PMC28200280_421,7736,mainly,O
PMC28200280_421,7736,parkinsonism,O
PMC28200280_421,7736,),O
PMC28200280_421,7736,and,O
PMC28200280_421,7736,suicidal,B-Symptom
PMC28200280_421,7736,ideation,I-Symptom
PMC28200280_421,7736,while,O
PMC28200280_421,7736,on,O
PMC28200280_421,7736,fluoxetine,B-Drug
PMC28200280_421,7736,0,O
PMC28213950_227,7737,INTRODUCTION,O
PMC28213950_227,7737,:,O
PMC28213950_227,7737,This,O
PMC28213950_227,7737,case,O
PMC28213950_227,7737,report,O
PMC28213950_227,7737,describes,O
PMC28213950_227,7737,the,O
PMC28213950_227,7737,effects,O
PMC28213950_227,7737,of,O
PMC28213950_227,7737,psychotropic,O
PMC28213950_227,7737,treatment,O
PMC28213950_227,7737,",",O
PMC28213950_227,7737,quetiapine,B-Drug
PMC28213950_227,7737,in,O
PMC28213950_227,7737,particular,O
PMC28213950_227,7737,",",O
PMC28213950_227,7737,on,O
PMC28213950_227,7737,systemic,O
PMC28213950_227,7737,inflammation,B-Symptom
PMC28213950_227,7737,",",O
PMC28213950_227,7737,pain,B-Symptom
PMC28213950_227,7737,",",O
PMC28213950_227,7737,general,O
PMC28213950_227,7737,functioning,O
PMC28213950_227,7737,and,O
PMC28213950_227,7737,major,B-Disease
PMC28213950_227,7737,depression,I-Disease
PMC28213950_227,7737,in,O
PMC28213950_227,7737,the,O
PMC28213950_227,7737,treatment,O
PMC28213950_227,7737,of,O
PMC28213950_227,7737,a,O
PMC28213950_227,7737,woman,O
PMC28213950_227,7737,with,O
PMC28213950_227,7737,arthritis,B-Disease
PMC28213950_227,7737,0,O
PMC28213950_462,7738,CONCLUSIONS,O
PMC28213950_462,7738,:,O
PMC28213950_462,7738,We,O
PMC28213950_462,7738,suggest,O
PMC28213950_462,7738,that,O
PMC28213950_462,7738,the,O
PMC28213950_462,7738,treatment,O
PMC28213950_462,7738,particularly,O
PMC28213950_462,7738,with,O
PMC28213950_462,7738,quetiapine,B-Drug
PMC28213950_462,7738,may,O
PMC28213950_462,7738,have,O
PMC28213950_462,7738,anti,O
PMC28213950_462,7738,-,O
PMC28213950_462,7738,inflammatory,O
PMC28213950_462,7738,effects,O
PMC28213950_462,7738,in,O
PMC28213950_462,7738,arthritis,B-Disease
PMC28213950_462,7738,and,O
PMC28213950_462,7738,comorbid,O
PMC28213950_462,7738,major,B-Disease
PMC28213950_462,7738,depression,I-Disease
PMC28213950_462,7738,",",O
PMC28213950_462,7738,which,O
PMC28213950_462,7738,eventually,O
PMC28213950_462,7738,led,O
PMC28213950_462,7738,to,O
PMC28213950_462,7738,a,O
PMC28213950_462,7738,remission,O
PMC28213950_462,7738,of,O
PMC28213950_462,7738,pain,B-Symptom
PMC28213950_462,7738,and,O
PMC28213950_462,7738,depression,B-Disease
PMC28213950_462,7738,and,O
PMC28213950_462,7738,to,O
PMC28213950_462,7738,normal,O
PMC28213950_462,7738,general,O
PMC28213950_462,7738,function,O
PMC28213950_462,7738,0,O
PMC28213950_664,7739,CASE,O
PMC28213950_664,7739,PRESENTATION,O
PMC28213950_664,7739,:,O
PMC28213950_664,7739,A,O
PMC28213950_664,7739,_,O
PMC28213950_664,7739,_,O
PMC28213950_664,7739,number,O
PMC28213950_664,7739,_,O
PMC28213950_664,7739,_,O
PMC28213950_664,7739,-,O
PMC28213950_664,7739,year,O
PMC28213950_664,7739,-,O
PMC28213950_664,7739,old,O
PMC28213950_664,7739,Caucasian,O
PMC28213950_664,7739,Australian,O
PMC28213950_664,7739,woman,O
PMC28213950_664,7739,with,O
PMC28213950_664,7739,arthritis,B-Disease
PMC28213950_664,7739,",",O
PMC28213950_664,7739,pain,B-Symptom
PMC28213950_664,7739,and,O
PMC28213950_664,7739,depression,B-Disease
PMC28213950_664,7739,was,O
PMC28213950_664,7739,treated,O
PMC28213950_664,7739,with,O
PMC28213950_664,7739,a,O
PMC28213950_664,7739,course,O
PMC28213950_664,7739,of,O
PMC28213950_664,7739,escitalopram,O
PMC28213950_664,7739,",",O
PMC28213950_664,7739,mirtazapine,O
PMC28213950_664,7739,and,O
PMC28213950_664,7739,quetiapine,B-Drug
PMC28213950_664,7739,0,O
PMC28274930_355,7740,Candidate,O
PMC28274930_355,7740,predictors,O
PMC28274930_355,7740,included,O
PMC28274930_355,7740,age,O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,race,O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,sex,O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,initial,O
PMC28274930_355,7740,Beck,O
PMC28274930_355,7740,Depression,O
PMC28274930_355,7740,Inventory,O
PMC28274930_355,7740,(,O
PMC28274930_355,7740,iBDI,O
PMC28274930_355,7740,),O
PMC28274930_355,7740,score,O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,treatment,O
PMC28274930_355,7740,received,O
PMC28274930_355,7740,(,O
PMC28274930_355,7740,sertraline,B-Drug
PMC28274930_355,7740,or,O
PMC28274930_355,7740,bupropion,O
PMC28274930_355,7740,),O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,family,O
PMC28274930_355,7740,history,O
PMC28274930_355,7740,of,O
PMC28274930_355,7740,depression,O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,extant,O
PMC28274930_355,7740,diabetes,O
PMC28274930_355,7740,complications,O
PMC28274930_355,7740,(,O
PMC28274930_355,7740,eDC,O
PMC28274930_355,7740,),O
PMC28274930_355,7740,",",O
PMC28274930_355,7740,and,O
PMC28274930_355,7740,A,O
PMC28274930_355,7740,_,O
PMC28274930_355,7740,_,O
PMC28274930_355,7740,number,O
PMC28274930_355,7740,_,O
PMC28274930_355,7740,_,O
PMC28274930_355,7740,C,O
PMC28274930_355,7740,level,O
PMC28274930_355,7740,0,O
PMC28316030_194,7741,CONCLUSIONS,O
PMC28316030_194,7741,:,O
PMC28316030_194,7741,Twelve,O
PMC28316030_194,7741,weeks,O
PMC28316030_194,7741,of,O
PMC28316030_194,7741,treatment,O
PMC28316030_194,7741,with,O
PMC28316030_194,7741,montelukast,B-Drug
PMC28316030_194,7741,protected,O
PMC28316030_194,7741,against,O
PMC28316030_194,7741,aspirin,O
PMC28316030_194,7741,-,O
PMC28316030_194,7741,induced,O
PMC28316030_194,7741,bronchospasm,B-Symptom
PMC28316030_194,7741,in,O
PMC28316030_194,7741,_,O
PMC28316030_194,7741,_,O
PMC28316030_194,7741,number,O
PMC28316030_194,7741,_,O
PMC28316030_194,7741,_,O
PMC28316030_194,7741,%,O
PMC28316030_194,7741,of,O
PMC28316030_194,7741,the,O
PMC28316030_194,7741,AIA,O
PMC28316030_194,7741,cases,O
PMC28316030_194,7741,0,O
PMC28356450_889,7742,BACKGROUND,O
PMC28356450_889,7742,:,O
PMC28356450_889,7742,Combinations,O
PMC28356450_889,7742,of,O
PMC28356450_889,7742,trastuzumab,O
PMC28356450_889,7742,with,O
PMC28356450_889,7742,either,O
PMC28356450_889,7742,docetaxel,B-Drug
PMC28356450_889,7742,or,O
PMC28356450_889,7742,vinorelbine,O
PMC28356450_889,7742,are,O
PMC28356450_889,7742,considered,O
PMC28356450_889,7742,valuable,O
PMC28356450_889,7742,treatment,O
PMC28356450_889,7742,options,O
PMC28356450_889,7742,for,O
PMC28356450_889,7742,HER,O
PMC28356450_889,7742,_,O
PMC28356450_889,7742,_,O
PMC28356450_889,7742,number,O
PMC28356450_889,7742,_,O
PMC28356450_889,7742,_,O
PMC28356450_889,7742,-,O
PMC28356450_889,7742,positive,O
PMC28356450_889,7742,metastatic,B-Disease
PMC28356450_889,7742,breast,I-Disease
PMC28356450_889,7742,cancer,I-Disease
PMC28356450_889,7742,patients,O
PMC28356450_889,7742,0,O
PMC28405460_94,7743,A,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,number,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,-,O
PMC28405460_94,7743,year,O
PMC28405460_94,7743,-,O
PMC28405460_94,7743,old,O
PMC28405460_94,7743,man,O
PMC28405460_94,7743,had,O
PMC28405460_94,7743,been,O
PMC28405460_94,7743,treated,O
PMC28405460_94,7743,with,O
PMC28405460_94,7743,carbamazepine,B-Drug
PMC28405460_94,7743,(,O
PMC28405460_94,7743,CBZ,O
PMC28405460_94,7743,),O
PMC28405460_94,7743,for,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,number,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,years,O
PMC28405460_94,7743,and,O
PMC28405460_94,7743,warfarin,O
PMC28405460_94,7743,with,O
PMC28405460_94,7743,bucolome,O
PMC28405460_94,7743,for,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,number,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,years,O
PMC28405460_94,7743,before,O
PMC28405460_94,7743,developing,O
PMC28405460_94,7743,hyponatremia,B-Symptom
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,number,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,days,O
PMC28405460_94,7743,after,O
PMC28405460_94,7743,an,O
PMC28405460_94,7743,injection,O
PMC28405460_94,7743,of,O
PMC28405460_94,7743,interferon,O
PMC28405460_94,7743,-,O
PMC28405460_94,7743,alpha,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,number,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,_,O
PMC28405460_94,7743,b,O
PMC28405460_94,7743,and,O
PMC28405460_94,7743,starting,O
PMC28405460_94,7743,oral,O
PMC28405460_94,7743,ribavirin,O
PMC28405460_94,7743,for,O
PMC28405460_94,7743,chronic,O
PMC28405460_94,7743,hepatitis,O
PMC28405460_94,7743,C,O
PMC28405460_94,7743,virus,O
PMC28405460_94,7743,infection,O
PMC28405460_94,7743,0,O
PMC28458630_625,7744,CONCLUSIONS,O
PMC28458630_625,7744,:,O
PMC28458630_625,7744,The,O
PMC28458630_625,7744,antibiotics,O
PMC28458630_625,7744,recommended,O
PMC28458630_625,7744,by,O
PMC28458630_625,7744,the,O
PMC28458630_625,7744,WHO,O
PMC28458630_625,7744,-,O
PMC28458630_625,7744,-,O
PMC28458630_625,7744,ciprofloxacin,B-Drug
PMC28458630_625,7744,",",O
PMC28458630_625,7744,ceftriaxone,O
PMC28458630_625,7744,and,O
PMC28458630_625,7744,pivmecillinam,O
PMC28458630_625,7744,-,O
PMC28458630_625,7744,-,O
PMC28458630_625,7744,are,O
PMC28458630_625,7744,effective,O
PMC28458630_625,7744,in,O
PMC28458630_625,7744,reducing,O
PMC28458630_625,7744,the,O
PMC28458630_625,7744,clinical,O
PMC28458630_625,7744,and,O
PMC28458630_625,7744,bacteriological,O
PMC28458630_625,7744,signs,O
PMC28458630_625,7744,and,O
PMC28458630_625,7744,symptoms,O
PMC28458630_625,7744,of,O
PMC28458630_625,7744,dysentery,O
PMC28458630_625,7744,and,O
PMC28458630_625,7744,thus,O
PMC28458630_625,7744,can,O
PMC28458630_625,7744,be,O
PMC28458630_625,7744,expected,O
PMC28458630_625,7744,to,O
PMC28458630_625,7744,decrease,O
PMC28458630_625,7744,diarrhoea,B-Symptom
PMC28458630_625,7744,mortality,O
PMC28458630_625,7744,attributable,O
PMC28458630_625,7744,to,O
PMC28458630_625,7744,dysentery,O
PMC28458630_625,7744,0,O
PMC28461180_499,7745,Role,O
PMC28461180_499,7745,of,O
PMC28461180_499,7745,extended,O
PMC28461180_499,7745,release,O
PMC28461180_499,7745,quetiapine,B-Drug
PMC28461180_499,7745,in,O
PMC28461180_499,7745,the,O
PMC28461180_499,7745,management,O
PMC28461180_499,7745,of,O
PMC28461180_499,7745,bipolar,B-Disease
PMC28461180_499,7745,disorders,I-Disease
PMC28461180_499,7745,0,O
PMC28461190_833,7746,In,O
PMC28461190_833,7746,these,O
PMC28461190_833,7746,last,O
PMC28461190_833,7746,four,O
PMC28461190_833,7746,years,O
PMC28461190_833,7746,",",O
PMC28461190_833,7746,the,O
PMC28461190_833,7746,only,O
PMC28461190_833,7746,randomized,O
PMC28461190_833,7746,",",O
PMC28461190_833,7746,clinically,O
PMC28461190_833,7746,relevant,O
PMC28461190_833,7746,study,O
PMC28461190_833,7746,in,O
PMC28461190_833,7746,bipolar,B-Disease
PMC28461190_833,7746,patients,O
PMC28461190_833,7746,with,O
PMC28461190_833,7746,comorbid,O
PMC28461190_833,7746,alcoholism,O
PMC28461190_833,7746,is,O
PMC28461190_833,7746,that,O
PMC28461190_833,7746,of,O
PMC28461190_833,7746,Brown,O
PMC28461190_833,7746,and,O
PMC28461190_833,7746,colleagues,O
PMC28461190_833,7746,(,O
PMC28461190_833,7746,_,O
PMC28461190_833,7746,_,O
PMC28461190_833,7746,number,O
PMC28461190_833,7746,_,O
PMC28461190_833,7746,_,O
PMC28461190_833,7746,),O
PMC28461190_833,7746,showing,O
PMC28461190_833,7746,that,O
PMC28461190_833,7746,quetiapine,B-Drug
PMC28461190_833,7746,therapy,O
PMC28461190_833,7746,decreased,O
PMC28461190_833,7746,depressive,B-Symptom
PMC28461190_833,7746,symptoms,I-Symptom
PMC28461190_833,7746,in,O
PMC28461190_833,7746,the,O
PMC28461190_833,7746,early,O
PMC28461190_833,7746,weeks,O
PMC28461190_833,7746,of,O
PMC28461190_833,7746,use,O
PMC28461190_833,7746,",",O
PMC28461190_833,7746,without,O
PMC28461190_833,7746,modifying,O
PMC28461190_833,7746,alcohol,O
PMC28461190_833,7746,use,O
PMC28461190_833,7746,0,O
PMC28461190_879,7747,Topiramate,B-Drug
PMC28461190_879,7747,deserves,O
PMC28461190_879,7747,to,O
PMC28461190_879,7747,be,O
PMC28461190_879,7747,investigated,O
PMC28461190_879,7747,in,O
PMC28461190_879,7747,bipolar,B-Disease
PMC28461190_879,7747,patients,O
PMC28461190_879,7747,with,O
PMC28461190_879,7747,comorbid,O
PMC28461190_879,7747,alcoholism,O
PMC28461190_879,7747,since,O
PMC28461190_879,7747,this,O
PMC28461190_879,7747,compound,O
PMC28461190_879,7747,effectively,O
PMC28461190_879,7747,improves,O
PMC28461190_879,7747,physical,O
PMC28461190_879,7747,health,O
PMC28461190_879,7747,and,O
PMC28461190_879,7747,quality,O
PMC28461190_879,7747,of,O
PMC28461190_879,7747,life,O
PMC28461190_879,7747,of,O
PMC28461190_879,7747,alcohol,O
PMC28461190_879,7747,-,O
PMC28461190_879,7747,dependent,O
PMC28461190_879,7747,individuals,O
PMC28461190_879,7747,0,O
PMC28461480_92,7748,Akathisia,B-Symptom
PMC28461480_92,7748,was,O
PMC28461480_92,7748,rare,O
PMC28461480_92,7748,",",O
PMC28461480_92,7748,but,O
PMC28461480_92,7748,prolongation,B-Symptom
PMC28461480_92,7748,of,I-Symptom
PMC28461480_92,7748,the,I-Symptom
PMC28461480_92,7748,corrected,I-Symptom
PMC28461480_92,7748,QT,I-Symptom
PMC28461480_92,7748,(,O
PMC28461480_92,7748,QTc,O
PMC28461480_92,7748,),O
PMC28461480_92,7748,interval,O
PMC28461480_92,7748,was,O
PMC28461480_92,7748,comparable,O
PMC28461480_92,7748,to,O
PMC28461480_92,7748,haloperidol,O
PMC28461480_92,7748,and,O
PMC28461480_92,7748,ziprasidone,B-Drug
PMC28461480_92,7748,",",O
PMC28461480_92,7748,which,O
PMC28461480_92,7748,is,O
PMC28461480_92,7748,of,O
PMC28461480_92,7748,particular,O
PMC28461480_92,7748,concern,O
PMC28461480_92,7748,0,O
PMC28475630_47,7749,CONCLUSION,O
PMC28475630_47,7749,:,O
PMC28475630_47,7749,Doctors,O
PMC28475630_47,7749,may,O
PMC28475630_47,7749,wish,O
PMC28475630_47,7749,to,O
PMC28475630_47,7749,consider,O
PMC28475630_47,7749,fluvoxamine,B-Drug
PMC28475630_47,7749,as,O
PMC28475630_47,7749,an,O
PMC28475630_47,7749,alternative,O
PMC28475630_47,7749,approach,O
PMC28475630_47,7749,in,O
PMC28475630_47,7749,treating,O
PMC28475630_47,7749,akathisia,B-Symptom
PMC28475630_47,7749,associated,O
PMC28475630_47,7749,with,O
PMC28475630_47,7749,antipsychotic,O
PMC28475630_47,7749,drugs,O
PMC28475630_47,7749,such,O
PMC28475630_47,7749,as,O
PMC28475630_47,7749,aripiprazole,O
PMC28475630_47,7749,0,O
PMC28475630_582,7750,RESULTS,O
PMC28475630_582,7750,:,O
PMC28475630_582,7750,The,O
PMC28475630_582,7750,global,O
PMC28475630_582,7750,score,O
PMC28475630_582,7750,on,O
PMC28475630_582,7750,the,O
PMC28475630_582,7750,Barnes,O
PMC28475630_582,7750,Akathisia,O
PMC28475630_582,7750,Scale,O
PMC28475630_582,7750,in,O
PMC28475630_582,7750,the,O
PMC28475630_582,7750,two,O
PMC28475630_582,7750,patients,O
PMC28475630_582,7750,with,O
PMC28475630_582,7750,schizophrenia,O
PMC28475630_582,7750,treated,O
PMC28475630_582,7750,with,O
PMC28475630_582,7750,aripiprazole,O
PMC28475630_582,7750,decreased,O
PMC28475630_582,7750,after,O
PMC28475630_582,7750,fluvoxamine,B-Drug
PMC28475630_582,7750,monotherapy,O
PMC28475630_582,7750,0,O
PMC28480600_573,7751,Two,O
PMC28480600_573,7751,premature,O
PMC28480600_573,7751,twins,O
PMC28480600_573,7751,(,O
PMC28480600_573,7751,_,O
PMC28480600_573,7751,_,O
PMC28480600_573,7751,number,O
PMC28480600_573,7751,_,O
PMC28480600_573,7751,_,O
PMC28480600_573,7751,weeks,O
PMC28480600_573,7751,gestation,O
PMC28480600_573,7751,),O
PMC28480600_573,7751,were,O
PMC28480600_573,7751,born,O
PMC28480600_573,7751,to,O
PMC28480600_573,7751,a,O
PMC28480600_573,7751,woman,O
PMC28480600_573,7751,who,O
PMC28480600_573,7751,had,O
PMC28480600_573,7751,used,O
PMC28480600_573,7751,paroxetine,B-Drug
PMC28480600_573,7751,during,O
PMC28480600_573,7751,pregnancy,O
PMC28480600_573,7751,for,O
PMC28480600_573,7751,an,O
PMC28480600_573,7751,anxiety,O
PMC28480600_573,7751,-,O
PMC28480600_573,7751,depression,B-Disease
PMC28480600_573,7751,disorder,I-Disease
PMC28480600_573,7751,0,O
PMC28516820_608,7752,METHODS,O
PMC28516820_608,7752,:,O
PMC28516820_608,7752,Patients,O
PMC28516820_608,7752,>,O
PMC28516820_608,7752,or,O
PMC28516820_608,7752,=,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,number,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,years,O
PMC28516820_608,7752,of,O
PMC28516820_608,7752,age,O
PMC28516820_608,7752,admitted,O
PMC28516820_608,7752,to,O
PMC28516820_608,7752,the,O
PMC28516820_608,7752,emergency,O
PMC28516820_608,7752,ward,O
PMC28516820_608,7752,for,O
PMC28516820_608,7752,symptoms,O
PMC28516820_608,7752,of,O
PMC28516820_608,7752,psychosis,B-Disease
PMC28516820_608,7752,were,O
PMC28516820_608,7752,consecutively,O
PMC28516820_608,7752,randomized,O
PMC28516820_608,7752,to,O
PMC28516820_608,7752,risperidone,O
PMC28516820_608,7752,(,O
PMC28516820_608,7752,n,O
PMC28516820_608,7752,=,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,number,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,),O
PMC28516820_608,7752,",",O
PMC28516820_608,7752,olanzapine,B-Drug
PMC28516820_608,7752,(,O
PMC28516820_608,7752,n,O
PMC28516820_608,7752,=,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,number,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,),O
PMC28516820_608,7752,",",O
PMC28516820_608,7752,quetiapine,B-Drug
PMC28516820_608,7752,(,O
PMC28516820_608,7752,n,O
PMC28516820_608,7752,=,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,number,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,),O
PMC28516820_608,7752,",",O
PMC28516820_608,7752,or,O
PMC28516820_608,7752,ziprasidone,B-Drug
PMC28516820_608,7752,(,O
PMC28516820_608,7752,n,O
PMC28516820_608,7752,=,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,number,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,),O
PMC28516820_608,7752,",",O
PMC28516820_608,7752,and,O
PMC28516820_608,7752,followed,O
PMC28516820_608,7752,for,O
PMC28516820_608,7752,up,O
PMC28516820_608,7752,to,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,number,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,_,O
PMC28516820_608,7752,years,O
PMC28516820_608,7752,0,O
PMC28535050_660,7753,METHOD,O
PMC28535050_660,7753,:,O
PMC28535050_660,7753,Economic,O
PMC28535050_660,7753,evaluation,O
PMC28535050_660,7753,alongside,O
PMC28535050_660,7753,a,O
PMC28535050_660,7753,double,O
PMC28535050_660,7753,-,O
PMC28535050_660,7753,blind,O
PMC28535050_660,7753,randomised,O
PMC28535050_660,7753,placebo,O
PMC28535050_660,7753,-,O
PMC28535050_660,7753,controlled,O
PMC28535050_660,7753,trial,O
PMC28535050_660,7753,(,O
PMC28535050_660,7753,National,O
PMC28535050_660,7753,Research,O
PMC28535050_660,7753,Register,O
PMC28535050_660,7753,Trial,O
PMC28535050_660,7753,Number,O
PMC28535050_660,7753,N,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,number,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,),O
PMC28535050_660,7753,of,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,number,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,hypertensive,O
PMC28535050_660,7753,patients,O
PMC28535050_660,7753,receiving,O
PMC28535050_660,7753,an,O
PMC28535050_660,7753,antihypertensive,O
PMC28535050_660,7753,regimen,O
PMC28535050_660,7753,(,O
PMC28535050_660,7753,labetalol,O
PMC28535050_660,7753,or,O
PMC28535050_660,7753,lisinopril,B-Drug
PMC28535050_660,7753,),O
PMC28535050_660,7753,within,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,number,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,hours,O
PMC28535050_660,7753,post,O
PMC28535050_660,7753,stroke,O
PMC28535050_660,7753,versus,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,number,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,_,O
PMC28535050_660,7753,receiving,O
PMC28535050_660,7753,placebo,O
PMC28535050_660,7753,0,O
PMC28549740_595,7754,The,O
PMC28549740_595,7754,aim,O
PMC28549740_595,7754,of,O
PMC28549740_595,7754,this,O
PMC28549740_595,7754,study,O
PMC28549740_595,7754,was,O
PMC28549740_595,7754,to,O
PMC28549740_595,7754,determine,O
PMC28549740_595,7754,the,O
PMC28549740_595,7754,role,O
PMC28549740_595,7754,of,O
PMC28549740_595,7754,the,O
PMC28549740_595,7754,anxiolytic,O
PMC28549740_595,7754,effect,O
PMC28549740_595,7754,of,O
PMC28549740_595,7754,paroxetine,B-Drug
PMC28549740_595,7754,on,O
PMC28549740_595,7754,the,O
PMC28549740_595,7754,prevention,O
PMC28549740_595,7754,of,O
PMC28549740_595,7754,migraine,O
PMC28549740_595,7754,0,O
PMC28594790_603,7755,He,O
PMC28594790_603,7755,was,O
PMC28594790_603,7755,taking,O
PMC28594790_603,7755,atenolol,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,number,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,mg,O
PMC28594790_603,7755,/,O
PMC28594790_603,7755,day,O
PMC28594790_603,7755,",",O
PMC28594790_603,7755,amlodipine,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,number,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,mg,O
PMC28594790_603,7755,/,O
PMC28594790_603,7755,day,O
PMC28594790_603,7755,",",O
PMC28594790_603,7755,and,O
PMC28594790_603,7755,a,O
PMC28594790_603,7755,combination,O
PMC28594790_603,7755,of,O
PMC28594790_603,7755,lisinopril,B-Drug
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,number,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,mg,O
PMC28594790_603,7755,/,O
PMC28594790_603,7755,hydrochlorothiazide,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,number,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,_,O
PMC28594790_603,7755,mg,O
PMC28594790_603,7755,daily,O
PMC28594790_603,7755,but,O
PMC28594790_603,7755,experienced,O
PMC28594790_603,7755,several,O
PMC28594790_603,7755,hypertension,B-Symptom
PMC28594790_603,7755,peaks,O
PMC28594790_603,7755,and,O
PMC28594790_603,7755,hypotension,B-Symptom
PMC28594790_603,7755,0,O
PMC28618440_261,7756,Review,O
PMC28618440_261,7756,of,O
PMC28618440_261,7756,topiramate,B-Drug
PMC28618440_261,7756,for,O
PMC28618440_261,7756,the,O
PMC28618440_261,7756,treatment,O
PMC28618440_261,7756,of,O
PMC28618440_261,7756,epilepsy,B-Disease
PMC28618440_261,7756,in,O
PMC28618440_261,7756,elderly,O
PMC28618440_261,7756,patients,O
PMC28618440_261,7756,0,O
PMC28619300_352,7757,CONCLUSION,O
PMC28619300_352,7757,:,O
PMC28619300_352,7757,SLT,O
PMC28619300_352,7757,may,O
PMC28619300_352,7757,be,O
PMC28619300_352,7757,effective,O
PMC28619300_352,7757,in,O
PMC28619300_352,7757,reducing,O
PMC28619300_352,7757,elevated,O
PMC28619300_352,7757,IOP,O
PMC28619300_352,7757,following,O
PMC28619300_352,7757,subtenon,O
PMC28619300_352,7757,injection,O
PMC28619300_352,7757,of,O
PMC28619300_352,7757,triamcinolone,B-Drug
PMC28619300_352,7757,acetonide,O
PMC28619300_352,7757,and,O
PMC28619300_352,7757,should,O
PMC28619300_352,7757,be,O
PMC28619300_352,7757,considered,O
PMC28619300_352,7757,before,O
PMC28619300_352,7757,glaucoma,B-Disease
PMC28619300_352,7757,surgery,O
PMC28619300_352,7757,0,O
PMC28619370_319,7758,Is,O
PMC28619370_319,7758,monthly,O
PMC28619370_319,7758,retreatment,O
PMC28619370_319,7758,with,O
PMC28619370_319,7758,intravitreal,O
PMC28619370_319,7758,bevacizumab,B-Drug
PMC28619370_319,7758,(,O
PMC28619370_319,7758,Avastin,B-Drug
PMC28619370_319,7758,),O
PMC28619370_319,7758,necessary,O
PMC28619370_319,7758,in,O
PMC28619370_319,7758,neovascular,O
PMC28619370_319,7758,age,O
PMC28619370_319,7758,-,O
PMC28619370_319,7758,related,O
PMC28619370_319,7758,macular,O
PMC28619370_319,7758,degeneration,O
PMC28619370_319,7758,?,O
PMC28680380_1015,7758,CONCLUSION,O
PMC28680380_1015,7758,:,O
PMC28680380_1015,7758,Doctors,O
PMC28680380_1015,7758,should,O
PMC28680380_1015,7758,consider,O
PMC28680380_1015,7758,that,O
PMC28680380_1015,7758,fluvoxamine,B-Drug
PMC28680380_1015,7758,may,O
PMC28680380_1015,7758,be,O
PMC28680380_1015,7758,an,O
PMC28680380_1015,7758,alternative,O
PMC28680380_1015,7758,approach,O
PMC28680380_1015,7758,in,O
PMC28680380_1015,7758,treating,O
PMC28680380_1015,7758,akathisia,B-Symptom
PMC28680380_1015,7758,associated,O
PMC28680380_1015,7758,with,O
PMC28680380_1015,7758,atypical,O
PMC28680380_1015,7758,antipsychotic,O
PMC28680380_1015,7758,drugs,O
PMC28680380_1015,7758,0,O
PMC28680390_202,7759,METHODS,O
PMC28680390_202,7759,:,O
PMC28680390_202,7759,We,O
PMC28680390_202,7759,report,O
PMC28680390_202,7759,on,O
PMC28680390_202,7759,five,O
PMC28680390_202,7759,Japanese,O
PMC28680390_202,7759,men,O
PMC28680390_202,7759,(,O
PMC28680390_202,7759,an,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,number,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,year,O
PMC28680390_202,7759,old,O
PMC28680390_202,7759,(,O
PMC28680390_202,7759,acute,O
PMC28680390_202,7759,aortic,O
PMC28680390_202,7759,dissociation,O
PMC28680390_202,7759,:,O
PMC28680390_202,7759,Stanford,O
PMC28680390_202,7759,type,O
PMC28680390_202,7759,A,O
PMC28680390_202,7759,),O
PMC28680390_202,7759,",",O
PMC28680390_202,7759,a,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,number,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,year,O
PMC28680390_202,7759,old,O
PMC28680390_202,7759,(,O
PMC28680390_202,7759,traumatic,O
PMC28680390_202,7759,subarachnoid,B-Symptom
PMC28680390_202,7759,hemorrhage,I-Symptom
PMC28680390_202,7759,and,O
PMC28680390_202,7759,brain,O
PMC28680390_202,7759,contusion,B-Symptom
PMC28680390_202,7759,),O
PMC28680390_202,7759,",",O
PMC28680390_202,7759,a,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,number,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,year,O
PMC28680390_202,7759,old,O
PMC28680390_202,7759,(,O
PMC28680390_202,7759,sepsis,O
PMC28680390_202,7759,by,O
PMC28680390_202,7759,pyelonephritis,O
PMC28680390_202,7759,),O
PMC28680390_202,7759,",",O
PMC28680390_202,7759,an,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,number,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,year,O
PMC28680390_202,7759,old,O
PMC28680390_202,7759,(,O
PMC28680390_202,7759,cerebral,O
PMC28680390_202,7759,infarction,O
PMC28680390_202,7759,),O
PMC28680390_202,7759,",",O
PMC28680390_202,7759,and,O
PMC28680390_202,7759,an,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,number,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,year,O
PMC28680390_202,7759,old,O
PMC28680390_202,7759,(,O
PMC28680390_202,7759,pulmonary,O
PMC28680390_202,7759,emphysema,O
PMC28680390_202,7759,and,O
PMC28680390_202,7759,severe,O
PMC28680390_202,7759,pneumonia,O
PMC28680390_202,7759,),O
PMC28680390_202,7759,),O
PMC28680390_202,7759,in,O
PMC28680390_202,7759,which,O
PMC28680390_202,7759,the,O
PMC28680390_202,7759,selective,O
PMC28680390_202,7759,serotonin,O
PMC28680390_202,7759,reuptake,O
PMC28680390_202,7759,inhibitor,O
PMC28680390_202,7759,and,O
PMC28680390_202,7759,sigma,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,number,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,_,O
PMC28680390_202,7759,receptor,O
PMC28680390_202,7759,agonist,O
PMC28680390_202,7759,fluvoxamine,B-Drug
PMC28680390_202,7759,was,O
PMC28680390_202,7759,effective,O
PMC28680390_202,7759,in,O
PMC28680390_202,7759,ameliorating,O
PMC28680390_202,7759,the,O
PMC28680390_202,7759,delirium,B-Symptom
PMC28680390_202,7759,of,O
PMC28680390_202,7759,the,O
PMC28680390_202,7759,patients,O
PMC28680390_202,7759,0,O
PMC28680390_322,7760,Sigma,O
PMC28680390_322,7760,_,O
PMC28680390_322,7760,_,O
PMC28680390_322,7760,number,O
PMC28680390_322,7760,_,O
PMC28680390_322,7760,_,O
PMC28680390_322,7760,receptor,O
PMC28680390_322,7760,agonist,O
PMC28680390_322,7760,fluvoxamine,B-Drug
PMC28680390_322,7760,for,O
PMC28680390_322,7760,delirium,B-Symptom
PMC28680390_322,7760,in,O
PMC28680390_322,7760,intensive,O
PMC28680390_322,7760,care,O
PMC28680390_322,7760,units,O
PMC28680390_322,7760,:,O
PMC28680390_322,7760,report,O
PMC28680390_322,7760,of,O
PMC28680390_322,7760,five,O
PMC28680390_322,7760,cases,O
PMC28680390_322,7760,0,O
PMC28680390_671,7761,CONCLUSION,O
PMC28680390_671,7761,:,O
PMC28680390_671,7761,Doctors,O
PMC28680390_671,7761,should,O
PMC28680390_671,7761,consider,O
PMC28680390_671,7761,fluvoxamine,B-Drug
PMC28680390_671,7761,as,O
PMC28680390_671,7761,an,O
PMC28680390_671,7761,alternative,O
PMC28680390_671,7761,approach,O
PMC28680390_671,7761,to,O
PMC28680390_671,7761,treating,O
PMC28680390_671,7761,delirium,B-Symptom
PMC28680390_671,7761,in,O
PMC28680390_671,7761,ICU,O
PMC28680390_671,7761,patients,O
PMC28680390_671,7761,in,O
PMC28680390_671,7761,order,O
PMC28680390_671,7761,to,O
PMC28680390_671,7761,avoid,O
PMC28680390_671,7761,the,O
PMC28680390_671,7761,risk,O
PMC28680390_671,7761,of,O
PMC28680390_671,7761,side,O
PMC28680390_671,7761,effects,O
PMC28680390_671,7761,and,O
PMC28680390_671,7761,increased,O
PMC28680390_671,7761,mortality,O
PMC28680390_671,7761,from,O
PMC28680390_671,7761,antipsychotic,O
PMC28680390_671,7761,drugs,O
PMC28680390_671,7761,0,O
PMC28743380_48,7762,Lamotrigine,B-Drug
PMC28743380_48,7762,(,O
PMC28743380_48,7762,LTG,O
PMC28743380_48,7762,),O
PMC28743380_48,7762,is,O
PMC28743380_48,7762,a,O
PMC28743380_48,7762,broad,O
PMC28743380_48,7762,spectrum,O
PMC28743380_48,7762,antiepileptic,O
PMC28743380_48,7762,drug,O
PMC28743380_48,7762,(,O
PMC28743380_48,7762,AED,O
PMC28743380_48,7762,),O
PMC28743380_48,7762,",",O
PMC28743380_48,7762,effective,O
PMC28743380_48,7762,against,O
PMC28743380_48,7762,both,O
PMC28743380_48,7762,generalized,O
PMC28743380_48,7762,and,O
PMC28743380_48,7762,partial,B-Symptom
PMC28743380_48,7762,seizures,I-Symptom
PMC28743380_48,7762,0,O
PMC28757440_62,7763,Docetaxel,B-Drug
PMC28757440_62,7763,-,O
PMC28757440_62,7763,induced,O
PMC28757440_62,7763,photolichenoid,B-Symptom
PMC28757440_62,7763,eruption,I-Symptom
PMC28757440_62,7763,0,O
PMC28776070_254,7764,Trazodone,B-Drug
PMC28776070_254,7764,effects,O
PMC28776070_254,7764,on,O
PMC28776070_254,7764,[,O
PMC28776070_254,7764,H,O
PMC28776070_254,7764,],O
PMC28776070_254,7764,-,O
PMC28776070_254,7764,paroxetine,O
PMC28776070_254,7764,and,O
PMC28776070_254,7764,alpha,O
PMC28776070_254,7764,(,O
PMC28776070_254,7764,_,O
PMC28776070_254,7764,_,O
PMC28776070_254,7764,number,O
PMC28776070_254,7764,_,O
PMC28776070_254,7764,_,O
PMC28776070_254,7764,),O
PMC28776070_254,7764,-,O
PMC28776070_254,7764,adrenoreceptors,O
PMC28776070_254,7764,in,O
PMC28776070_254,7764,platelets,O
PMC28776070_254,7764,of,O
PMC28776070_254,7764,patients,O
PMC28776070_254,7764,with,O
PMC28776070_254,7764,major,B-Disease
PMC28776070_254,7764,depression,I-Disease
PMC28776070_254,7764,0,O
PMC28776070_44,7765,The,O
PMC28776070_44,7765,lack,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,information,O
PMC28776070_44,7765,on,O
PMC28776070_44,7765,its,O
PMC28776070_44,7765,effects,O
PMC28776070_44,7765,in,O
PMC28776070_44,7765,vivo,O
PMC28776070_44,7765,prompted,O
PMC28776070_44,7765,us,O
PMC28776070_44,7765,to,O
PMC28776070_44,7765,evaluate,O
PMC28776070_44,7765,alpha,O
PMC28776070_44,7765,(,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,number,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,-,O
PMC28776070_44,7765,adrenoceptors,O
PMC28776070_44,7765,by,O
PMC28776070_44,7765,means,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,the,O
PMC28776070_44,7765,specific,O
PMC28776070_44,7765,binding,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,[,O
PMC28776070_44,7765,(,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,number,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,H,O
PMC28776070_44,7765,],O
PMC28776070_44,7765,-,O
PMC28776070_44,7765,rauwolscine,O
PMC28776070_44,7765,",",O
PMC28776070_44,7765,and,O
PMC28776070_44,7765,the,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,number,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,-,O
PMC28776070_44,7765,HT,O
PMC28776070_44,7765,transporter,O
PMC28776070_44,7765,(,O
PMC28776070_44,7765,SERT,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,by,O
PMC28776070_44,7765,means,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,the,O
PMC28776070_44,7765,binding,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,[,O
PMC28776070_44,7765,(,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,number,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,H,O
PMC28776070_44,7765,],O
PMC28776070_44,7765,-,O
PMC28776070_44,7765,paroxetine,B-Drug
PMC28776070_44,7765,(,O
PMC28776070_44,7765,[,O
PMC28776070_44,7765,(,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,number,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,H,O
PMC28776070_44,7765,],O
PMC28776070_44,7765,-,O
PMC28776070_44,7765,Par,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,",",O
PMC28776070_44,7765,in,O
PMC28776070_44,7765,platelets,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,depressed,B-Disease
PMC28776070_44,7765,patients,O
PMC28776070_44,7765,",",O
PMC28776070_44,7765,before,O
PMC28776070_44,7765,and,O
PMC28776070_44,7765,after,O
PMC28776070_44,7765,one,O
PMC28776070_44,7765,month,O
PMC28776070_44,7765,of,O
PMC28776070_44,7765,treatment,O
PMC28776070_44,7765,with,O
PMC28776070_44,7765,trazodone,B-Drug
PMC28776070_44,7765,(,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,number,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,_,O
PMC28776070_44,7765,mg,O
PMC28776070_44,7765,/,O
PMC28776070_44,7765,day,O
PMC28776070_44,7765,),O
PMC28776070_44,7765,0,O
PMC28776090_149,7766,New,O
PMC28776090_149,7766,and,O
PMC28776090_149,7766,extended,O
PMC28776090_149,7766,-,O
PMC28776090_149,7766,action,O
PMC28776090_149,7766,treatments,O
PMC28776090_149,7766,in,O
PMC28776090_149,7766,the,O
PMC28776090_149,7766,management,O
PMC28776090_149,7766,of,O
PMC28776090_149,7766,ADHD,B-Disease
PMC28776090_149,7766,:,O
PMC28776090_149,7766,a,O
PMC28776090_149,7766,critical,O
PMC28776090_149,7766,appraisal,O
PMC28776090_149,7766,of,O
PMC28776090_149,7766,lisdexamfetamine,B-Drug
PMC28776090_149,7766,in,O
PMC28776090_149,7766,adults,O
PMC28776090_149,7766,and,O
PMC28776090_149,7766,children,O
PMC28776090_149,7766,0,O
PMC28776090_639,7767,One,O
PMC28776090_639,7767,such,O
PMC28776090_639,7767,recent,O
PMC28776090_639,7767,development,O
PMC28776090_639,7767,",",O
PMC28776090_639,7767,lisdexamfetamine,B-Drug
PMC28776090_639,7767,(,O
PMC28776090_639,7767,LDX,O
PMC28776090_639,7767,),O
PMC28776090_639,7767,was,O
PMC28776090_639,7767,FDA,O
PMC28776090_639,7767,approved,O
PMC28776090_639,7767,for,O
PMC28776090_639,7767,treating,O
PMC28776090_639,7767,ADHD,B-Disease
PMC28776090_639,7767,in,O
PMC28776090_639,7767,children,O
PMC28776090_639,7767,in,O
PMC28776090_639,7767,early,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,number,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,and,O
PMC28776090_639,7767,in,O
PMC28776090_639,7767,adults,O
PMC28776090_639,7767,in,O
PMC28776090_639,7767,early,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,number,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,_,O
PMC28776090_639,7767,0,O
PMC28784050_986,7768,Effect,O
PMC28784050_986,7768,of,O
PMC28784050_986,7768,amlodipine,O
PMC28784050_986,7768,and,O
PMC28784050_986,7768,lisinopril,B-Drug
PMC28784050_986,7768,on,O
PMC28784050_986,7768,microalbuminuria,B-Symptom
PMC28784050_986,7768,in,O
PMC28784050_986,7768,patients,O
PMC28784050_986,7768,with,O
PMC28784050_986,7768,essential,O
PMC28784050_986,7768,hypertension,O
PMC28784050_986,7768,:,O
PMC28784050_986,7768,A,O
PMC28784050_986,7768,prospective,O
PMC28784050_986,7768,study,O
PMC28784050_986,7768,0,O
PMC28811050_145,7769,The,O
PMC28811050_145,7769,opposite,O
PMC28811050_145,7769,effects,O
PMC28811050_145,7769,of,O
PMC28811050_145,7769,fluvoxamine,B-Drug
PMC28811050_145,7769,and,O
PMC28811050_145,7769,sertraline,B-Drug
PMC28811050_145,7769,in,O
PMC28811050_145,7769,the,O
PMC28811050_145,7769,treatment,O
PMC28811050_145,7769,of,O
PMC28811050_145,7769,psychotic,B-Disease
PMC28811050_145,7769,major,I-Disease
PMC28811050_145,7769,depression,I-Disease
PMC28811050_145,7769,:,O
PMC28811050_145,7769,a,O
PMC28811050_145,7769,case,O
PMC28811050_145,7769,report,O
PMC28811050_145,7769,0,O
PMC28811050_326,7770,METHODS,O
PMC28811050_326,7770,:,O
PMC28811050_326,7770,We,O
PMC28811050_326,7770,report,O
PMC28811050_326,7770,on,O
PMC28811050_326,7770,a,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,number,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,-,O
PMC28811050_326,7770,year,O
PMC28811050_326,7770,-,O
PMC28811050_326,7770,old,O
PMC28811050_326,7770,Japanese,O
PMC28811050_326,7770,woman,O
PMC28811050_326,7770,in,O
PMC28811050_326,7770,whom,O
PMC28811050_326,7770,fluvoxamine,B-Drug
PMC28811050_326,7770,(,O
PMC28811050_326,7770,a,O
PMC28811050_326,7770,SSRI,O
PMC28811050_326,7770,with,O
PMC28811050_326,7770,sigma,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,number,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,receptor,O
PMC28811050_326,7770,agonist,O
PMC28811050_326,7770,),O
PMC28811050_326,7770,and,O
PMC28811050_326,7770,sertraline,B-Drug
PMC28811050_326,7770,(,O
PMC28811050_326,7770,a,O
PMC28811050_326,7770,SSRI,O
PMC28811050_326,7770,with,O
PMC28811050_326,7770,sigma,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,number,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,_,O
PMC28811050_326,7770,receptor,O
PMC28811050_326,7770,antagonist,O
PMC28811050_326,7770,),O
PMC28811050_326,7770,showed,O
PMC28811050_326,7770,the,O
PMC28811050_326,7770,opposite,O
PMC28811050_326,7770,effects,O
PMC28811050_326,7770,on,O
PMC28811050_326,7770,psychotic,O
PMC28811050_326,7770,symptoms,O
PMC28811050_326,7770,in,O
PMC28811050_326,7770,the,O
PMC28811050_326,7770,treatment,O
PMC28811050_326,7770,of,O
PMC28811050_326,7770,psychotic,B-Disease
PMC28811050_326,7770,major,I-Disease
PMC28811050_326,7770,depression,I-Disease
PMC28811050_326,7770,0,O
PMC28811050_611,7771,In,O
PMC28811050_611,7771,several,O
PMC28811050_611,7771,studies,O
PMC28811050_611,7771,",",O
PMC28811050_611,7771,monotherapy,O
PMC28811050_611,7771,of,O
PMC28811050_611,7771,SSRIs,O
PMC28811050_611,7771,such,O
PMC28811050_611,7771,as,O
PMC28811050_611,7771,fluvoxamine,B-Drug
PMC28811050_611,7771,has,O
PMC28811050_611,7771,been,O
PMC28811050_611,7771,shown,O
PMC28811050_611,7771,to,O
PMC28811050_611,7771,be,O
PMC28811050_611,7771,effective,O
PMC28811050_611,7771,in,O
PMC28811050_611,7771,the,O
PMC28811050_611,7771,treatment,O
PMC28811050_611,7771,of,O
PMC28811050_611,7771,psychotic,B-Disease
PMC28811050_611,7771,major,I-Disease
PMC28811050_611,7771,depression,I-Disease
PMC28811050_611,7771,0,O
PMC28811050_680,7772,RESULTS,O
PMC28811050_680,7772,:,O
PMC28811050_680,7772,Symptoms,O
PMC28811050_680,7772,of,O
PMC28811050_680,7772,depression,O
PMC28811050_680,7772,and,O
PMC28811050_680,7772,psychosis,B-Symptom
PMC28811050_680,7772,in,O
PMC28811050_680,7772,the,O
PMC28811050_680,7772,patient,O
PMC28811050_680,7772,who,O
PMC28811050_680,7772,was,O
PMC28811050_680,7772,non,O
PMC28811050_680,7772,-,O
PMC28811050_680,7772,respondent,O
PMC28811050_680,7772,to,O
PMC28811050_680,7772,antipsychotic,O
PMC28811050_680,7772,drugs,O
PMC28811050_680,7772,improved,O
PMC28811050_680,7772,after,O
PMC28811050_680,7772,fluvoxamine,B-Drug
PMC28811050_680,7772,monotherapy,O
PMC28811050_680,7772,0,O
PMC28811050_830,7773,CONCLUSION,O
PMC28811050_830,7773,:,O
PMC28811050_830,7773,Doctors,O
PMC28811050_830,7773,should,O
PMC28811050_830,7773,consider,O
PMC28811050_830,7773,the,O
PMC28811050_830,7773,monotherapy,O
PMC28811050_830,7773,of,O
PMC28811050_830,7773,sigma,O
PMC28811050_830,7773,_,O
PMC28811050_830,7773,_,O
PMC28811050_830,7773,number,O
PMC28811050_830,7773,_,O
PMC28811050_830,7773,_,O
PMC28811050_830,7773,receptor,O
PMC28811050_830,7773,agonist,O
PMC28811050_830,7773,fluvoxamine,B-Drug
PMC28811050_830,7773,as,O
PMC28811050_830,7773,an,O
PMC28811050_830,7773,alternative,O
PMC28811050_830,7773,approach,O
PMC28811050_830,7773,to,O
PMC28811050_830,7773,treating,O
PMC28811050_830,7773,psychotic,B-Disease
PMC28811050_830,7773,major,I-Disease
PMC28811050_830,7773,depression,I-Disease
PMC28811050_830,7773,0,O
PMC28862560_993,7774,Residual,O
PMC28862560_993,7774,triamcinolone,B-Drug
PMC28862560_993,7774,acetonide,O
PMC28862560_993,7774,at,O
PMC28862560_993,7774,macular,O
PMC28862560_993,7774,hole,O
PMC28862560_993,7774,after,O
PMC28862560_993,7774,vitreous,O
PMC28862560_993,7774,surgery,O
PMC28862560_993,7774,0,O
PMC28863340_418,7775,Common,O
PMC28863340_418,7775,toxicities,O
PMC28863340_418,7775,associated,O
PMC28863340_418,7775,with,O
PMC28863340_418,7775,bevacizumab,B-Drug
PMC28863340_418,7775,include,O
PMC28863340_418,7775,hypertension,O
PMC28863340_418,7775,",",O
PMC28863340_418,7775,bleeding,B-Symptom
PMC28863340_418,7775,episodes,O
PMC28863340_418,7775,",",O
PMC28863340_418,7775,and,O
PMC28863340_418,7775,thrombotic,B-Symptom
PMC28863340_418,7775,events,I-Symptom
PMC28863340_418,7775,0,O
PMC28955890_533,7776,BACKGROUND,O
PMC28955890_533,7776,:,O
PMC28955890_533,7776,An,O
PMC28955890_533,7776,advance,O
PMC28955890_533,7776,in,O
PMC28955890_533,7776,the,O
PMC28955890_533,7776,treatment,O
PMC28955890_533,7776,of,O
PMC28955890_533,7776,schizophrenia,B-Disease
PMC28955890_533,7776,is,O
PMC28955890_533,7776,the,O
PMC28955890_533,7776,development,O
PMC28955890_533,7776,of,O
PMC28955890_533,7776,long,O
PMC28955890_533,7776,-,O
PMC28955890_533,7776,acting,O
PMC28955890_533,7776,intramuscular,O
PMC28955890_533,7776,formulations,O
PMC28955890_533,7776,of,O
PMC28955890_533,7776,antipsychotics,O
PMC28955890_533,7776,",",O
PMC28955890_533,7776,such,O
PMC28955890_533,7776,as,O
PMC28955890_533,7776,olanzapine,B-Drug
PMC28955890_533,7776,long,O
PMC28955890_533,7776,-,O
PMC28955890_533,7776,acting,O
PMC28955890_533,7776,injection,O
PMC28955890_533,7776,(,O
PMC28955890_533,7776,LAI,O
PMC28955890_533,7776,),O
PMC28955890_533,7776,0,O
PMC28981650_534,7777,Olanzapine,B-Drug
PMC28981650_534,7777,LAI,O
PMC28981650_534,7777,appears,O
PMC28981650_534,7777,to,O
PMC28981650_534,7777,be,O
PMC28981650_534,7777,an,O
PMC28981650_534,7777,effective,O
PMC28981650_534,7777,antipsychotic,O
PMC28981650_534,7777,at,O
PMC28981650_534,7777,dosages,O
PMC28981650_534,7777,of,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,mg,O
PMC28981650_534,7777,every,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,weeks,O
PMC28981650_534,7777,",",O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,mg,O
PMC28981650_534,7777,every,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,weeks,O
PMC28981650_534,7777,and,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,mg,O
PMC28981650_534,7777,every,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,weeks,O
PMC28981650_534,7777,in,O
PMC28981650_534,7777,patients,O
PMC28981650_534,7777,with,O
PMC28981650_534,7777,acute,B-Disease
PMC28981650_534,7777,schizophrenia,I-Disease
PMC28981650_534,7777,",",O
PMC28981650_534,7777,and,O
PMC28981650_534,7777,at,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,mg,O
PMC28981650_534,7777,every,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,weeks,O
PMC28981650_534,7777,",",O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,mg,O
PMC28981650_534,7777,every,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,weeks,O
PMC28981650_534,7777,and,O
PMC28981650_534,7777,at,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,mg,O
PMC28981650_534,7777,every,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,number,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,_,O
PMC28981650_534,7777,weeks,O
PMC28981650_534,7777,for,O
PMC28981650_534,7777,the,O
PMC28981650_534,7777,maintenance,O
PMC28981650_534,7777,treatment,O
PMC28981650_534,7777,of,O
PMC28981650_534,7777,stable,O
PMC28981650_534,7777,patients,O
PMC28981650_534,7777,0,O
PMC29002350_965,7778,METHODS,O
PMC29002350_965,7778,:,O
PMC29002350_965,7778,We,O
PMC29002350_965,7778,report,O
PMC29002350_965,7778,on,O
PMC29002350_965,7778,a,O
PMC29002350_965,7778,Japanese,O
PMC29002350_965,7778,woman,O
PMC29002350_965,7778,(,O
PMC29002350_965,7778,an,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,number,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,-,O
PMC29002350_965,7778,year,O
PMC29002350_965,7778,-,O
PMC29002350_965,7778,old,O
PMC29002350_965,7778,(,O
PMC29002350_965,7778,open,O
PMC29002350_965,7778,reduction,O
PMC29002350_965,7778,and,O
PMC29002350_965,7778,internal,O
PMC29002350_965,7778,fixation,O
PMC29002350_965,7778,of,O
PMC29002350_965,7778,the,O
PMC29002350_965,7778,right,O
PMC29002350_965,7778,femoral,O
PMC29002350_965,7778,neck,O
PMC29002350_965,7778,fracture,O
PMC29002350_965,7778,),O
PMC29002350_965,7778,",",O
PMC29002350_965,7778,and,O
PMC29002350_965,7778,two,O
PMC29002350_965,7778,Japanese,O
PMC29002350_965,7778,men,O
PMC29002350_965,7778,(,O
PMC29002350_965,7778,an,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,number,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,-,O
PMC29002350_965,7778,year,O
PMC29002350_965,7778,-,O
PMC29002350_965,7778,old,O
PMC29002350_965,7778,(,O
PMC29002350_965,7778,abdominal,O
PMC29002350_965,7778,aortic,O
PMC29002350_965,7778,aneurysm,O
PMC29002350_965,7778,stent,O
PMC29002350_965,7778,grafting,O
PMC29002350_965,7778,),O
PMC29002350_965,7778,",",O
PMC29002350_965,7778,and,O
PMC29002350_965,7778,a,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,number,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,-,O
PMC29002350_965,7778,year,O
PMC29002350_965,7778,-,O
PMC29002350_965,7778,old,O
PMC29002350_965,7778,(,O
PMC29002350_965,7778,right,O
PMC29002350_965,7778,upper,O
PMC29002350_965,7778,lobectomy,O
PMC29002350_965,7778,due,O
PMC29002350_965,7778,to,O
PMC29002350_965,7778,lung,O
PMC29002350_965,7778,tumour,O
PMC29002350_965,7778,),O
PMC29002350_965,7778,),O
PMC29002350_965,7778,in,O
PMC29002350_965,7778,which,O
PMC29002350_965,7778,the,O
PMC29002350_965,7778,selective,O
PMC29002350_965,7778,serotonin,O
PMC29002350_965,7778,reuptake,O
PMC29002350_965,7778,inhibitor,O
PMC29002350_965,7778,and,O
PMC29002350_965,7778,sigma,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,number,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,_,O
PMC29002350_965,7778,receptor,O
PMC29002350_965,7778,agonist,O
PMC29002350_965,7778,fluvoxamine,B-Drug
PMC29002350_965,7778,was,O
PMC29002350_965,7778,effective,O
PMC29002350_965,7778,in,O
PMC29002350_965,7778,ameliorating,O
PMC29002350_965,7778,the,O
PMC29002350_965,7778,postoperative,O
PMC29002350_965,7778,delirium,B-Symptom
PMC29002350_965,7778,of,O
PMC29002350_965,7778,these,O
PMC29002350_965,7778,patients,O
PMC29002350_965,7778,0,O
PMC29070080_614,7779,We,O
PMC29070080_614,7779,report,O
PMC29070080_614,7779,an,O
PMC29070080_614,7779,adverse,O
PMC29070080_614,7779,drug,O
PMC29070080_614,7779,reaction,O
PMC29070080_614,7779,to,O
PMC29070080_614,7779,paroxetine,B-Drug
PMC29070080_614,7779,and,O
PMC29070080_614,7779,sertraline,B-Drug
PMC29070080_614,7779,in,O
PMC29070080_614,7779,a,O
PMC29070080_614,7779,patient,O
PMC29070080_614,7779,of,O
PMC29070080_614,7779,panic,O
PMC29070080_614,7779,disorder,O
PMC29070080_614,7779,",",O
PMC29070080_614,7779,who,O
PMC29070080_614,7779,initially,O
PMC29070080_614,7779,developed,O
PMC29070080_614,7779,a,O
PMC29070080_614,7779,maculopapular,B-Symptom
PMC29070080_614,7779,",",I-Symptom
PMC29070080_614,7779,erythematous,I-Symptom
PMC29070080_614,7779,",",I-Symptom
PMC29070080_614,7779,pruritic,I-Symptom
PMC29070080_614,7779,rash,I-Symptom
PMC29070080_614,7779,in,O
PMC29070080_614,7779,the,O
PMC29070080_614,7779,third,O
PMC29070080_614,7779,week,O
PMC29070080_614,7779,with,O
PMC29070080_614,7779,sertraline,B-Drug
PMC29070080_614,7779,_,O
PMC29070080_614,7779,_,O
PMC29070080_614,7779,number,O
PMC29070080_614,7779,_,O
PMC29070080_614,7779,_,O
PMC29070080_614,7779,mg,O
PMC29070080_614,7779,/,O
PMC29070080_614,7779,day,O
PMC29070080_614,7779,0,O
PMC29080540_531,7780,BACKGROUND,O
PMC29080540_531,7780,:,O
PMC29080540_531,7780,Duration,O
PMC29080540_531,7780,of,O
PMC29080540_531,7780,efficacy,O
PMC29080540_531,7780,and,O
PMC29080540_531,7780,safety,O
PMC29080540_531,7780,of,O
PMC29080540_531,7780,lisdexamfetamine,B-Drug
PMC29080540_531,7780,dimesylate,I-Drug
PMC29080540_531,7780,(,O
PMC29080540_531,7780,LDX,B-Drug
PMC29080540_531,7780,),O
PMC29080540_531,7780,was,O
PMC29080540_531,7780,assessed,O
PMC29080540_531,7780,in,O
PMC29080540_531,7780,adults,O
PMC29080540_531,7780,(,O
PMC29080540_531,7780,_,O
PMC29080540_531,7780,_,O
PMC29080540_531,7780,number,O
PMC29080540_531,7780,_,O
PMC29080540_531,7780,_,O
PMC29080540_531,7780,years,O
PMC29080540_531,7780,),O
PMC29080540_531,7780,with,O
PMC29080540_531,7780,attention,B-Disease
PMC29080540_531,7780,-,I-Disease
PMC29080540_531,7780,deficit,I-Disease
PMC29080540_531,7780,/,I-Disease
PMC29080540_531,7780,hyperactivity,I-Disease
PMC29080540_531,7780,disorder,I-Disease
PMC29080540_531,7780,(,O
PMC29080540_531,7780,ADHD,B-Disease
PMC29080540_531,7780,),O
PMC29080540_531,7780,using,O
PMC29080540_531,7780,the,O
PMC29080540_531,7780,simulated,O
PMC29080540_531,7780,adult,O
PMC29080540_531,7780,workplace,O
PMC29080540_531,7780,environment,O
PMC29080540_531,7780,0,O
PMC29080540_571,7781,Randomized,O
PMC29080540_571,7781,",",O
PMC29080540_571,7781,double,O
PMC29080540_571,7781,-,O
PMC29080540_571,7781,blind,O
PMC29080540_571,7781,",",O
PMC29080540_571,7781,placebo,O
PMC29080540_571,7781,-,O
PMC29080540_571,7781,controlled,O
PMC29080540_571,7781,",",O
PMC29080540_571,7781,crossover,O
PMC29080540_571,7781,study,O
PMC29080540_571,7781,of,O
PMC29080540_571,7781,the,O
PMC29080540_571,7781,efficacy,O
PMC29080540_571,7781,and,O
PMC29080540_571,7781,safety,O
PMC29080540_571,7781,of,O
PMC29080540_571,7781,lisdexamfetamine,B-Drug
PMC29080540_571,7781,dimesylate,I-Drug
PMC29080540_571,7781,in,O
PMC29080540_571,7781,adults,O
PMC29080540_571,7781,with,O
PMC29080540_571,7781,attention,B-Disease
PMC29080540_571,7781,-,I-Disease
PMC29080540_571,7781,deficit,I-Disease
PMC29080540_571,7781,/,I-Disease
PMC29080540_571,7781,hyperactivity,I-Disease
PMC29080540_571,7781,disorder,I-Disease
PMC29080540_571,7781,:,O
PMC29080540_571,7781,novel,O
PMC29080540_571,7781,findings,O
PMC29080540_571,7781,using,O
PMC29080540_571,7781,a,O
PMC29080540_571,7781,simulated,O
PMC29080540_571,7781,adult,O
PMC29080540_571,7781,workplace,O
PMC29080540_571,7781,environment,O
PMC29080540_571,7781,design,O
PMC29080540_571,7781,0,O
PMC29088520_128,7782,Intravitreal,O
PMC29088520_128,7782,versus,O
PMC29088520_128,7782,posterior,O
PMC29088520_128,7782,subtenon,O
PMC29088520_128,7782,injection,O
PMC29088520_128,7782,of,O
PMC29088520_128,7782,triamcinolone,B-Drug
PMC29088520_128,7782,acetonide,O
PMC29088520_128,7782,for,O
PMC29088520_128,7782,diabetic,O
PMC29088520_128,7782,macular,O
PMC29088520_128,7782,edema,O
PMC29088520_128,7782,0,O
PMC29088520_15,7783,Sixty,O
PMC29088520_15,7783,eyes,O
PMC29088520_15,7783,of,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,number,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,patients,O
PMC29088520_15,7783,who,O
PMC29088520_15,7783,had,O
PMC29088520_15,7783,diffuse,O
PMC29088520_15,7783,diabetic,O
PMC29088520_15,7783,macular,O
PMC29088520_15,7783,edema,O
PMC29088520_15,7783,were,O
PMC29088520_15,7783,assigned,O
PMC29088520_15,7783,to,O
PMC29088520_15,7783,receive,O
PMC29088520_15,7783,a,O
PMC29088520_15,7783,single,O
PMC29088520_15,7783,intravitreal,O
PMC29088520_15,7783,injection,O
PMC29088520_15,7783,(,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,number,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,mg,O
PMC29088520_15,7783,),O
PMC29088520_15,7783,or,O
PMC29088520_15,7783,a,O
PMC29088520_15,7783,single,O
PMC29088520_15,7783,posterior,O
PMC29088520_15,7783,subtenon,O
PMC29088520_15,7783,injection,O
PMC29088520_15,7783,(,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,number,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,_,O
PMC29088520_15,7783,mg,O
PMC29088520_15,7783,),O
PMC29088520_15,7783,of,O
PMC29088520_15,7783,triamcinolone,B-Drug
PMC29088520_15,7783,acetonide,O
PMC29088520_15,7783,0,O
PMC29126820_464,7784,Ziprasidone,B-Drug
PMC29126820_464,7784,and,O
PMC29126820_464,7784,its,O
PMC29126820_464,7784,association,O
PMC29126820_464,7784,with,O
PMC29126820_464,7784,sudden,O
PMC29126820_464,7784,cardiac,O
PMC29126820_464,7784,death,O
PMC29126820_464,7784,-,O
PMC29126820_464,7784,a,O
PMC29126820_464,7784,case,O
PMC29126820_464,7784,report,O
PMC29126820_464,7784,0,O
PMC29182970_1006,7785,We,O
PMC29182970_1006,7785,report,O
PMC29182970_1006,7785,the,O
PMC29182970_1006,7785,case,O
PMC29182970_1006,7785,of,O
PMC29182970_1006,7785,a,O
PMC29182970_1006,7785,patient,O
PMC29182970_1006,7785,who,O
PMC29182970_1006,7785,developed,O
PMC29182970_1006,7785,acute,O
PMC29182970_1006,7785,-,O
PMC29182970_1006,7785,onset,O
PMC29182970_1006,7785,hyponatraemia,B-Symptom
PMC29182970_1006,7785,that,O
PMC29182970_1006,7785,progressed,O
PMC29182970_1006,7785,rapidly,O
PMC29182970_1006,7785,to,O
PMC29182970_1006,7785,serious,O
PMC29182970_1006,7785,neurological,O
PMC29182970_1006,7785,dysfunction,O
PMC29182970_1006,7785,shortly,O
PMC29182970_1006,7785,after,O
PMC29182970_1006,7785,the,O
PMC29182970_1006,7785,introduction,O
PMC29182970_1006,7785,of,O
PMC29182970_1006,7785,citalopram,B-Drug
PMC29182970_1006,7785,0,O
PMC29183243_746,7786,Escitalopram,O
PMC29183243_746,7786,is,O
PMC29183243_746,7786,a,O
PMC29183243_746,7786,newer,O
PMC29183243_746,7786,SSRI,O
PMC29183243_746,7786,",",O
PMC29183243_746,7786,an,O
PMC29183243_746,7786,S,O
PMC29183243_746,7786,-,O
PMC29183243_746,7786,enantiomer,O
PMC29183243_746,7786,of,O
PMC29183243_746,7786,citalopram,B-Drug
PMC29183243_746,7786,",",O
PMC29183243_746,7786,which,O
PMC29183243_746,7786,is,O
PMC29183243_746,7786,both,O
PMC29183243_746,7786,safe,O
PMC29183243_746,7786,and,O
PMC29183243_746,7786,effective,O
PMC29183243_746,7786,in,O
PMC29183243_746,7786,the,O
PMC29183243_746,7786,treatment,O
PMC29183243_746,7786,of,O
PMC29183243_746,7786,depression,B-Disease
PMC29183243_746,7786,0,O
PMC29187850_80,7787,By,O
PMC29187850_80,7787,examining,O
PMC29187850_80,7787,irritability,B-Symptom
PMC29187850_80,7787,in,O
PMC29187850_80,7787,a,O
PMC29187850_80,7787,broader,O
PMC29187850_80,7787,spectrum,O
PMC29187850_80,7787,",",O
PMC29187850_80,7787,a,O
PMC29187850_80,7787,tailor,O
PMC29187850_80,7787,-,O
PMC29187850_80,7787,made,O
PMC29187850_80,7787,treatment,O
PMC29187850_80,7787,can,O
PMC29187850_80,7787,be,O
PMC29187850_80,7787,provided,O
PMC29187850_80,7787,0,O
PMC29187850_80,7788,In,O
PMC29187850_80,7788,general,O
PMC29187850_80,7788,",",O
PMC29187850_80,7788,I,O
PMC29187850_80,7788,recommend,O
PMC29187850_80,7788,as,O
PMC29187850_80,7788,a,O
PMC29187850_80,7788,first,O
PMC29187850_80,7788,step,O
PMC29187850_80,7788,a,O
PMC29187850_80,7788,selective,O
PMC29187850_80,7788,serotonin,O
PMC29187850_80,7788,reuptake,O
PMC29187850_80,7788,inhibitor,O
PMC29187850_80,7788,(,O
PMC29187850_80,7788,SSRI,O
PMC29187850_80,7788,),O
PMC29187850_80,7788,",",O
PMC29187850_80,7788,such,O
PMC29187850_80,7788,as,O
PMC29187850_80,7788,sertraline,B-Drug
PMC29187850_80,7788,",",O
PMC29187850_80,7788,or,O
PMC29187850_80,7788,the,O
PMC29187850_80,7788,mood,O
PMC29187850_80,7788,stabilizer,O
PMC29187850_80,7788,valproate,O
PMC29187850_80,7788,;,O
PMC29187850_80,7788,they,O
PMC29187850_80,7788,both,O
PMC29187850_80,7788,have,O
PMC29187850_80,7788,a,O
PMC29187850_80,7788,mild,O
PMC29187850_80,7788,side,O
PMC29187850_80,7788,effect,O
PMC29187850_80,7788,profile,O
PMC29187850_80,7788,0,O
PMC29278900_342,7789,In,O
PMC29278900_342,7789,bulimia,B-Disease
PMC29278900_342,7789,nervosa,I-Disease
PMC29278900_342,7789,",",O
PMC29278900_342,7789,both,O
PMC29278900_342,7789,fluoxetine,B-Drug
PMC29278900_342,7789,and,O
PMC29278900_342,7789,cognitive,O
PMC29278900_342,7789,behavior,O
PMC29278900_342,7789,therapy,O
PMC29278900_342,7789,have,O
PMC29278900_342,7789,been,O
PMC29278900_342,7789,found,O
PMC29278900_342,7789,to,O
PMC29278900_342,7789,be,O
PMC29278900_342,7789,effective,O
PMC29278900_342,7789,0,O
PMC29294090_251,7790,Cyclosporin,O
PMC29294090_251,7790,",",O
PMC29294090_251,7790,mycophenolate,O
PMC29294090_251,7790,mofetil,O
PMC29294090_251,7790,and,O
PMC29294090_251,7790,prednisone,B-Drug
PMC29294090_251,7790,were,O
PMC29294090_251,7790,used,O
PMC29294090_251,7790,for,O
PMC29294090_251,7790,postoperative,O
PMC29294090_251,7790,immunosuppression,O
PMC29294090_251,7790,0,O
PMC29334770_947,7791,Increasing,O
PMC29334770_947,7791,the,O
PMC29334770_947,7791,epidural,O
PMC29334770_947,7791,dose,O
PMC29334770_947,7791,of,O
PMC29334770_947,7791,Buprenorphine,B-Drug
PMC29334770_947,7791,from,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,number,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,mcg,O
PMC29334770_947,7791,to,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,number,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,_,O
PMC29334770_947,7791,mcg,O
PMC29334770_947,7791,proved,O
PMC29334770_947,7791,to,O
PMC29334770_947,7791,produce,B-Symptom
PMC29334770_947,7791,prolonged,I-Symptom
PMC29334770_947,7791,analgesia,I-Symptom
PMC29334770_947,7791,comparable,O
PMC29334770_947,7791,to,O
PMC29334770_947,7791,intrathecal,O
PMC29334770_947,7791,Buprenorphine,O
PMC29334770_947,7791,without,O
PMC29334770_947,7791,compromising,O
PMC29334770_947,7791,patient,O
PMC29334770_947,7791,safety,O
PMC29334770_947,7791,and,O
PMC29334770_947,7791,neonatal,O
PMC29334770_947,7791,outcome,O
PMC29334770_947,7791,0,O
PMC29347170_677,7792,Triamcinolone,B-Drug
PMC29347170_677,7792,acetonide,O
PMC29347170_677,7792,appears,O
PMC29347170_677,7792,to,O
PMC29347170_677,7792,be,O
PMC29347170_677,7792,more,O
PMC29347170_677,7792,effective,O
PMC29347170_677,7792,treatment,O
PMC29347170_677,7792,for,O
PMC29347170_677,7792,diabetic,O
PMC29347170_677,7792,macular,O
PMC29347170_677,7792,edema,O
PMC29347170_677,7792,than,O
PMC29347170_677,7792,bevacizumab,B-Drug
PMC29347170_677,7792,0,O
PMC29382990_716,7793,CONCLUSIONS,O
PMC29382990_716,7793,:,O
PMC29382990_716,7793,Adjunctive,O
PMC29382990_716,7793,quetiapine,B-Drug
PMC29382990_716,7793,treatment,O
PMC29382990_716,7793,alters,B-Symptom
PMC29382990_716,7793,sleep,I-Symptom
PMC29382990_716,7793,architecture,I-Symptom
PMC29382990_716,7793,in,O
PMC29382990_716,7793,patients,O
PMC29382990_716,7793,with,O
PMC29382990_716,7793,major,B-Disease
PMC29382990_716,7793,depressive,I-Disease
PMC29382990_716,7793,disorder,I-Disease
PMC29382990_716,7793,or,O
PMC29382990_716,7793,bipolar,B-Disease
PMC29382990_716,7793,disorder,I-Disease
PMC29382990_716,7793,",",O
PMC29382990_716,7793,which,O
PMC29382990_716,7793,may,O
PMC29382990_716,7793,partially,O
PMC29382990_716,7793,explain,O
PMC29382990_716,7793,its,O
PMC29382990_716,7793,early,O
PMC29382990_716,7793,antidepressant,O
PMC29382990_716,7793,properties,O
PMC29382990_716,7793,0,O
PMC29383060_894,7794,The,O
PMC29383060_894,7794,most,O
PMC29383060_894,7794,significant,O
PMC29383060_894,7794,studies,O
PMC29383060_894,7794,published,O
PMC29383060_894,7794,to,O
PMC29383060_894,7794,date,O
PMC29383060_894,7794,",",O
PMC29383060_894,7794,on,O
PMC29383060_894,7794,the,O
PMC29383060_894,7794,use,O
PMC29383060_894,7794,of,O
PMC29383060_894,7794,olanzapine,B-Drug
PMC29383060_894,7794,pamoate,O
PMC29383060_894,7794,in,O
PMC29383060_894,7794,schizophrenia,B-Disease
PMC29383060_894,7794,",",O
PMC29383060_894,7794,are,O
PMC29383060_894,7794,reviewed,O
PMC29383060_894,7794,in,O
PMC29383060_894,7794,this,O
PMC29383060_894,7794,article,O
PMC29383060_894,7794,0,O
PMC29456730_843,7795,In,O
PMC29456730_843,7795,this,O
PMC29456730_843,7795,paper,O
PMC29456730_843,7795,the,O
PMC29456730_843,7795,employment,O
PMC29456730_843,7795,of,O
PMC29456730_843,7795,anti,O
PMC29456730_843,7795,-,O
PMC29456730_843,7795,LTs,O
PMC29456730_843,7795,in,O
PMC29456730_843,7795,allergic,O
PMC29456730_843,7795,cutaneous,O
PMC29456730_843,7795,diseases,O
PMC29456730_843,7795,is,O
PMC29456730_843,7795,analyzed,O
PMC29456730_843,7795,showing,O
PMC29456730_843,7795,that,O
PMC29456730_843,7795,several,O
PMC29456730_843,7795,studies,O
PMC29456730_843,7795,have,O
PMC29456730_843,7795,recently,O
PMC29456730_843,7795,reported,O
PMC29456730_843,7795,a,O
PMC29456730_843,7795,beneficial,O
PMC29456730_843,7795,effects,O
PMC29456730_843,7795,of,O
PMC29456730_843,7795,these,O
PMC29456730_843,7795,agents,O
PMC29456730_843,7795,(,O
PMC29456730_843,7795,montelukast,B-Drug
PMC29456730_843,7795,and,O
PMC29456730_843,7795,zafirlukast,O
PMC29456730_843,7795,as,O
PMC29456730_843,7795,well,O
PMC29456730_843,7795,as,O
PMC29456730_843,7795,zileuton,O
PMC29456730_843,7795,),O
PMC29456730_843,7795,for,O
PMC29456730_843,7795,the,O
PMC29456730_843,7795,treatment,O
PMC29456730_843,7795,of,O
PMC29456730_843,7795,some,O
PMC29456730_843,7795,allergic,O
PMC29456730_843,7795,cutaneous,O
PMC29456730_843,7795,related,O
PMC29456730_843,7795,diseases,O
PMC29456730_843,7795,-,O
PMC29456730_843,7795,like,O
PMC29456730_843,7795,chronic,O
PMC29456730_843,7795,urticaria,O
PMC29456730_843,7795,and,O
PMC29456730_843,7795,atopic,B-Symptom
PMC29456730_843,7795,eczema,I-Symptom
PMC29456730_843,7795,although,O
PMC29456730_843,7795,their,O
PMC29456730_843,7795,proper,O
PMC29456730_843,7795,application,O
PMC29456730_843,7795,remains,O
PMC29456730_843,7795,to,O
PMC29456730_843,7795,be,O
PMC29456730_843,7795,established,O
PMC29456730_843,7795,0,O
PMC29459510_305,7796,Trazodone,B-Drug
PMC29459510_305,7796,for,O
PMC29459510_305,7796,the,O
PMC29459510_305,7796,treatment,O
PMC29459510_305,7796,of,O
PMC29459510_305,7796,fibromyalgia,B-Disease
PMC29459510_305,7796,:,O
PMC29459510_305,7796,an,O
PMC29459510_305,7796,open,O
PMC29459510_305,7796,-,O
PMC29459510_305,7796,label,O
PMC29459510_305,7796,",",O
PMC29459510_305,7796,_,O
PMC29459510_305,7796,_,O
PMC29459510_305,7796,number,O
PMC29459510_305,7796,_,O
PMC29459510_305,7796,_,O
PMC29459510_305,7796,-,O
PMC29459510_305,7796,week,O
PMC29459510_305,7796,study,O
PMC29459510_305,7796,0,O
PMC29459510_317,7797,BACKGROUND,O
PMC29459510_317,7797,:,O
PMC29459510_317,7797,Despite,O
PMC29459510_317,7797,its,O
PMC29459510_317,7797,frequent,O
PMC29459510_317,7797,use,O
PMC29459510_317,7797,as,O
PMC29459510_317,7797,a,O
PMC29459510_317,7797,hypnotic,O
PMC29459510_317,7797,",",O
PMC29459510_317,7797,trazodone,B-Drug
PMC29459510_317,7797,has,O
PMC29459510_317,7797,not,O
PMC29459510_317,7797,been,O
PMC29459510_317,7797,systematically,O
PMC29459510_317,7797,assessed,O
PMC29459510_317,7797,in,O
PMC29459510_317,7797,fibromyalgia,B-Disease
PMC29459510_317,7797,patients,O
PMC29459510_317,7797,0,O
PMC29459510_408,7798,RESULTS,O
PMC29459510_408,7798,:,O
PMC29459510_408,7798,Trazodone,B-Drug
PMC29459510_408,7798,markedly,O
PMC29459510_408,7798,improved,O
PMC29459510_408,7798,sleep,B-Symptom
PMC29459510_408,7798,quality,I-Symptom
PMC29459510_408,7798,",",O
PMC29459510_408,7798,with,O
PMC29459510_408,7798,large,O
PMC29459510_408,7798,effect,O
PMC29459510_408,7798,sizes,O
PMC29459510_408,7798,in,O
PMC29459510_408,7798,total,O
PMC29459510_408,7798,PSQI,O
PMC29459510_408,7798,score,O
PMC29459510_408,7798,as,O
PMC29459510_408,7798,well,O
PMC29459510_408,7798,on,O
PMC29459510_408,7798,sleep,O
PMC29459510_408,7798,quality,O
PMC29459510_408,7798,",",O
PMC29459510_408,7798,sleep,O
PMC29459510_408,7798,duration,O
PMC29459510_408,7798,and,O
PMC29459510_408,7798,sleep,O
PMC29459510_408,7798,efficiency,O
PMC29459510_408,7798,0,O
PMC29459510_475,7799,Unexpectedly,O
PMC29459510_475,7799,",",O
PMC29459510_475,7799,the,O
PMC29459510_475,7799,most,O
PMC29459510_475,7799,frequent,O
PMC29459510_475,7799,and,O
PMC29459510_475,7799,severe,O
PMC29459510_475,7799,side,O
PMC29459510_475,7799,effect,O
PMC29459510_475,7799,associated,O
PMC29459510_475,7799,with,O
PMC29459510_475,7799,trazodone,B-Drug
PMC29459510_475,7799,in,O
PMC29459510_475,7799,our,O
PMC29459510_475,7799,sample,O
PMC29459510_475,7799,was,O
PMC29459510_475,7799,tachycardia,B-Symptom
PMC29459510_475,7799,",",O
PMC29459510_475,7799,which,O
PMC29459510_475,7799,was,O
PMC29459510_475,7799,reported,O
PMC29459510_475,7799,by,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,number,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,(,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,number,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,_,O
PMC29459510_475,7799,%,O
PMC29459510_475,7799,),O
PMC29459510_475,7799,patients,O
PMC29459510_475,7799,0,O
PMC29459510_483,7800,In,O
PMC29459510_483,7800,the,O
PMC29459510_483,7800,present,O
PMC29459510_483,7800,study,O
PMC29459510_483,7800,have,O
PMC29459510_483,7800,we,O
PMC29459510_483,7800,evaluated,O
PMC29459510_483,7800,the,O
PMC29459510_483,7800,potential,O
PMC29459510_483,7800,effectiveness,O
PMC29459510_483,7800,and,O
PMC29459510_483,7800,tolerability,O
PMC29459510_483,7800,of,O
PMC29459510_483,7800,trazodone,B-Drug
PMC29459510_483,7800,in,O
PMC29459510_483,7800,the,O
PMC29459510_483,7800,treatment,O
PMC29459510_483,7800,of,O
PMC29459510_483,7800,fibromyalgia,B-Disease
PMC29459510_483,7800,0,O
PMC29459510_60,7801,CONCLUSIONS,O
PMC29459510_60,7801,:,O
PMC29459510_60,7801,In,O
PMC29459510_60,7801,doses,O
PMC29459510_60,7801,higher,O
PMC29459510_60,7801,than,O
PMC29459510_60,7801,those,O
PMC29459510_60,7801,usually,O
PMC29459510_60,7801,prescribed,O
PMC29459510_60,7801,as,O
PMC29459510_60,7801,hypnotic,O
PMC29459510_60,7801,",",O
PMC29459510_60,7801,the,O
PMC29459510_60,7801,utility,O
PMC29459510_60,7801,of,O
PMC29459510_60,7801,trazodone,B-Drug
PMC29459510_60,7801,in,O
PMC29459510_60,7801,fibromyalgia,B-Disease
PMC29459510_60,7801,management,O
PMC29459510_60,7801,surpasses,O
PMC29459510_60,7801,its,O
PMC29459510_60,7801,hypnotic,O
PMC29459510_60,7801,activity,O
PMC29459510_60,7801,0,O
PMC29459510_615,7802,METHODS,O
PMC29459510_615,7802,:,O
PMC29459510_615,7802,A,O
PMC29459510_615,7802,flexible,O
PMC29459510_615,7802,dose,O
PMC29459510_615,7802,of,O
PMC29459510_615,7802,trazodone,B-Drug
PMC29459510_615,7802,(,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,number,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,mg,O
PMC29459510_615,7802,/,O
PMC29459510_615,7802,day,O
PMC29459510_615,7802,),O
PMC29459510_615,7802,",",O
PMC29459510_615,7802,was,O
PMC29459510_615,7802,administered,O
PMC29459510_615,7802,to,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,number,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,fibromyalgia,B-Disease
PMC29459510_615,7802,patients,O
PMC29459510_615,7802,for,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,number,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,_,O
PMC29459510_615,7802,weeks,O
PMC29459510_615,7802,0,O
PMC29478130_523,7803,Duloxetine,B-Drug
PMC29478130_523,7803,is,O
PMC29478130_523,7803,a,O
PMC29478130_523,7803,balanced,O
PMC29478130_523,7803,and,O
PMC29478130_523,7803,potent,O
PMC29478130_523,7803,serotonin,O
PMC29478130_523,7803,and,O
PMC29478130_523,7803,noradrenaline,O
PMC29478130_523,7803,reuptake,O
PMC29478130_523,7803,inhibitor,O
PMC29478130_523,7803,(,O
PMC29478130_523,7803,SNRI,O
PMC29478130_523,7803,),O
PMC29478130_523,7803,and,O
PMC29478130_523,7803,has,O
PMC29478130_523,7803,adverse,O
PMC29478130_523,7803,effects,O
PMC29478130_523,7803,that,O
PMC29478130_523,7803,are,O
PMC29478130_523,7803,commonly,O
PMC29478130_523,7803,associated,O
PMC29478130_523,7803,with,O
PMC29478130_523,7803,such,O
PMC29478130_523,7803,drugs,O
PMC29478130_523,7803,",",O
PMC29478130_523,7803,including,O
PMC29478130_523,7803,nausea,B-Symptom
PMC29478130_523,7803,",",O
PMC29478130_523,7803,dry,B-Symptom
PMC29478130_523,7803,mouth,I-Symptom
PMC29478130_523,7803,",",O
PMC29478130_523,7803,constipation,B-Symptom
PMC29478130_523,7803,",",O
PMC29478130_523,7803,insomnia,B-Symptom
PMC29478130_523,7803,",",O
PMC29478130_523,7803,and,O
PMC29478130_523,7803,dizziness,B-Symptom
PMC29478130_523,7803,0,O
PMC29478130_792,7804,Cholestatic,B-Symptom
PMC29478130_792,7804,jaundice,I-Symptom
PMC29478130_792,7804,induced,O
PMC29478130_792,7804,by,O
PMC29478130_792,7804,duloxetine,B-Drug
PMC29478130_792,7804,in,O
PMC29478130_792,7804,a,O
PMC29478130_792,7804,patient,O
PMC29478130_792,7804,with,O
PMC29478130_792,7804,major,B-Disease
PMC29478130_792,7804,depressive,I-Disease
PMC29478130_792,7804,disorder,I-Disease
PMC29478130_792,7804,0,O
PMC29478440_188,7805,Phase,O
PMC29478440_188,7805,I,O
PMC29478440_188,7805,/,O
PMC29478440_188,7805,II,O
PMC29478440_188,7805,study,O
PMC29478440_188,7805,of,O
PMC29478440_188,7805,capecitabine,O
PMC29478440_188,7805,plus,O
PMC29478440_188,7805,oxaliplatin,O
PMC29478440_188,7805,(,O
PMC29478440_188,7805,XELOX,O
PMC29478440_188,7805,),O
PMC29478440_188,7805,plus,O
PMC29478440_188,7805,bevacizumab,B-Drug
PMC29478440_188,7805,as,O
PMC29478440_188,7805,first,O
PMC29478440_188,7805,-,O
PMC29478440_188,7805,line,O
PMC29478440_188,7805,therapy,O
PMC29478440_188,7805,in,O
PMC29478440_188,7805,Japanese,O
PMC29478440_188,7805,patients,O
PMC29478440_188,7805,with,O
PMC29478440_188,7805,metastatic,B-Disease
PMC29478440_188,7805,colorectal,I-Disease
PMC29478440_188,7805,cancer,I-Disease
PMC29478440_188,7805,0,O
PMC29509500_233,7806,In,O
PMC29509500_233,7806,these,O
PMC29509500_233,7806,reports,O
PMC29509500_233,7806,majority,O
PMC29509500_233,7806,of,O
PMC29509500_233,7806,patients,O
PMC29509500_233,7806,were,O
PMC29509500_233,7806,in,O
PMC29509500_233,7806,younger,O
PMC29509500_233,7806,age,O
PMC29509500_233,7806,group,O
PMC29509500_233,7806,",",O
PMC29509500_233,7806,females,O
PMC29509500_233,7806,and,O
PMC29509500_233,7806,the,O
PMC29509500_233,7806,interval,O
PMC29509500_233,7806,until,O
PMC29509500_233,7806,onset,O
PMC29509500_233,7806,of,O
PMC29509500_233,7806,tardive,O
PMC29509500_233,7806,dyskinesia,B-Symptom
PMC29509500_233,7806,after,O
PMC29509500_233,7806,initiation,O
PMC29509500_233,7806,of,O
PMC29509500_233,7806,risperidone,O
PMC29509500_233,7806,or,O
PMC29509500_233,7806,olanzapine,B-Drug
PMC29509500_233,7806,was,O
PMC29509500_233,7806,within,O
PMC29509500_233,7806,one,O
PMC29509500_233,7806,year,O
PMC29509500_233,7806,0,O
PMC29509500_438,7807,The,O
PMC29509500_438,7807,published,O
PMC29509500_438,7807,twenty,O
PMC29509500_438,7807,two,O
PMC29509500_438,7807,cases,O
PMC29509500_438,7807,of,O
PMC29509500_438,7807,risperidone,O
PMC29509500_438,7807,(,O
PMC29509500_438,7807,N,O
PMC29509500_438,7807,=,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,number,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,),O
PMC29509500_438,7807,or,O
PMC29509500_438,7807,olanzapine,B-Drug
PMC29509500_438,7807,(,O
PMC29509500_438,7807,N,O
PMC29509500_438,7807,=,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,number,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,_,O
PMC29509500_438,7807,),O
PMC29509500_438,7807,induced,O
PMC29509500_438,7807,tardive,B-Symptom
PMC29509500_438,7807,dyskinesia,I-Symptom
PMC29509500_438,7807,were,O
PMC29509500_438,7807,critically,O
PMC29509500_438,7807,reviewed,O
PMC29509500_438,7807,and,O
PMC29509500_438,7807,an,O
PMC29509500_438,7807,attempt,O
PMC29509500_438,7807,is,O
PMC29509500_438,7807,being,O
PMC29509500_438,7807,made,O
PMC29509500_438,7807,to,O
PMC29509500_438,7807,clarify,O
PMC29509500_438,7807,the,O
PMC29509500_438,7807,various,O
PMC29509500_438,7807,issues,O
PMC29509500_438,7807,associated,O
PMC29509500_438,7807,with,O
PMC29509500_438,7807,them,O
PMC29509500_438,7807,0,O
PMC29509520_886,7808,Escitalopram,O
PMC29509520_886,7808,Versus,O
PMC29509520_886,7808,Citalopram,B-Drug
PMC29509520_886,7808,and,O
PMC29509520_886,7808,Sertraline,B-Drug
PMC29509520_886,7808,:,O
PMC29509520_886,7808,A,O
PMC29509520_886,7808,Double,O
PMC29509520_886,7808,-,O
PMC29509520_886,7808,Blind,O
PMC29509520_886,7808,Controlled,O
PMC29509520_886,7808,",",O
PMC29509520_886,7808,Multi,O
PMC29509520_886,7808,-,O
PMC29509520_886,7808,centric,O
PMC29509520_886,7808,Trial,O
PMC29509520_886,7808,in,O
PMC29509520_886,7808,Indian,O
PMC29509520_886,7808,Patients,O
PMC29509520_886,7808,with,O
PMC29509520_886,7808,Unipolar,B-Disease
PMC29509520_886,7808,Major,I-Disease
PMC29509520_886,7808,Depression,I-Disease
PMC29509520_886,7808,0,O
PMC29515480_633,7809,Ziprasidone,B-Drug
PMC29515480_633,7809,",",O
PMC29515480_633,7809,yet,O
PMC29515480_633,7809,another,O
PMC29515480_633,7809,atypical,O
PMC29515480_633,7809,antipsychotic,O
PMC29515480_633,7809,",",O
PMC29515480_633,7809,has,O
PMC29515480_633,7809,been,O
PMC29515480_633,7809,associated,O
PMC29515480_633,7809,",",O
PMC29515480_633,7809,in,O
PMC29515480_633,7809,this,O
PMC29515480_633,7809,report,O
PMC29515480_633,7809,",",O
PMC29515480_633,7809,with,O
PMC29515480_633,7809,development,O
PMC29515480_633,7809,of,O
PMC29515480_633,7809,photo,B-Symptom
PMC29515480_633,7809,-,I-Symptom
PMC29515480_633,7809,allergic,I-Symptom
PMC29515480_633,7809,skin,I-Symptom
PMC29515480_633,7809,reaction,I-Symptom
PMC29515480_633,7809,in,O
PMC29515480_633,7809,therapeutic,O
PMC29515480_633,7809,doses,O
PMC29515480_633,7809,0,O
PMC29523700_449,7810,OBJECTIVE,O
PMC29523700_449,7810,:,O
PMC29523700_449,7810,The,O
PMC29523700_449,7810,purpose,O
PMC29523700_449,7810,of,O
PMC29523700_449,7810,this,O
PMC29523700_449,7810,study,O
PMC29523700_449,7810,was,O
PMC29523700_449,7810,to,O
PMC29523700_449,7810,investigate,O
PMC29523700_449,7810,the,O
PMC29523700_449,7810,efficacy,O
PMC29523700_449,7810,and,O
PMC29523700_449,7810,safety,O
PMC29523700_449,7810,of,O
PMC29523700_449,7810,Fixed,O
PMC29523700_449,7810,Dose,O
PMC29523700_449,7810,Combination,O
PMC29523700_449,7810,(,O
PMC29523700_449,7810,FDC,O
PMC29523700_449,7810,),O
PMC29523700_449,7810,of,O
PMC29523700_449,7810,olanzapine,B-Drug
PMC29523700_449,7810,_,O
PMC29523700_449,7810,_,O
PMC29523700_449,7810,number,O
PMC29523700_449,7810,_,O
PMC29523700_449,7810,_,O
PMC29523700_449,7810,mg,O
PMC29523700_449,7810,and,O
PMC29523700_449,7810,fluoxetine,B-Drug
PMC29523700_449,7810,_,O
PMC29523700_449,7810,_,O
PMC29523700_449,7810,number,O
PMC29523700_449,7810,_,O
PMC29523700_449,7810,_,O
PMC29523700_449,7810,mg,O
PMC29523700_449,7810,in,O
PMC29523700_449,7810,Indian,O
PMC29523700_449,7810,patients,O
PMC29523700_449,7810,with,O
PMC29523700_449,7810,severe,O
PMC29523700_449,7810,or,O
PMC29523700_449,7810,treatment,O
PMC29523700_449,7810,resistant,O
PMC29523700_449,7810,depression,B-Disease
PMC29523700_449,7810,0,O
PMC29543460_1,7811,A,O
PMC29543460_1,7811,male,O
PMC29543460_1,7811,patient,O
PMC29543460_1,7811,with,O
PMC29543460_1,7811,bipolar,O
PMC29543460_1,7811,disorder,O
PMC29543460_1,7811,who,O
PMC29543460_1,7811,developed,O
PMC29543460_1,7811,Stevens,B-Disease
PMC29543460_1,7811,Johnson,I-Disease
PMC29543460_1,7811,Syndrome,I-Disease
PMC29543460_1,7811,following,O
PMC29543460_1,7811,treatment,O
PMC29543460_1,7811,with,O
PMC29543460_1,7811,a,O
PMC29543460_1,7811,combination,O
PMC29543460_1,7811,of,O
PMC29543460_1,7811,sodium,O
PMC29543460_1,7811,valproate,O
PMC29543460_1,7811,and,O
PMC29543460_1,7811,lamotrigine,B-Drug
PMC29543460_1,7811,is,O
PMC29543460_1,7811,reported,O
PMC29543460_1,7811,0,O
PMC29543460_849,7812,Stevens,B-Disease
PMC29543460_849,7812,johnson,I-Disease
PMC29543460_849,7812,syndrome,I-Disease
PMC29543460_849,7812,in,O
PMC29543460_849,7812,a,O
PMC29543460_849,7812,bipolar,B-Disease
PMC29543460_849,7812,patient,O
PMC29543460_849,7812,treated,O
PMC29543460_849,7812,with,O
PMC29543460_849,7812,lamotrigine,B-Drug
PMC29543460_849,7812,0,O
PMC29559200_580,7813,Biweekly,O
PMC29559200_580,7813,docetaxel,B-Drug
PMC29559200_580,7813,",",O
PMC29559200_580,7813,cisplatin,O
PMC29559200_580,7813,",",O
PMC29559200_580,7813,and,O
PMC29559200_580,7813,_,O
PMC29559200_580,7813,_,O
PMC29559200_580,7813,number,O
PMC29559200_580,7813,_,O
PMC29559200_580,7813,_,O
PMC29559200_580,7813,-,O
PMC29559200_580,7813,fluorouracil,O
PMC29559200_580,7813,(,O
PMC29559200_580,7813,DCF,O
PMC29559200_580,7813,),O
PMC29559200_580,7813,chemotherapy,O
PMC29559200_580,7813,for,O
PMC29559200_580,7813,advanced,O
PMC29559200_580,7813,esophageal,B-Disease
PMC29559200_580,7813,squamous,I-Disease
PMC29559200_580,7813,cell,I-Disease
PMC29559200_580,7813,carcinoma,I-Disease
PMC29559200_580,7813,:,O
PMC29559200_580,7813,a,O
PMC29559200_580,7813,phase,O
PMC29559200_580,7813,I,O
PMC29559200_580,7813,dose,O
PMC29559200_580,7813,-,O
PMC29559200_580,7813,escalation,O
PMC29559200_580,7813,study,O
PMC29559200_580,7813,0,O
PMC29562500_197,7814,Although,O
PMC29562500_197,7814,effective,O
PMC29562500_197,7814,",",O
PMC29562500_197,7814,venlafaxine,B-Drug
PMC29562500_197,7814,too,O
PMC29562500_197,7814,carries,O
PMC29562500_197,7814,a,O
PMC29562500_197,7814,risk,O
PMC29562500_197,7814,for,O
PMC29562500_197,7814,manic,B-Symptom
PMC29562500_197,7814,switch,O
PMC29562500_197,7814,in,O
PMC29562500_197,7814,bipolar,B-Disease
PMC29562500_197,7814,affective,O
PMC29562500_197,7814,disorder,O
PMC29562500_197,7814,patients,O
PMC29562500_197,7814,0,O
PMC29566900_431,7815,Randomized,O
PMC29566900_431,7815,controlled,O
PMC29566900_431,7815,trial,O
PMC29566900_431,7815,of,O
PMC29566900_431,7815,fish,O
PMC29566900_431,7815,oil,O
PMC29566900_431,7815,and,O
PMC29566900_431,7815,montelukast,B-Drug
PMC29566900_431,7815,and,O
PMC29566900_431,7815,their,O
PMC29566900_431,7815,combination,O
PMC29566900_431,7815,on,O
PMC29566900_431,7815,airway,B-Symptom
PMC29566900_431,7815,inflammation,I-Symptom
PMC29566900_431,7815,and,O
PMC29566900_431,7815,hyperpnea,O
PMC29566900_431,7815,-,O
PMC29566900_431,7815,induced,O
PMC29566900_431,7815,bronchoconstriction,B-Symptom
PMC29566900_431,7815,0,O
PMC29566900_662,7816,BACKGROUND,O
PMC29566900_662,7816,:,O
PMC29566900_662,7816,Both,O
PMC29566900_662,7816,fish,O
PMC29566900_662,7816,oil,O
PMC29566900_662,7816,and,O
PMC29566900_662,7816,montelukast,B-Drug
PMC29566900_662,7816,have,O
PMC29566900_662,7816,been,O
PMC29566900_662,7816,shown,O
PMC29566900_662,7816,to,O
PMC29566900_662,7816,reduce,O
PMC29566900_662,7816,the,O
PMC29566900_662,7816,severity,O
PMC29566900_662,7816,of,O
PMC29566900_662,7816,exercise,B-Symptom
PMC29566900_662,7816,-,I-Symptom
PMC29566900_662,7816,induced,I-Symptom
PMC29566900_662,7816,bronchoconstriction,I-Symptom
PMC29566900_662,7816,(,O
PMC29566900_662,7816,EIB,O
PMC29566900_662,7816,),O
PMC29566900_662,7816,0,O
PMC29592190_296,7817,A,O
PMC29592190_296,7817,case,O
PMC29592190_296,7817,of,O
PMC29592190_296,7817,paroxetine,B-Drug
PMC29592190_296,7817,-,O
PMC29592190_296,7817,induced,O
PMC29592190_296,7817,galactorrhoea,B-Symptom
PMC29592190_296,7817,with,O
PMC29592190_296,7817,normal,O
PMC29592190_296,7817,serum,O
PMC29592190_296,7817,prolactin,O
PMC29592190_296,7817,level,O
PMC29592190_296,7817,0,O
PMC29592190_561,7818,The,O
PMC29592190_561,7818,following,O
PMC29592190_561,7818,case,O
PMC29592190_561,7818,report,O
PMC29592190_561,7818,highlights,O
PMC29592190_561,7818,an,O
PMC29592190_561,7818,interesting,O
PMC29592190_561,7818,observation,O
PMC29592190_561,7818,of,O
PMC29592190_561,7818,paroxetine,B-Drug
PMC29592190_561,7818,-,O
PMC29592190_561,7818,induced,O
PMC29592190_561,7818,galactorrhoea,B-Symptom
PMC29592190_561,7818,at,O
PMC29592190_561,7818,therapeutic,O
PMC29592190_561,7818,dosage,O
PMC29592190_561,7818,and,O
PMC29592190_561,7818,serum,O
PMC29592190_561,7818,prolactin,O
PMC29592190_561,7818,values,O
PMC29592190_561,7818,of,O
PMC29592190_561,7818,this,O
PMC29592190_561,7818,patient,O
PMC29592190_561,7818,comes,O
PMC29592190_561,7818,out,O
PMC29592190_561,7818,to,O
PMC29592190_561,7818,be,O
PMC29592190_561,7818,normal,O
PMC29592190_561,7818,0,O
PMC29628400_5,7819,Buprenorphine,B-Drug
PMC29628400_5,7819,as,O
PMC29628400_5,7819,a,O
PMC29628400_5,7819,detoxifying,O
PMC29628400_5,7819,agent,O
PMC29628400_5,7819,for,O
PMC29628400_5,7819,opioids,O
PMC29628400_5,7819,reportedly,O
PMC29628400_5,7819,gave,O
PMC29628400_5,7819,better,O
PMC29628400_5,7819,symptom,O
PMC29628400_5,7819,control,O
PMC29628400_5,7819,in,O
PMC29628400_5,7819,the,O
PMC29628400_5,7819,first,O
PMC29628400_5,7819,week,O
PMC29628400_5,7819,but,O
PMC29628400_5,7819,high,O
PMC29628400_5,7819,rates,O
PMC29628400_5,7819,of,O
PMC29628400_5,7819,dependence,O
PMC29628400_5,7819,induction,O
PMC29628400_5,7819,were,O
PMC29628400_5,7819,reported,O
PMC29628400_5,7819,0,O
PMC29630050_679,7820,Fluoxetine,B-Drug
PMC29630050_679,7820,induced,O
PMC29630050_679,7820,akathisia,B-Symptom
PMC29630050_679,7820,and,O
PMC29630050_679,7820,suicidally,B-Symptom
PMC29630050_679,7820,0,O
PMC29638480_282,7821,Primary,O
PMC29638480_282,7821,hypersomnia,O
PMC29638480_282,7821,:,O
PMC29638480_282,7821,response,O
PMC29638480_282,7821,to,O
PMC29638480_282,7821,fluoxetine,B-Drug
PMC29638480_282,7821,and,O
PMC29638480_282,7821,methylphenidate,B-Drug
PMC29638480_282,7821,0,O
PMC29708790_351,7822,A,O
PMC29708790_351,7822,comparative,O
PMC29708790_351,7822,study,O
PMC29708790_351,7822,of,O
PMC29708790_351,7822,side,O
PMC29708790_351,7822,-,O
PMC29708790_351,7822,effects,O
PMC29708790_351,7822,of,O
PMC29708790_351,7822,lithium,O
PMC29708790_351,7822,",",O
PMC29708790_351,7822,carbamazepine,B-Drug
PMC29708790_351,7822,and,O
PMC29708790_351,7822,haloperidol,O
PMC29708790_351,7822,in,O
PMC29708790_351,7822,acute,O
PMC29708790_351,7822,mania,O
PMC29708790_351,7822,0,O
PMC29787390_916,7823,Carbamazepine,B-Drug
PMC29787390_916,7823,-,O
PMC29787390_916,7823,Induced,O
PMC29787390_916,7823,Stevens,B-Disease
PMC29787390_916,7823,-,I-Disease
PMC29787390_916,7823,Johnson,I-Disease
PMC29787390_916,7823,Syndrome,I-Disease
PMC29787390_916,7823,Sparing,O
PMC29787390_916,7823,the,O
PMC29787390_916,7823,Skin,O
PMC29787390_916,7823,Previously,O
PMC29787390_916,7823,Affected,O
PMC29787390_916,7823,by,O
PMC29787390_916,7823,Herpes,O
PMC29787390_916,7823,Zoster,O
PMC29787390_916,7823,Infection,O
PMC29787390_916,7823,in,O
PMC29787390_916,7823,a,O
PMC29787390_916,7823,Patient,O
PMC29787390_916,7823,with,O
PMC29787390_916,7823,Systemic,O
PMC29787390_916,7823,Lupus,O
PMC29787390_916,7823,Erythematosus,O
PMC29787390_916,7823,:,O
PMC29787390_916,7823,A,O
PMC29787390_916,7823,Reverse,O
PMC29787390_916,7823,Isotopic,O
PMC29787390_916,7823,Phenomenon,O
PMC29787390_916,7823,0,O
PMC29897060_37,7824,Herein,O
PMC29897060_37,7824,",",O
PMC29897060_37,7824,we,O
PMC29897060_37,7824,report,O
PMC29897060_37,7824,a,O
PMC29897060_37,7824,case,O
PMC29897060_37,7824,of,O
PMC29897060_37,7824,drug,O
PMC29897060_37,7824,-,O
PMC29897060_37,7824,induced,O
PMC29897060_37,7824,bullous,B-Symptom
PMC29897060_37,7824,SS,O
PMC29897060_37,7824,with,O
PMC29897060_37,7824,ocular,O
PMC29897060_37,7824,and,O
PMC29897060_37,7824,mucosal,O
PMC29897060_37,7824,involvement,O
PMC29897060_37,7824,",",O
PMC29897060_37,7824,glomerulonephritis,B-Symptom
PMC29897060_37,7824,",",O
PMC29897060_37,7824,and,O
PMC29897060_37,7824,multiple,O
PMC29897060_37,7824,autoimmune,O
PMC29897060_37,7824,features,O
PMC29897060_37,7824,including,O
PMC29897060_37,7824,clinical,O
PMC29897060_37,7824,polychondritis,O
PMC29897060_37,7824,with,O
PMC29897060_37,7824,antitype,O
PMC29897060_37,7824,II,O
PMC29897060_37,7824,collagen,O
PMC29897060_37,7824,antibodies,O
PMC29897060_37,7824,",",O
PMC29897060_37,7824,ANCAs,O
PMC29897060_37,7824,",",O
PMC29897060_37,7824,antinuclear,O
PMC29897060_37,7824,(,O
PMC29897060_37,7824,HEp,O
PMC29897060_37,7824,_,O
PMC29897060_37,7824,_,O
PMC29897060_37,7824,number,O
PMC29897060_37,7824,_,O
PMC29897060_37,7824,_,O
PMC29897060_37,7824,),O
PMC29897060_37,7824,",",O
PMC29897060_37,7824,and,O
PMC29897060_37,7824,antihistone,O
PMC29897060_37,7824,antibodies,O
PMC29897060_37,7824,in,O
PMC29897060_37,7824,a,O
PMC29897060_37,7824,patient,O
PMC29897060_37,7824,on,O
PMC29897060_37,7824,hydralazine,O
PMC29897060_37,7824,and,O
PMC29897060_37,7824,carbamazepine,B-Drug
PMC29897060_37,7824,0,O
PMC29908280_89,7825,An,O
PMC29908280_89,7825,investigation,O
PMC29908280_89,7825,of,O
PMC29908280_89,7825,topiramate,B-Drug
PMC29908280_89,7825,-,O
PMC29908280_89,7825,induced,O
PMC29908280_89,7825,cognitive,B-Symptom
PMC29908280_89,7825,impairments,I-Symptom
PMC29908280_89,7825,in,O
PMC29908280_89,7825,family,O
PMC29908280_89,7825,members,O
PMC29908280_89,7825,with,O
PMC29908280_89,7825,epilepsy,B-Disease
PMC29908280_89,7825,may,O
PMC29908280_89,7825,throw,O
PMC29908280_89,7825,light,O
PMC29908280_89,7825,on,O
PMC29908280_89,7825,the,O
PMC29908280_89,7825,subject,O
PMC29908280_89,7825,0,O
PMC29959100_634,7826,Clinical,O
PMC29959100_634,7826,evidence,O
PMC29959100_634,7826,of,O
PMC29959100_634,7826,this,O
PMC29959100_634,7826,brief,O
PMC29959100_634,7826,interventional,O
PMC29959100_634,7826,case,O
PMC29959100_634,7826,report,O
PMC29959100_634,7826,indicates,O
PMC29959100_634,7826,that,O
PMC29959100_634,7826,one,O
PMC29959100_634,7826,patient,O
PMC29959100_634,7826,affected,O
PMC29959100_634,7826,by,O
PMC29959100_634,7826,recent,O
PMC29959100_634,7826,serous,O
PMC29959100_634,7826,macular,B-Symptom
PMC29959100_634,7826,detachment,I-Symptom
PMC29959100_634,7826,-,O
PMC29959100_634,7826,complicated,O
PMC29959100_634,7826,TDS,O
PMC29959100_634,7826,did,O
PMC29959100_634,7826,not,O
PMC29959100_634,7826,benefit,O
PMC29959100_634,7826,from,O
PMC29959100_634,7826,_,O
PMC29959100_634,7826,_,O
PMC29959100_634,7826,number,O
PMC29959100_634,7826,_,O
PMC29959100_634,7826,_,O
PMC29959100_634,7826,consecutive,O
PMC29959100_634,7826,monthly,O
PMC29959100_634,7826,intravitreal,O
PMC29959100_634,7826,Avastin,B-Drug
PMC29959100_634,7826,treatments,O
PMC29959100_634,7826,0,O
PMC29988060_18,7827,The,O
PMC29988060_18,7827,immediate,O
PMC29988060_18,7827,-,O
PMC29988060_18,7827,release,O
PMC29988060_18,7827,formulation,O
PMC29988060_18,7827,of,O
PMC29988060_18,7827,lamotrigine,B-Drug
PMC29988060_18,7827,(,O
PMC29988060_18,7827,LTG,O
PMC29988060_18,7827,-,O
PMC29988060_18,7827,IR,O
PMC29988060_18,7827,),O
PMC29988060_18,7827,has,O
PMC29988060_18,7827,been,O
PMC29988060_18,7827,approved,O
PMC29988060_18,7827,for,O
PMC29988060_18,7827,primary,O
PMC29988060_18,7827,generalized,O
PMC29988060_18,7827,tonic,B-Symptom
PMC29988060_18,7827,-,I-Symptom
PMC29988060_18,7827,clonic,I-Symptom
PMC29988060_18,7827,seizures,I-Symptom
PMC29988060_18,7827,since,O
PMC29988060_18,7827,_,O
PMC29988060_18,7827,_,O
PMC29988060_18,7827,number,O
PMC29988060_18,7827,_,O
PMC29988060_18,7827,_,O
PMC29988060_18,7827,0,O
PMC29988060_794,7828,The,O
PMC29988060_794,7828,ease,O
PMC29988060_794,7828,of,O
PMC29988060_794,7828,conversion,O
PMC29988060_794,7828,between,O
PMC29988060_794,7828,the,O
PMC29988060_794,7828,formulations,O
PMC29988060_794,7828,also,O
PMC29988060_794,7828,makes,O
PMC29988060_794,7828,lamotrigine,B-Drug
PMC29988060_794,7828,an,O
PMC29988060_794,7828,attractive,O
PMC29988060_794,7828,treatment,O
PMC29988060_794,7828,option,O
PMC29988060_794,7828,for,O
PMC29988060_794,7828,patients,O
PMC29988060_794,7828,with,O
PMC29988060_794,7828,primary,O
PMC29988060_794,7828,generalized,O
PMC29988060_794,7828,tonic,B-Symptom
PMC29988060_794,7828,-,I-Symptom
PMC29988060_794,7828,clonic,I-Symptom
PMC29988060_794,7828,seizures,I-Symptom
PMC29988060_794,7828,0,O
PMC30009080_468,7829,Treatment,O
PMC30009080_468,7829,options,O
PMC30009080_468,7829,for,O
PMC30009080_468,7829,ADHD,B-Disease
PMC30009080_468,7829,in,O
PMC30009080_468,7829,the,O
PMC30009080_468,7829,Netherlands,O
PMC30009080_468,7829,have,O
PMC30009080_468,7829,increased,O
PMC30009080_468,7829,with,O
PMC30009080_468,7829,the,O
PMC30009080_468,7829,introduction,O
PMC30009080_468,7829,of,O
PMC30009080_468,7829,the,O
PMC30009080_468,7829,extended,O
PMC30009080_468,7829,-,O
PMC30009080_468,7829,release,O
PMC30009080_468,7829,formulations,O
PMC30009080_468,7829,of,O
PMC30009080_468,7829,methylphenidate,B-Drug
PMC30009080_468,7829,(,O
PMC30009080_468,7829,MPH,O
PMC30009080_468,7829,ER,O
PMC30009080_468,7829,",",O
PMC30009080_468,7829,Concerta,B-Drug
PMC30009080_468,7829,(,O
PMC30009080_468,7829,),O
PMC30009080_468,7829,),O
PMC30009080_468,7829,in,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,number,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,and,O
PMC30009080_468,7829,atomoxetine,O
PMC30009080_468,7829,(,O
PMC30009080_468,7829,ATX,O
PMC30009080_468,7829,",",O
PMC30009080_468,7829,Strattera,O
PMC30009080_468,7829,(,O
PMC30009080_468,7829,),O
PMC30009080_468,7829,),O
PMC30009080_468,7829,in,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,number,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,_,O
PMC30009080_468,7829,",",O
PMC30009080_468,7829,but,O
PMC30009080_468,7829,data,O
PMC30009080_468,7829,on,O
PMC30009080_468,7829,the,O
PMC30009080_468,7829,effect,O
PMC30009080_468,7829,on,O
PMC30009080_468,7829,drug,O
PMC30009080_468,7829,usage,O
PMC30009080_468,7829,patterns,O
PMC30009080_468,7829,are,O
PMC30009080_468,7829,scarce,O
PMC30009080_468,7829,0,O
PMC30019040_383,7830,In,O
PMC30019040_383,7830,addition,O
PMC30019040_383,7830,",",O
PMC30019040_383,7830,supplementing,O
PMC30019040_383,7830,antibiotic,O
PMC30019040_383,7830,therapy,O
PMC30019040_383,7830,with,O
PMC30019040_383,7830,lisinopril,B-Drug
PMC30019040_383,7830,or,O
PMC30019040_383,7830,derivatives,O
PMC30019040_383,7830,with,O
PMC30019040_383,7830,endothelial,O
PMC30019040_383,7830,protective,O
PMC30019040_383,7830,activities,O
PMC30019040_383,7830,may,O
PMC30019040_383,7830,decrease,O
PMC30019040_383,7830,the,O
PMC30019040_383,7830,severity,O
PMC30019040_383,7830,of,O
PMC30019040_383,7830,leptospirosis,O
PMC30019040_383,7830,0,O
PMC30032520_389,7831,The,O
PMC30032520_389,7831,aim,O
PMC30032520_389,7831,of,O
PMC30032520_389,7831,this,O
PMC30032520_389,7831,study,O
PMC30032520_389,7831,was,O
PMC30032520_389,7831,to,O
PMC30032520_389,7831,identify,O
PMC30032520_389,7831,published,O
PMC30032520_389,7831,data,O
PMC30032520_389,7831,for,O
PMC30032520_389,7831,three,O
PMC30032520_389,7831,pharmacological,O
PMC30032520_389,7831,treatments,O
PMC30032520_389,7831,:,O
PMC30032520_389,7831,pregabalin,O
PMC30032520_389,7831,",",O
PMC30032520_389,7831,lidocaine,O
PMC30032520_389,7831,plaster,O
PMC30032520_389,7831,",",O
PMC30032520_389,7831,and,O
PMC30032520_389,7831,duloxetine,B-Drug
PMC30032520_389,7831,",",O
PMC30032520_389,7831,which,O
PMC30032520_389,7831,are,O
PMC30032520_389,7831,typically,O
PMC30032520_389,7831,used,O
PMC30032520_389,7831,at,O
PMC30032520_389,7831,_,O
PMC30032520_389,7831,_,O
PMC30032520_389,7831,number,O
PMC30032520_389,7831,_,O
PMC30032520_389,7831,_,O
PMC30032520_389,7831,(,O
PMC30032520_389,7831,nd,O
PMC30032520_389,7831,),O
PMC30032520_389,7831,line,O
PMC30032520_389,7831,or,O
PMC30032520_389,7831,later,O
PMC30032520_389,7831,in,O
PMC30032520_389,7831,UK,O
PMC30032520_389,7831,patients,O
PMC30032520_389,7831,with,O
PMC30032520_389,7831,neuropathic,B-Symptom
PMC30032520_389,7831,pain,I-Symptom
PMC30032520_389,7831,0,O
PMC30046240_158,7832,Duloxetine,B-Drug
PMC30046240_158,7832,has,O
PMC30046240_158,7832,proven,O
PMC30046240_158,7832,efficacy,O
PMC30046240_158,7832,in,O
PMC30046240_158,7832,managing,O
PMC30046240_158,7832,pain,B-Symptom
PMC30046240_158,7832,and,O
PMC30046240_158,7832,mood,O
PMC30046240_158,7832,symptoms,O
PMC30046240_158,7832,in,O
PMC30046240_158,7832,adult,O
PMC30046240_158,7832,FMS,O
PMC30046240_158,7832,patients,O
PMC30046240_158,7832,with,O
PMC30046240_158,7832,and,O
PMC30046240_158,7832,without,O
PMC30046240_158,7832,major,B-Disease
PMC30046240_158,7832,depressive,I-Disease
PMC30046240_158,7832,disorder,I-Disease
PMC30046240_158,7832,0,O
PMC30046330_221,7833,Treatment,O
PMC30046330_221,7833,of,O
PMC30046330_221,7833,trigeminal,B-Disease
PMC30046330_221,7833,neuralgia,I-Disease
PMC30046330_221,7833,(,O
PMC30046330_221,7833,TN,O
PMC30046330_221,7833,),O
PMC30046330_221,7833,is,O
PMC30046330_221,7833,achieved,O
PMC30046330_221,7833,by,O
PMC30046330_221,7833,using,O
PMC30046330_221,7833,adjuvant,O
PMC30046330_221,7833,analgesics,O
PMC30046330_221,7833,like,O
PMC30046330_221,7833,antiepileptics,O
PMC30046330_221,7833,",",O
PMC30046330_221,7833,with,O
PMC30046330_221,7833,carbamazepine,B-Drug
PMC30046330_221,7833,(,O
PMC30046330_221,7833,CBZ,O
PMC30046330_221,7833,),O
PMC30046330_221,7833,being,O
PMC30046330_221,7833,the,O
PMC30046330_221,7833,first,O
PMC30046330_221,7833,-,O
PMC30046330_221,7833,line,O
PMC30046330_221,7833,approach,O
PMC30046330_221,7833,for,O
PMC30046330_221,7833,TN,O
PMC30046330_221,7833,patients,O
PMC30046330_221,7833,",",O
PMC30046330_221,7833,although,O
PMC30046330_221,7833,side,O
PMC30046330_221,7833,effects,O
PMC30046330_221,7833,may,O
PMC30046330_221,7833,be,O
PMC30046330_221,7833,present,O
PMC30046330_221,7833,0,O
PMC30048970_610,7834,We,O
PMC30048970_610,7834,present,O
PMC30048970_610,7834,the,O
PMC30048970_610,7834,case,O
PMC30048970_610,7834,of,O
PMC30048970_610,7834,a,O
PMC30048970_610,7834,PI,O
PMC30048970_610,7834,-,O
PMC30048970_610,7834,OCD,B-Disease
PMC30048970_610,7834,patient,O
PMC30048970_610,7834,who,O
PMC30048970_610,7834,developed,O
PMC30048970_610,7834,severe,O
PMC30048970_610,7834,nausea,B-Symptom
PMC30048970_610,7834,after,O
PMC30048970_610,7834,response,O
PMC30048970_610,7834,to,O
PMC30048970_610,7834,off,O
PMC30048970_610,7834,-,O
PMC30048970_610,7834,label,O
PMC30048970_610,7834,doses,O
PMC30048970_610,7834,of,O
PMC30048970_610,7834,the,O
PMC30048970_610,7834,selective,O
PMC30048970_610,7834,serotonin,O
PMC30048970_610,7834,reuptake,O
PMC30048970_610,7834,inhibitor,O
PMC30048970_610,7834,(,O
PMC30048970_610,7834,SSRI,O
PMC30048970_610,7834,),O
PMC30048970_610,7834,",",O
PMC30048970_610,7834,fluoxetine,B-Drug
PMC30048970_610,7834,0,O
PMC30064920_944,7835,Of,O
PMC30064920_944,7835,the,O
PMC30064920_944,7835,Phase,O
PMC30064920_944,7835,II,O
PMC30064920_944,7835,pharmacotherapies,O
PMC30064920_944,7835,",",O
PMC30064920_944,7835,lorcaserin,O
PMC30064920_944,7835,",",O
PMC30064920_944,7835,taranabant,O
PMC30064920_944,7835,",",O
PMC30064920_944,7835,topiramate,B-Drug
PMC30064920_944,7835,and,O
PMC30064920_944,7835,bupropion,O
PMC30064920_944,7835,with,O
PMC30064920_944,7835,naltrexone,O
PMC30064920_944,7835,have,O
PMC30064920_944,7835,demonstrated,O
PMC30064920_944,7835,significant,O
PMC30064920_944,7835,weight,B-Symptom
PMC30064920_944,7835,loss,I-Symptom
PMC30064920_944,7835,compared,O
PMC30064920_944,7835,to,O
PMC30064920_944,7835,placebo,O
PMC30064920_944,7835,at,O
PMC30064920_944,7835,_,O
PMC30064920_944,7835,_,O
PMC30064920_944,7835,number,O
PMC30064920_944,7835,_,O
PMC30064920_944,7835,_,O
PMC30064920_944,7835,months,O
PMC30064920_944,7835,0,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,number,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,cases,O
PMC30112450_492,7836,of,O
PMC30112450_492,7836,schizophrenia,B-Disease
PMC30112450_492,7836,meeting,O
PMC30112450_492,7836,Spitzer,O
PMC30112450_492,7836,',O
PMC30112450_492,7836,s,O
PMC30112450_492,7836,Research,O
PMC30112450_492,7836,Diagnostic,O
PMC30112450_492,7836,Criteria,O
PMC30112450_492,7836,and,O
PMC30112450_492,7836,nonrespondent,O
PMC30112450_492,7836,to,O
PMC30112450_492,7836,conventional,O
PMC30112450_492,7836,treatment,O
PMC30112450_492,7836,were,O
PMC30112450_492,7836,treated,O
PMC30112450_492,7836,with,O
PMC30112450_492,7836,carbamazepine,B-Drug
PMC30112450_492,7836,",",O
PMC30112450_492,7836,either,O
PMC30112450_492,7836,alone,O
PMC30112450_492,7836,or,O
PMC30112450_492,7836,in,O
PMC30112450_492,7836,combination,O
PMC30112450_492,7836,with,O
PMC30112450_492,7836,neuroleptics,O
PMC30112450_492,7836,and,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,number,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,_,O
PMC30112450_492,7836,cases,O
PMC30112450_492,7836,had,O
PMC30112450_492,7836,shown,O
PMC30112450_492,7836,improvement,O
PMC30112450_492,7836,0,O
PMC30182570_982,7837,METHODS,O
PMC30182570_982,7837,:,O
PMC30182570_982,7837,We,O
PMC30182570_982,7837,further,O
PMC30182570_982,7837,investigated,O
PMC30182570_982,7837,axillary,O
PMC30182570_982,7837,treatment,O
PMC30182570_982,7837,in,O
PMC30182570_982,7837,a,O
PMC30182570_982,7837,retrospective,O
PMC30182570_982,7837,analysis,O
PMC30182570_982,7837,of,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,consecutive,O
PMC30182570_982,7837,patients,O
PMC30182570_982,7837,",",O
PMC30182570_982,7837,aged,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,years,O
PMC30182570_982,7837,",",O
PMC30182570_982,7837,with,O
PMC30182570_982,7837,operable,O
PMC30182570_982,7837,breast,B-Disease
PMC30182570_982,7837,cancer,I-Disease
PMC30182570_982,7837,and,O
PMC30182570_982,7837,a,O
PMC30182570_982,7837,clinically,O
PMC30182570_982,7837,clear,O
PMC30182570_982,7837,axilla,O
PMC30182570_982,7837,",",O
PMC30182570_982,7837,treated,O
PMC30182570_982,7837,between,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,and,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,;,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,received,O
PMC30182570_982,7837,and,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,did,O
PMC30182570_982,7837,not,O
PMC30182570_982,7837,receive,O
PMC30182570_982,7837,axillary,O
PMC30182570_982,7837,dissection,O
PMC30182570_982,7837,;,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,mg,O
PMC30182570_982,7837,/,O
PMC30182570_982,7837,day,O
PMC30182570_982,7837,tamoxifen,B-Drug
PMC30182570_982,7837,was,O
PMC30182570_982,7837,prescribed,O
PMC30182570_982,7837,for,O
PMC30182570_982,7837,at,O
PMC30182570_982,7837,least,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,number,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,_,O
PMC30182570_982,7837,years,O
PMC30182570_982,7837,0,O
PMC30225980_757,7838,Efficacy,O
PMC30225980_757,7838,and,O
PMC30225980_757,7838,tolerability,O
PMC30225980_757,7838,of,O
PMC30225980_757,7838,lisdexamfetamine,B-Drug
PMC30225980_757,7838,dimesylate,O
PMC30225980_757,7838,in,O
PMC30225980_757,7838,children,O
PMC30225980_757,7838,with,O
PMC30225980_757,7838,attention,B-Disease
PMC30225980_757,7838,-,I-Disease
PMC30225980_757,7838,deficit,I-Disease
PMC30225980_757,7838,/,I-Disease
PMC30225980_757,7838,hyperactivity,I-Disease
PMC30225980_757,7838,disorder,I-Disease
PMC30225980_757,7838,:,O
PMC30225980_757,7838,sex,O
PMC30225980_757,7838,and,O
PMC30225980_757,7838,age,O
PMC30225980_757,7838,effects,O
PMC30225980_757,7838,and,O
PMC30225980_757,7838,effect,O
PMC30225980_757,7838,size,O
PMC30225980_757,7838,across,O
PMC30225980_757,7838,the,O
PMC30225980_757,7838,day,O
PMC30225980_757,7838,0,O
PMC30316070_181,7839,In,O
PMC30316070_181,7839,conclusion,O
PMC30316070_181,7839,",",O
PMC30316070_181,7839,we,O
PMC30316070_181,7839,show,O
PMC30316070_181,7839,that,O
PMC30316070_181,7839,fluoxetine,B-Drug
PMC30316070_181,7839,exerts,O
PMC30316070_181,7839,both,O
PMC30316070_181,7839,harmful,O
PMC30316070_181,7839,and,O
PMC30316070_181,7839,beneficial,O
PMC30316070_181,7839,age,O
PMC30316070_181,7839,-,O
PMC30316070_181,7839,dependent,O
PMC30316070_181,7839,effects,O
PMC30316070_181,7839,on,O
PMC30316070_181,7839,depressive,O
PMC30316070_181,7839,behavior,O
PMC30316070_181,7839,",",O
PMC30316070_181,7839,body,B-Symptom
PMC30316070_181,7839,weight,I-Symptom
PMC30316070_181,7839,and,O
PMC30316070_181,7839,wakefulness,B-Symptom
PMC30316070_181,7839,",",O
PMC30316070_181,7839,which,O
PMC30316070_181,7839,may,O
PMC30316070_181,7839,relate,O
PMC30316070_181,7839,",",O
PMC30316070_181,7839,in,O
PMC30316070_181,7839,part,O
PMC30316070_181,7839,",",O
PMC30316070_181,7839,to,O
PMC30316070_181,7839,differential,O
PMC30316070_181,7839,fluoxetine,O
PMC30316070_181,7839,-,O
PMC30316070_181,7839,induced,O
PMC30316070_181,7839,neuroplasticity,O
PMC30316070_181,7839,in,O
PMC30316070_181,7839,the,O
PMC30316070_181,7839,amygdala,O
PMC30316070_181,7839,0,O
PMC30389860_905,7840,METHODS,O
PMC30389860_905,7840,:,O
PMC30389860_905,7840,To,O
PMC30389860_905,7840,investigate,O
PMC30389860_905,7840,potential,O
PMC30389860_905,7840,efficacy,O
PMC30389860_905,7840,for,O
PMC30389860_905,7840,relieving,O
PMC30389860_905,7840,nicotine,B-Symptom
PMC30389860_905,7840,withdrawal,I-Symptom
PMC30389860_905,7840,symptoms,I-Symptom
PMC30389860_905,7840,and,O
PMC30389860_905,7840,promoting,O
PMC30389860_905,7840,smoking,O
PMC30389860_905,7840,abstinence,O
PMC30389860_905,7840,",",O
PMC30389860_905,7840,we,O
PMC30389860_905,7840,conducted,O
PMC30389860_905,7840,a,O
PMC30389860_905,7840,randomized,O
PMC30389860_905,7840,",",O
PMC30389860_905,7840,double,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,blind,O
PMC30389860_905,7840,",",O
PMC30389860_905,7840,placebo,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,controlled,O
PMC30389860_905,7840,",",O
PMC30389860_905,7840,phase,O
PMC30389860_905,7840,II,O
PMC30389860_905,7840,study,O
PMC30389860_905,7840,of,O
PMC30389860_905,7840,once,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,a,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,day,O
PMC30389860_905,7840,osmotic,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,release,O
PMC30389860_905,7840,oral,O
PMC30389860_905,7840,system,O
PMC30389860_905,7840,methylphenidate,B-Drug
PMC30389860_905,7840,(,O
PMC30389860_905,7840,OROS,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,MPH,O
PMC30389860_905,7840,",",O
PMC30389860_905,7840,Concerta,O
PMC30389860_905,7840,),O
PMC30389860_905,7840,at,O
PMC30389860_905,7840,a,O
PMC30389860_905,7840,target,O
PMC30389860_905,7840,dose,O
PMC30389860_905,7840,of,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,number,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,-,O
PMC30389860_905,7840,mg,O
PMC30389860_905,7840,/,O
PMC30389860_905,7840,day,O
PMC30389860_905,7840,for,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,number,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,weeks,O
PMC30389860_905,7840,compared,O
PMC30389860_905,7840,with,O
PMC30389860_905,7840,placebo,O
PMC30389860_905,7840,in,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,number,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,_,O
PMC30389860_905,7840,adult,O
PMC30389860_905,7840,cigarette,O
PMC30389860_905,7840,smokers,O
PMC30389860_905,7840,0,O
PMC30446570_541,7841,This,O
PMC30446570_541,7841,study,O
PMC30446570_541,7841,addresses,O
PMC30446570_541,7841,whether,O
PMC30446570_541,7841,duloxetine,B-Drug
PMC30446570_541,7841,and,O
PMC30446570_541,7841,venlafaxine,B-Drug
PMC30446570_541,7841,XR,O
PMC30446570_541,7841,are,O
PMC30446570_541,7841,interchangeable,O
PMC30446570_541,7841,in,O
PMC30446570_541,7841,their,O
PMC30446570_541,7841,patterns,O
PMC30446570_541,7841,of,O
PMC30446570_541,7841,use,O
PMC30446570_541,7841,with,O
PMC30446570_541,7841,patients,O
PMC30446570_541,7841,who,O
PMC30446570_541,7841,are,O
PMC30446570_541,7841,depressed,B-Disease
PMC30446570_541,7841,or,O
PMC30446570_541,7841,are,O
PMC30446570_541,7841,used,O
PMC30446570_541,7841,more,O
PMC30446570_541,7841,selectively,O
PMC30446570_541,7841,based,O
PMC30446570_541,7841,on,O
PMC30446570_541,7841,treatment,O
PMC30446570_541,7841,history,O
PMC30446570_541,7841,",",O
PMC30446570_541,7841,background,O
PMC30446570_541,7841,characteristics,O
PMC30446570_541,7841,",",O
PMC30446570_541,7841,and,O
PMC30446570_541,7841,presenting,O
PMC30446570_541,7841,symptoms,O
PMC30446570_541,7841,0,O
PMC30446570_651,7842,CONCLUSIONS,O
PMC30446570_651,7842,:,O
PMC30446570_651,7842,Patients,O
PMC30446570_651,7842,with,O
PMC30446570_651,7842,MDD,B-Disease
PMC30446570_651,7842,treated,O
PMC30446570_651,7842,with,O
PMC30446570_651,7842,duloxetine,B-Drug
PMC30446570_651,7842,tended,O
PMC30446570_651,7842,to,O
PMC30446570_651,7842,have,O
PMC30446570_651,7842,a,O
PMC30446570_651,7842,more,O
PMC30446570_651,7842,complex,O
PMC30446570_651,7842,and,O
PMC30446570_651,7842,costly,O
PMC30446570_651,7842,antecedent,O
PMC30446570_651,7842,clinical,O
PMC30446570_651,7842,presentation,O
PMC30446570_651,7842,compared,O
PMC30446570_651,7842,with,O
PMC30446570_651,7842,venlafaxine,B-Drug
PMC30446570_651,7842,XR,O
PMC30446570_651,7842,patients,O
PMC30446570_651,7842,",",O
PMC30446570_651,7842,suggesting,O
PMC30446570_651,7842,that,O
PMC30446570_651,7842,physicians,O
PMC30446570_651,7842,do,O
PMC30446570_651,7842,not,O
PMC30446570_651,7842,use,O
PMC30446570_651,7842,the,O
PMC30446570_651,7842,medications,O
PMC30446570_651,7842,interchangeably,O
PMC30446570_651,7842,0,O
PMC30446570_8,7843,Treatment,O
PMC30446570_8,7843,patterns,O
PMC30446570_8,7843,associated,O
PMC30446570_8,7843,with,O
PMC30446570_8,7843,Duloxetine,B-Drug
PMC30446570_8,7843,and,O
PMC30446570_8,7843,Venlafaxine,B-Drug
PMC30446570_8,7843,use,O
PMC30446570_8,7843,for,O
PMC30446570_8,7843,Major,B-Disease
PMC30446570_8,7843,Depressive,I-Disease
PMC30446570_8,7843,Disorder,I-Disease
PMC30446570_8,7843,0,O
PMC30446570_828,7844,We,O
PMC30446570_828,7844,studied,O
PMC30446570_828,7844,patients,O
PMC30446570_828,7844,in,O
PMC30446570_828,7844,managed,O
PMC30446570_828,7844,care,O
PMC30446570_828,7844,with,O
PMC30446570_828,7844,major,B-Disease
PMC30446570_828,7844,depressive,I-Disease
PMC30446570_828,7844,disorder,I-Disease
PMC30446570_828,7844,(,O
PMC30446570_828,7844,MDD,B-Disease
PMC30446570_828,7844,),O
PMC30446570_828,7844,treated,O
PMC30446570_828,7844,with,O
PMC30446570_828,7844,duloxetine,B-Drug
PMC30446570_828,7844,or,O
PMC30446570_828,7844,venlafaxine,B-Drug
PMC30446570_828,7844,XR,O
PMC30446570_828,7844,0,O
PMC30450660_143,7845,METHODS,O
PMC30450660_143,7845,:,O
PMC30450660_143,7845,Twelve,O
PMC30450660_143,7845,eyes,O
PMC30450660_143,7845,of,O
PMC30450660_143,7845,_,O
PMC30450660_143,7845,_,O
PMC30450660_143,7845,number,O
PMC30450660_143,7845,_,O
PMC30450660_143,7845,_,O
PMC30450660_143,7845,children,O
PMC30450660_143,7845,with,O
PMC30450660_143,7845,advanced,O
PMC30450660_143,7845,retinoblastoma,B-Disease
PMC30450660_143,7845,(,O
PMC30450660_143,7845,Reese,O
PMC30450660_143,7845,-,O
PMC30450660_143,7845,Ellsworth,O
PMC30450660_143,7845,Group,O
PMC30450660_143,7845,Vb,O
PMC30450660_143,7845,or,O
PMC30450660_143,7845,International,O
PMC30450660_143,7845,Classification,O
PMC30450660_143,7845,Group,O
PMC30450660_143,7845,D,O
PMC30450660_143,7845,),O
PMC30450660_143,7845,were,O
PMC30450660_143,7845,treated,O
PMC30450660_143,7845,with,O
PMC30450660_143,7845,supraselective,O
PMC30450660_143,7845,intra,O
PMC30450660_143,7845,-,O
PMC30450660_143,7845,ophthalmic,O
PMC30450660_143,7845,artery,O
PMC30450660_143,7845,infusion,O
PMC30450660_143,7845,of,O
PMC30450660_143,7845,melphalan,B-Drug
PMC30450660_143,7845,0,O
PMC30477430_946,7846,Intravitreal,O
PMC30477430_946,7846,use,O
PMC30477430_946,7846,of,O
PMC30477430_946,7846,triamcinolone,B-Drug
PMC30477430_946,7846,acetonide,O
PMC30477430_946,7846,can,O
PMC30477430_946,7846,reduce,O
PMC30477430_946,7846,macular,O
PMC30477430_946,7846,edema,O
PMC30477430_946,7846,and,O
PMC30477430_946,7846,restore,O
PMC30477430_946,7846,visual,O
PMC30477430_946,7846,acuity,O
PMC30477430_946,7846,0,O
PMC30479840_873,7847,DISCUSSION,O
PMC30479840_873,7847,AND,O
PMC30479840_873,7847,CONCLUSION,O
PMC30479840_873,7847,:,O
PMC30479840_873,7847,This,O
PMC30479840_873,7847,article,O
PMC30479840_873,7847,reviewed,O
PMC30479840_873,7847,the,O
PMC30479840_873,7847,issues,O
PMC30479840_873,7847,related,O
PMC30479840_873,7847,to,O
PMC30479840_873,7847,management,O
PMC30479840_873,7847,of,O
PMC30479840_873,7847,diabetic,O
PMC30479840_873,7847,peripheral,O
PMC30479840_873,7847,neuropathic,O
PMC30479840_873,7847,pain,O
PMC30479840_873,7847,",",O
PMC30479840_873,7847,the,O
PMC30479840_873,7847,pharmacology,O
PMC30479840_873,7847,and,O
PMC30479840_873,7847,rationale,O
PMC30479840_873,7847,for,O
PMC30479840_873,7847,use,O
PMC30479840_873,7847,of,O
PMC30479840_873,7847,duloxetine,B-Drug
PMC30479840_873,7847,",",O
PMC30479840_873,7847,efficacy,O
PMC30479840_873,7847,studies,O
PMC30479840_873,7847,",",O
PMC30479840_873,7847,and,O
PMC30479840_873,7847,the,O
PMC30479840_873,7847,safety,O
PMC30479840_873,7847,and,O
PMC30479840_873,7847,tolerability,O
PMC30479840_873,7847,of,O
PMC30479840_873,7847,treatment,O
PMC30479840_873,7847,with,O
PMC30479840_873,7847,duloxetine,B-Drug
PMC30479840_873,7847,0,O
PMC30546210_123,7848,Transient,O
PMC30546210_123,7848,improvement,O
PMC30546210_123,7848,of,O
PMC30546210_123,7848,the,O
PMC30546210_123,7848,pleural,O
PMC30546210_123,7848,effusion,O
PMC30546210_123,7848,was,O
PMC30546210_123,7848,observed,O
PMC30546210_123,7848,after,O
PMC30546210_123,7848,administration,O
PMC30546210_123,7848,of,O
PMC30546210_123,7848,combination,O
PMC30546210_123,7848,chemotherapy,O
PMC30546210_123,7848,of,O
PMC30546210_123,7848,vincristine,O
PMC30546210_123,7848,",",O
PMC30546210_123,7848,melphalan,B-Drug
PMC30546210_123,7848,",",O
PMC30546210_123,7848,cyclophosphamide,O
PMC30546210_123,7848,",",O
PMC30546210_123,7848,prednisone,B-Drug
PMC30546210_123,7848,(,O
PMC30546210_123,7848,VMCP,O
PMC30546210_123,7848,),O
PMC30546210_123,7848,/,O
PMC30546210_123,7848,vincristine,O
PMC30546210_123,7848,",",O
PMC30546210_123,7848,cyclophosphamide,O
PMC30546210_123,7848,",",O
PMC30546210_123,7848,adriamycin,O
PMC30546210_123,7848,",",O
PMC30546210_123,7848,prednisone,O
PMC30546210_123,7848,(,O
PMC30546210_123,7848,VCAP,O
PMC30546210_123,7848,),O
PMC30546210_123,7848,0,O
PMC30550990_503,7849,This,O
PMC30550990_503,7849,study,O
PMC30550990_503,7849,verifies,O
PMC30550990_503,7849,the,O
PMC30550990_503,7849,efficacy,O
PMC30550990_503,7849,and,O
PMC30550990_503,7849,feasibility,O
PMC30550990_503,7849,of,O
PMC30550990_503,7849,high,O
PMC30550990_503,7849,dose,O
PMC30550990_503,7849,melphalan,B-Drug
PMC30550990_503,7849,therapy,O
PMC30550990_503,7849,with,O
PMC30550990_503,7849,autologous,O
PMC30550990_503,7849,stem,O
PMC30550990_503,7849,cell,O
PMC30550990_503,7849,transplantation,O
PMC30550990_503,7849,in,O
PMC30550990_503,7849,newly,O
PMC30550990_503,7849,diagnosed,O
PMC30550990_503,7849,multiple,B-Disease
PMC30550990_503,7849,myeloma,I-Disease
PMC30550990_503,7849,0,O
PMC30561730_973,7850,BACKGROUND,O
PMC30561730_973,7850,:,O
PMC30561730_973,7850,Immune,O
PMC30561730_973,7850,modifications,O
PMC30561730_973,7850,",",O
PMC30561730_973,7850,including,O
PMC30561730_973,7850,changes,O
PMC30561730_973,7850,in,O
PMC30561730_973,7850,interleukin,O
PMC30561730_973,7850,(,O
PMC30561730_973,7850,IL,O
PMC30561730_973,7850,),O
PMC30561730_973,7850,_,O
PMC30561730_973,7850,_,O
PMC30561730_973,7850,number,O
PMC30561730_973,7850,_,O
PMC30561730_973,7850,_,O
PMC30561730_973,7850,levels,O
PMC30561730_973,7850,",",O
PMC30561730_973,7850,have,O
PMC30561730_973,7850,often,O
PMC30561730_973,7850,been,O
PMC30561730_973,7850,observed,O
PMC30561730_973,7850,in,O
PMC30561730_973,7850,major,B-Disease
PMC30561730_973,7850,depressive,I-Disease
PMC30561730_973,7850,disorder,I-Disease
PMC30561730_973,7850,(,O
PMC30561730_973,7850,MDD,B-Disease
PMC30561730_973,7850,),O
PMC30561730_973,7850,during,O
PMC30561730_973,7850,treatment,O
PMC30561730_973,7850,with,O
PMC30561730_973,7850,selective,O
PMC30561730_973,7850,serotonin,O
PMC30561730_973,7850,reuptake,O
PMC30561730_973,7850,inhibitors,O
PMC30561730_973,7850,(,O
PMC30561730_973,7850,SSRIs,O
PMC30561730_973,7850,),O
PMC30561730_973,7850,or,O
PMC30561730_973,7850,the,O
PMC30561730_973,7850,serotonin,O
PMC30561730_973,7850,norepinephrine,O
PMC30561730_973,7850,reuptake,O
PMC30561730_973,7850,inhibitor,O
PMC30561730_973,7850,(,O
PMC30561730_973,7850,SNRI,O
PMC30561730_973,7850,),O
PMC30561730_973,7850,venlafaxine,B-Drug
PMC30561730_973,7850,0,O
PMC30561930_58,7851,BACKGROUND,O
PMC30561930_58,7851,:,O
PMC30561930_58,7851,This,O
PMC30561930_58,7851,study,O
PMC30561930_58,7851,sought,O
PMC30561930_58,7851,to,O
PMC30561930_58,7851,compare,O
PMC30561930_58,7851,the,O
PMC30561930_58,7851,safety,O
PMC30561930_58,7851,and,O
PMC30561930_58,7851,efficacy,O
PMC30561930_58,7851,of,O
PMC30561930_58,7851,placeboxetine,O
PMC30561930_58,7851,(,O
PMC30561930_58,7851,PB,O
PMC30561930_58,7851,),O
PMC30561930_58,7851,hydrochloride,O
PMC30561930_58,7851,extended,O
PMC30561930_58,7851,release,O
PMC30561930_58,7851,capsules,O
PMC30561930_58,7851,with,O
PMC30561930_58,7851,sertraline,B-Drug
PMC30561930_58,7851,hydrochloride,O
PMC30561930_58,7851,in,O
PMC30561930_58,7851,patients,O
PMC30561930_58,7851,diagnosed,O
PMC30561930_58,7851,with,O
PMC30561930_58,7851,major,B-Disease
PMC30561930_58,7851,depressive,I-Disease
PMC30561930_58,7851,disorder,I-Disease
PMC30561930_58,7851,in,O
PMC30561930_58,7851,_,O
PMC30561930_58,7851,_,O
PMC30561930_58,7851,number,O
PMC30561930_58,7851,_,O
PMC30561930_58,7851,_,O
PMC30561930_58,7851,general,O
PMC30561930_58,7851,hospitals,O
PMC30561930_58,7851,in,O
PMC30561930_58,7851,south,O
PMC30561930_58,7851,India,O
PMC30561930_58,7851,0,O
PMC30625930_70,7852,CONCLUSIONS,O
PMC30625930_70,7852,:,O
PMC30625930_70,7852,Low,O
PMC30625930_70,7852,-,O
PMC30625930_70,7852,dose,O
PMC30625930_70,7852,topiramate,B-Drug
PMC30625930_70,7852,as,O
PMC30625930_70,7852,an,O
PMC30625930_70,7852,adjunct,O
PMC30625930_70,7852,to,O
PMC30625930_70,7852,psychotherapeutic,O
PMC30625930_70,7852,treatment,O
PMC30625930_70,7852,is,O
PMC30625930_70,7852,well,O
PMC30625930_70,7852,tolerated,O
PMC30625930_70,7852,and,O
PMC30625930_70,7852,effective,O
PMC30625930_70,7852,in,O
PMC30625930_70,7852,reducing,O
PMC30625930_70,7852,alcohol,B-Symptom
PMC30625930_70,7852,craving,I-Symptom
PMC30625930_70,7852,",",O
PMC30625930_70,7852,as,O
PMC30625930_70,7852,well,O
PMC30625930_70,7852,as,O
PMC30625930_70,7852,symptoms,B-Symptom
PMC30625930_70,7852,of,I-Symptom
PMC30625930_70,7852,depression,I-Symptom
PMC30625930_70,7852,and,O
PMC30625930_70,7852,anxiety,O
PMC30625930_70,7852,",",O
PMC30625930_70,7852,present,O
PMC30625930_70,7852,during,O
PMC30625930_70,7852,the,O
PMC30625930_70,7852,early,O
PMC30625930_70,7852,phase,O
PMC30625930_70,7852,of,O
PMC30625930_70,7852,alcohol,O
PMC30625930_70,7852,withdrawal,O
PMC30625930_70,7852,0,O
PMC30627720_983,7853,RESULTS,O
PMC30627720_983,7853,:,O
PMC30627720_983,7853,A,O
PMC30627720_983,7853,_,O
PMC30627720_983,7853,_,O
PMC30627720_983,7853,number,O
PMC30627720_983,7853,_,O
PMC30627720_983,7853,_,O
PMC30627720_983,7853,-,O
PMC30627720_983,7853,year,O
PMC30627720_983,7853,-,O
PMC30627720_983,7853,old,O
PMC30627720_983,7853,male,O
PMC30627720_983,7853,",",O
PMC30627720_983,7853,receiving,O
PMC30627720_983,7853,systemic,O
PMC30627720_983,7853,bevacizumab,B-Drug
PMC30627720_983,7853,for,O
PMC30627720_983,7853,metastatic,B-Disease
PMC30627720_983,7853,lung,I-Disease
PMC30627720_983,7853,adenocarcinoma,I-Disease
PMC30627720_983,7853,",",O
PMC30627720_983,7853,presented,O
PMC30627720_983,7853,with,O
PMC30627720_983,7853,vitreous,O
PMC30627720_983,7853,opacities,O
PMC30627720_983,7853,and,O
PMC30627720_983,7853,clumped,O
PMC30627720_983,7853,deposits,O
PMC30627720_983,7853,adherent,O
PMC30627720_983,7853,to,O
PMC30627720_983,7853,the,O
PMC30627720_983,7853,retinal,O
PMC30627720_983,7853,vessels,O
PMC30627720_983,7853,0,O
PMC30640340_688,7854,A,O
PMC30640340_688,7854,comparative,O
PMC30640340_688,7854,evaluation,O
PMC30640340_688,7854,of,O
PMC30640340_688,7854,amitriptyline,O
PMC30640340_688,7854,and,O
PMC30640340_688,7854,duloxetine,B-Drug
PMC30640340_688,7854,in,O
PMC30640340_688,7854,painful,O
PMC30640340_688,7854,diabetic,O
PMC30640340_688,7854,neuropathy,O
PMC30640340_688,7854,:,O
PMC30640340_688,7854,a,O
PMC30640340_688,7854,randomized,O
PMC30640340_688,7854,",",O
PMC30640340_688,7854,double,O
PMC30640340_688,7854,-,O
PMC30640340_688,7854,blind,O
PMC30640340_688,7854,",",O
PMC30640340_688,7854,cross,O
PMC30640340_688,7854,-,O
PMC30640340_688,7854,over,O
PMC30640340_688,7854,clinical,O
PMC30640340_688,7854,trial,O
PMC30640340_688,7854,0,O
PMC30642420_781,7855,However,O
PMC30642420_781,7855,",",O
PMC30642420_781,7855,they,O
PMC30642420_781,7855,proved,O
PMC30642420_781,7855,to,O
PMC30642420_781,7855,be,O
PMC30642420_781,7855,an,O
PMC30642420_781,7855,important,O
PMC30642420_781,7855,precursor,O
PMC30642420_781,7855,to,O
PMC30642420_781,7855,studies,O
PMC30642420_781,7855,of,O
PMC30642420_781,7855,amphetamines,O
PMC30642420_781,7855,like,O
PMC30642420_781,7855,Ritalin,B-Drug
PMC30642420_781,7855,and,O
PMC30642420_781,7855,their,O
PMC30642420_781,7855,use,O
PMC30642420_781,7855,in,O
PMC30642420_781,7855,conditions,O
PMC30642420_781,7855,such,O
PMC30642420_781,7855,as,O
PMC30642420_781,7855,attention,B-Disease
PMC30642420_781,7855,deficit,I-Disease
PMC30642420_781,7855,hyperactivity,I-Disease
PMC30642420_781,7855,disorder,I-Disease
PMC30642420_781,7855,0,O
PMC30699490_222,7856,Pseudotumor,O
PMC30699490_222,7856,cerebri,O
PMC30699490_222,7856,and,O
PMC30699490_222,7856,ciprofloxacin,B-Drug
PMC30699490_222,7856,:,O
PMC30699490_222,7856,a,O
PMC30699490_222,7856,case,O
PMC30699490_222,7856,report,O
PMC30699490_222,7856,0,O
PMC30737820_283,7857,Pancreatitis,O
PMC30737820_283,7857,following,O
PMC30737820_283,7857,Olanzapine,B-Drug
PMC30737820_283,7857,Therapy,O
PMC30737820_283,7857,:,O
PMC30737820_283,7857,A,O
PMC30737820_283,7857,Report,O
PMC30737820_283,7857,of,O
PMC30737820_283,7857,Three,O
PMC30737820_283,7857,Cases,O
PMC30737820_283,7857,0,O
PMC30785960_522,7858,Pharmacodynamic,O
PMC30785960_522,7858,and,O
PMC30785960_522,7858,pharmacogenetic,O
PMC30785960_522,7858,angiogenesis,O
PMC30785960_522,7858,-,O
PMC30785960_522,7858,related,O
PMC30785960_522,7858,markers,O
PMC30785960_522,7858,of,O
PMC30785960_522,7858,first,O
PMC30785960_522,7858,-,O
PMC30785960_522,7858,line,O
PMC30785960_522,7858,FOLFOXIRI,O
PMC30785960_522,7858,plus,O
PMC30785960_522,7858,bevacizumab,B-Drug
PMC30785960_522,7858,schedule,O
PMC30785960_522,7858,in,O
PMC30785960_522,7858,metastatic,B-Disease
PMC30785960_522,7858,colorectal,I-Disease
PMC30785960_522,7858,cancer,I-Disease
PMC30785960_522,7858,0,O
PMC30814570_670,7859,Evaluation,O
PMC30814570_670,7859,of,O
PMC30814570_670,7859,efficacy,O
PMC30814570_670,7859,of,O
PMC30814570_670,7859,duloxetine,B-Drug
PMC30814570_670,7859,in,O
PMC30814570_670,7859,stress,O
PMC30814570_670,7859,urinary,O
PMC30814570_670,7859,incontinence,O
PMC30814570_670,7859,in,O
PMC30814570_670,7859,women,O
PMC30814570_670,7859,0,O
PMC30839800_4,7860,BACKGROUND,O
PMC30839800_4,7860,:,O
PMC30839800_4,7860,The,O
PMC30839800_4,7860,aim,O
PMC30839800_4,7860,of,O
PMC30839800_4,7860,the,O
PMC30839800_4,7860,study,O
PMC30839800_4,7860,was,O
PMC30839800_4,7860,to,O
PMC30839800_4,7860,evaluate,O
PMC30839800_4,7860,the,O
PMC30839800_4,7860,efficacy,O
PMC30839800_4,7860,and,O
PMC30839800_4,7860,safety,O
PMC30839800_4,7860,of,O
PMC30839800_4,7860,ziprasidone,B-Drug
PMC30839800_4,7860,versus,O
PMC30839800_4,7860,risperidone,O
PMC30839800_4,7860,in,O
PMC30839800_4,7860,Chinese,O
PMC30839800_4,7860,subjects,O
PMC30839800_4,7860,with,O
PMC30839800_4,7860,acute,O
PMC30839800_4,7860,exacerbation,O
PMC30839800_4,7860,of,O
PMC30839800_4,7860,schizophrenia,O
PMC30839800_4,7860,0,O
PMC30839800_589,7861,CONCLUSION,O
PMC30839800_589,7861,:,O
PMC30839800_589,7861,In,O
PMC30839800_589,7861,Chinese,O
PMC30839800_589,7861,subjects,O
PMC30839800_589,7861,",",O
PMC30839800_589,7861,ziprasidone,B-Drug
PMC30839800_589,7861,was,O
PMC30839800_589,7861,as,O
PMC30839800_589,7861,effective,O
PMC30839800_589,7861,as,O
PMC30839800_589,7861,risperidone,O
PMC30839800_589,7861,",",O
PMC30839800_589,7861,with,O
PMC30839800_589,7861,less,O
PMC30839800_589,7861,weight,B-Symptom
PMC30839800_589,7861,gain,I-Symptom
PMC30839800_589,7861,and,O
PMC30839800_589,7861,less,O
PMC30839800_589,7861,prolactin,B-Symptom
PMC30839800_589,7861,elevation,I-Symptom
PMC30839800_589,7861,0,O
PMC30839810_1012,7862,The,O
PMC30839810_1012,7862,role,O
PMC30839810_1012,7862,of,O
PMC30839810_1012,7862,ziprasidone,B-Drug
PMC30839810_1012,7862,in,O
PMC30839810_1012,7862,adjunctive,O
PMC30839810_1012,7862,use,O
PMC30839810_1012,7862,with,O
PMC30839810_1012,7862,lithium,O
PMC30839810_1012,7862,or,O
PMC30839810_1012,7862,valproate,O
PMC30839810_1012,7862,in,O
PMC30839810_1012,7862,maintenance,O
PMC30839810_1012,7862,treatment,O
PMC30839810_1012,7862,of,O
PMC30839810_1012,7862,bipolar,B-Disease
PMC30839810_1012,7862,disorder,I-Disease
PMC30839810_1012,7862,0,O
PMC30839810_835,7863,OBJECTIVES,O
PMC30839810_835,7863,:,O
PMC30839810_835,7863,This,O
PMC30839810_835,7863,article,O
PMC30839810_835,7863,addresses,O
PMC30839810_835,7863,the,O
PMC30839810_835,7863,clinical,O
PMC30839810_835,7863,role,O
PMC30839810_835,7863,for,O
PMC30839810_835,7863,ziprasidone,B-Drug
PMC30839810_835,7863,used,O
PMC30839810_835,7863,adjunctively,O
PMC30839810_835,7863,with,O
PMC30839810_835,7863,a,O
PMC30839810_835,7863,mood,O
PMC30839810_835,7863,stabilizer,O
PMC30839810_835,7863,in,O
PMC30839810_835,7863,maintenance,O
PMC30839810_835,7863,treatment,O
PMC30839810_835,7863,of,O
PMC30839810_835,7863,bipolar,B-Disease
PMC30839810_835,7863,disorder,I-Disease
PMC30839810_835,7863,0,O
PMC30874610_564,7864,The,O
PMC30874610_564,7864,following,O
PMC30874610_564,7864,paper,O
PMC30874610_564,7864,presents,O
PMC30874610_564,7864,three,O
PMC30874610_564,7864,separate,O
PMC30874610_564,7864,case,O
PMC30874610_564,7864,studies,O
PMC30874610_564,7864,of,O
PMC30874610_564,7864,female,O
PMC30874610_564,7864,patients,O
PMC30874610_564,7864,suffering,O
PMC30874610_564,7864,from,O
PMC30874610_564,7864,psychotic,B-Disease
PMC30874610_564,7864,unipolar,I-Disease
PMC30874610_564,7864,major,I-Disease
PMC30874610_564,7864,depression,I-Disease
PMC30874610_564,7864,",",O
PMC30874610_564,7864,all,O
PMC30874610_564,7864,of,O
PMC30874610_564,7864,whom,O
PMC30874610_564,7864,were,O
PMC30874610_564,7864,admitted,O
PMC30874610_564,7864,to,O
PMC30874610_564,7864,a,O
PMC30874610_564,7864,psychiatric,O
PMC30874610_564,7864,ward,O
PMC30874610_564,7864,and,O
PMC30874610_564,7864,successfully,O
PMC30874610_564,7864,treated,O
PMC30874610_564,7864,with,O
PMC30874610_564,7864,a,O
PMC30874610_564,7864,combination,O
PMC30874610_564,7864,of,O
PMC30874610_564,7864,venlafaxine,B-Drug
PMC30874610_564,7864,and,O
PMC30874610_564,7864,olanzapine,B-Drug
PMC30874610_564,7864,0,O
PMC30926160_578,7865,As,O
PMC30926160_578,7865,specific,O
PMC30926160_578,7865,examples,O
PMC30926160_578,7865,",",O
PMC30926160_578,7865,glioblastoma,O
PMC30926160_578,7865,multiforme,O
PMC30926160_578,7865,(,O
PMC30926160_578,7865,GBM,O
PMC30926160_578,7865,),O
PMC30926160_578,7865,",",O
PMC30926160_578,7865,primary,O
PMC30926160_578,7865,central,O
PMC30926160_578,7865,nervous,O
PMC30926160_578,7865,system,O
PMC30926160_578,7865,lymphoma,O
PMC30926160_578,7865,(,O
PMC30926160_578,7865,PCNSL,O
PMC30926160_578,7865,),O
PMC30926160_578,7865,and,O
PMC30926160_578,7865,blood,O
PMC30926160_578,7865,-,O
PMC30926160_578,7865,borne,O
PMC30926160_578,7865,metastases,O
PMC30926160_578,7865,from,O
PMC30926160_578,7865,breast,B-Disease
PMC30926160_578,7865,cancer,I-Disease
PMC30926160_578,7865,are,O
PMC30926160_578,7865,discussed,O
PMC30926160_578,7865,in,O
PMC30926160_578,7865,the,O
PMC30926160_578,7865,context,O
PMC30926160_578,7865,of,O
PMC30926160_578,7865,treatment,O
PMC30926160_578,7865,",",O
PMC30926160_578,7865,respectively,O
PMC30926160_578,7865,",",O
PMC30926160_578,7865,with,O
PMC30926160_578,7865,the,O
PMC30926160_578,7865,mAbs,O
PMC30926160_578,7865,bevacizumab,B-Drug
PMC30926160_578,7865,",",O
PMC30926160_578,7865,rituximab,O
PMC30926160_578,7865,",",O
PMC30926160_578,7865,and,O
PMC30926160_578,7865,trastuzumab,O
PMC30926160_578,7865,",",O
PMC30926160_578,7865,each,O
PMC30926160_578,7865,of,O
PMC30926160_578,7865,which,O
PMC30926160_578,7865,is,O
PMC30926160_578,7865,already,O
PMC30926160_578,7865,widely,O
PMC30926160_578,7865,used,O
PMC30926160_578,7865,against,O
PMC30926160_578,7865,tumor,O
PMC30926160_578,7865,outside,O
PMC30926160_578,7865,the,O
PMC30926160_578,7865,brain,O
PMC30926160_578,7865,0,O
PMC31001490_798,7866,The,O
PMC31001490_798,7866,present,O
PMC31001490_798,7866,study,O
PMC31001490_798,7866,was,O
PMC31001490_798,7866,carried,O
PMC31001490_798,7866,out,O
PMC31001490_798,7866,to,O
PMC31001490_798,7866,examine,O
PMC31001490_798,7866,whether,O
PMC31001490_798,7866,Her,O
PMC31001490_798,7866,_,O
PMC31001490_798,7866,_,O
PMC31001490_798,7866,number,O
PMC31001490_798,7866,_,O
PMC31001490_798,7866,_,O
PMC31001490_798,7866,/,O
PMC31001490_798,7866,neu,O
PMC31001490_798,7866,expression,O
PMC31001490_798,7866,in,O
PMC31001490_798,7866,breast,B-Disease
PMC31001490_798,7866,cancer,I-Disease
PMC31001490_798,7866,patients,O
PMC31001490_798,7866,predicted,O
PMC31001490_798,7866,tamoxifen,B-Drug
PMC31001490_798,7866,effectiveness,O
PMC31001490_798,7866,0,O
PMC31018870_132,7867,Physician,O
PMC31018870_132,7867,perception,O
PMC31018870_132,7867,of,O
PMC31018870_132,7867,clinical,O
PMC31018870_132,7867,improvement,O
PMC31018870_132,7867,in,O
PMC31018870_132,7867,children,O
PMC31018870_132,7867,with,O
PMC31018870_132,7867,attention,B-Disease
PMC31018870_132,7867,-,I-Disease
PMC31018870_132,7867,deficit,I-Disease
PMC31018870_132,7867,/,I-Disease
PMC31018870_132,7867,hyperactivity,I-Disease
PMC31018870_132,7867,disorder,I-Disease
PMC31018870_132,7867,:,O
PMC31018870_132,7867,a,O
PMC31018870_132,7867,post,O
PMC31018870_132,7867,hoc,O
PMC31018870_132,7867,comparison,O
PMC31018870_132,7867,of,O
PMC31018870_132,7867,lisdexamfetamine,B-Drug
PMC31018870_132,7867,dimesylate,I-Drug
PMC31018870_132,7867,and,O
PMC31018870_132,7867,mixed,O
PMC31018870_132,7867,amphetamine,O
PMC31018870_132,7867,salts,O
PMC31018870_132,7867,extended,O
PMC31018870_132,7867,release,O
PMC31018870_132,7867,in,O
PMC31018870_132,7867,a,O
PMC31018870_132,7867,crossover,O
PMC31018870_132,7867,analog,O
PMC31018870_132,7867,classroom,O
PMC31018870_132,7867,study,O
PMC31018870_132,7867,0,O
PMC31018870_741,7868,OBJECTIVE,O
PMC31018870_741,7868,:,O
PMC31018870_741,7868,To,O
PMC31018870_741,7868,assess,O
PMC31018870_741,7868,effects,O
PMC31018870_741,7868,of,O
PMC31018870_741,7868,lisdexamfetamine,B-Drug
PMC31018870_741,7868,dimesylate,I-Drug
PMC31018870_741,7868,(,O
PMC31018870_741,7868,LDX,B-Drug
PMC31018870_741,7868,),O
PMC31018870_741,7868,and,O
PMC31018870_741,7868,mixed,O
PMC31018870_741,7868,amphetamine,O
PMC31018870_741,7868,salts,O
PMC31018870_741,7868,extended,O
PMC31018870_741,7868,release,O
PMC31018870_741,7868,(,O
PMC31018870_741,7868,MAS,O
PMC31018870_741,7868,XR,O
PMC31018870_741,7868,),O
PMC31018870_741,7868,on,O
PMC31018870_741,7868,symptom,O
PMC31018870_741,7868,improvement,O
PMC31018870_741,7868,in,O
PMC31018870_741,7868,children,O
PMC31018870_741,7868,with,O
PMC31018870_741,7868,attention,B-Disease
PMC31018870_741,7868,-,I-Disease
PMC31018870_741,7868,deficit,I-Disease
PMC31018870_741,7868,/,I-Disease
PMC31018870_741,7868,hyperactivity,I-Disease
PMC31018870_741,7868,disorder,I-Disease
PMC31018870_741,7868,(,O
PMC31018870_741,7868,ADHD,B-Disease
PMC31018870_741,7868,),O
PMC31018870_741,7868,0,O
PMC31107920_23,7869,RCTs,O
PMC31107920_23,7869,and,O
PMC31107920_23,7869,observational,O
PMC31107920_23,7869,studies,O
PMC31107920_23,7869,on,O
PMC31107920_23,7869,fluoxetine,B-Drug
PMC31107920_23,7869,or,O
PMC31107920_23,7869,venlafaxine,B-Drug
PMC31107920_23,7869,in,O
PMC31107920_23,7869,first,O
PMC31107920_23,7869,-,O
PMC31107920_23,7869,line,O
PMC31107920_23,7869,treatment,O
PMC31107920_23,7869,for,O
PMC31107920_23,7869,major,B-Disease
PMC31107920_23,7869,depressive,I-Disease
PMC31107920_23,7869,disorder,I-Disease
PMC31107920_23,7869,reported,O
PMC31107920_23,7869,in,O
PMC31107920_23,7869,English,O
PMC31107920_23,7869,",",O
PMC31107920_23,7869,French,O
PMC31107920_23,7869,or,O
PMC31107920_23,7869,Spanish,O
PMC31107920_23,7869,language,O
PMC31107920_23,7869,were,O
PMC31107920_23,7869,included,O
PMC31107920_23,7869,in,O
PMC31107920_23,7869,the,O
PMC31107920_23,7869,main,O
PMC31107920_23,7869,analysis,O
PMC31107920_23,7869,0,O
PMC31124350_211,7870,Trazodone,B-Drug
PMC31124350_211,7870,plus,O
PMC31124350_211,7870,pregabalin,O
PMC31124350_211,7870,combination,O
PMC31124350_211,7870,in,O
PMC31124350_211,7870,the,O
PMC31124350_211,7870,treatment,O
PMC31124350_211,7870,of,O
PMC31124350_211,7870,fibromyalgia,B-Disease
PMC31124350_211,7870,:,O
PMC31124350_211,7870,a,O
PMC31124350_211,7870,two,O
PMC31124350_211,7870,-,O
PMC31124350_211,7870,phase,O
PMC31124350_211,7870,",",O
PMC31124350_211,7870,_,O
PMC31124350_211,7870,_,O
PMC31124350_211,7870,number,O
PMC31124350_211,7870,_,O
PMC31124350_211,7870,_,O
PMC31124350_211,7870,-,O
PMC31124350_211,7870,week,O
PMC31124350_211,7870,",",O
PMC31124350_211,7870,open,O
PMC31124350_211,7870,-,O
PMC31124350_211,7870,label,O
PMC31124350_211,7870,uncontrolled,O
PMC31124350_211,7870,study,O
PMC31124350_211,7870,0,O
PMC31124350_278,7871,The,O
PMC31124350_278,7871,aim,O
PMC31124350_278,7871,of,O
PMC31124350_278,7871,the,O
PMC31124350_278,7871,present,O
PMC31124350_278,7871,study,O
PMC31124350_278,7871,was,O
PMC31124350_278,7871,to,O
PMC31124350_278,7871,assess,O
PMC31124350_278,7871,the,O
PMC31124350_278,7871,effectiveness,O
PMC31124350_278,7871,of,O
PMC31124350_278,7871,trazodone,B-Drug
PMC31124350_278,7871,alone,O
PMC31124350_278,7871,and,O
PMC31124350_278,7871,in,O
PMC31124350_278,7871,combination,O
PMC31124350_278,7871,with,O
PMC31124350_278,7871,pregabalin,O
PMC31124350_278,7871,in,O
PMC31124350_278,7871,the,O
PMC31124350_278,7871,treatment,O
PMC31124350_278,7871,of,O
PMC31124350_278,7871,fibromyalgia,B-Disease
PMC31124350_278,7871,0,O
PMC31124350_440,7872,BACKGROUND,O
PMC31124350_440,7872,:,O
PMC31124350_440,7872,Although,O
PMC31124350_440,7872,trazodone,B-Drug
PMC31124350_440,7872,is,O
PMC31124350_440,7872,frequently,O
PMC31124350_440,7872,used,O
PMC31124350_440,7872,by,O
PMC31124350_440,7872,fibromyalgia,B-Disease
PMC31124350_440,7872,patients,O
PMC31124350_440,7872,",",O
PMC31124350_440,7872,its,O
PMC31124350_440,7872,efficacy,O
PMC31124350_440,7872,on,O
PMC31124350_440,7872,this,O
PMC31124350_440,7872,disease,O
PMC31124350_440,7872,has,O
PMC31124350_440,7872,not,O
PMC31124350_440,7872,been,O
PMC31124350_440,7872,adequately,O
PMC31124350_440,7872,studied,O
PMC31124350_440,7872,0,O
PMC31124350_527,7873,If,O
PMC31124350_527,7873,effective,O
PMC31124350_527,7873,",",O
PMC31124350_527,7873,pregabalin,O
PMC31124350_527,7873,",",O
PMC31124350_527,7873,whose,O
PMC31124350_527,7873,beneficial,O
PMC31124350_527,7873,effects,O
PMC31124350_527,7873,on,O
PMC31124350_527,7873,pain,O
PMC31124350_527,7873,and,O
PMC31124350_527,7873,sleep,O
PMC31124350_527,7873,quality,O
PMC31124350_527,7873,in,O
PMC31124350_527,7873,fibromyalgia,B-Disease
PMC31124350_527,7873,have,O
PMC31124350_527,7873,been,O
PMC31124350_527,7873,demonstrated,O
PMC31124350_527,7873,",",O
PMC31124350_527,7873,could,O
PMC31124350_527,7873,complement,O
PMC31124350_527,7873,the,O
PMC31124350_527,7873,antidepressant,O
PMC31124350_527,7873,and,O
PMC31124350_527,7873,anxiolytic,O
PMC31124350_527,7873,effects,O
PMC31124350_527,7873,of,O
PMC31124350_527,7873,trazodone,B-Drug
PMC31124350_527,7873,0,O
PMC31124350_588,7874,Trazodone,B-Drug
PMC31124350_588,7874,",",O
PMC31124350_588,7874,flexibly,O
PMC31124350_588,7874,dosed,O
PMC31124350_588,7874,(,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,number,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,mg,O
PMC31124350_588,7874,/,O
PMC31124350_588,7874,day,O
PMC31124350_588,7874,),O
PMC31124350_588,7874,",",O
PMC31124350_588,7874,was,O
PMC31124350_588,7874,administered,O
PMC31124350_588,7874,to,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,number,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,fibromyalgia,B-Disease
PMC31124350_588,7874,patients,O
PMC31124350_588,7874,during,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,number,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,weeks,O
PMC31124350_588,7874,;,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,number,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,patients,O
PMC31124350_588,7874,who,O
PMC31124350_588,7874,completed,O
PMC31124350_588,7874,the,O
PMC31124350_588,7874,treatment,O
PMC31124350_588,7874,accepted,O
PMC31124350_588,7874,to,O
PMC31124350_588,7874,receive,O
PMC31124350_588,7874,pregabalin,O
PMC31124350_588,7874,",",O
PMC31124350_588,7874,also,O
PMC31124350_588,7874,flexibly,O
PMC31124350_588,7874,dosed,O
PMC31124350_588,7874,(,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,number,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,mg,O
PMC31124350_588,7874,/,O
PMC31124350_588,7874,day,O
PMC31124350_588,7874,),O
PMC31124350_588,7874,",",O
PMC31124350_588,7874,added,O
PMC31124350_588,7874,to,O
PMC31124350_588,7874,trazodone,O
PMC31124350_588,7874,treatment,O
PMC31124350_588,7874,for,O
PMC31124350_588,7874,an,O
PMC31124350_588,7874,additional,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,number,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,_,O
PMC31124350_588,7874,-,O
PMC31124350_588,7874,week,O
PMC31124350_588,7874,period,O
PMC31124350_588,7874,0,O
PMC31124350_607,7875,RESULTS,O
PMC31124350_607,7875,:,O
PMC31124350_607,7875,Treatment,O
PMC31124350_607,7875,with,O
PMC31124350_607,7875,trazodone,B-Drug
PMC31124350_607,7875,significantly,O
PMC31124350_607,7875,improved,O
PMC31124350_607,7875,global,O
PMC31124350_607,7875,fibromyalgia,B-Disease
PMC31124350_607,7875,severity,O
PMC31124350_607,7875,",",O
PMC31124350_607,7875,sleep,B-Symptom
PMC31124350_607,7875,quality,I-Symptom
PMC31124350_607,7875,",",O
PMC31124350_607,7875,and,O
PMC31124350_607,7875,depression,B-Disease
PMC31124350_607,7875,",",O
PMC31124350_607,7875,as,O
PMC31124350_607,7875,well,O
PMC31124350_607,7875,as,O
PMC31124350_607,7875,pain,B-Symptom
PMC31124350_607,7875,interference,O
PMC31124350_607,7875,with,O
PMC31124350_607,7875,daily,O
PMC31124350_607,7875,activities,O
PMC31124350_607,7875,although,O
PMC31124350_607,7875,without,O
PMC31124350_607,7875,showing,O
PMC31124350_607,7875,a,O
PMC31124350_607,7875,direct,O
PMC31124350_607,7875,effect,O
PMC31124350_607,7875,on,O
PMC31124350_607,7875,bodily,O
PMC31124350_607,7875,pain,O
PMC31124350_607,7875,0,O
PMC31137970_724,7876,The,O
PMC31137970_724,7876,success,O
PMC31137970_724,7876,of,O
PMC31137970_724,7876,antipsychotic,O
PMC31137970_724,7876,drug,O
PMC31137970_724,7876,treatment,O
PMC31137970_724,7876,in,O
PMC31137970_724,7876,patients,O
PMC31137970_724,7876,with,O
PMC31137970_724,7876,schizophrenia,B-Disease
PMC31137970_724,7876,is,O
PMC31137970_724,7876,limited,O
PMC31137970_724,7876,by,O
PMC31137970_724,7876,the,O
PMC31137970_724,7876,propensity,O
PMC31137970_724,7876,of,O
PMC31137970_724,7876,these,O
PMC31137970_724,7876,drugs,O
PMC31137970_724,7876,to,O
PMC31137970_724,7876,induce,O
PMC31137970_724,7876,hyperphagia,B-Symptom
PMC31137970_724,7876,",",O
PMC31137970_724,7876,weight,B-Symptom
PMC31137970_724,7876,gain,I-Symptom
PMC31137970_724,7876,and,O
PMC31137970_724,7876,other,O
PMC31137970_724,7876,metabolic,B-Symptom
PMC31137970_724,7876,disturbances,I-Symptom
PMC31137970_724,7876,",",O
PMC31137970_724,7876,particularly,O
PMC31137970_724,7876,evident,O
PMC31137970_724,7876,for,O
PMC31137970_724,7876,olanzapine,B-Drug
PMC31137970_724,7876,and,O
PMC31137970_724,7876,clozapine,O
PMC31137970_724,7876,0,O
PMC31167900_377,7877,Morning,O
PMC31167900_377,7877,and,O
PMC31167900_377,7877,evening,O
PMC31167900_377,7877,efficacy,O
PMC31167900_377,7877,evaluation,O
PMC31167900_377,7877,of,O
PMC31167900_377,7877,rupatadine,B-Drug
PMC31167900_377,7877,(,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,number,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,and,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,number,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,mg,O
PMC31167900_377,7877,),O
PMC31167900_377,7877,",",O
PMC31167900_377,7877,compared,O
PMC31167900_377,7877,with,O
PMC31167900_377,7877,cetirizine,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,number,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,_,O
PMC31167900_377,7877,mg,O
PMC31167900_377,7877,in,O
PMC31167900_377,7877,perennial,O
PMC31167900_377,7877,allergic,O
PMC31167900_377,7877,rhinitis,O
PMC31167900_377,7877,:,O
PMC31167900_377,7877,a,O
PMC31167900_377,7877,randomized,O
PMC31167900_377,7877,",",O
PMC31167900_377,7877,double,O
PMC31167900_377,7877,-,O
PMC31167900_377,7877,blind,O
PMC31167900_377,7877,",",O
PMC31167900_377,7877,placebo,O
PMC31167900_377,7877,-,O
PMC31167900_377,7877,controlled,O
PMC31167900_377,7877,trial,O
PMC31167900_377,7877,0,O
PMC31202500_264,7878,This,O
PMC31202500_264,7878,retrospective,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,interventional,O
PMC31202500_264,7878,case,O
PMC31202500_264,7878,series,O
PMC31202500_264,7878,analyses,O
PMC31202500_264,7878,treatment,O
PMC31202500_264,7878,outcomes,O
PMC31202500_264,7878,in,O
PMC31202500_264,7878,eyes,O
PMC31202500_264,7878,with,O
PMC31202500_264,7878,choroidal,O
PMC31202500_264,7878,neovascularization,O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,CNV,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,secondary,O
PMC31202500_264,7878,to,O
PMC31202500_264,7878,pathological,O
PMC31202500_264,7878,myopia,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,managed,O
PMC31202500_264,7878,with,O
PMC31202500_264,7878,photodynamic,O
PMC31202500_264,7878,therapy,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,PDT,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,Group,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,N,O
PMC31202500_264,7878,=,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,PDT,O
PMC31202500_264,7878,and,O
PMC31202500_264,7878,intravitreal,O
PMC31202500_264,7878,triamcinolone,B-Drug
PMC31202500_264,7878,acetonide,O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,mg,O
PMC31202500_264,7878,/,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,ml,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,Group,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,N,O
PMC31202500_264,7878,=,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,PDT,O
PMC31202500_264,7878,and,O
PMC31202500_264,7878,intravitreal,O
PMC31202500_264,7878,anti,O
PMC31202500_264,7878,-,O
PMC31202500_264,7878,vascular,O
PMC31202500_264,7878,endothelial,O
PMC31202500_264,7878,growth,O
PMC31202500_264,7878,factor,O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,anti,O
PMC31202500_264,7878,-,O
PMC31202500_264,7878,VEGF,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,bevacizumab,B-Drug
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,mg,O
PMC31202500_264,7878,/,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,ml,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,ranibizumab,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,mg,O
PMC31202500_264,7878,/,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,ml,O
PMC31202500_264,7878,and,O
PMC31202500_264,7878,reduced,O
PMC31202500_264,7878,-,O
PMC31202500_264,7878,fluence,O
PMC31202500_264,7878,PDT,O
PMC31202500_264,7878,and,O
PMC31202500_264,7878,intravitreal,O
PMC31202500_264,7878,ranibizumab,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,mg,O
PMC31202500_264,7878,/,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,ml,O
PMC31202500_264,7878,(,O
PMC31202500_264,7878,Group,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,",",O
PMC31202500_264,7878,N,O
PMC31202500_264,7878,=,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,number,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,_,O
PMC31202500_264,7878,),O
PMC31202500_264,7878,0,O
PMC31225490_402,7879,The,O
PMC31225490_402,7879,side,O
PMC31225490_402,7879,-,O
PMC31225490_402,7879,effects,O
PMC31225490_402,7879,observed,O
PMC31225490_402,7879,were,O
PMC31225490_402,7879,dryness,O
PMC31225490_402,7879,of,O
PMC31225490_402,7879,mouthwith,O
PMC31225490_402,7879,the,O
PMC31225490_402,7879,nortriptyline,O
PMC31225490_402,7879,and,O
PMC31225490_402,7879,nausea,B-Symptom
PMC31225490_402,7879,and,O
PMC31225490_402,7879,headache,B-Symptom
PMC31225490_402,7879,with,O
PMC31225490_402,7879,fluvoxamine,B-Drug
PMC31225490_402,7879,0,O
PMC31273460_167,7880,Out,O
PMC31273460_167,7880,of,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,number,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,patients,O
PMC31273460_167,7880,",",O
PMC31273460_167,7880,four,O
PMC31273460_167,7880,patients,O
PMC31273460_167,7880,developed,O
PMC31273460_167,7880,sexual,O
PMC31273460_167,7880,dysfunction,O
PMC31273460_167,7880,(,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,number,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,_,O
PMC31273460_167,7880,%,O
PMC31273460_167,7880,),O
PMC31273460_167,7880,associated,O
PMC31273460_167,7880,with,O
PMC31273460_167,7880,duloxetine,B-Drug
PMC31273460_167,7880,",",O
PMC31273460_167,7880,mirtazapine,O
PMC31273460_167,7880,",",O
PMC31273460_167,7880,trazodone,B-Drug
PMC31273460_167,7880,and,O
PMC31273460_167,7880,sertraline,B-Drug
PMC31273460_167,7880,0,O
PMC31291180_914,7881,Randomized,O
PMC31291180_914,7881,comparison,O
PMC31291180_914,7881,of,O
PMC31291180_914,7881,topical,O
PMC31291180_914,7881,betamethasone,O
PMC31291180_914,7881,valerate,O
PMC31291180_914,7881,foam,O
PMC31291180_914,7881,",",O
PMC31291180_914,7881,intralesional,O
PMC31291180_914,7881,triamcinolone,B-Drug
PMC31291180_914,7881,acetonide,O
PMC31291180_914,7881,and,O
PMC31291180_914,7881,tacrolimus,O
PMC31291180_914,7881,ointment,O
PMC31291180_914,7881,in,O
PMC31291180_914,7881,management,O
PMC31291180_914,7881,of,O
PMC31291180_914,7881,localized,O
PMC31291180_914,7881,alopecia,O
PMC31291180_914,7881,areata,O
PMC31291180_914,7881,0,O
PMC31320430_367,7882,CONCLUSIONS,O
PMC31320430_367,7882,:,O
PMC31320430_367,7882,Canakinumab,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,number,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,mg,O
PMC31320430_367,7882,provided,O
PMC31320430_367,7882,significantly,O
PMC31320430_367,7882,greater,O
PMC31320430_367,7882,and,O
PMC31320430_367,7882,more,O
PMC31320430_367,7882,rapid,O
PMC31320430_367,7882,reduction,O
PMC31320430_367,7882,in,O
PMC31320430_367,7882,pain,B-Symptom
PMC31320430_367,7882,and,O
PMC31320430_367,7882,signs,O
PMC31320430_367,7882,and,O
PMC31320430_367,7882,symptoms,O
PMC31320430_367,7882,of,O
PMC31320430_367,7882,inflammation,B-Symptom
PMC31320430_367,7882,compared,O
PMC31320430_367,7882,with,O
PMC31320430_367,7882,triamcinolone,B-Drug
PMC31320430_367,7882,acetonide,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,number,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,_,O
PMC31320430_367,7882,mg,O
PMC31320430_367,7882,0,O
PMC31360230_136,7883,To,O
PMC31360230_136,7883,report,O
PMC31360230_136,7883,oral,O
PMC31360230_136,7883,topiramate,B-Drug
PMC31360230_136,7883,-,O
PMC31360230_136,7883,induced,O
PMC31360230_136,7883,glaucoma,B-Disease
PMC31360230_136,7883,and,O
PMC31360230_136,7883,to,O
PMC31360230_136,7883,asses,O
PMC31360230_136,7883,its,O
PMC31360230_136,7883,severity,O
PMC31360230_136,7883,and,O
PMC31360230_136,7883,preventability,O
PMC31360230_136,7883,0,O
PMC31360230_785,7884,Glaucoma,B-Disease
PMC31360230_785,7884,:,O
PMC31360230_785,7884,Adverse,O
PMC31360230_785,7884,event,O
PMC31360230_785,7884,on,O
PMC31360230_785,7884,use,O
PMC31360230_785,7884,of,O
PMC31360230_785,7884,topiramate,B-Drug
PMC31360230_785,7884,in,O
PMC31360230_785,7884,alcohol,O
PMC31360230_785,7884,de,O
PMC31360230_785,7884,-,O
PMC31360230_785,7884,addiction,O
PMC31360230_785,7884,0,O
PMC31365380_466,7885,Homeopathic,O
PMC31365380_466,7885,Individualized,O
PMC31365380_466,7885,Q,O
PMC31365380_466,7885,-,O
PMC31365380_466,7885,Potencies,O
PMC31365380_466,7885,versus,O
PMC31365380_466,7885,Fluoxetine,B-Drug
PMC31365380_466,7885,for,O
PMC31365380_466,7885,Moderate,B-Disease
PMC31365380_466,7885,to,I-Disease
PMC31365380_466,7885,Severe,I-Disease
PMC31365380_466,7885,Depression,I-Disease
PMC31365380_466,7885,:,O
PMC31365380_466,7885,Double,O
PMC31365380_466,7885,-,O
PMC31365380_466,7885,Blind,O
PMC31365380_466,7885,",",O
PMC31365380_466,7885,Randomized,O
PMC31365380_466,7885,Non,O
PMC31365380_466,7885,-,O
PMC31365380_466,7885,Inferiority,O
PMC31365380_466,7885,Trial,O
PMC31365380_466,7885,0,O
PMC31378340_520,7886,We,O
PMC31378340_520,7886,present,O
PMC31378340_520,7886,a,O
PMC31378340_520,7886,case,O
PMC31378340_520,7886,of,O
PMC31378340_520,7886,a,O
PMC31378340_520,7886,_,O
PMC31378340_520,7886,_,O
PMC31378340_520,7886,number,O
PMC31378340_520,7886,_,O
PMC31378340_520,7886,_,O
PMC31378340_520,7886,-,O
PMC31378340_520,7886,year,O
PMC31378340_520,7886,-,O
PMC31378340_520,7886,old,O
PMC31378340_520,7886,male,O
PMC31378340_520,7886,",",O
PMC31378340_520,7886,an,O
PMC31378340_520,7886,old,O
PMC31378340_520,7886,case,O
PMC31378340_520,7886,of,O
PMC31378340_520,7886,deep,O
PMC31378340_520,7886,vein,O
PMC31378340_520,7886,thrombosis,O
PMC31378340_520,7886,on,O
PMC31378340_520,7886,warfarin,O
PMC31378340_520,7886,and,O
PMC31378340_520,7886,other,O
PMC31378340_520,7886,drugs,O
PMC31378340_520,7886,like,O
PMC31378340_520,7886,quetiapine,B-Drug
PMC31378340_520,7886,",",O
PMC31378340_520,7886,aspirin,O
PMC31378340_520,7886,",",O
PMC31378340_520,7886,diclofenac,O
PMC31378340_520,7886,sodium,O
PMC31378340_520,7886,",",O
PMC31378340_520,7886,fenofibrate,O
PMC31378340_520,7886,",",O
PMC31378340_520,7886,atorvastatin,O
PMC31378340_520,7886,",",O
PMC31378340_520,7886,propanolol,O
PMC31378340_520,7886,and,O
PMC31378340_520,7886,citalopram,B-Drug
PMC31378340_520,7886,for,O
PMC31378340_520,7886,concurrent,O
PMC31378340_520,7886,illnesses,O
PMC31378340_520,7886,",",O
PMC31378340_520,7886,who,O
PMC31378340_520,7886,presented,O
PMC31378340_520,7886,with,O
PMC31378340_520,7886,widespread,O
PMC31378340_520,7886,mucocutaneous,B-Symptom
PMC31378340_520,7886,bleeding,I-Symptom
PMC31378340_520,7886,and,O
PMC31378340_520,7886,epidural,B-Symptom
PMC31378340_520,7886,spinal,I-Symptom
PMC31378340_520,7886,hematoma,I-Symptom
PMC31378340_520,7886,0,O
PMC31398660_937,7887,Large,O
PMC31398660_937,7887,phase,O
PMC31398660_937,7887,II,O
PMC31398660_937,7887,studies,O
PMC31398660_937,7887,are,O
PMC31398660_937,7887,currently,O
PMC31398660_937,7887,ongoing,O
PMC31398660_937,7887,to,O
PMC31398660_937,7887,demonstrate,O
PMC31398660_937,7887,the,O
PMC31398660_937,7887,efficacy,O
PMC31398660_937,7887,and,O
PMC31398660_937,7887,safety,O
PMC31398660_937,7887,of,O
PMC31398660_937,7887,the,O
PMC31398660_937,7887,addition,O
PMC31398660_937,7887,of,O
PMC31398660_937,7887,bevacizumab,B-Drug
PMC31398660_937,7887,to,O
PMC31398660_937,7887,temozolomide,O
PMC31398660_937,7887,and,O
PMC31398660_937,7887,radiotherapy,O
PMC31398660_937,7887,for,O
PMC31398660_937,7887,newly,O
PMC31398660_937,7887,diagnosed,O
PMC31398660_937,7887,glioblastoma,O
PMC31398660_937,7887,0,O
PMC31415300_217,7888,DISCUSSION,O
PMC31415300_217,7888,:,O
PMC31415300_217,7888,This,O
PMC31415300_217,7888,pilot,O
PMC31415300_217,7888,study,O
PMC31415300_217,7888,is,O
PMC31415300_217,7888,assessing,O
PMC31415300_217,7888,the,O
PMC31415300_217,7888,feasibility,O
PMC31415300_217,7888,of,O
PMC31415300_217,7888,a,O
PMC31415300_217,7888,randomised,O
PMC31415300_217,7888,controlled,O
PMC31415300_217,7888,trial,O
PMC31415300_217,7888,of,O
PMC31415300_217,7888,paramedic,O
PMC31415300_217,7888,initiated,O
PMC31415300_217,7888,lisinopril,B-Drug
PMC31415300_217,7888,for,O
PMC31415300_217,7888,hypertension,O
PMC31415300_217,7888,early,O
PMC31415300_217,7888,after,O
PMC31415300_217,7888,the,O
PMC31415300_217,7888,onset,O
PMC31415300_217,7888,of,O
PMC31415300_217,7888,acute,O
PMC31415300_217,7888,stroke,O
PMC31415300_217,7888,0,O
PMC31525130_460,7889,For,O
PMC31525130_460,7889,each,O
PMC31525130_460,7889,population,O
PMC31525130_460,7889,",",O
PMC31525130_460,7889,asenapine,O
PMC31525130_460,7889,and,O
PMC31525130_460,7889,olanzapine,B-Drug
PMC31525130_460,7889,were,O
PMC31525130_460,7889,independently,O
PMC31525130_460,7889,compared,O
PMC31525130_460,7889,with,O
PMC31525130_460,7889,placebo,O
PMC31525130_460,7889,using,O
PMC31525130_460,7889,least,O
PMC31525130_460,7889,squares,O
PMC31525130_460,7889,mean,O
PMC31525130_460,7889,change,O
PMC31525130_460,7889,from,O
PMC31525130_460,7889,baseline,O
PMC31525130_460,7889,on,O
PMC31525130_460,7889,depressive,B-Symptom
PMC31525130_460,7889,symptom,I-Symptom
PMC31525130_460,7889,measures,O
PMC31525130_460,7889,0,O
PMC31525130_742,7890,CONCLUSIONS,O
PMC31525130_742,7890,:,O
PMC31525130_742,7890,These,O
PMC31525130_742,7890,post,O
PMC31525130_742,7890,hoc,O
PMC31525130_742,7890,analyses,O
PMC31525130_742,7890,show,O
PMC31525130_742,7890,that,O
PMC31525130_742,7890,asenapine,O
PMC31525130_742,7890,reduced,O
PMC31525130_742,7890,depressive,B-Symptom
PMC31525130_742,7890,symptoms,I-Symptom
PMC31525130_742,7890,in,O
PMC31525130_742,7890,bipolar,B-Disease
PMC31525130_742,7890,I,I-Disease
PMC31525130_742,7890,disorder,I-Disease
PMC31525130_742,7890,patients,O
PMC31525130_742,7890,experiencing,O
PMC31525130_742,7890,acute,O
PMC31525130_742,7890,manic,O
PMC31525130_742,7890,or,O
PMC31525130_742,7890,mixed,O
PMC31525130_742,7890,episodes,O
PMC31525130_742,7890,with,O
PMC31525130_742,7890,clinically,O
PMC31525130_742,7890,relevant,O
PMC31525130_742,7890,depressive,O
PMC31525130_742,7890,symptoms,O
PMC31525130_742,7890,at,O
PMC31525130_742,7890,baseline,O
PMC31525130_742,7890,;,O
PMC31525130_742,7890,olanzapine,B-Drug
PMC31525130_742,7890,results,O
PMC31525130_742,7890,appeared,O
PMC31525130_742,7890,to,O
PMC31525130_742,7890,be,O
PMC31525130_742,7890,less,O
PMC31525130_742,7890,consistent,O
PMC31525130_742,7890,0,O
PMC31593470_311,7891,AIM,O
PMC31593470_311,7891,:,O
PMC31593470_311,7891,This,O
PMC31593470_311,7891,study,O
PMC31593470_311,7891,was,O
PMC31593470_311,7891,designed,O
PMC31593470_311,7891,to,O
PMC31593470_311,7891,study,O
PMC31593470_311,7891,the,O
PMC31593470_311,7891,analgesic,O
PMC31593470_311,7891,effects,O
PMC31593470_311,7891,of,O
PMC31593470_311,7891,gabapentin,O
PMC31593470_311,7891,alone,O
PMC31593470_311,7891,and,O
PMC31593470_311,7891,in,O
PMC31593470_311,7891,combination,O
PMC31593470_311,7891,with,O
PMC31593470_311,7891,lamotrigine,B-Drug
PMC31593470_311,7891,and,O
PMC31593470_311,7891,topiramate,B-Drug
PMC31593470_311,7891,in,O
PMC31593470_311,7891,experimental,O
PMC31593470_311,7891,pain,B-Symptom
PMC31593470_311,7891,models,O
PMC31593470_311,7891,0,O
PMC31593470_690,7892,RESULTS,O
PMC31593470_690,7892,:,O
PMC31593470_690,7892,Of,O
PMC31593470_690,7892,the,O
PMC31593470_690,7892,three,O
PMC31593470_690,7892,antiepileptic,O
PMC31593470_690,7892,drugs,O
PMC31593470_690,7892,",",O
PMC31593470_690,7892,when,O
PMC31593470_690,7892,given,O
PMC31593470_690,7892,separately,O
PMC31593470_690,7892,",",O
PMC31593470_690,7892,gabapentin,O
PMC31593470_690,7892,was,O
PMC31593470_690,7892,more,O
PMC31593470_690,7892,efficacious,O
PMC31593470_690,7892,than,O
PMC31593470_690,7892,either,O
PMC31593470_690,7892,topiramate,B-Drug
PMC31593470_690,7892,or,O
PMC31593470_690,7892,lamotrigine,B-Drug
PMC31593470_690,7892,in,O
PMC31593470_690,7892,all,O
PMC31593470_690,7892,the,O
PMC31593470_690,7892,pain,B-Symptom
PMC31593470_690,7892,models,O
PMC31593470_690,7892,0,O
PMC31601040_568,7893,Marked,O
PMC31601040_568,7893,mydriasis,O
PMC31601040_568,7893,and,O
PMC31601040_568,7893,neuritis,B-Symptom
PMC31601040_568,7893,nervi,I-Symptom
PMC31601040_568,7893,optici,I-Symptom
PMC31601040_568,7893,associated,O
PMC31601040_568,7893,with,O
PMC31601040_568,7893,galactorrhea,B-Symptom
PMC31601040_568,7893,following,O
PMC31601040_568,7893,citalopram,B-Drug
PMC31601040_568,7893,treatment,O
PMC31601040_568,7893,:,O
PMC31601040_568,7893,a,O
PMC31601040_568,7893,case,O
PMC31601040_568,7893,report,O
PMC31601040_568,7893,and,O
PMC31601040_568,7893,discussion,O
PMC31601040_568,7893,0,O
PMC31628340_760,7894,Risperidone,O
PMC31628340_760,7894,",",O
PMC31628340_760,7894,quetiapine,B-Drug
PMC31628340_760,7894,",",O
PMC31628340_760,7894,and,O
PMC31628340_760,7894,aripiprazole,O
PMC31628340_760,7894,have,O
PMC31628340_760,7894,been,O
PMC31628340_760,7894,associated,O
PMC31628340_760,7894,with,O
PMC31628340_760,7894,tardive,B-Symptom
PMC31628340_760,7894,dystonia,I-Symptom
PMC31628340_760,7894,among,O
PMC31628340_760,7894,other,O
PMC31628340_760,7894,side,O
PMC31628340_760,7894,effects,O
PMC31628340_760,7894,0,O
PMC31699790_976,7895,OBJECTIVE,O
PMC31699790_976,7895,:,O
PMC31699790_976,7895,THIS,O
PMC31699790_976,7895,STUDY,O
PMC31699790_976,7895,COMPARED,O
PMC31699790_976,7895,ADHERENCE,O
PMC31699790_976,7895,AND,O
PMC31699790_976,7895,PERSISTENCE,O
PMC31699790_976,7895,OF,O
PMC31699790_976,7895,THREE,O
PMC31699790_976,7895,BRANDED,O
PMC31699790_976,7895,ANTIDEPRESSANTS,O
PMC31699790_976,7895,:,O
PMC31699790_976,7895,the,O
PMC31699790_976,7895,serotonin,O
PMC31699790_976,7895,and,O
PMC31699790_976,7895,norepinephrine,O
PMC31699790_976,7895,reuptake,O
PMC31699790_976,7895,inhibitors,O
PMC31699790_976,7895,(,O
PMC31699790_976,7895,SNRIs,O
PMC31699790_976,7895,),O
PMC31699790_976,7895,duloxetine,B-Drug
PMC31699790_976,7895,and,O
PMC31699790_976,7895,venlafaxine,B-Drug
PMC31699790_976,7895,XR,O
PMC31699790_976,7895,",",O
PMC31699790_976,7895,and,O
PMC31699790_976,7895,the,O
PMC31699790_976,7895,selective,O
PMC31699790_976,7895,serotonin,O
PMC31699790_976,7895,reuptake,O
PMC31699790_976,7895,inhibitor,O
PMC31699790_976,7895,(,O
PMC31699790_976,7895,SSRI,O
PMC31699790_976,7895,),O
PMC31699790_976,7895,escitalopram,O
PMC31699790_976,7895,;,O
PMC31699790_976,7895,and,O
PMC31699790_976,7895,generic,O
PMC31699790_976,7895,selective,O
PMC31699790_976,7895,SSRIs,O
PMC31699790_976,7895,",",O
PMC31699790_976,7895,and,O
PMC31699790_976,7895,examined,O
PMC31699790_976,7895,demographic,O
PMC31699790_976,7895,and,O
PMC31699790_976,7895,clinical,O
PMC31699790_976,7895,predictors,O
PMC31699790_976,7895,of,O
PMC31699790_976,7895,adherence,O
PMC31699790_976,7895,and,O
PMC31699790_976,7895,persistence,O
PMC31699790_976,7895,in,O
PMC31699790_976,7895,patients,O
PMC31699790_976,7895,with,O
PMC31699790_976,7895,major,B-Disease
PMC31699790_976,7895,depressive,I-Disease
PMC31699790_976,7895,disorder,I-Disease
PMC31699790_976,7895,in,O
PMC31699790_976,7895,usual,O
PMC31699790_976,7895,care,O
PMC31699790_976,7895,settings,O
PMC31699790_976,7895,0,O
PMC31717210_850,7896,BACKGROUND,O
PMC31717210_850,7896,:,O
PMC31717210_850,7896,To,O
PMC31717210_850,7896,report,O
PMC31717210_850,7896,a,O
PMC31717210_850,7896,case,O
PMC31717210_850,7896,of,O
PMC31717210_850,7896,branch,O
PMC31717210_850,7896,retinal,B-Symptom
PMC31717210_850,7896,vein,I-Symptom
PMC31717210_850,7896,occlusion,I-Symptom
PMC31717210_850,7896,in,O
PMC31717210_850,7896,a,O
PMC31717210_850,7896,young,O
PMC31717210_850,7896,adult,O
PMC31717210_850,7896,with,O
PMC31717210_850,7896,bipolar,B-Disease
PMC31717210_850,7896,mood,I-Disease
PMC31717210_850,7896,disorder,I-Disease
PMC31717210_850,7896,treated,O
PMC31717210_850,7896,with,O
PMC31717210_850,7896,quetiapine,B-Drug
PMC31717210_850,7896,fumarate,O
PMC31717210_850,7896,0,O
PMC31750150_1019,7897,Tamoxifen,B-Drug
PMC31750150_1019,7897,downregulation,O
PMC31750150_1019,7897,of,O
PMC31750150_1019,7897,miR,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,number,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,increases,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,number,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,_,O
PMC31750150_1019,7897,and,O
PMC31750150_1019,7897,promotes,O
PMC31750150_1019,7897,breast,B-Disease
PMC31750150_1019,7897,cancer,I-Disease
PMC31750150_1019,7897,cell,O
PMC31750150_1019,7897,survival,O
PMC31750150_1019,7897,and,O
PMC31750150_1019,7897,endocrine,O
PMC31750150_1019,7897,resistance,O
PMC31750150_1019,7897,0,O
PMC31784840_32,7898,CONCLUSIONS,O
PMC31784840_32,7898,:,O
PMC31784840_32,7898,There,O
PMC31784840_32,7898,was,O
PMC31784840_32,7898,no,O
PMC31784840_32,7898,substantial,O
PMC31784840_32,7898,difference,O
PMC31784840_32,7898,in,O
PMC31784840_32,7898,anti,O
PMC31784840_32,7898,-,O
PMC31784840_32,7898,depressive,O
PMC31784840_32,7898,effectiveness,O
PMC31784840_32,7898,among,O
PMC31784840_32,7898,olanzapine,B-Drug
PMC31784840_32,7898,",",O
PMC31784840_32,7898,quetiapine,B-Drug
PMC31784840_32,7898,",",O
PMC31784840_32,7898,risperidone,O
PMC31784840_32,7898,or,O
PMC31784840_32,7898,ziprasidone,B-Drug
PMC31784840_32,7898,in,O
PMC31784840_32,7898,this,O
PMC31784840_32,7898,clinically,O
PMC31784840_32,7898,relevant,O
PMC31784840_32,7898,sample,O
PMC31784840_32,7898,of,O
PMC31784840_32,7898,patients,O
PMC31784840_32,7898,acutely,O
PMC31784840_32,7898,admitted,O
PMC31784840_32,7898,to,O
PMC31784840_32,7898,hospital,O
PMC31784840_32,7898,for,O
PMC31784840_32,7898,symptoms,O
PMC31784840_32,7898,of,O
PMC31784840_32,7898,psychosis,B-Symptom
PMC31784840_32,7898,0,O
PMC31790080_736,7899,Though,O
PMC31790080_736,7899,cutaneous,O
PMC31790080_736,7899,side,O
PMC31790080_736,7899,effects,O
PMC31790080_736,7899,are,O
PMC31790080_736,7899,known,O
PMC31790080_736,7899,to,O
PMC31790080_736,7899,occur,O
PMC31790080_736,7899,with,O
PMC31790080_736,7899,it,O
PMC31790080_736,7899,",",O
PMC31790080_736,7899,isolated,O
PMC31790080_736,7899,pure,O
PMC31790080_736,7899,pruritus,B-Symptom
PMC31790080_736,7899,is,O
PMC31790080_736,7899,rarely,O
PMC31790080_736,7899,reported,O
PMC31790080_736,7899,with,O
PMC31790080_736,7899,topiramate,B-Drug
PMC31790080_736,7899,in,O
PMC31790080_736,7899,the,O
PMC31790080_736,7899,literature,O
PMC31790080_736,7899,0,O
PMC31805910_446,7900,The,O
PMC31805910_446,7900,open,O
PMC31805910_446,7900,-,O
PMC31805910_446,7900,label,O
PMC31805910_446,7900,OBSEER,O
PMC31805910_446,7900,study,O
PMC31805910_446,7900,evaluated,O
PMC31805910_446,7900,the,O
PMC31805910_446,7900,effectiveness,O
PMC31805910_446,7900,and,O
PMC31805910_446,7900,tolerability,O
PMC31805910_446,7900,of,O
PMC31805910_446,7900,Equasym,B-Drug
PMC31805910_446,7900,XL,O
PMC31805910_446,7900,(,O
PMC31805910_446,7900,),O
PMC31805910_446,7900,",",O
PMC31805910_446,7900,a,O
PMC31805910_446,7900,modified,O
PMC31805910_446,7900,-,O
PMC31805910_446,7900,release,O
PMC31805910_446,7900,methylphenidate,B-Drug
PMC31805910_446,7900,",",O
PMC31805910_446,7900,in,O
PMC31805910_446,7900,routine,O
PMC31805910_446,7900,care,O
PMC31805910_446,7900,of,O
PMC31805910_446,7900,children,O
PMC31805910_446,7900,and,O
PMC31805910_446,7900,adolescents,O
PMC31805910_446,7900,(,O
PMC31805910_446,7900,aged,O
PMC31805910_446,7900,_,O
PMC31805910_446,7900,_,O
PMC31805910_446,7900,number,O
PMC31805910_446,7900,_,O
PMC31805910_446,7900,_,O
PMC31805910_446,7900,years,O
PMC31805910_446,7900,),O
PMC31805910_446,7900,with,O
PMC31805910_446,7900,ADHD,B-Disease
PMC31805910_446,7900,0,O
PMC31806160_144,7901,Eligible,O
PMC31806160_144,7901,patients,O
PMC31806160_144,7901,",",O
PMC31806160_144,7901,aged,O
PMC31806160_144,7901,_,O
PMC31806160_144,7901,_,O
PMC31806160_144,7901,number,O
PMC31806160_144,7901,_,O
PMC31806160_144,7901,_,O
PMC31806160_144,7901,years,O
PMC31806160_144,7901,",",O
PMC31806160_144,7901,were,O
PMC31806160_144,7901,diagnosed,O
PMC31806160_144,7901,with,O
PMC31806160_144,7901,ADHD,B-Disease
PMC31806160_144,7901,and,O
PMC31806160_144,7901,about,O
PMC31806160_144,7901,to,O
PMC31806160_144,7901,begin,O
PMC31806160_144,7901,treatment,O
PMC31806160_144,7901,with,O
PMC31806160_144,7901,Equasym,B-Drug
PMC31806160_144,7901,XL,O
PMC31806160_144,7901,(,O
PMC31806160_144,7901,),O
PMC31806160_144,7901,0,O
PMC31806160_98,7902,This,O
PMC31806160_98,7902,study,O
PMC31806160_98,7902,investigated,O
PMC31806160_98,7902,the,O
PMC31806160_98,7902,effectiveness,O
PMC31806160_98,7902,",",O
PMC31806160_98,7902,on,O
PMC31806160_98,7902,symptoms,O
PMC31806160_98,7902,and,O
PMC31806160_98,7902,impairment,O
PMC31806160_98,7902,",",O
PMC31806160_98,7902,and,O
PMC31806160_98,7902,safety,O
PMC31806160_98,7902,of,O
PMC31806160_98,7902,Equasym,B-Drug
PMC31806160_98,7902,XL,O
PMC31806160_98,7902,(,O
PMC31806160_98,7902,),O
PMC31806160_98,7902,",",O
PMC31806160_98,7902,a,O
PMC31806160_98,7902,combination,O
PMC31806160_98,7902,of,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,number,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,%,O
PMC31806160_98,7902,immediate,O
PMC31806160_98,7902,-,O
PMC31806160_98,7902,release,O
PMC31806160_98,7902,and,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,number,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,_,O
PMC31806160_98,7902,%,O
PMC31806160_98,7902,modified,O
PMC31806160_98,7902,-,O
PMC31806160_98,7902,release,O
PMC31806160_98,7902,MPH,O
PMC31806160_98,7902,",",O
PMC31806160_98,7902,in,O
PMC31806160_98,7902,the,O
PMC31806160_98,7902,treatment,O
PMC31806160_98,7902,of,O
PMC31806160_98,7902,ADHD,B-Disease
PMC31806160_98,7902,in,O
PMC31806160_98,7902,daily,O
PMC31806160_98,7902,clinical,O
PMC31806160_98,7902,practice,O
PMC31806160_98,7902,0,O
PMC31806350_344,7903,Children,O
PMC31806350_344,7903,and,O
PMC31806350_344,7903,adolescents,O
PMC31806350_344,7903,(,O
PMC31806350_344,7903,aged,O
PMC31806350_344,7903,_,O
PMC31806350_344,7903,_,O
PMC31806350_344,7903,number,O
PMC31806350_344,7903,_,O
PMC31806350_344,7903,_,O
PMC31806350_344,7903,years,O
PMC31806350_344,7903,),O
PMC31806350_344,7903,with,O
PMC31806350_344,7903,ADHD,B-Disease
PMC31806350_344,7903,and,O
PMC31806350_344,7903,attending,O
PMC31806350_344,7903,school,O
PMC31806350_344,7903,were,O
PMC31806350_344,7903,included,O
PMC31806350_344,7903,if,O
PMC31806350_344,7903,Equasym,B-Drug
PMC31806350_344,7903,XL,O
PMC31806350_344,7903,(,O
PMC31806350_344,7903,),O
PMC31806350_344,7903,treatment,O
PMC31806350_344,7903,was,O
PMC31806350_344,7903,planned,O
PMC31806350_344,7903,by,O
PMC31806350_344,7903,the,O
PMC31806350_344,7903,treating,O
PMC31806350_344,7903,physician,O
PMC31806350_344,7903,0,O
PMC31818680_844,7904,At,O
PMC31818680_844,7904,the,O
PMC31818680_844,7904,present,O
PMC31818680_844,7904,time,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,there,O
PMC31818680_844,7904,is,O
PMC31818680_844,7904,solid,O
PMC31818680_844,7904,evidence,O
PMC31818680_844,7904,supporting,O
PMC31818680_844,7904,the,O
PMC31818680_844,7904,use,O
PMC31818680_844,7904,of,O
PMC31818680_844,7904,lithium,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,the,O
PMC31818680_844,7904,anticonvulsants,O
PMC31818680_844,7904,valproate,O
PMC31818680_844,7904,and,O
PMC31818680_844,7904,carbamazepine,B-Drug
PMC31818680_844,7904,",",O
PMC31818680_844,7904,and,O
PMC31818680_844,7904,the,O
PMC31818680_844,7904,antipsychotics,O
PMC31818680_844,7904,chlorpromazine,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,haloperidol,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,risperidone,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,olanzapine,B-Drug
PMC31818680_844,7904,",",O
PMC31818680_844,7904,quetiapine,B-Drug
PMC31818680_844,7904,",",O
PMC31818680_844,7904,ziprasidone,B-Drug
PMC31818680_844,7904,",",O
PMC31818680_844,7904,aripiprazole,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,and,O
PMC31818680_844,7904,asenapine,O
PMC31818680_844,7904,in,O
PMC31818680_844,7904,acute,O
PMC31818680_844,7904,mania,O
PMC31818680_844,7904,",",O
PMC31818680_844,7904,and,O
PMC31818680_844,7904,some,O
PMC31818680_844,7904,evidence,O
PMC31818680_844,7904,supporting,O
PMC31818680_844,7904,the,O
PMC31818680_844,7904,use,O
PMC31818680_844,7904,of,O
PMC31818680_844,7904,clozapine,O
PMC31818680_844,7904,or,O
PMC31818680_844,7904,electroconvulsive,O
PMC31818680_844,7904,therapy,O
PMC31818680_844,7904,in,O
PMC31818680_844,7904,treatment,O
PMC31818680_844,7904,-,O
PMC31818680_844,7904,refractory,O
PMC31818680_844,7904,cases,O
PMC31818680_844,7904,0,O
PMC31823850_255,7905,Effect,O
PMC31823850_255,7905,of,O
PMC31823850_255,7905,initial,O
PMC31823850_255,7905,ziprasidone,B-Drug
PMC31823850_255,7905,dose,O
PMC31823850_255,7905,on,O
PMC31823850_255,7905,treatment,O
PMC31823850_255,7905,outcome,O
PMC31823850_255,7905,of,O
PMC31823850_255,7905,korean,O
PMC31823850_255,7905,patients,O
PMC31823850_255,7905,with,O
PMC31823850_255,7905,acute,O
PMC31823850_255,7905,manic,O
PMC31823850_255,7905,or,O
PMC31823850_255,7905,mixed,O
PMC31823850_255,7905,episodes,O
PMC31823850_255,7905,0,O
PMC31823850_936,7906,OBJECTIVE,O
PMC31823850_936,7906,:,O
PMC31823850_936,7906,We,O
PMC31823850_936,7906,investigated,O
PMC31823850_936,7906,the,O
PMC31823850_936,7906,efficacy,O
PMC31823850_936,7906,and,O
PMC31823850_936,7906,tolerability,O
PMC31823850_936,7906,of,O
PMC31823850_936,7906,ziprasidone,B-Drug
PMC31823850_936,7906,combined,O
PMC31823850_936,7906,with,O
PMC31823850_936,7906,divalproex,O
PMC31823850_936,7906,to,O
PMC31823850_936,7906,determine,O
PMC31823850_936,7906,the,O
PMC31823850_936,7906,relationship,O
PMC31823850_936,7906,between,O
PMC31823850_936,7906,the,O
PMC31823850_936,7906,initial,O
PMC31823850_936,7906,dose,O
PMC31823850_936,7906,of,O
PMC31823850_936,7906,ziprasidone,B-Drug
PMC31823850_936,7906,and,O
PMC31823850_936,7906,the,O
PMC31823850_936,7906,treatment,O
PMC31823850_936,7906,effect,O
PMC31823850_936,7906,among,O
PMC31823850_936,7906,Korean,O
PMC31823850_936,7906,patients,O
PMC31823850_936,7906,with,O
PMC31823850_936,7906,acute,O
PMC31823850_936,7906,bipolar,B-Disease
PMC31823850_936,7906,manic,O
PMC31823850_936,7906,or,O
PMC31823850_936,7906,mixed,O
PMC31823850_936,7906,disorders,O
PMC31823850_936,7906,0,O
PMC31840530_435,7907,METHODS,O
PMC31840530_435,7907,:,O
PMC31840530_435,7907,Multicenter,O
PMC31840530_435,7907,",",O
PMC31840530_435,7907,prospective,O
PMC31840530_435,7907,",",O
PMC31840530_435,7907,_,O
PMC31840530_435,7907,_,O
PMC31840530_435,7907,number,O
PMC31840530_435,7907,_,O
PMC31840530_435,7907,_,O
PMC31840530_435,7907,-,O
PMC31840530_435,7907,month,O
PMC31840530_435,7907,",",O
PMC31840530_435,7907,non,O
PMC31840530_435,7907,-,O
PMC31840530_435,7907,interventional,O
PMC31840530_435,7907,study,O
PMC31840530_435,7907,in,O
PMC31840530_435,7907,adult,O
PMC31840530_435,7907,outpatients,O
PMC31840530_435,7907,with,O
PMC31840530_435,7907,a,O
PMC31840530_435,7907,depressive,O
PMC31840530_435,7907,episode,O
PMC31840530_435,7907,and,O
PMC31840530_435,7907,starting,O
PMC31840530_435,7907,treatment,O
PMC31840530_435,7907,with,O
PMC31840530_435,7907,duloxetine,B-Drug
PMC31840530_435,7907,0,O
PMC31904690_307,7908,Although,O
PMC31904690_307,7908,carbamazepine,B-Drug
PMC31904690_307,7908,(,I-Drug
PMC31904690_307,7908,CBZ,I-Drug
PMC31904690_307,7908,),O
PMC31904690_307,7908,is,O
PMC31904690_307,7908,the,O
PMC31904690_307,7908,most,O
PMC31904690_307,7908,common,O
PMC31904690_307,7908,cause,O
PMC31904690_307,7908,of,O
PMC31904690_307,7908,SJS,B-Disease
PMC31904690_307,7908,",",O
PMC31904690_307,7908,a,O
PMC31904690_307,7908,new,O
PMC31904690_307,7908,anticonvulsant,O
PMC31904690_307,7908,",",O
PMC31904690_307,7908,oxcarbazepine,O
PMC31904690_307,7908,",",O
PMC31904690_307,7908,which,O
PMC31904690_307,7908,is,O
PMC31904690_307,7908,structurally,O
PMC31904690_307,7908,related,O
PMC31904690_307,7908,to,O
PMC31904690_307,7908,CBZ,O
PMC31904690_307,7908,",",O
PMC31904690_307,7908,has,O
PMC31904690_307,7908,been,O
PMC31904690_307,7908,shown,O
PMC31904690_307,7908,to,O
PMC31904690_307,7908,induce,O
PMC31904690_307,7908,SJS,O
PMC31904690_307,7908,0,O
PMC31918680_675,7909,The,O
PMC31918680_675,7909,management,O
PMC31918680_675,7909,of,O
PMC31918680_675,7909,schizophrenia,B-Disease
PMC31918680_675,7909,:,O
PMC31918680_675,7909,focus,O
PMC31918680_675,7909,on,O
PMC31918680_675,7909,extended,O
PMC31918680_675,7909,-,O
PMC31918680_675,7909,release,O
PMC31918680_675,7909,quetiapine,B-Drug
PMC31918680_675,7909,fumarate,O
PMC31918680_675,7909,0,O
PMC31951350_300,7910,Several,O
PMC31951350_300,7910,antiepileptic,O
PMC31951350_300,7910,drugs,O
PMC31951350_300,7910,like,O
PMC31951350_300,7910,carbamazepine,B-Drug
PMC31951350_300,7910,",",O
PMC31951350_300,7910,phenytoin,O
PMC31951350_300,7910,",",O
PMC31951350_300,7910,lamotrigine,B-Drug
PMC31951350_300,7910,",",O
PMC31951350_300,7910,felbamate,O
PMC31951350_300,7910,are,O
PMC31951350_300,7910,effective,O
PMC31951350_300,7910,in,O
PMC31951350_300,7910,neuropathic,B-Symptom
PMC31951350_300,7910,pain,I-Symptom
PMC31951350_300,7910,and,O
PMC31951350_300,7910,trigeminal,O
PMC31951350_300,7910,neuralgia,O
PMC31951350_300,7910,0,O
PMC31975640_140,7911,Fluvoxamine,B-Drug
PMC31975640_140,7911,may,O
PMC31975640_140,7911,prevent,O
PMC31975640_140,7911,onset,O
PMC31975640_140,7911,of,O
PMC31975640_140,7911,psychosis,B-Disease
PMC31975640_140,7911,:,O
PMC31975640_140,7911,a,O
PMC31975640_140,7911,case,O
PMC31975640_140,7911,report,O
PMC31975640_140,7911,of,O
PMC31975640_140,7911,a,O
PMC31975640_140,7911,patient,O
PMC31975640_140,7911,at,O
PMC31975640_140,7911,ultra,O
PMC31975640_140,7911,-,O
PMC31975640_140,7911,high,O
PMC31975640_140,7911,risk,O
PMC31975640_140,7911,of,O
PMC31975640_140,7911,psychotic,B-Disease
PMC31975640_140,7911,disorder,I-Disease
PMC31975640_140,7911,0,O
PMC31975640_160,7912,CONCLUSION,O
PMC31975640_160,7912,:,O
PMC31975640_160,7912,Fluvoxamine,B-Drug
PMC31975640_160,7912,",",O
PMC31975640_160,7912,a,O
PMC31975640_160,7912,sigma,O
PMC31975640_160,7912,_,O
PMC31975640_160,7912,_,O
PMC31975640_160,7912,number,O
PMC31975640_160,7912,_,O
PMC31975640_160,7912,_,O
PMC31975640_160,7912,receptor,O
PMC31975640_160,7912,agonist,O
PMC31975640_160,7912,",",O
PMC31975640_160,7912,may,O
PMC31975640_160,7912,be,O
PMC31975640_160,7912,effective,O
PMC31975640_160,7912,in,O
PMC31975640_160,7912,preventing,O
PMC31975640_160,7912,patients,O
PMC31975640_160,7912,at,O
PMC31975640_160,7912,UHR,O
PMC31975640_160,7912,of,O
PMC31975640_160,7912,psychotic,B-Disease
PMC31975640_160,7912,disorder,I-Disease
PMC31975640_160,7912,from,O
PMC31975640_160,7912,onset,O
PMC31975640_160,7912,of,O
PMC31975640_160,7912,psychosis,O
PMC31975640_160,7912,via,O
PMC31975640_160,7912,its,O
PMC31975640_160,7912,neuroprotective,O
PMC31975640_160,7912,/,O
PMC31975640_160,7912,neurotropic,O
PMC31975640_160,7912,actions,O
PMC31975640_160,7912,",",O
PMC31975640_160,7912,independent,O
PMC31975640_160,7912,of,O
PMC31975640_160,7912,its,O
PMC31975640_160,7912,antidepressive,O
PMC31975640_160,7912,effects,O
PMC31975640_160,7912,0,O
PMC31975640_358,7913,In,O
PMC31975640_358,7913,addition,O
PMC31975640_358,7913,",",O
PMC31975640_358,7913,it,O
PMC31975640_358,7913,is,O
PMC31975640_358,7913,likely,O
PMC31975640_358,7913,that,O
PMC31975640_358,7913,an,O
PMC31975640_358,7913,additional,O
PMC31975640_358,7913,dose,O
PMC31975640_358,7913,of,O
PMC31975640_358,7913,fluvoxamine,B-Drug
PMC31975640_358,7913,(,O
PMC31975640_358,7913,_,O
PMC31975640_358,7913,_,O
PMC31975640_358,7913,number,O
PMC31975640_358,7913,_,O
PMC31975640_358,7913,_,O
PMC31975640_358,7913,mg,O
PMC31975640_358,7913,/,O
PMC31975640_358,7913,day,O
PMC31975640_358,7913,),O
PMC31975640_358,7913,improved,O
PMC31975640_358,7913,his,O
PMC31975640_358,7913,psychotic,B-Symptom
PMC31975640_358,7913,-,I-Symptom
PMC31975640_358,7913,like,I-Symptom
PMC31975640_358,7913,prodromal,I-Symptom
PMC31975640_358,7913,symptoms,I-Symptom
PMC31975640_358,7913,directly,O
PMC31975640_358,7913,",",O
PMC31975640_358,7913,independent,O
PMC31975640_358,7913,of,O
PMC31975640_358,7913,its,O
PMC31975640_358,7913,antidepressive,O
PMC31975640_358,7913,effects,O
PMC31975640_358,7913,0,O
PMC31975640_673,7914,RESULTS,O
PMC31975640_673,7914,:,O
PMC31975640_673,7914,Our,O
PMC31975640_673,7914,patient,O
PMC31975640_673,7914,',O
PMC31975640_673,7914,s,O
PMC31975640_673,7914,depressive,O
PMC31975640_673,7914,symptoms,O
PMC31975640_673,7914,were,O
PMC31975640_673,7914,reduced,O
PMC31975640_673,7914,and,O
PMC31975640_673,7914,maintained,O
PMC31975640_673,7914,below,O
PMC31975640_673,7914,remission,O
PMC31975640_673,7914,as,O
PMC31975640_673,7914,a,O
PMC31975640_673,7914,result,O
PMC31975640_673,7914,of,O
PMC31975640_673,7914,treatment,O
PMC31975640_673,7914,with,O
PMC31975640_673,7914,_,O
PMC31975640_673,7914,_,O
PMC31975640_673,7914,number,O
PMC31975640_673,7914,_,O
PMC31975640_673,7914,_,O
PMC31975640_673,7914,mg,O
PMC31975640_673,7914,/,O
PMC31975640_673,7914,day,O
PMC31975640_673,7914,of,O
PMC31975640_673,7914,fluvoxamine,B-Drug
PMC31975640_673,7914,0,O
PMC31985230_347,7915,Olopatadine,O
PMC31985230_347,7915,hydrochloride,O
PMC31985230_347,7915,and,O
PMC31985230_347,7915,rupatadine,B-Drug
PMC31985230_347,7915,fumarate,O
PMC31985230_347,7915,in,O
PMC31985230_347,7915,seasonal,O
PMC31985230_347,7915,allergic,O
PMC31985230_347,7915,rhinitis,O
PMC31985230_347,7915,:,O
PMC31985230_347,7915,A,O
PMC31985230_347,7915,comparative,O
PMC31985230_347,7915,study,O
PMC31985230_347,7915,of,O
PMC31985230_347,7915,efficacy,O
PMC31985230_347,7915,and,O
PMC31985230_347,7915,safety,O
PMC31985230_347,7915,0,O
PMC31985230_88,7916,OBJECTIVE,O
PMC31985230_88,7916,:,O
PMC31985230_88,7916,To,O
PMC31985230_88,7916,compare,O
PMC31985230_88,7916,the,O
PMC31985230_88,7916,efficacy,O
PMC31985230_88,7916,and,O
PMC31985230_88,7916,safety,O
PMC31985230_88,7916,of,O
PMC31985230_88,7916,olopatadine,O
PMC31985230_88,7916,and,O
PMC31985230_88,7916,rupatadine,B-Drug
PMC31985230_88,7916,in,O
PMC31985230_88,7916,seasonal,O
PMC31985230_88,7916,allergic,O
PMC31985230_88,7916,rhinitis,O
PMC31985230_88,7916,(,O
PMC31985230_88,7916,SAR,O
PMC31985230_88,7916,),O
PMC31985230_88,7916,0,O
PMC31992790_179,7917,INTRODUCTION,O
PMC31992790_179,7917,:,O
PMC31992790_179,7917,This,O
PMC31992790_179,7917,is,O
PMC31992790_179,7917,the,O
PMC31992790_179,7917,first,O
PMC31992790_179,7917,report,O
PMC31992790_179,7917,of,O
PMC31992790_179,7917,possible,O
PMC31992790_179,7917,direct,O
PMC31992790_179,7917,stimulation,O
PMC31992790_179,7917,of,O
PMC31992790_179,7917,hormone,O
PMC31992790_179,7917,-,O
PMC31992790_179,7917,resistant,O
PMC31992790_179,7917,prostate,B-Disease
PMC31992790_179,7917,cancer,I-Disease
PMC31992790_179,7917,or,O
PMC31992790_179,7917,interference,O
PMC31992790_179,7917,of,O
PMC31992790_179,7917,docetaxel,B-Drug
PMC31992790_179,7917,cytotoxicity,O
PMC31992790_179,7917,of,O
PMC31992790_179,7917,prostate,B-Disease
PMC31992790_179,7917,cancer,I-Disease
PMC31992790_179,7917,in,O
PMC31992790_179,7917,a,O
PMC31992790_179,7917,patient,O
PMC31992790_179,7917,with,O
PMC31992790_179,7917,biochemical,O
PMC31992790_179,7917,relapse,O
PMC31992790_179,7917,of,O
PMC31992790_179,7917,prostatic,O
PMC31992790_179,7917,-,O
PMC31992790_179,7917,specific,O
PMC31992790_179,7917,antigen,O
PMC31992790_179,7917,0,O
PMC32042680_831,7918,The,O
PMC32042680_831,7918,clinical,O
PMC32042680_831,7918,experience,O
PMC32042680_831,7918,of,O
PMC32042680_831,7918,treating,O
PMC32042680_831,7918,ADHD,B-Disease
PMC32042680_831,7918,with,O
PMC32042680_831,7918,a,O
PMC32042680_831,7918,modified,O
PMC32042680_831,7918,-,O
PMC32042680_831,7918,release,O
PMC32042680_831,7918,MPH,B-Drug
PMC32042680_831,7918,preparation,O
PMC32042680_831,7918,(,O
PMC32042680_831,7918,Equasym,B-Drug
PMC32042680_831,7918,XL,O
PMC32042680_831,7918,),O
PMC32042680_831,7918,is,O
PMC32042680_831,7918,illustrated,O
PMC32042680_831,7918,with,O
PMC32042680_831,7918,case,O
PMC32042680_831,7918,studies,O
PMC32042680_831,7918,0,O
PMC32106260_487,7919,Until,O
PMC32106260_487,7919,recently,O
PMC32106260_487,7919,",",O
PMC32106260_487,7919,only,O
PMC32106260_487,7919,therapy,O
PMC32106260_487,7919,with,O
PMC32106260_487,7919,docetaxel,B-Drug
PMC32106260_487,7919,and,O
PMC32106260_487,7919,prednisone,B-Drug
PMC32106260_487,7919,has,O
PMC32106260_487,7919,been,O
PMC32106260_487,7919,shown,O
PMC32106260_487,7919,to,O
PMC32106260_487,7919,prolong,O
PMC32106260_487,7919,survival,O
PMC32106260_487,7919,in,O
PMC32106260_487,7919,men,O
PMC32106260_487,7919,with,O
PMC32106260_487,7919,metastatic,B-Disease
PMC32106260_487,7919,CRPC,I-Disease
PMC32106260_487,7919,0,O
PMC32181690_3,7920,An,O
PMC32181690_3,7920,injection,O
PMC32181690_3,7920,of,O
PMC32181690_3,7920,triamcinolone,B-Drug
PMC32181690_3,7920,acetonide,I-Drug
PMC32181690_3,7920,(,O
PMC32181690_3,7920,_,O
PMC32181690_3,7920,_,O
PMC32181690_3,7920,number,O
PMC32181690_3,7920,_,O
PMC32181690_3,7920,_,O
PMC32181690_3,7920,mg,O
PMC32181690_3,7920,),O
PMC32181690_3,7920,into,O
PMC32181690_3,7920,the,O
PMC32181690_3,7920,vitreous,O
PMC32181690_3,7920,resulted,O
PMC32181690_3,7920,in,O
PMC32181690_3,7920,gradual,O
PMC32181690_3,7920,resolution,O
PMC32181690_3,7920,of,O
PMC32181690_3,7920,subretinal,O
PMC32181690_3,7920,fluid,O
PMC32181690_3,7920,and,O
PMC32181690_3,7920,improvement,O
PMC32181690_3,7920,of,O
PMC32181690_3,7920,visual,B-Symptom
PMC32181690_3,7920,acuity,I-Symptom
PMC32181690_3,7920,0,O
PMC32190330_895,7921,Haloperidol,O
PMC32190330_895,7921,is,O
PMC32190330_895,7921,the,O
PMC32190330_895,7921,gold,O
PMC32190330_895,7921,standard,O
PMC32190330_895,7921,for,O
PMC32190330_895,7921,treatment,O
PMC32190330_895,7921,",",O
PMC32190330_895,7921,although,O
PMC32190330_895,7921,quetiapine,B-Drug
PMC32190330_895,7921,has,O
PMC32190330_895,7921,been,O
PMC32190330_895,7921,successfully,O
PMC32190330_895,7921,used,O
PMC32190330_895,7921,in,O
PMC32190330_895,7921,the,O
PMC32190330_895,7921,management,O
PMC32190330_895,7921,of,O
PMC32190330_895,7921,delirium,B-Symptom
PMC32190330_895,7921,0,O
PMC32190690_707,7922,The,O
PMC32190690_707,7922,anticonvulsant,O
PMC32190690_707,7922,carbamazepine,B-Drug
PMC32190690_707,7922,has,O
PMC32190690_707,7922,a,O
PMC32190690_707,7922,high,O
PMC32190690_707,7922,incidence,O
PMC32190690_707,7922,of,O
PMC32190690_707,7922,cutaneous,B-Symptom
PMC32190690_707,7922,adverse,O
PMC32190690_707,7922,drug,O
PMC32190690_707,7922,reactions,O
PMC32190690_707,7922,0,O
PMC32190690_717,7923,A,O
PMC32190690_717,7923,recent,O
PMC32190690_717,7923,prospective,O
PMC32190690_717,7923,clinical,O
PMC32190690_717,7923,trial,O
PMC32190690_717,7923,in,O
PMC32190690_717,7923,Taiwan,O
PMC32190690_717,7923,has,O
PMC32190690_717,7923,indicated,O
PMC32190690_717,7923,that,O
PMC32190690_717,7923,HLA,O
PMC32190690_717,7923,-,O
PMC32190690_717,7923,B,O
PMC32190690_717,7923,*,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,number,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,screening,O
PMC32190690_717,7923,will,O
PMC32190690_717,7923,reduce,O
PMC32190690_717,7923,the,O
PMC32190690_717,7923,incidence,O
PMC32190690_717,7923,of,O
PMC32190690_717,7923,life,O
PMC32190690_717,7923,-,O
PMC32190690_717,7923,threatening,O
PMC32190690_717,7923,adverse,O
PMC32190690_717,7923,reactions,O
PMC32190690_717,7923,to,O
PMC32190690_717,7923,carbamazepine,B-Drug
PMC32190690_717,7923,",",O
PMC32190690_717,7923,while,O
PMC32190690_717,7923,a,O
PMC32190690_717,7923,genome,O
PMC32190690_717,7923,-,O
PMC32190690_717,7923,wide,O
PMC32190690_717,7923,association,O
PMC32190690_717,7923,study,O
PMC32190690_717,7923,has,O
PMC32190690_717,7923,identified,O
PMC32190690_717,7923,the,O
PMC32190690_717,7923,HLA,O
PMC32190690_717,7923,-,O
PMC32190690_717,7923,A,O
PMC32190690_717,7923,*,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,number,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,_,O
PMC32190690_717,7923,allele,O
PMC32190690_717,7923,as,O
PMC32190690_717,7923,a,O
PMC32190690_717,7923,genetic,O
PMC32190690_717,7923,risk,O
PMC32190690_717,7923,factor,O
PMC32190690_717,7923,for,O
PMC32190690_717,7923,the,O
PMC32190690_717,7923,full,O
PMC32190690_717,7923,spectrum,O
PMC32190690_717,7923,of,O
PMC32190690_717,7923,carbamazepine,B-Drug
PMC32190690_717,7923,-,O
PMC32190690_717,7923,induced,O
PMC32190690_717,7923,cutaneous,B-Symptom
PMC32190690_717,7923,adverse,O
PMC32190690_717,7923,drug,O
PMC32190690_717,7923,reactions,O
PMC32190690_717,7923,in,O
PMC32190690_717,7923,a,O
PMC32190690_717,7923,European,O
PMC32190690_717,7923,population,O
PMC32190690_717,7923,0,O
PMC32200850_183,7924,We,O
PMC32200850_183,7924,present,O
PMC32200850_183,7924,a,O
PMC32200850_183,7924,case,O
PMC32200850_183,7924,of,O
PMC32200850_183,7924,_,O
PMC32200850_183,7924,_,O
PMC32200850_183,7924,number,O
PMC32200850_183,7924,_,O
PMC32200850_183,7924,_,O
PMC32200850_183,7924,-,O
PMC32200850_183,7924,year,O
PMC32200850_183,7924,-,O
PMC32200850_183,7924,old,O
PMC32200850_183,7924,man,O
PMC32200850_183,7924,suffering,O
PMC32200850_183,7924,from,O
PMC32200850_183,7924,Ramsay,B-Disease
PMC32200850_183,7924,Hunt,I-Disease
PMC32200850_183,7924,syndrome,I-Disease
PMC32200850_183,7924,with,O
PMC32200850_183,7924,grade,O
PMC32200850_183,7924,V,O
PMC32200850_183,7924,facial,O
PMC32200850_183,7924,palsy,O
PMC32200850_183,7924,treated,O
PMC32200850_183,7924,effectively,O
PMC32200850_183,7924,with,O
PMC32200850_183,7924,rehabilitation,O
PMC32200850_183,7924,program,O
PMC32200850_183,7924,",",O
PMC32200850_183,7924,after,O
PMC32200850_183,7924,the,O
PMC32200850_183,7924,termination,O
PMC32200850_183,7924,of,O
PMC32200850_183,7924,the,O
PMC32200850_183,7924,combination,O
PMC32200850_183,7924,therapy,O
PMC32200850_183,7924,of,O
PMC32200850_183,7924,acyclovir,O
PMC32200850_183,7924,and,O
PMC32200850_183,7924,prednisone,B-Drug
PMC32200850_183,7924,0,O
PMC32222430_544,7925,Double,O
PMC32222430_544,7925,versus,O
PMC32222430_544,7925,single,O
PMC32222430_544,7925,high,O
PMC32222430_544,7925,-,O
PMC32222430_544,7925,dose,O
PMC32222430_544,7925,melphalan,B-Drug
PMC32222430_544,7925,_,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,number,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,mg,O
PMC32222430_544,7925,/,O
PMC32222430_544,7925,m,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,number,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,and,O
PMC32222430_544,7925,autologous,O
PMC32222430_544,7925,stem,O
PMC32222430_544,7925,cell,O
PMC32222430_544,7925,transplantation,O
PMC32222430_544,7925,for,O
PMC32222430_544,7925,multiple,B-Disease
PMC32222430_544,7925,myeloma,I-Disease
PMC32222430_544,7925,:,O
PMC32222430_544,7925,a,O
PMC32222430_544,7925,region,O
PMC32222430_544,7925,-,O
PMC32222430_544,7925,based,O
PMC32222430_544,7925,study,O
PMC32222430_544,7925,in,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,number,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,_,O
PMC32222430_544,7925,patients,O
PMC32222430_544,7925,from,O
PMC32222430_544,7925,the,O
PMC32222430_544,7925,Nordic,O
PMC32222430_544,7925,area,O
PMC32222431_403,7925,The,O
PMC32222431_403,7925,group,O
PMC32222431_403,7925,assigned,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,patients,O
PMC32222431_403,7925,with,O
PMC32222431_403,7925,untreated,O
PMC32222431_403,7925,MM,O
PMC32222431_403,7925,below,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,years,O
PMC32222431_403,7925,of,O
PMC32222431_403,7925,age,O
PMC32222431_403,7925,to,O
PMC32222431_403,7925,receive,O
PMC32222431_403,7925,VAD,O
PMC32222431_403,7925,(,O
PMC32222431_403,7925,vincristine,O
PMC32222431_403,7925,",",O
PMC32222431_403,7925,adriamycin,O
PMC32222431_403,7925,and,O
PMC32222431_403,7925,dexamethasone,O
PMC32222431_403,7925,),O
PMC32222431_403,7925,as,O
PMC32222431_403,7925,induction,O
PMC32222431_403,7925,therapy,O
PMC32222431_403,7925,and,O
PMC32222431_403,7925,afterwards,O
PMC32222431_403,7925,assigned,O
PMC32222431_403,7925,these,O
PMC32222431_403,7925,patients,O
PMC32222431_403,7925,randomly,O
PMC32222431_403,7925,to,O
PMC32222431_403,7925,single,O
PMC32222431_403,7925,or,O
PMC32222431_403,7925,double,O
PMC32222431_403,7925,transplantation,O
PMC32222431_403,7925,conditioned,O
PMC32222431_403,7925,by,O
PMC32222431_403,7925,melphalan,B-Drug
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,mg,O
PMC32222431_403,7925,/,O
PMC32222431_403,7925,m,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,and,O
PMC32222431_403,7925,TBI,O
PMC32222431_403,7925,(,O
PMC32222431_403,7925,standard,O
PMC32222431_403,7925,single,O
PMC32222431_403,7925,transplantation,O
PMC32222431_403,7925,),O
PMC32222431_403,7925,or,O
PMC32222431_403,7925,melphalan,B-Drug
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,mg,O
PMC32222431_403,7925,/,O
PMC32222431_403,7925,m,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,followed,O
PMC32222431_403,7925,by,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,mg,O
PMC32222431_403,7925,/,O
PMC32222431_403,7925,m,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,number,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,_,O
PMC32222431_403,7925,and,O
PMC32222431_403,7925,TBI,O
PMC32222431_403,7925,(,O
PMC32222431_403,7925,experimental,O
PMC32222431_403,7925,double,O
PMC32222431_403,7925,transplantation,O
PMC32222431_403,7925,),O
PMC32222431_403,7925,0,O
PMC32222431_403,7926,_,O
PMC32222431_403,7926,_,O
PMC32222431_403,7926,number,O
PMC32222431_403,7926,_,O
PMC32222431_403,7926,_,O
PMC32222431_403,7926,Following,O
PMC32222431_403,7926,a,O
PMC32222431_403,7926,median,O
PMC32222431_403,7926,observation,O
PMC32222431_403,7926,of,O
PMC32222431_403,7926,approximately,O
PMC32222431_403,7926,six,O
PMC32222431_403,7926,years,O
PMC32222431_403,7926,",",O
PMC32222431_403,7926,response,O
PMC32222431_403,7926,rates,O
PMC32222431_403,7926,in,O
PMC32222431_403,7926,the,O
PMC32222431_403,7926,two,O
PMC32222431_403,7926,groups,O
PMC32222431_403,7926,were,O
PMC32222431_403,7926,not,O
PMC32222431_403,7926,significantly,O
PMC32222431_403,7926,different,O
PMC32222431_403,7926,",",O
PMC32222431_403,7926,but,O
PMC32222431_403,7926,the,O
PMC32222431_403,7926,probabilities,O
PMC32222431_403,7926,of,O
PMC32222431_403,7926,event,O
PMC32222431_403,7926,free,O
PMC32222431_403,7926,survival,O
PMC32222431_403,7926,and,O
PMC32222431_403,7926,overall,O
PMC32222431_403,7926,survival,O
PMC32222431_403,7926,were,O
PMC32222431_403,7926,prolonged,O
PMC32222431_403,7926,with,O
PMC32222431_403,7926,a,O
PMC32222431_403,7926,double,O
PMC32222431_403,7926,transplant,O
PMC32222431_403,7926,benefit,O
PMC32222431_403,7926,that,O
PMC32222431_403,7926,had,O
PMC32222431_403,7926,not,O
PMC32222431_403,7926,been,O
PMC32222431_403,7926,evident,O
PMC32222431_403,7926,in,O
PMC32222431_403,7926,early,O
PMC32222431_403,7926,analyses,O
PMC32222431_403,7926,0,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,number,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,This,O
PMC32222431_403,7927,important,O
PMC32222431_403,7927,study,O
PMC32222431_403,7927,demonstrates,O
PMC32222431_403,7927,that,O
PMC32222431_403,7927,double,O
PMC32222431_403,7927,transplantation,O
PMC32222431_403,7927,is,O
PMC32222431_403,7927,one,O
PMC32222431_403,7927,of,O
PMC32222431_403,7927,the,O
PMC32222431_403,7927,options,O
PMC32222431_403,7927,for,O
PMC32222431_403,7927,treating,O
PMC32222431_403,7927,myeloma,B-Disease
PMC32222431_403,7927,",",O
PMC32222431_403,7927,particularly,O
PMC32222431_403,7927,those,O
PMC32222431_403,7927,younger,O
PMC32222431_403,7927,than,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,number,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,_,O
PMC32222431_403,7927,years,O
PMC32222431_403,7927,of,O
PMC32222431_403,7927,age,O
PMC32222431_403,7927,who,O
PMC32222431_403,7927,have,O
PMC32222431_403,7927,a,O
PMC32222431_403,7927,suboptimal,O
PMC32222431_403,7927,response,O
PMC32222431_403,7927,to,O
PMC32222431_403,7927,a,O
PMC32222431_403,7927,single,O
PMC32222431_403,7927,transplant,O
PMC32222431_403,7927,0,O
PMC32252980_504,7928,Efficacy,O
PMC32252980_504,7928,of,O
PMC32252980_504,7928,lisdexamfetamine,B-Drug
PMC32252980_504,7928,dimesylate,I-Drug
PMC32252980_504,7928,in,O
PMC32252980_504,7928,children,O
PMC32252980_504,7928,with,O
PMC32252980_504,7928,attention,B-Disease
PMC32252980_504,7928,-,I-Disease
PMC32252980_504,7928,deficit,I-Disease
PMC32252980_504,7928,/,I-Disease
PMC32252980_504,7928,hyperactivity,I-Disease
PMC32252980_504,7928,disorder,I-Disease
PMC32252980_504,7928,previously,O
PMC32252980_504,7928,treated,O
PMC32252980_504,7928,with,O
PMC32252980_504,7928,methylphenidate,B-Drug
PMC32252980_504,7928,:,O
PMC32252980_504,7928,a,O
PMC32252980_504,7928,post,O
PMC32252980_504,7928,hoc,O
PMC32252980_504,7928,analysis,O
PMC32252980_504,7928,0,O
PMC32320040_1018,7929,Pretreatment,O
PMC32320040_1018,7929,metabotypes,O
PMC32320040_1018,7929,may,O
PMC32320040_1018,7929,predict,O
PMC32320040_1018,7929,which,O
PMC32320040_1018,7929,depressed,B-Disease
PMC32320040_1018,7929,patients,O
PMC32320040_1018,7929,will,O
PMC32320040_1018,7929,respond,O
PMC32320040_1018,7929,to,O
PMC32320040_1018,7929,acute,O
PMC32320040_1018,7929,treatment,O
PMC32320040_1018,7929,(,O
PMC32320040_1018,7929,_,O
PMC32320040_1018,7929,_,O
PMC32320040_1018,7929,number,O
PMC32320040_1018,7929,_,O
PMC32320040_1018,7929,_,O
PMC32320040_1018,7929,weeks,O
PMC32320040_1018,7929,),O
PMC32320040_1018,7929,with,O
PMC32320040_1018,7929,sertraline,B-Drug
PMC32320040_1018,7929,or,O
PMC32320040_1018,7929,placebo,O
PMC32320040_1018,7929,0,O
PMC32365240_587,7930,Exercise,O
PMC32365240_587,7930,as,O
PMC32365240_587,7930,migraine,O
PMC32365240_587,7930,prophylaxis,O
PMC32365240_587,7930,:,O
PMC32365240_587,7930,a,O
PMC32365240_587,7930,randomized,O
PMC32365240_587,7930,study,O
PMC32365240_587,7930,using,O
PMC32365240_587,7930,relaxation,O
PMC32365240_587,7930,and,O
PMC32365240_587,7930,topiramate,B-Drug
PMC32365240_587,7930,as,O
PMC32365240_587,7930,controls,O
PMC32365240_587,7930,0,O
PMC32365240_959,7931,METHODS,O
PMC32365240_959,7931,:,O
PMC32365240_959,7931,In,O
PMC32365240_959,7931,a,O
PMC32365240_959,7931,randomized,O
PMC32365240_959,7931,",",O
PMC32365240_959,7931,controlled,O
PMC32365240_959,7931,trial,O
PMC32365240_959,7931,of,O
PMC32365240_959,7931,adults,O
PMC32365240_959,7931,with,O
PMC32365240_959,7931,migraine,O
PMC32365240_959,7931,",",O
PMC32365240_959,7931,exercising,O
PMC32365240_959,7931,for,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,number,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,minutes,O
PMC32365240_959,7931,three,O
PMC32365240_959,7931,times,O
PMC32365240_959,7931,a,O
PMC32365240_959,7931,week,O
PMC32365240_959,7931,was,O
PMC32365240_959,7931,compared,O
PMC32365240_959,7931,to,O
PMC32365240_959,7931,relaxation,O
PMC32365240_959,7931,according,O
PMC32365240_959,7931,to,O
PMC32365240_959,7931,a,O
PMC32365240_959,7931,recorded,O
PMC32365240_959,7931,programme,O
PMC32365240_959,7931,or,O
PMC32365240_959,7931,daily,O
PMC32365240_959,7931,topiramate,B-Drug
PMC32365240_959,7931,use,O
PMC32365240_959,7931,",",O
PMC32365240_959,7931,which,O
PMC32365240_959,7931,was,O
PMC32365240_959,7931,slowly,O
PMC32365240_959,7931,increased,O
PMC32365240_959,7931,to,O
PMC32365240_959,7931,the,O
PMC32365240_959,7931,individual,O
PMC32365240_959,7931,',O
PMC32365240_959,7931,s,O
PMC32365240_959,7931,highest,O
PMC32365240_959,7931,tolerable,O
PMC32365240_959,7931,dose,O
PMC32365240_959,7931,(,O
PMC32365240_959,7931,maximum,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,number,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,_,O
PMC32365240_959,7931,mg,O
PMC32365240_959,7931,/,O
PMC32365240_959,7931,day,O
PMC32365240_959,7931,),O
PMC32365240_959,7931,0,O
PMC32371330_535,7932,Switching,O
PMC32371330_535,7932,to,O
PMC32371330_535,7932,quetiapine,B-Drug
PMC32371330_535,7932,for,O
PMC32371330_535,7932,risperidone,O
PMC32371330_535,7932,-,O
PMC32371330_535,7932,induced,O
PMC32371330_535,7932,amenorrhea,O
PMC32371330_535,7932,:,O
PMC32371330_535,7932,Report,O
PMC32371330_535,7932,of,O
PMC32371330_535,7932,two,O
PMC32371330_535,7932,cases,O
PMC32371330_535,7932,0,O
PMC32407430_429,7933,PURPOSE,O
PMC32407430_429,7933,:,O
PMC32407430_429,7933,To,O
PMC32407430_429,7933,evaluate,O
PMC32407430_429,7933,the,O
PMC32407430_429,7933,efficacy,O
PMC32407430_429,7933,",",O
PMC32407430_429,7933,tolerability,O
PMC32407430_429,7933,",",O
PMC32407430_429,7933,and,O
PMC32407430_429,7933,effects,O
PMC32407430_429,7933,on,O
PMC32407430_429,7933,behavior,O
PMC32407430_429,7933,and,O
PMC32407430_429,7933,psychosocial,O
PMC32407430_429,7933,functioning,O
PMC32407430_429,7933,of,O
PMC32407430_429,7933,lamotrigine,B-Drug
PMC32407430_429,7933,monotherapy,O
PMC32407430_429,7933,in,O
PMC32407430_429,7933,children,O
PMC32407430_429,7933,with,O
PMC32407430_429,7933,newly,O
PMC32407430_429,7933,diagnosed,O
PMC32407430_429,7933,typical,O
PMC32407430_429,7933,absence,O
PMC32407430_429,7933,seizures,O
PMC32407430_429,7933,0,O
PMC32531500_897,7934,Topiramate,B-Drug
PMC32531500_897,7934,plus,O
PMC32531500_897,7934,nortriptyline,O
PMC32531500_897,7934,in,O
PMC32531500_897,7934,the,O
PMC32531500_897,7934,preventive,O
PMC32531500_897,7934,treatment,O
PMC32531500_897,7934,of,O
PMC32531500_897,7934,migraine,O
PMC32531500_897,7934,:,O
PMC32531500_897,7934,a,O
PMC32531500_897,7934,controlled,O
PMC32531500_897,7934,study,O
PMC32531500_897,7934,for,O
PMC32531500_897,7934,nonresponders,O
PMC32531500_897,7934,0,O
PMC32571010_356,7935,Moreover,O
PMC32571010_356,7935,",",O
PMC32571010_356,7935,cinnarizine,O
PMC32571010_356,7935,and,O
PMC32571010_356,7935,trazodone,B-Drug
PMC32571010_356,7935,were,O
PMC32571010_356,7935,proven,O
PMC32571010_356,7935,to,O
PMC32571010_356,7935,be,O
PMC32571010_356,7935,good,O
PMC32571010_356,7935,candidates,O
PMC32571010_356,7935,as,O
PMC32571010_356,7935,skin,O
PMC32571010_356,7935,-,O
PMC32571010_356,7935,whitening,O
PMC32571010_356,7935,agents,O
PMC32571010_356,7935,for,O
PMC32571010_356,7935,treatment,O
PMC32571010_356,7935,of,O
PMC32571010_356,7935,skin,O
PMC32571010_356,7935,hyperpigmentation,B-Symptom
PMC32571010_356,7935,0,O
PMC32583940_372,7936,Meta,O
PMC32583940_372,7936,-,O
PMC32583940_372,7936,analysis,O
PMC32583940_372,7936,of,O
PMC32583940_372,7936,phase,O
PMC32583940_372,7936,II,O
PMC32583940_372,7936,trials,O
PMC32583940_372,7936,of,O
PMC32583940_372,7936,docetaxel,B-Drug
PMC32583940_372,7936,alone,O
PMC32583940_372,7936,or,O
PMC32583940_372,7936,in,O
PMC32583940_372,7936,combination,O
PMC32583940_372,7936,with,O
PMC32583940_372,7936,chemotherapy,O
PMC32583940_372,7936,in,O
PMC32583940_372,7936,metastatic,B-Disease
PMC32583940_372,7936,breast,I-Disease
PMC32583940_372,7936,cancer,I-Disease
PMC32583940_372,7936,0,O
PMC32600650_862,7937,Two,O
PMC32600650_862,7937,-,O
PMC32600650_862,7937,year,O
PMC32600650_862,7937,sustained,O
PMC32600650_862,7937,weight,B-Symptom
PMC32600650_862,7937,loss,I-Symptom
PMC32600650_862,7937,and,O
PMC32600650_862,7937,metabolic,O
PMC32600650_862,7937,benefits,O
PMC32600650_862,7937,with,O
PMC32600650_862,7937,controlled,O
PMC32600650_862,7937,-,O
PMC32600650_862,7937,release,O
PMC32600650_862,7937,phentermine,O
PMC32600650_862,7937,/,O
PMC32600650_862,7937,topiramate,B-Drug
PMC32600650_862,7937,in,O
PMC32600650_862,7937,obese,B-Disease
PMC32600650_862,7937,and,O
PMC32600650_862,7937,overweight,O
PMC32600650_862,7937,adults,O
PMC32600650_862,7937,(,O
PMC32600650_862,7937,SEQUEL,O
PMC32600650_862,7937,),O
PMC32600650_862,7937,:,O
PMC32600650_862,7937,a,O
PMC32600650_862,7937,randomized,O
PMC32600650_862,7937,",",O
PMC32600650_862,7937,placebo,O
PMC32600650_862,7937,-,O
PMC32600650_862,7937,controlled,O
PMC32600650_862,7937,",",O
PMC32600650_862,7937,phase,O
PMC32600650_862,7937,_,O
PMC32600650_862,7937,_,O
PMC32600650_862,7937,number,O
PMC32600650_862,7937,_,O
PMC32600650_862,7937,_,O
PMC32600650_862,7937,extension,O
PMC32600650_862,7937,study,O
PMC32600650_862,7937,0,O
PMC32657150_156,7938,Tolerance,O
PMC32657150_156,7938,to,O
PMC32657150_156,7938,the,O
PMC32657150_156,7938,prophylactic,O
PMC32657150_156,7938,effects,O
PMC32657150_156,7938,of,O
PMC32657150_156,7938,carbamazepine,B-Drug
PMC32657150_156,7938,and,O
PMC32657150_156,7938,related,O
PMC32657150_156,7938,mood,O
PMC32657150_156,7938,stabilizers,O
PMC32657150_156,7938,in,O
PMC32657150_156,7938,the,O
PMC32657150_156,7938,treatment,O
PMC32657150_156,7938,of,O
PMC32657150_156,7938,bipolar,B-Disease
PMC32657150_156,7938,disorders,I-Disease
PMC32657150_156,7938,0,O
PMC32692150_630,7939,Chemotherapy,O
PMC32692150_630,7939,with,O
PMC32692150_630,7939,cyclophosphamide,O
PMC32692150_630,7939,",",O
PMC32692150_630,7939,doxorubicin,O
PMC32692150_630,7939,",",O
PMC32692150_630,7939,vincristine,O
PMC32692150_630,7939,",",O
PMC32692150_630,7939,and,O
PMC32692150_630,7939,prednisone,B-Drug
PMC32692150_630,7939,(,O
PMC32692150_630,7939,CHOP,O
PMC32692150_630,7939,),O
PMC32692150_630,7939,has,O
PMC32692150_630,7939,long,O
PMC32692150_630,7939,been,O
PMC32692150_630,7939,a,O
PMC32692150_630,7939,standard,O
PMC32692150_630,7939,treatment,O
PMC32692150_630,7939,for,O
PMC32692150_630,7939,lymphoma,B-Disease
PMC32692150_630,7939,0,O
PMC32751120_921,7940,Paroxetine,B-Drug
PMC32751120_921,7940,-,O
PMC32751120_921,7940,induced,O
PMC32751120_921,7940,severe,O
PMC32751120_921,7940,sleep,O
PMC32751120_921,7940,bruxism,O
PMC32751120_921,7940,successfully,O
PMC32751120_921,7940,treated,O
PMC32751120_921,7940,with,O
PMC32751120_921,7940,buspirone,O
PMC32751120_921,7940,0,O
PMC32755390_25,7941,OBJECTIVE,O
PMC32755390_25,7941,:,O
PMC32755390_25,7941,This,O
PMC32755390_25,7941,study,O
PMC32755390_25,7941,aims,O
PMC32755390_25,7941,to,O
PMC32755390_25,7941,investigate,O
PMC32755390_25,7941,the,O
PMC32755390_25,7941,in,O
PMC32755390_25,7941,vitro,O
PMC32755390_25,7941,effects,O
PMC32755390_25,7941,of,O
PMC32755390_25,7941,Ulinastatin,O
PMC32755390_25,7941,(,O
PMC32755390_25,7941,UTI,O
PMC32755390_25,7941,),O
PMC32755390_25,7941,and,O
PMC32755390_25,7941,Taxotere,B-Drug
PMC32755390_25,7941,(,O
PMC32755390_25,7941,TXT,O
PMC32755390_25,7941,),O
PMC32755390_25,7941,on,O
PMC32755390_25,7941,cell,O
PMC32755390_25,7941,proliferation,O
PMC32755390_25,7941,;,O
PMC32755390_25,7941,cell,O
PMC32755390_25,7941,apoptosis,O
PMC32755390_25,7941,;,O
PMC32755390_25,7941,xenografted,O
PMC32755390_25,7941,tumor,O
PMC32755390_25,7941,growth,O
PMC32755390_25,7941,;,O
PMC32755390_25,7941,and,O
PMC32755390_25,7941,expression,O
PMC32755390_25,7941,of,O
PMC32755390_25,7941,insulin,O
PMC32755390_25,7941,-,O
PMC32755390_25,7941,like,O
PMC32755390_25,7941,growth,O
PMC32755390_25,7941,factor,O
PMC32755390_25,7941,receptor,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,number,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,(,O
PMC32755390_25,7941,IGF,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,number,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,R,O
PMC32755390_25,7941,),O
PMC32755390_25,7941,",",O
PMC32755390_25,7941,platelet,O
PMC32755390_25,7941,-,O
PMC32755390_25,7941,derived,O
PMC32755390_25,7941,growth,O
PMC32755390_25,7941,factor,O
PMC32755390_25,7941,A,O
PMC32755390_25,7941,(,O
PMC32755390_25,7941,PDGFA,O
PMC32755390_25,7941,),O
PMC32755390_25,7941,",",O
PMC32755390_25,7941,nerve,O
PMC32755390_25,7941,growth,O
PMC32755390_25,7941,factor,O
PMC32755390_25,7941,(,O
PMC32755390_25,7941,NGF,O
PMC32755390_25,7941,),O
PMC32755390_25,7941,",",O
PMC32755390_25,7941,c,O
PMC32755390_25,7941,-,O
PMC32755390_25,7941,Jun,O
PMC32755390_25,7941,N,O
PMC32755390_25,7941,-,O
PMC32755390_25,7941,terminal,O
PMC32755390_25,7941,kinase,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,number,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,(,O
PMC32755390_25,7941,JNk,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,number,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,),O
PMC32755390_25,7941,",",O
PMC32755390_25,7941,and,O
PMC32755390_25,7941,NF,O
PMC32755390_25,7941,-,O
PMC32755390_25,7941,B,O
PMC32755390_25,7941,in,O
PMC32755390_25,7941,a,O
PMC32755390_25,7941,human,O
PMC32755390_25,7941,primary,O
PMC32755390_25,7941,breast,B-Disease
PMC32755390_25,7941,cancer,I-Disease
PMC32755390_25,7941,cells,O
PMC32755390_25,7941,and,O
PMC32755390_25,7941,breast,O
PMC32755390_25,7941,cancer,O
PMC32755390_25,7941,cell,O
PMC32755390_25,7941,line,O
PMC32755390_25,7941,MDA,O
PMC32755390_25,7941,-,O
PMC32755390_25,7941,MB,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,number,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,_,O
PMC32755390_25,7941,0,O
PMC32791310_954,7942,METHODS,O
PMC32791310_954,7942,:,O
PMC32791310_954,7942,A,O
PMC32791310_954,7942,total,O
PMC32791310_954,7942,of,O
PMC32791310_954,7942,_,O
PMC32791310_954,7942,_,O
PMC32791310_954,7942,number,O
PMC32791310_954,7942,_,O
PMC32791310_954,7942,_,O
PMC32791310_954,7942,subjects,O
PMC32791310_954,7942,with,O
PMC32791310_954,7942,an,O
PMC32791310_954,7942,episode,O
PMC32791310_954,7942,of,O
PMC32791310_954,7942,DSM,O
PMC32791310_954,7942,-,O
PMC32791310_954,7942,IV,O
PMC32791310_954,7942,major,O
PMC32791310_954,7942,depression,B-Disease
PMC32791310_954,7942,were,O
PMC32791310_954,7942,randomly,O
PMC32791310_954,7942,assigned,O
PMC32791310_954,7942,to,O
PMC32791310_954,7942,treatment,O
PMC32791310_954,7942,with,O
PMC32791310_954,7942,escitalopram,O
PMC32791310_954,7942,or,O
PMC32791310_954,7942,nortriptyline,O
PMC32791310_954,7942,0,O
PMC32902781_519,7943,Treatment,O
PMC32902781_519,7943,of,O
PMC32902781_519,7943,hormone,O
PMC32902781_519,7943,refractory,O
PMC32902781_519,7943,metastatic,B-Disease
PMC32902781_519,7943,prostate,I-Disease
PMC32902781_519,7943,cancer,I-Disease
PMC32902781_519,7943,with,O
PMC32902781_519,7943,Docetaxel,B-Drug
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,number,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,mg,O
PMC32902781_519,7943,/,O
PMC32902781_519,7943,m,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,number,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,every,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,number,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,weeks,O
PMC32902781_519,7943,(,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,number,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,W,O
PMC32902781_519,7943,),O
PMC32902781_519,7943,in,O
PMC32902781_519,7943,combination,O
PMC32902781_519,7943,with,O
PMC32902781_519,7943,daily,O
PMC32902781_519,7943,prednisone,B-Drug
PMC32902781_519,7943,has,O
PMC32902781_519,7943,been,O
PMC32902781_519,7943,shown,O
PMC32902781_519,7943,to,O
PMC32902781_519,7943,prolong,O
PMC32902781_519,7943,survival,O
PMC32902781_519,7943,and,O
PMC32902781_519,7943,to,O
PMC32902781_519,7943,have,O
PMC32902781_519,7943,the,O
PMC32902781_519,7943,same,O
PMC32902781_519,7943,efficacy,O
PMC32902781_519,7943,in,O
PMC32902781_519,7943,healthy,O
PMC32902781_519,7943,elderly,O
PMC32902781_519,7943,as,O
PMC32902781_519,7943,in,O
PMC32902781_519,7943,younger,O
PMC32902781_519,7943,patients,O
PMC32902781_519,7943,[,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,number,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,_,O
PMC32902781_519,7943,],O
PMC32902781_519,7943,0,O
PMC32960640_484,7944,METHOD,O
PMC32960640_484,7944,:,O
PMC32960640_484,7944,In,O
PMC32960640_484,7944,a,O
PMC32960640_484,7944,single,O
PMC32960640_484,7944,blind,O
PMC32960640_484,7944,randomized,O
PMC32960640_484,7944,study,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,patients,O
PMC32960640_484,7944,with,O
PMC32960640_484,7944,unipolar,O
PMC32960640_484,7944,resistant,O
PMC32960640_484,7944,depression,O
PMC32960640_484,7944,to,O
PMC32960640_484,7944,one,O
PMC32960640_484,7944,antidepressant,O
PMC32960640_484,7944,treatment,O
PMC32960640_484,7944,were,O
PMC32960640_484,7944,enrolled,O
PMC32960640_484,7944,to,O
PMC32960640_484,7944,receive,O
PMC32960640_484,7944,",",O
PMC32960640_484,7944,in,O
PMC32960640_484,7944,combination,O
PMC32960640_484,7944,with,O
PMC32960640_484,7944,venlafaxine,B-Drug
PMC32960640_484,7944,(,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,mg,O
PMC32960640_484,7944,),O
PMC32960640_484,7944,",",O
PMC32960640_484,7944,either,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,sessions,O
PMC32960640_484,7944,of,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,Hz,O
PMC32960640_484,7944,rTMS,O
PMC32960640_484,7944,(,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,pulses,O
PMC32960640_484,7944,per,O
PMC32960640_484,7944,session,O
PMC32960640_484,7944,),O
PMC32960640_484,7944,applied,O
PMC32960640_484,7944,over,O
PMC32960640_484,7944,the,O
PMC32960640_484,7944,left,O
PMC32960640_484,7944,dorsolateral,O
PMC32960640_484,7944,prefrontal,O
PMC32960640_484,7944,cortex,O
PMC32960640_484,7944,(,O
PMC32960640_484,7944,DLPFC,O
PMC32960640_484,7944,),O
PMC32960640_484,7944,or,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,sessions,O
PMC32960640_484,7944,of,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,Hz,O
PMC32960640_484,7944,rTMS,O
PMC32960640_484,7944,(,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,number,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,_,O
PMC32960640_484,7944,stimulations,O
PMC32960640_484,7944,per,O
PMC32960640_484,7944,sessions,O
PMC32960640_484,7944,),O
PMC32960640_484,7944,applied,O
PMC32960640_484,7944,over,O
PMC32960640_484,7944,the,O
PMC32960640_484,7944,right,O
PMC32960640_484,7944,DLPFC,O
PMC32960640_484,7944,0,O
PMC32960640_945,7945,CONCLUSION,O
PMC32960640_945,7945,:,O
PMC32960640_945,7945,Low,O
PMC32960640_945,7945,-,O
PMC32960640_945,7945,and,O
PMC32960640_945,7945,high,O
PMC32960640_945,7945,-,O
PMC32960640_945,7945,frequency,O
PMC32960640_945,7945,rTMS,O
PMC32960640_945,7945,seems,O
PMC32960640_945,7945,to,O
PMC32960640_945,7945,be,O
PMC32960640_945,7945,effective,O
PMC32960640_945,7945,as,O
PMC32960640_945,7945,an,O
PMC32960640_945,7945,add,O
PMC32960640_945,7945,-,O
PMC32960640_945,7945,on,O
PMC32960640_945,7945,treatment,O
PMC32960640_945,7945,to,O
PMC32960640_945,7945,venlafaxine,B-Drug
PMC32960640_945,7945,as,O
PMC32960640_945,7945,monotherapy,O
PMC32960640_945,7945,in,O
PMC32960640_945,7945,pharmacological,O
PMC32960640_945,7945,refractory,O
PMC32960640_945,7945,major,B-Disease
PMC32960640_945,7945,depression,I-Disease
PMC32960640_945,7945,(,O
PMC32960640_945,7945,stage,O
PMC32960640_945,7945,_,O
PMC32960640_945,7945,_,O
PMC32960640_945,7945,number,O
PMC32960640_945,7945,_,O
PMC32960640_945,7945,_,O
PMC32960640_945,7945,),O
PMC32960640_945,7945,0,O
PMC32966860_133,7946,A,O
PMC32966860_133,7946,secondary,O
PMC32966860_133,7946,aim,O
PMC32966860_133,7946,was,O
PMC32966860_133,7946,to,O
PMC32966860_133,7946,assess,O
PMC32966860_133,7946,whether,O
PMC32966860_133,7946,Prednisone,B-Drug
PMC32966860_133,7946,",",O
PMC32966860_133,7946,a,O
PMC32966860_133,7946,drug,O
PMC32966860_133,7946,that,O
PMC32966860_133,7946,induces,O
PMC32966860_133,7946,insulin,O
PMC32966860_133,7946,resistance,O
PMC32966860_133,7946,and,O
PMC32966860_133,7946,stimulates,O
PMC32966860_133,7946,HCV,O
PMC32966860_133,7946,viral,O
PMC32966860_133,7946,entry,O
PMC32966860_133,7946,and,O
PMC32966860_133,7946,replication,O
PMC32966860_133,7946,in,O
PMC32966860_133,7946,replicon,O
PMC32966860_133,7946,culture,O
PMC32966860_133,7946,systems,O
PMC32966860_133,7946,",",O
PMC32966860_133,7946,increases,O
PMC32966860_133,7946,HCV,O
PMC32966860_133,7946,viral,O
PMC32966860_133,7946,load,O
PMC32966860_133,7946,in,O
PMC32966860_133,7946,this,O
PMC32966860_133,7946,population,O
PMC32966860_133,7946,0,O
PMC33027050_327,7947,CONCLUSIONS,O
PMC33027050_327,7947,:,O
PMC33027050_327,7947,Inhaled,O
PMC33027050_327,7947,corticosteroids,O
PMC33027050_327,7947,and,O
PMC33027050_327,7947,montelukast,B-Drug
PMC33027050_327,7947,have,O
PMC33027050_327,7947,a,O
PMC33027050_327,7947,significant,O
PMC33027050_327,7947,role,O
PMC33027050_327,7947,in,O
PMC33027050_327,7947,controlling,O
PMC33027050_327,7947,the,O
PMC33027050_327,7947,pulmonary,O
PMC33027050_327,7947,functions,O
PMC33027050_327,7947,and,O
PMC33027050_327,7947,the,O
PMC33027050_327,7947,inflammatory,O
PMC33027050_327,7947,process,O
PMC33027050_327,7947,in,O
PMC33027050_327,7947,children,O
PMC33027050_327,7947,with,O
PMC33027050_327,7947,mild,O
PMC33027050_327,7947,persistent,O
PMC33027050_327,7947,asthma,B-Disease
PMC33027050_327,7947,",",O
PMC33027050_327,7947,although,O
PMC33027050_327,7947,inhaled,O
PMC33027050_327,7947,corticosteroids,O
PMC33027050_327,7947,seem,O
PMC33027050_327,7947,to,O
PMC33027050_327,7947,yield,O
PMC33027050_327,7947,a,O
PMC33027050_327,7947,better,O
PMC33027050_327,7947,response,O
PMC33027050_327,7947,0,O
PMC33064110_207,7948,CONCLUSIONS,O
PMC33064110_207,7948,:,O
PMC33064110_207,7948,Olanzapine,B-Drug
PMC33064110_207,7948,-,O
PMC33064110_207,7948,induced,O
PMC33064110_207,7948,weight,B-Symptom
PMC33064110_207,7948,gain,I-Symptom
PMC33064110_207,7948,is,O
PMC33064110_207,7948,associated,O
PMC33064110_207,7948,with,O
PMC33064110_207,7948,reduced,O
PMC33064110_207,7948,appetite,O
PMC33064110_207,7948,-,O
PMC33064110_207,7948,inhibiting,O
PMC33064110_207,7948,POMC,O
PMC33064110_207,7948,and,O
PMC33064110_207,7948,increased,O
PMC33064110_207,7948,NPY,O
PMC33064110_207,7948,0,O
PMC33148570_109,7949,Citalopram,B-Drug
PMC33148570_109,7949,and,O
PMC33148570_109,7949,paroxetine,B-Drug
PMC33148570_109,7949,are,O
PMC33148570_109,7949,selective,O
PMC33148570_109,7949,serotonin,O
PMC33148570_109,7949,reuptake,O
PMC33148570_109,7949,inhibitors,O
PMC33148570_109,7949,and,O
PMC33148570_109,7949,also,O
PMC33148570_109,7949,have,O
PMC33148570_109,7949,antinociceptive,B-Symptom
PMC33148570_109,7949,effects,I-Symptom
PMC33148570_109,7949,0,O
PMC33181740_209,7950,PURPOSE,O
PMC33181740_209,7950,:,O
PMC33181740_209,7950,According,O
PMC33181740_209,7950,to,O
PMC33181740_209,7950,the,O
PMC33181740_209,7950,National,O
PMC33181740_209,7950,Surgical,O
PMC33181740_209,7950,Adjuvant,O
PMC33181740_209,7950,Breast,O
PMC33181740_209,7950,and,O
PMC33181740_209,7950,Bowel,O
PMC33181740_209,7950,Project,O
PMC33181740_209,7950,P,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,number,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,(,O
PMC33181740_209,7950,NSABP,O
PMC33181740_209,7950,-,O
PMC33181740_209,7950,P,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,number,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,),O
PMC33181740_209,7950,study,O
PMC33181740_209,7950,",",O
PMC33181740_209,7950,tamoxifen,B-Drug
PMC33181740_209,7950,can,O
PMC33181740_209,7950,prevent,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,number,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,%,O
PMC33181740_209,7950,of,O
PMC33181740_209,7950,invasive,B-Disease
PMC33181740_209,7950,breast,I-Disease
PMC33181740_209,7950,cancers,I-Disease
PMC33181740_209,7950,in,O
PMC33181740_209,7950,patients,O
PMC33181740_209,7950,who,O
PMC33181740_209,7950,have,O
PMC33181740_209,7950,a,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,number,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,-,O
PMC33181740_209,7950,year,O
PMC33181740_209,7950,risk,O
PMC33181740_209,7950,of,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,number,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,_,O
PMC33181740_209,7950,%,O
PMC33181740_209,7950,or,O
PMC33181740_209,7950,more,O
PMC33181740_209,7950,0,O
PMC33199800_584,7951,BACKGROUND,O
PMC33199800_584,7951,:,O
PMC33199800_584,7951,Neoadjuvant,O
PMC33199800_584,7951,chemotherapy,O
PMC33199800_584,7951,with,O
PMC33199800_584,7951,concurrent,O
PMC33199800_584,7951,docetaxel,B-Drug
PMC33199800_584,7951,",",O
PMC33199800_584,7951,doxorubicin,O
PMC33199800_584,7951,and,O
PMC33199800_584,7951,cyclophosphamide,O
PMC33199800_584,7951,is,O
PMC33199800_584,7951,commonly,O
PMC33199800_584,7951,used,O
PMC33199800_584,7951,for,O
PMC33199800_584,7951,patients,O
PMC33199800_584,7951,with,O
PMC33199800_584,7951,locally,O
PMC33199800_584,7951,advanced,B-Disease
PMC33199800_584,7951,breast,I-Disease
PMC33199800_584,7951,cancer,I-Disease
PMC33199800_584,7951,0,O
PMC33201440_323,7952,Lamotrigine,B-Drug
PMC33201440_323,7952,(,O
PMC33201440_323,7952,an,O
PMC33201440_323,7952,anticonvulsant,O
PMC33201440_323,7952,drug,O
PMC33201440_323,7952,),O
PMC33201440_323,7952,has,O
PMC33201440_323,7952,a,O
PMC33201440_323,7952,lesser,O
PMC33201440_323,7952,effect,O
PMC33201440_323,7952,on,O
PMC33201440_323,7952,the,O
PMC33201440_323,7952,muscle,B-Symptom
PMC33201440_323,7952,twitch,I-Symptom
PMC33201440_323,7952,amplitude,O
PMC33201440_323,7952,",",O
PMC33201440_323,7952,tetanic,B-Symptom
PMC33201440_323,7952,fade,I-Symptom
PMC33201440_323,7952,",",O
PMC33201440_323,7952,and,O
PMC33201440_323,7952,prolonged,O
PMC33201440_323,7952,twitch,O
PMC33201440_323,7952,duration,O
PMC33201440_323,7952,as,O
PMC33201440_323,7952,compared,O
PMC33201440_323,7952,with,O
PMC33201440_323,7952,KCNQ,O
PMC33201440_323,7952,openers,O
PMC33201440_323,7952,0,O
PMC33269280_247,7953,Among,O
PMC33269280_247,7953,the,O
PMC33269280_247,7953,adverse,O
PMC33269280_247,7953,reactions,O
PMC33269280_247,7953,of,O
PMC33269280_247,7953,carbamazepine,B-Drug
PMC33269280_247,7953,",",O
PMC33269280_247,7953,most,O
PMC33269280_247,7953,often,O
PMC33269280_247,7953,reported,O
PMC33269280_247,7953,are,O
PMC33269280_247,7953,skin,B-Symptom
PMC33269280_247,7953,reactions,I-Symptom
PMC33269280_247,7953,(,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,number,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,%,O
PMC33269280_247,7953,),O
PMC33269280_247,7953,",",O
PMC33269280_247,7953,hematological,O
PMC33269280_247,7953,(,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,number,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,%,O
PMC33269280_247,7953,),O
PMC33269280_247,7953,",",O
PMC33269280_247,7953,hepatic,O
PMC33269280_247,7953,disorder,O
PMC33269280_247,7953,(,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,number,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,_,O
PMC33269280_247,7953,%,O
PMC33269280_247,7953,),O
PMC33269280_247,7953,0,O
PMC33358440_655,7954,A,O
PMC33358440_655,7954,_,O
PMC33358440_655,7954,_,O
PMC33358440_655,7954,number,O
PMC33358440_655,7954,_,O
PMC33358440_655,7954,_,O
PMC33358440_655,7954,week,O
PMC33358440_655,7954,randomized,O
PMC33358440_655,7954,double,O
PMC33358440_655,7954,-,O
PMC33358440_655,7954,blind,O
PMC33358440_655,7954,placebo,O
PMC33358440_655,7954,-,O
PMC33358440_655,7954,controlled,O
PMC33358440_655,7954,trial,O
PMC33358440_655,7954,of,O
PMC33358440_655,7954,ziprasidone,B-Drug
PMC33358440_655,7954,for,O
PMC33358440_655,7954,the,O
PMC33358440_655,7954,acute,O
PMC33358440_655,7954,depressive,O
PMC33358440_655,7954,mixed,O
PMC33358440_655,7954,state,O
PMC33358440_655,7954,0,O
PMC33358940_430,7955,CONCLUSION,O
PMC33358940_430,7955,:,O
PMC33358940_430,7955,Eplerenone,O
PMC33358940_430,7955,and,O
PMC33358940_430,7955,lisinopril,B-Drug
PMC33358940_430,7955,combination,O
PMC33358940_430,7955,showed,O
PMC33358940_430,7955,additional,O
PMC33358940_430,7955,benefits,O
PMC33358940_430,7955,on,O
PMC33358940_430,7955,type,O
PMC33358940_430,7955,_,O
PMC33358940_430,7955,_,O
PMC33358940_430,7955,number,O
PMC33358940_430,7955,_,O
PMC33358940_430,7955,_,O
PMC33358940_430,7955,diabetic,B-Disease
PMC33358940_430,7955,nephropathy,I-Disease
PMC33358940_430,7955,compared,O
PMC33358940_430,7955,to,O
PMC33358940_430,7955,monotherapy,O
PMC33358940_430,7955,of,O
PMC33358940_430,7955,each,O
PMC33358940_430,7955,drug,O
PMC33358940_430,7955,0,O
PMC33446850_321,7956,BACKGROUND,O
PMC33446850_321,7956,:,O
PMC33446850_321,7956,Carbamazepine,B-Drug
PMC33446850_321,7956,(,O
PMC33446850_321,7956,CBZ,B-Drug
PMC33446850_321,7956,),O
PMC33446850_321,7956,is,O
PMC33446850_321,7956,a,O
PMC33446850_321,7956,first,O
PMC33446850_321,7956,-,O
PMC33446850_321,7956,line,O
PMC33446850_321,7956,antiepileptic,O
PMC33446850_321,7956,drug,O
PMC33446850_321,7956,(,O
PMC33446850_321,7956,AED,O
PMC33446850_321,7956,),O
PMC33446850_321,7956,",",O
PMC33446850_321,7956,although,O
PMC33446850_321,7956,it,O
PMC33446850_321,7956,is,O
PMC33446850_321,7956,also,O
PMC33446850_321,7956,used,O
PMC33446850_321,7956,for,O
PMC33446850_321,7956,the,O
PMC33446850_321,7956,treatments,O
PMC33446850_321,7956,of,O
PMC33446850_321,7956,psychiatric,O
PMC33446850_321,7956,disorders,O
PMC33446850_321,7956,and,O
PMC33446850_321,7956,neuropathic,B-Symptom
PMC33446850_321,7956,pain,I-Symptom
PMC33446850_321,7956,0,O
PMC33456050_459,7957,Epilepsies,B-Disease
PMC33456050_459,7957,with,O
PMC33456050_459,7957,primary,O
PMC33456050_459,7957,or,O
PMC33456050_459,7957,unclassified,O
PMC33456050_459,7957,GTCs,O
PMC33456050_459,7957,can,O
PMC33456050_459,7957,respond,O
PMC33456050_459,7957,to,O
PMC33456050_459,7957,any,O
PMC33456050_459,7957,one,O
PMC33456050_459,7957,of,O
PMC33456050_459,7957,the,O
PMC33456050_459,7957,five,O
PMC33456050_459,7957,broad,O
PMC33456050_459,7957,-,O
PMC33456050_459,7957,spectrum,O
PMC33456050_459,7957,antiepileptic,O
PMC33456050_459,7957,drugs,O
PMC33456050_459,7957,(,O
PMC33456050_459,7957,AEDs,O
PMC33456050_459,7957,),O
PMC33456050_459,7957,:,O
PMC33456050_459,7957,valproate,O
PMC33456050_459,7957,",",O
PMC33456050_459,7957,lamotrigine,B-Drug
PMC33456050_459,7957,",",O
PMC33456050_459,7957,levetiracetam,O
PMC33456050_459,7957,",",O
PMC33456050_459,7957,topiramate,B-Drug
PMC33456050_459,7957,and,O
PMC33456050_459,7957,zonisamide,O
PMC33456050_459,7957,0,O
PMC33502460_952,7958,Secondary,O
PMC33502460_952,7958,Bilateral,O
PMC33502460_952,7958,Angle,O
PMC33502460_952,7958,Closure,O
PMC33502460_952,7958,Glaucoma,B-Disease
PMC33502460_952,7958,due,O
PMC33502460_952,7958,to,O
PMC33502460_952,7958,Topiramate,B-Drug
PMC33502460_952,7958,0,O
PMC33564960_525,7959,CONCLUSIONS,O
PMC33564960_525,7959,:,O
PMC33564960_525,7959,Based,O
PMC33564960_525,7959,on,O
PMC33564960_525,7959,the,O
PMC33564960_525,7959,large,O
PMC33564960_525,7959,sample,O
PMC33564960_525,7959,size,O
PMC33564960_525,7959,",",O
PMC33564960_525,7959,our,O
PMC33564960_525,7959,data,O
PMC33564960_525,7959,strongly,O
PMC33564960_525,7959,suggests,O
PMC33564960_525,7959,that,O
PMC33564960_525,7959,there,O
PMC33564960_525,7959,is,O
PMC33564960_525,7959,no,O
PMC33564960_525,7959,single,O
PMC33564960_525,7959,miRNA,O
PMC33564960_525,7959,profile,O
PMC33564960_525,7959,predictive,O
PMC33564960_525,7959,of,O
PMC33564960_525,7959,outcome,O
PMC33564960_525,7959,following,O
PMC33564960_525,7959,adjuvant,O
PMC33564960_525,7959,Tamoxifen,B-Drug
PMC33564960_525,7959,treatment,O
PMC33564960_525,7959,in,O
PMC33564960_525,7959,a,O
PMC33564960_525,7959,broad,O
PMC33564960_525,7959,cohort,O
PMC33564960_525,7959,of,O
PMC33564960_525,7959,ER,O
PMC33564960_525,7959,+,O
PMC33564960_525,7959,breast,B-Disease
PMC33564960_525,7959,cancer,I-Disease
PMC33564960_525,7959,patients,O
PMC33564960_525,7959,0,O
PMC33593160_152,7960,Topiramate,B-Drug
PMC33593160_152,7960,is,O
PMC33593160_152,7960,an,O
PMC33593160_152,7960,antiepileptic,O
PMC33593160_152,7960,drug,O
PMC33593160_152,7960,known,O
PMC33593160_152,7960,to,O
PMC33593160_152,7960,ameliorate,O
PMC33593160_152,7960,insulin,O
PMC33593160_152,7960,resistance,O
PMC33593160_152,7960,besides,O
PMC33593160_152,7960,reducing,B-Symptom
PMC33593160_152,7960,body,I-Symptom
PMC33593160_152,7960,weight,I-Symptom
PMC33593160_152,7960,0,O
PMC33644250_809,7961,PURPOSE,O
PMC33644250_809,7961,:,O
PMC33644250_809,7961,To,O
PMC33644250_809,7961,compare,O
PMC33644250_809,7961,the,O
PMC33644250_809,7961,effectiveness,O
PMC33644250_809,7961,of,O
PMC33644250_809,7961,intravitreal,O
PMC33644250_809,7961,injections,O
PMC33644250_809,7961,of,O
PMC33644250_809,7961,bevacizumab,B-Drug
PMC33644250_809,7961,and,O
PMC33644250_809,7961,ranibizumab,O
PMC33644250_809,7961,in,O
PMC33644250_809,7961,patients,O
PMC33644250_809,7961,with,O
PMC33644250_809,7961,treatment,O
PMC33644250_809,7961,-,O
PMC33644250_809,7961,naive,O
PMC33644250_809,7961,polypoidal,B-Disease
PMC33644250_809,7961,choroidal,I-Disease
PMC33644250_809,7961,vasculopathy,I-Disease
PMC33644250_809,7961,(,O
PMC33644250_809,7961,PCV,O
PMC33644250_809,7961,),O
PMC33644250_809,7961,0,O
PMC33682980_636,7962,An,O
PMC33682980_636,7962,unusual,O
PMC33682980_636,7962,case,O
PMC33682980_636,7962,of,O
PMC33682980_636,7962,serotonin,B-Disease
PMC33682980_636,7962,syndrome,I-Disease
PMC33682980_636,7962,with,O
PMC33682980_636,7962,oxycodone,O
PMC33682980_636,7962,and,O
PMC33682980_636,7962,citalopram,B-Drug
PMC33682980_636,7962,0,O
PMC33720450_220,7963,METHODS,O
PMC33720450_220,7963,:,O
PMC33720450_220,7963,Thirty,O
PMC33720450_220,7963,out,O
PMC33720450_220,7963,of,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,number,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,our,O
PMC33720450_220,7963,patients,O
PMC33720450_220,7963,with,O
PMC33720450_220,7963,Behcet,O
PMC33720450_220,7963,',O
PMC33720450_220,7963,s,O
PMC33720450_220,7963,syndrome,O
PMC33720450_220,7963,were,O
PMC33720450_220,7963,randomly,O
PMC33720450_220,7963,treated,O
PMC33720450_220,7963,by,O
PMC33720450_220,7963,phenytoin,O
PMC33720450_220,7963,syrup,O
PMC33720450_220,7963,and,O
PMC33720450_220,7963,the,O
PMC33720450_220,7963,remaining,O
PMC33720450_220,7963,were,O
PMC33720450_220,7963,advised,O
PMC33720450_220,7963,to,O
PMC33720450_220,7963,use,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,number,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,_,O
PMC33720450_220,7963,%,O
PMC33720450_220,7963,triamcinolone,B-Drug
PMC33720450_220,7963,acetonide,O
PMC33720450_220,7963,ointment,O
PMC33720450_220,7963,0,O
PMC33720450_676,7964,Here,O
PMC33720450_676,7964,the,O
PMC33720450_676,7964,therapeutic,O
PMC33720450_676,7964,effect,O
PMC33720450_676,7964,of,O
PMC33720450_676,7964,triamcinolone,B-Drug
PMC33720450_676,7964,acetonide,O
PMC33720450_676,7964,ointment,O
PMC33720450_676,7964,as,O
PMC33720450_676,7964,a,O
PMC33720450_676,7964,relatively,O
PMC33720450_676,7964,expensive,O
PMC33720450_676,7964,medication,O
PMC33720450_676,7964,has,O
PMC33720450_676,7964,been,O
PMC33720450_676,7964,compared,O
PMC33720450_676,7964,with,O
PMC33720450_676,7964,phenytoin,O
PMC33720450_676,7964,syrup,O
PMC33720450_676,7964,on,O
PMC33720450_676,7964,aphthous,B-Symptom
PMC33720450_676,7964,ulcers,I-Symptom
PMC33720450_676,7964,in,O
PMC33720450_676,7964,patients,O
PMC33720450_676,7964,with,O
PMC33720450_676,7964,Behcet,O
PMC33720450_676,7964,',O
PMC33720450_676,7964,s,O
PMC33720450_676,7964,syndrome,O
PMC33720450_676,7964,0,O
PMC33720450_851,7965,CONCLUSION,O
PMC33720450_851,7965,:,O
PMC33720450_851,7965,The,O
PMC33720450_851,7965,effectiveness,O
PMC33720450_851,7965,of,O
PMC33720450_851,7965,triamcinolone,B-Drug
PMC33720450_851,7965,acetonide,O
PMC33720450_851,7965,ointment,O
PMC33720450_851,7965,was,O
PMC33720450_851,7965,more,O
PMC33720450_851,7965,than,O
PMC33720450_851,7965,phenytoin,O
PMC33720450_851,7965,on,O
PMC33720450_851,7965,aphthous,B-Symptom
PMC33720450_851,7965,ulcers,I-Symptom
PMC33720450_851,7965,in,O
PMC33720450_851,7965,patients,O
PMC33720450_851,7965,with,O
PMC33720450_851,7965,Behcet,O
PMC33720450_851,7965,',O
PMC33720450_851,7965,s,O
PMC33720450_851,7965,syndrome,O
PMC33720450_851,7965,0,O
PMC33720450_887,7966,Comparing,O
PMC33720450_887,7966,the,O
PMC33720450_887,7966,Effect,O
PMC33720450_887,7966,of,O
PMC33720450_887,7966,Phenytoin,O
PMC33720450_887,7966,Syrup,O
PMC33720450_887,7966,and,O
PMC33720450_887,7966,Triamcinolone,B-Drug
PMC33720450_887,7966,Acetonide,O
PMC33720450_887,7966,Ointment,O
PMC33720450_887,7966,on,O
PMC33720450_887,7966,Aphthous,B-Symptom
PMC33720450_887,7966,Ulcers,I-Symptom
PMC33720450_887,7966,in,O
PMC33720450_887,7966,Patients,O
PMC33720450_887,7966,with,O
PMC33720450_887,7966,Behcet,O
PMC33720450_887,7966,',O
PMC33720450_887,7966,s,O
PMC33720450_887,7966,Syndrome,O
PMC33720450_887,7966,0,O
PMC33725660_107,7967,OBJECTIVE,O
PMC33725660_107,7967,:,O
PMC33725660_107,7967,Lamotrigine,B-Drug
PMC33725660_107,7967,is,O
PMC33725660_107,7967,a,O
PMC33725660_107,7967,widely,O
PMC33725660_107,7967,used,O
PMC33725660_107,7967,medication,O
PMC33725660_107,7967,for,O
PMC33725660_107,7967,psychiatric,O
PMC33725660_107,7967,disorders,O
PMC33725660_107,7967,and,O
PMC33725660_107,7967,epilepsy,B-Disease
PMC33725660_107,7967,",",O
PMC33725660_107,7967,but,O
PMC33725660_107,7967,the,O
PMC33725660_107,7967,adverse,O
PMC33725660_107,7967,effects,O
PMC33725660_107,7967,of,O
PMC33725660_107,7967,this,O
PMC33725660_107,7967,drug,O
PMC33725660_107,7967,in,O
PMC33725660_107,7967,adolescent,O
PMC33725660_107,7967,Korean,O
PMC33725660_107,7967,patients,O
PMC33725660_107,7967,have,O
PMC33725660_107,7967,not,O
PMC33725660_107,7967,yet,O
PMC33725660_107,7967,been,O
PMC33725660_107,7967,investigated,O
PMC33725660_107,7967,0,O
PMC33725660_710,7968,All,O
PMC33725660_710,7968,of,O
PMC33725660_710,7968,these,O
PMC33725660_710,7968,rashes,B-Symptom
PMC33725660_710,7968,were,O
PMC33725660_710,7968,observed,O
PMC33725660_710,7968,within,O
PMC33725660_710,7968,_,O
PMC33725660_710,7968,_,O
PMC33725660_710,7968,number,O
PMC33725660_710,7968,_,O
PMC33725660_710,7968,_,O
PMC33725660_710,7968,weeks,O
PMC33725660_710,7968,of,O
PMC33725660_710,7968,the,O
PMC33725660_710,7968,initiation,O
PMC33725660_710,7968,of,O
PMC33725660_710,7968,the,O
PMC33725660_710,7968,lamotrigine,B-Drug
PMC33725660_710,7968,therapy,O
PMC33725660_710,7968,0,O
PMC33751550_909,7969,Predictors,O
PMC33751550_909,7969,of,O
PMC33751550_909,7969,Treatment,O
PMC33751550_909,7969,with,O
PMC33751550_909,7969,Duloxetine,B-Drug
PMC33751550_909,7969,or,O
PMC33751550_909,7969,Venlafaxine,B-Drug
PMC33751550_909,7969,XR,O
PMC33751550_909,7969,among,O
PMC33751550_909,7969,Adult,O
PMC33751550_909,7969,Patients,O
PMC33751550_909,7969,Treated,O
PMC33751550_909,7969,for,O
PMC33751550_909,7969,Depression,B-Disease
PMC33751550_909,7969,in,O
PMC33751550_909,7969,Primary,O
PMC33751550_909,7969,Care,O
PMC33751550_909,7969,Practices,O
PMC33751550_909,7969,in,O
PMC33751550_909,7969,the,O
PMC33751550_909,7969,United,O
PMC33751550_909,7969,Kingdom,O
PMC33751550_909,7969,0,O
PMC33768790_66,7970,The,O
PMC33768790_66,7970,cessation,O
PMC33768790_66,7970,of,O
PMC33768790_66,7970,olanzapine,O
PMC33768790_66,7970,significantly,O
PMC33768790_66,7970,decreased,O
PMC33768790_66,7970,high,O
PMC33768790_66,7970,-,O
PMC33768790_66,7970,sensitivity,O
PMC33768790_66,7970,C,O
PMC33768790_66,7970,-,O
PMC33768790_66,7970,reactive,O
PMC33768790_66,7970,protein,O
PMC33768790_66,7970,and,O
PMC33768790_66,7970,increased,O
PMC33768790_66,7970,adiponectin,O
PMC33768790_66,7970,",",O
PMC33768790_66,7970,proposing,O
PMC33768790_66,7970,that,O
PMC33768790_66,7970,inflammation,O
PMC33768790_66,7970,and,O
PMC33768790_66,7970,reduced,O
PMC33768790_66,7970,adiponectin,O
PMC33768790_66,7970,level,O
PMC33768790_66,7970,may,O
PMC33768790_66,7970,be,O
PMC33768790_66,7970,associated,O
PMC33768790_66,7970,with,O
PMC33768790_66,7970,olanzapin,B-Drug
PMC33768790_66,7970,-,O
PMC33768790_66,7970,induced,O
PMC33768790_66,7970,hypertriglyceridemia,B-Symptom
PMC33768790_66,7970,0,O
PMC33881800_819,7971,Because,O
PMC33881800_819,7971,both,O
PMC33881800_819,7971,imipramine,O
PMC33881800_819,7971,and,O
PMC33881800_819,7971,citalopram,B-Drug
PMC33881800_819,7971,have,O
PMC33881800_819,7971,been,O
PMC33881800_819,7971,commonly,O
PMC33881800_819,7971,used,O
PMC33881800_819,7971,to,O
PMC33881800_819,7971,treat,O
PMC33881800_819,7971,depression,B-Disease
PMC33881800_819,7971,",",O
PMC33881800_819,7971,which,O
PMC33881800_819,7971,commonly,O
PMC33881800_819,7971,occurs,O
PMC33881800_819,7971,in,O
PMC33881800_819,7971,glioma,B-Disease
PMC33881800_819,7971,patients,O
PMC33881800_819,7971,",",O
PMC33881800_819,7971,it,O
PMC33881800_819,7971,would,O
PMC33881800_819,7971,be,O
PMC33881800_819,7971,interesting,O
PMC33881800_819,7971,to,O
PMC33881800_819,7971,conduct,O
PMC33881800_819,7971,large,O
PMC33881800_819,7971,epidemiological,O
PMC33881800_819,7971,studies,O
PMC33881800_819,7971,to,O
PMC33881800_819,7971,investigate,O
PMC33881800_819,7971,the,O
PMC33881800_819,7971,actual,O
PMC33881800_819,7971,benefit,O
PMC33881800_819,7971,that,O
PMC33881800_819,7971,these,O
PMC33881800_819,7971,two,O
PMC33881800_819,7971,drugs,O
PMC33881800_819,7971,would,O
PMC33881800_819,7971,provide,O
PMC33881800_819,7971,for,O
PMC33881800_819,7971,malignant,O
PMC33881800_819,7971,glioma,O
PMC33881800_819,7971,patients,O
PMC33881800_819,7971,when,O
PMC33881800_819,7971,delivered,O
PMC33881800_819,7971,during,O
PMC33881800_819,7971,their,O
PMC33881800_819,7971,glioma,O
PMC33881800_819,7971,treatment,O
PMC33881800_819,7971,0,O
PMC33959260_490,7972,Trazodone,B-Drug
PMC33959260_490,7972,in,O
PMC33959260_490,7972,methandone,O
PMC33959260_490,7972,induced,O
PMC33959260_490,7972,erectile,B-Symptom
PMC33959260_490,7972,dysfunction,I-Symptom
PMC33959260_490,7972,0,O
PMC33959260_631,7973,We,O
PMC33959260_631,7973,conducted,O
PMC33959260_631,7973,this,O
PMC33959260_631,7973,study,O
PMC33959260_631,7973,to,O
PMC33959260_631,7973,evaluate,O
PMC33959260_631,7973,the,O
PMC33959260_631,7973,efficacy,O
PMC33959260_631,7973,of,O
PMC33959260_631,7973,Trazodone,B-Drug
PMC33959260_631,7973,(,O
PMC33959260_631,7973,an,O
PMC33959260_631,7973,antidepressant,O
PMC33959260_631,7973,which,O
PMC33959260_631,7973,can,O
PMC33959260_631,7973,improve,O
PMC33959260_631,7973,sexual,O
PMC33959260_631,7973,function,O
PMC33959260_631,7973,),O
PMC33959260_631,7973,on,O
PMC33959260_631,7973,this,O
PMC33959260_631,7973,sexual,B-Symptom
PMC33959260_631,7973,dysfunction,I-Symptom
PMC33959260_631,7973,0,O
PMC33959680_14,7974,This,O
PMC33959680_14,7974,suggests,O
PMC33959680_14,7974,that,O
PMC33959680_14,7974,topiramate,B-Drug
PMC33959680_14,7974,could,O
PMC33959680_14,7974,attenuate,O
PMC33959680_14,7974,the,O
PMC33959680_14,7974,ongoing,O
PMC33959680_14,7974,weight,B-Symptom
PMC33959680_14,7974,gain,I-Symptom
PMC33959680_14,7974,from,O
PMC33959680_14,7974,lithium,O
PMC33959680_14,7974,and,O
PMC33959680_14,7974,risperidone,O
PMC33959680_14,7974,0,O
PMC33980880_928,7975,In,O
PMC33980880_928,7975,combination,O
PMC33980880_928,7975,with,O
PMC33980880_928,7975,prednisone,B-Drug
PMC33980880_928,7975,",",O
PMC33980880_928,7975,cabazitaxel,O
PMC33980880_928,7975,",",O
PMC33980880_928,7975,which,O
PMC33980880_928,7975,was,O
PMC33980880_928,7975,approved,O
PMC33980880_928,7975,in,O
PMC33980880_928,7975,the,O
PMC33980880_928,7975,United,O
PMC33980880_928,7975,States,O
PMC33980880_928,7975,in,O
PMC33980880_928,7975,_,O
PMC33980880_928,7975,_,O
PMC33980880_928,7975,number,O
PMC33980880_928,7975,_,O
PMC33980880_928,7975,_,O
PMC33980880_928,7975,",",O
PMC33980880_928,7975,is,O
PMC33980880_928,7975,indicated,O
PMC33980880_928,7975,for,O
PMC33980880_928,7975,patients,O
PMC33980880_928,7975,with,O
PMC33980880_928,7975,metastatic,B-Disease
PMC33980880_928,7975,CRPC,I-Disease
PMC33980880_928,7975,previously,O
PMC33980880_928,7975,treated,O
PMC33980880_928,7975,with,O
PMC33980880_928,7975,a,O
PMC33980880_928,7975,docetaxel,B-Drug
PMC33980880_928,7975,-,O
PMC33980880_928,7975,containing,O
PMC33980880_928,7975,regimen,O
PMC33980880_928,7975,0,O
PMC34020170_290,7976,CASE,O
PMC34020170_290,7976,REPORTS,O
PMC34020170_290,7976,:,O
PMC34020170_290,7976,Two,O
PMC34020170_290,7976,cases,O
PMC34020170_290,7976,are,O
PMC34020170_290,7976,described,O
PMC34020170_290,7976,that,O
PMC34020170_290,7976,respectively,O
PMC34020170_290,7976,illustrate,O
PMC34020170_290,7976,the,O
PMC34020170_290,7976,use,O
PMC34020170_290,7976,of,O
PMC34020170_290,7976,hydrocortisone,B-Drug
PMC34020170_290,7976,and,O
PMC34020170_290,7976,placebo,O
PMC34020170_290,7976,",",O
PMC34020170_290,7976,in,O
PMC34020170_290,7976,combination,O
PMC34020170_290,7976,with,O
PMC34020170_290,7976,PE,O
PMC34020170_290,7976,",",O
PMC34020170_290,7976,for,O
PMC34020170_290,7976,the,O
PMC34020170_290,7976,treatment,O
PMC34020170_290,7976,of,O
PMC34020170_290,7976,combat,O
PMC34020170_290,7976,-,O
PMC34020170_290,7976,related,O
PMC34020170_290,7976,PTSD,B-Disease
PMC34020170_290,7976,0,O
PMC34020170_600,7977,The,O
PMC34020170_600,7977,veteran,O
PMC34020170_600,7977,receiving,O
PMC34020170_600,7977,hydrocortisone,B-Drug
PMC34020170_600,7977,augmentation,O
PMC34020170_600,7977,of,O
PMC34020170_600,7977,PE,O
PMC34020170_600,7977,displayed,O
PMC34020170_600,7977,an,O
PMC34020170_600,7977,accelerated,O
PMC34020170_600,7977,and,O
PMC34020170_600,7977,ultimately,O
PMC34020170_600,7977,greater,O
PMC34020170_600,7977,decline,O
PMC34020170_600,7977,in,O
PMC34020170_600,7977,PTSD,O
PMC34020170_600,7977,symptoms,O
PMC34020170_600,7977,than,O
PMC34020170_600,7977,the,O
PMC34020170_600,7977,veteran,O
PMC34020170_600,7977,receiving,O
PMC34020170_600,7977,placebo,O
PMC34020170_600,7977,0,O
PMC34039860_382,7978,CONCLUSIONS,O
PMC34039860_382,7978,:,O
PMC34039860_382,7978,Gambogic,O
PMC34039860_382,7978,acid,O
PMC34039860_382,7978,plus,O
PMC34039860_382,7978,docetaxel,B-Drug
PMC34039860_382,7978,produced,O
PMC34039860_382,7978,a,O
PMC34039860_382,7978,synergistic,O
PMC34039860_382,7978,anti,O
PMC34039860_382,7978,-,O
PMC34039860_382,7978,tumor,O
PMC34039860_382,7978,effect,O
PMC34039860_382,7978,in,O
PMC34039860_382,7978,gastrointestinal,B-Disease
PMC34039860_382,7978,cancer,I-Disease
PMC34039860_382,7978,cells,O
PMC34039860_382,7978,",",O
PMC34039860_382,7978,suggesting,O
PMC34039860_382,7978,that,O
PMC34039860_382,7978,the,O
PMC34039860_382,7978,drug,O
PMC34039860_382,7978,combination,O
PMC34039860_382,7978,may,O
PMC34039860_382,7978,offer,O
PMC34039860_382,7978,a,O
PMC34039860_382,7978,novel,O
PMC34039860_382,7978,treatment,O
PMC34039860_382,7978,option,O
PMC34039860_382,7978,for,O
PMC34039860_382,7978,patients,O
PMC34039860_382,7978,with,O
PMC34039860_382,7978,gastric,B-Disease
PMC34039860_382,7978,and,I-Disease
PMC34039860_382,7978,colorectal,I-Disease
PMC34039860_382,7978,cancers,I-Disease
PMC34039860_382,7978,0,O
PMC34045930_877,7979,BACKGROUND,O
PMC34045930_877,7979,:,O
PMC34045930_877,7979,We,O
PMC34045930_877,7979,evaluated,O
PMC34045930_877,7979,the,O
PMC34045930_877,7979,effects,O
PMC34045930_877,7979,of,O
PMC34045930_877,7979,once,O
PMC34045930_877,7979,-,O
PMC34045930_877,7979,daily,O
PMC34045930_877,7979,extended,O
PMC34045930_877,7979,-,O
PMC34045930_877,7979,release,O
PMC34045930_877,7979,quetiapine,B-Drug
PMC34045930_877,7979,fumarate,O
PMC34045930_877,7979,(,O
PMC34045930_877,7979,quetiapine,B-Drug
PMC34045930_877,7979,XR,I-Drug
PMC34045930_877,7979,),O
PMC34045930_877,7979,on,O
PMC34045930_877,7979,patient,O
PMC34045930_877,7979,-,O
PMC34045930_877,7979,reported,O
PMC34045930_877,7979,outcomes,O
PMC34045930_877,7979,in,O
PMC34045930_877,7979,generalized,B-Disease
PMC34045930_877,7979,anxiety,I-Disease
PMC34045930_877,7979,disorder,I-Disease
PMC34045930_877,7979,(,O
PMC34045930_877,7979,GAD,B-Disease
PMC34045930_877,7979,),O
PMC34045930_877,7979,0,O
PMC34052350_659,7980,PURPOSE,O
PMC34052350_659,7980,:,O
PMC34052350_659,7980,Abiraterone,O
PMC34052350_659,7980,is,O
PMC34052350_659,7980,the,O
PMC34052350_659,7980,active,O
PMC34052350_659,7980,metabolite,O
PMC34052350_659,7980,of,O
PMC34052350_659,7980,the,O
PMC34052350_659,7980,pro,O
PMC34052350_659,7980,-,O
PMC34052350_659,7980,drug,O
PMC34052350_659,7980,abiraterone,O
PMC34052350_659,7980,acetate,O
PMC34052350_659,7980,(,O
PMC34052350_659,7980,AA,O
PMC34052350_659,7980,),O
PMC34052350_659,7980,and,O
PMC34052350_659,7980,a,O
PMC34052350_659,7980,selective,O
PMC34052350_659,7980,inhibitor,O
PMC34052350_659,7980,of,O
PMC34052350_659,7980,CYP,O
PMC34052350_659,7980,_,O
PMC34052350_659,7980,_,O
PMC34052350_659,7980,number,O
PMC34052350_659,7980,_,O
PMC34052350_659,7980,_,O
PMC34052350_659,7980,",",O
PMC34052350_659,7980,a,O
PMC34052350_659,7980,key,O
PMC34052350_659,7980,enzyme,O
PMC34052350_659,7980,in,O
PMC34052350_659,7980,testosterone,O
PMC34052350_659,7980,synthesis,O
PMC34052350_659,7980,",",O
PMC34052350_659,7980,and,O
PMC34052350_659,7980,improves,O
PMC34052350_659,7980,overall,O
PMC34052350_659,7980,survival,O
PMC34052350_659,7980,in,O
PMC34052350_659,7980,postdocetaxel,B-Drug
PMC34052350_659,7980,metastatic,B-Disease
PMC34052350_659,7980,castration,I-Disease
PMC34052350_659,7980,-,I-Disease
PMC34052350_659,7980,resistant,I-Disease
PMC34052350_659,7980,prostate,I-Disease
PMC34052350_659,7980,cancer,I-Disease
PMC34052350_659,7980,(,O
PMC34052350_659,7980,mCRPC,B-Disease
PMC34052350_659,7980,),O
PMC34052350_659,7980,0,O
PMC34077070_11,7981,Still,O
PMC34077070_11,7981,suffering,O
PMC34077070_11,7981,from,O
PMC34077070_11,7981,inattention,O
PMC34077070_11,7981,and,O
PMC34077070_11,7981,hyperactivity,O
PMC34077070_11,7981,",",O
PMC34077070_11,7981,the,O
PMC34077070_11,7981,patient,O
PMC34077070_11,7981,began,O
PMC34077070_11,7981,college,O
PMC34077070_11,7981,when,O
PMC34077070_11,7981,he,O
PMC34077070_11,7981,was,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,number,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,",",O
PMC34077070_11,7981,but,O
PMC34077070_11,7981,did,O
PMC34077070_11,7981,not,O
PMC34077070_11,7981,receive,O
PMC34077070_11,7981,stimulant,O
PMC34077070_11,7981,medication,O
PMC34077070_11,7981,until,O
PMC34077070_11,7981,three,O
PMC34077070_11,7981,years,O
PMC34077070_11,7981,later,O
PMC34077070_11,7981,",",O
PMC34077070_11,7981,when,O
PMC34077070_11,7981,Ritalin,B-Drug
PMC34077070_11,7981,_,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,number,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,_,O
PMC34077070_11,7981,mg,O
PMC34077070_11,7981,daily,O
PMC34077070_11,7981,was,O
PMC34077070_11,7981,re,O
PMC34077070_11,7981,-,O
PMC34077070_11,7981,established,O
PMC34077070_11,7981,0,O
PMC34077070_425,7982,When,O
PMC34077070_425,7982,he,O
PMC34077070_425,7982,was,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,number,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,",",O
PMC34077070_425,7982,his,O
PMC34077070_425,7982,medication,O
PMC34077070_425,7982,was,O
PMC34077070_425,7982,changed,O
PMC34077070_425,7982,to,O
PMC34077070_425,7982,desipramine,O
PMC34077070_425,7982,(,O
PMC34077070_425,7982,Norpramin,O
PMC34077070_425,7982,),O
PMC34077070_425,7982,",",O
PMC34077070_425,7982,and,O
PMC34077070_425,7982,both,O
PMC34077070_425,7982,Ritalin,B-Drug
PMC34077070_425,7982,and,O
PMC34077070_425,7982,Ritalin,B-Drug
PMC34077070_425,7982,SR,O
PMC34077070_425,7982,were,O
PMC34077070_425,7982,discontinued,O
PMC34077070_425,7982,;,O
PMC34077070_425,7982,and,O
PMC34077070_425,7982,at,O
PMC34077070_425,7982,age,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,number,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,",",O
PMC34077070_425,7982,when,O
PMC34077070_425,7982,he,O
PMC34077070_425,7982,developed,O
PMC34077070_425,7982,obsessive,O
PMC34077070_425,7982,-,O
PMC34077070_425,7982,compulsive,O
PMC34077070_425,7982,symptoms,O
PMC34077070_425,7982,",",O
PMC34077070_425,7982,his,O
PMC34077070_425,7982,medication,O
PMC34077070_425,7982,was,O
PMC34077070_425,7982,changed,O
PMC34077070_425,7982,to,O
PMC34077070_425,7982,clomipramine,O
PMC34077070_425,7982,(,O
PMC34077070_425,7982,Anafranil,O
PMC34077070_425,7982,),O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,number,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,_,O
PMC34077070_425,7982,mg,O
PMC34077070_425,7982,daily,O
PMC34077070_425,7982,0,O
PMC34077070_701,7983,Finally,O
PMC34077070_701,7983,",",O
PMC34077070_701,7983,on,O
PMC34077070_701,7983,a,O
PMC34077070_701,7983,dosage,O
PMC34077070_701,7983,of,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,number,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,mg,O
PMC34077070_701,7983,extended,O
PMC34077070_701,7983,-,O
PMC34077070_701,7983,release,O
PMC34077070_701,7983,methylphenidate,B-Drug
PMC34077070_701,7983,(,O
PMC34077070_701,7983,Concerta,O
PMC34077070_701,7983,),O
PMC34077070_701,7983,",",O
PMC34077070_701,7983,his,O
PMC34077070_701,7983,symptoms,O
PMC34077070_701,7983,of,O
PMC34077070_701,7983,Attention,O
PMC34077070_701,7983,Deficit,O
PMC34077070_701,7983,Hyperactivity,O
PMC34077070_701,7983,Disorder,O
PMC34077070_701,7983,have,O
PMC34077070_701,7983,improved,O
PMC34077070_701,7983,dramatically,O
PMC34077070_701,7983,and,O
PMC34077070_701,7983,no,O
PMC34077070_701,7983,further,O
PMC34077070_701,7983,use,O
PMC34077070_701,7983,of,O
PMC34077070_701,7983,methylphenidate,O
PMC34077070_701,7983,has,O
PMC34077070_701,7983,been,O
PMC34077070_701,7983,recorded,O
PMC34077070_701,7983,during,O
PMC34077070_701,7983,the,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,number,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,_,O
PMC34077070_701,7983,months,O
PMC34077070_701,7983,preceding,O
PMC34077070_701,7983,this,O
PMC34077070_701,7983,report,O
PMC34077070_701,7983,0,O
PMC34077070_882,7984,At,O
PMC34077070_882,7984,that,O
PMC34077070_882,7984,point,O
PMC34077070_882,7984,",",O
PMC34077070_882,7984,the,O
PMC34077070_882,7984,patient,O
PMC34077070_882,7984,',O
PMC34077070_882,7984,s,O
PMC34077070_882,7984,daily,O
PMC34077070_882,7984,Ritalin,B-Drug
PMC34077070_882,7984,dosage,O
PMC34077070_882,7984,was,O
PMC34077070_882,7984,reduced,O
PMC34077070_882,7984,to,O
PMC34077070_882,7984,_,O
PMC34077070_882,7984,_,O
PMC34077070_882,7984,number,O
PMC34077070_882,7984,_,O
PMC34077070_882,7984,_,O
PMC34077070_882,7984,mg,O
PMC34077070_882,7984,daily,O
PMC34077070_882,7984,orally,O
PMC34077070_882,7984,",",O
PMC34077070_882,7984,but,O
PMC34077070_882,7984,he,O
PMC34077070_882,7984,still,O
PMC34077070_882,7984,experienced,O
PMC34077070_882,7984,pronounced,O
PMC34077070_882,7984,symptoms,O
PMC34077070_882,7984,of,O
PMC34077070_882,7984,",",O
PMC34077070_882,7984,Attention,B-Disease
PMC34077070_882,7984,Deficit,I-Disease
PMC34077070_882,7984,Hyperactivity,I-Disease
PMC34077070_882,7984,Disorder,I-Disease
PMC34077070_882,7984,so,O
PMC34077070_882,7984,this,O
PMC34077070_882,7984,dosage,O
PMC34077070_882,7984,was,O
PMC34077070_882,7984,raised,O
PMC34077070_882,7984,again,O
PMC34077070_882,7984,0,O
PMC34122020_984,7985,The,O
PMC34122020_984,7985,primary,O
PMC34122020_984,7985,objective,O
PMC34122020_984,7985,of,O
PMC34122020_984,7985,this,O
PMC34122020_984,7985,study,O
PMC34122020_984,7985,is,O
PMC34122020_984,7985,to,O
PMC34122020_984,7985,review,O
PMC34122020_984,7985,the,O
PMC34122020_984,7985,efficacy,O
PMC34122020_984,7985,of,O
PMC34122020_984,7985,duloxetine,B-Drug
PMC34122020_984,7985,in,O
PMC34122020_984,7985,treating,O
PMC34122020_984,7985,chronic,O
PMC34122020_984,7985,pain,O
PMC34122020_984,7985,using,O
PMC34122020_984,7985,the,O
PMC34122020_984,7985,Initiative,O
PMC34122020_984,7985,on,O
PMC34122020_984,7985,Methods,O
PMC34122020_984,7985,",",O
PMC34122020_984,7985,Measurement,O
PMC34122020_984,7985,",",O
PMC34122020_984,7985,and,O
PMC34122020_984,7985,Pain,O
PMC34122020_984,7985,Assessment,O
PMC34122020_984,7985,in,O
PMC34122020_984,7985,Clinical,O
PMC34122020_984,7985,Trials,O
PMC34122020_984,7985,(,O
PMC34122020_984,7985,IMMPACT,O
PMC34122020_984,7985,),O
PMC34122020_984,7985,recommendations,O
PMC34122020_984,7985,for,O
PMC34122020_984,7985,clinical,O
PMC34122020_984,7985,significance,O
PMC34122020_984,7985,across,O
PMC34122020_984,7985,chronic,O
PMC34122020_984,7985,pain,O
PMC34122020_984,7985,states,O
PMC34122020_984,7985,0,O
PMC34182190_237,7986,The,O
PMC34182190_237,7986,mean,O
PMC34182190_237,7986,change,O
PMC34182190_237,7986,in,O
PMC34182190_237,7986,best,O
PMC34182190_237,7986,corrected,O
PMC34182190_237,7986,visual,B-Symptom
PMC34182190_237,7986,acuity,I-Symptom
PMC34182190_237,7986,non,O
PMC34182190_237,7986,-,O
PMC34182190_237,7986,significantly,O
PMC34182190_237,7986,favoured,O
PMC34182190_237,7986,bevacizumab,B-Drug
PMC34182190_237,7986,(,O
PMC34182190_237,7986,treatment,O
PMC34182190_237,7986,effect,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,number,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,logMAR,O
PMC34182190_237,7986,units,O
PMC34182190_237,7986,(,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,number,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,to,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,number,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,_,O
PMC34182190_237,7986,),O
PMC34182190_237,7986,),O
PMC34182190_237,7986,0,O
PMC34193980_569,7987,Depression,B-Disease
PMC34193980_569,7987,treatment,O
PMC34193980_569,7987,with,O
PMC34193980_569,7987,duloxetine,B-Drug
PMC34193980_569,7987,and,O
PMC34193980_569,7987,reduction,O
PMC34193980_569,7987,of,O
PMC34193980_569,7987,inability,O
PMC34193980_569,7987,to,O
PMC34193980_569,7987,work,O
PMC34193980_569,7987,0,O
PMC34204190_892,7988,An,O
PMC34204190_892,7988,unusual,O
PMC34204190_892,7988,cause,O
PMC34204190_892,7988,of,O
PMC34204190_892,7988,anaemia,O
PMC34204190_892,7988,of,O
PMC34204190_892,7988,chronic,O
PMC34204190_892,7988,disease,O
PMC34204190_892,7988,:,O
PMC34204190_892,7988,lisinopril,B-Drug
PMC34204190_892,7988,-,O
PMC34204190_892,7988,induced,O
PMC34204190_892,7988,chronic,O
PMC34204190_892,7988,inflammatory,B-Symptom
PMC34204190_892,7988,state,O
PMC34204190_892,7988,0,O
PMC34204190_998,7989,We,O
PMC34204190_998,7989,report,O
PMC34204190_998,7989,the,O
PMC34204190_998,7989,case,O
PMC34204190_998,7989,of,O
PMC34204190_998,7989,a,O
PMC34204190_998,7989,patient,O
PMC34204190_998,7989,with,O
PMC34204190_998,7989,severe,O
PMC34204190_998,7989,systemic,O
PMC34204190_998,7989,symptoms,O
PMC34204190_998,7989,(,O
PMC34204190_998,7989,weight,B-Symptom
PMC34204190_998,7989,loss,I-Symptom
PMC34204190_998,7989,",",O
PMC34204190_998,7989,malaise,B-Symptom
PMC34204190_998,7989,",",O
PMC34204190_998,7989,and,O
PMC34204190_998,7989,anorexia,B-Symptom
PMC34204190_998,7989,),O
PMC34204190_998,7989,",",O
PMC34204190_998,7989,eosinophilic,O
PMC34204190_998,7989,oesophagitis,B-Symptom
PMC34204190_998,7989,",",O
PMC34204190_998,7989,and,O
PMC34204190_998,7989,raised,O
PMC34204190_998,7989,inflammatory,O
PMC34204190_998,7989,markers,O
PMC34204190_998,7989,coinciding,O
PMC34204190_998,7989,with,O
PMC34204190_998,7989,the,O
PMC34204190_998,7989,use,O
PMC34204190_998,7989,of,O
PMC34204190_998,7989,lisinopril,B-Drug
PMC34204190_998,7989,0,O
PMC34204920_832,7990,We,O
PMC34204920_832,7990,describe,O
PMC34204920_832,7990,a,O
PMC34204920_832,7990,stable,O
PMC34204920_832,7990,bipolar,B-Disease
PMC34204920_832,7990,female,O
PMC34204920_832,7990,patient,O
PMC34204920_832,7990,on,O
PMC34204920_832,7990,medications,O
PMC34204920_832,7990,that,O
PMC34204920_832,7990,got,O
PMC34204920_832,7990,switched,O
PMC34204920_832,7990,into,O
PMC34204920_832,7990,mania,O
PMC34204920_832,7990,due,O
PMC34204920_832,7990,to,O
PMC34204920_832,7990,higher,O
PMC34204920_832,7990,doses,O
PMC34204920_832,7990,of,O
PMC34204920_832,7990,prednisone,B-Drug
PMC34204920_832,7990,prescribed,O
PMC34204920_832,7990,for,O
PMC34204920_832,7990,her,O
PMC34204920_832,7990,severe,O
PMC34204920_832,7990,sinusitis,B-Disease
PMC34204920_832,7990,0,O
PMC34206560_187,7991,Clinical,O
PMC34206560_187,7991,Practice,O
PMC34206560_187,7991,Associated,O
PMC34206560_187,7991,with,O
PMC34206560_187,7991,a,O
PMC34206560_187,7991,Switch,O
PMC34206560_187,7991,from,O
PMC34206560_187,7991,and,O
PMC34206560_187,7991,to,O
PMC34206560_187,7991,Ziprasidone,B-Drug
PMC34206560_187,7991,during,O
PMC34206560_187,7991,Routine,O
PMC34206560_187,7991,Inpatient,O
PMC34206560_187,7991,Treatment,O
PMC34206560_187,7991,of,O
PMC34206560_187,7991,Patients,O
PMC34206560_187,7991,with,O
PMC34206560_187,7991,Schizophrenia,B-Disease
PMC34206560_187,7991,0,O
PMC34221420_154,7992,CONCLUSION,O
PMC34221420_154,7992,:,O
PMC34221420_154,7992,Visual,B-Symptom
PMC34221420_154,7992,acuity,I-Symptom
PMC34221420_154,7992,improved,O
PMC34221420_154,7992,significantly,O
PMC34221420_154,7992,after,O
PMC34221420_154,7992,sub,O
PMC34221420_154,7992,-,O
PMC34221420_154,7992,Tenon,O
PMC34221420_154,7992,injection,O
PMC34221420_154,7992,of,O
PMC34221420_154,7992,triamcinolone,B-Drug
PMC34221420_154,7992,acetonide,I-Drug
PMC34221420_154,7992,without,O
PMC34221420_154,7992,photoreceptor,O
PMC34221420_154,7992,recovery,O
PMC34221420_154,7992,in,O
PMC34221420_154,7992,eyes,O
PMC34221420_154,7992,with,O
PMC34221420_154,7992,CME,O
PMC34221420_154,7992,0,O
PMC34221420_645,7993,METHODS,O
PMC34221420_645,7993,:,O
PMC34221420_645,7993,We,O
PMC34221420_645,7993,reviewed,O
PMC34221420_645,7993,the,O
PMC34221420_645,7993,medical,O
PMC34221420_645,7993,records,O
PMC34221420_645,7993,for,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,number,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,consecutive,O
PMC34221420_645,7993,eyes,O
PMC34221420_645,7993,with,O
PMC34221420_645,7993,diabetic,B-Disease
PMC34221420_645,7993,macular,I-Disease
PMC34221420_645,7993,edema,I-Disease
PMC34221420_645,7993,treated,O
PMC34221420_645,7993,by,O
PMC34221420_645,7993,sub,O
PMC34221420_645,7993,-,O
PMC34221420_645,7993,Tenon,O
PMC34221420_645,7993,injection,O
PMC34221420_645,7993,of,O
PMC34221420_645,7993,triamcinolone,B-Drug
PMC34221420_645,7993,acetonide,O
PMC34221420_645,7993,and,O
PMC34221420_645,7993,assessed,O
PMC34221420_645,7993,at,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,number,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,_,O
PMC34221420_645,7993,months,O
PMC34221420_645,7993,postoperatively,O
PMC34221420_645,7993,0,O
PMC34299570_1002,7994,Comparison,O
PMC34299570_1002,7994,of,O
PMC34299570_1002,7994,the,O
PMC34299570_1002,7994,effect,O
PMC34299570_1002,7994,of,O
PMC34299570_1002,7994,combination,O
PMC34299570_1002,7994,of,O
PMC34299570_1002,7994,triamcinolone,O
PMC34299570_1002,7994,acetonide,O
PMC34299570_1002,7994,and,O
PMC34299570_1002,7994,vitamin,O
PMC34299570_1002,7994,a,O
PMC34299570_1002,7994,mouthwash,O
PMC34299570_1002,7994,with,O
PMC34299570_1002,7994,triamcinolone,B-Drug
PMC34299570_1002,7994,mouthwash,O
PMC34299570_1002,7994,alone,O
PMC34299570_1002,7994,on,O
PMC34299570_1002,7994,oral,O
PMC34299570_1002,7994,lichen,O
PMC34299570_1002,7994,planus,O
PMC34299570_1002,7994,0,O
PMC34348920_386,7995,The,O
PMC34348920_386,7995,effects,O
PMC34348920_386,7995,of,O
PMC34348920_386,7995,sertraline,B-Drug
PMC34348920_386,7995,on,O
PMC34348920_386,7995,blood,O
PMC34348920_386,7995,lipids,O
PMC34348920_386,7995,",",O
PMC34348920_386,7995,glucose,O
PMC34348920_386,7995,",",O
PMC34348920_386,7995,insulin,O
PMC34348920_386,7995,and,O
PMC34348920_386,7995,HBA,O
PMC34348920_386,7995,_,O
PMC34348920_386,7995,_,O
PMC34348920_386,7995,number,O
PMC34348920_386,7995,_,O
PMC34348920_386,7995,_,O
PMC34348920_386,7995,C,O
PMC34348920_386,7995,levels,O
PMC34348920_386,7995,:,O
PMC34348920_386,7995,A,O
PMC34348920_386,7995,prospective,O
PMC34348920_386,7995,clinical,O
PMC34348920_386,7995,trial,O
PMC34348920_386,7995,on,O
PMC34348920_386,7995,depressive,B-Disease
PMC34348920_386,7995,patients,O
PMC34348920_386,7995,0,O
PMC34366590_85,7996,Montelukast,B-Drug
PMC34366590_85,7996,versus,O
PMC34366590_85,7996,inhaled,O
PMC34366590_85,7996,corticosteroids,O
PMC34366590_85,7996,in,O
PMC34366590_85,7996,the,O
PMC34366590_85,7996,management,O
PMC34366590_85,7996,of,O
PMC34366590_85,7996,pediatric,O
PMC34366590_85,7996,mild,O
PMC34366590_85,7996,persistent,O
PMC34366590_85,7996,asthma,B-Disease
PMC34366590_85,7996,0,O
PMC34376320_643,7997,Before,O
PMC34376320_643,7997,treatment,O
PMC34376320_643,7997,with,O
PMC34376320_643,7997,sertraline,B-Drug
PMC34376320_643,7997,",",O
PMC34376320_643,7997,the,O
PMC34376320_643,7997,grade,O
PMC34376320_643,7997,of,O
PMC34376320_643,7997,pruritus,O
PMC34376320_643,7997,in,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,number,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,(,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,number,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,%,O
PMC34376320_643,7997,),O
PMC34376320_643,7997,patients,O
PMC34376320_643,7997,was,O
PMC34376320_643,7997,moderate,O
PMC34376320_643,7997,and,O
PMC34376320_643,7997,severe,O
PMC34376320_643,7997,in,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,number,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,(,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,number,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,_,O
PMC34376320_643,7997,%,O
PMC34376320_643,7997,),O
PMC34376320_643,7997,patients,O
PMC34376320_643,7997,0,O
PMC34376460_628,7998,Review,O
PMC34376460_628,7998,of,O
PMC34376460_628,7998,Efficacy,O
PMC34376460_628,7998,and,O
PMC34376460_628,7998,Safety,O
PMC34376460_628,7998,of,O
PMC34376460_628,7998,Duloxetine,B-Drug
PMC34376460_628,7998,_,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,number,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,to,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,number,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,_,O
PMC34376460_628,7998,mg,O
PMC34376460_628,7998,Once,O
PMC34376460_628,7998,Daily,O
PMC34376460_628,7998,in,O
PMC34376460_628,7998,Patients,O
PMC34376460_628,7998,with,O
PMC34376460_628,7998,Diabetic,O
PMC34376460_628,7998,Peripheral,O
PMC34376460_628,7998,Neuropathic,O
PMC34376460_628,7998,Pain,O
PMC34376460_628,7998,0,O
PMC34463540_501,7999,INTRODUCTION,O
PMC34463540_501,7999,:,O
PMC34463540_501,7999,Tamoxifen,B-Drug
PMC34463540_501,7999,is,O
PMC34463540_501,7999,an,O
PMC34463540_501,7999,effective,O
PMC34463540_501,7999,treatment,O
PMC34463540_501,7999,for,O
PMC34463540_501,7999,breast,B-Disease
PMC34463540_501,7999,cancer,I-Disease
PMC34463540_501,7999,but,O
PMC34463540_501,7999,an,O
PMC34463540_501,7999,undesirable,O
PMC34463540_501,7999,side,O
PMC34463540_501,7999,-,O
PMC34463540_501,7999,effect,O
PMC34463540_501,7999,is,O
PMC34463540_501,7999,an,O
PMC34463540_501,7999,increased,O
PMC34463540_501,7999,risk,O
PMC34463540_501,7999,of,O
PMC34463540_501,7999,endometrial,B-Disease
PMC34463540_501,7999,cancer,I-Disease
PMC34463540_501,7999,",",O
PMC34463540_501,7999,particularly,O
PMC34463540_501,7999,rare,O
PMC34463540_501,7999,tumor,O
PMC34463540_501,7999,types,O
PMC34463540_501,7999,associated,O
PMC34463540_501,7999,with,O
PMC34463540_501,7999,poor,O
PMC34463540_501,7999,prognosis,O
PMC34463540_501,7999,0,O
PMC34468580_364,8000,CONCLUSION,O
PMC34468580_364,8000,:,O
PMC34468580_364,8000,Administration,O
PMC34468580_364,8000,of,O
PMC34468580_364,8000,oxybutynin,O
PMC34468580_364,8000,successfully,O
PMC34468580_364,8000,reduced,O
PMC34468580_364,8000,excessive,O
PMC34468580_364,8000,sweating,B-Symptom
PMC34468580_364,8000,in,O
PMC34468580_364,8000,patients,O
PMC34468580_364,8000,experiencing,O
PMC34468580_364,8000,a,O
PMC34468580_364,8000,major,O
PMC34468580_364,8000,depressive,B-Disease
PMC34468580_364,8000,disorder,I-Disease
PMC34468580_364,8000,and,O
PMC34468580_364,8000,treated,O
PMC34468580_364,8000,with,O
PMC34468580_364,8000,sertraline,B-Drug
PMC34468580_364,8000,0,O
PMC34519890_940,8001,Her,O
PMC34519890_940,8001,worsening,O
PMC34519890_940,8001,in,O
PMC34519890_940,8001,the,O
PMC34519890_940,8001,first,O
PMC34519890_940,8001,year,O
PMC34519890_940,8001,was,O
PMC34519890_940,8001,characterized,O
PMC34519890_940,8001,by,O
PMC34519890_940,8001,obsessive,B-Symptom
PMC34519890_940,8001,-,I-Symptom
PMC34519890_940,8001,compulsive,I-Symptom
PMC34519890_940,8001,behaviours,I-Symptom
PMC34519890_940,8001,",",O
PMC34519890_940,8001,body,O
PMC34519890_940,8001,-,O
PMC34519890_940,8001,image,O
PMC34519890_940,8001,misperceptions,O
PMC34519890_940,8001,and,O
PMC34519890_940,8001,panic,B-Symptom
PMC34519890_940,8001,attacks,I-Symptom
PMC34519890_940,8001,",",O
PMC34519890_940,8001,improved,O
PMC34519890_940,8001,for,O
PMC34519890_940,8001,a,O
PMC34519890_940,8001,period,O
PMC34519890_940,8001,using,O
PMC34519890_940,8001,olanzapine,B-Drug
PMC34519890_940,8001,0,O
PMC34523120_232,8002,We,O
PMC34523120_232,8002,hereby,O
PMC34523120_232,8002,report,O
PMC34523120_232,8002,our,O
PMC34523120_232,8002,experience,O
PMC34523120_232,8002,with,O
PMC34523120_232,8002,topiramate,B-Drug
PMC34523120_232,8002,treatment,O
PMC34523120_232,8002,in,O
PMC34523120_232,8002,patients,O
PMC34523120_232,8002,with,O
PMC34523120_232,8002,refractory,O
PMC34523120_232,8002,CDH,O
PMC34523120_232,8002,0,O
PMC34616470_796,8003,Thus,O
PMC34616470_796,8003,",",O
PMC34616470_796,8003,add,O
PMC34616470_796,8003,-,O
PMC34616470_796,8003,on,O
PMC34616470_796,8003,treatment,O
PMC34616470_796,8003,with,O
PMC34616470_796,8003,lamotrigine,B-Drug
PMC34616470_796,8003,alone,O
PMC34616470_796,8003,or,O
PMC34616470_796,8003,in,O
PMC34616470_796,8003,combination,O
PMC34616470_796,8003,with,O
PMC34616470_796,8003,olanzapine,B-Drug
PMC34616470_796,8003,was,O
PMC34616470_796,8003,an,O
PMC34616470_796,8003,effective,O
PMC34616470_796,8003,strategy,O
PMC34616470_796,8003,to,O
PMC34616470_796,8003,improve,O
PMC34616470_796,8003,the,O
PMC34616470_796,8003,quality,O
PMC34616470_796,8003,of,O
PMC34616470_796,8003,life,O
PMC34616470_796,8003,in,O
PMC34616470_796,8003,bipolar,B-Disease
PMC34616470_796,8003,depression,I-Disease
PMC34616470_796,8003,0,O
PMC34616470_822,8004,Subsyndromal,O
PMC34616470_822,8004,depression,B-Disease
PMC34616470_822,8004,that,O
PMC34616470_822,8004,present,O
PMC34616470_822,8004,after,O
PMC34616470_822,8004,the,O
PMC34616470_822,8004,disappearance,O
PMC34616470_822,8004,of,O
PMC34616470_822,8004,the,O
PMC34616470_822,8004,manic,O
PMC34616470_822,8004,or,O
PMC34616470_822,8004,mixed,O
PMC34616470_822,8004,state,O
PMC34616470_822,8004,was,O
PMC34616470_822,8004,suggested,O
PMC34616470_822,8004,to,O
PMC34616470_822,8004,be,O
PMC34616470_822,8004,practical,O
PMC34616470_822,8004,indication,O
PMC34616470_822,8004,for,O
PMC34616470_822,8004,the,O
PMC34616470_822,8004,use,O
PMC34616470_822,8004,of,O
PMC34616470_822,8004,lamotrigine,B-Drug
PMC34616470_822,8004,0,O
PMC34616470_855,8005,Case,O
PMC34616470_855,8005,_,O
PMC34616470_855,8005,_,O
PMC34616470_855,8005,number,O
PMC34616470_855,8005,_,O
PMC34616470_855,8005,_,O
PMC34616470_855,8005,showed,O
PMC34616470_855,8005,hippocampal,O
PMC34616470_855,8005,atrophy,O
PMC34616470_855,8005,and,O
PMC34616470_855,8005,a,O
PMC34616470_855,8005,persistent,O
PMC34616470_855,8005,dull,O
PMC34616470_855,8005,headache,B-Symptom
PMC34616470_855,8005,that,O
PMC34616470_855,8005,preceded,O
PMC34616470_855,8005,the,O
PMC34616470_855,8005,use,O
PMC34616470_855,8005,of,O
PMC34616470_855,8005,lamotrigine,B-Drug
PMC34616470_855,8005,0,O
PMC34661310_647,8006,XELIRI,O
PMC34661310_647,8006,-,O
PMC34661310_647,8006,bevacizumab,O
PMC34661310_647,8006,versus,O
PMC34661310_647,8006,FOLFIRI,O
PMC34661310_647,8006,-,O
PMC34661310_647,8006,bevacizumab,B-Drug
PMC34661310_647,8006,as,O
PMC34661310_647,8006,first,O
PMC34661310_647,8006,-,O
PMC34661310_647,8006,line,O
PMC34661310_647,8006,treatment,O
PMC34661310_647,8006,in,O
PMC34661310_647,8006,patients,O
PMC34661310_647,8006,with,O
PMC34661310_647,8006,metastatic,B-Disease
PMC34661310_647,8006,colorectal,I-Disease
PMC34661310_647,8006,cancer,I-Disease
PMC34661310_647,8006,:,O
PMC34661310_647,8006,a,O
PMC34661310_647,8006,Hellenic,O
PMC34661310_647,8006,Cooperative,O
PMC34661310_647,8006,Oncology,O
PMC34661310_647,8006,Group,O
PMC34661310_647,8006,phase,O
PMC34661310_647,8006,II,O
PMC34661310_647,8006,trial,O
PMC34661310_647,8006,with,O
PMC34661310_647,8006,collateral,O
PMC34661310_647,8006,biomarker,O
PMC34661310_647,8006,analysis,O
PMC34661310_647,8006,0,O
PMC34661330_293,8007,We,O
PMC34661330_293,8007,processed,O
PMC34661330_293,8007,and,O
PMC34661330_293,8007,analysed,O
PMC34661330_293,8007,CSF,O
PMC34661330_293,8007,samples,O
PMC34661330_293,8007,from,O
PMC34661330_293,8007,a,O
PMC34661330_293,8007,total,O
PMC34661330_293,8007,of,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,number,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,patients,O
PMC34661330_293,8007,with,O
PMC34661330_293,8007,SPMS,B-Disease
PMC34661330_293,8007,",",O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,number,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,patients,O
PMC34661330_293,8007,with,O
PMC34661330_293,8007,SPMS,O
PMC34661330_293,8007,treated,O
PMC34661330_293,8007,with,O
PMC34661330_293,8007,lamotrigine,B-Drug
PMC34661330_293,8007,",",O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,number,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,patients,O
PMC34661330_293,8007,with,O
PMC34661330_293,8007,non,B-Disease
PMC34661330_293,8007,-,I-Disease
PMC34661330_293,8007,inflammatory,I-Disease
PMC34661330_293,8007,neurological,I-Disease
PMC34661330_293,8007,disorders,I-Disease
PMC34661330_293,8007,(,O
PMC34661330_293,8007,NIND,O
PMC34661330_293,8007,),O
PMC34661330_293,8007,and,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,number,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,healthy,O
PMC34661330_293,8007,controls,O
PMC34661330_293,8007,(,O
PMC34661330_293,8007,HC,O
PMC34661330_293,8007,),O
PMC34661330_293,8007,for,O
PMC34661330_293,8007,the,O
PMC34661330_293,8007,levels,O
PMC34661330_293,8007,of,O
PMC34661330_293,8007,these,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,number,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,_,O
PMC34661330_293,8007,selected,O
PMC34661330_293,8007,potential,O
PMC34661330_293,8007,protein,O
PMC34661330_293,8007,biomarkers,O
PMC34661330_293,8007,0,O
PMC34760820_563,8008,Chronic,O
PMC34760820_563,8008,migraine,O
PMC34760820_563,8008,prevention,O
PMC34760820_563,8008,with,O
PMC34760820_563,8008,topiramate,B-Drug
PMC34760820_563,8008,0,O
PMC34808860_1035,8009,Medication,O
PMC34808860_1035,8009,adherence,O
PMC34808860_1035,8009,and,O
PMC34808860_1035,8009,utilization,O
PMC34808860_1035,8009,in,O
PMC34808860_1035,8009,patients,O
PMC34808860_1035,8009,with,O
PMC34808860_1035,8009,schizophrenia,B-Disease
PMC34808860_1035,8009,or,O
PMC34808860_1035,8009,bipolar,B-Disease
PMC34808860_1035,8009,disorder,I-Disease
PMC34808860_1035,8009,receiving,O
PMC34808860_1035,8009,aripiprazole,O
PMC34808860_1035,8009,",",O
PMC34808860_1035,8009,quetiapine,B-Drug
PMC34808860_1035,8009,",",O
PMC34808860_1035,8009,or,O
PMC34808860_1035,8009,ziprasidone,B-Drug
PMC34808860_1035,8009,at,O
PMC34808860_1035,8009,hospital,O
PMC34808860_1035,8009,discharge,O
PMC34808860_1035,8009,:,O
PMC34808860_1035,8009,a,O
PMC34808860_1035,8009,retrospective,O
PMC34808860_1035,8009,cohort,O
PMC34808860_1035,8009,study,O
PMC34808860_1035,8009,0,O
PMC34808860_817,8010,METHODS,O
PMC34808860_817,8010,:,O
PMC34808860_817,8010,Using,O
PMC34808860_817,8010,a,O
PMC34808860_817,8010,database,O
PMC34808860_817,8010,linking,O
PMC34808860_817,8010,hospital,O
PMC34808860_817,8010,admission,O
PMC34808860_817,8010,records,O
PMC34808860_817,8010,to,O
PMC34808860_817,8010,health,O
PMC34808860_817,8010,insurance,O
PMC34808860_817,8010,claims,O
PMC34808860_817,8010,",",O
PMC34808860_817,8010,we,O
PMC34808860_817,8010,identified,O
PMC34808860_817,8010,all,O
PMC34808860_817,8010,patients,O
PMC34808860_817,8010,hospitalized,O
PMC34808860_817,8010,for,O
PMC34808860_817,8010,schizophrenia,B-Disease
PMC34808860_817,8010,(,O
PMC34808860_817,8010,ICD,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,number,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,-,O
PMC34808860_817,8010,CM,O
PMC34808860_817,8010,diagnosis,O
PMC34808860_817,8010,code,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,number,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,_,O
PMC34808860_817,8010,0,O
PMC34808860_817,8011,XX,O
PMC34808860_817,8011,),O
PMC34808860_817,8011,or,O
PMC34808860_817,8011,bipolar,B-Disease
PMC34808860_817,8011,disorder,I-Disease
PMC34808860_817,8011,(,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,number,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,",",O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,number,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,",",O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,number,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,_,O
PMC34808860_817,8011,0,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,number,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,),O
PMC34808860_817,8012,between,O
PMC34808860_817,8012,January,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,number,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,",",O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,number,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,and,O
PMC34808860_817,8012,September,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,number,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,",",O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,number,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,_,O
PMC34808860_817,8012,who,O
PMC34808860_817,8012,received,O
PMC34808860_817,8012,aripiprazole,O
PMC34808860_817,8012,",",O
PMC34808860_817,8012,quetiapine,B-Drug
PMC34808860_817,8012,",",O
PMC34808860_817,8012,or,O
PMC34808860_817,8012,ziprasidone,B-Drug
PMC34808860_817,8012,at,O
PMC34808860_817,8012,discharge,O
PMC34808860_817,8012,0,O
PMC34842900_1013,8013,MATERIALS,O
PMC34842900_1013,8013,AND,O
PMC34842900_1013,8013,METHODS,O
PMC34842900_1013,8013,:,O
PMC34842900_1013,8013,Ten,O
PMC34842900_1013,8013,NSCLC,B-Disease
PMC34842900_1013,8013,patients,O
PMC34842900_1013,8013,treated,O
PMC34842900_1013,8013,with,O
PMC34842900_1013,8013,bevacizumab,B-Drug
PMC34842900_1013,8013,underwent,O
PMC34842900_1013,8013,DECT,O
PMC34842900_1013,8013,0,O
PMC34856260_267,8014,Phase,O
PMC34856260_267,8014,I,O
PMC34856260_267,8014,trial,O
PMC34856260_267,8014,of,O
PMC34856260_267,8014,split,O
PMC34856260_267,8014,-,O
PMC34856260_267,8014,dose,O
PMC34856260_267,8014,induction,O
PMC34856260_267,8014,docetaxel,B-Drug
PMC34856260_267,8014,",",O
PMC34856260_267,8014,cisplatin,O
PMC34856260_267,8014,",",O
PMC34856260_267,8014,and,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,number,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,-,O
PMC34856260_267,8014,fluorouracil,O
PMC34856260_267,8014,(,O
PMC34856260_267,8014,TPF,O
PMC34856260_267,8014,),O
PMC34856260_267,8014,chemotherapy,O
PMC34856260_267,8014,followed,O
PMC34856260_267,8014,by,O
PMC34856260_267,8014,curative,O
PMC34856260_267,8014,surgery,O
PMC34856260_267,8014,combined,O
PMC34856260_267,8014,with,O
PMC34856260_267,8014,postoperative,O
PMC34856260_267,8014,radiotherapy,O
PMC34856260_267,8014,in,O
PMC34856260_267,8014,patients,O
PMC34856260_267,8014,with,O
PMC34856260_267,8014,locally,O
PMC34856260_267,8014,advanced,O
PMC34856260_267,8014,oral,O
PMC34856260_267,8014,and,O
PMC34856260_267,8014,oropharyngeal,B-Disease
PMC34856260_267,8014,squamous,I-Disease
PMC34856260_267,8014,cell,I-Disease
PMC34856260_267,8014,cancer,I-Disease
PMC34856260_267,8014,(,O
PMC34856260_267,8014,TISOC,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,number,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,_,O
PMC34856260_267,8014,),O
PMC34856260_267,8014,0,O
PMC34888660_240,8015,OBJECTIVE,O
PMC34888660_240,8015,:,O
PMC34888660_240,8015,It,O
PMC34888660_240,8015,is,O
PMC34888660_240,8015,postulated,O
PMC34888660_240,8015,that,O
PMC34888660_240,8015,ritalin,B-Drug
PMC34888660_240,8015,may,O
PMC34888660_240,8015,adversely,O
PMC34888660_240,8015,affect,O
PMC34888660_240,8015,sleep,B-Symptom
PMC34888660_240,8015,",",O
PMC34888660_240,8015,appetite,B-Symptom
PMC34888660_240,8015,",",O
PMC34888660_240,8015,weight,B-Symptom
PMC34888660_240,8015,and,O
PMC34888660_240,8015,growth,O
PMC34888660_240,8015,of,O
PMC34888660_240,8015,some,O
PMC34888660_240,8015,children,O
PMC34888660_240,8015,with,O
PMC34888660_240,8015,ADHD,B-Disease
PMC34888660_240,8015,0,O
PMC34888660_640,8016,CONCLUSION,O
PMC34888660_640,8016,:,O
PMC34888660_640,8016,Administration,O
PMC34888660_640,8016,of,O
PMC34888660_640,8016,melatonin,O
PMC34888660_640,8016,along,O
PMC34888660_640,8016,with,O
PMC34888660_640,8016,ritalin,B-Drug
PMC34888660_640,8016,improves,O
PMC34888660_640,8016,height,B-Symptom
PMC34888660_640,8016,and,O
PMC34888660_640,8016,weight,B-Symptom
PMC34888660_640,8016,growth,O
PMC34888660_640,8016,of,O
PMC34888660_640,8016,children,O
PMC34888660_640,8016,0,O
PMC34888660_722,8017,Dietary,O
PMC34888660_722,8017,intake,O
PMC34888660_722,8017,",",O
PMC34888660_722,8017,growth,O
PMC34888660_722,8017,and,O
PMC34888660_722,8017,development,O
PMC34888660_722,8017,of,O
PMC34888660_722,8017,children,O
PMC34888660_722,8017,with,O
PMC34888660_722,8017,ADHD,B-Disease
PMC34888660_722,8017,in,O
PMC34888660_722,8017,a,O
PMC34888660_722,8017,randomized,O
PMC34888660_722,8017,clinical,O
PMC34888660_722,8017,trial,O
PMC34888660_722,8017,of,O
PMC34888660_722,8017,Ritalin,B-Drug
PMC34888660_722,8017,and,O
PMC34888660_722,8017,Melatonin,O
PMC34888660_722,8017,co,O
PMC34888660_722,8017,-,O
PMC34888660_722,8017,administration,O
PMC34888660_722,8017,:,O
PMC34888660_722,8017,Through,O
PMC34888660_722,8017,circadian,B-Symptom
PMC34888660_722,8017,cycle,I-Symptom
PMC34888660_722,8017,modification,I-Symptom
PMC34888660_722,8017,or,O
PMC34888660_722,8017,appetite,O
PMC34888660_722,8017,enhancement,O
PMC34888660_722,8017,?,O
PMC34898180_139,8017,Drugs,O
PMC34898180_139,8017,like,O
PMC34898180_139,8017,methylphenidate,B-Drug
PMC34898180_139,8017,(,O
PMC34898180_139,8017,Ritalin,B-Drug
PMC34898180_139,8017,",",O
PMC34898180_139,8017,Concerta,B-Drug
PMC34898180_139,8017,),O
PMC34898180_139,8017,",",O
PMC34898180_139,8017,dextroamphetamine,O
PMC34898180_139,8017,(,O
PMC34898180_139,8017,Dexedrine,O
PMC34898180_139,8017,),O
PMC34898180_139,8017,",",O
PMC34898180_139,8017,and,O
PMC34898180_139,8017,dextroamphetamine,O
PMC34898180_139,8017,-,O
PMC34898180_139,8017,amphetamine,B-Drug
PMC34898180_139,8017,(,O
PMC34898180_139,8017,Adderall,B-Drug
PMC34898180_139,8017,),O
PMC34898180_139,8017,help,O
PMC34898180_139,8017,people,O
PMC34898180_139,8017,with,O
PMC34898180_139,8017,ADHD,B-Disease
PMC34898180_139,8017,feel,B-Symptom
PMC34898180_139,8017,more,I-Symptom
PMC34898180_139,8017,focused,I-Symptom
PMC34898180_139,8017,0,O
PMC34928440_951,8018,Thalidomide,O
PMC34928440_951,8018,and,O
PMC34928440_951,8018,dexamethasone,O
PMC34928440_951,8018,vs,O
PMC34928440_951,8018,0,O
PMC34928440_951,8019,bortezomib,O
PMC34928440_951,8019,and,O
PMC34928440_951,8019,dexamethasone,O
PMC34928440_951,8019,for,O
PMC34928440_951,8019,melphalan,B-Drug
PMC34928440_951,8019,refractory,O
PMC34928440_951,8019,myeloma,B-Disease
PMC34928440_951,8019,:,O
PMC34928440_951,8019,a,O
PMC34928440_951,8019,randomized,O
PMC34928440_951,8019,study,O
PMC34928440_951,8019,0,O
PMC34930060_414,8020,Treatment,O
PMC34930060_414,8020,was,O
PMC34930060_414,8020,started,O
PMC34930060_414,8020,with,O
PMC34930060_414,8020,prednisone,B-Drug
PMC34930060_414,8020,and,O
PMC34930060_414,8020,azithromycin,O
PMC34930060_414,8020,with,O
PMC34930060_414,8020,subsequent,O
PMC34930060_414,8020,improvement,O
PMC34930060_414,8020,in,O
PMC34930060_414,8020,vision,O
PMC34930060_414,8020,0,O
PMC34961170_803,8021,INTRODUCTION,O
PMC34961170_803,8021,:,O
PMC34961170_803,8021,The,O
PMC34961170_803,8021,taxanes,O
PMC34961170_803,8021,paclitaxel,O
PMC34961170_803,8021,and,O
PMC34961170_803,8021,docetaxel,B-Drug
PMC34961170_803,8021,are,O
PMC34961170_803,8021,widely,O
PMC34961170_803,8021,used,O
PMC34961170_803,8021,in,O
PMC34961170_803,8021,the,O
PMC34961170_803,8021,treatment,O
PMC34961170_803,8021,of,O
PMC34961170_803,8021,breast,O
PMC34961170_803,8021,",",O
PMC34961170_803,8021,ovarian,O
PMC34961170_803,8021,",",O
PMC34961170_803,8021,and,O
PMC34961170_803,8021,other,O
PMC34961170_803,8021,cancers,B-Disease
PMC34961170_803,8021,0,O
PMC34964100_942,8022,Update,O
PMC34964100_942,8022,on,O
PMC34964100_942,8022,extended,O
PMC34964100_942,8022,release,O
PMC34964100_942,8022,quetiapine,B-Drug
PMC34964100_942,8022,fumarate,O
PMC34964100_942,8022,in,O
PMC34964100_942,8022,schizophrenia,B-Disease
PMC34964100_942,8022,and,O
PMC34964100_942,8022,bipolar,B-Disease
PMC34964100_942,8022,disorders,I-Disease
PMC34964100_942,8022,0,O
PMC34965260_121,8023,Controlling,O
PMC34965260_121,8023,for,O
PMC34965260_121,8023,cross,O
PMC34965260_121,8023,-,O
PMC34965260_121,8023,cohort,O
PMC34965260_121,8023,differences,O
PMC34965260_121,8023,",",O
PMC34965260_121,8023,duloxetine,B-Drug
PMC34965260_121,8023,patients,O
PMC34965260_121,8023,were,O
PMC34965260_121,8023,less,O
PMC34965260_121,8023,likely,O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,be,O
PMC34965260_121,8023,hospitalized,O
PMC34965260_121,8023,due,O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,an,O
PMC34965260_121,8023,intervertebral,B-Disease
PMC34965260_121,8023,disc,I-Disease
PMC34965260_121,8023,disorder,I-Disease
PMC34965260_121,8023,or,O
PMC34965260_121,8023,major,B-Disease
PMC34965260_121,8023,depressive,I-Disease
PMC34965260_121,8023,disorder,I-Disease
PMC34965260_121,8023,",",O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,have,O
PMC34965260_121,8023,a,O
PMC34965260_121,8023,physician,O
PMC34965260_121,8023,office,O
PMC34965260_121,8023,visit,O
PMC34965260_121,8023,due,O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,nonspecific,O
PMC34965260_121,8023,backache,O
PMC34965260_121,8023,/,O
PMC34965260_121,8023,other,O
PMC34965260_121,8023,back,B-Symptom
PMC34965260_121,8023,/,I-Symptom
PMC34965260_121,8023,neck,I-Symptom
PMC34965260_121,8023,pain,I-Symptom
PMC34965260_121,8023,(,O
PMC34965260_121,8023,NB,O
PMC34965260_121,8023,/,O
PMC34965260_121,8023,OB,O
PMC34965260_121,8023,/,O
PMC34965260_121,8023,NP,O
PMC34965260_121,8023,),O
PMC34965260_121,8023,disorder,O
PMC34965260_121,8023,",",O
PMC34965260_121,8023,or,O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,go,O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,specialty,O
PMC34965260_121,8023,care,O
PMC34965260_121,8023,due,O
PMC34965260_121,8023,to,O
PMC34965260_121,8023,a,O
PMC34965260_121,8023,soft,O
PMC34965260_121,8023,tissue,O
PMC34965260_121,8023,",",O
PMC34965260_121,8023,NB,O
PMC34965260_121,8023,/,O
PMC34965260_121,8023,OP,O
PMC34965260_121,8023,/,O
PMC34965260_121,8023,NP,O
PMC34965260_121,8023,",",O
PMC34965260_121,8023,or,O
PMC34965260_121,8023,intervertebral,O
PMC34965260_121,8023,disc,O
PMC34965260_121,8023,disorder,O
PMC34965260_121,8023,0,O
PMC34965260_310,8024,METHODS,O
PMC34965260_310,8024,:,O
PMC34965260_310,8024,Commercially,O
PMC34965260_310,8024,insured,O
PMC34965260_310,8024,patients,O
PMC34965260_310,8024,with,O
PMC34965260_310,8024,fibromyalgia,B-Disease
PMC34965260_310,8024,and,O
PMC34965260_310,8024,aged,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,number,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,years,O
PMC34965260_310,8024,who,O
PMC34965260_310,8024,initiated,O
PMC34965260_310,8024,duloxetine,B-Drug
PMC34965260_310,8024,or,O
PMC34965260_310,8024,pregabalin,O
PMC34965260_310,8024,in,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,number,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,with,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,number,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,_,O
PMC34965260_310,8024,-,O
PMC34965260_310,8024,month,O
PMC34965260_310,8024,continuous,O
PMC34965260_310,8024,enrollment,O
PMC34965260_310,8024,before,O
PMC34965260_310,8024,and,O
PMC34965260_310,8024,after,O
PMC34965260_310,8024,initiation,O
PMC34965260_310,8024,were,O
PMC34965260_310,8024,identified,O
PMC34965260_310,8024,0,O
PMC34969030_400,8025,METHODS,O
PMC34969030_400,8025,:,O
PMC34969030_400,8025,The,O
PMC34969030_400,8025,sample,O
PMC34969030_400,8025,included,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,number,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,patients,O
PMC34969030_400,8025,",",O
PMC34969030_400,8025,affected,O
PMC34969030_400,8025,by,O
PMC34969030_400,8025,anxiety,O
PMC34969030_400,8025,and,O
PMC34969030_400,8025,/,O
PMC34969030_400,8025,or,O
PMC34969030_400,8025,mood,B-Disease
PMC34969030_400,8025,disorders,I-Disease
PMC34969030_400,8025,with,O
PMC34969030_400,8025,or,O
PMC34969030_400,8025,without,O
PMC34969030_400,8025,comorbidity,O
PMC34969030_400,8025,",",O
PMC34969030_400,8025,who,O
PMC34969030_400,8025,had,O
PMC34969030_400,8025,been,O
PMC34969030_400,8025,taken,O
PMC34969030_400,8025,Duloxetine,B-Drug
PMC34969030_400,8025,for,O
PMC34969030_400,8025,at,O
PMC34969030_400,8025,least,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,number,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,_,O
PMC34969030_400,8025,month,O
PMC34969030_400,8025,0,O
PMC35037870_924,8026,A,O
PMC35037870_924,8026,comparison,O
PMC35037870_924,8026,of,O
PMC35037870_924,8026,survival,O
PMC35037870_924,8026,outcomes,O
PMC35037870_924,8026,and,O
PMC35037870_924,8026,side,O
PMC35037870_924,8026,effects,O
PMC35037870_924,8026,of,O
PMC35037870_924,8026,toremifene,O
PMC35037870_924,8026,or,O
PMC35037870_924,8026,tamoxifen,B-Drug
PMC35037870_924,8026,therapy,O
PMC35037870_924,8026,in,O
PMC35037870_924,8026,premenopausal,O
PMC35037870_924,8026,estrogen,O
PMC35037870_924,8026,and,O
PMC35037870_924,8026,progesterone,O
PMC35037870_924,8026,receptor,O
PMC35037870_924,8026,positive,O
PMC35037870_924,8026,breast,B-Disease
PMC35037870_924,8026,cancer,I-Disease
PMC35037870_924,8026,patients,O
PMC35037870_924,8026,:,O
PMC35037870_924,8026,a,O
PMC35037870_924,8026,retrospective,O
PMC35037870_924,8026,cohort,O
PMC35037870_924,8026,study,O
PMC35037870_924,8026,0,O
PMC35061530_1009,8027,In,O
PMC35061530_1009,8027,one,O
PMC35061530_1009,8027,case,O
PMC35061530_1009,8027,",",O
PMC35061530_1009,8027,phantom,O
PMC35061530_1009,8027,limb,B-Symptom
PMC35061530_1009,8027,pain,I-Symptom
PMC35061530_1009,8027,responded,O
PMC35061530_1009,8027,partially,O
PMC35061530_1009,8027,to,O
PMC35061530_1009,8027,treatment,O
PMC35061530_1009,8027,with,O
PMC35061530_1009,8027,high,O
PMC35061530_1009,8027,doses,O
PMC35061530_1009,8027,of,O
PMC35061530_1009,8027,paroxetine,B-Drug
PMC35061530_1009,8027,",",O
PMC35061530_1009,8027,and,O
PMC35061530_1009,8027,then,O
PMC35061530_1009,8027,replacement,O
PMC35061530_1009,8027,with,O
PMC35061530_1009,8027,milnacipran,O
PMC35061530_1009,8027,further,O
PMC35061530_1009,8027,improved,O
PMC35061530_1009,8027,the,O
PMC35061530_1009,8027,pain,O
PMC35061530_1009,8027,relief,O
PMC35061530_1009,8027,and,O
PMC35061530_1009,8027,long,O
PMC35061530_1009,8027,-,O
PMC35061530_1009,8027,term,O
PMC35061530_1009,8027,full,O
PMC35061530_1009,8027,pain,O
PMC35061530_1009,8027,relief,O
PMC35061530_1009,8027,was,O
PMC35061530_1009,8027,achieved,O
PMC35061530_1009,8027,0,O
PMC35075520_919,8028,For,O
PMC35075520_919,8028,sleep,O
PMC35075520_919,8028,",",O
PMC35075520_919,8028,pregabalin,O
PMC35075520_919,8028,improved,O
PMC35075520_919,8028,sleep,O
PMC35075520_919,8028,continuity,O
PMC35075520_919,8028,(,O
PMC35075520_919,8028,P,O
PMC35075520_919,8028,<,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,number,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,),O
PMC35075520_919,8028,",",O
PMC35075520_919,8028,whereas,O
PMC35075520_919,8028,duloxetine,B-Drug
PMC35075520_919,8028,increased,O
PMC35075520_919,8028,wake,B-Symptom
PMC35075520_919,8028,and,O
PMC35075520_919,8028,reduced,B-Symptom
PMC35075520_919,8028,total,I-Symptom
PMC35075520_919,8028,sleep,I-Symptom
PMC35075520_919,8028,time,O
PMC35075520_919,8028,(,O
PMC35075520_919,8028,P,O
PMC35075520_919,8028,<,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,number,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,and,O
PMC35075520_919,8028,P,O
PMC35075520_919,8028,<,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,number,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,_,O
PMC35075520_919,8028,),O
PMC35075520_919,8028,0,O
PMC35078930_689,8029,Taken,O
PMC35078930_689,8029,together,O
PMC35078930_689,8029,",",O
PMC35078930_689,8029,our,O
PMC35078930_689,8029,findings,O
PMC35078930_689,8029,suggest,O
PMC35078930_689,8029,that,O
PMC35078930_689,8029,fluoxetine,B-Drug
PMC35078930_689,8029,treatment,O
PMC35078930_689,8029,targets,O
PMC35078930_689,8029,steps,O
PMC35078930_689,8029,of,O
PMC35078930_689,8029,early,O
PMC35078930_689,8029,colon,B-Disease
PMC35078930_689,8029,carcinogenesis,I-Disease
PMC35078930_689,8029,0,O
PMC35141850_481,8030,He,O
PMC35141850_481,8030,developed,O
PMC35141850_481,8030,sleepwalking,B-Symptom
PMC35141850_481,8030,three,O
PMC35141850_481,8030,to,O
PMC35141850_481,8030,four,O
PMC35141850_481,8030,nights,O
PMC35141850_481,8030,per,O
PMC35141850_481,8030,week,O
PMC35141850_481,8030,which,O
PMC35141850_481,8030,resolved,O
PMC35141850_481,8030,after,O
PMC35141850_481,8030,stopping,O
PMC35141850_481,8030,quetiapine,B-Drug
PMC35141850_481,8030,while,O
PMC35141850_481,8030,being,O
PMC35141850_481,8030,compliant,O
PMC35141850_481,8030,with,O
PMC35141850_481,8030,bi,O
PMC35141850_481,8030,-,O
PMC35141850_481,8030,level,O
PMC35141850_481,8030,positive,O
PMC35141850_481,8030,pressure,O
PMC35141850_481,8030,ventilation,O
PMC35141850_481,8030,therapy,O
PMC35141850_481,8030,0,O
PMC35189800_960,8031,A,O
PMC35189800_960,8031,randomized,O
PMC35189800_960,8031,clinical,O
PMC35189800_960,8031,trial,O
PMC35189800_960,8031,of,O
PMC35189800_960,8031,fibromyalgia,B-Disease
PMC35189800_960,8031,treatment,O
PMC35189800_960,8031,with,O
PMC35189800_960,8031,acupuncture,O
PMC35189800_960,8031,compared,O
PMC35189800_960,8031,with,O
PMC35189800_960,8031,fluoxetine,B-Drug
PMC35189800_960,8031,0,O
PMC35192730_799,8032,She,O
PMC35192730_799,8032,was,O
PMC35192730_799,8032,diagnosed,O
PMC35192730_799,8032,with,O
PMC35192730_799,8032,drug,O
PMC35192730_799,8032,-,O
PMC35192730_799,8032,induced,O
PMC35192730_799,8032,hypersensitivity,O
PMC35192730_799,8032,syndrome,O
PMC35192730_799,8032,(,O
PMC35192730_799,8032,DHS,O
PMC35192730_799,8032,),O
PMC35192730_799,8032,to,O
PMC35192730_799,8032,lamotrigine,B-Drug
PMC35192730_799,8032,0,O
PMC35197820_776,8033,Outcomes,O
PMC35197820_776,8033,of,O
PMC35197820_776,8033,sustained,O
PMC35197820_776,8033,-,O
PMC35197820_776,8033,release,O
PMC35197820_776,8033,formulation,O
PMC35197820_776,8033,of,O
PMC35197820_776,8033,valproate,O
PMC35197820_776,8033,and,O
PMC35197820_776,8033,topiramate,B-Drug
PMC35197820_776,8033,monotherapy,O
PMC35197820_776,8033,in,O
PMC35197820_776,8033,patients,O
PMC35197820_776,8033,with,O
PMC35197820_776,8033,epilepsy,B-Disease
PMC35197820_776,8033,:,O
PMC35197820_776,8033,a,O
PMC35197820_776,8033,multi,O
PMC35197820_776,8033,-,O
PMC35197820_776,8033,centre,O
PMC35197820_776,8033,",",O
PMC35197820_776,8033,cohort,O
PMC35197820_776,8033,study,O
PMC35197820_776,8033,0,O
PMC35204630_777,8034,The,O
PMC35204630_777,8034,findings,O
PMC35204630_777,8034,of,O
PMC35204630_777,8034,a,O
PMC35204630_777,8034,systematic,O
PMC35204630_777,8034,review,O
PMC35204630_777,8034,and,O
PMC35204630_777,8034,meta,O
PMC35204630_777,8034,-,O
PMC35204630_777,8034,analysis,O
PMC35204630_777,8034,in,O
PMC35204630_777,8034,this,O
PMC35204630_777,8034,paper,O
PMC35204630_777,8034,indicate,O
PMC35204630_777,8034,that,O
PMC35204630_777,8034,the,O
PMC35204630_777,8034,intravitreal,O
PMC35204630_777,8034,administration,O
PMC35204630_777,8034,of,O
PMC35204630_777,8034,bevacizumab,B-Drug
PMC35204630_777,8034,is,O
PMC35204630_777,8034,superior,O
PMC35204630_777,8034,to,O
PMC35204630_777,8034,nonpharmaceutical,O
PMC35204630_777,8034,treatments,O
PMC35204630_777,8034,for,O
PMC35204630_777,8034,age,O
PMC35204630_777,8034,-,O
PMC35204630_777,8034,related,O
PMC35204630_777,8034,macular,B-Disease
PMC35204630_777,8034,degeneration,I-Disease
PMC35204630_777,8034,(,O
PMC35204630_777,8034,AMD,B-Disease
PMC35204630_777,8034,),O
PMC35204630_777,8034,and,O
PMC35204630_777,8034,diabetic,B-Disease
PMC35204630_777,8034,macular,I-Disease
PMC35204630_777,8034,edema,I-Disease
PMC35204630_777,8034,(,O
PMC35204630_777,8034,DME,B-Disease
PMC35204630_777,8034,),O
PMC35204630_777,8034,",",O
PMC35204630_777,8034,but,O
PMC35204630_777,8034,inconclusive,O
PMC35204630_777,8034,for,O
PMC35204630_777,8034,retinal,O
PMC35204630_777,8034,vein,O
PMC35204630_777,8034,occlusion,O
PMC35204630_777,8034,",",O
PMC35204630_777,8034,given,O
PMC35204630_777,8034,the,O
PMC35204630_777,8034,limited,O
PMC35204630_777,8034,evidence,O
PMC35204630_777,8034,0,O
PMC35225490_20,8035,In,O
PMC35225490_20,8035,ovarian,B-Disease
PMC35225490_20,8035,cancer,I-Disease
PMC35225490_20,8035,cells,O
PMC35225490_20,8035,obtained,O
PMC35225490_20,8035,from,O
PMC35225490_20,8035,patients,O
PMC35225490_20,8035,following,O
PMC35225490_20,8035,platinum,O
PMC35225490_20,8035,-,O
PMC35225490_20,8035,based,O
PMC35225490_20,8035,chemotherapy,O
PMC35225490_20,8035,",",O
PMC35225490_20,8035,unhooking,O
PMC35225490_20,8035,of,O
PMC35225490_20,8035,cisplatin,O
PMC35225490_20,8035,-,O
PMC35225490_20,8035,induced,O
PMC35225490_20,8035,ICLs,O
PMC35225490_20,8035,was,O
PMC35225490_20,8035,observed,O
PMC35225490_20,8035,at,O
PMC35225490_20,8035,_,O
PMC35225490_20,8035,_,O
PMC35225490_20,8035,number,O
PMC35225490_20,8035,_,O
PMC35225490_20,8035,_,O
PMC35225490_20,8035,hours,O
PMC35225490_20,8035,",",O
PMC35225490_20,8035,but,O
PMC35225490_20,8035,no,O
PMC35225490_20,8035,unhooking,O
PMC35225490_20,8035,of,O
PMC35225490_20,8035,melphalan,B-Drug
PMC35225490_20,8035,-,O
PMC35225490_20,8035,induced,O
PMC35225490_20,8035,ICLs,O
PMC35225490_20,8035,0,O
PMC35234420_445,8036,Bortezomib,O
PMC35234420_445,8036,in,O
PMC35234420_445,8036,combination,O
PMC35234420_445,8036,with,O
PMC35234420_445,8036,low,O
PMC35234420_445,8036,-,O
PMC35234420_445,8036,dose,O
PMC35234420_445,8036,oral,O
PMC35234420_445,8036,melphalan,B-Drug
PMC35234420_445,8036,",",O
PMC35234420_445,8036,dexamethasone,O
PMC35234420_445,8036,and,O
PMC35234420_445,8036,thalidomide,O
PMC35234420_445,8036,for,O
PMC35234420_445,8036,relapsed,O
PMC35234420_445,8036,elderly,O
PMC35234420_445,8036,patients,O
PMC35234420_445,8036,with,O
PMC35234420_445,8036,multiple,B-Disease
PMC35234420_445,8036,myeloma,I-Disease
PMC35234420_445,8036,0,O
PMC35273960_572,8037,Methylphenidate,B-Drug
PMC35273960_572,8037,(,O
PMC35273960_572,8037,MPH,B-Drug
PMC35273960_572,8037,),O
PMC35273960_572,8037,",",O
PMC35273960_572,8037,commercially,O
PMC35273960_572,8037,called,O
PMC35273960_572,8037,Ritalin,B-Drug
PMC35273960_572,8037,or,O
PMC35273960_572,8037,Concerta,B-Drug
PMC35273960_572,8037,",",O
PMC35273960_572,8037,has,O
PMC35273960_572,8037,been,O
PMC35273960_572,8037,widely,O
PMC35273960_572,8037,used,O
PMC35273960_572,8037,as,O
PMC35273960_572,8037,a,O
PMC35273960_572,8037,drug,O
PMC35273960_572,8037,for,O
PMC35273960_572,8037,Attention,B-Disease
PMC35273960_572,8037,Deficit,I-Disease
PMC35273960_572,8037,Hyperactivity,I-Disease
PMC35273960_572,8037,Disorder,I-Disease
PMC35273960_572,8037,(,I-Disease
PMC35273960_572,8037,ADHD,I-Disease
PMC35273960_572,8037,),O
PMC35273960_572,8037,0,O
PMC35292250_30,8038,PURPOSE,O
PMC35292250_30,8038,:,O
PMC35292250_30,8038,This,O
PMC35292250_30,8038,study,O
PMC35292250_30,8038,assessed,O
PMC35292250_30,8038,the,O
PMC35292250_30,8038,association,O
PMC35292250_30,8038,between,O
PMC35292250_30,8038,the,O
PMC35292250_30,8038,ratio,O
PMC35292250_30,8038,of,O
PMC35292250_30,8038,leukotriene,O
PMC35292250_30,8038,E,O
PMC35292250_30,8038,(,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,number,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,),O
PMC35292250_30,8038,(,O
PMC35292250_30,8038,LTE,O
PMC35292250_30,8038,(,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,number,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,_,O
PMC35292250_30,8038,),O
PMC35292250_30,8038,),O
PMC35292250_30,8038,to,O
PMC35292250_30,8038,fractional,O
PMC35292250_30,8038,exhaled,O
PMC35292250_30,8038,nitric,O
PMC35292250_30,8038,oxide,O
PMC35292250_30,8038,(,O
PMC35292250_30,8038,FE,O
PMC35292250_30,8038,(,O
PMC35292250_30,8038,NO,O
PMC35292250_30,8038,),O
PMC35292250_30,8038,),O
PMC35292250_30,8038,in,O
PMC35292250_30,8038,the,O
PMC35292250_30,8038,response,O
PMC35292250_30,8038,of,O
PMC35292250_30,8038,children,O
PMC35292250_30,8038,with,O
PMC35292250_30,8038,exercise,O
PMC35292250_30,8038,-,O
PMC35292250_30,8038,induced,O
PMC35292250_30,8038,bronchoconstriction,B-Symptom
PMC35292250_30,8038,(,O
PMC35292250_30,8038,EIB,O
PMC35292250_30,8038,),O
PMC35292250_30,8038,enrolled,O
PMC35292250_30,8038,in,O
PMC35292250_30,8038,a,O
PMC35292250_30,8038,therapeutic,O
PMC35292250_30,8038,trial,O
PMC35292250_30,8038,with,O
PMC35292250_30,8038,montelukast,B-Drug
PMC35292250_30,8038,or,O
PMC35292250_30,8038,inhaled,O
PMC35292250_30,8038,corticosteroid,O
PMC35292250_30,8038,(,O
PMC35292250_30,8038,fluticasone,O
PMC35292250_30,8038,propionate,O
PMC35292250_30,8038,[,O
PMC35292250_30,8038,FP,O
PMC35292250_30,8038,],O
PMC35292250_30,8038,),O
PMC35292250_30,8038,0,O
PMC35308600_21,8039,Rhabdomyolysis,B-Symptom
PMC35308600_21,8039,following,O
PMC35308600_21,8039,Acute,O
PMC35308600_21,8039,Extended,O
PMC35308600_21,8039,-,O
PMC35308600_21,8039,Release,O
PMC35308600_21,8039,Quetiapine,B-Drug
PMC35308600_21,8039,Poisoning,O
PMC35308600_21,8039,:,O
PMC35308600_21,8039,A,O
PMC35308600_21,8039,Case,O
PMC35308600_21,8039,Report,O
PMC35308600_21,8039,0,O
PMC35338440_1017,8040,CASE,O
PMC35338440_1017,8040,PRESENTATION,O
PMC35338440_1017,8040,:,O
PMC35338440_1017,8040,A,O
PMC35338440_1017,8040,_,O
PMC35338440_1017,8040,_,O
PMC35338440_1017,8040,number,O
PMC35338440_1017,8040,_,O
PMC35338440_1017,8040,_,O
PMC35338440_1017,8040,-,O
PMC35338440_1017,8040,year,O
PMC35338440_1017,8040,-,O
PMC35338440_1017,8040,old,O
PMC35338440_1017,8040,Caucasian,O
PMC35338440_1017,8040,woman,O
PMC35338440_1017,8040,with,O
PMC35338440_1017,8040,known,O
PMC35338440_1017,8040,Parkinson,B-Disease
PMC35338440_1017,8040,',I-Disease
PMC35338440_1017,8040,s,I-Disease
PMC35338440_1017,8040,disease,I-Disease
PMC35338440_1017,8040,was,O
PMC35338440_1017,8040,being,O
PMC35338440_1017,8040,treated,O
PMC35338440_1017,8040,with,O
PMC35338440_1017,8040,quetiapine,B-Drug
PMC35338440_1017,8040,for,O
PMC35338440_1017,8040,hallucinations,B-Symptom
PMC35338440_1017,8040,0,O
PMC35345760_161,8041,Prescriptions,O
PMC35345760_161,8041,for,O
PMC35345760_161,8041,lithium,O
PMC35345760_161,8041,",",O
PMC35345760_161,8041,lamotrigine,B-Drug
PMC35345760_161,8041,",",O
PMC35345760_161,8041,carbamazepine,O
PMC35345760_161,8041,and,O
PMC35345760_161,8041,valproate,O
PMC35345760_161,8041,were,O
PMC35345760_161,8041,used,O
PMC35345760_161,8041,as,O
PMC35345760_161,8041,proxies,O
PMC35345760_161,8041,for,O
PMC35345760_161,8041,bipolar,B-Disease
PMC35345760_161,8041,disorder,I-Disease
PMC35345760_161,8041,0,O
PMC35369430_59,8042,CONCLUSION,O
PMC35369430_59,8042,:,O
PMC35369430_59,8042,The,O
PMC35369430_59,8042,results,O
PMC35369430_59,8042,from,O
PMC35369430_59,8042,this,O
PMC35369430_59,8042,study,O
PMC35369430_59,8042,indicated,O
PMC35369430_59,8042,that,O
PMC35369430_59,8042,topiramate,B-Drug
PMC35369430_59,8042,reduces,O
PMC35369430_59,8042,voluntary,O
PMC35369430_59,8042,alcohol,O
PMC35369430_59,8042,intake,O
PMC35369430_59,8042,and,O
PMC35369430_59,8042,support,O
PMC35369430_59,8042,our,O
PMC35369430_59,8042,previous,O
PMC35369430_59,8042,findings,O
PMC35369430_59,8042,that,O
PMC35369430_59,8042,the,O
PMC35369430_59,8042,increase,O
PMC35369430_59,8042,of,O
PMC35369430_59,8042,beta,O
PMC35369430_59,8042,-,O
PMC35369430_59,8042,endorphin,O
PMC35369430_59,8042,level,O
PMC35369430_59,8042,is,O
PMC35369430_59,8042,responsible,O
PMC35369430_59,8042,at,O
PMC35369430_59,8042,least,O
PMC35369430_59,8042,partly,O
PMC35369430_59,8042,for,O
PMC35369430_59,8042,the,O
PMC35369430_59,8042,effectiveness,O
PMC35369430_59,8042,of,O
PMC35369430_59,8042,drugs,O
PMC35369430_59,8042,in,O
PMC35369430_59,8042,treating,O
PMC35369430_59,8042,the,O
PMC35369430_59,8042,alcohol,O
PMC35369430_59,8042,addiction,O
PMC35369430_59,8042,0,O
PMC35483750_570,8043,The,O
PMC35483750_570,8043,anticonvulsant,O
PMC35483750_570,8043,",",O
PMC35483750_570,8043,lamotrigine,B-Drug
PMC35483750_570,8043,(,O
PMC35483750_570,8043,LMG,B-Drug
PMC35483750_570,8043,),O
PMC35483750_570,8043,",",O
PMC35483750_570,8043,reduces,O
PMC35483750_570,8043,interictal,O
PMC35483750_570,8043,epileptiform,O
PMC35483750_570,8043,discharges,O
PMC35483750_570,8043,and,O
PMC35483750_570,8043,is,O
PMC35483750_570,8043,effective,O
PMC35483750_570,8043,in,O
PMC35483750_570,8043,seizures,B-Symptom
PMC35483750_570,8043,in,O
PMC35483750_570,8043,patients,O
PMC35483750_570,8043,with,O
PMC35483750_570,8043,both,O
PMC35483750_570,8043,primary,B-Disease
PMC35483750_570,8043,and,I-Disease
PMC35483750_570,8043,partial,I-Disease
PMC35483750_570,8043,epilepsy,I-Disease
PMC35483750_570,8043,syndromes,O
PMC35483750_570,8043,0,O
PMC35492830_922,8044,The,O
PMC35492830_922,8044,high,O
PMC35492830_922,8044,dropout,O
PMC35492830_922,8044,rate,O
PMC35492830_922,8044,due,O
PMC35492830_922,8044,to,O
PMC35492830_922,8044,adverse,O
PMC35492830_922,8044,events,O
PMC35492830_922,8044,suggests,O
PMC35492830_922,8044,that,O
PMC35492830_922,8044,some,O
PMC35492830_922,8044,MDD,B-Disease
PMC35492830_922,8044,patients,O
PMC35492830_922,8044,may,O
PMC35492830_922,8044,not,O
PMC35492830_922,8044,be,O
PMC35492830_922,8044,able,O
PMC35492830_922,8044,to,O
PMC35492830_922,8044,tolerate,O
PMC35492830_922,8044,quetiapine,B-Drug
PMC35492830_922,8044,XR,O
PMC35492830_922,8044,0,O
PMC35513990_168,8045,Durable,O
PMC35513990_168,8045,complete,O
PMC35513990_168,8045,remission,O
PMC35513990_168,8045,of,O
PMC35513990_168,8045,a,O
PMC35513990_168,8045,brainstem,O
PMC35513990_168,8045,glioma,O
PMC35513990_168,8045,treated,O
PMC35513990_168,8045,with,O
PMC35513990_168,8045,a,O
PMC35513990_168,8045,combination,O
PMC35513990_168,8045,of,O
PMC35513990_168,8045,bevacizumab,B-Drug
PMC35513990_168,8045,and,O
PMC35513990_168,8045,cetuximab,O
PMC35513990_168,8045,0,O
PMC35536500_536,8046,OBJECTIVE,O
PMC35536500_536,8046,:,O
PMC35536500_536,8046,To,O
PMC35536500_536,8046,compare,O
PMC35536500_536,8046,total,O
PMC35536500_536,8046,medical,O
PMC35536500_536,8046,costs,O
PMC35536500_536,8046,and,O
PMC35536500_536,8046,utilization,O
PMC35536500_536,8046,over,O
PMC35536500_536,8046,a,O
PMC35536500_536,8046,_,O
PMC35536500_536,8046,_,O
PMC35536500_536,8046,number,O
PMC35536500_536,8046,_,O
PMC35536500_536,8046,_,O
PMC35536500_536,8046,-,O
PMC35536500_536,8046,month,O
PMC35536500_536,8046,period,O
PMC35536500_536,8046,in,O
PMC35536500_536,8046,commercially,O
PMC35536500_536,8046,insured,O
PMC35536500_536,8046,patients,O
PMC35536500_536,8046,receiving,O
PMC35536500_536,8046,FDA,O
PMC35536500_536,8046,-,O
PMC35536500_536,8046,approved,O
PMC35536500_536,8046,adjunctive,O
PMC35536500_536,8046,atypical,O
PMC35536500_536,8046,antipsychotics,O
PMC35536500_536,8046,(,O
PMC35536500_536,8046,aripiprazole,O
PMC35536500_536,8046,",",O
PMC35536500_536,8046,olanzapine,B-Drug
PMC35536500_536,8046,",",O
PMC35536500_536,8046,or,O
PMC35536500_536,8046,quetiapine,B-Drug
PMC35536500_536,8046,),O
PMC35536500_536,8046,for,O
PMC35536500_536,8046,depression,B-Disease
PMC35536500_536,8046,0,O
PMC35542280_443,8047,A,O
PMC35542280_443,8047,critical,O
PMC35542280_443,8047,review,O
PMC35542280_443,8047,of,O
PMC35542280_443,8047,the,O
PMC35542280_443,8047,recent,O
PMC35542280_443,8047,literature,O
PMC35542280_443,8047,and,O
PMC35542280_443,8047,selected,O
PMC35542280_443,8047,therapy,O
PMC35542280_443,8047,guidelines,O
PMC35542280_443,8047,since,O
PMC35542280_443,8047,_,O
PMC35542280_443,8047,_,O
PMC35542280_443,8047,number,O
PMC35542280_443,8047,_,O
PMC35542280_443,8047,_,O
PMC35542280_443,8047,on,O
PMC35542280_443,8047,the,O
PMC35542280_443,8047,use,O
PMC35542280_443,8047,of,O
PMC35542280_443,8047,lamotrigine,B-Drug
PMC35542280_443,8047,in,O
PMC35542280_443,8047,bipolar,B-Disease
PMC35542280_443,8047,disorder,I-Disease
PMC35542280_443,8047,0,O
PMC35545360_469,8048,BACKGROUND,O
PMC35545360_469,8048,:,O
PMC35545360_469,8048,To,O
PMC35545360_469,8048,examine,O
PMC35545360_469,8048,the,O
PMC35545360_469,8048,efficacy,O
PMC35545360_469,8048,of,O
PMC35545360_469,8048,lisdexamfetamine,B-Drug
PMC35545360_469,8048,dimesylate,I-Drug
PMC35545360_469,8048,(,O
PMC35545360_469,8048,LDX,O
PMC35545360_469,8048,),O
PMC35545360_469,8048,in,O
PMC35545360_469,8048,adults,O
PMC35545360_469,8048,with,O
PMC35545360_469,8048,attention,B-Disease
PMC35545360_469,8048,-,I-Disease
PMC35545360_469,8048,deficit,I-Disease
PMC35545360_469,8048,/,I-Disease
PMC35545360_469,8048,hyperactivity,I-Disease
PMC35545360_469,8048,disorder,I-Disease
PMC35545360_469,8048,(,I-Disease
PMC35545360_469,8048,ADHD,I-Disease
PMC35545360_469,8048,),O
PMC35545360_469,8048,who,O
PMC35545360_469,8048,remained,O
PMC35545360_469,8048,symptomatic,O
PMC35545360_469,8048,(,O
PMC35545360_469,8048,ADHD,O
PMC35545360_469,8048,Rating,O
PMC35545360_469,8048,Scale,O
PMC35545360_469,8048,IV,O
PMC35545360_469,8048,[,O
PMC35545360_469,8048,ADHD,O
PMC35545360_469,8048,-,O
PMC35545360_469,8048,RS,O
PMC35545360_469,8048,-,O
PMC35545360_469,8048,IV,O
PMC35545360_469,8048,],O
PMC35545360_469,8048,total,O
PMC35545360_469,8048,score,O
PMC35545360_469,8048,>,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,number,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,),O
PMC35545360_469,8048,on,O
PMC35545360_469,8048,amphetamine,O
PMC35545360_469,8048,(,O
PMC35545360_469,8048,AMPH,O
PMC35545360_469,8048,),O
PMC35545360_469,8048,therapy,O
PMC35545360_469,8048,(,O
PMC35545360_469,8048,mixed,O
PMC35545360_469,8048,AMPH,O
PMC35545360_469,8048,salts,O
PMC35545360_469,8048,and,O
PMC35545360_469,8048,/,O
PMC35545360_469,8048,or,O
PMC35545360_469,8048,d,O
PMC35545360_469,8048,-,O
PMC35545360_469,8048,AMPH,O
PMC35545360_469,8048,formulations,O
PMC35545360_469,8048,),O
PMC35545360_469,8048,prior,O
PMC35545360_469,8048,to,O
PMC35545360_469,8048,enrollment,O
PMC35545360_469,8048,in,O
PMC35545360_469,8048,a,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,number,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,_,O
PMC35545360_469,8048,-,O
PMC35545360_469,8048,week,O
PMC35545360_469,8048,placebo,O
PMC35545360_469,8048,-,O
PMC35545360_469,8048,controlled,O
PMC35545360_469,8048,LDX,O
PMC35545360_469,8048,trial,O
PMC35545360_469,8048,vs,O
PMC35545360_469,8048,the,O
PMC35545360_469,8048,overall,O
PMC35545360_469,8048,study,O
PMC35545360_469,8048,population,O
PMC35545360_469,8048,0,O
PMC35545360_766,8049,Efficacy,O
PMC35545360_766,8049,of,O
PMC35545360_766,8049,lisdexamfetamine,B-Drug
PMC35545360_766,8049,dimesylate,I-Drug
PMC35545360_766,8049,in,O
PMC35545360_766,8049,adults,O
PMC35545360_766,8049,with,O
PMC35545360_766,8049,attention,B-Disease
PMC35545360_766,8049,-,I-Disease
PMC35545360_766,8049,deficit,I-Disease
PMC35545360_766,8049,/,I-Disease
PMC35545360_766,8049,hyperactivity,I-Disease
PMC35545360_766,8049,disorder,I-Disease
PMC35545360_766,8049,previously,O
PMC35545360_766,8049,treated,O
PMC35545360_766,8049,with,O
PMC35545360_766,8049,amphetamines,O
PMC35545360_766,8049,:,O
PMC35545360_766,8049,analyses,O
PMC35545360_766,8049,from,O
PMC35545360_766,8049,a,O
PMC35545360_766,8049,randomized,O
PMC35545360_766,8049,",",O
PMC35545360_766,8049,double,O
PMC35545360_766,8049,-,O
PMC35545360_766,8049,blind,O
PMC35545360_766,8049,",",O
PMC35545360_766,8049,multicenter,O
PMC35545360_766,8049,",",O
PMC35545360_766,8049,placebo,O
PMC35545360_766,8049,-,O
PMC35545360_766,8049,controlled,O
PMC35545360_766,8049,titration,O
PMC35545360_766,8049,study,O
PMC35545360_766,8049,0,O
PMC35555500_772,8050,The,O
PMC35555500_772,8050,median,O
PMC35555500_772,8050,antihyperalgesia,B-Symptom
PMC35555500_772,8050,/,O
PMC35555500_772,8050,analgesia,O
PMC35555500_772,8050,ratio,O
PMC35555500_772,8050,(,O
PMC35555500_772,8050,secondary,O
PMC35555500_772,8050,hyperalgesia,O
PMC35555500_772,8050,/,O
PMC35555500_772,8050,heat,O
PMC35555500_772,8050,injury,O
PMC35555500_772,8050,relative,O
PMC35555500_772,8050,to,O
PMC35555500_772,8050,placebo,O
PMC35555500_772,8050,),O
PMC35555500_772,8050,for,O
PMC35555500_772,8050,low,O
PMC35555500_772,8050,-,O
PMC35555500_772,8050,dose,O
PMC35555500_772,8050,morphine,O
PMC35555500_772,8050,was,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,(,O
PMC35555500_772,8050,interquartile,O
PMC35555500_772,8050,range,O
PMC35555500_772,8050,:,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,;,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,),O
PMC35555500_772,8050,",",O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,(,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,;,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,),O
PMC35555500_772,8050,for,O
PMC35555500_772,8050,high,O
PMC35555500_772,8050,-,O
PMC35555500_772,8050,dose,O
PMC35555500_772,8050,morphine,O
PMC35555500_772,8050,",",O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,(,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,;,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,),O
PMC35555500_772,8050,for,O
PMC35555500_772,8050,low,O
PMC35555500_772,8050,-,O
PMC35555500_772,8050,dose,O
PMC35555500_772,8050,buprenorphine,B-Drug
PMC35555500_772,8050,",",O
PMC35555500_772,8050,and,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,(,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,;,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,),O
PMC35555500_772,8050,for,O
PMC35555500_772,8050,high,O
PMC35555500_772,8050,-,O
PMC35555500_772,8050,dose,O
PMC35555500_772,8050,buprenorphine,B-Drug
PMC35555500_772,8050,(,O
PMC35555500_772,8050,P,O
PMC35555500_772,8050,>,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,number,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,_,O
PMC35555500_772,8050,),O
PMC35555500_772,8050,0,O
PMC35559750_813,8051,PURPOSE,O
PMC35559750_813,8051,:,O
PMC35559750_813,8051,In,O
PMC35559750_813,8051,this,O
PMC35559750_813,8051,paper,O
PMC35559750_813,8051,three,O
PMC35559750_813,8051,cases,O
PMC35559750_813,8051,of,O
PMC35559750_813,8051,deep,O
PMC35559750_813,8051,venous,O
PMC35559750_813,8051,Thrombosis,O
PMC35559750_813,8051,(,O
PMC35559750_813,8051,DVT,O
PMC35559750_813,8051,),O
PMC35559750_813,8051,following,O
PMC35559750_813,8051,the,O
PMC35559750_813,8051,use,O
PMC35559750_813,8051,of,O
PMC35559750_813,8051,olanzapine,B-Drug
PMC35559750_813,8051,and,O
PMC35559750_813,8051,risperidone,O
PMC35559750_813,8051,are,O
PMC35559750_813,8051,presented,O
PMC35559750_813,8051,0,O
PMC35563310_979,8052,CONCLUSION,O
PMC35563310_979,8052,:,O
PMC35563310_979,8052,The,O
PMC35563310_979,8052,efficacy,O
PMC35563310_979,8052,of,O
PMC35563310_979,8052,IM,O
PMC35563310_979,8052,olanzapine,B-Drug
PMC35563310_979,8052,_,O
PMC35563310_979,8052,_,O
PMC35563310_979,8052,number,O
PMC35563310_979,8052,_,O
PMC35563310_979,8052,_,O
PMC35563310_979,8052,mg,O
PMC35563310_979,8052,in,O
PMC35563310_979,8052,patients,O
PMC35563310_979,8052,with,O
PMC35563310_979,8052,exacerbation,O
PMC35563310_979,8052,of,O
PMC35563310_979,8052,schizophrenia,B-Disease
PMC35563310_979,8052,with,O
PMC35563310_979,8052,acute,O
PMC35563310_979,8052,psychotic,O
PMC35563310_979,8052,agitation,B-Symptom
PMC35563310_979,8052,was,O
PMC35563310_979,8052,greater,O
PMC35563310_979,8052,than,O
PMC35563310_979,8052,IM,O
PMC35563310_979,8052,placebo,O
PMC35563310_979,8052,in,O
PMC35563310_979,8052,the,O
PMC35563310_979,8052,primary,O
PMC35563310_979,8052,efficacy,O
PMC35563310_979,8052,measure,O
PMC35563310_979,8052,",",O
PMC35563310_979,8052,PANSS,O
PMC35563310_979,8052,-,O
PMC35563310_979,8052,EC,O
PMC35563310_979,8052,0,O
PMC35581620_969,8053,This,O
PMC35581620_969,8053,finding,O
PMC35581620_969,8053,may,O
PMC35581620_969,8053,be,O
PMC35581620_969,8053,of,O
PMC35581620_969,8053,great,O
PMC35581620_969,8053,potential,O
PMC35581620_969,8053,benefit,O
PMC35581620_969,8053,in,O
PMC35581620_969,8053,chemotherapy,O
PMC35581620_969,8053,of,O
PMC35581620_969,8053,breast,B-Disease
PMC35581620_969,8053,cancer,I-Disease
PMC35581620_969,8053,;,O
PMC35581620_969,8053,since,O
PMC35581620_969,8053,much,O
PMC35581620_969,8053,lower,O
PMC35581620_969,8053,doses,O
PMC35581620_969,8053,of,O
PMC35581620_969,8053,tamoxifen,B-Drug
PMC35581620_969,8053,may,O
PMC35581620_969,8053,be,O
PMC35581620_969,8053,needed,O
PMC35581620_969,8053,to,O
PMC35581620_969,8053,produce,O
PMC35581620_969,8053,the,O
PMC35581620_969,8053,same,O
PMC35581620_969,8053,cytotoxic,O
PMC35581620_969,8053,effect,O
PMC35581620_969,8053,and,O
PMC35581620_969,8053,side,O
PMC35581620_969,8053,effects,O
PMC35581620_969,8053,will,O
PMC35581620_969,8053,be,O
PMC35581620_969,8053,reduced,O
PMC35581620_969,8053,0,O
PMC35605050_718,8054,SSRIs,O
PMC35605050_718,8054,such,O
PMC35605050_718,8054,as,O
PMC35605050_718,8054,fluoxetine,B-Drug
PMC35605050_718,8054,",",O
PMC35605050_718,8054,paroxetine,B-Drug
PMC35605050_718,8054,",",O
PMC35605050_718,8054,sertraline,B-Drug
PMC35605050_718,8054,and,O
PMC35605050_718,8054,citalopram,B-Drug
PMC35605050_718,8054,are,O
PMC35605050_718,8054,not,O
PMC35605050_718,8054,only,O
PMC35605050_718,8054,considered,O
PMC35605050_718,8054,to,O
PMC35605050_718,8054,be,O
PMC35605050_718,8054,free,O
PMC35605050_718,8054,from,O
PMC35605050_718,8054,the,O
PMC35605050_718,8054,cardiotoxicity,O
PMC35605050_718,8054,of,O
PMC35605050_718,8054,their,O
PMC35605050_718,8054,predecessors,O
PMC35605050_718,8054,but,O
PMC35605050_718,8054,also,O
PMC35605050_718,8054,to,O
PMC35605050_718,8054,function,O
PMC35605050_718,8054,as,O
PMC35605050_718,8054,safe,O
PMC35605050_718,8054,and,O
PMC35605050_718,8054,efficacious,O
PMC35605050_718,8054,agents,O
PMC35605050_718,8054,against,O
PMC35605050_718,8054,depression,B-Disease
PMC35605050_718,8054,",",O
PMC35605050_718,8054,platelet,B-Symptom
PMC35605050_718,8054,activation,I-Symptom
PMC35605050_718,8054,",",O
PMC35605050_718,8054,atherosclerosis,B-Disease
PMC35605050_718,8054,and,O
PMC35605050_718,8054,development,O
PMC35605050_718,8054,and,O
PMC35605050_718,8054,prognosis,O
PMC35605050_718,8054,of,O
PMC35605050_718,8054,coronary,O
PMC35605050_718,8054,heart,O
PMC35605050_718,8054,disease,O
PMC35605050_718,8054,0,O
PMC35648210_511,8055,While,O
PMC35648210_511,8055,indicated,O
PMC35648210_511,8055,for,O
PMC35648210_511,8055,schizophrenia,B-Disease
PMC35648210_511,8055,and,O
PMC35648210_511,8055,acute,O
PMC35648210_511,8055,mania,O
PMC35648210_511,8055,",",O
PMC35648210_511,8055,ziprasidone,B-Drug
PMC35648210_511,8055,',O
PMC35648210_511,8055,s,O
PMC35648210_511,8055,evidence,O
PMC35648210_511,8055,base,O
PMC35648210_511,8055,and,O
PMC35648210_511,8055,use,O
PMC35648210_511,8055,in,O
PMC35648210_511,8055,clinical,O
PMC35648210_511,8055,practice,O
PMC35648210_511,8055,extends,O
PMC35648210_511,8055,beyond,O
PMC35648210_511,8055,these,O
PMC35648210_511,8055,regulatory,O
PMC35648210_511,8055,approvals,O
PMC35648210_511,8055,0,O
PMC35667220_685,8056,BCAAs,O
PMC35667220_685,8056,seem,O
PMC35667220_685,8056,to,O
PMC35667220_685,8056,be,O
PMC35667220_685,8056,implicated,O
PMC35667220_685,8056,in,O
PMC35667220_685,8056,mechanisms,O
PMC35667220_685,8056,of,O
PMC35667220_685,8056,recovery,O
PMC35667220_685,8056,from,O
PMC35667220_685,8056,a,O
PMC35667220_685,8056,depressed,B-Disease
PMC35667220_685,8056,state,O
PMC35667220_685,8056,following,O
PMC35667220_685,8056,sertraline,B-Drug
PMC35667220_685,8056,treatment,O
PMC35667220_685,8056,0,O
PMC35684020_711,8057,This,O
PMC35684020_711,8057,study,O
PMC35684020_711,8057,examined,O
PMC35684020_711,8057,clinical,O
PMC35684020_711,8057,response,O
PMC35684020_711,8057,and,O
PMC35684020_711,8057,symptomatic,O
PMC35684020_711,8057,remission,O
PMC35684020_711,8057,in,O
PMC35684020_711,8057,analyses,O
PMC35684020_711,8057,of,O
PMC35684020_711,8057,_,O
PMC35684020_711,8057,_,O
PMC35684020_711,8057,number,O
PMC35684020_711,8057,_,O
PMC35684020_711,8057,_,O
PMC35684020_711,8057,studies,O
PMC35684020_711,8057,of,O
PMC35684020_711,8057,lisdexamfetamine,B-Drug
PMC35684020_711,8057,dimesylate,I-Drug
PMC35684020_711,8057,(,O
PMC35684020_711,8057,LDX,B-Drug
PMC35684020_711,8057,),O
PMC35684020_711,8057,in,O
PMC35684020_711,8057,adults,O
PMC35684020_711,8057,with,O
PMC35684020_711,8057,ADHD,B-Disease
PMC35684020_711,8057,0,O
PMC3569240_618,8058,RESULTS,O
PMC3569240_618,8058,:,O
PMC3569240_618,8058,Data,O
PMC3569240_618,8058,",",O
PMC3569240_618,8058,based,O
PMC3569240_618,8058,on,O
PMC3569240_618,8058,a,O
PMC3569240_618,8058,group,O
PMC3569240_618,8058,of,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,number,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,patients,O
PMC3569240_618,8058,",",O
PMC3569240_618,8058,who,O
PMC3569240_618,8058,were,O
PMC3569240_618,8058,included,O
PMC3569240_618,8058,in,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,number,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,_,O
PMC3569240_618,8058,different,O
PMC3569240_618,8058,randomized,O
PMC3569240_618,8058,clinical,O
PMC3569240_618,8058,trials,O
PMC3569240_618,8058,",",O
PMC3569240_618,8058,confirms,O
PMC3569240_618,8058,that,O
PMC3569240_618,8058,fluoxetine,B-Drug
PMC3569240_618,8058,is,O
PMC3569240_618,8058,safe,O
PMC3569240_618,8058,and,O
PMC3569240_618,8058,effective,O
PMC3569240_618,8058,in,O
PMC3569240_618,8058,the,O
PMC3569240_618,8058,treatment,O
PMC3569240_618,8058,of,O
PMC3569240_618,8058,depression,B-Disease
PMC3569240_618,8058,from,O
PMC3569240_618,8058,the,O
PMC3569240_618,8058,first,O
PMC3569240_618,8058,week,O
PMC3569240_618,8058,of,O
PMC3569240_618,8058,therapy,O
PMC3569240_618,8058,0,O
PMC35700390_994,8059,We,O
PMC35700390_994,8059,describe,O
PMC35700390_994,8059,a,O
PMC35700390_994,8059,unique,O
PMC35700390_994,8059,case,O
PMC35700390_994,8059,of,O
PMC35700390_994,8059,TS,O
PMC35700390_994,8059,with,O
PMC35700390_994,8059,PKD,O
PMC35700390_994,8059,-,O
PMC35700390_994,8059,like,O
PMC35700390_994,8059,episodic,O
PMC35700390_994,8059,dyskinesia,B-Symptom
PMC35700390_994,8059,that,O
PMC35700390_994,8059,responded,O
PMC35700390_994,8059,to,O
PMC35700390_994,8059,carbamazepine,B-Drug
PMC35700390_994,8059,0,O
PMC35701960_727,8060,Pharmacoeconomic,O
PMC35701960_727,8060,evaluation,O
PMC35701960_727,8060,of,O
PMC35701960_727,8060,venlafaxine,B-Drug
PMC35701960_727,8060,compared,O
PMC35701960_727,8060,with,O
PMC35701960_727,8060,citalopram,B-Drug
PMC35701960_727,8060,in,O
PMC35701960_727,8060,generalized,B-Disease
PMC35701960_727,8060,anxiety,I-Disease
PMC35701960_727,8060,disorder,I-Disease
PMC35701960_727,8060,0,O
PMC35734590_265,8061,Carbamazepine,B-Drug
PMC35734590_265,8061,induced,O
PMC35734590_265,8061,severe,O
PMC35734590_265,8061,cutaneous,B-Symptom
PMC35734590_265,8061,vasculitis,I-Symptom
PMC35734590_265,8061,0,O
PMC35744630_479,8062,This,O
PMC35744630_479,8062,case,O
PMC35744630_479,8062,highlights,O
PMC35744630_479,8062,the,O
PMC35744630_479,8062,development,O
PMC35744630_479,8062,of,O
PMC35744630_479,8062,dyskinesia,B-Symptom
PMC35744630_479,8062,in,O
PMC35744630_479,8062,a,O
PMC35744630_479,8062,depressed,B-Disease
PMC35744630_479,8062,patient,O
PMC35744630_479,8062,treated,O
PMC35744630_479,8062,with,O
PMC35744630_479,8062,low,O
PMC35744630_479,8062,dose,O
PMC35744630_479,8062,amisulpride,O
PMC35744630_479,8062,and,O
PMC35744630_479,8062,fluvoxamine,B-Drug
PMC35744630_479,8062,0,O
PMC35745120_331,8063,Comparison,O
PMC35745120_331,8063,of,O
PMC35745120_331,8063,intravitreal,O
PMC35745120_331,8063,bevacizumab,B-Drug
PMC35745120_331,8063,",",O
PMC35745120_331,8063,intravitreal,O
PMC35745120_331,8063,triamcinolone,B-Drug
PMC35745120_331,8063,acetonide,O
PMC35745120_331,8063,",",O
PMC35745120_331,8063,and,O
PMC35745120_331,8063,macular,O
PMC35745120_331,8063,grid,O
PMC35745120_331,8063,augmentation,O
PMC35745120_331,8063,in,O
PMC35745120_331,8063,refractory,B-Disease
PMC35745120_331,8063,diffuse,I-Disease
PMC35745120_331,8063,diabetic,I-Disease
PMC35745120_331,8063,macular,I-Disease
PMC35745120_331,8063,edema,I-Disease
PMC35745120_331,8063,:,O
PMC35745120_331,8063,A,O
PMC35745120_331,8063,prospective,O
PMC35745120_331,8063,",",O
PMC35745120_331,8063,randomized,O
PMC35745120_331,8063,study,O
PMC35745120_331,8063,0,O
PMC35809250_266,8064,Treatment,O
PMC35809250_266,8064,with,O
PMC35809250_266,8064,methylprednisolone,O
PMC35809250_266,8064,and,O
PMC35809250_266,8064,prednisone,B-Drug
PMC35809250_266,8064,led,O
PMC35809250_266,8064,to,O
PMC35809250_266,8064,the,O
PMC35809250_266,8064,resolution,O
PMC35809250_266,8064,of,O
PMC35809250_266,8064,the,O
PMC35809250_266,8064,neutropenia,B-Symptom
PMC35809250_266,8064,and,O
PMC35809250_266,8064,complete,O
PMC35809250_266,8064,recovery,O
PMC35809250_266,8064,of,O
PMC35809250_266,8064,the,O
PMC35809250_266,8064,skin,O
PMC35809250_266,8064,lesions,O
PMC35809250_266,8064,0,O
PMC35812310_964,8065,Thus,O
PMC35812310_964,8065,",",O
PMC35812310_964,8065,the,O
PMC35812310_964,8065,current,O
PMC35812310_964,8065,work,O
PMC35812310_964,8065,identifies,O
PMC35812310_964,8065,a,O
PMC35812310_964,8065,novel,O
PMC35812310_964,8065,pharmacological,O
PMC35812310_964,8065,action,O
PMC35812310_964,8065,of,O
PMC35812310_964,8065,paroxetine,B-Drug
PMC35812310_964,8065,as,O
PMC35812310_964,8065,a,O
PMC35812310_964,8065,protector,O
PMC35812310_964,8065,of,O
PMC35812310_964,8065,endothelial,O
PMC35812310_964,8065,cells,O
PMC35812310_964,8065,against,O
PMC35812310_964,8065,hyperglycemic,O
PMC35812310_964,8065,injury,O
PMC35812310_964,8065,and,O
PMC35812310_964,8065,raises,O
PMC35812310_964,8065,the,O
PMC35812310_964,8065,potential,O
PMC35812310_964,8065,of,O
PMC35812310_964,8065,repurposing,O
PMC35812310_964,8065,of,O
PMC35812310_964,8065,this,O
PMC35812310_964,8065,drug,O
PMC35812310_964,8065,for,O
PMC35812310_964,8065,the,O
PMC35812310_964,8065,experimental,O
PMC35812310_964,8065,therapy,O
PMC35812310_964,8065,of,O
PMC35812310_964,8065,diabetic,O
PMC35812310_964,8065,cardiovascular,O
PMC35812310_964,8065,complications,O
PMC35812310_964,8065,0,O
PMC35823150_270,8066,A,O
PMC35823150_270,8066,direct,O
PMC35823150_270,8066,comparison,O
PMC35823150_270,8066,of,O
PMC35823150_270,8066,efficacy,O
PMC35823150_270,8066,between,O
PMC35823150_270,8066,desloratadine,O
PMC35823150_270,8066,and,O
PMC35823150_270,8066,rupatadine,B-Drug
PMC35823150_270,8066,in,O
PMC35823150_270,8066,seasonal,O
PMC35823150_270,8066,allergic,B-Symptom
PMC35823150_270,8066,rhinoconjunctivitis,I-Symptom
PMC35823150_270,8066,:,O
PMC35823150_270,8066,a,O
PMC35823150_270,8066,randomized,O
PMC35823150_270,8066,",",O
PMC35823150_270,8066,double,O
PMC35823150_270,8066,-,O
PMC35823150_270,8066,blind,O
PMC35823150_270,8066,",",O
PMC35823150_270,8066,placebo,O
PMC35823150_270,8066,-,O
PMC35823150_270,8066,controlled,O
PMC35823150_270,8066,study,O
PMC35823150_270,8066,0,O
PMC35823150_286,8067,The,O
PMC35823150_286,8067,objective,O
PMC35823150_286,8067,of,O
PMC35823150_286,8067,this,O
PMC35823150_286,8067,study,O
PMC35823150_286,8067,was,O
PMC35823150_286,8067,to,O
PMC35823150_286,8067,evaluate,O
PMC35823150_286,8067,the,O
PMC35823150_286,8067,effects,O
PMC35823150_286,8067,of,O
PMC35823150_286,8067,rupatadine,B-Drug
PMC35823150_286,8067,(,O
PMC35823150_286,8067,RUP,O
PMC35823150_286,8067,),O
PMC35823150_286,8067,versus,O
PMC35823150_286,8067,desloratadine,O
PMC35823150_286,8067,(,O
PMC35823150_286,8067,DES,O
PMC35823150_286,8067,),O
PMC35823150_286,8067,in,O
PMC35823150_286,8067,subjects,O
PMC35823150_286,8067,with,O
PMC35823150_286,8067,seasonal,O
PMC35823150_286,8067,allergic,O
PMC35823150_286,8067,rhinitis,O
PMC35823150_286,8067,(,O
PMC35823150_286,8067,SAR,O
PMC35823150_286,8067,),O
PMC35823150_286,8067,0,O
PMC35832440_332,8068,An,O
PMC35832440_332,8068,improvement,O
PMC35832440_332,8068,in,O
PMC35832440_332,8068,hypoxia,B-Symptom
PMC35832440_332,8068,after,O
PMC35832440_332,8068,a,O
PMC35832440_332,8068,single,O
PMC35832440_332,8068,dose,O
PMC35832440_332,8068,of,O
PMC35832440_332,8068,bevacizumab,B-Drug
PMC35832440_332,8068,was,O
PMC35832440_332,8068,predictive,O
PMC35832440_332,8068,of,O
PMC35832440_332,8068,a,O
PMC35832440_332,8068,greater,O
PMC35832440_332,8068,reduction,O
PMC35832440_332,8068,in,O
PMC35832440_332,8068,T,O
PMC35832440_332,8068,_,O
PMC35832440_332,8068,_,O
PMC35832440_332,8068,number,O
PMC35832440_332,8068,_,O
PMC35832440_332,8068,_,O
PMC35832440_332,8068,-,O
PMC35832440_332,8068,weighted,O
PMC35832440_332,8068,contrast,O
PMC35832440_332,8068,-,O
PMC35832440_332,8068,enhanced,O
PMC35832440_332,8068,volumes,O
PMC35832440_332,8068,at,O
PMC35832440_332,8068,first,O
PMC35832440_332,8068,follow,O
PMC35832440_332,8068,-,O
PMC35832440_332,8068,up,O
PMC35832440_332,8068,0,O
PMC35858340_915,8069,Bevacizumab,B-Drug
PMC35858340_915,8069,as,O
PMC35858340_915,8069,first,O
PMC35858340_915,8069,-,O
PMC35858340_915,8069,line,O
PMC35858340_915,8069,therapy,O
PMC35858340_915,8069,in,O
PMC35858340_915,8069,advanced,O
PMC35858340_915,8069,non,O
PMC35858340_915,8069,-,O
PMC35858340_915,8069,small,O
PMC35858340_915,8069,-,O
PMC35858340_915,8069,cell,O
PMC35858340_915,8069,lung,O
PMC35858340_915,8069,cancer,O
PMC35858340_915,8069,:,O
PMC35858340_915,8069,a,O
PMC35858340_915,8069,brazilian,O
PMC35858340_915,8069,center,O
PMC35858340_915,8069,experience,O
PMC35858340_915,8069,0,O
PMC35877150_303,8070,Prednisone,B-Drug
PMC35877150_303,8070,-,O
PMC35877150_303,8070,treated,O
PMC35877150_303,8070,patients,O
PMC35877150_303,8070,had,O
PMC35877150_303,8070,higher,O
PMC35877150_303,8070,levels,O
PMC35877150_303,8070,of,O
PMC35877150_303,8070,depressive,B-Symptom
PMC35877150_303,8070,symptoms,I-Symptom
PMC35877150_303,8070,and,O
PMC35877150_303,8070,subjective,O
PMC35877150_303,8070,and,O
PMC35877150_303,8070,objective,O
PMC35877150_303,8070,cognitive,B-Symptom
PMC35877150_303,8070,deficits,I-Symptom
PMC35877150_303,8070,than,O
PMC35877150_303,8070,those,O
PMC35877150_303,8070,not,O
PMC35877150_303,8070,taking,O
PMC35877150_303,8070,prednisone,O
PMC35877150_303,8070,0,O
PMC35906010_280,8071,In,O
PMC35906010_280,8071,most,O
PMC35906010_280,8071,of,O
PMC35906010_280,8071,these,O
PMC35906010_280,8071,cases,O
PMC35906010_280,8071,(,O
PMC35906010_280,8071,_,O
PMC35906010_280,8071,_,O
PMC35906010_280,8071,number,O
PMC35906010_280,8071,_,O
PMC35906010_280,8071,_,O
PMC35906010_280,8071,%,O
PMC35906010_280,8071,),O
PMC35906010_280,8071,",",O
PMC35906010_280,8071,patients,O
PMC35906010_280,8071,received,O
PMC35906010_280,8071,duloxetine,B-Drug
PMC35906010_280,8071,for,O
PMC35906010_280,8071,the,O
PMC35906010_280,8071,treatment,O
PMC35906010_280,8071,of,O
PMC35906010_280,8071,depression,B-Disease
PMC35906010_280,8071,0,O
PMC35935470_737,8072,Feasibility,O
PMC35935470_737,8072,of,O
PMC35935470_737,8072,perioperative,O
PMC35935470_737,8072,chemotherapy,O
PMC35935470_737,8072,with,O
PMC35935470_737,8072,infusional,O
PMC35935470_737,8072,_,O
PMC35935470_737,8072,_,O
PMC35935470_737,8072,number,O
PMC35935470_737,8072,_,O
PMC35935470_737,8072,_,O
PMC35935470_737,8072,-,O
PMC35935470_737,8072,FU,O
PMC35935470_737,8072,",",O
PMC35935470_737,8072,leucovorin,O
PMC35935470_737,8072,",",O
PMC35935470_737,8072,and,O
PMC35935470_737,8072,oxaliplatin,O
PMC35935470_737,8072,with,O
PMC35935470_737,8072,(,O
PMC35935470_737,8072,FLOT,O
PMC35935470_737,8072,),O
PMC35935470_737,8072,or,O
PMC35935470_737,8072,without,O
PMC35935470_737,8072,(,O
PMC35935470_737,8072,FLO,O
PMC35935470_737,8072,),O
PMC35935470_737,8072,docetaxel,B-Drug
PMC35935470_737,8072,in,O
PMC35935470_737,8072,elderly,O
PMC35935470_737,8072,patients,O
PMC35935470_737,8072,with,O
PMC35935470_737,8072,locally,O
PMC35935470_737,8072,advanced,O
PMC35935470_737,8072,esophagogastric,O
PMC35935470_737,8072,cancer,O
PMC35935470_737,8072,0,O
PMC36002770_384,8073,Although,O
PMC36002770_384,8073,a,O
PMC36002770_384,8073,contribution,O
PMC36002770_384,8073,of,O
PMC36002770_384,8073,aripiprazole,O
PMC36002770_384,8073,and,O
PMC36002770_384,8073,paroxetine,B-Drug
PMC36002770_384,8073,cannot,O
PMC36002770_384,8073,completely,O
PMC36002770_384,8073,be,O
PMC36002770_384,8073,ruled,O
PMC36002770_384,8073,out,O
PMC36002770_384,8073,",",O
PMC36002770_384,8073,the,O
PMC36002770_384,8073,most,O
PMC36002770_384,8073,probable,O
PMC36002770_384,8073,factor,O
PMC36002770_384,8073,underlying,O
PMC36002770_384,8073,the,O
PMC36002770_384,8073,thromboembolic,B-Symptom
PMC36002770_384,8073,event,I-Symptom
PMC36002770_384,8073,seems,O
PMC36002770_384,8073,to,O
PMC36002770_384,8073,be,O
PMC36002770_384,8073,hyperprolactinemia,B-Symptom
PMC36002770_384,8073,",",O
PMC36002770_384,8073,which,O
PMC36002770_384,8073,was,O
PMC36002770_384,8073,caused,O
PMC36002770_384,8073,by,O
PMC36002770_384,8073,amisulpride,O
PMC36002770_384,8073,treatment,O
PMC36002770_384,8073,0,O
PMC36002770_518,8074,In,O
PMC36002770_518,8074,the,O
PMC36002770_518,8074,present,O
PMC36002770_518,8074,paper,O
PMC36002770_518,8074,we,O
PMC36002770_518,8074,describe,O
PMC36002770_518,8074,a,O
PMC36002770_518,8074,case,O
PMC36002770_518,8074,of,O
PMC36002770_518,8074,pulmonary,O
PMC36002770_518,8074,embolism,O
PMC36002770_518,8074,in,O
PMC36002770_518,8074,a,O
PMC36002770_518,8074,female,O
PMC36002770_518,8074,bipolar,B-Disease
PMC36002770_518,8074,patient,O
PMC36002770_518,8074,",",O
PMC36002770_518,8074,receiving,O
PMC36002770_518,8074,treatment,O
PMC36002770_518,8074,with,O
PMC36002770_518,8074,amisulpride,O
PMC36002770_518,8074,",",O
PMC36002770_518,8074,aripiprazole,O
PMC36002770_518,8074,",",O
PMC36002770_518,8074,and,O
PMC36002770_518,8074,paroxetine,B-Drug
PMC36002770_518,8074,0,O
PMC36035280_962,8075,Preliminary,O
PMC36035280_962,8075,findings,O
PMC36035280_962,8075,suggest,O
PMC36035280_962,8075,no,O
PMC36035280_962,8075,significant,O
PMC36035280_962,8075,adverse,O
PMC36035280_962,8075,maternal,O
PMC36035280_962,8075,or,O
PMC36035280_962,8075,neonatal,O
PMC36035280_962,8075,outcomes,O
PMC36035280_962,8075,related,O
PMC36035280_962,8075,to,O
PMC36035280_962,8075,the,O
PMC36035280_962,8075,use,O
PMC36035280_962,8075,of,O
PMC36035280_962,8075,buprenorphine,B-Drug
PMC36035280_962,8075,+,O
PMC36035280_962,8075,naloxone,O
PMC36035280_962,8075,for,O
PMC36035280_962,8075,the,O
PMC36035280_962,8075,treatment,O
PMC36035280_962,8075,of,O
PMC36035280_962,8075,opioid,O
PMC36035280_962,8075,dependence,O
PMC36035280_962,8075,during,O
PMC36035280_962,8075,pregnancy,O
PMC36035280_962,8075,0,O
PMC36070800_853,8076,BACKGROUND,O
PMC36070800_853,8076,:,O
PMC36070800_853,8076,Sertraline,B-Drug
PMC36070800_853,8076,",",O
PMC36070800_853,8076,a,O
PMC36070800_853,8076,selective,O
PMC36070800_853,8076,serotonin,O
PMC36070800_853,8076,reuptake,O
PMC36070800_853,8076,inhibitor,O
PMC36070800_853,8076,(,O
PMC36070800_853,8076,SSRI,O
PMC36070800_853,8076,),O
PMC36070800_853,8076,",",O
PMC36070800_853,8076,is,O
PMC36070800_853,8076,the,O
PMC36070800_853,8076,most,O
PMC36070800_853,8076,commonly,O
PMC36070800_853,8076,prescribed,O
PMC36070800_853,8076,therapy,O
PMC36070800_853,8076,for,O
PMC36070800_853,8076,maternal,O
PMC36070800_853,8076,depression,B-Disease
PMC36070800_853,8076,0,O
PMC36083090_702,8077,An,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,number,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,year,O
PMC36083090_702,8077,old,O
PMC36083090_702,8077,male,O
PMC36083090_702,8077,diagnosed,O
PMC36083090_702,8077,as,O
PMC36083090_702,8077,a,O
PMC36083090_702,8077,case,O
PMC36083090_702,8077,of,O
PMC36083090_702,8077,bipolar,B-Disease
PMC36083090_702,8077,affective,I-Disease
PMC36083090_702,8077,disorder,I-Disease
PMC36083090_702,8077,(,O
PMC36083090_702,8077,BPAD,O
PMC36083090_702,8077,),O
PMC36083090_702,8077,",",O
PMC36083090_702,8077,developed,O
PMC36083090_702,8077,neuroleptic,O
PMC36083090_702,8077,malignant,O
PMC36083090_702,8077,syndrome,O
PMC36083090_702,8077,(,O
PMC36083090_702,8077,NMS,O
PMC36083090_702,8077,),O
PMC36083090_702,8077,following,O
PMC36083090_702,8077,treatment,O
PMC36083090_702,8077,with,O
PMC36083090_702,8077,olanzapine,B-Drug
PMC36083090_702,8077,(,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,number,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,_,O
PMC36083090_702,8077,mg,O
PMC36083090_702,8077,per,O
PMC36083090_702,8077,day,O
PMC36083090_702,8077,),O
PMC36083090_702,8077,",",O
PMC36083090_702,8077,an,O
PMC36083090_702,8077,atypical,O
PMC36083090_702,8077,antipsychotic,O
PMC36083090_702,8077,drug,O
PMC36083090_702,8077,0,O
PMC36088830_142,8078,BACKGROUND,O
PMC36088830_142,8078,:,O
PMC36088830_142,8078,Lisdexamfetamine,B-Drug
PMC36088830_142,8078,dimesylate,I-Drug
PMC36088830_142,8078,(,O
PMC36088830_142,8078,LDX,O
PMC36088830_142,8078,),O
PMC36088830_142,8078,",",O
PMC36088830_142,8078,a,O
PMC36088830_142,8078,prodrug,O
PMC36088830_142,8078,consisting,O
PMC36088830_142,8078,of,O
PMC36088830_142,8078,d,O
PMC36088830_142,8078,-,O
PMC36088830_142,8078,amphetamine,O
PMC36088830_142,8078,and,O
PMC36088830_142,8078,l,O
PMC36088830_142,8078,-,O
PMC36088830_142,8078,lysine,O
PMC36088830_142,8078,",",O
PMC36088830_142,8078,is,O
PMC36088830_142,8078,being,O
PMC36088830_142,8078,studied,O
PMC36088830_142,8078,in,O
PMC36088830_142,8078,clinical,O
PMC36088830_142,8078,trials,O
PMC36088830_142,8078,of,O
PMC36088830_142,8078,major,B-Disease
PMC36088830_142,8078,depressive,I-Disease
PMC36088830_142,8078,disorder,I-Disease
PMC36088830_142,8078,0,O
PMC36169550_437,8079,The,O
PMC36169550_437,8079,patients,O
PMC36169550_437,8079,were,O
PMC36169550_437,8079,given,O
PMC36169550_437,8079,either,O
PMC36169550_437,8079,montelukast,B-Drug
PMC36169550_437,8079,or,O
PMC36169550_437,8079,placebo,O
PMC36169550_437,8079,along,O
PMC36169550_437,8079,with,O
PMC36169550_437,8079,standard,O
PMC36169550_437,8079,therapy,O
PMC36169550_437,8079,throughout,O
PMC36169550_437,8079,the,O
PMC36169550_437,8079,hospital,O
PMC36169550_437,8079,stay,O
PMC36169550_437,8079,for,O
PMC36169550_437,8079,acute,O
PMC36169550_437,8079,asthma,B-Disease
PMC36169550_437,8079,0,O
PMC36169550_505,8080,METHODS,O
PMC36169550_505,8080,:,O
PMC36169550_505,8080,A,O
PMC36169550_505,8080,randomized,O
PMC36169550_505,8080,",",O
PMC36169550_505,8080,double,O
PMC36169550_505,8080,blind,O
PMC36169550_505,8080,",",O
PMC36169550_505,8080,placebo,O
PMC36169550_505,8080,-,O
PMC36169550_505,8080,controlled,O
PMC36169550_505,8080,trial,O
PMC36169550_505,8080,was,O
PMC36169550_505,8080,conducted,O
PMC36169550_505,8080,at,O
PMC36169550_505,8080,the,O
PMC36169550_505,8080,Aga,O
PMC36169550_505,8080,Khan,O
PMC36169550_505,8080,University,O
PMC36169550_505,8080,Hospital,O
PMC36169550_505,8080,to,O
PMC36169550_505,8080,assess,O
PMC36169550_505,8080,the,O
PMC36169550_505,8080,efficacy,O
PMC36169550_505,8080,of,O
PMC36169550_505,8080,oral,O
PMC36169550_505,8080,montelukast,B-Drug
PMC36169550_505,8080,on,O
PMC36169550_505,8080,patients,O
PMC36169550_505,8080,of,O
PMC36169550_505,8080,_,O
PMC36169550_505,8080,_,O
PMC36169550_505,8080,number,O
PMC36169550_505,8080,_,O
PMC36169550_505,8080,_,O
PMC36169550_505,8080,years,O
PMC36169550_505,8080,of,O
PMC36169550_505,8080,age,O
PMC36169550_505,8080,and,O
PMC36169550_505,8080,above,O
PMC36169550_505,8080,who,O
PMC36169550_505,8080,were,O
PMC36169550_505,8080,hospitalized,O
PMC36169550_505,8080,with,O
PMC36169550_505,8080,acute,O
PMC36169550_505,8080,asthma,O
PMC36169550_505,8080,exacerbation,O
PMC36169550_505,8080,0,O
PMC36194360_379,8081,Sentra,O
PMC36194360_379,8081,PM,O
PMC36194360_379,8081,(,O
PMC36194360_379,8081,a,O
PMC36194360_379,8081,Medical,O
PMC36194360_379,8081,Food,O
PMC36194360_379,8081,),O
PMC36194360_379,8081,and,O
PMC36194360_379,8081,Trazodone,B-Drug
PMC36194360_379,8081,in,O
PMC36194360_379,8081,the,O
PMC36194360_379,8081,Management,O
PMC36194360_379,8081,of,O
PMC36194360_379,8081,Sleep,O
PMC36194360_379,8081,Disorders,O
PMC36194360_379,8081,0,O
PMC36194360_433,8082,The,O
PMC36194360_433,8082,results,O
PMC36194360_433,8082,showed,O
PMC36194360_433,8082,improvement,O
PMC36194360_433,8082,in,O
PMC36194360_433,8082,sleep,B-Symptom
PMC36194360_433,8082,latency,I-Symptom
PMC36194360_433,8082,for,O
PMC36194360_433,8082,the,O
PMC36194360_433,8082,Sentra,O
PMC36194360_433,8082,PM,O
PMC36194360_433,8082,and,O
PMC36194360_433,8082,combination,O
PMC36194360_433,8082,of,O
PMC36194360_433,8082,Sentra,O
PMC36194360_433,8082,PM,O
PMC36194360_433,8082,and,O
PMC36194360_433,8082,trazodone,B-Drug
PMC36194360_433,8082,(,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,number,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,and,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,number,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,minutes,O
PMC36194360_433,8082,P,O
PMC36194360_433,8082,<,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,number,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,_,O
PMC36194360_433,8082,),O
PMC36194360_433,8082,0,O
PMC36216570_627,8083,Randomised,O
PMC36216570_627,8083,phase,O
PMC36216570_627,8083,_,O
PMC36216570_627,8083,_,O
PMC36216570_627,8083,number,O
PMC36216570_627,8083,_,O
PMC36216570_627,8083,_,O
PMC36216570_627,8083,open,O
PMC36216570_627,8083,-,O
PMC36216570_627,8083,label,O
PMC36216570_627,8083,trial,O
PMC36216570_627,8083,of,O
PMC36216570_627,8083,first,O
PMC36216570_627,8083,-,O
PMC36216570_627,8083,line,O
PMC36216570_627,8083,treatment,O
PMC36216570_627,8083,with,O
PMC36216570_627,8083,gemcitabine,O
PMC36216570_627,8083,in,O
PMC36216570_627,8083,association,O
PMC36216570_627,8083,with,O
PMC36216570_627,8083,docetaxel,B-Drug
PMC36216570_627,8083,or,O
PMC36216570_627,8083,paclitaxel,O
PMC36216570_627,8083,in,O
PMC36216570_627,8083,women,O
PMC36216570_627,8083,with,O
PMC36216570_627,8083,metastatic,B-Disease
PMC36216570_627,8083,breast,I-Disease
PMC36216570_627,8083,cancer,I-Disease
PMC36216570_627,8083,:,O
PMC36216570_627,8083,a,O
PMC36216570_627,8083,comparison,O
PMC36216570_627,8083,of,O
PMC36216570_627,8083,different,O
PMC36216570_627,8083,schedules,O
PMC36216570_627,8083,and,O
PMC36216570_627,8083,treatments,O
PMC36216570_627,8083,0,O
PMC36224240_368,8084,This,O
PMC36224240_368,8084,case,O
PMC36224240_368,8084,reports,O
PMC36224240_368,8084,the,O
PMC36224240_368,8084,development,O
PMC36224240_368,8084,of,O
PMC36224240_368,8084,severe,O
PMC36224240_368,8084,akathisia,B-Symptom
PMC36224240_368,8084,in,O
PMC36224240_368,8084,a,O
PMC36224240_368,8084,patient,O
PMC36224240_368,8084,being,O
PMC36224240_368,8084,treated,O
PMC36224240_368,8084,with,O
PMC36224240_368,8084,ziprasidone,B-Drug
PMC36224240_368,8084,for,O
PMC36224240_368,8084,bipolar,B-Disease
PMC36224240_368,8084,depression,I-Disease
PMC36224240_368,8084,0,O
PMC36224240_910,8085,Persistent,O
PMC36224240_910,8085,akathisia,B-Symptom
PMC36224240_910,8085,masquerading,O
PMC36224240_910,8085,as,O
PMC36224240_910,8085,agitated,B-Disease
PMC36224240_910,8085,depression,I-Disease
PMC36224240_910,8085,after,O
PMC36224240_910,8085,use,O
PMC36224240_910,8085,of,O
PMC36224240_910,8085,ziprasidone,B-Drug
PMC36224240_910,8085,in,O
PMC36224240_910,8085,the,O
PMC36224240_910,8085,treatment,O
PMC36224240_910,8085,of,O
PMC36224240_910,8085,bipolar,B-Disease
PMC36224240_910,8085,depression,I-Disease
PMC36224240_910,8085,0,O
PMC36264090_970,8086,Clinical,O
PMC36264090_970,8086,utility,O
PMC36264090_970,8086,of,O
PMC36264090_970,8086,phentermine,O
PMC36264090_970,8086,/,O
PMC36264090_970,8086,topiramate,B-Drug
PMC36264090_970,8086,(,O
PMC36264090_970,8086,Qsymia,O
PMC36264090_970,8086,),O
PMC36264090_970,8086,combination,O
PMC36264090_970,8086,for,O
PMC36264090_970,8086,the,O
PMC36264090_970,8086,treatment,O
PMC36264090_970,8086,of,O
PMC36264090_970,8086,obesity,B-Disease
PMC36264090_970,8086,0,O
PMC36265770_363,8087,Then,O
PMC36265770_363,8087,",",O
PMC36265770_363,8087,during,O
PMC36265770_363,8087,therapy,O
PMC36265770_363,8087,with,O
PMC36265770_363,8087,rifampicin,O
PMC36265770_363,8087,monthly,O
PMC36265770_363,8087,",",O
PMC36265770_363,8087,minocycline,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,number,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,mg,O
PMC36265770_363,8087,daily,O
PMC36265770_363,8087,",",O
PMC36265770_363,8087,moxifloxacin,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,number,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,mg,O
PMC36265770_363,8087,daily,O
PMC36265770_363,8087,",",O
PMC36265770_363,8087,and,O
PMC36265770_363,8087,prednisone,B-Drug
PMC36265770_363,8087,(,O
PMC36265770_363,8087,the,O
PMC36265770_363,8087,latter,O
PMC36265770_363,8087,to,O
PMC36265770_363,8087,treat,O
PMC36265770_363,8087,type,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,number,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,_,O
PMC36265770_363,8087,leprosy,B-Symptom
PMC36265770_363,8087,reaction,I-Symptom
PMC36265770_363,8087,),O
PMC36265770_363,8087,",",O
PMC36265770_363,8087,the,O
PMC36265770_363,8087,patient,O
PMC36265770_363,8087,complained,O
PMC36265770_363,8087,of,O
PMC36265770_363,8087,high,O
PMC36265770_363,8087,fever,B-Symptom
PMC36265770_363,8087,associated,O
PMC36265770_363,8087,with,O
PMC36265770_363,8087,erythema,B-Symptom
PMC36265770_363,8087,",",O
PMC36265770_363,8087,swelling,B-Symptom
PMC36265770_363,8087,",",O
PMC36265770_363,8087,and,O
PMC36265770_363,8087,pain,B-Symptom
PMC36265770_363,8087,in,O
PMC36265770_363,8087,the,O
PMC36265770_363,8087,left,O
PMC36265770_363,8087,thigh,O
PMC36265770_363,8087,0,O
PMC36363210_104,8088,The,O
PMC36363210_104,8088,most,O
PMC36363210_104,8088,common,O
PMC36363210_104,8088,substances,O
PMC36363210_104,8088,mentioned,O
PMC36363210_104,8088,with,O
PMC36363210_104,8088,Adderall,B-Drug
PMC36363210_104,8088,were,O
PMC36363210_104,8088,alcohol,O
PMC36363210_104,8088,(,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,number,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,%,O
PMC36363210_104,8088,),O
PMC36363210_104,8088,and,O
PMC36363210_104,8088,stimulants,O
PMC36363210_104,8088,(,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,number,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,%,O
PMC36363210_104,8088,),O
PMC36363210_104,8088,",",O
PMC36363210_104,8088,and,O
PMC36363210_104,8088,the,O
PMC36363210_104,8088,most,O
PMC36363210_104,8088,common,O
PMC36363210_104,8088,side,O
PMC36363210_104,8088,effects,O
PMC36363210_104,8088,were,O
PMC36363210_104,8088,sleep,O
PMC36363210_104,8088,deprivation,O
PMC36363210_104,8088,(,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,number,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,%,O
PMC36363210_104,8088,),O
PMC36363210_104,8088,and,O
PMC36363210_104,8088,loss,B-Symptom
PMC36363210_104,8088,of,I-Symptom
PMC36363210_104,8088,appetite,I-Symptom
PMC36363210_104,8088,(,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,number,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,_,O
PMC36363210_104,8088,%,O
PMC36363210_104,8088,),O
PMC36363210_104,8088,0,O
PMC36372260_1004,8089,Moreover,O
PMC36372260_1004,8089,",",O
PMC36372260_1004,8089,the,O
PMC36372260_1004,8089,number,O
PMC36372260_1004,8089,of,O
PMC36372260_1004,8089,weeks,O
PMC36372260_1004,8089,with,O
PMC36372260_1004,8089,no,O
PMC36372260_1004,8089,or,O
PMC36372260_1004,8089,minimal,O
PMC36372260_1004,8089,anxiety,B-Symptom
PMC36372260_1004,8089,symptoms,O
PMC36372260_1004,8089,was,O
PMC36372260_1004,8089,estimated,O
PMC36372260_1004,8089,to,O
PMC36372260_1004,8089,be,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,number,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,for,O
PMC36372260_1004,8089,pregabalin,O
PMC36372260_1004,8089,and,O
PMC36372260_1004,8089,only,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,number,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,_,O
PMC36372260_1004,8089,for,O
PMC36372260_1004,8089,venlafaxine,B-Drug
PMC36372260_1004,8089,XR,O
PMC36372260_1004,8089,0,O
PMC36372260_1011,8090,CONCLUSIONS,O
PMC36372260_1011,8090,:,O
PMC36372260_1011,8090,Assuming,O
PMC36372260_1011,8090,a,O
PMC36372260_1011,8090,threshold,O
PMC36372260_1011,8090,of,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,number,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,",",O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,number,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,_,O
PMC36372260_1011,8090,per,O
PMC36372260_1011,8090,quality,O
PMC36372260_1011,8090,adjusted,O
PMC36372260_1011,8090,life,O
PMC36372260_1011,8090,year,O
PMC36372260_1011,8090,",",O
PMC36372260_1011,8090,pregabalin,O
PMC36372260_1011,8090,is,O
PMC36372260_1011,8090,cost,O
PMC36372260_1011,8090,-,O
PMC36372260_1011,8090,effective,O
PMC36372260_1011,8090,in,O
PMC36372260_1011,8090,comparison,O
PMC36372260_1011,8090,with,O
PMC36372260_1011,8090,venlafaxine,B-Drug
PMC36372260_1011,8090,XR,O
PMC36372260_1011,8090,in,O
PMC36372260_1011,8090,the,O
PMC36372260_1011,8090,treatment,O
PMC36372260_1011,8090,of,O
PMC36372260_1011,8090,generalized,O
PMC36372260_1011,8090,anxiety,B-Disease
PMC36372260_1011,8090,disorder,I-Disease
PMC36372260_1011,8090,in,O
PMC36372260_1011,8090,Portugal,O
PMC36372260_1011,8090,0,O
PMC36375340_455,8091,Fluoroquinolones,O
PMC36375340_455,8091,like,O
PMC36375340_455,8091,ciprofloxacin,B-Drug
PMC36375340_455,8091,may,O
PMC36375340_455,8091,be,O
PMC36375340_455,8091,considered,O
PMC36375340_455,8091,as,O
PMC36375340_455,8091,a,O
PMC36375340_455,8091,useful,O
PMC36375340_455,8091,alternative,O
PMC36375340_455,8091,in,O
PMC36375340_455,8091,vancomycin,O
PMC36375340_455,8091,-,O
PMC36375340_455,8091,resistant,O
PMC36375340_455,8091,endophthalmitis,O
PMC36375340_455,8091,0,O
PMC36381250_933,8092,The,O
PMC36381250_933,8092,long,O
PMC36381250_933,8092,-,O
PMC36381250_933,8092,term,O
PMC36381250_933,8092,treatment,O
PMC36381250_933,8092,with,O
PMC36381250_933,8092,the,O
PMC36381250_933,8092,estrogen,O
PMC36381250_933,8092,antagonist,O
PMC36381250_933,8092,tamoxifen,B-Drug
PMC36381250_933,8092,",",O
PMC36381250_933,8092,developed,O
PMC36381250_933,8092,to,O
PMC36381250_933,8092,target,O
PMC36381250_933,8092,breast,B-Disease
PMC36381250_933,8092,cancer,I-Disease
PMC36381250_933,8092,overexpressing,O
PMC36381250_933,8092,estrogen,O
PMC36381250_933,8092,receptors,O
PMC36381250_933,8092,ER,O
PMC36381250_933,8092,",",O
PMC36381250_933,8092,presents,O
PMC36381250_933,8092,agonist,O
PMC36381250_933,8092,activity,O
PMC36381250_933,8092,on,O
PMC36381250_933,8092,the,O
PMC36381250_933,8092,G,O
PMC36381250_933,8092,protein,O
PMC36381250_933,8092,-,O
PMC36381250_933,8092,coupled,O
PMC36381250_933,8092,estrogen,O
PMC36381250_933,8092,receptor,O
PMC36381250_933,8092,which,O
PMC36381250_933,8092,is,O
PMC36381250_933,8092,associated,O
PMC36381250_933,8092,with,O
PMC36381250_933,8092,an,O
PMC36381250_933,8092,increased,O
PMC36381250_933,8092,incidence,O
PMC36381250_933,8092,of,O
PMC36381250_933,8092,endometrial,B-Disease
PMC36381250_933,8092,cancer,I-Disease
PMC36381250_933,8092,and,O
PMC36381250_933,8092,breast,O
PMC36381250_933,8092,cancer,O
PMC36381250_933,8092,resistance,O
PMC36381250_933,8092,to,O
PMC36381250_933,8092,hormonotherapy,O
PMC36381250_933,8092,0,O
PMC36385770_941,8093,The,O
PMC36385770_941,8093,results,O
PMC36385770_941,8093,showed,O
PMC36385770_941,8093,that,O
PMC36385770_941,8093,Astragalus,O
PMC36385770_941,8093,granules,O
PMC36385770_941,8093,could,O
PMC36385770_941,8093,effectively,O
PMC36385770_941,8093,reduce,O
PMC36385770_941,8093,URTI,O
PMC36385770_941,8093,in,O
PMC36385770_941,8093,children,O
PMC36385770_941,8093,with,O
PMC36385770_941,8093,nephrotic,O
PMC36385770_941,8093,syndrome,O
PMC36385770_941,8093,compared,O
PMC36385770_941,8093,with,O
PMC36385770_941,8093,prednisone,B-Drug
PMC36385770_941,8093,treatment,O
PMC36385770_941,8093,alone,O
PMC36385770_941,8093,(,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,number,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,%,O
PMC36385770_941,8093,versus,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,number,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,%,O
PMC36385770_941,8093,;,O
PMC36385770_941,8093,RR,O
PMC36385770_941,8093,=,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,number,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,and,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,number,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,%,O
PMC36385770_941,8093,CI,O
PMC36385770_941,8093,=,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,number,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,_,O
PMC36385770_941,8093,0,O
PMC36385770_941,8094,_,O
PMC36385770_941,8094,_,O
PMC36385770_941,8094,number,O
PMC36385770_941,8094,_,O
PMC36385770_941,8094,_,O
PMC36385770_941,8094,),O
PMC36385770_941,8094,0,O
PMC36406080_385,8095,Double,O
PMC36406080_385,8095,-,O
PMC36406080_385,8095,blind,O
PMC36406080_385,8095,",",O
PMC36406080_385,8095,comparative,O
PMC36406080_385,8095,study,O
PMC36406080_385,8095,of,O
PMC36406080_385,8095,milnacipran,O
PMC36406080_385,8095,and,O
PMC36406080_385,8095,paroxetine,B-Drug
PMC36406080_385,8095,in,O
PMC36406080_385,8095,Japanese,O
PMC36406080_385,8095,patients,O
PMC36406080_385,8095,with,O
PMC36406080_385,8095,major,B-Disease
PMC36406080_385,8095,depression,I-Disease
PMC36406080_385,8095,0,O
PMC36406080_498,8096,BACKGROUND,O
PMC36406080_498,8096,AND,O
PMC36406080_498,8096,METHODS,O
PMC36406080_498,8096,:,O
PMC36406080_498,8096,A,O
PMC36406080_498,8096,double,O
PMC36406080_498,8096,-,O
PMC36406080_498,8096,blind,O
PMC36406080_498,8096,",",O
PMC36406080_498,8096,parallel,O
PMC36406080_498,8096,-,O
PMC36406080_498,8096,group,O
PMC36406080_498,8096,",",O
PMC36406080_498,8096,controlled,O
PMC36406080_498,8096,study,O
PMC36406080_498,8096,was,O
PMC36406080_498,8096,performed,O
PMC36406080_498,8096,to,O
PMC36406080_498,8096,investigate,O
PMC36406080_498,8096,if,O
PMC36406080_498,8096,milnacipran,O
PMC36406080_498,8096,was,O
PMC36406080_498,8096,noninferior,O
PMC36406080_498,8096,to,O
PMC36406080_498,8096,paroxetine,B-Drug
PMC36406080_498,8096,in,O
PMC36406080_498,8096,terms,O
PMC36406080_498,8096,of,O
PMC36406080_498,8096,improvement,O
PMC36406080_498,8096,in,O
PMC36406080_498,8096,symptoms,O
PMC36406080_498,8096,of,O
PMC36406080_498,8096,depression,B-Symptom
PMC36406080_498,8096,in,O
PMC36406080_498,8096,Japanese,O
PMC36406080_498,8096,patients,O
PMC36406080_498,8096,with,O
PMC36406080_498,8096,major,B-Disease
PMC36406080_498,8096,depressive,I-Disease
PMC36406080_498,8096,disorders,I-Disease
PMC36406080_498,8096,in,O
PMC36406080_498,8096,a,O
PMC36406080_498,8096,fixed,O
PMC36406080_498,8096,-,O
PMC36406080_498,8096,dose,O
PMC36406080_498,8096,design,O
PMC36406080_498,8096,0,O
PMC36409150_157,8097,Targeting,O
PMC36409150_157,8097,the,O
PMC36409150_157,8097,Vav,O
PMC36409150_157,8097,_,O
PMC36409150_157,8097,_,O
PMC36409150_157,8097,number,O
PMC36409150_157,8097,_,O
PMC36409150_157,8097,_,O
PMC36409150_157,8097,oncogene,O
PMC36409150_157,8097,enhances,O
PMC36409150_157,8097,docetaxel,B-Drug
PMC36409150_157,8097,-,O
PMC36409150_157,8097,induced,O
PMC36409150_157,8097,apoptosis,O
PMC36409150_157,8097,through,O
PMC36409150_157,8097,the,O
PMC36409150_157,8097,inhibition,O
PMC36409150_157,8097,of,O
PMC36409150_157,8097,androgen,O
PMC36409150_157,8097,receptor,O
PMC36409150_157,8097,phosphorylation,O
PMC36409150_157,8097,in,O
PMC36409150_157,8097,LNCaP,O
PMC36409150_157,8097,prostate,B-Disease
PMC36409150_157,8097,cancer,I-Disease
PMC36409150_157,8097,cells,O
PMC36409150_157,8097,under,O
PMC36409150_157,8097,chronic,O
PMC36409150_157,8097,hypoxia,O
PMC36409150_157,8097,0,O
PMC36444000_495,8098,BACKGROUND,O
PMC36444000_495,8098,:,O
PMC36444000_495,8098,A,O
PMC36444000_495,8098,phase,O
PMC36444000_495,8098,I,O
PMC36444000_495,8098,study,O
PMC36444000_495,8098,to,O
PMC36444000_495,8098,assess,O
PMC36444000_495,8098,the,O
PMC36444000_495,8098,maximum,O
PMC36444000_495,8098,tolerated,O
PMC36444000_495,8098,dose,O
PMC36444000_495,8098,(,O
PMC36444000_495,8098,MTD,O
PMC36444000_495,8098,),O
PMC36444000_495,8098,of,O
PMC36444000_495,8098,a,O
PMC36444000_495,8098,short,O
PMC36444000_495,8098,course,O
PMC36444000_495,8098,of,O
PMC36444000_495,8098,afatinib,O
PMC36444000_495,8098,in,O
PMC36444000_495,8098,combination,O
PMC36444000_495,8098,with,O
PMC36444000_495,8098,docetaxel,B-Drug
PMC36444000_495,8098,for,O
PMC36444000_495,8098,the,O
PMC36444000_495,8098,treatment,O
PMC36444000_495,8098,of,O
PMC36444000_495,8098,solid,O
PMC36444000_495,8098,tumors,O
PMC36444000_495,8098,0,O
PMC36460350_394,8099,Randomized,O
PMC36460350_394,8099,controlled,O
PMC36460350_394,8099,trials,O
PMC36460350_394,8099,(,O
PMC36460350_394,8099,RCTs,O
PMC36460350_394,8099,),O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,five,O
PMC36460350_394,8099,years,O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,aromatase,O
PMC36460350_394,8099,inhibitors,O
PMC36460350_394,8099,(,O
PMC36460350_394,8099,AI,O
PMC36460350_394,8099,),O
PMC36460350_394,8099,versus,O
PMC36460350_394,8099,five,O
PMC36460350_394,8099,years,O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,tamoxifen,B-Drug
PMC36460350_394,8099,in,O
PMC36460350_394,8099,the,O
PMC36460350_394,8099,treatment,O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,post,O
PMC36460350_394,8099,-,O
PMC36460350_394,8099,menopausal,O
PMC36460350_394,8099,women,O
PMC36460350_394,8099,with,O
PMC36460350_394,8099,early,O
PMC36460350_394,8099,stage,O
PMC36460350_394,8099,breast,B-Disease
PMC36460350_394,8099,cancer,I-Disease
PMC36460350_394,8099,",",O
PMC36460350_394,8099,show,O
PMC36460350_394,8099,benefit,O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,AI,O
PMC36460350_394,8099,in,O
PMC36460350_394,8099,terms,O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,disease,O
PMC36460350_394,8099,free,O
PMC36460350_394,8099,survival,O
PMC36460350_394,8099,(,O
PMC36460350_394,8099,DFS,O
PMC36460350_394,8099,),O
PMC36460350_394,8099,but,O
PMC36460350_394,8099,not,O
PMC36460350_394,8099,overall,O
PMC36460350_394,8099,survival,O
PMC36460350_394,8099,(,O
PMC36460350_394,8099,OS,O
PMC36460350_394,8099,),O
PMC36460350_394,8099,and,O
PMC36460350_394,8099,indicate,O
PMC36460350_394,8099,higher,O
PMC36460350_394,8099,risk,O
PMC36460350_394,8099,of,O
PMC36460350_394,8099,fracture,O
PMC36460350_394,8099,with,O
PMC36460350_394,8099,AI,O
PMC36460350_394,8099,0,O
PMC36537560_866,8100,BACKGROUND,O
PMC36537560_866,8100,:,O
PMC36537560_866,8100,Lamotrigine,B-Drug
PMC36537560_866,8100,is,O
PMC36537560_866,8100,an,O
PMC36537560_866,8100,anticonvulsant,O
PMC36537560_866,8100,drug,O
PMC36537560_866,8100,indicated,O
PMC36537560_866,8100,for,O
PMC36537560_866,8100,the,O
PMC36537560_866,8100,maintenance,O
PMC36537560_866,8100,treatment,O
PMC36537560_866,8100,of,O
PMC36537560_866,8100,bipolar,B-Disease
PMC36537560_866,8100,I,I-Disease
PMC36537560_866,8100,disorder,I-Disease
PMC36537560_866,8100,and,O
PMC36537560_866,8100,for,O
PMC36537560_866,8100,various,O
PMC36537560_866,8100,types,O
PMC36537560_866,8100,of,O
PMC36537560_866,8100,epilepsy,B-Disease
PMC36537560_866,8100,0,O
PMC36537630_745,8101,Hypertriglyceridemia,O
PMC36537630_745,8101,was,O
PMC36537630_745,8101,associated,O
PMC36537630_745,8101,with,O
PMC36537630_745,8101,clozapine,O
PMC36537630_745,8101,(,O
PMC36537630_745,8101,odds,O
PMC36537630_745,8101,ratio,O
PMC36537630_745,8101,[,O
PMC36537630_745,8101,OR,O
PMC36537630_745,8101,],O
PMC36537630_745,8101,=,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,number,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,",",O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,number,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,%,O
PMC36537630_745,8101,confidence,O
PMC36537630_745,8101,interval,O
PMC36537630_745,8101,[,O
PMC36537630_745,8101,CI,O
PMC36537630_745,8101,],O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,number,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,_,O
PMC36537630_745,8101,0,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,number,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,),O
PMC36537630_745,8102,",",O
PMC36537630_745,8102,reduced,O
PMC36537630_745,8102,high,B-Symptom
PMC36537630_745,8102,-,I-Symptom
PMC36537630_745,8102,density,I-Symptom
PMC36537630_745,8102,lipoprotein,I-Symptom
PMC36537630_745,8102,with,O
PMC36537630_745,8102,both,O
PMC36537630_745,8102,clozapine,O
PMC36537630_745,8102,and,O
PMC36537630_745,8102,olanzapine,B-Drug
PMC36537630_745,8102,(,O
PMC36537630_745,8102,OR,O
PMC36537630_745,8102,=,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,number,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,",",O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,number,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,%,O
PMC36537630_745,8102,CI,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,number,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,_,O
PMC36537630_745,8102,0,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,number,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,;,O
PMC36537630_745,8103,and,O
PMC36537630_745,8103,OR,O
PMC36537630_745,8103,=,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,number,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,",",O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,number,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,%,O
PMC36537630_745,8103,CI,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,number,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,_,O
PMC36537630_745,8103,0,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,number,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,),O
PMC36537630_745,8104,",",O
PMC36537630_745,8104,hypertension,O
PMC36537630_745,8104,with,O
PMC36537630_745,8104,perphenazine,O
PMC36537630_745,8104,(,O
PMC36537630_745,8104,OR,O
PMC36537630_745,8104,=,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,number,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,",",O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,number,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,%,O
PMC36537630_745,8104,CI,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,number,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,_,O
PMC36537630_745,8104,0,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,number,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,),O
PMC36537630_745,8105,",",O
PMC36537630_745,8105,and,O
PMC36537630_745,8105,hyperglycemia,O
PMC36537630_745,8105,inversely,O
PMC36537630_745,8105,with,O
PMC36537630_745,8105,ziprasidone,B-Drug
PMC36537630_745,8105,(,O
PMC36537630_745,8105,OR,O
PMC36537630_745,8105,=,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,number,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,",",O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,number,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,%,O
PMC36537630_745,8105,CI,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,number,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,_,O
PMC36537630_745,8105,0,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,number,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,),O
PMC36537630_745,8106,and,O
PMC36537630_745,8106,positively,O
PMC36537630_745,8106,with,O
PMC36537630_745,8106,haloperidol,O
PMC36537630_745,8106,(,O
PMC36537630_745,8106,OR,O
PMC36537630_745,8106,=,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,number,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,",",O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,number,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,%,O
PMC36537630_745,8106,CI,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,number,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,_,O
PMC36537630_745,8106,0,O
PMC36537630_745,8107,_,O
PMC36537630_745,8107,_,O
PMC36537630_745,8107,number,O
PMC36537630_745,8107,_,O
PMC36537630_745,8107,_,O
PMC36537630_745,8107,),O
PMC36537630_745,8107,0,O
PMC36588980_34,8108,The,O
PMC36588980_34,8108,pharmacological,O
PMC36588980_34,8108,treatments,O
PMC36588980_34,8108,of,O
PMC36588980_34,8108,choice,O
PMC36588980_34,8108,today,O
PMC36588980_34,8108,for,O
PMC36588980_34,8108,post,B-Disease
PMC36588980_34,8108,-,I-Disease
PMC36588980_34,8108,traumatic,I-Disease
PMC36588980_34,8108,stress,I-Disease
PMC36588980_34,8108,disorder,I-Disease
PMC36588980_34,8108,are,O
PMC36588980_34,8108,antidepressants,O
PMC36588980_34,8108,from,O
PMC36588980_34,8108,the,O
PMC36588980_34,8108,subgroup,O
PMC36588980_34,8108,selective,O
PMC36588980_34,8108,serotonin,O
PMC36588980_34,8108,reuptake,O
PMC36588980_34,8108,inhibitors,O
PMC36588980_34,8108,",",O
PMC36588980_34,8108,especially,O
PMC36588980_34,8108,sertraline,B-Drug
PMC36588980_34,8108,0,O
PMC36612320_38,8109,Duloxetine,B-Drug
PMC36612320_38,8109,is,O
PMC36612320_38,8109,one,O
PMC36612320_38,8109,of,O
PMC36612320_38,8109,three,O
PMC36612320_38,8109,FDA,O
PMC36612320_38,8109,approved,O
PMC36612320_38,8109,medications,O
PMC36612320_38,8109,(,O
PMC36612320_38,8109,the,O
PMC36612320_38,8109,other,O
PMC36612320_38,8109,two,O
PMC36612320_38,8109,being,O
PMC36612320_38,8109,milnacipran,O
PMC36612320_38,8109,and,O
PMC36612320_38,8109,pregabalin,O
PMC36612320_38,8109,),O
PMC36612320_38,8109,for,O
PMC36612320_38,8109,the,O
PMC36612320_38,8109,treatment,O
PMC36612320_38,8109,of,O
PMC36612320_38,8109,FM,B-Disease
PMC36612320_38,8109,0,O
PMC36614820_738,8110,Therapeutic,O
PMC36614820_738,8110,options,O
PMC36614820_738,8110,in,O
PMC36614820_738,8110,docetaxel,B-Drug
PMC36614820_738,8110,-,O
PMC36614820_738,8110,refractory,O
PMC36614820_738,8110,metastatic,B-Disease
PMC36614820_738,8110,castration,O
PMC36614820_738,8110,-,O
PMC36614820_738,8110,resistant,O
PMC36614820_738,8110,prostate,O
PMC36614820_738,8110,cancer,O
PMC36614820_738,8110,:,O
PMC36614820_738,8110,a,O
PMC36614820_738,8110,cost,O
PMC36614820_738,8110,-,O
PMC36614820_738,8110,effectiveness,O
PMC36614820_738,8110,analysis,O
PMC36614820_738,8110,0,O
PMC36636050_148,8111,There,O
PMC36636050_148,8111,are,O
PMC36636050_148,8111,now,O
PMC36636050_148,8111,several,O
PMC36636050_148,8111,agents,O
PMC36636050_148,8111,that,O
PMC36636050_148,8111,are,O
PMC36636050_148,8111,well,O
PMC36636050_148,8111,established,O
PMC36636050_148,8111,for,O
PMC36636050_148,8111,the,O
PMC36636050_148,8111,treatment,O
PMC36636050_148,8111,of,O
PMC36636050_148,8111,acute,O
PMC36636050_148,8111,mania,O
PMC36636050_148,8111,(,O
PMC36636050_148,8111,lithium,O
PMC36636050_148,8111,",",O
PMC36636050_148,8111,divalproex,O
PMC36636050_148,8111,",",O
PMC36636050_148,8111,carbamazepine,B-Drug
PMC36636050_148,8111,",",O
PMC36636050_148,8111,nearly,O
PMC36636050_148,8111,all,O
PMC36636050_148,8111,antipsychotics,O
PMC36636050_148,8111,),O
PMC36636050_148,8111,",",O
PMC36636050_148,8111,acute,O
PMC36636050_148,8111,bipolar,B-Disease
PMC36636050_148,8111,depression,I-Disease
PMC36636050_148,8111,(,O
PMC36636050_148,8111,lamotrigine,B-Drug
PMC36636050_148,8111,",",O
PMC36636050_148,8111,quetiapine,B-Drug
PMC36636050_148,8111,",",O
PMC36636050_148,8111,olanzapine,B-Drug
PMC36636050_148,8111,/,O
PMC36636050_148,8111,fluoxetine,B-Drug
PMC36636050_148,8111,combination,O
PMC36636050_148,8111,),O
PMC36636050_148,8111,",",O
PMC36636050_148,8111,and,O
PMC36636050_148,8111,relapse,O
PMC36636050_148,8111,prevention,O
PMC36636050_148,8111,(,O
PMC36636050_148,8111,lithium,O
PMC36636050_148,8111,",",O
PMC36636050_148,8111,lamotrigine,B-Drug
PMC36636050_148,8111,",",O
PMC36636050_148,8111,divalproex,O
PMC36636050_148,8111,",",O
PMC36636050_148,8111,most,O
PMC36636050_148,8111,second,O
PMC36636050_148,8111,generation,O
PMC36636050_148,8111,antipsychotics,O
PMC36636050_148,8111,),O
PMC36636050_148,8111,0,O
PMC36636050_65,8112,These,O
PMC36636050_65,8112,include,O
PMC36636050_65,8112,eslicarbazepine,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,cariprazine,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,MEM,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,number,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,memantine,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,tamoxifen,B-Drug
PMC36636050_65,8112,and,O
PMC36636050_65,8112,pentazocine,O
PMC36636050_65,8112,for,O
PMC36636050_65,8112,acute,O
PMC36636050_65,8112,mania,O
PMC36636050_65,8112,;,O
PMC36636050_65,8112,pramipexole,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,modafinil,B-Drug
PMC36636050_65,8112,",",O
PMC36636050_65,8112,armodafinil,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,divalproex,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,lurasidone,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,agomelatine,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,cariprazine,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,lisedexamfetamine,B-Drug
PMC36636050_65,8112,",",O
PMC36636050_65,8112,riluzole,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,RG,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,number,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,bifeprunox,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,ropinirole,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,GSK,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,number,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,_,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,and,O
PMC36636050_65,8112,magnetic,O
PMC36636050_65,8112,stimulation,O
PMC36636050_65,8112,for,O
PMC36636050_65,8112,bipolar,B-Disease
PMC36636050_65,8112,depression,I-Disease
PMC36636050_65,8112,;,O
PMC36636050_65,8112,and,O
PMC36636050_65,8112,asenapine,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,lurasidone,O
PMC36636050_65,8112,",",O
PMC36636050_65,8112,and,O
PMC36636050_65,8112,cariprazine,O
PMC36636050_65,8112,for,O
PMC36636050_65,8112,relapse,O
PMC36636050_65,8112,prevention,O
PMC36636050_65,8112,0,O
PMC36636080_212,8113,OBJECTIVES,O
PMC36636080_212,8113,:,O
PMC36636080_212,8113,With,O
PMC36636080_212,8113,this,O
PMC36636080_212,8113,article,O
PMC36636080_212,8113,",",O
PMC36636080_212,8113,we,O
PMC36636080_212,8113,provide,O
PMC36636080_212,8113,information,O
PMC36636080_212,8113,on,O
PMC36636080_212,8113,a,O
PMC36636080_212,8113,relatively,O
PMC36636080_212,8113,new,O
PMC36636080_212,8113,antipsychotic,O
PMC36636080_212,8113,ziprasidone,B-Drug
PMC36636080_212,8113,released,O
PMC36636080_212,8113,in,O
PMC36636080_212,8113,_,O
PMC36636080_212,8113,_,O
PMC36636080_212,8113,number,O
PMC36636080_212,8113,_,O
PMC36636080_212,8113,_,O
PMC36636080_212,8113,by,O
PMC36636080_212,8113,Pfizer,O
PMC36636080_212,8113,for,O
PMC36636080_212,8113,the,O
PMC36636080_212,8113,treatment,O
PMC36636080_212,8113,of,O
PMC36636080_212,8113,schizophrenia,B-Disease
PMC36636080_212,8113,0,O
PMC36636080_36,8114,Ziprasidone,B-Drug
PMC36636080_36,8114,hydrocloride,O
PMC36636080_36,8114,:,O
PMC36636080_36,8114,what,O
PMC36636080_36,8114,role,O
PMC36636080_36,8114,in,O
PMC36636080_36,8114,the,O
PMC36636080_36,8114,management,O
PMC36636080_36,8114,of,O
PMC36636080_36,8114,schizophrenia,B-Disease
PMC36636080_36,8114,?,O
PMC36655720_706,8114,Erlotinib,O
PMC36655720_706,8114,has,O
PMC36655720_706,8114,been,O
PMC36655720_706,8114,evaluated,O
PMC36655720_706,8114,as,O
PMC36655720_706,8114,a,O
PMC36655720_706,8114,single,O
PMC36655720_706,8114,agent,O
PMC36655720_706,8114,in,O
PMC36655720_706,8114,recurrent,O
PMC36655720_706,8114,ovarian,B-Disease
PMC36655720_706,8114,cancer,I-Disease
PMC36655720_706,8114,",",O
PMC36655720_706,8114,as,O
PMC36655720_706,8114,well,O
PMC36655720_706,8114,as,O
PMC36655720_706,8114,in,O
PMC36655720_706,8114,combination,O
PMC36655720_706,8114,with,O
PMC36655720_706,8114,chemotherapeutic,O
PMC36655720_706,8114,agents,O
PMC36655720_706,8114,in,O
PMC36655720_706,8114,the,O
PMC36655720_706,8114,first,O
PMC36655720_706,8114,-,O
PMC36655720_706,8114,line,O
PMC36655720_706,8114,and,O
PMC36655720_706,8114,recurrent,O
PMC36655720_706,8114,settings,O
PMC36655720_706,8114,",",O
PMC36655720_706,8114,and,O
PMC36655720_706,8114,in,O
PMC36655720_706,8114,combination,O
PMC36655720_706,8114,with,O
PMC36655720_706,8114,the,O
PMC36655720_706,8114,antiangiogenic,O
PMC36655720_706,8114,agent,O
PMC36655720_706,8114,bevacizumab,B-Drug
PMC36655720_706,8114,in,O
PMC36655720_706,8114,the,O
PMC36655720_706,8114,recurrent,O
PMC36655720_706,8114,setting,O
PMC36655720_706,8114,",",O
PMC36655720_706,8114,as,O
PMC36655720_706,8114,well,O
PMC36655720_706,8114,as,O
PMC36655720_706,8114,in,O
PMC36655720_706,8114,the,O
PMC36655720_706,8114,maintenance,O
PMC36655720_706,8114,setting,O
PMC36655720_706,8114,after,O
PMC36655720_706,8114,completion,O
PMC36655720_706,8114,of,O
PMC36655720_706,8114,first,O
PMC36655720_706,8114,-,O
PMC36655720_706,8114,line,O
PMC36655720_706,8114,chemotherapy,O
PMC36655720_706,8114,0,O
PMC36661940_238,8115,The,O
PMC36661940_238,8115,review,O
PMC36661940_238,8115,charts,O
PMC36661940_238,8115,advances,O
PMC36661940_238,8115,in,O
PMC36661940_238,8115,pharmaceutical,O
PMC36661940_238,8115,development,O
PMC36661940_238,8115,from,O
PMC36661940_238,8115,the,O
PMC36661940_238,8115,introduction,O
PMC36661940_238,8115,of,O
PMC36661940_238,8115,once,O
PMC36661940_238,8115,-,O
PMC36661940_238,8115,daily,O
PMC36661940_238,8115,formulations,O
PMC36661940_238,8115,of,O
PMC36661940_238,8115,amphetamine,B-Drug
PMC36661940_238,8115,through,O
PMC36661940_238,8115,to,O
PMC36661940_238,8115,lisdexamfetamine,O
PMC36661940_238,8115,",",O
PMC36661940_238,8115,which,O
PMC36661940_238,8115,is,O
PMC36661940_238,8115,the,O
PMC36661940_238,8115,first,O
PMC36661940_238,8115,d,O
PMC36661940_238,8115,-,O
PMC36661940_238,8115,amphetamine,O
PMC36661940_238,8115,prodrug,O
PMC36661940_238,8115,approved,O
PMC36661940_238,8115,for,O
PMC36661940_238,8115,the,O
PMC36661940_238,8115,management,O
PMC36661940_238,8115,of,O
PMC36661940_238,8115,ADHD,B-Disease
PMC36661940_238,8115,in,O
PMC36661940_238,8115,children,O
PMC36661940_238,8115,",",O
PMC36661940_238,8115,adolescents,O
PMC36661940_238,8115,and,O
PMC36661940_238,8115,adults,O
PMC36661940_238,8115,0,O
PMC36661940_354,8116,How,O
PMC36661940_354,8116,lisdexamfetamine,B-Drug
PMC36661940_354,8116,',O
PMC36661940_354,8116,s,O
PMC36661940_354,8116,distinctive,O
PMC36661940_354,8116,pharmacokinetic,O
PMC36661940_354,8116,/,O
PMC36661940_354,8116,pharmacodynamic,O
PMC36661940_354,8116,profile,O
PMC36661940_354,8116,translates,O
PMC36661940_354,8116,into,O
PMC36661940_354,8116,sustained,O
PMC36661940_354,8116,efficacy,O
PMC36661940_354,8116,as,O
PMC36661940_354,8116,a,O
PMC36661940_354,8116,treatment,O
PMC36661940_354,8116,for,O
PMC36661940_354,8116,ADHD,B-Disease
PMC36661940_354,8116,and,O
PMC36661940_354,8116,its,O
PMC36661940_354,8116,reduced,O
PMC36661940_354,8116,potential,O
PMC36661940_354,8116,for,O
PMC36661940_354,8116,recreational,O
PMC36661940_354,8116,abuse,O
PMC36661940_354,8116,is,O
PMC36661940_354,8116,also,O
PMC36661940_354,8116,discussed,O
PMC36661940_354,8116,0,O
PMC36671150_779,8117,fluoxetine,B-Drug
PMC36671150_779,8117,),O
PMC36671150_779,8117,can,O
PMC36671150_779,8117,reduce,O
PMC36671150_779,8117,anxiety,B-Symptom
PMC36671150_779,8117,and,O
PMC36671150_779,8117,anxiety,B-Symptom
PMC36671150_779,8117,-,O
PMC36671150_779,8117,related,O
PMC36671150_779,8117,behaviors,O
PMC36671150_779,8117,0,O
PMC36688900_17,8118,In,O
PMC36688900_17,8118,a,O
PMC36688900_17,8118,recent,O
PMC36688900_17,8118,article,O
PMC36688900_17,8118,",",O
PMC36688900_17,8118,Lund,O
PMC36688900_17,8118,et,O
PMC36688900_17,8118,al,O
PMC36688900_17,8118,sought,O
PMC36688900_17,8118,to,O
PMC36688900_17,8118,compare,O
PMC36688900_17,8118,maternal,O
PMC36688900_17,8118,and,O
PMC36688900_17,8118,neonatal,O
PMC36688900_17,8118,outcomes,O
PMC36688900_17,8118,of,O
PMC36688900_17,8118,various,O
PMC36688900_17,8118,treatment,O
PMC36688900_17,8118,regimens,O
PMC36688900_17,8118,for,O
PMC36688900_17,8118,opioid,O
PMC36688900_17,8118,dependence,O
PMC36688900_17,8118,during,O
PMC36688900_17,8118,pregnancy,O
PMC36688900_17,8118,0,O
PMC36688900_17,8119,_,O
PMC36688900_17,8119,_,O
PMC36688900_17,8119,number,O
PMC36688900_17,8119,_,O
PMC36688900_17,8119,_,O
PMC36688900_17,8119,In,O
PMC36688900_17,8119,their,O
PMC36688900_17,8119,background,O
PMC36688900_17,8119,",",O
PMC36688900_17,8119,discussion,O
PMC36688900_17,8119,the,O
PMC36688900_17,8119,authors,O
PMC36688900_17,8119,state,O
PMC36688900_17,8119,that,O
PMC36688900_17,8119,"""",O
PMC36688900_17,8119,In,O
PMC36688900_17,8119,the,O
PMC36688900_17,8119,United,O
PMC36688900_17,8119,States,O
PMC36688900_17,8119,buprenorphine,B-Drug
PMC36688900_17,8119,plus,O
PMC36688900_17,8119,naloxone,O
PMC36688900_17,8119,[,O
PMC36688900_17,8119,Suboxone,B-Drug
PMC36688900_17,8119,(,O
PMC36688900_17,8119,),O
PMC36688900_17,8119,],O
PMC36688900_17,8119,has,O
PMC36688900_17,8119,been,O
PMC36688900_17,8119,the,O
PMC36688900_17,8119,preferred,O
PMC36688900_17,8119,form,O
PMC36688900_17,8119,of,O
PMC36688900_17,8119,prescribed,O
PMC36688900_17,8119,buprenorphine,B-Drug
PMC36688900_17,8119,due,O
PMC36688900_17,8119,to,O
PMC36688900_17,8119,its,O
PMC36688900_17,8119,reduced,O
PMC36688900_17,8119,abuse,O
PMC36688900_17,8119,liability,O
PMC36688900_17,8119,relative,O
PMC36688900_17,8119,to,O
PMC36688900_17,8119,buprenorphine,B-Drug
PMC36688900_17,8119,alone,O
PMC36688900_17,8119,[,O
PMC36688900_17,8119,Subutex,O
PMC36688900_17,8119,(,O
PMC36688900_17,8119,),O
PMC36688900_17,8119,],O
PMC36688900_17,8119,0,O
PMC36688900_17,8120,"""",O
PMC36705080_624,8120,Successful,O
PMC36705080_624,8120,ziprasidone,B-Drug
PMC36705080_624,8120,monotherapy,O
PMC36705080_624,8120,in,O
PMC36705080_624,8120,a,O
PMC36705080_624,8120,case,O
PMC36705080_624,8120,of,O
PMC36705080_624,8120,delusional,O
PMC36705080_624,8120,parasitosis,B-Disease
PMC36705080_624,8120,:,O
PMC36705080_624,8120,a,O
PMC36705080_624,8120,one,O
PMC36705080_624,8120,-,O
PMC36705080_624,8120,year,O
PMC36705080_624,8120,followup,O
PMC36705080_624,8120,0,O
PMC36798760_827,8121,Phase,O
PMC36798760_827,8121,II,O
PMC36798760_827,8121,trial,O
PMC36798760_827,8121,of,O
PMC36798760_827,8121,preoperative,O
PMC36798760_827,8121,radiochemotherapy,O
PMC36798760_827,8121,with,O
PMC36798760_827,8121,concurrent,O
PMC36798760_827,8121,bevacizumab,B-Drug
PMC36798760_827,8121,",",O
PMC36798760_827,8121,capecitabine,O
PMC36798760_827,8121,and,O
PMC36798760_827,8121,oxaliplatin,O
PMC36798760_827,8121,in,O
PMC36798760_827,8121,patients,O
PMC36798760_827,8121,with,O
PMC36798760_827,8121,locally,O
PMC36798760_827,8121,advanced,O
PMC36798760_827,8121,rectal,B-Disease
PMC36798760_827,8121,cancer,I-Disease
PMC36798760_827,8121,0,O
PMC36827340_762,8122,Bevacizumab,B-Drug
PMC36827340_762,8122,for,O
PMC36827340_762,8122,the,O
PMC36827340_762,8122,treatment,O
PMC36827340_762,8122,of,O
PMC36827340_762,8122,glioblastoma,B-Disease
PMC36827340_762,8122,0,O
PMC36934290_196,8123,Rediscovering,O
PMC36934290_196,8123,trazodone,B-Drug
PMC36934290_196,8123,for,O
PMC36934290_196,8123,the,O
PMC36934290_196,8123,treatment,O
PMC36934290_196,8123,of,O
PMC36934290_196,8123,major,B-Disease
PMC36934290_196,8123,depressive,I-Disease
PMC36934290_196,8123,disorder,I-Disease
PMC36934290_196,8123,0,O
PMC36934290_22,8124,Trazodone,B-Drug
PMC36934290_22,8124,is,O
PMC36934290_22,8124,effective,O
PMC36934290_22,8124,in,O
PMC36934290_22,8124,controlling,O
PMC36934290_22,8124,a,O
PMC36934290_22,8124,wide,O
PMC36934290_22,8124,range,O
PMC36934290_22,8124,of,O
PMC36934290_22,8124,symptoms,O
PMC36934290_22,8124,of,O
PMC36934290_22,8124,depression,B-Symptom
PMC36934290_22,8124,",",O
PMC36934290_22,8124,while,O
PMC36934290_22,8124,avoiding,O
PMC36934290_22,8124,the,O
PMC36934290_22,8124,negative,O
PMC36934290_22,8124,effects,O
PMC36934290_22,8124,on,O
PMC36934290_22,8124,sleep,O
PMC36934290_22,8124,seen,O
PMC36934290_22,8124,with,O
PMC36934290_22,8124,SSRI,O
PMC36934290_22,8124,antidepressants,O
PMC36934290_22,8124,0,O
PMC36934290_272,8125,The,O
PMC36934290_272,8125,most,O
PMC36934290_272,8125,common,O
PMC36934290_272,8125,adverse,O
PMC36934290_272,8125,effects,O
PMC36934290_272,8125,reported,O
PMC36934290_272,8125,with,O
PMC36934290_272,8125,trazodone,B-Drug
PMC36934290_272,8125,are,O
PMC36934290_272,8125,drowsiness,B-Symptom
PMC36934290_272,8125,(,O
PMC36934290_272,8125,somnolence,B-Symptom
PMC36934290_272,8125,/,O
PMC36934290_272,8125,sedation,B-Symptom
PMC36934290_272,8125,),O
PMC36934290_272,8125,",",O
PMC36934290_272,8125,headache,B-Symptom
PMC36934290_272,8125,",",O
PMC36934290_272,8125,dizziness,B-Symptom
PMC36934290_272,8125,and,O
PMC36934290_272,8125,dry,B-Symptom
PMC36934290_272,8125,mouth,I-Symptom
PMC36934290_272,8125,0,O
PMC36934290_398,8126,Although,O
PMC36934290_398,8126,trazodone,B-Drug
PMC36934290_398,8126,is,O
PMC36934290_398,8126,approved,O
PMC36934290_398,8126,for,O
PMC36934290_398,8126,the,O
PMC36934290_398,8126,treatment,O
PMC36934290_398,8126,of,O
PMC36934290_398,8126,depression,B-Disease
PMC36934290_398,8126,",",O
PMC36934290_398,8126,evidence,O
PMC36934290_398,8126,supports,O
PMC36934290_398,8126,the,O
PMC36934290_398,8126,use,O
PMC36934290_398,8126,of,O
PMC36934290_398,8126,low,O
PMC36934290_398,8126,-,O
PMC36934290_398,8126,dose,O
PMC36934290_398,8126,trazodone,B-Drug
PMC36934290_398,8126,as,O
PMC36934290_398,8126,an,O
PMC36934290_398,8126,off,O
PMC36934290_398,8126,-,O
PMC36934290_398,8126,label,O
PMC36934290_398,8126,hypnotic,O
PMC36934290_398,8126,for,O
PMC36934290_398,8126,the,O
PMC36934290_398,8126,treatment,O
PMC36934290_398,8126,of,O
PMC36934290_398,8126,sleep,O
PMC36934290_398,8126,disorders,O
PMC36934290_398,8126,in,O
PMC36934290_398,8126,patients,O
PMC36934290_398,8126,with,O
PMC36934290_398,8126,MDD,B-Disease
PMC36934290_398,8126,0,O
PMC36935810_172,8127,METHODS,O
PMC36935810_172,8127,:,O
PMC36935810_172,8127,This,O
PMC36935810_172,8127,is,O
PMC36935810_172,8127,a,O
PMC36935810_172,8127,retrospective,O
PMC36935810_172,8127,review,O
PMC36935810_172,8127,of,O
PMC36935810_172,8127,all,O
PMC36935810_172,8127,retinoblastoma,B-Disease
PMC36935810_172,8127,patients,O
PMC36935810_172,8127,treated,O
PMC36935810_172,8127,with,O
PMC36935810_172,8127,intra,O
PMC36935810_172,8127,-,O
PMC36935810_172,8127,arterial,O
PMC36935810_172,8127,melphalan,B-Drug
PMC36935810_172,8127,at,O
PMC36935810_172,8127,the,O
PMC36935810_172,8127,University,O
PMC36935810_172,8127,of,O
PMC36935810_172,8127,California,O
PMC36935810_172,8127,",",O
PMC36935810_172,8127,San,O
PMC36935810_172,8127,Francisco,O
PMC36935810_172,8127,from,O
PMC36935810_172,8127,March,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,number,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,to,O
PMC36935810_172,8127,August,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,number,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,_,O
PMC36935810_172,8127,0,O
PMC36935810_391,8128,CONCLUSION,O
PMC36935810_391,8128,:,O
PMC36935810_391,8128,Superselective,O
PMC36935810_391,8128,intra,O
PMC36935810_391,8128,-,O
PMC36935810_391,8128,arterial,O
PMC36935810_391,8128,melphalan,B-Drug
PMC36935810_391,8128,therapy,O
PMC36935810_391,8128,is,O
PMC36935810_391,8128,effective,O
PMC36935810_391,8128,for,O
PMC36935810_391,8128,less,O
PMC36935810_391,8128,advanced,O
PMC36935810_391,8128,eyes,O
PMC36935810_391,8128,but,O
PMC36935810_391,8128,further,O
PMC36935810_391,8128,modifications,O
PMC36935810_391,8128,to,O
PMC36935810_391,8128,therapy,O
PMC36935810_391,8128,are,O
PMC36935810_391,8128,required,O
PMC36935810_391,8128,to,O
PMC36935810_391,8128,improve,O
PMC36935810_391,8128,results,O
PMC36935810_391,8128,in,O
PMC36935810_391,8128,eyes,O
PMC36935810_391,8128,with,O
PMC36935810_391,8128,advanced,O
PMC36935810_391,8128,retinoblastoma,B-Disease
PMC36935810_391,8128,0,O
PMC36935810_999,8129,This,O
PMC36935810_999,8129,report,O
PMC36935810_999,8129,describes,O
PMC36935810_999,8129,our,O
PMC36935810_999,8129,results,O
PMC36935810_999,8129,using,O
PMC36935810_999,8129,superselective,O
PMC36935810_999,8129,intra,O
PMC36935810_999,8129,-,O
PMC36935810_999,8129,arterial,O
PMC36935810_999,8129,melphalan,B-Drug
PMC36935810_999,8129,in,O
PMC36935810_999,8129,patients,O
PMC36935810_999,8129,with,O
PMC36935810_999,8129,newly,O
PMC36935810_999,8129,diagnosed,O
PMC36935810_999,8129,retinoblastoma,B-Disease
PMC36935810_999,8129,and,O
PMC36935810_999,8129,those,O
PMC36935810_999,8129,who,O
PMC36935810_999,8129,were,O
PMC36935810_999,8129,treated,O
PMC36935810_999,8129,for,O
PMC36935810_999,8129,progression,O
PMC36935810_999,8129,after,O
PMC36935810_999,8129,systemic,O
PMC36935810_999,8129,chemotherapy,O
PMC36935810_999,8129,0,O
PMC36953260_807,8130,The,O
PMC36953260_807,8130,effect,O
PMC36953260_807,8130,of,O
PMC36953260_807,8130,CYP,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,number,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,C,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,number,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,_,O
PMC36953260_807,8130,polymorphisms,O
PMC36953260_807,8130,on,O
PMC36953260_807,8130,tamoxifen,B-Drug
PMC36953260_807,8130,sensitivity,O
PMC36953260_807,8130,may,O
PMC36953260_807,8130,therefore,O
PMC36953260_807,8130,not,O
PMC36953260_807,8130,only,O
PMC36953260_807,8130,be,O
PMC36953260_807,8130,mediated,O
PMC36953260_807,8130,by,O
PMC36953260_807,8130,a,O
PMC36953260_807,8130,variation,O
PMC36953260_807,8130,in,O
PMC36953260_807,8130,tamoxifen,B-Drug
PMC36953260_807,8130,metabolite,O
PMC36953260_807,8130,levels,O
PMC36953260_807,8130,but,O
PMC36953260_807,8130,also,O
PMC36953260_807,8130,by,O
PMC36953260_807,8130,an,O
PMC36953260_807,8130,effect,O
PMC36953260_807,8130,on,O
PMC36953260_807,8130,breast,B-Disease
PMC36953260_807,8130,cancer,I-Disease
PMC36953260_807,8130,risk,O
PMC36953260_807,8130,and,O
PMC36953260_807,8130,molecular,O
PMC36953260_807,8130,subtype,O
PMC36953260_807,8130,due,O
PMC36953260_807,8130,to,O
PMC36953260_807,8130,variation,O
PMC36953260_807,8130,in,O
PMC36953260_807,8130,lifelong,O
PMC36953260_807,8130,exposure,O
PMC36953260_807,8130,to,O
PMC36953260_807,8130,estrogens,O
PMC36953260_807,8130,0,O
PMC36980980_180,8131,Patients,O
PMC36980980_180,8131,with,O
PMC36980980_180,8131,(,O
PMC36980980_180,8131,sub,O
PMC36980980_180,8131,),O
PMC36980980_180,8131,chronic,B-Symptom
PMC36980980_180,8131,pain,I-Symptom
PMC36980980_180,8131,and,O
PMC36980980_180,8131,a,O
PMC36980980_180,8131,depressive,B-Disease
PMC36980980_180,8131,disorder,I-Disease
PMC36980980_180,8131,are,O
PMC36980980_180,8131,randomized,O
PMC36980980_180,8131,to,O
PMC36980980_180,8131,either,O
PMC36980980_180,8131,a,O
PMC36980980_180,8131,),O
PMC36980980_180,8131,collaborative,O
PMC36980980_180,8131,care,O
PMC36980980_180,8131,with,O
PMC36980980_180,8131,duloxetine,B-Drug
PMC36980980_180,8131,",",O
PMC36980980_180,8131,b,O
PMC36980980_180,8131,),O
PMC36980980_180,8131,collaborative,O
PMC36980980_180,8131,care,O
PMC36980980_180,8131,with,O
PMC36980980_180,8131,placebo,O
PMC36980980_180,8131,or,O
PMC36980980_180,8131,c,O
PMC36980980_180,8131,),O
PMC36980980_180,8131,duloxetine,B-Drug
PMC36980980_180,8131,alone,O
PMC36980980_180,8131,0,O
PMC36993220_622,8132,In,O
PMC36993220_622,8132,Phase,O
PMC36993220_622,8132,I,O
PMC36993220_622,8132,",",O
PMC36993220_622,8132,II,O
PMC36993220_622,8132,",",O
PMC36993220_622,8132,and,O
PMC36993220_622,8132,II,O
PMC36993220_622,8132,trials,O
PMC36993220_622,8132,for,O
PMC36993220_622,8132,DME,B-Disease
PMC36993220_622,8132,",",O
PMC36993220_622,8132,ranibizumab,O
PMC36993220_622,8132,has,O
PMC36993220_622,8132,been,O
PMC36993220_622,8132,shown,O
PMC36993220_622,8132,to,O
PMC36993220_622,8132,be,O
PMC36993220_622,8132,superior,O
PMC36993220_622,8132,to,O
PMC36993220_622,8132,macular,O
PMC36993220_622,8132,laser,O
PMC36993220_622,8132,photocoagulation,O
PMC36993220_622,8132,and,O
PMC36993220_622,8132,intraocular,O
PMC36993220_622,8132,triamcinolone,B-Drug
PMC36993220_622,8132,acetonide,O
PMC36993220_622,8132,injections,O
PMC36993220_622,8132,for,O
PMC36993220_622,8132,improving,O
PMC36993220_622,8132,visual,B-Symptom
PMC36993220_622,8132,acuity,I-Symptom
PMC36993220_622,8132,and,O
PMC36993220_622,8132,drying,O
PMC36993220_622,8132,the,O
PMC36993220_622,8132,macula,O
PMC36993220_622,8132,0,O
PMC36998430_771,8133,A,O
PMC36998430_771,8133,phase,O
PMC36998430_771,8133,I,O
PMC36998430_771,8133,study,O
PMC36998430_771,8133,of,O
PMC36998430_771,8133,ABT,O
PMC36998430_771,8133,_,O
PMC36998430_771,8133,_,O
PMC36998430_771,8133,number,O
PMC36998430_771,8133,_,O
PMC36998430_771,8133,_,O
PMC36998430_771,8133,plus,O
PMC36998430_771,8133,bevacizumab,B-Drug
PMC36998430_771,8133,in,O
PMC36998430_771,8133,advanced,O
PMC36998430_771,8133,solid,O
PMC36998430_771,8133,tumors,O
PMC36998430_771,8133,0,O
PMC37001620_521,8134,This,O
PMC37001620_521,8134,study,O
PMC37001620_521,8134,was,O
PMC37001620_521,8134,done,O
PMC37001620_521,8134,to,O
PMC37001620_521,8134,find,O
PMC37001620_521,8134,out,O
PMC37001620_521,8134,the,O
PMC37001620_521,8134,role,O
PMC37001620_521,8134,of,O
PMC37001620_521,8134,topiramate,B-Drug
PMC37001620_521,8134,therapy,O
PMC37001620_521,8134,in,O
PMC37001620_521,8134,infraorbital,O
PMC37001620_521,8134,nerve,O
PMC37001620_521,8134,paresthesia,B-Symptom
PMC37001620_521,8134,after,O
PMC37001620_521,8134,miniplate,O
PMC37001620_521,8134,fixation,O
PMC37001620_521,8134,in,O
PMC37001620_521,8134,zygomatic,O
PMC37001620_521,8134,complxex,O
PMC37001620_521,8134,fractures,O
PMC37001620_521,8134,0,O
PMC37060630_130,8135,We,O
PMC37060630_130,8135,describe,O
PMC37060630_130,8135,here,O
PMC37060630_130,8135,the,O
PMC37060630_130,8135,case,O
PMC37060630_130,8135,of,O
PMC37060630_130,8135,a,O
PMC37060630_130,8135,_,O
PMC37060630_130,8135,_,O
PMC37060630_130,8135,number,O
PMC37060630_130,8135,_,O
PMC37060630_130,8135,_,O
PMC37060630_130,8135,-,O
PMC37060630_130,8135,year,O
PMC37060630_130,8135,-,O
PMC37060630_130,8135,old,O
PMC37060630_130,8135,woman,O
PMC37060630_130,8135,who,O
PMC37060630_130,8135,developed,O
PMC37060630_130,8135,acute,O
PMC37060630_130,8135,liver,O
PMC37060630_130,8135,failure,O
PMC37060630_130,8135,during,O
PMC37060630_130,8135,the,O
PMC37060630_130,8135,treatment,O
PMC37060630_130,8135,of,O
PMC37060630_130,8135,ADHD,B-Disease
PMC37060630_130,8135,with,O
PMC37060630_130,8135,Adderall,B-Drug
PMC37060630_130,8135,0,O
PMC37060630_163,8136,Use,O
PMC37060630_163,8136,of,O
PMC37060630_163,8136,prescribed,O
PMC37060630_163,8136,Adderall,B-Drug
PMC37060630_163,8136,without,O
PMC37060630_163,8136,intention,O
PMC37060630_163,8136,to,O
PMC37060630_163,8136,overdose,O
PMC37060630_163,8136,as,O
PMC37060630_163,8136,a,O
PMC37060630_163,8136,cause,O
PMC37060630_163,8136,of,O
PMC37060630_163,8136,acute,O
PMC37060630_163,8136,liver,O
PMC37060630_163,8136,injury,O
PMC37060630_163,8136,is,O
PMC37060630_163,8136,extremely,O
PMC37060630_163,8136,rare,O
PMC37060630_163,8136,",",O
PMC37060630_163,8136,and,O
PMC37060630_163,8136,to,O
PMC37060630_163,8136,our,O
PMC37060630_163,8136,knowledge,O
PMC37060630_163,8136,no,O
PMC37060630_163,8136,cases,O
PMC37060630_163,8136,have,O
PMC37060630_163,8136,been,O
PMC37060630_163,8136,reported,O
PMC37060630_163,8136,in,O
PMC37060630_163,8136,the,O
PMC37060630_163,8136,English,O
PMC37060630_163,8136,literature,O
PMC37060630_163,8136,0,O
PMC37060630_61,8137,Adderall,B-Drug
PMC37060630_61,8137,induced,O
PMC37060630_61,8137,acute,O
PMC37060630_61,8137,liver,O
PMC37060630_61,8137,injury,O
PMC37060630_61,8137,:,O
PMC37060630_61,8137,a,O
PMC37060630_61,8137,rare,O
PMC37060630_61,8137,case,O
PMC37060630_61,8137,and,O
PMC37060630_61,8137,review,O
PMC37060630_61,8137,of,O
PMC37060630_61,8137,the,O
PMC37060630_61,8137,literature,O
PMC37060630_61,8137,0,O
PMC37060630_82,8138,Adderall,B-Drug
PMC37060630_82,8138,(,O
PMC37060630_82,8138,dextroamphetamine,O
PMC37060630_82,8138,/,O
PMC37060630_82,8138,amphetamine,B-Drug
PMC37060630_82,8138,),O
PMC37060630_82,8138,is,O
PMC37060630_82,8138,a,O
PMC37060630_82,8138,widely,O
PMC37060630_82,8138,prescribed,O
PMC37060630_82,8138,medicine,O
PMC37060630_82,8138,for,O
PMC37060630_82,8138,the,O
PMC37060630_82,8138,treatment,O
PMC37060630_82,8138,of,O
PMC37060630_82,8138,attention,B-Disease
PMC37060630_82,8138,-,I-Disease
PMC37060630_82,8138,deficit,I-Disease
PMC37060630_82,8138,/,I-Disease
PMC37060630_82,8138,hyperactivity,I-Disease
PMC37060630_82,8138,disorder,I-Disease
PMC37060630_82,8138,(,I-Disease
PMC37060630_82,8138,ADHD,I-Disease
PMC37060630_82,8138,),O
PMC37060630_82,8138,and,O
PMC37060630_82,8138,is,O
PMC37060630_82,8138,considered,O
PMC37060630_82,8138,safe,O
PMC37060630_82,8138,with,O
PMC37060630_82,8138,due,O
PMC37060630_82,8138,precautions,O
PMC37060630_82,8138,0,O
PMC37077710_75,8139,Interestingly,O
PMC37077710_75,8139,",",O
PMC37077710_75,8139,systemic,O
PMC37077710_75,8139,application,O
PMC37077710_75,8139,of,O
PMC37077710_75,8139,carboplatin,O
PMC37077710_75,8139,and,O
PMC37077710_75,8139,melphalan,B-Drug
PMC37077710_75,8139,demonstrated,O
PMC37077710_75,8139,significant,O
PMC37077710_75,8139,reduction,O
PMC37077710_75,8139,in,O
PMC37077710_75,8139,the,O
PMC37077710_75,8139,tumor,O
PMC37077710_75,8139,population,O
PMC37077710_75,8139,",",O
PMC37077710_75,8139,which,O
PMC37077710_75,8139,could,O
PMC37077710_75,8139,be,O
PMC37077710_75,8139,quantitatively,O
PMC37077710_75,8139,analyzed,O
PMC37077710_75,8139,by,O
PMC37077710_75,8139,the,O
PMC37077710_75,8139,estimation,O
PMC37077710_75,8139,of,O
PMC37077710_75,8139,the,O
PMC37077710_75,8139,mean,O
PMC37077710_75,8139,intensity,O
PMC37077710_75,8139,of,O
PMC37077710_75,8139,GFP,O
PMC37077710_75,8139,0,O
PMC37119020_253,8140,We,O
PMC37119020_253,8140,investigated,O
PMC37119020_253,8140,the,O
PMC37119020_253,8140,potential,O
PMC37119020_253,8140,therapeutic,O
PMC37119020_253,8140,efficacy,O
PMC37119020_253,8140,and,O
PMC37119020_253,8140,mechanism,O
PMC37119020_253,8140,of,O
PMC37119020_253,8140,rupatadine,B-Drug
PMC37119020_253,8140,",",O
PMC37119020_253,8140,a,O
PMC37119020_253,8140,dual,O
PMC37119020_253,8140,antagonist,O
PMC37119020_253,8140,of,O
PMC37119020_253,8140,histamine,O
PMC37119020_253,8140,and,O
PMC37119020_253,8140,platelet,O
PMC37119020_253,8140,-,O
PMC37119020_253,8140,activation,O
PMC37119020_253,8140,factor,O
PMC37119020_253,8140,(,O
PMC37119020_253,8140,PAF,O
PMC37119020_253,8140,),O
PMC37119020_253,8140,",",O
PMC37119020_253,8140,in,O
PMC37119020_253,8140,bleomycin,O
PMC37119020_253,8140,-,O
PMC37119020_253,8140,(,O
PMC37119020_253,8140,BLM,O
PMC37119020_253,8140,-,O
PMC37119020_253,8140,),O
PMC37119020_253,8140,and,O
PMC37119020_253,8140,silica,O
PMC37119020_253,8140,-,O
PMC37119020_253,8140,induced,O
PMC37119020_253,8140,pulmonary,B-Disease
PMC37119020_253,8140,fibrosis,I-Disease
PMC37119020_253,8140,0,O
PMC37119020_407,8141,Rupatadine,B-Drug
PMC37119020_407,8141,promoted,O
PMC37119020_407,8141,the,O
PMC37119020_407,8141,resolution,O
PMC37119020_407,8141,of,O
PMC37119020_407,8141,pulmonary,B-Symptom
PMC37119020_407,8141,inflammation,I-Symptom
PMC37119020_407,8141,and,O
PMC37119020_407,8141,fibrosis,O
PMC37119020_407,8141,in,O
PMC37119020_407,8141,a,O
PMC37119020_407,8141,dose,O
PMC37119020_407,8141,-,O
PMC37119020_407,8141,dependent,O
PMC37119020_407,8141,manner,O
PMC37119020_407,8141,",",O
PMC37119020_407,8141,as,O
PMC37119020_407,8141,indicated,O
PMC37119020_407,8141,by,O
PMC37119020_407,8141,the,O
PMC37119020_407,8141,reductions,O
PMC37119020_407,8141,in,O
PMC37119020_407,8141,inflammation,O
PMC37119020_407,8141,score,O
PMC37119020_407,8141,",",O
PMC37119020_407,8141,collagen,O
PMC37119020_407,8141,deposition,O
PMC37119020_407,8141,and,O
PMC37119020_407,8141,epithelial,O
PMC37119020_407,8141,-,O
PMC37119020_407,8141,mesenchymal,O
PMC37119020_407,8141,transformation,O
PMC37119020_407,8141,",",O
PMC37119020_407,8141,and,O
PMC37119020_407,8141,infiltration,O
PMC37119020_407,8141,or,O
PMC37119020_407,8141,expression,O
PMC37119020_407,8141,of,O
PMC37119020_407,8141,inflammatory,O
PMC37119020_407,8141,cells,O
PMC37119020_407,8141,or,O
PMC37119020_407,8141,cytokines,O
PMC37119020_407,8141,in,O
PMC37119020_407,8141,the,O
PMC37119020_407,8141,fibrotic,O
PMC37119020_407,8141,lung,O
PMC37119020_407,8141,tissue,O
PMC37119020_407,8141,0,O
PMC37119020_415,8142,Rupatadine,B-Drug
PMC37119020_415,8142,holds,O
PMC37119020_415,8142,promise,O
PMC37119020_415,8142,as,O
PMC37119020_415,8142,a,O
PMC37119020_415,8142,novel,O
PMC37119020_415,8142,drug,O
PMC37119020_415,8142,to,O
PMC37119020_415,8142,treat,O
PMC37119020_415,8142,the,O
PMC37119020_415,8142,devastating,O
PMC37119020_415,8142,disease,O
PMC37119020_415,8142,of,O
PMC37119020_415,8142,pulmonary,B-Disease
PMC37119020_415,8142,fibrosis,I-Disease
PMC37119020_415,8142,0,O
PMC37144560_369,8143,Bevacizumab,B-Drug
PMC37144560_369,8143,and,O
PMC37144560_369,8143,oral,O
PMC37144560_369,8143,metronomic,O
PMC37144560_369,8143,cyclophosphamide,O
PMC37144560_369,8143,in,O
PMC37144560_369,8143,platinum,O
PMC37144560_369,8143,-,O
PMC37144560_369,8143,resistant,O
PMC37144560_369,8143,ovarian,B-Disease
PMC37144560_369,8143,cancer,I-Disease
PMC37144560_369,8143,0,O
PMC37230010_649,8144,The,O
PMC37230010_649,8144,exact,O
PMC37230010_649,8144,pathogenesis,O
PMC37230010_649,8144,of,O
PMC37230010_649,8144,DRESS,B-Symptom
PMC37230010_649,8144,syndrome,I-Symptom
PMC37230010_649,8144,is,O
PMC37230010_649,8144,not,O
PMC37230010_649,8144,completely,O
PMC37230010_649,8144,understood,O
PMC37230010_649,8144,",",O
PMC37230010_649,8144,while,O
PMC37230010_649,8144,it,O
PMC37230010_649,8144,is,O
PMC37230010_649,8144,reported,O
PMC37230010_649,8144,that,O
PMC37230010_649,8144,amoxicillin,O
PMC37230010_649,8144,could,O
PMC37230010_649,8144,trigger,O
PMC37230010_649,8144,it,O
PMC37230010_649,8144,in,O
PMC37230010_649,8144,patients,O
PMC37230010_649,8144,who,O
PMC37230010_649,8144,are,O
PMC37230010_649,8144,taking,O
PMC37230010_649,8144,allopurinol,O
PMC37230010_649,8144,",",O
PMC37230010_649,8144,sulfasalazine,O
PMC37230010_649,8144,",",O
PMC37230010_649,8144,NSAIDs,O
PMC37230010_649,8144,",",O
PMC37230010_649,8144,carbamazepine,B-Drug
PMC37230010_649,8144,",",O
PMC37230010_649,8144,strontium,O
PMC37230010_649,8144,ranelate,O
PMC37230010_649,8144,",",O
PMC37230010_649,8144,lisinopril,B-Drug
PMC37230010_649,8144,",",O
PMC37230010_649,8144,lansoprazole,O
PMC37230010_649,8144,",",O
PMC37230010_649,8144,and,O
PMC37230010_649,8144,minocycline,O
PMC37230010_649,8144,0,O
PMC37254140_753,8145,PURPOSE,O
PMC37254140_753,8145,:,O
PMC37254140_753,8145,Topiramate,B-Drug
PMC37254140_753,8145,(,O
PMC37254140_753,8145,TPM,O
PMC37254140_753,8145,),O
PMC37254140_753,8145,is,O
PMC37254140_753,8145,known,O
PMC37254140_753,8145,to,O
PMC37254140_753,8145,cause,O
PMC37254140_753,8145,language,O
PMC37254140_753,8145,impairment,O
PMC37254140_753,8145,in,O
PMC37254140_753,8145,healthy,O
PMC37254140_753,8145,volunteers,O
PMC37254140_753,8145,and,O
PMC37254140_753,8145,patients,O
PMC37254140_753,8145,with,O
PMC37254140_753,8145,epilepsy,B-Disease
PMC37254140_753,8145,0,O
PMC37259030_1016,8146,Lamotrigine,B-Drug
PMC37259030_1016,8146,augmentation,O
PMC37259030_1016,8146,of,O
PMC37259030_1016,8146,serotonin,O
PMC37259030_1016,8146,reuptake,O
PMC37259030_1016,8146,inhibitors,O
PMC37259030_1016,8146,in,O
PMC37259030_1016,8146,severe,O
PMC37259030_1016,8146,and,O
PMC37259030_1016,8146,long,O
PMC37259030_1016,8146,-,O
PMC37259030_1016,8146,term,O
PMC37259030_1016,8146,treatment,O
PMC37259030_1016,8146,-,O
PMC37259030_1016,8146,resistant,O
PMC37259030_1016,8146,obsessive,B-Disease
PMC37259030_1016,8146,-,I-Disease
PMC37259030_1016,8146,compulsive,I-Disease
PMC37259030_1016,8146,disorder,I-Disease
PMC37259030_1016,8146,0,O
PMC37265860_343,8147,Lisdexamfetamine,B-Drug
PMC37265860_343,8147,(,O
PMC37265860_343,8147,LDX,O
PMC37265860_343,8147,),O
PMC37265860_343,8147,has,O
PMC37265860_343,8147,been,O
PMC37265860_343,8147,a,O
PMC37265860_343,8147,recent,O
PMC37265860_343,8147,addition,O
PMC37265860_343,8147,to,O
PMC37265860_343,8147,the,O
PMC37265860_343,8147,treatment,O
PMC37265860_343,8147,armamentarium,O
PMC37265860_343,8147,for,O
PMC37265860_343,8147,Attention,B-Disease
PMC37265860_343,8147,Deficit,I-Disease
PMC37265860_343,8147,Hyperactivity,I-Disease
PMC37265860_343,8147,Disorder,I-Disease
PMC37265860_343,8147,(,O
PMC37265860_343,8147,ADHD,O
PMC37265860_343,8147,),O
PMC37265860_343,8147,0,O
PMC37265860_515,8148,Update,O
PMC37265860_515,8148,on,O
PMC37265860_515,8148,optimal,O
PMC37265860_515,8148,use,O
PMC37265860_515,8148,of,O
PMC37265860_515,8148,lisdexamfetamine,B-Drug
PMC37265860_515,8148,in,O
PMC37265860_515,8148,the,O
PMC37265860_515,8148,treatment,O
PMC37265860_515,8148,of,O
PMC37265860_515,8148,ADHD,B-Disease
PMC37265860_515,8148,0,O
PMC37285980_436,8149,A,O
PMC37285980_436,8149,_,O
PMC37285980_436,8149,_,O
PMC37285980_436,8149,number,O
PMC37285980_436,8149,_,O
PMC37285980_436,8149,_,O
PMC37285980_436,8149,-,O
PMC37285980_436,8149,year,O
PMC37285980_436,8149,-,O
PMC37285980_436,8149,old,O
PMC37285980_436,8149,male,O
PMC37285980_436,8149,with,O
PMC37285980_436,8149,juvenile,O
PMC37285980_436,8149,myoclonic,B-Disease
PMC37285980_436,8149,epilepsy,I-Disease
PMC37285980_436,8149,was,O
PMC37285980_436,8149,admitted,O
PMC37285980_436,8149,to,O
PMC37285980_436,8149,the,O
PMC37285980_436,8149,neurological,O
PMC37285980_436,8149,department,O
PMC37285980_436,8149,for,O
PMC37285980_436,8149,convulsive,B-Symptom
PMC37285980_436,8149,seizures,I-Symptom
PMC37285980_436,8149,just,O
PMC37285980_436,8149,after,O
PMC37285980_436,8149,lamotrigine,B-Drug
PMC37285980_436,8149,was,O
PMC37285980_436,8149,discontinued,O
PMC37285980_436,8149,0,O
PMC37295020_406,8150,This,O
PMC37295020_406,8150,study,O
PMC37295020_406,8150,will,O
PMC37295020_406,8150,assess,O
PMC37295020_406,8150,the,O
PMC37295020_406,8150,efficacy,O
PMC37295020_406,8150,and,O
PMC37295020_406,8150,safety,O
PMC37295020_406,8150,of,O
PMC37295020_406,8150,oral,O
PMC37295020_406,8150,prednisone,B-Drug
PMC37295020_406,8150,as,O
PMC37295020_406,8150,an,O
PMC37295020_406,8150,add,O
PMC37295020_406,8150,-,O
PMC37295020_406,8150,on,O
PMC37295020_406,8150,therapy,O
PMC37295020_406,8150,to,O
PMC37295020_406,8150,verapamil,O
PMC37295020_406,8150,and,O
PMC37295020_406,8150,compare,O
PMC37295020_406,8150,it,O
PMC37295020_406,8150,to,O
PMC37295020_406,8150,a,O
PMC37295020_406,8150,monotherapy,O
PMC37295020_406,8150,with,O
PMC37295020_406,8150,verapamil,O
PMC37295020_406,8150,in,O
PMC37295020_406,8150,the,O
PMC37295020_406,8150,initial,O
PMC37295020_406,8150,prophylactic,O
PMC37295020_406,8150,treatment,O
PMC37295020_406,8150,of,O
PMC37295020_406,8150,a,O
PMC37295020_406,8150,cluster,B-Symptom
PMC37295020_406,8150,episode,O
PMC37295020_406,8150,0,O
PMC37295300_723,8151,METHODS,O
PMC37295300_723,8151,:,O
PMC37295300_723,8151,Twenty,O
PMC37295300_723,8151,adults,O
PMC37295300_723,8151,with,O
PMC37295300_723,8151,schizophrenia,B-Disease
PMC37295300_723,8151,or,O
PMC37295300_723,8151,other,O
PMC37295300_723,8151,psychotic,O
PMC37295300_723,8151,disorders,O
PMC37295300_723,8151,were,O
PMC37295300_723,8151,randomized,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,number,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,:,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,number,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,to,O
PMC37295300_723,8151,ziprasidone,B-Drug
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,number,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,mg,O
PMC37295300_723,8151,/,O
PMC37295300_723,8151,day,O
PMC37295300_723,8151,or,O
PMC37295300_723,8151,olanzapine,B-Drug
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,number,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,mg,O
PMC37295300_723,8151,/,O
PMC37295300_723,8151,day,O
PMC37295300_723,8151,for,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,number,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,_,O
PMC37295300_723,8151,weeks,O
PMC37295300_723,8151,0,O
PMC37298230_214,8152,Outcomes,O
PMC37298230_214,8152,analyzed,O
PMC37298230_214,8152,were,O
PMC37298230_214,8152,the,O
PMC37298230_214,8152,frequency,O
PMC37298230_214,8152,of,O
PMC37298230_214,8152,febrile,B-Symptom
PMC37298230_214,8152,neutropenia,I-Symptom
PMC37298230_214,8152,",",O
PMC37298230_214,8152,bacteremia,B-Symptom
PMC37298230_214,8152,",",O
PMC37298230_214,8152,duration,O
PMC37298230_214,8152,of,O
PMC37298230_214,8152,antibiotic,O
PMC37298230_214,8152,therapy,O
PMC37298230_214,8152,and,O
PMC37298230_214,8152,hospitalization,O
PMC37298230_214,8152,",",O
PMC37298230_214,8152,and,O
PMC37298230_214,8152,antimicrobial,O
PMC37298230_214,8152,resistance,O
PMC37298230_214,8152,to,O
PMC37298230_214,8152,ciprofloxacin,B-Drug
PMC37298230_214,8152,and,O
PMC37298230_214,8152,extended,O
PMC37298230_214,8152,-,O
PMC37298230_214,8152,spectrum,O
PMC37298230_214,8152,beta,O
PMC37298230_214,8152,-,O
PMC37298230_214,8152,lactamase,O
PMC37298230_214,8152,[,O
PMC37298230_214,8152,ESBL,O
PMC37298230_214,8152,],O
PMC37298230_214,8152,production,O
PMC37298230_214,8152,0,O
PMC37298390_424,8153,ATX,O
PMC37298390_424,8153,_,O
PMC37298390_424,8153,_,O
PMC37298390_424,8153,number,O
PMC37298390_424,8153,_,O
PMC37298390_424,8153,_,O
PMC37298390_424,8153,also,O
PMC37298390_424,8153,increased,O
PMC37298390_424,8153,multiple,O
PMC37298390_424,8153,myeloma,O
PMC37298390_424,8153,cells,O
PMC37298390_424,8153,',O
PMC37298390_424,8153,sensitivity,O
PMC37298390_424,8153,against,O
PMC37298390_424,8153,melphalan,B-Drug
PMC37298390_424,8153,",",O
PMC37298390_424,8153,a,O
PMC37298390_424,8153,DNA,O
PMC37298390_424,8153,damaging,O
PMC37298390_424,8153,agent,O
PMC37298390_424,8153,commonly,O
PMC37298390_424,8153,used,O
PMC37298390_424,8153,for,O
PMC37298390_424,8153,treatment,O
PMC37298390_424,8153,of,O
PMC37298390_424,8153,multiple,B-Disease
PMC37298390_424,8153,myeloma,I-Disease
PMC37298390_424,8153,0,O
PMC37433290_1037,8154,A,O
PMC37433290_1037,8154,quick,O
PMC37433290_1037,8154,review,O
PMC37433290_1037,8154,of,O
PMC37433290_1037,8154,carbamazepine,B-Drug
PMC37433290_1037,8154,pharmacokinetics,O
PMC37433290_1037,8154,in,O
PMC37433290_1037,8154,epilepsy,B-Disease
PMC37433290_1037,8154,from,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,number,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,to,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,number,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,_,O
PMC37433290_1037,8154,0,O
PMC37433290_434,8155,BACKGROUND,O
PMC37433290_434,8155,:,O
PMC37433290_434,8155,Carbamazepine,B-Drug
PMC37433290_434,8155,has,O
PMC37433290_434,8155,been,O
PMC37433290_434,8155,used,O
PMC37433290_434,8155,as,O
PMC37433290_434,8155,AEDs,O
PMC37433290_434,8155,since,O
PMC37433290_434,8155,_,O
PMC37433290_434,8155,_,O
PMC37433290_434,8155,number,O
PMC37433290_434,8155,_,O
PMC37433290_434,8155,_,O
PMC37433290_434,8155,",",O
PMC37433290_434,8155,and,O
PMC37433290_434,8155,is,O
PMC37433290_434,8155,most,O
PMC37433290_434,8155,effective,O
PMC37433290_434,8155,against,O
PMC37433290_434,8155,partial,B-Symptom
PMC37433290_434,8155,seizures,I-Symptom
PMC37433290_434,8155,0,O
PMC37452890_995,8156,CONCLUSION,O
PMC37452890_995,8156,:,O
PMC37452890_995,8156,Sequential,O
PMC37452890_995,8156,adjuvant,O
PMC37452890_995,8156,chemotherapy,O
PMC37452890_995,8156,with,O
PMC37452890_995,8156,FEC,O
PMC37452890_995,8156,followed,O
PMC37452890_995,8156,by,O
PMC37452890_995,8156,docetaxel,B-Drug
PMC37452890_995,8156,achieved,O
PMC37452890_995,8156,comparable,O
PMC37452890_995,8156,DFS,O
PMC37452890_995,8156,results,O
PMC37452890_995,8156,to,O
PMC37452890_995,8156,FEC,O
PMC37452890_995,8156,alone,O
PMC37452890_995,8156,in,O
PMC37452890_995,8156,luminal,O
PMC37452890_995,8156,A,O
PMC37452890_995,8156,phenotype,O
PMC37452890_995,8156,subgroups,O
PMC37452890_995,8156,of,O
PMC37452890_995,8156,breast,B-Disease
PMC37452890_995,8156,cancer,I-Disease
PMC37452890_995,8156,0,O
PMC37474900_840,8157,The,O
PMC37474900_840,8157,effect,O
PMC37474900_840,8157,of,O
PMC37474900_840,8157,fluoxetine,B-Drug
PMC37474900_840,8157,on,O
PMC37474900_840,8157,progression,O
PMC37474900_840,8157,in,O
PMC37474900_840,8157,progressive,O
PMC37474900_840,8157,multiple,B-Disease
PMC37474900_840,8157,sclerosis,I-Disease
PMC37474900_840,8157,:,O
PMC37474900_840,8157,a,O
PMC37474900_840,8157,double,O
PMC37474900_840,8157,-,O
PMC37474900_840,8157,blind,O
PMC37474900_840,8157,",",O
PMC37474900_840,8157,randomized,O
PMC37474900_840,8157,",",O
PMC37474900_840,8157,placebo,O
PMC37474900_840,8157,-,O
PMC37474900_840,8157,controlled,O
PMC37474900_840,8157,trial,O
PMC37474900_840,8157,0,O
PMC37488240_299,8158,The,O
PMC37488240_299,8158,aim,O
PMC37488240_299,8158,of,O
PMC37488240_299,8158,this,O
PMC37488240_299,8158,study,O
PMC37488240_299,8158,is,O
PMC37488240_299,8158,to,O
PMC37488240_299,8158,assess,O
PMC37488240_299,8158,the,O
PMC37488240_299,8158,efficacy,O
PMC37488240_299,8158,and,O
PMC37488240_299,8158,safety,O
PMC37488240_299,8158,of,O
PMC37488240_299,8158,the,O
PMC37488240_299,8158,homeopathic,O
PMC37488240_299,8158,individualized,O
PMC37488240_299,8158,treatment,O
PMC37488240_299,8158,versus,O
PMC37488240_299,8158,placebo,O
PMC37488240_299,8158,or,O
PMC37488240_299,8158,fluoxetine,B-Drug
PMC37488240_299,8158,in,O
PMC37488240_299,8158,peri,O
PMC37488240_299,8158,-,O
PMC37488240_299,8158,and,O
PMC37488240_299,8158,postmenopausal,O
PMC37488240_299,8158,women,O
PMC37488240_299,8158,with,O
PMC37488240_299,8158,moderate,O
PMC37488240_299,8158,to,O
PMC37488240_299,8158,severe,O
PMC37488240_299,8158,depression,B-Disease
PMC37488240_299,8158,0,O
PMC37505910_338,8159,Treatment,O
PMC37505910_338,8159,of,O
PMC37505910_338,8159,corneal,O
PMC37505910_338,8159,neovascularization,O
PMC37505910_338,8159,in,O
PMC37505910_338,8159,ocular,O
PMC37505910_338,8159,chemical,O
PMC37505910_338,8159,injury,O
PMC37505910_338,8159,with,O
PMC37505910_338,8159,an,O
PMC37505910_338,8159,off,O
PMC37505910_338,8159,-,O
PMC37505910_338,8159,label,O
PMC37505910_338,8159,use,O
PMC37505910_338,8159,of,O
PMC37505910_338,8159,subconjunctival,O
PMC37505910_338,8159,bevacizumab,B-Drug
PMC37505910_338,8159,:,O
PMC37505910_338,8159,a,O
PMC37505910_338,8159,case,O
PMC37505910_338,8159,report,O
PMC37505910_338,8159,0,O
PMC37506980_176,8160,Study,O
PMC37506980_176,8160,protocol,O
PMC37506980_176,8160,of,O
PMC37506980_176,8160,the,O
PMC37506980_176,8160,Diabetes,O
PMC37506980_176,8160,and,O
PMC37506980_176,8160,Depression,O
PMC37506980_176,8160,Study,O
PMC37506980_176,8160,(,O
PMC37506980_176,8160,DAD,O
PMC37506980_176,8160,),O
PMC37506980_176,8160,:,O
PMC37506980_176,8160,a,O
PMC37506980_176,8160,multi,O
PMC37506980_176,8160,-,O
PMC37506980_176,8160,center,O
PMC37506980_176,8160,randomized,O
PMC37506980_176,8160,controlled,O
PMC37506980_176,8160,trial,O
PMC37506980_176,8160,to,O
PMC37506980_176,8160,compare,O
PMC37506980_176,8160,the,O
PMC37506980_176,8160,efficacy,O
PMC37506980_176,8160,of,O
PMC37506980_176,8160,a,O
PMC37506980_176,8160,diabetes,O
PMC37506980_176,8160,-,O
PMC37506980_176,8160,specific,O
PMC37506980_176,8160,cognitive,O
PMC37506980_176,8160,behavioral,O
PMC37506980_176,8160,group,O
PMC37506980_176,8160,therapy,O
PMC37506980_176,8160,versus,O
PMC37506980_176,8160,sertraline,B-Drug
PMC37506980_176,8160,in,O
PMC37506980_176,8160,patients,O
PMC37506980_176,8160,with,O
PMC37506980_176,8160,major,B-Disease
PMC37506980_176,8160,depression,I-Disease
PMC37506980_176,8160,and,O
PMC37506980_176,8160,poorly,O
PMC37506980_176,8160,controlled,O
PMC37506980_176,8160,diabetes,B-Disease
PMC37506980_176,8160,mellitus,I-Disease
PMC37506980_176,8160,0,O
PMC37514260_115,8161,CONCLUSIONS,O
PMC37514260_115,8161,:,O
PMC37514260_115,8161,This,O
PMC37514260_115,8161,post,O
PMC37514260_115,8161,hoc,O
PMC37514260_115,8161,analysis,O
PMC37514260_115,8161,showed,O
PMC37514260_115,8161,that,O
PMC37514260_115,8161,",",O
PMC37514260_115,8161,at,O
PMC37514260_115,8161,the,O
PMC37514260_115,8161,doses,O
PMC37514260_115,8161,tested,O
PMC37514260_115,8161,",",O
PMC37514260_115,8161,patients,O
PMC37514260_115,8161,treated,O
PMC37514260_115,8161,with,O
PMC37514260_115,8161,lisdexamfetamine,B-Drug
PMC37514260_115,8161,showed,O
PMC37514260_115,8161,statistically,O
PMC37514260_115,8161,significantly,O
PMC37514260_115,8161,greater,O
PMC37514260_115,8161,improvement,O
PMC37514260_115,8161,in,O
PMC37514260_115,8161,symptoms,O
PMC37514260_115,8161,of,O
PMC37514260_115,8161,ADHD,B-Disease
PMC37514260_115,8161,than,O
PMC37514260_115,8161,those,O
PMC37514260_115,8161,receiving,O
PMC37514260_115,8161,OROS,O
PMC37514260_115,8161,-,O
PMC37514260_115,8161,MPH,O
PMC37514260_115,8161,",",O
PMC37514260_115,8161,as,O
PMC37514260_115,8161,assessed,O
PMC37514260_115,8161,using,O
PMC37514260_115,8161,the,O
PMC37514260_115,8161,ADHD,O
PMC37514260_115,8161,-,O
PMC37514260_115,8161,RS,O
PMC37514260_115,8161,-,O
PMC37514260_115,8161,IV,O
PMC37514260_115,8161,and,O
PMC37514260_115,8161,CGI,O
PMC37514260_115,8161,-,O
PMC37514260_115,8161,I,O
PMC37514260_115,8161,0,O
PMC37514260_122,8162,The,O
PMC37514260_122,8162,mean,O
PMC37514260_122,8162,(,O
PMC37514260_122,8162,standard,O
PMC37514260_122,8162,deviation,O
PMC37514260_122,8162,),O
PMC37514260_122,8162,ADHD,B-Disease
PMC37514260_122,8162,-,O
PMC37514260_122,8162,RS,O
PMC37514260_122,8162,-,O
PMC37514260_122,8162,IV,O
PMC37514260_122,8162,total,O
PMC37514260_122,8162,score,O
PMC37514260_122,8162,at,O
PMC37514260_122,8162,baseline,O
PMC37514260_122,8162,was,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,number,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,(,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,number,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,),O
PMC37514260_122,8162,for,O
PMC37514260_122,8162,lisdexamfetamine,B-Drug
PMC37514260_122,8162,",",O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,number,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,(,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,number,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,),O
PMC37514260_122,8162,for,O
PMC37514260_122,8162,placebo,O
PMC37514260_122,8162,and,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,number,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,(,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,number,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,_,O
PMC37514260_122,8162,),O
PMC37514260_122,8162,for,O
PMC37514260_122,8162,OROS,O
PMC37514260_122,8162,-,O
PMC37514260_122,8162,MPH,O
PMC37514260_122,8162,0,O
PMC37514260_162,8163,The,O
PMC37514260_162,8163,overall,O
PMC37514260_162,8163,frequency,O
PMC37514260_162,8163,of,O
PMC37514260_162,8163,TEAEs,O
PMC37514260_162,8163,and,O
PMC37514260_162,8163,the,O
PMC37514260_162,8163,frequencies,O
PMC37514260_162,8163,of,O
PMC37514260_162,8163,decreased,B-Symptom
PMC37514260_162,8163,appetite,I-Symptom
PMC37514260_162,8163,",",O
PMC37514260_162,8163,insomnia,B-Symptom
PMC37514260_162,8163,",",O
PMC37514260_162,8163,decreased,B-Symptom
PMC37514260_162,8163,weight,I-Symptom
PMC37514260_162,8163,",",O
PMC37514260_162,8163,nausea,B-Symptom
PMC37514260_162,8163,and,O
PMC37514260_162,8163,anorexia,B-Disease
PMC37514260_162,8163,TEAEs,O
PMC37514260_162,8163,were,O
PMC37514260_162,8163,greater,O
PMC37514260_162,8163,in,O
PMC37514260_162,8163,patients,O
PMC37514260_162,8163,treated,O
PMC37514260_162,8163,with,O
PMC37514260_162,8163,lisdexamfetamine,B-Drug
PMC37514260_162,8163,than,O
PMC37514260_162,8163,in,O
PMC37514260_162,8163,those,O
PMC37514260_162,8163,treated,O
PMC37514260_162,8163,with,O
PMC37514260_162,8163,OROS,O
PMC37514260_162,8163,-,O
PMC37514260_162,8163,MPH,O
PMC37514260_162,8163,",",O
PMC37514260_162,8163,whereas,O
PMC37514260_162,8163,headache,B-Symptom
PMC37514260_162,8163,and,O
PMC37514260_162,8163,nasopharyngitis,B-Symptom
PMC37514260_162,8163,were,O
PMC37514260_162,8163,more,O
PMC37514260_162,8163,frequently,O
PMC37514260_162,8163,reported,O
PMC37514260_162,8163,in,O
PMC37514260_162,8163,patients,O
PMC37514260_162,8163,receiving,O
PMC37514260_162,8163,OROS,O
PMC37514260_162,8163,-,O
PMC37514260_162,8163,MPH,O
PMC37514260_162,8163,0,O
PMC37514260_205,8164,A,O
PMC37514260_205,8164,post,O
PMC37514260_205,8164,hoc,O
PMC37514260_205,8164,comparison,O
PMC37514260_205,8164,of,O
PMC37514260_205,8164,the,O
PMC37514260_205,8164,effects,O
PMC37514260_205,8164,of,O
PMC37514260_205,8164,lisdexamfetamine,B-Drug
PMC37514260_205,8164,dimesylate,O
PMC37514260_205,8164,and,O
PMC37514260_205,8164,osmotic,O
PMC37514260_205,8164,-,O
PMC37514260_205,8164,release,O
PMC37514260_205,8164,oral,O
PMC37514260_205,8164,system,O
PMC37514260_205,8164,methylphenidate,B-Drug
PMC37514260_205,8164,on,O
PMC37514260_205,8164,symptoms,O
PMC37514260_205,8164,of,O
PMC37514260_205,8164,attention,O
PMC37514260_205,8164,-,O
PMC37514260_205,8164,deficit,O
PMC37514260_205,8164,hyperactivity,O
PMC37514260_205,8164,disorder,O
PMC37514260_205,8164,in,O
PMC37514260_205,8164,children,O
PMC37514260_205,8164,and,O
PMC37514260_205,8164,adolescents,O
PMC37514260_205,8164,0,O
PMC37514260_373,8165,This,O
PMC37514260_373,8165,post,O
PMC37514260_373,8165,hoc,O
PMC37514260_373,8165,analysis,O
PMC37514260_373,8165,provides,O
PMC37514260_373,8165,the,O
PMC37514260_373,8165,first,O
PMC37514260_373,8165,parallel,O
PMC37514260_373,8165,-,O
PMC37514260_373,8165,group,O
PMC37514260_373,8165,comparison,O
PMC37514260_373,8165,of,O
PMC37514260_373,8165,the,O
PMC37514260_373,8165,effect,O
PMC37514260_373,8165,of,O
PMC37514260_373,8165,lisdexamfetamine,B-Drug
PMC37514260_373,8165,dimesylate,I-Drug
PMC37514260_373,8165,(,O
PMC37514260_373,8165,lisdexamfetamine,B-Drug
PMC37514260_373,8165,),O
PMC37514260_373,8165,and,O
PMC37514260_373,8165,osmotic,O
PMC37514260_373,8165,-,O
PMC37514260_373,8165,release,O
PMC37514260_373,8165,oral,O
PMC37514260_373,8165,system,O
PMC37514260_373,8165,methylphenidate,B-Drug
PMC37514260_373,8165,(,O
PMC37514260_373,8165,OROS,O
PMC37514260_373,8165,-,O
PMC37514260_373,8165,MPH,O
PMC37514260_373,8165,),O
PMC37514260_373,8165,on,O
PMC37514260_373,8165,symptoms,O
PMC37514260_373,8165,of,O
PMC37514260_373,8165,ADHD,B-Disease
PMC37514260_373,8165,in,O
PMC37514260_373,8165,children,O
PMC37514260_373,8165,and,O
PMC37514260_373,8165,adolescents,O
PMC37514260_373,8165,0,O
PMC37543700_380,8166,Results,O
PMC37543700_380,8166,of,O
PMC37543700_380,8166,a,O
PMC37543700_380,8166,combination,O
PMC37543700_380,8166,of,O
PMC37543700_380,8166,bleomycin,O
PMC37543700_380,8166,and,O
PMC37543700_380,8166,triamcinolone,B-Drug
PMC37543700_380,8166,acetonide,O
PMC37543700_380,8166,in,O
PMC37543700_380,8166,the,O
PMC37543700_380,8166,treatment,O
PMC37543700_380,8166,of,O
PMC37543700_380,8166,keloids,B-Symptom
PMC37543700_380,8166,and,O
PMC37543700_380,8166,hypertrophic,B-Symptom
PMC37543700_380,8166,scars,I-Symptom
PMC37543700_380,8166,0,O
PMC37543700_961,8167,In,O
PMC37543700_961,8167,conclusion,O
PMC37543700_961,8167,",",O
PMC37543700_961,8167,combined,O
PMC37543700_961,8167,treatment,O
PMC37543700_961,8167,with,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,number,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,IU,O
PMC37543700_961,8167,of,O
PMC37543700_961,8167,bleomycin,O
PMC37543700_961,8167,and,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,number,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,mg,O
PMC37543700_961,8167,of,O
PMC37543700_961,8167,triamcinolone,B-Drug
PMC37543700_961,8167,acetonide,O
PMC37543700_961,8167,to,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,number,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,cm,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,number,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,_,O
PMC37543700_961,8167,was,O
PMC37543700_961,8167,considered,O
PMC37543700_961,8167,to,O
PMC37543700_961,8167,be,O
PMC37543700_961,8167,an,O
PMC37543700_961,8167,acceptable,O
PMC37543700_961,8167,procedure,O
PMC37543700_961,8167,for,O
PMC37543700_961,8167,the,O
PMC37543700_961,8167,treatment,O
PMC37543700_961,8167,of,O
PMC37543700_961,8167,keloids,B-Symptom
PMC37543700_961,8167,0,O
PMC37638430_16,8168,A,O
PMC37638430_16,8168,double,O
PMC37638430_16,8168,-,O
PMC37638430_16,8168,blind,O
PMC37638430_16,8168,",",O
PMC37638430_16,8168,randomized,O
PMC37638430_16,8168,",",O
PMC37638430_16,8168,placebo,O
PMC37638430_16,8168,-,O
PMC37638430_16,8168,controlled,O
PMC37638430_16,8168,study,O
PMC37638430_16,8168,assessing,O
PMC37638430_16,8168,the,O
PMC37638430_16,8168,efficacy,O
PMC37638430_16,8168,and,O
PMC37638430_16,8168,tolerability,O
PMC37638430_16,8168,of,O
PMC37638430_16,8168,desvenlafaxine,B-Drug
PMC37638430_16,8168,_,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,number,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,and,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,number,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,_,O
PMC37638430_16,8168,mg,O
PMC37638430_16,8168,/,O
PMC37638430_16,8168,day,O
PMC37638430_16,8168,in,O
PMC37638430_16,8168,adult,O
PMC37638430_16,8168,outpatients,O
PMC37638430_16,8168,with,O
PMC37638430_16,8168,major,B-Disease
PMC37638430_16,8168,depressive,I-Disease
PMC37638430_16,8168,disorder,I-Disease
PMC37638430_16,8168,0,O
PMC37638430_91,8169,METHODS,O
PMC37638430_91,8169,:,O
PMC37638430_91,8169,Adult,O
PMC37638430_91,8169,outpatients,O
PMC37638430_91,8169,with,O
PMC37638430_91,8169,DSM,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,IV,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,defined,O
PMC37638430_91,8169,major,B-Disease
PMC37638430_91,8169,depressive,I-Disease
PMC37638430_91,8169,disorder,I-Disease
PMC37638430_91,8169,and,O
PMC37638430_91,8169,a,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,item,O
PMC37638430_91,8169,Hamilton,O
PMC37638430_91,8169,Rating,O
PMC37638430_91,8169,Scale,O
PMC37638430_91,8169,for,O
PMC37638430_91,8169,Depression,O
PMC37638430_91,8169,(,O
PMC37638430_91,8169,HAM,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,D,O
PMC37638430_91,8169,(,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,),O
PMC37638430_91,8169,),O
PMC37638430_91,8169,total,O
PMC37638430_91,8169,score,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,were,O
PMC37638430_91,8169,randomly,O
PMC37638430_91,8169,assigned,O
PMC37638430_91,8169,to,O
PMC37638430_91,8169,receive,O
PMC37638430_91,8169,placebo,O
PMC37638430_91,8169,or,O
PMC37638430_91,8169,desvenlafaxine,B-Drug
PMC37638430_91,8169,(,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,or,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,mg,O
PMC37638430_91,8169,/,O
PMC37638430_91,8169,day,O
PMC37638430_91,8169,),O
PMC37638430_91,8169,after,O
PMC37638430_91,8169,a,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,to,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,day,O
PMC37638430_91,8169,single,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,blind,O
PMC37638430_91,8169,placebo,O
PMC37638430_91,8169,lead,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,in,O
PMC37638430_91,8169,period,O
PMC37638430_91,8169,in,O
PMC37638430_91,8169,an,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,week,O
PMC37638430_91,8169,",",O
PMC37638430_91,8169,phase,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,number,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,_,O
PMC37638430_91,8169,",",O
PMC37638430_91,8169,fixed,O
PMC37638430_91,8169,-,O
PMC37638430_91,8169,dose,O
PMC37638430_91,8169,trial,O
PMC37638430_91,8169,0,O
PMC37641140_978,8170,The,O
PMC37641140_978,8170,ability,O
PMC37641140_978,8170,of,O
PMC37641140_978,8170,Montelukast,B-Drug
PMC37641140_978,8170,to,O
PMC37641140_978,8170,inhibit,O
PMC37641140_978,8170,growth,O
PMC37641140_978,8170,of,O
PMC37641140_978,8170,human,O
PMC37641140_978,8170,colon,B-Disease
PMC37641140_978,8170,cancer,I-Disease
PMC37641140_978,8170,xenograft,O
PMC37641140_978,8170,was,O
PMC37641140_978,8170,further,O
PMC37641140_978,8170,validated,O
PMC37641140_978,8170,by,O
PMC37641140_978,8170,using,O
PMC37641140_978,8170,two,O
PMC37641140_978,8170,additional,O
PMC37641140_978,8170,colon,O
PMC37641140_978,8170,cancer,O
PMC37641140_978,8170,cell,O
PMC37641140_978,8170,lines,O
PMC37641140_978,8170,",",O
PMC37641140_978,8170,SW,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,number,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,and,O
PMC37641140_978,8170,HT,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,number,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,_,O
PMC37641140_978,8170,0,O
PMC37653340_980,8171,HBV,B-Disease
PMC37653340_980,8171,reactivation,I-Disease
PMC37653340_980,8171,in,O
PMC37653340_980,8171,an,O
PMC37653340_980,8171,occult,O
PMC37653340_980,8171,HBV,B-Disease
PMC37653340_980,8171,infection,O
PMC37653340_980,8171,patient,O
PMC37653340_980,8171,treated,O
PMC37653340_980,8171,with,O
PMC37653340_980,8171,prednisone,B-Drug
PMC37653340_980,8171,for,O
PMC37653340_980,8171,nephrotic,O
PMC37653340_980,8171,syndrome,O
PMC37653340_980,8171,:,O
PMC37653340_980,8171,case,O
PMC37653340_980,8171,report,O
PMC37653340_980,8171,and,O
PMC37653340_980,8171,literature,O
PMC37653340_980,8171,review,O
PMC37653340_980,8171,0,O
PMC37706450_345,8172,This,O
PMC37706450_345,8172,study,O
PMC37706450_345,8172,was,O
PMC37706450_345,8172,a,O
PMC37706450_345,8172,comparative,O
PMC37706450_345,8172,investigation,O
PMC37706450_345,8172,of,O
PMC37706450_345,8172,the,O
PMC37706450_345,8172,clinical,O
PMC37706450_345,8172,efficacy,O
PMC37706450_345,8172,and,O
PMC37706450_345,8172,safety,O
PMC37706450_345,8172,of,O
PMC37706450_345,8172,IM,O
PMC37706450_345,8172,olanzapine,B-Drug
PMC37706450_345,8172,and,O
PMC37706450_345,8172,IM,O
PMC37706450_345,8172,levomepromazine,O
PMC37706450_345,8172,in,O
PMC37706450_345,8172,agitated,O
PMC37706450_345,8172,elderly,O
PMC37706450_345,8172,patients,O
PMC37706450_345,8172,with,O
PMC37706450_345,8172,schizophrenia,B-Disease
PMC37706450_345,8172,at,O
PMC37706450_345,8172,_,O
PMC37706450_345,8172,_,O
PMC37706450_345,8172,number,O
PMC37706450_345,8172,_,O
PMC37706450_345,8172,_,O
PMC37706450_345,8172,hours,O
PMC37706450_345,8172,post,O
PMC37706450_345,8172,-,O
PMC37706450_345,8172,dose,O
PMC37706450_345,8172,0,O
PMC37709820_735,8173,Active,O
PMC37709820_735,8173,metabolites,O
PMC37709820_735,8173,as,O
PMC37709820_735,8173,antidepressant,O
PMC37709820_735,8173,drugs,O
PMC37709820_735,8173,:,O
PMC37709820_735,8173,the,O
PMC37709820_735,8173,role,O
PMC37709820_735,8173,of,O
PMC37709820_735,8173,norquetiapine,O
PMC37709820_735,8173,in,O
PMC37709820_735,8173,the,O
PMC37709820_735,8173,mechanism,O
PMC37709820_735,8173,of,O
PMC37709820_735,8173,action,O
PMC37709820_735,8173,of,O
PMC37709820_735,8173,quetiapine,B-Drug
PMC37709820_735,8173,in,O
PMC37709820_735,8173,the,O
PMC37709820_735,8173,treatment,O
PMC37709820_735,8173,of,O
PMC37709820_735,8173,mood,B-Disease
PMC37709820_735,8173,disorders,I-Disease
PMC37709820_735,8173,0,O
PMC37720910_836,8174,CONCLUSIONS,O
PMC37720910_836,8174,:,O
PMC37720910_836,8174,Data,O
PMC37720910_836,8174,encourage,O
PMC37720910_836,8174,further,O
PMC37720910_836,8174,studies,O
PMC37720910_836,8174,on,O
PMC37720910_836,8174,the,O
PMC37720910_836,8174,predictive,O
PMC37720910_836,8174,potential,O
PMC37720910_836,8174,of,O
PMC37720910_836,8174,CD,O
PMC37720910_836,8174,_,O
PMC37720910_836,8174,_,O
PMC37720910_836,8174,number,O
PMC37720910_836,8174,_,O
PMC37720910_836,8174,_,O
PMC37720910_836,8174,+,O
PMC37720910_836,8174,CECs,O
PMC37720910_836,8174,in,O
PMC37720910_836,8174,GBM,B-Disease
PMC37720910_836,8174,patients,O
PMC37720910_836,8174,treated,O
PMC37720910_836,8174,with,O
PMC37720910_836,8174,bevacizumab,B-Drug
PMC37720910_836,8174,0,O
PMC37722790_79,8175,Our,O
PMC37722790_79,8175,results,O
PMC37722790_79,8175,and,O
PMC37722790_79,8175,the,O
PMC37722790_79,8175,literature,O
PMC37722790_79,8175,data,O
PMC37722790_79,8175,indicate,O
PMC37722790_79,8175,that,O
PMC37722790_79,8175,quetiapine,B-Drug
PMC37722790_79,8175,could,O
PMC37722790_79,8175,help,O
PMC37722790_79,8175,both,O
PMC37722790_79,8175,as,O
PMC37722790_79,8175,a,O
PMC37722790_79,8175,neuronal,O
PMC37722790_79,8175,protector,O
PMC37722790_79,8175,and,O
PMC37722790_79,8175,to,O
PMC37722790_79,8175,resolve,O
PMC37722790_79,8175,neuropsychiatric,B-Symptom
PMC37722790_79,8175,problems,I-Symptom
PMC37722790_79,8175,caused,O
PMC37722790_79,8175,by,O
PMC37722790_79,8175,the,O
PMC37722790_79,8175,ischemia,B-Symptom
PMC37722790_79,8175,in,O
PMC37722790_79,8175,cerebral,B-Symptom
PMC37722790_79,8175,ischemia,I-Symptom
PMC37722790_79,8175,cases,O
PMC37722790_79,8175,0,O
PMC37727690_609,8176,CONCLUSION,O
PMC37727690_609,8176,:,O
PMC37727690_609,8176,Intravitreal,O
PMC37727690_609,8176,bevacizumab,B-Drug
PMC37727690_609,8176,injection,O
PMC37727690_609,8176,was,O
PMC37727690_609,8176,effective,O
PMC37727690_609,8176,for,O
PMC37727690_609,8176,treatment,O
PMC37727690_609,8176,of,O
PMC37727690_609,8176,retinal,B-Disease
PMC37727690_609,8176,vein,I-Disease
PMC37727690_609,8176,branch,I-Disease
PMC37727690_609,8176,occlusion,I-Disease
PMC37727690_609,8176,0,O
PMC37787930_114,8177,Lamotrigine,B-Drug
PMC37787930_114,8177,is,O
PMC37787930_114,8177,a,O
PMC37787930_114,8177,newer,O
PMC37787930_114,8177,",",O
PMC37787930_114,8177,unrelated,O
PMC37787930_114,8177,antiepileptic,O
PMC37787930_114,8177,drug,O
PMC37787930_114,8177,that,O
PMC37787930_114,8177,causes,O
PMC37787930_114,8177,skin,B-Symptom
PMC37787930_114,8177,rashes,I-Symptom
PMC37787930_114,8177,in,O
PMC37787930_114,8177,_,O
PMC37787930_114,8177,_,O
PMC37787930_114,8177,number,O
PMC37787930_114,8177,_,O
PMC37787930_114,8177,_,O
PMC37787930_114,8177,%,O
PMC37787930_114,8177,of,O
PMC37787930_114,8177,new,O
PMC37787930_114,8177,users,O
PMC37787930_114,8177,0,O
PMC37787930_911,8178,Higher,O
PMC37787930_911,8178,starting,O
PMC37787930_911,8178,dose,O
PMC37787930_911,8178,or,O
PMC37787930_911,8178,rapid,O
PMC37787930_911,8178,escalation,O
PMC37787930_911,8178,",",O
PMC37787930_911,8178,concurrent,O
PMC37787930_911,8178,treatment,O
PMC37787930_911,8178,with,O
PMC37787930_911,8178,valproic,O
PMC37787930_911,8178,acid,O
PMC37787930_911,8178,",",O
PMC37787930_911,8178,and,O
PMC37787930_911,8178,a,O
PMC37787930_911,8178,previous,O
PMC37787930_911,8178,history,O
PMC37787930_911,8178,of,O
PMC37787930_911,8178,a,O
PMC37787930_911,8178,rash,B-Symptom
PMC37787930_911,8178,with,O
PMC37787930_911,8178,other,O
PMC37787930_911,8178,antiepileptic,O
PMC37787930_911,8178,drugs,O
PMC37787930_911,8178,are,O
PMC37787930_911,8178,well,O
PMC37787930_911,8178,recognized,O
PMC37787930_911,8178,risk,O
PMC37787930_911,8178,factors,O
PMC37787930_911,8178,for,O
PMC37787930_911,8178,lamotrigine,B-Drug
PMC37787930_911,8178,related,O
PMC37787930_911,8178,serious,O
PMC37787930_911,8178,rashes,O
PMC37787930_911,8178,0,O
PMC37836840_929,8179,OBJECTIVE,O
PMC37836840_929,8179,:,O
PMC37836840_929,8179,Combination,O
PMC37836840_929,8179,therapy,O
PMC37836840_929,8179,of,O
PMC37836840_929,8179,lisinopril,B-Drug
PMC37836840_929,8179,and,O
PMC37836840_929,8179,rosuvastatin,O
PMC37836840_929,8179,may,O
PMC37836840_929,8179,be,O
PMC37836840_929,8179,an,O
PMC37836840_929,8179,important,O
PMC37836840_929,8179,concept,O
PMC37836840_929,8179,in,O
PMC37836840_929,8179,developing,O
PMC37836840_929,8179,more,O
PMC37836840_929,8179,effective,O
PMC37836840_929,8179,strategies,O
PMC37836840_929,8179,to,O
PMC37836840_929,8179,treat,O
PMC37836840_929,8179,and,O
PMC37836840_929,8179,prevent,O
PMC37836840_929,8179,atherosclerosis,B-Disease
PMC37836840_929,8179,",",O
PMC37836840_929,8179,coronary,B-Disease
PMC37836840_929,8179,heart,I-Disease
PMC37836840_929,8179,disease,I-Disease
PMC37836840_929,8179,",",O
PMC37836840_929,8179,and,O
PMC37836840_929,8179,co,O
PMC37836840_929,8179,-,O
PMC37836840_929,8179,morbid,O
PMC37836840_929,8179,metabolic,B-Disease
PMC37836840_929,8179,disorders,I-Disease
PMC37836840_929,8179,0,O
PMC37840630_412,8180,Health,O
PMC37840630_412,8180,-,O
PMC37840630_412,8180,related,O
PMC37840630_412,8180,quality,O
PMC37840630_412,8180,of,O
PMC37840630_412,8180,life,O
PMC37840630_412,8180,and,O
PMC37840630_412,8180,functional,O
PMC37840630_412,8180,outcomes,O
PMC37840630_412,8180,from,O
PMC37840630_412,8180,a,O
PMC37840630_412,8180,randomized,O
PMC37840630_412,8180,",",O
PMC37840630_412,8180,controlled,O
PMC37840630_412,8180,study,O
PMC37840630_412,8180,of,O
PMC37840630_412,8180,lisdexamfetamine,B-Drug
PMC37840630_412,8180,dimesylate,I-Drug
PMC37840630_412,8180,in,O
PMC37840630_412,8180,children,O
PMC37840630_412,8180,and,O
PMC37840630_412,8180,adolescents,O
PMC37840630_412,8180,with,O
PMC37840630_412,8180,attention,B-Disease
PMC37840630_412,8180,deficit,I-Disease
PMC37840630_412,8180,hyperactivity,I-Disease
PMC37840630_412,8180,disorder,I-Disease
PMC37840630_412,8180,0,O
PMC37840630_557,8181,A,O
PMC37840630_557,8181,pivotal,O
PMC37840630_557,8181,",",O
PMC37840630_557,8181,_,O
PMC37840630_557,8181,_,O
PMC37840630_557,8181,number,O
PMC37840630_557,8181,_,O
PMC37840630_557,8181,_,O
PMC37840630_557,8181,-,O
PMC37840630_557,8181,week,O
PMC37840630_557,8181,",",O
PMC37840630_557,8181,randomized,O
PMC37840630_557,8181,",",O
PMC37840630_557,8181,double,O
PMC37840630_557,8181,-,O
PMC37840630_557,8181,blind,O
PMC37840630_557,8181,",",O
PMC37840630_557,8181,placebo,O
PMC37840630_557,8181,-,O
PMC37840630_557,8181,controlled,O
PMC37840630_557,8181,",",O
PMC37840630_557,8181,phase,O
PMC37840630_557,8181,II,O
PMC37840630_557,8181,study,O
PMC37840630_557,8181,in,O
PMC37840630_557,8181,children,O
PMC37840630_557,8181,and,O
PMC37840630_557,8181,adolescents,O
PMC37840630_557,8181,in,O
PMC37840630_557,8181,ten,O
PMC37840630_557,8181,European,O
PMC37840630_557,8181,countries,O
PMC37840630_557,8181,demonstrated,O
PMC37840630_557,8181,that,O
PMC37840630_557,8181,the,O
PMC37840630_557,8181,stimulant,O
PMC37840630_557,8181,prodrug,O
PMC37840630_557,8181,lisdexamfetamine,B-Drug
PMC37840630_557,8181,dimesylate,I-Drug
PMC37840630_557,8181,(,O
PMC37840630_557,8181,LDX,O
PMC37840630_557,8181,),O
PMC37840630_557,8181,is,O
PMC37840630_557,8181,an,O
PMC37840630_557,8181,effective,O
PMC37840630_557,8181,and,O
PMC37840630_557,8181,generally,O
PMC37840630_557,8181,well,O
PMC37840630_557,8181,-,O
PMC37840630_557,8181,tolerated,O
PMC37840630_557,8181,treatment,O
PMC37840630_557,8181,for,O
PMC37840630_557,8181,symptoms,O
PMC37840630_557,8181,of,O
PMC37840630_557,8181,ADHD,O
PMC37840630_557,8181,0,O
PMC37853170_637,8182,She,O
PMC37853170_637,8182,was,O
PMC37853170_637,8182,diagnosed,O
PMC37853170_637,8182,with,O
PMC37853170_637,8182,Wegener,B-Disease
PMC37853170_637,8182,',I-Disease
PMC37853170_637,8182,s,I-Disease
PMC37853170_637,8182,granulomatosis,I-Disease
PMC37853170_637,8182,limited,O
PMC37853170_637,8182,to,O
PMC37853170_637,8182,the,O
PMC37853170_637,8182,eye,O
PMC37853170_637,8182,and,O
PMC37853170_637,8182,was,O
PMC37853170_637,8182,treated,O
PMC37853170_637,8182,with,O
PMC37853170_637,8182,oral,O
PMC37853170_637,8182,cyclophosphamide,O
PMC37853170_637,8182,and,O
PMC37853170_637,8182,prednisone,B-Drug
PMC37853170_637,8182,followed,O
PMC37853170_637,8182,by,O
PMC37853170_637,8182,weekly,O
PMC37853170_637,8182,methotrexate,O
PMC37853170_637,8182,with,O
PMC37853170_637,8182,good,O
PMC37853170_637,8182,response,O
PMC37853170_637,8182,0,O
PMC37853610_315,8183,Under,O
PMC37853610_315,8183,the,O
PMC37853610_315,8183,diagnosis,O
PMC37853610_315,8183,of,O
PMC37853610_315,8183,Fahr,B-Disease
PMC37853610_315,8183,',I-Disease
PMC37853610_315,8183,s,I-Disease
PMC37853610_315,8183,disease,I-Disease
PMC37853610_315,8183,(,O
PMC37853610_315,8183,FD,O
PMC37853610_315,8183,),O
PMC37853610_315,8183,",",O
PMC37853610_315,8183,we,O
PMC37853610_315,8183,treated,O
PMC37853610_315,8183,with,O
PMC37853610_315,8183,quetiapine,B-Drug
PMC37853610_315,8183,(,O
PMC37853610_315,8183,_,O
PMC37853610_315,8183,_,O
PMC37853610_315,8183,number,O
PMC37853610_315,8183,_,O
PMC37853610_315,8183,_,O
PMC37853610_315,8183,mg,O
PMC37853610_315,8183,/,O
PMC37853610_315,8183,day,O
PMC37853610_315,8183,),O
PMC37853610_315,8183,",",O
PMC37853610_315,8183,which,O
PMC37853610_315,8183,completely,O
PMC37853610_315,8183,abolished,O
PMC37853610_315,8183,his,O
PMC37853610_315,8183,symptoms,O
PMC37853610_315,8183,and,O
PMC37853610_315,8183,he,O
PMC37853610_315,8183,showed,O
PMC37853610_315,8183,no,O
PMC37853610_315,8183,other,O
PMC37853610_315,8183,side,O
PMC37853610_315,8183,effect,O
PMC37853610_315,8183,0,O
PMC37854500_764,8184,Repeated,O
PMC37854500_764,8184,administration,O
PMC37854500_764,8184,of,O
PMC37854500_764,8184,the,O
PMC37854500_764,8184,antidepressants,O
PMC37854500_764,8184,imipramine,O
PMC37854500_764,8184,(,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,number,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,mg,O
PMC37854500_764,8184,/,O
PMC37854500_764,8184,kg,O
PMC37854500_764,8184,),O
PMC37854500_764,8184,",",O
PMC37854500_764,8184,fluoxetine,B-Drug
PMC37854500_764,8184,(,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,number,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,mg,O
PMC37854500_764,8184,/,O
PMC37854500_764,8184,kg,O
PMC37854500_764,8184,),O
PMC37854500_764,8184,and,O
PMC37854500_764,8184,bupropion,O
PMC37854500_764,8184,(,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,number,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,_,O
PMC37854500_764,8184,mg,O
PMC37854500_764,8184,/,O
PMC37854500_764,8184,kg,O
PMC37854500_764,8184,),O
PMC37854500_764,8184,significantly,O
PMC37854500_764,8184,reversed,O
PMC37854500_764,8184,depression,B-Disease
PMC37854500_764,8184,-,O
PMC37854500_764,8184,like,O
PMC37854500_764,8184,behaviour,O
PMC37854500_764,8184,induced,O
PMC37854500_764,8184,by,O
PMC37854500_764,8184,CFA,O
PMC37854500_764,8184,0,O
PMC37865460_698,8185,AREAS,O
PMC37865460_698,8185,COVERED,O
PMC37865460_698,8185,:,O
PMC37865460_698,8185,This,O
PMC37865460_698,8185,review,O
PMC37865460_698,8185,describes,O
PMC37865460_698,8185,the,O
PMC37865460_698,8185,pharmacology,O
PMC37865460_698,8185,and,O
PMC37865460_698,8185,clinical,O
PMC37865460_698,8185,trials,O
PMC37865460_698,8185,data,O
PMC37865460_698,8185,for,O
PMC37865460_698,8185,phentermine,O
PMC37865460_698,8185,/,O
PMC37865460_698,8185,topiramate,B-Drug
PMC37865460_698,8185,ER,O
PMC37865460_698,8185,and,O
PMC37865460_698,8185,its,O
PMC37865460_698,8185,role,O
PMC37865460_698,8185,in,O
PMC37865460_698,8185,a,O
PMC37865460_698,8185,complications,O
PMC37865460_698,8185,-,O
PMC37865460_698,8185,centric,O
PMC37865460_698,8185,approach,O
PMC37865460_698,8185,to,O
PMC37865460_698,8185,medical,O
PMC37865460_698,8185,care,O
PMC37865460_698,8185,of,O
PMC37865460_698,8185,the,O
PMC37865460_698,8185,overweight,O
PMC37865460_698,8185,and,O
PMC37865460_698,8185,obese,B-Disease
PMC37865460_698,8185,patient,O
PMC37865460_698,8185,0,O
PMC37888180_416,8186,Combination,O
PMC37888180_416,8186,therapy,O
PMC37888180_416,8186,with,O
PMC37888180_416,8186,triamcinolone,B-Drug
PMC37888180_416,8186,acetonide,O
PMC37888180_416,8186,and,O
PMC37888180_416,8186,bevacizumab,B-Drug
PMC37888180_416,8186,for,O
PMC37888180_416,8186,the,O
PMC37888180_416,8186,treatment,O
PMC37888180_416,8186,of,O
PMC37888180_416,8186,severe,O
PMC37888180_416,8186,radiation,O
PMC37888180_416,8186,maculopathy,O
PMC37888180_416,8186,in,O
PMC37888180_416,8186,patients,O
PMC37888180_416,8186,with,O
PMC37888180_416,8186,posterior,O
PMC37888180_416,8186,uveal,O
PMC37888180_416,8186,melanoma,B-Disease
PMC37888180_416,8186,0,O
PMC37920580_530,8187,Duloxetine,B-Drug
PMC37920580_530,8187,",",O
PMC37920580_530,8187,a,O
PMC37920580_530,8187,serotonin,O
PMC37920580_530,8187,and,O
PMC37920580_530,8187,noradrenaline,O
PMC37920580_530,8187,reuptake,O
PMC37920580_530,8187,inhibitor,O
PMC37920580_530,8187,",",O
PMC37920580_530,8187,and,O
PMC37920580_530,8187,celecoxib,O
PMC37920580_530,8187,",",O
PMC37920580_530,8187,a,O
PMC37920580_530,8187,non,O
PMC37920580_530,8187,-,O
PMC37920580_530,8187,steroidal,O
PMC37920580_530,8187,anti,O
PMC37920580_530,8187,-,O
PMC37920580_530,8187,inflammatory,O
PMC37920580_530,8187,drug,O
PMC37920580_530,8187,",",O
PMC37920580_530,8187,are,O
PMC37920580_530,8187,commonly,O
PMC37920580_530,8187,used,O
PMC37920580_530,8187,analgesics,O
PMC37920580_530,8187,for,O
PMC37920580_530,8187,persistent,O
PMC37920580_530,8187,pain,B-Symptom
PMC37920580_530,8187,",",O
PMC37920580_530,8187,however,O
PMC37920580_530,8187,with,O
PMC37920580_530,8187,moderate,O
PMC37920580_530,8187,gastrointestinal,B-Symptom
PMC37920580_530,8187,side,O
PMC37920580_530,8187,effects,O
PMC37920580_530,8187,or,O
PMC37920580_530,8187,analgesia,O
PMC37920580_530,8187,tolerance,B-Symptom
PMC37920580_530,8187,0,O
PMC3793140_613,8188,MATERIAL,O
PMC3793140_613,8188,AND,O
PMC3793140_613,8188,METHOD,O
PMC3793140_613,8188,:,O
PMC3793140_613,8188,MEDLINE,O
PMC3793140_613,8188,was,O
PMC3793140_613,8188,searched,O
PMC3793140_613,8188,with,O
PMC3793140_613,8188,the,O
PMC3793140_613,8188,combination,O
PMC3793140_613,8188,of,O
PMC3793140_613,8188,each,O
PMC3793140_613,8188,one,O
PMC3793140_613,8188,of,O
PMC3793140_613,8188,the,O
PMC3793140_613,8188,key,O
PMC3793140_613,8188,words,O
PMC3793140_613,8188,:,O
PMC3793140_613,8188,risperidone,O
PMC3793140_613,8188,",",O
PMC3793140_613,8188,olanzapine,B-Drug
PMC3793140_613,8188,and,O
PMC3793140_613,8188,quetiapine,B-Drug
PMC3793140_613,8188,with,O
PMC3793140_613,8188,key,O
PMC3793140_613,8188,words,O
PMC3793140_613,8188,that,O
PMC3793140_613,8188,refered,O
PMC3793140_613,8188,to,O
PMC3793140_613,8188,every,O
PMC3793140_613,8188,DSM,O
PMC3793140_613,8188,-,O
PMC3793140_613,8188,IV,O
PMC3793140_613,8188,diagnosis,O
PMC3793140_613,8188,other,O
PMC3793140_613,8188,than,O
PMC3793140_613,8188,schizophrenia,B-Disease
PMC3793140_613,8188,and,O
PMC3793140_613,8188,other,O
PMC3793140_613,8188,psychotic,O
PMC3793140_613,8188,disorders,O
PMC3793140_613,8188,",",O
PMC3793140_613,8188,bipolar,B-Disease
PMC3793140_613,8188,disorder,I-Disease
PMC3793140_613,8188,and,O
PMC3793140_613,8188,dementia,B-Disease
PMC3793140_613,8188,and,O
PMC3793140_613,8188,memory,B-Disease
PMC3793140_613,8188,disorders,I-Disease
PMC3793140_613,8188,0,O
PMC37948720_985,8189,Available,O
PMC37948720_985,8189,studies,O
PMC37948720_985,8189,specifically,O
PMC37948720_985,8189,addressing,O
PMC37948720_985,8189,the,O
PMC37948720_985,8189,role,O
PMC37948720_985,8189,of,O
PMC37948720_985,8189,montelukast,B-Drug
PMC37948720_985,8189,in,O
PMC37948720_985,8189,the,O
PMC37948720_985,8189,elderly,O
PMC37948720_985,8189,are,O
PMC37948720_985,8189,scarce,O
PMC37948720_985,8189,;,O
PMC37948720_985,8189,however,O
PMC37948720_985,8189,",",O
PMC37948720_985,8189,leukotriene,O
PMC37948720_985,8189,modifiers,O
PMC37948720_985,8189,have,O
PMC37948720_985,8189,been,O
PMC37948720_985,8189,demonstrated,O
PMC37948720_985,8189,to,O
PMC37948720_985,8189,be,O
PMC37948720_985,8189,safe,O
PMC37948720_985,8189,in,O
PMC37948720_985,8189,this,O
PMC37948720_985,8189,age,O
PMC37948720_985,8189,group,O
PMC37948720_985,8189,",",O
PMC37948720_985,8189,even,O
PMC37948720_985,8189,though,O
PMC37948720_985,8189,cases,O
PMC37948720_985,8189,of,O
PMC37948720_985,8189,acute,O
PMC37948720_985,8189,hepatitis,B-Disease
PMC37948720_985,8189,and,O
PMC37948720_985,8189,occurrence,O
PMC37948720_985,8189,of,O
PMC37948720_985,8189,Churg,O
PMC37948720_985,8189,-,O
PMC37948720_985,8189,Strauss,O
PMC37948720_985,8189,syndrome,O
PMC37948720_985,8189,have,O
PMC37948720_985,8189,been,O
PMC37948720_985,8189,described,O
PMC37948720_985,8189,in,O
PMC37948720_985,8189,elderly,O
PMC37948720_985,8189,patients,O
PMC37948720_985,8189,;,O
PMC37948720_985,8189,whether,O
PMC37948720_985,8189,this,O
PMC37948720_985,8189,is,O
PMC37948720_985,8189,associated,O
PMC37948720_985,8189,with,O
PMC37948720_985,8189,age,O
PMC37948720_985,8189,is,O
PMC37948720_985,8189,to,O
PMC37948720_985,8189,be,O
PMC37948720_985,8189,confirmed,O
PMC37948720_985,8189,0,O
PMC37962990_704,8190,Serotonin,O
PMC37962990_704,8190,Transporter,O
PMC37962990_704,8190,Polymorphism,O
PMC37962990_704,8190,(,O
PMC37962990_704,8190,_,O
PMC37962990_704,8190,_,O
PMC37962990_704,8190,number,O
PMC37962990_704,8190,_,O
PMC37962990_704,8190,_,O
PMC37962990_704,8190,-,O
PMC37962990_704,8190,HTTLPR,O
PMC37962990_704,8190,),O
PMC37962990_704,8190,and,O
PMC37962990_704,8190,Citalopram,B-Drug
PMC37962990_704,8190,Effectiveness,O
PMC37962990_704,8190,in,O
PMC37962990_704,8190,Iranian,O
PMC37962990_704,8190,Patients,O
PMC37962990_704,8190,with,O
PMC37962990_704,8190,Major,B-Disease
PMC37962990_704,8190,Depressive,I-Disease
PMC37962990_704,8190,Disorder,I-Disease
PMC37962990_704,8190,0,O
PMC37992820_612,8191,Targeted,O
PMC37992820_612,8191,delivery,O
PMC37992820_612,8191,of,O
PMC37992820_612,8191,L,O
PMC37992820_612,8191,_,O
PMC37992820_612,8191,_,O
PMC37992820_612,8191,number,O
PMC37992820_612,8191,_,O
PMC37992820_612,8191,_,O
PMC37992820_612,8191,mTNF,O
PMC37992820_612,8191,-,O
PMC37992820_612,8191,synergistically,O
PMC37992820_612,8191,increases,O
PMC37992820_612,8191,the,O
PMC37992820_612,8191,antitumor,O
PMC37992820_612,8191,activity,O
PMC37992820_612,8191,of,O
PMC37992820_612,8191,melphalan,B-Drug
PMC37992820_612,8191,and,O
PMC37992820_612,8191,gemcitabine,O
PMC37992820_612,8191,",",O
PMC37992820_612,8191,but,O
PMC37992820_612,8191,optimal,O
PMC37992820_612,8191,administration,O
PMC37992820_612,8191,schedules,O
PMC37992820_612,8191,are,O
PMC37992820_612,8191,required,O
PMC37992820_612,8191,0,O
PMC38077050_117,8192,CONCLUSION,O
PMC38077050_117,8192,:,O
PMC38077050_117,8192,Sertraline,B-Drug
PMC38077050_117,8192,seems,O
PMC38077050_117,8192,to,O
PMC38077050_117,8192,have,O
PMC38077050_117,8192,a,O
PMC38077050_117,8192,protective,O
PMC38077050_117,8192,effect,O
PMC38077050_117,8192,on,O
PMC38077050_117,8192,cisplatin,O
PMC38077050_117,8192,ototoxicity,O
PMC38077050_117,8192,and,O
PMC38077050_117,8192,could,O
PMC38077050_117,8192,be,O
PMC38077050_117,8192,used,O
PMC38077050_117,8192,to,O
PMC38077050_117,8192,prevent,O
PMC38077050_117,8192,the,O
PMC38077050_117,8192,ototoxicity,B-Symptom
PMC38077050_117,8192,and,O
PMC38077050_117,8192,also,O
PMC38077050_117,8192,to,O
PMC38077050_117,8192,treat,O
PMC38077050_117,8192,the,O
PMC38077050_117,8192,depression,B-Disease
PMC38077050_117,8192,that,O
PMC38077050_117,8192,occurred,O
PMC38077050_117,8192,in,O
PMC38077050_117,8192,cancer,B-Disease
PMC38077050_117,8192,patients,O
PMC38077050_117,8192,together,O
PMC38077050_117,8192,0,O
PMC38077050_68,8193,Possible,O
PMC38077050_68,8193,protective,O
PMC38077050_68,8193,effect,O
PMC38077050_68,8193,of,O
PMC38077050_68,8193,sertraline,B-Drug
PMC38077050_68,8193,against,O
PMC38077050_68,8193,cisplatin,O
PMC38077050_68,8193,-,O
PMC38077050_68,8193,induced,O
PMC38077050_68,8193,ototoxicity,B-Symptom
PMC38077050_68,8193,:,O
PMC38077050_68,8193,an,O
PMC38077050_68,8193,experimental,O
PMC38077050_68,8193,study,O
PMC38077050_68,8193,0,O
PMC38139240_6,8194,Psychostimulants,O
PMC38139240_6,8194,like,O
PMC38139240_6,8194,Adderall,B-Drug
PMC38139240_6,8194,and,O
PMC38139240_6,8194,Ritalin,B-Drug
PMC38139240_6,8194,are,O
PMC38139240_6,8194,widely,O
PMC38139240_6,8194,used,O
PMC38139240_6,8194,for,O
PMC38139240_6,8194,cognitive,B-Symptom
PMC38139240_6,8194,enhancement,I-Symptom
PMC38139240_6,8194,by,O
PMC38139240_6,8194,people,O
PMC38139240_6,8194,without,O
PMC38139240_6,8194,ADHD,B-Disease
PMC38139240_6,8194,",",O
PMC38139240_6,8194,although,O
PMC38139240_6,8194,the,O
PMC38139240_6,8194,empirical,O
PMC38139240_6,8194,literature,O
PMC38139240_6,8194,has,O
PMC38139240_6,8194,shown,O
PMC38139240_6,8194,little,O
PMC38139240_6,8194,conclusive,O
PMC38139240_6,8194,evidence,O
PMC38139240_6,8194,for,O
PMC38139240_6,8194,effectiveness,O
PMC38139240_6,8194,in,O
PMC38139240_6,8194,this,O
PMC38139240_6,8194,population,O
PMC38139240_6,8194,0,O
PMC38163840_668,8195,Studies,O
PMC38163840_668,8195,on,O
PMC38163840_668,8195,stroke,O
PMC38163840_668,8195,imply,O
PMC38163840_668,8195,that,O
PMC38163840_668,8195,LEV,O
PMC38163840_668,8195,is,O
PMC38163840_668,8195,a,O
PMC38163840_668,8195,useful,O
PMC38163840_668,8195,alternative,O
PMC38163840_668,8195,to,O
PMC38163840_668,8195,carbamazepine,B-Drug
PMC38163840_668,8195,for,O
PMC38163840_668,8195,preventing,O
PMC38163840_668,8195,post,O
PMC38163840_668,8195,-,O
PMC38163840_668,8195,stroke,O
PMC38163840_668,8195,seizures,B-Symptom
PMC38163840_668,8195,in,O
PMC38163840_668,8195,terms,O
PMC38163840_668,8195,of,O
PMC38163840_668,8195,efficacy,O
PMC38163840_668,8195,and,O
PMC38163840_668,8195,safety,O
PMC38163840_668,8195,0,O
PMC38180060_241,8196,The,O
PMC38180060_241,8196,atypical,O
PMC38180060_241,8196,antipsychotic,O
PMC38180060_241,8196,olanzapine,B-Drug
PMC38180060_241,8196,is,O
PMC38180060_241,8196,often,O
PMC38180060_241,8196,associated,O
PMC38180060_241,8196,with,O
PMC38180060_241,8196,serious,O
PMC38180060_241,8196,metabolic,O
PMC38180060_241,8196,side,O
PMC38180060_241,8196,effects,O
PMC38180060_241,8196,including,O
PMC38180060_241,8196,weight,B-Symptom
PMC38180060_241,8196,gain,I-Symptom
PMC38180060_241,8196,and,O
PMC38180060_241,8196,increased,O
PMC38180060_241,8196,visceral,O
PMC38180060_241,8196,fat,O
PMC38180060_241,8196,0,O
PMC38180060_517,8197,It,O
PMC38180060_517,8197,is,O
PMC38180060_517,8197,thus,O
PMC38180060_517,8197,possible,O
PMC38180060_517,8197,that,O
PMC38180060_517,8197,treatments,O
PMC38180060_517,8197,that,O
PMC38180060_517,8197,alter,O
PMC38180060_517,8197,gut,O
PMC38180060_517,8197,microbiota,O
PMC38180060_517,8197,composition,O
PMC38180060_517,8197,could,O
PMC38180060_517,8197,ameliorate,O
PMC38180060_517,8197,olanzapine,B-Drug
PMC38180060_517,8197,-,O
PMC38180060_517,8197,induced,O
PMC38180060_517,8197,weight,B-Symptom
PMC38180060_517,8197,gain,I-Symptom
PMC38180060_517,8197,and,O
PMC38180060_517,8197,associated,O
PMC38180060_517,8197,metabolic,O
PMC38180060_517,8197,syndrome,O
PMC38180060_517,8197,0,O
PMC38180990_748,8198,Clinical,O
PMC38180990_748,8198,efficacy,O
PMC38180990_748,8198,and,O
PMC38180990_748,8198,safety,O
PMC38180990_748,8198,of,O
PMC38180990_748,8198,fluoxetine,B-Drug
PMC38180990_748,8198,in,O
PMC38180990_748,8198,generalized,O
PMC38180990_748,8198,anxiety,B-Disease
PMC38180990_748,8198,disorder,I-Disease
PMC38180990_748,8198,in,O
PMC38180990_748,8198,Chinese,O
PMC38180990_748,8198,patients,O
PMC38180990_748,8198,0,O
PMC38212880_335,8199,Sertraline,B-Drug
PMC38212880_335,8199,and,O
PMC38212880_335,8199,rolipram,O
PMC38212880_335,8199,had,O
PMC38212880_335,8199,no,O
PMC38212880_335,8199,effect,O
PMC38212880_335,8199,on,O
PMC38212880_335,8199,virus,O
PMC38212880_335,8199,replication,O
PMC38212880_335,8199,in,O
PMC38212880_335,8199,vitro,O
PMC38212880_335,8199,and,O
PMC38212880_335,8199,in,O
PMC38212880_335,8199,vivo,O
PMC38212880_335,8199,",",O
PMC38212880_335,8199,but,O
PMC38212880_335,8199,significantly,O
PMC38212880_335,8199,reduced,O
PMC38212880_335,8199,lung,O
PMC38212880_335,8199,inflammation,B-Symptom
PMC38212880_335,8199,0,O
PMC38292490_837,8200,Effects,O
PMC38292490_837,8200,of,O
PMC38292490_837,8200,oxcarbazepine,O
PMC38292490_837,8200,versus,O
PMC38292490_837,8200,carbamazepine,B-Drug
PMC38292490_837,8200,on,O
PMC38292490_837,8200,tinnitus,O
PMC38292490_837,8200,:,O
PMC38292490_837,8200,A,O
PMC38292490_837,8200,randomized,O
PMC38292490_837,8200,double,O
PMC38292490_837,8200,-,O
PMC38292490_837,8200,blind,O
PMC38292490_837,8200,placebo,O
PMC38292490_837,8200,-,O
PMC38292490_837,8200,controlled,O
PMC38292490_837,8200,clinical,O
PMC38292490_837,8200,trial,O
PMC38292490_837,8200,0,O
PMC38318680_0,8201,CASE,O
PMC38318680_0,8201,PRESENTATION,O
PMC38318680_0,8201,:,O
PMC38318680_0,8201,A,O
PMC38318680_0,8201,_,O
PMC38318680_0,8201,_,O
PMC38318680_0,8201,number,O
PMC38318680_0,8201,_,O
PMC38318680_0,8201,_,O
PMC38318680_0,8201,-,O
PMC38318680_0,8201,year,O
PMC38318680_0,8201,-,O
PMC38318680_0,8201,old,O
PMC38318680_0,8201,man,O
PMC38318680_0,8201,with,O
PMC38318680_0,8201,metastatic,O
PMC38318680_0,8201,rectal,O
PMC38318680_0,8201,cancer,O
PMC38318680_0,8201,was,O
PMC38318680_0,8201,treated,O
PMC38318680_0,8201,with,O
PMC38318680_0,8201,bevacizumab,B-Drug
PMC38318680_0,8201,0,O
PMC38359230_204,8202,OBJECTIVES,O
PMC38359230_204,8202,:,O
PMC38359230_204,8202,The,O
PMC38359230_204,8202,aim,O
PMC38359230_204,8202,of,O
PMC38359230_204,8202,this,O
PMC38359230_204,8202,study,O
PMC38359230_204,8202,was,O
PMC38359230_204,8202,to,O
PMC38359230_204,8202,compare,O
PMC38359230_204,8202,the,O
PMC38359230_204,8202,efficacy,O
PMC38359230_204,8202,and,O
PMC38359230_204,8202,safety,O
PMC38359230_204,8202,of,O
PMC38359230_204,8202,the,O
PMC38359230_204,8202,prodrug,O
PMC38359230_204,8202,psychostimulant,O
PMC38359230_204,8202,lisdexamfetamine,B-Drug
PMC38359230_204,8202,dimesylate,I-Drug
PMC38359230_204,8202,(,O
PMC38359230_204,8202,LDX,O
PMC38359230_204,8202,),O
PMC38359230_204,8202,and,O
PMC38359230_204,8202,the,O
PMC38359230_204,8202,non,O
PMC38359230_204,8202,-,O
PMC38359230_204,8202,stimulant,O
PMC38359230_204,8202,noradrenergic,O
PMC38359230_204,8202,compound,O
PMC38359230_204,8202,atomoxetine,O
PMC38359230_204,8202,(,O
PMC38359230_204,8202,ATX,O
PMC38359230_204,8202,),O
PMC38359230_204,8202,in,O
PMC38359230_204,8202,children,O
PMC38359230_204,8202,and,O
PMC38359230_204,8202,adolescents,O
PMC38359230_204,8202,with,O
PMC38359230_204,8202,attention,B-Disease
PMC38359230_204,8202,-,I-Disease
PMC38359230_204,8202,deficit,I-Disease
PMC38359230_204,8202,/,I-Disease
PMC38359230_204,8202,hyperactivity,I-Disease
PMC38359230_204,8202,disorder,I-Disease
PMC38359230_204,8202,(,O
PMC38359230_204,8202,ADHD,O
PMC38359230_204,8202,),O
PMC38359230_204,8202,who,O
PMC38359230_204,8202,had,O
PMC38359230_204,8202,previously,O
PMC38359230_204,8202,responded,O
PMC38359230_204,8202,inadequately,O
PMC38359230_204,8202,to,O
PMC38359230_204,8202,methylphenidate,B-Drug
PMC38359230_204,8202,(,O
PMC38359230_204,8202,MPH,O
PMC38359230_204,8202,),O
PMC38359230_204,8202,0,O
PMC38422150_26,8203,Other,O
PMC38422150_26,8203,authors,O
PMC38422150_26,8203,have,O
PMC38422150_26,8203,hypothesized,O
PMC38422150_26,8203,and,O
PMC38422150_26,8203,confirmed,O
PMC38422150_26,8203,that,O
PMC38422150_26,8203,duloxetine,B-Drug
PMC38422150_26,8203,has,O
PMC38422150_26,8203,greater,O
PMC38422150_26,8203,initial,O
PMC38422150_26,8203,noradrenergic,O
PMC38422150_26,8203,effects,O
PMC38422150_26,8203,than,O
PMC38422150_26,8203,venlafaxine,B-Drug
PMC38422150_26,8203,and,O
PMC38422150_26,8203,is,O
PMC38422150_26,8203,effective,O
PMC38422150_26,8203,in,O
PMC38422150_26,8203,patients,O
PMC38422150_26,8203,with,O
PMC38422150_26,8203,panic,B-Disease
PMC38422150_26,8203,disorder,I-Disease
PMC38422150_26,8203,0,O
PMC38436410_512,8204,Adult,O
PMC38436410_512,8204,patients,O
PMC38436410_512,8204,with,O
PMC38436410_512,8204,CLBP,B-Disease
PMC38436410_512,8204,who,O
PMC38436410_512,8204,initiated,O
PMC38436410_512,8204,duloxetine,B-Drug
PMC38436410_512,8204,or,O
PMC38436410_512,8204,SOC,O
PMC38436410_512,8204,between,O
PMC38436410_512,8204,November,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,number,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,and,O
PMC38436410_512,8204,April,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,number,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,_,O
PMC38436410_512,8204,were,O
PMC38436410_512,8204,identified,O
PMC38436410_512,8204,0,O
PMC38472630_203,8205,Antiepileptic,O
PMC38472630_203,8205,Drugs,O
PMC38472630_203,8205,(,O
PMC38472630_203,8205,AEDs,O
PMC38472630_203,8205,),O
PMC38472630_203,8205,such,O
PMC38472630_203,8205,as,O
PMC38472630_203,8205,lamotrigine,B-Drug
PMC38472630_203,8205,",",O
PMC38472630_203,8205,gabapentin,O
PMC38472630_203,8205,",",O
PMC38472630_203,8205,and,O
PMC38472630_203,8205,oxcarbazepine,O
PMC38472630_203,8205,may,O
PMC38472630_203,8205,have,O
PMC38472630_203,8205,the,O
PMC38472630_203,8205,potential,O
PMC38472630_203,8205,to,O
PMC38472630_203,8205,increase,O
PMC38472630_203,8205,the,O
PMC38472630_203,8205,risk,O
PMC38472630_203,8205,of,O
PMC38472630_203,8205,self,B-Symptom
PMC38472630_203,8205,-,I-Symptom
PMC38472630_203,8205,harm,I-Symptom
PMC38472630_203,8205,or,O
PMC38472630_203,8205,suicidal,B-Symptom
PMC38472630_203,8205,behavior,I-Symptom
PMC38472630_203,8205,0,O
PMC38496100_497,8206,CONCLUSIONS,O
PMC38496100_497,8206,:,O
PMC38496100_497,8206,Haloperidol,O
PMC38496100_497,8206,",",O
PMC38496100_497,8206,risperidone,O
PMC38496100_497,8206,",",O
PMC38496100_497,8206,olanzapine,B-Drug
PMC38496100_497,8206,",",O
PMC38496100_497,8206,and,O
PMC38496100_497,8206,quetiapine,B-Drug
PMC38496100_497,8206,were,O
PMC38496100_497,8206,equally,O
PMC38496100_497,8206,efficacious,O
PMC38496100_497,8206,and,O
PMC38496100_497,8206,safe,O
PMC38496100_497,8206,in,O
PMC38496100_497,8206,the,O
PMC38496100_497,8206,treatment,O
PMC38496100_497,8206,of,O
PMC38496100_497,8206,delirium,B-Symptom
PMC38496100_497,8206,0,O
PMC38507010_439,8207,Hallucinations,B-Symptom
PMC38507010_439,8207,in,O
PMC38507010_439,8207,acutely,O
PMC38507010_439,8207,admitted,O
PMC38507010_439,8207,patients,O
PMC38507010_439,8207,with,O
PMC38507010_439,8207,psychosis,B-Disease
PMC38507010_439,8207,",",O
PMC38507010_439,8207,and,O
PMC38507010_439,8207,effectiveness,O
PMC38507010_439,8207,of,O
PMC38507010_439,8207,risperidone,O
PMC38507010_439,8207,",",O
PMC38507010_439,8207,olanzapine,B-Drug
PMC38507010_439,8207,",",O
PMC38507010_439,8207,quetiapine,B-Drug
PMC38507010_439,8207,",",O
PMC38507010_439,8207,and,O
PMC38507010_439,8207,ziprasidone,B-Drug
PMC38507010_439,8207,:,O
PMC38507010_439,8207,a,O
PMC38507010_439,8207,pragmatic,O
PMC38507010_439,8207,",",O
PMC38507010_439,8207,randomized,O
PMC38507010_439,8207,study,O
PMC38507010_439,8207,0,O
PMC38517060_820,8208,OBJECTIVE,O
PMC38517060_820,8208,:,O
PMC38517060_820,8208,This,O
PMC38517060_820,8208,was,O
PMC38517060_820,8208,a,O
PMC38517060_820,8208,retrospective,O
PMC38517060_820,8208,subgroup,O
PMC38517060_820,8208,analysis,O
PMC38517060_820,8208,of,O
PMC38517060_820,8208,data,O
PMC38517060_820,8208,from,O
PMC38517060_820,8208,a,O
PMC38517060_820,8208,multicenter,O
PMC38517060_820,8208,",",O
PMC38517060_820,8208,randomized,O
PMC38517060_820,8208,",",O
PMC38517060_820,8208,phase,O
PMC38517060_820,8208,II,O
PMC38517060_820,8208,clinical,O
PMC38517060_820,8208,trial,O
PMC38517060_820,8208,evaluating,O
PMC38517060_820,8208,pemetrexed,O
PMC38517060_820,8208,+,O
PMC38517060_820,8208,carboplatin,O
PMC38517060_820,8208,versus,O
PMC38517060_820,8208,docetaxel,B-Drug
PMC38517060_820,8208,+,O
PMC38517060_820,8208,carboplatin,O
PMC38517060_820,8208,in,O
PMC38517060_820,8208,elderly,O
PMC38517060_820,8208,chemo,O
PMC38517060_820,8208,-,O
PMC38517060_820,8208,naive,O
PMC38517060_820,8208,patients,O
PMC38517060_820,8208,with,O
PMC38517060_820,8208,advanced,O
PMC38517060_820,8208,",",O
PMC38517060_820,8208,nonsquamous,O
PMC38517060_820,8208,non,B-Disease
PMC38517060_820,8208,-,I-Disease
PMC38517060_820,8208,small,I-Disease
PMC38517060_820,8208,cell,I-Disease
PMC38517060_820,8208,lung,I-Disease
PMC38517060_820,8208,cancer,I-Disease
PMC38517060_820,8208,(,O
PMC38517060_820,8208,NSCLC,O
PMC38517060_820,8208,),O
PMC38517060_820,8208,0,O
PMC38522770_858,8209,METHODS,O
PMC38522770_858,8209,:,O
PMC38522770_858,8209,A,O
PMC38522770_858,8209,systematic,O
PMC38522770_858,8209,literature,O
PMC38522770_858,8209,search,O
PMC38522770_858,8209,was,O
PMC38522770_858,8209,conducted,O
PMC38522770_858,8209,in,O
PMC38522770_858,8209,MEDLINE,O
PMC38522770_858,8209,and,O
PMC38522770_858,8209,PsycINFO,O
PMC38522770_858,8209,in,O
PMC38522770_858,8209,March,O
PMC38522770_858,8209,_,O
PMC38522770_858,8209,_,O
PMC38522770_858,8209,number,O
PMC38522770_858,8209,_,O
PMC38522770_858,8209,_,O
PMC38522770_858,8209,using,O
PMC38522770_858,8209,the,O
PMC38522770_858,8209,MeSH,O
PMC38522770_858,8209,terms,O
PMC38522770_858,8209,:,O
PMC38522770_858,8209,attention,B-Disease
PMC38522770_858,8209,deficit,I-Disease
PMC38522770_858,8209,disorder,I-Disease
PMC38522770_858,8209,with,I-Disease
PMC38522770_858,8209,hyperactivity,I-Disease
PMC38522770_858,8209,/,O
PMC38522770_858,8209,drug,O
PMC38522770_858,8209,therapy,O
PMC38522770_858,8209,;,O
PMC38522770_858,8209,methylphenidate,B-Drug
PMC38522770_858,8209,/,O
PMC38522770_858,8209,therapeutic,O
PMC38522770_858,8209,use,O
PMC38522770_858,8209,and,O
PMC38522770_858,8209,All,O
PMC38522770_858,8209,Fields,O
PMC38522770_858,8209,:,O
PMC38522770_858,8209,Concerta,B-Drug
PMC38522770_858,8209,;,O
PMC38522770_858,8209,Ritalin,B-Drug
PMC38522770_858,8209,LA,O
PMC38522770_858,8209,;,O
PMC38522770_858,8209,OROS,O
PMC38522770_858,8209,and,O
PMC38522770_858,8209,ADHD,B-Disease
PMC38522770_858,8209,;,O
PMC38522770_858,8209,Medikinet,O
PMC38522770_858,8209,;,O
PMC38522770_858,8209,Equasym,B-Drug
PMC38522770_858,8209,XL,O
PMC38522770_858,8209,and,O
PMC38522770_858,8209,ADHD,B-Disease
PMC38522770_858,8209,;,O
PMC38522770_858,8209,long,O
PMC38522770_858,8209,-,O
PMC38522770_858,8209,acting,O
PMC38522770_858,8209,methylphenidate,B-Drug
PMC38522770_858,8209,;,O
PMC38522770_858,8209,Diffucaps,O
PMC38522770_858,8209,and,O
PMC38522770_858,8209,ADHD,B-Disease
PMC38522770_858,8209,;,O
PMC38522770_858,8209,SODAS,O
PMC38522770_858,8209,and,O
PMC38522770_858,8209,methylphenidate,B-Drug
PMC38522770_858,8209,0,O
PMC38540890_749,8210,Self,O
PMC38540890_749,8210,-,O
PMC38540890_749,8210,Reported,O
PMC38540890_749,8210,quality,O
PMC38540890_749,8210,of,O
PMC38540890_749,8210,life,O
PMC38540890_749,8210,in,O
PMC38540890_749,8210,adults,O
PMC38540890_749,8210,with,O
PMC38540890_749,8210,attention,B-Disease
PMC38540890_749,8210,-,I-Disease
PMC38540890_749,8210,deficit,I-Disease
PMC38540890_749,8210,/,I-Disease
PMC38540890_749,8210,hyperactivity,I-Disease
PMC38540890_749,8210,disorder,I-Disease
PMC38540890_749,8210,and,O
PMC38540890_749,8210,executive,O
PMC38540890_749,8210,function,O
PMC38540890_749,8210,impairment,O
PMC38540890_749,8210,treated,O
PMC38540890_749,8210,with,O
PMC38540890_749,8210,lisdexamfetamine,B-Drug
PMC38540890_749,8210,dimesylate,I-Drug
PMC38540890_749,8210,:,O
PMC38540890_749,8210,a,O
PMC38540890_749,8210,randomized,O
PMC38540890_749,8210,",",O
PMC38540890_749,8210,double,O
PMC38540890_749,8210,-,O
PMC38540890_749,8210,blind,O
PMC38540890_749,8210,",",O
PMC38540890_749,8210,multicenter,O
PMC38540890_749,8210,",",O
PMC38540890_749,8210,placebo,O
PMC38540890_749,8210,-,O
PMC38540890_749,8210,controlled,O
PMC38540890_749,8210,",",O
PMC38540890_749,8210,parallel,O
PMC38540890_749,8210,-,O
PMC38540890_749,8210,group,O
PMC38540890_749,8210,study,O
PMC38540890_749,8210,0,O
PMC38589410_750,8211,Montelukast,B-Drug
PMC38589410_750,8211,as,O
PMC38589410_750,8211,a,O
PMC38589410_750,8211,successful,O
PMC38589410_750,8211,treatment,O
PMC38589410_750,8211,for,O
PMC38589410_750,8211,eosinophilic,O
PMC38589410_750,8211,cystitis,O
PMC38589410_750,8211,in,O
PMC38589410_750,8211,an,O
PMC38589410_750,8211,asthmatic,B-Disease
PMC38589410_750,8211,woman,O
PMC38589410_750,8211,patient,O
PMC38589410_750,8211,0,O
PMC38599540_177,8212,METHODS,O
PMC38599540_177,8212,:,O
PMC38599540_177,8212,The,O
PMC38599540_177,8212,induction,O
PMC38599540_177,8212,of,O
PMC38599540_177,8212,apoptosis,O
PMC38599540_177,8212,in,O
PMC38599540_177,8212,tamoxifen,B-Drug
PMC38599540_177,8212,-,O
PMC38599540_177,8212,resistant,O
PMC38599540_177,8212,and,O
PMC38599540_177,8212,-,O
PMC38599540_177,8212,sensitive,O
PMC38599540_177,8212,breast,B-Disease
PMC38599540_177,8212,cancer,I-Disease
PMC38599540_177,8212,cells,O
PMC38599540_177,8212,was,O
PMC38599540_177,8212,measured,O
PMC38599540_177,8212,by,O
PMC38599540_177,8212,flow,O
PMC38599540_177,8212,cytometry,O
PMC38599540_177,8212,following,O
PMC38599540_177,8212,treatment,O
PMC38599540_177,8212,with,O
PMC38599540_177,8212,persintamoxifen,O
PMC38599540_177,8212,0,O
PMC38627430_551,8213,Analysis,O
PMC38627430_551,8213,of,O
PMC38627430_551,8213,individual,O
PMC38627430_551,8213,items,O
PMC38627430_551,8213,on,O
PMC38627430_551,8213,the,O
PMC38627430_551,8213,attention,O
PMC38627430_551,8213,-,O
PMC38627430_551,8213,deficit,O
PMC38627430_551,8213,/,O
PMC38627430_551,8213,hyperactivity,O
PMC38627430_551,8213,disorder,O
PMC38627430_551,8213,symptom,O
PMC38627430_551,8213,rating,O
PMC38627430_551,8213,scale,O
PMC38627430_551,8213,in,O
PMC38627430_551,8213,children,O
PMC38627430_551,8213,and,O
PMC38627430_551,8213,adults,O
PMC38627430_551,8213,:,O
PMC38627430_551,8213,the,O
PMC38627430_551,8213,effects,O
PMC38627430_551,8213,of,O
PMC38627430_551,8213,age,O
PMC38627430_551,8213,and,O
PMC38627430_551,8213,sex,O
PMC38627430_551,8213,in,O
PMC38627430_551,8213,pivotal,O
PMC38627430_551,8213,trials,O
PMC38627430_551,8213,of,O
PMC38627430_551,8213,lisdexamfetamine,B-Drug
PMC38627430_551,8213,dimesylate,I-Drug
PMC38627430_551,8213,0,O
PMC38635080_423,8214,We,O
PMC38635080_423,8214,present,O
PMC38635080_423,8214,a,O
PMC38635080_423,8214,single,O
PMC38635080_423,8214,case,O
PMC38635080_423,8214,of,O
PMC38635080_423,8214,a,O
PMC38635080_423,8214,_,O
PMC38635080_423,8214,_,O
PMC38635080_423,8214,number,O
PMC38635080_423,8214,_,O
PMC38635080_423,8214,_,O
PMC38635080_423,8214,-,O
PMC38635080_423,8214,year,O
PMC38635080_423,8214,-,O
PMC38635080_423,8214,old,O
PMC38635080_423,8214,Filipino,O
PMC38635080_423,8214,man,O
PMC38635080_423,8214,who,O
PMC38635080_423,8214,presented,O
PMC38635080_423,8214,with,O
PMC38635080_423,8214,a,O
PMC38635080_423,8214,generalized,B-Symptom
PMC38635080_423,8214,discoid,I-Symptom
PMC38635080_423,8214,rash,I-Symptom
PMC38635080_423,8214,after,O
PMC38635080_423,8214,starting,O
PMC38635080_423,8214,lisinopril,B-Drug
PMC38635080_423,8214,0,O
PMC38635080_956,8215,The,O
PMC38635080_956,8215,rash,B-Symptom
PMC38635080_956,8215,persisted,O
PMC38635080_956,8215,despite,O
PMC38635080_956,8215,discontinuation,O
PMC38635080_956,8215,of,O
PMC38635080_956,8215,lisinopril,B-Drug
PMC38635080_956,8215,",",O
PMC38635080_956,8215,and,O
PMC38635080_956,8215,over,O
PMC38635080_956,8215,the,O
PMC38635080_956,8215,next,O
PMC38635080_956,8215,three,O
PMC38635080_956,8215,months,O
PMC38635080_956,8215,",",O
PMC38635080_956,8215,he,O
PMC38635080_956,8215,developed,O
PMC38635080_956,8215,rapidly,O
PMC38635080_956,8215,progressive,O
PMC38635080_956,8215,parkinsonism,B-Disease
PMC38635080_956,8215,0,O
PMC38681030_1003,8216,Added,O
PMC38681030_1003,8216,to,O
PMC38681030_1003,8216,that,O
PMC38681030_1003,8216,",",O
PMC38681030_1003,8216,she,O
PMC38681030_1003,8216,developed,O
PMC38681030_1003,8216,weight,B-Symptom
PMC38681030_1003,8216,gain,I-Symptom
PMC38681030_1003,8216,that,O
PMC38681030_1003,8216,was,O
PMC38681030_1003,8216,alarmingly,O
PMC38681030_1003,8216,high,O
PMC38681030_1003,8216,and,O
PMC38681030_1003,8216,such,O
PMC38681030_1003,8216,high,O
PMC38681030_1003,8216,gain,B-Symptom
PMC38681030_1003,8216,in,I-Symptom
PMC38681030_1003,8216,weight,I-Symptom
PMC38681030_1003,8216,with,O
PMC38681030_1003,8216,olanzapine,B-Drug
PMC38681030_1003,8216,",",O
PMC38681030_1003,8216,to,O
PMC38681030_1003,8216,our,O
PMC38681030_1003,8216,knowledge,O
PMC38681030_1003,8216,",",O
PMC38681030_1003,8216,has,O
PMC38681030_1003,8216,not,O
PMC38681030_1003,8216,been,O
PMC38681030_1003,8216,reported,O
PMC38681030_1003,8216,0,O
PMC38714200_10,8217,A,O
PMC38714200_10,8217,randomized,O
PMC38714200_10,8217,",",O
PMC38714200_10,8217,double,O
PMC38714200_10,8217,-,O
PMC38714200_10,8217,blind,O
PMC38714200_10,8217,trial,O
PMC38714200_10,8217,of,O
PMC38714200_10,8217,lisinopril,B-Drug
PMC38714200_10,8217,and,O
PMC38714200_10,8217,losartan,O
PMC38714200_10,8217,for,O
PMC38714200_10,8217,the,O
PMC38714200_10,8217,treatment,O
PMC38714200_10,8217,of,O
PMC38714200_10,8217,cardiomyopathy,B-Disease
PMC38714200_10,8217,in,O
PMC38714200_10,8217,duchenne,O
PMC38714200_10,8217,muscular,O
PMC38714200_10,8217,dystrophy,O
PMC38714200_10,8217,0,O
PMC38714200_1022,8218,The,O
PMC38714200_1022,8218,purpose,O
PMC38714200_1022,8218,of,O
PMC38714200_1022,8218,this,O
PMC38714200_1022,8218,multicenter,O
PMC38714200_1022,8218,double,O
PMC38714200_1022,8218,-,O
PMC38714200_1022,8218,blind,O
PMC38714200_1022,8218,prospective,O
PMC38714200_1022,8218,study,O
PMC38714200_1022,8218,was,O
PMC38714200_1022,8218,to,O
PMC38714200_1022,8218,compare,O
PMC38714200_1022,8218,efficacy,O
PMC38714200_1022,8218,and,O
PMC38714200_1022,8218,safety,O
PMC38714200_1022,8218,of,O
PMC38714200_1022,8218,lisinopril,B-Drug
PMC38714200_1022,8218,versus,O
PMC38714200_1022,8218,losartan,O
PMC38714200_1022,8218,in,O
PMC38714200_1022,8218,the,O
PMC38714200_1022,8218,treatment,O
PMC38714200_1022,8218,of,O
PMC38714200_1022,8218,newly,O
PMC38714200_1022,8218,diagnosed,O
PMC38714200_1022,8218,CM,B-Disease
PMC38714200_1022,8218,in,O
PMC38714200_1022,8218,boys,O
PMC38714200_1022,8218,with,O
PMC38714200_1022,8218,DMD,B-Disease
PMC38714200_1022,8218,0,O
PMC38714200_904,8219,OBJECTIVES,O
PMC38714200_904,8219,:,O
PMC38714200_904,8219,This,O
PMC38714200_904,8219,study,O
PMC38714200_904,8219,sought,O
PMC38714200_904,8219,to,O
PMC38714200_904,8219,compare,O
PMC38714200_904,8219,the,O
PMC38714200_904,8219,effectiveness,O
PMC38714200_904,8219,and,O
PMC38714200_904,8219,safety,O
PMC38714200_904,8219,of,O
PMC38714200_904,8219,an,O
PMC38714200_904,8219,angiotensin,O
PMC38714200_904,8219,converting,O
PMC38714200_904,8219,enzyme,O
PMC38714200_904,8219,inhibitor,O
PMC38714200_904,8219,(,O
PMC38714200_904,8219,ACE,O
PMC38714200_904,8219,-,O
PMC38714200_904,8219,I,O
PMC38714200_904,8219,),O
PMC38714200_904,8219,(,O
PMC38714200_904,8219,lisinopril,B-Drug
PMC38714200_904,8219,),O
PMC38714200_904,8219,vs,O
PMC38714200_904,8219,0,O
PMC38714200_904,8220,an,O
PMC38714200_904,8220,angiotensin,O
PMC38714200_904,8220,receptor,O
PMC38714200_904,8220,blocker,O
PMC38714200_904,8220,(,O
PMC38714200_904,8220,ARB,O
PMC38714200_904,8220,),O
PMC38714200_904,8220,(,O
PMC38714200_904,8220,losartan,O
PMC38714200_904,8220,),O
PMC38714200_904,8220,for,O
PMC38714200_904,8220,the,O
PMC38714200_904,8220,treatment,O
PMC38714200_904,8220,of,O
PMC38714200_904,8220,cardiomyopathy,B-Disease
PMC38714200_904,8220,(,O
PMC38714200_904,8220,CM,O
PMC38714200_904,8220,),O
PMC38714200_904,8220,in,O
PMC38714200_904,8220,boys,O
PMC38714200_904,8220,with,O
PMC38714200_904,8220,Duchenne,B-Disease
PMC38714200_904,8220,muscular,I-Disease
PMC38714200_904,8220,dystrophy,I-Disease
PMC38714200_904,8220,(,O
PMC38714200_904,8220,DMD,O
PMC38714200_904,8220,),O
PMC38714200_904,8220,0,O
PMC38765920_57,8221,Risk,O
PMC38765920_57,8221,of,O
PMC38765920_57,8221,Mortality,O
PMC38765920_57,8221,(,O
PMC38765920_57,8221,including,O
PMC38765920_57,8221,Sudden,O
PMC38765920_57,8221,Cardiac,O
PMC38765920_57,8221,Death,O
PMC38765920_57,8221,),O
PMC38765920_57,8221,and,O
PMC38765920_57,8221,Major,O
PMC38765920_57,8221,Cardiovascular,B-Disease
PMC38765920_57,8221,Events,I-Disease
PMC38765920_57,8221,in,O
PMC38765920_57,8221,Users,O
PMC38765920_57,8221,of,O
PMC38765920_57,8221,Olanzapine,B-Drug
PMC38765920_57,8221,and,O
PMC38765920_57,8221,Other,O
PMC38765920_57,8221,Antipsychotics,O
PMC38765920_57,8221,:,O
PMC38765920_57,8221,A,O
PMC38765920_57,8221,Study,O
PMC38765920_57,8221,with,O
PMC38765920_57,8221,the,O
PMC38765920_57,8221,General,O
PMC38765920_57,8221,Practice,O
PMC38765920_57,8221,Research,O
PMC38765920_57,8221,Database,O
PMC38765920_57,8221,0,O
PMC38767150_596,8222,Neuroleptic,O
PMC38767150_596,8222,malign,O
PMC38767150_596,8222,syndrome,O
PMC38767150_596,8222,could,O
PMC38767150_596,8222,not,O
PMC38767150_596,8222,be,O
PMC38767150_596,8222,ruled,O
PMC38767150_596,8222,out,O
PMC38767150_596,8222,by,O
PMC38767150_596,8222,the,O
PMC38767150_596,8222,administration,O
PMC38767150_596,8222,of,O
PMC38767150_596,8222,quetiapine,B-Drug
PMC38767150_596,8222,;,O
PMC38767150_596,8222,this,O
PMC38767150_596,8222,prevented,O
PMC38767150_596,8222,the,O
PMC38767150_596,8222,quick,O
PMC38767150_596,8222,use,O
PMC38767150_596,8222,of,O
PMC38767150_596,8222,other,O
PMC38767150_596,8222,potent,O
PMC38767150_596,8222,D,O
PMC38767150_596,8222,_,O
PMC38767150_596,8222,_,O
PMC38767150_596,8222,number,O
PMC38767150_596,8222,_,O
PMC38767150_596,8222,_,O
PMC38767150_596,8222,antagonists,O
PMC38767150_596,8222,0,O
PMC38781040_898,8223,We,O
PMC38781040_898,8223,describe,O
PMC38781040_898,8223,the,O
PMC38781040_898,8223,case,O
PMC38781040_898,8223,of,O
PMC38781040_898,8223,a,O
PMC38781040_898,8223,_,O
PMC38781040_898,8223,_,O
PMC38781040_898,8223,number,O
PMC38781040_898,8223,_,O
PMC38781040_898,8223,_,O
PMC38781040_898,8223,-,O
PMC38781040_898,8223,year,O
PMC38781040_898,8223,-,O
PMC38781040_898,8223,old,O
PMC38781040_898,8223,man,O
PMC38781040_898,8223,known,O
PMC38781040_898,8223,for,O
PMC38781040_898,8223,dysthymic,B-Disease
PMC38781040_898,8223,disorder,I-Disease
PMC38781040_898,8223,in,O
PMC38781040_898,8223,remission,O
PMC38781040_898,8223,on,O
PMC38781040_898,8223,quetiapine,B-Drug
PMC38781040_898,8223,and,O
PMC38781040_898,8223,venlafaxine,B-Drug
PMC38781040_898,8223,who,O
PMC38781040_898,8223,experienced,O
PMC38781040_898,8223,a,O
PMC38781040_898,8223,first,O
PMC38781040_898,8223,lifetime,O
PMC38781040_898,8223,episode,O
PMC38781040_898,8223,of,O
PMC38781040_898,8223,hypomania,B-Symptom
PMC38781040_898,8223,with,O
PMC38781040_898,8223,the,O
PMC38781040_898,8223,introduction,O
PMC38781040_898,8223,of,O
PMC38781040_898,8223,bupropion,O
PMC38781040_898,8223,SR,O
PMC38781040_898,8223,for,O
PMC38781040_898,8223,smoking,O
PMC38781040_898,8223,cessation,O
PMC38781040_898,8223,0,O
PMC38801690_784,8224,METHODS,O
PMC38801690_784,8224,:,O
PMC38801690_784,8224,We,O
PMC38801690_784,8224,investigated,O
PMC38801690_784,8224,in,O
PMC38801690_784,8224,a,O
PMC38801690_784,8224,series,O
PMC38801690_784,8224,of,O
PMC38801690_784,8224,_,O
PMC38801690_784,8224,_,O
PMC38801690_784,8224,number,O
PMC38801690_784,8224,_,O
PMC38801690_784,8224,_,O
PMC38801690_784,8224,patients,O
PMC38801690_784,8224,whether,O
PMC38801690_784,8224,the,O
PMC38801690_784,8224,frequency,O
PMC38801690_784,8224,and,O
PMC38801690_784,8224,severity,O
PMC38801690_784,8224,of,O
PMC38801690_784,8224,hot,B-Symptom
PMC38801690_784,8224,flashes,I-Symptom
PMC38801690_784,8224,were,O
PMC38801690_784,8224,related,O
PMC38801690_784,8224,to,O
PMC38801690_784,8224,concentrations,O
PMC38801690_784,8224,of,O
PMC38801690_784,8224,tamoxifen,B-Drug
PMC38801690_784,8224,and,O
PMC38801690_784,8224,its,O
PMC38801690_784,8224,metabolites,O
PMC38801690_784,8224,0,O
PMC38891780_566,8225,Comparing,O
PMC38891780_566,8225,methadone,O
PMC38891780_566,8225,and,O
PMC38891780_566,8225,buprenorphine,B-Drug
PMC38891780_566,8225,maintenance,O
PMC38891780_566,8225,with,O
PMC38891780_566,8225,methadone,O
PMC38891780_566,8225,-,O
PMC38891780_566,8225,assisted,O
PMC38891780_566,8225,withdrawal,O
PMC38891780_566,8225,for,O
PMC38891780_566,8225,the,O
PMC38891780_566,8225,treatment,O
PMC38891780_566,8225,of,O
PMC38891780_566,8225,opioid,O
PMC38891780_566,8225,dependence,O
PMC38891780_566,8225,during,O
PMC38891780_566,8225,pregnancy,O
PMC38891780_566,8225,:,O
PMC38891780_566,8225,maternal,O
PMC38891780_566,8225,and,O
PMC38891780_566,8225,neonatal,O
PMC38891780_566,8225,outcomes,O
PMC38891780_566,8225,0,O
PMC38921190_189,8226,Sublingual,O
PMC38921190_189,8226,buprenorphine,B-Drug
PMC38921190_189,8226,for,O
PMC38921190_189,8226,acute,O
PMC38921190_189,8226,renal,O
PMC38921190_189,8226,colic,O
PMC38921190_189,8226,pain,O
PMC38921190_189,8226,management,O
PMC38921190_189,8226,:,O
PMC38921190_189,8226,a,O
PMC38921190_189,8226,double,O
PMC38921190_189,8226,-,O
PMC38921190_189,8226,blind,O
PMC38921190_189,8226,",",O
PMC38921190_189,8226,randomized,O
PMC38921190_189,8226,controlled,O
PMC38921190_189,8226,trial,O
PMC38921190_189,8226,0,O
PMC38937520_953,8227,We,O
PMC38937520_953,8227,reviewed,O
PMC38937520_953,8227,the,O
PMC38937520_953,8227,medical,O
PMC38937520_953,8227,records,O
PMC38937520_953,8227,of,O
PMC38937520_953,8227,_,O
PMC38937520_953,8227,_,O
PMC38937520_953,8227,number,O
PMC38937520_953,8227,_,O
PMC38937520_953,8227,_,O
PMC38937520_953,8227,patients,O
PMC38937520_953,8227,treated,O
PMC38937520_953,8227,by,O
PMC38937520_953,8227,intravitreal,O
PMC38937520_953,8227,bevacizumab,B-Drug
PMC38937520_953,8227,(,O
PMC38937520_953,8227,Avastin,B-Drug
PMC38937520_953,8227,),O
PMC38937520_953,8227,injections,O
PMC38937520_953,8227,for,O
PMC38937520_953,8227,macular,O
PMC38937520_953,8227,edema,O
PMC38937520_953,8227,due,O
PMC38937520_953,8227,to,O
PMC38937520_953,8227,CRVO,O
PMC38937520_953,8227,0,O
PMC38979130_900,8228,Some,O
PMC38979130_900,8228,clinical,O
PMC38979130_900,8228,trials,O
PMC38979130_900,8228,showed,O
PMC38979130_900,8228,that,O
PMC38979130_900,8228,bevacizumab,B-Drug
PMC38979130_900,8228,might,O
PMC38979130_900,8228,be,O
PMC38979130_900,8228,useful,O
PMC38979130_900,8228,in,O
PMC38979130_900,8228,the,O
PMC38979130_900,8228,treatment,O
PMC38979130_900,8228,of,O
PMC38979130_900,8228,DLBCL,B-Disease
PMC38979130_900,8228,0,O
PMC38981830_12,8229,RESULTS,O
PMC38981830_12,8229,:,O
PMC38981830_12,8229,Both,O
PMC38981830_12,8229,doses,O
PMC38981830_12,8229,of,O
PMC38981830_12,8229,zileuton,O
PMC38981830_12,8229,decreased,O
PMC38981830_12,8229,the,O
PMC38981830_12,8229,mean,O
PMC38981830_12,8229,[,O
PMC38981830_12,8229,SE,O
PMC38981830_12,8229,],O
PMC38981830_12,8229,arrhythmia,O
PMC38981830_12,8229,score,O
PMC38981830_12,8229,(,O
PMC38981830_12,8229,zileuton,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,mg,O
PMC38981830_12,8229,/,O
PMC38981830_12,8229,kg,O
PMC38981830_12,8229,:,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,[,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,],O
PMC38981830_12,8229,;,O
PMC38981830_12,8229,zileuton,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,mg,O
PMC38981830_12,8229,/,O
PMC38981830_12,8229,kg,O
PMC38981830_12,8229,:,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,[,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,],O
PMC38981830_12,8229,vs,O
PMC38981830_12,8229,control,O
PMC38981830_12,8229,:,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,[,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,],O
PMC38981830_12,8229,;,O
PMC38981830_12,8229,P,O
PMC38981830_12,8229,<,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,),O
PMC38981830_12,8229,",",O
PMC38981830_12,8229,the,O
PMC38981830_12,8229,duration,O
PMC38981830_12,8229,of,O
PMC38981830_12,8229,ventricular,B-Symptom
PMC38981830_12,8229,tachycardia,I-Symptom
PMC38981830_12,8229,",",O
PMC38981830_12,8229,and,O
PMC38981830_12,8229,the,O
PMC38981830_12,8229,total,O
PMC38981830_12,8229,length,O
PMC38981830_12,8229,of,O
PMC38981830_12,8229,arrhythmias,B-Symptom
PMC38981830_12,8229,",",O
PMC38981830_12,8229,but,O
PMC38981830_12,8229,montelukast,B-Drug
PMC38981830_12,8229,was,O
PMC38981830_12,8229,not,O
PMC38981830_12,8229,effective,O
PMC38981830_12,8229,to,O
PMC38981830_12,8229,decrease,O
PMC38981830_12,8229,the,O
PMC38981830_12,8229,ventricular,B-Symptom
PMC38981830_12,8229,arrhythmias,I-Symptom
PMC38981830_12,8229,during,O
PMC38981830_12,8229,the,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,number,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,_,O
PMC38981830_12,8229,minutes,O
PMC38981830_12,8229,of,O
PMC38981830_12,8229,reperfusion,O
PMC38981830_12,8229,0,O
PMC38981830_206,8230,CONCLUSIONS,O
PMC38981830_206,8230,:,O
PMC38981830_206,8230,The,O
PMC38981830_206,8230,results,O
PMC38981830_206,8230,indicate,O
PMC38981830_206,8230,for,O
PMC38981830_206,8230,the,O
PMC38981830_206,8230,first,O
PMC38981830_206,8230,time,O
PMC38981830_206,8230,that,O
PMC38981830_206,8230,zileuton,O
PMC38981830_206,8230,exerts,O
PMC38981830_206,8230,an,O
PMC38981830_206,8230,antiarrhythmic,O
PMC38981830_206,8230,effect,O
PMC38981830_206,8230,at,O
PMC38981830_206,8230,different,O
PMC38981830_206,8230,doses,O
PMC38981830_206,8230,and,O
PMC38981830_206,8230,that,O
PMC38981830_206,8230,montelukast,B-Drug
PMC38981830_206,8230,is,O
PMC38981830_206,8230,not,O
PMC38981830_206,8230,effective,O
PMC38981830_206,8230,against,O
PMC38981830_206,8230,I,O
PMC38981830_206,8230,/,O
PMC38981830_206,8230,R,O
PMC38981830_206,8230,-,O
PMC38981830_206,8230,induced,O
PMC38981830_206,8230,arrhythmias,B-Symptom
PMC38981830_206,8230,0,O
PMC38981830_906,8231,OBJECTIVE,O
PMC38981830_906,8231,:,O
PMC38981830_906,8231,We,O
PMC38981830_906,8231,assessed,O
PMC38981830_906,8231,the,O
PMC38981830_906,8231,possible,O
PMC38981830_906,8231,protective,O
PMC38981830_906,8231,effects,O
PMC38981830_906,8231,of,O
PMC38981830_906,8231,zileuton,O
PMC38981830_906,8231,and,O
PMC38981830_906,8231,montelukast,B-Drug
PMC38981830_906,8231,against,O
PMC38981830_906,8231,I,O
PMC38981830_906,8231,/,O
PMC38981830_906,8231,R,O
PMC38981830_906,8231,-,O
PMC38981830_906,8231,induced,O
PMC38981830_906,8231,arrhythmias,B-Symptom
PMC38981830_906,8231,0,O
PMC38994710_721,8232,OBJECTIVE,O
PMC38994710_721,8232,:,O
PMC38994710_721,8232,This,O
PMC38994710_721,8232,pilot,O
PMC38994710_721,8232,study,O
PMC38994710_721,8232,examined,O
PMC38994710_721,8232,the,O
PMC38994710_721,8232,sensitivity,O
PMC38994710_721,8232,and,O
PMC38994710_721,8232,responsiveness,O
PMC38994710_721,8232,of,O
PMC38994710_721,8232,the,O
PMC38994710_721,8232,CDR,O
PMC38994710_721,8232,-,O
PMC38994710_721,8232,CBT,O
PMC38994710_721,8232,for,O
PMC38994710_721,8232,assessing,O
PMC38994710_721,8232,cognitive,O
PMC38994710_721,8232,function,O
PMC38994710_721,8232,in,O
PMC38994710_721,8232,adults,O
PMC38994710_721,8232,with,O
PMC38994710_721,8232,ADHD,B-Disease
PMC38994710_721,8232,prior,O
PMC38994710_721,8232,to,O
PMC38994710_721,8232,and,O
PMC38994710_721,8232,up,O
PMC38994710_721,8232,to,O
PMC38994710_721,8232,_,O
PMC38994710_721,8232,_,O
PMC38994710_721,8232,number,O
PMC38994710_721,8232,_,O
PMC38994710_721,8232,_,O
PMC38994710_721,8232,h,O
PMC38994710_721,8232,postdose,O
PMC38994710_721,8232,during,O
PMC38994710_721,8232,treatment,O
PMC38994710_721,8232,with,O
PMC38994710_721,8232,lisdexamfetamine,B-Drug
PMC38994710_721,8232,dimesylate,I-Drug
PMC38994710_721,8232,(,O
PMC38994710_721,8232,LDX,O
PMC38994710_721,8232,),O
PMC38994710_721,8232,or,O
PMC38994710_721,8232,mixed,O
PMC38994710_721,8232,amphetamine,O
PMC38994710_721,8232,salts,O
PMC38994710_721,8232,immediate,O
PMC38994710_721,8232,release,O
PMC38994710_721,8232,(,O
PMC38994710_721,8232,MAS,O
PMC38994710_721,8232,-,O
PMC38994710_721,8232,IR,O
PMC38994710_721,8232,;,O
PMC38994710_721,8232,various,O
PMC38994710_721,8232,generics,O
PMC38994710_721,8232,available,O
PMC38994710_721,8232,),O
PMC38994710_721,8232,0,O
PMC39002600_842,8233,BACKGROUND,O
PMC39002600_842,8233,:,O
PMC39002600_842,8233,Melphalan,B-Drug
PMC39002600_842,8233,resistance,O
PMC39002600_842,8233,has,O
PMC39002600_842,8233,been,O
PMC39002600_842,8233,considered,O
PMC39002600_842,8233,one,O
PMC39002600_842,8233,of,O
PMC39002600_842,8233,the,O
PMC39002600_842,8233,major,O
PMC39002600_842,8233,obstacles,O
PMC39002600_842,8233,to,O
PMC39002600_842,8233,improve,O
PMC39002600_842,8233,outcomes,O
PMC39002600_842,8233,in,O
PMC39002600_842,8233,multiple,B-Disease
PMC39002600_842,8233,myeloma,I-Disease
PMC39002600_842,8233,(,O
PMC39002600_842,8233,MM,O
PMC39002600_842,8233,),O
PMC39002600_842,8233,therapy,O
PMC39002600_842,8233,;,O
PMC39002600_842,8233,unfortunately,O
PMC39002600_842,8233,",",O
PMC39002600_842,8233,the,O
PMC39002600_842,8233,mechanistic,O
PMC39002600_842,8233,details,O
PMC39002600_842,8233,of,O
PMC39002600_842,8233,this,O
PMC39002600_842,8233,resistance,O
PMC39002600_842,8233,remain,O
PMC39002600_842,8233,unclear,O
PMC39002600_842,8233,0,O
PMC39021610_410,8234,Benefical,O
PMC39021610_410,8234,effects,O
PMC39021610_410,8234,of,O
PMC39021610_410,8234,sigma,O
PMC39021610_410,8234,_,O
PMC39021610_410,8234,_,O
PMC39021610_410,8234,number,O
PMC39021610_410,8234,_,O
PMC39021610_410,8234,_,O
PMC39021610_410,8234,agonist,O
PMC39021610_410,8234,fluvoxamine,B-Drug
PMC39021610_410,8234,for,O
PMC39021610_410,8234,tardive,B-Symptom
PMC39021610_410,8234,dyskinesia,I-Symptom
PMC39021610_410,8234,and,O
PMC39021610_410,8234,tardive,O
PMC39021610_410,8234,akathisia,B-Symptom
PMC39021610_410,8234,in,O
PMC39021610_410,8234,patients,O
PMC39021610_410,8234,with,O
PMC39021610_410,8234,schizophrenia,B-Disease
PMC39021610_410,8234,:,O
PMC39021610_410,8234,report,O
PMC39021610_410,8234,of,O
PMC39021610_410,8234,three,O
PMC39021610_410,8234,cases,O
PMC39021610_410,8234,0,O
PMC39051800_496,8235,Methylphenidate,B-Drug
PMC39051800_496,8235,hydrochloride,O
PMC39051800_496,8235,modified,O
PMC39051800_496,8235,-,O
PMC39051800_496,8235,release,O
PMC39051800_496,8235,in,O
PMC39051800_496,8235,adults,O
PMC39051800_496,8235,with,O
PMC39051800_496,8235,attention,B-Disease
PMC39051800_496,8235,deficit,I-Disease
PMC39051800_496,8235,hyperactivity,I-Disease
PMC39051800_496,8235,disorder,I-Disease
PMC39051800_496,8235,:,O
PMC39051800_496,8235,a,O
PMC39051800_496,8235,randomized,O
PMC39051800_496,8235,double,O
PMC39051800_496,8235,-,O
PMC39051800_496,8235,blind,O
PMC39051800_496,8235,placebo,O
PMC39051800_496,8235,-,O
PMC39051800_496,8235,controlled,O
PMC39051800_496,8235,trial,O
PMC39051800_496,8235,0,O
PMC39051800_594,8236,The,O
PMC39051800_594,8236,study,O
PMC39051800_594,8236,was,O
PMC39051800_594,8236,conducted,O
PMC39051800_594,8236,to,O
PMC39051800_594,8236,confirm,O
PMC39051800_594,8236,the,O
PMC39051800_594,8236,clinically,O
PMC39051800_594,8236,effective,O
PMC39051800_594,8236,and,O
PMC39051800_594,8236,safe,O
PMC39051800_594,8236,dose,O
PMC39051800_594,8236,of,O
PMC39051800_594,8236,methylphenidate,B-Drug
PMC39051800_594,8236,hydrochloride,I-Drug
PMC39051800_594,8236,modified,O
PMC39051800_594,8236,-,O
PMC39051800_594,8236,release,O
PMC39051800_594,8236,(,O
PMC39051800_594,8236,MPH,O
PMC39051800_594,8236,-,O
PMC39051800_594,8236,LA,O
PMC39051800_594,8236,),O
PMC39051800_594,8236,in,O
PMC39051800_594,8236,adults,O
PMC39051800_594,8236,with,O
PMC39051800_594,8236,ADHD,B-Disease
PMC39051800_594,8236,and,O
PMC39051800_594,8236,evaluate,O
PMC39051800_594,8236,the,O
PMC39051800_594,8236,maintenance,O
PMC39051800_594,8236,of,O
PMC39051800_594,8236,effect,O
PMC39051800_594,8236,of,O
PMC39051800_594,8236,MPH,O
PMC39051800_594,8236,-,O
PMC39051800_594,8236,LA,O
PMC39051800_594,8236,0,O
PMC39054870_930,8237,Reporting,O
PMC39054870_930,8237,a,O
PMC39054870_930,8237,Case,O
PMC39054870_930,8237,of,O
PMC39054870_930,8237,Injecting,O
PMC39054870_930,8237,Methylphenidate,B-Drug
PMC39054870_930,8237,(,O
PMC39054870_930,8237,Ritalin,O
PMC39054870_930,8237,),O
PMC39054870_930,8237,Tablets,O
PMC39054870_930,8237,",",O
PMC39054870_930,8237,Intensified,O
PMC39054870_930,8237,Symptoms,O
PMC39054870_930,8237,of,O
PMC39054870_930,8237,Schizoph,B-Disease
PMC39054870_930,8237,-,I-Disease
PMC39054870_930,8237,renia,I-Disease
PMC39054870_930,8237,or,O
PMC39054870_930,8237,Induce,O
PMC39054870_930,8237,Separate,O
PMC39054870_930,8237,Mental,B-Disease
PMC39054870_930,8237,Disorder,I-Disease
PMC39054870_930,8237,?,O
PMC39055410_453,8237,METHODS,O
PMC39055410_453,8237,:,O
PMC39055410_453,8237,Twenty,O
PMC39055410_453,8237,tree,O
PMC39055410_453,8237,patients,O
PMC39055410_453,8237,with,O
PMC39055410_453,8237,hip,O
PMC39055410_453,8237,osteonecrosis,B-Disease
PMC39055410_453,8237,who,O
PMC39055410_453,8237,were,O
PMC39055410_453,8237,hospitalized,O
PMC39055410_453,8237,in,O
PMC39055410_453,8237,the,O
PMC39055410_453,8237,Kerman,O
PMC39055410_453,8237,hospitals,O
PMC39055410_453,8237,after,O
PMC39055410_453,8237,using,O
PMC39055410_453,8237,Temgesic,B-Drug
PMC39055410_453,8237,and,O
PMC39055410_453,8237,Norgesic,O
PMC39055410_453,8237,were,O
PMC39055410_453,8237,followed,O
PMC39055410_453,8237,for,O
PMC39055410_453,8237,about,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,number,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,months,O
PMC39055410_453,8237,from,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,number,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,to,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,number,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,(,O
PMC39055410_453,8237,from,O
PMC39055410_453,8237,a,O
PMC39055410_453,8237,minimum,O
PMC39055410_453,8237,of,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,number,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,months,O
PMC39055410_453,8237,to,O
PMC39055410_453,8237,a,O
PMC39055410_453,8237,maximum,O
PMC39055410_453,8237,of,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,number,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,_,O
PMC39055410_453,8237,years,O
PMC39055410_453,8237,),O
PMC39055410_453,8237,0,O
PMC39123530_1026,8238,BACKGROUND,O
PMC39123530_1026,8238,:,O
PMC39123530_1026,8238,Topical,O
PMC39123530_1026,8238,bevacizumab,B-Drug
PMC39123530_1026,8238,is,O
PMC39123530_1026,8238,a,O
PMC39123530_1026,8238,potential,O
PMC39123530_1026,8238,treatment,O
PMC39123530_1026,8238,modality,O
PMC39123530_1026,8238,for,O
PMC39123530_1026,8238,corneal,O
PMC39123530_1026,8238,neovascularization,O
PMC39123530_1026,8238,",",O
PMC39123530_1026,8238,and,O
PMC39123530_1026,8238,several,O
PMC39123530_1026,8238,recent,O
PMC39123530_1026,8238,studies,O
PMC39123530_1026,8238,have,O
PMC39123530_1026,8238,demonstrated,O
PMC39123530_1026,8238,its,O
PMC39123530_1026,8238,efficacy,O
PMC39123530_1026,8238,0,O
PMC39158930_324,8239,Lisdexamfetamine,B-Drug
PMC39158930_324,8239,in,O
PMC39158930_324,8239,the,O
PMC39158930_324,8239,treatment,O
PMC39158930_324,8239,of,O
PMC39158930_324,8239,adolescents,O
PMC39158930_324,8239,and,O
PMC39158930_324,8239,children,O
PMC39158930_324,8239,with,O
PMC39158930_324,8239,attention,B-Disease
PMC39158930_324,8239,-,I-Disease
PMC39158930_324,8239,deficit,I-Disease
PMC39158930_324,8239,/,I-Disease
PMC39158930_324,8239,hyperactivity,I-Disease
PMC39158930_324,8239,disorder,I-Disease
PMC39158930_324,8239,0,O
PMC39171700_120,8240,AHS,B-Disease
PMC39171700_120,8240,is,O
PMC39171700_120,8240,rare,O
PMC39171700_120,8240,but,O
PMC39171700_120,8240,serious,O
PMC39171700_120,8240,reaction,O
PMC39171700_120,8240,with,O
PMC39171700_120,8240,carbamazepine,B-Drug
PMC39171700_120,8240,which,O
PMC39171700_120,8240,requires,O
PMC39171700_120,8240,vigilant,O
PMC39171700_120,8240,monitoring,O
PMC39171700_120,8240,by,O
PMC39171700_120,8240,physicians,O
PMC39171700_120,8240,to,O
PMC39171700_120,8240,avoid,O
PMC39171700_120,8240,major,O
PMC39171700_120,8240,consequences,O
PMC39171700_120,8240,0,O
PMC39181200_28,8241,Lisdexamfetamine,B-Drug
PMC39181200_28,8241,dimesylate,I-Drug
PMC39181200_28,8241,(,O
PMC39181200_28,8241,LDX,O
PMC39181200_28,8241,),O
PMC39181200_28,8241,is,O
PMC39181200_28,8241,a,O
PMC39181200_28,8241,long,O
PMC39181200_28,8241,-,O
PMC39181200_28,8241,acting,O
PMC39181200_28,8241,",",O
PMC39181200_28,8241,prodrug,O
PMC39181200_28,8241,stimulant,O
PMC39181200_28,8241,therapy,O
PMC39181200_28,8241,for,O
PMC39181200_28,8241,patients,O
PMC39181200_28,8241,with,O
PMC39181200_28,8241,attention,B-Disease
PMC39181200_28,8241,-,I-Disease
PMC39181200_28,8241,deficit,I-Disease
PMC39181200_28,8241,/,I-Disease
PMC39181200_28,8241,hyperactivity,I-Disease
PMC39181200_28,8241,disorder,I-Disease
PMC39181200_28,8241,(,O
PMC39181200_28,8241,ADHD,O
PMC39181200_28,8241,),O
PMC39181200_28,8241,0,O
PMC39181200_731,8242,Efficacy,O
PMC39181200_731,8242,of,O
PMC39181200_731,8242,lisdexamfetamine,B-Drug
PMC39181200_731,8242,dimesylate,I-Drug
PMC39181200_731,8242,throughout,O
PMC39181200_731,8242,the,O
PMC39181200_731,8242,day,O
PMC39181200_731,8242,in,O
PMC39181200_731,8242,children,O
PMC39181200_731,8242,and,O
PMC39181200_731,8242,adolescents,O
PMC39181200_731,8242,with,O
PMC39181200_731,8242,attention,B-Disease
PMC39181200_731,8242,-,I-Disease
PMC39181200_731,8242,deficit,I-Disease
PMC39181200_731,8242,/,I-Disease
PMC39181200_731,8242,hyperactivity,I-Disease
PMC39181200_731,8242,disorder,I-Disease
PMC39181200_731,8242,:,O
PMC39181200_731,8242,results,O
PMC39181200_731,8242,from,O
PMC39181200_731,8242,a,O
PMC39181200_731,8242,randomized,O
PMC39181200_731,8242,",",O
PMC39181200_731,8242,controlled,O
PMC39181200_731,8242,trial,O
PMC39181200_731,8242,0,O
PMC39204300_276,8243,Carbamazepine,B-Drug
PMC39204300_276,8243,-,O
PMC39204300_276,8243,induced,O
PMC39204300_276,8243,interstitial,B-Disease
PMC39204300_276,8243,pneumonitis,I-Disease
PMC39204300_276,8243,associated,O
PMC39204300_276,8243,with,O
PMC39204300_276,8243,pan,O
PMC39204300_276,8243,-,O
PMC39204300_276,8243,hypogammaglobulinemia,B-Symptom
PMC39204300_276,8243,0,O
PMC39214550_50,8244,RESULTS,O
PMC39214550_50,8244,:,O
PMC39214550_50,8244,Both,O
PMC39214550_50,8244,levocetirizine,O
PMC39214550_50,8244,and,O
PMC39214550_50,8244,desloratadine,O
PMC39214550_50,8244,in,O
PMC39214550_50,8244,monotherapy,O
PMC39214550_50,8244,",",O
PMC39214550_50,8244,or,O
PMC39214550_50,8244,in,O
PMC39214550_50,8244,combination,O
PMC39214550_50,8244,with,O
PMC39214550_50,8244,montelukast,B-Drug
PMC39214550_50,8244,",",O
PMC39214550_50,8244,were,O
PMC39214550_50,8244,effective,O
PMC39214550_50,8244,in,O
PMC39214550_50,8244,reducing,O
PMC39214550_50,8244,wheal,B-Symptom
PMC39214550_50,8244,and,O
PMC39214550_50,8244,flare,B-Symptom
PMC39214550_50,8244,in,O
PMC39214550_50,8244,SPT,O
PMC39214550_50,8244,0,O
PMC39259660_861,8245,Additionally,O
PMC39259660_861,8245,",",O
PMC39259660_861,8245,NF,O
PMC39259660_861,8245,-,O
PMC39259660_861,8245,B,O
PMC39259660_861,8245,participated,O
PMC39259660_861,8245,in,O
PMC39259660_861,8245,cell,O
PMC39259660_861,8245,growth,O
PMC39259660_861,8245,instead,O
PMC39259660_861,8245,of,O
PMC39259660_861,8245,the,O
PMC39259660_861,8245,estrogen,O
PMC39259660_861,8245,-,O
PMC39259660_861,8245,ER,O
PMC39259660_861,8245,axis,O
PMC39259660_861,8245,in,O
PMC39259660_861,8245,the,O
PMC39259660_861,8245,subline,O
PMC39259660_861,8245,and,O
PMC39259660_861,8245,consequently,O
PMC39259660_861,8245,",",O
PMC39259660_861,8245,interfering,O
PMC39259660_861,8245,with,O
PMC39259660_861,8245,the,O
PMC39259660_861,8245,NF,O
PMC39259660_861,8245,-,O
PMC39259660_861,8245,B,O
PMC39259660_861,8245,signals,O
PMC39259660_861,8245,induced,O
PMC39259660_861,8245,additive,O
PMC39259660_861,8245,anticancer,B-Disease
PMC39259660_861,8245,effects,O
PMC39259660_861,8245,with,O
PMC39259660_861,8245,tamoxifen,B-Drug
PMC39259660_861,8245,0,O
PMC39267680_316,8246,The,O
PMC39267680_316,8246,US,O
PMC39267680_316,8246,Food,O
PMC39267680_316,8246,and,O
PMC39267680_316,8246,Drug,O
PMC39267680_316,8246,Administration,O
PMC39267680_316,8246,(,O
PMC39267680_316,8246,FDA,O
PMC39267680_316,8246,),O
PMC39267680_316,8246,recently,O
PMC39267680_316,8246,approved,O
PMC39267680_316,8246,lorcaserin,O
PMC39267680_316,8246,and,O
PMC39267680_316,8246,the,O
PMC39267680_316,8246,combination,O
PMC39267680_316,8246,of,O
PMC39267680_316,8246,phentermine,O
PMC39267680_316,8246,and,O
PMC39267680_316,8246,extended,O
PMC39267680_316,8246,release,O
PMC39267680_316,8246,topiramate,B-Drug
PMC39267680_316,8246,(,O
PMC39267680_316,8246,phentermine,O
PMC39267680_316,8246,/,O
PMC39267680_316,8246,topiramate,B-Drug
PMC39267680_316,8246,ER,O
PMC39267680_316,8246,),O
PMC39267680_316,8246,for,O
PMC39267680_316,8246,the,O
PMC39267680_316,8246,treatment,O
PMC39267680_316,8246,of,O
PMC39267680_316,8246,obesity,B-Disease
PMC39267680_316,8246,in,O
PMC39267680_316,8246,conjunction,O
PMC39267680_316,8246,with,O
PMC39267680_316,8246,a,O
PMC39267680_316,8246,lifestyle,O
PMC39267680_316,8246,intervention,O
PMC39267680_316,8246,",",O
PMC39267680_316,8246,expanding,O
PMC39267680_316,8246,the,O
PMC39267680_316,8246,therapeutic,O
PMC39267680_316,8246,options,O
PMC39267680_316,8246,for,O
PMC39267680_316,8246,long,O
PMC39267680_316,8246,-,O
PMC39267680_316,8246,term,O
PMC39267680_316,8246,obesity,O
PMC39267680_316,8246,pharmacotherapy,O
PMC39267680_316,8246,",",O
PMC39267680_316,8246,which,O
PMC39267680_316,8246,was,O
PMC39267680_316,8246,previously,O
PMC39267680_316,8246,limited,O
PMC39267680_316,8246,to,O
PMC39267680_316,8246,orlistat,O
PMC39267680_316,8246,0,O
PMC39267680_474,8247,While,O
PMC39267680_474,8247,there,O
PMC39267680_474,8247,are,O
PMC39267680_474,8247,no,O
PMC39267680_474,8247,head,O
PMC39267680_474,8247,-,O
PMC39267680_474,8247,to,O
PMC39267680_474,8247,-,O
PMC39267680_474,8247,head,O
PMC39267680_474,8247,studies,O
PMC39267680_474,8247,among,O
PMC39267680_474,8247,the,O
PMC39267680_474,8247,currently,O
PMC39267680_474,8247,available,O
PMC39267680_474,8247,obesity,B-Disease
PMC39267680_474,8247,pharmacotherapy,O
PMC39267680_474,8247,agents,O
PMC39267680_474,8247,",",O
PMC39267680_474,8247,phentermine,O
PMC39267680_474,8247,/,O
PMC39267680_474,8247,topiramate,B-Drug
PMC39267680_474,8247,ER,O
PMC39267680_474,8247,appears,O
PMC39267680_474,8247,to,O
PMC39267680_474,8247,have,O
PMC39267680_474,8247,a,O
PMC39267680_474,8247,superior,O
PMC39267680_474,8247,weight,B-Symptom
PMC39267680_474,8247,loss,I-Symptom
PMC39267680_474,8247,profile,O
PMC39267680_474,8247,0,O
PMC39267680_992,8248,Management,O
PMC39267680_992,8248,of,O
PMC39267680_992,8248,obesity,B-Disease
PMC39267680_992,8248,and,O
PMC39267680_992,8248,cardiometabolic,B-Disease
PMC39267680_992,8248,risk,O
PMC39267680_992,8248,-,O
PMC39267680_992,8248,role,O
PMC39267680_992,8248,of,O
PMC39267680_992,8248,phentermine,O
PMC39267680_992,8248,/,O
PMC39267680_992,8248,extended,O
PMC39267680_992,8248,release,O
PMC39267680_992,8248,topiramate,B-Drug
PMC39267680_992,8248,0,O
PMC39270690_788,8249,Currently,O
PMC39270690_788,8249,",",O
PMC39270690_788,8249,five,O
PMC39270690_788,8249,molecular,O
PMC39270690_788,8249,targeted,O
PMC39270690_788,8249,agents,O
PMC39270690_788,8249,were,O
PMC39270690_788,8249,approved,O
PMC39270690_788,8249,for,O
PMC39270690_788,8249,treatment,O
PMC39270690_788,8249,of,O
PMC39270690_788,8249,advanced,O
PMC39270690_788,8249,NSCLC,B-Disease
PMC39270690_788,8249,:,O
PMC39270690_788,8249,Gefitinib,O
PMC39270690_788,8249,",",O
PMC39270690_788,8249,erlotinib,O
PMC39270690_788,8249,and,O
PMC39270690_788,8249,afatinib,O
PMC39270690_788,8249,for,O
PMC39270690_788,8249,positive,O
PMC39270690_788,8249,EGFR,O
PMC39270690_788,8249,mutation,O
PMC39270690_788,8249,",",O
PMC39270690_788,8249,crizotinib,O
PMC39270690_788,8249,for,O
PMC39270690_788,8249,positive,O
PMC39270690_788,8249,echinoderm,O
PMC39270690_788,8249,microtubule,O
PMC39270690_788,8249,-,O
PMC39270690_788,8249,associated,O
PMC39270690_788,8249,protein,O
PMC39270690_788,8249,-,O
PMC39270690_788,8249,like,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,number,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,(,O
PMC39270690_788,8249,EML,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,number,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,_,O
PMC39270690_788,8249,),O
PMC39270690_788,8249,-,O
PMC39270690_788,8249,ALK,O
PMC39270690_788,8249,translocation,O
PMC39270690_788,8249,and,O
PMC39270690_788,8249,bevacizumab,B-Drug
PMC39270690_788,8249,0,O
PMC39304810_513,8250,Duloxetine,B-Drug
PMC39304810_513,8250,treatment,O
PMC39304810_513,8250,adherence,O
PMC39304810_513,8250,across,O
PMC39304810_513,8250,mental,O
PMC39304810_513,8250,health,O
PMC39304810_513,8250,and,O
PMC39304810_513,8250,chronic,O
PMC39304810_513,8250,pain,O
PMC39304810_513,8250,conditions,O
PMC39304810_513,8250,0,O
PMC39309060_35,8251,CONCLUSIONS,O
PMC39309060_35,8251,:,O
PMC39309060_35,8251,To,O
PMC39309060_35,8251,the,O
PMC39309060_35,8251,best,O
PMC39309060_35,8251,of,O
PMC39309060_35,8251,our,O
PMC39309060_35,8251,knowledge,O
PMC39309060_35,8251,",",O
PMC39309060_35,8251,this,O
PMC39309060_35,8251,is,O
PMC39309060_35,8251,the,O
PMC39309060_35,8251,largest,O
PMC39309060_35,8251,population,O
PMC39309060_35,8251,based,O
PMC39309060_35,8251,study,O
PMC39309060_35,8251,that,O
PMC39309060_35,8251,shows,O
PMC39309060_35,8251,in,O
PMC39309060_35,8251,patients,O
PMC39309060_35,8251,with,O
PMC39309060_35,8251,breast,B-Disease
PMC39309060_35,8251,cancer,I-Disease
PMC39309060_35,8251,",",O
PMC39309060_35,8251,tamoxifen,B-Drug
PMC39309060_35,8251,use,O
PMC39309060_35,8251,for,O
PMC39309060_35,8251,more,O
PMC39309060_35,8251,than,O
PMC39309060_35,8251,three,O
PMC39309060_35,8251,years,O
PMC39309060_35,8251,or,O
PMC39309060_35,8251,patients,O
PMC39309060_35,8251,older,O
PMC39309060_35,8251,than,O
PMC39309060_35,8251,_,O
PMC39309060_35,8251,_,O
PMC39309060_35,8251,number,O
PMC39309060_35,8251,_,O
PMC39309060_35,8251,_,O
PMC39309060_35,8251,years,O
PMC39309060_35,8251,was,O
PMC39309060_35,8251,associated,O
PMC39309060_35,8251,with,O
PMC39309060_35,8251,a,O
PMC39309060_35,8251,significantly,O
PMC39309060_35,8251,increased,O
PMC39309060_35,8251,risk,O
PMC39309060_35,8251,for,O
PMC39309060_35,8251,developing,O
PMC39309060_35,8251,endometrial,B-Disease
PMC39309060_35,8251,cancer,I-Disease
PMC39309060_35,8251,0,O
PMC39319430_987,8252,PURPOSE,O
PMC39319430_987,8252,:,O
PMC39319430_987,8252,Tamoxifen,B-Drug
PMC39319430_987,8252,is,O
PMC39319430_987,8252,a,O
PMC39319430_987,8252,key,O
PMC39319430_987,8252,therapeutic,O
PMC39319430_987,8252,option,O
PMC39319430_987,8252,for,O
PMC39319430_987,8252,breast,B-Disease
PMC39319430_987,8252,cancer,I-Disease
PMC39319430_987,8252,treatment,O
PMC39319430_987,8252,0,O
PMC39337040_99,8253,Clinical,O
PMC39337040_99,8253,utility,O
PMC39337040_99,8253,of,O
PMC39337040_99,8253,orally,O
PMC39337040_99,8253,disintegrating,O
PMC39337040_99,8253,olanzapine,B-Drug
PMC39337040_99,8253,in,O
PMC39337040_99,8253,Chinese,O
PMC39337040_99,8253,patients,O
PMC39337040_99,8253,with,O
PMC39337040_99,8253,schizophrenia,B-Disease
PMC39337040_99,8253,:,O
PMC39337040_99,8253,a,O
PMC39337040_99,8253,review,O
PMC39337040_99,8253,of,O
PMC39337040_99,8253,effectiveness,O
PMC39337040_99,8253,",",O
PMC39337040_99,8253,patient,O
PMC39337040_99,8253,preference,O
PMC39337040_99,8253,",",O
PMC39337040_99,8253,adherence,O
PMC39337040_99,8253,",",O
PMC39337040_99,8253,and,O
PMC39337040_99,8253,other,O
PMC39337040_99,8253,properties,O
PMC39337040_99,8253,0,O
PMC39337130_1032,8254,Olanzapine,B-Drug
PMC39337130_1032,8254,use,O
PMC39337130_1032,8254,in,O
PMC39337130_1032,8254,a,O
PMC39337130_1032,8254,manic,O
PMC39337130_1032,8254,patient,O
PMC39337130_1032,8254,during,O
PMC39337130_1032,8254,second,O
PMC39337130_1032,8254,and,O
PMC39337130_1032,8254,third,O
PMC39337130_1032,8254,trimester,O
PMC39337130_1032,8254,pregnancy,O
PMC39337130_1032,8254,0,O
PMC39369170_825,8255,The,O
PMC39369170_825,8255,effect,O
PMC39369170_825,8255,of,O
PMC39369170_825,8255,Paroxetine,B-Drug
PMC39369170_825,8255,in,O
PMC39369170_825,8255,decreasing,O
PMC39369170_825,8255,the,O
PMC39369170_825,8255,frequency,O
PMC39369170_825,8255,of,O
PMC39369170_825,8255,spontaneous,B-Symptom
PMC39369170_825,8255,erection,I-Symptom
PMC39369170_825,8255,and,O
PMC39369170_825,8255,ejaculation,O
PMC39369170_825,8255,in,O
PMC39369170_825,8255,the,O
PMC39369170_825,8255,presented,O
PMC39369170_825,8255,case,O
PMC39369170_825,8255,is,O
PMC39369170_825,8255,thought,O
PMC39369170_825,8255,to,O
PMC39369170_825,8255,have,O
PMC39369170_825,8255,occurred,O
PMC39369170_825,8255,via,O
PMC39369170_825,8255,control,O
PMC39369170_825,8255,of,O
PMC39369170_825,8255,PTSD,O
PMC39369170_825,8255,symptoms,O
PMC39369170_825,8255,and,O
PMC39369170_825,8255,their,O
PMC39369170_825,8255,adverse,O
PMC39369170_825,8255,effects,O
PMC39369170_825,8255,on,O
PMC39369170_825,8255,ejaculation,O
PMC39369170_825,8255,0,O
PMC39397530_388,8256,Intravitreal,O
PMC39397530_388,8256,bevacizumab,B-Drug
PMC39397530_388,8256,in,O
PMC39397530_388,8256,combination,O
PMC39397530_388,8256,with,O
PMC39397530_388,8256,photocoagulation,O
PMC39397530_388,8256,treatment,O
PMC39397530_388,8256,of,O
PMC39397530_388,8256,ischemic,O
PMC39397530_388,8256,retinal,O
PMC39397530_388,8256,areas,O
PMC39397530_388,8256,may,O
PMC39397530_388,8256,be,O
PMC39397530_388,8256,a,O
PMC39397530_388,8256,good,O
PMC39397530_388,8256,alternative,O
PMC39397530_388,8256,for,O
PMC39397530_388,8256,patients,O
PMC39397530_388,8256,with,O
PMC39397530_388,8256,recurrent,O
PMC39397530_388,8256,vitreous,B-Symptom
PMC39397530_388,8256,haemorrhage,I-Symptom
PMC39397530_388,8256,due,O
PMC39397530_388,8256,to,O
PMC39397530_388,8256,Eales,B-Disease
PMC39397530_388,8256,disease,I-Disease
PMC39397530_388,8256,0,O
PMC39399410_404,8257,CONCLUSIONS,O
PMC39399410_404,8257,:,O
PMC39399410_404,8257,Both,O
PMC39399410_404,8257,Stimdate,O
PMC39399410_404,8257,and,O
PMC39399410_404,8257,Ritalin,B-Drug
PMC39399410_404,8257,had,O
PMC39399410_404,8257,comparable,O
PMC39399410_404,8257,clinical,O
PMC39399410_404,8257,efficacy,O
PMC39399410_404,8257,and,O
PMC39399410_404,8257,safety,O
PMC39399410_404,8257,in,O
PMC39399410_404,8257,children,O
PMC39399410_404,8257,with,O
PMC39399410_404,8257,ADHD,B-Disease
PMC39399410_404,8257,0,O
PMC39399410_604,8258,OBJECTIVE,O
PMC39399410_604,8258,:,O
PMC39399410_604,8258,To,O
PMC39399410_604,8258,compare,O
PMC39399410_604,8258,the,O
PMC39399410_604,8258,effectiveness,O
PMC39399410_604,8258,and,O
PMC39399410_604,8258,safety,O
PMC39399410_604,8258,of,O
PMC39399410_604,8258,the,O
PMC39399410_604,8258,methylphenidate,B-Drug
PMC39399410_604,8258,produced,O
PMC39399410_604,8258,in,O
PMC39399410_604,8258,Iran,O
PMC39399410_604,8258,(,O
PMC39399410_604,8258,Stimdate,O
PMC39399410_604,8258,),O
PMC39399410_604,8258,with,O
PMC39399410_604,8258,its,O
PMC39399410_604,8258,original,O
PMC39399410_604,8258,brand,O
PMC39399410_604,8258,(,O
PMC39399410_604,8258,Ritalin,B-Drug
PMC39399410_604,8258,),O
PMC39399410_604,8258,in,O
PMC39399410_604,8258,children,O
PMC39399410_604,8258,with,O
PMC39399410_604,8258,Attention,B-Disease
PMC39399410_604,8258,deficit,I-Disease
PMC39399410_604,8258,hyperactivity,I-Disease
PMC39399410_604,8258,disorder,I-Disease
PMC39399410_604,8258,(,O
PMC39399410_604,8258,ADHD,O
PMC39399410_604,8258,),O
PMC39399410_604,8258,0,O
PMC39399410_752,8259,Comparison,O
PMC39399410_752,8259,of,O
PMC39399410_752,8259,Two,O
PMC39399410_752,8259,brands,O
PMC39399410_752,8259,of,O
PMC39399410_752,8259,Methylphenidate,B-Drug
PMC39399410_752,8259,(,O
PMC39399410_752,8259,Stimdate,O
PMC39399410_752,8259,(,O
PMC39399410_752,8259,),O
PMC39399410_752,8259,vs,O
PMC39399410_752,8259,0,O
PMC39399410_752,8260,Ritalin,B-Drug
PMC39399410_752,8260,(,O
PMC39399410_752,8260,),O
PMC39399410_752,8260,),O
PMC39399410_752,8260,in,O
PMC39399410_752,8260,Children,O
PMC39399410_752,8260,and,O
PMC39399410_752,8260,Adolescents,O
PMC39399410_752,8260,with,O
PMC39399410_752,8260,Attention,B-Disease
PMC39399410_752,8260,Deficit,I-Disease
PMC39399410_752,8260,Hyperactivity,I-Disease
PMC39399410_752,8260,Disorder,I-Disease
PMC39399410_752,8260,:,O
PMC39399410_752,8260,A,O
PMC39399410_752,8260,Double,O
PMC39399410_752,8260,-,O
PMC39399410_752,8260,Blind,O
PMC39399410_752,8260,",",O
PMC39399410_752,8260,Randomized,O
PMC39399410_752,8260,Clinical,O
PMC39399410_752,8260,Trial,O
PMC39399410_752,8260,0,O
PMC39399430_907,8261,A,O
PMC39399430_907,8261,case,O
PMC39399430_907,8261,report,O
PMC39399430_907,8261,of,O
PMC39399430_907,8261,somnambulism,B-Symptom
PMC39399430_907,8261,associated,O
PMC39399430_907,8261,with,O
PMC39399430_907,8261,olanzapine,B-Drug
PMC39399430_907,8261,0,O
PMC39419690_881,8262,CONCLUSION,O
PMC39419690_881,8262,:,O
PMC39419690_881,8262,Docetaxel,B-Drug
PMC39419690_881,8262,can,O
PMC39419690_881,8262,cause,O
PMC39419690_881,8262,a,O
PMC39419690_881,8262,toxic,O
PMC39419690_881,8262,optic,B-Disease
PMC39419690_881,8262,neuropathy,I-Disease
PMC39419690_881,8262,possibly,O
PMC39419690_881,8262,due,O
PMC39419690_881,8262,to,O
PMC39419690_881,8262,an,O
PMC39419690_881,8262,ischemic,O
PMC39419690_881,8262,or,O
PMC39419690_881,8262,neurotoxic,O
PMC39419690_881,8262,mechanism,O
PMC39419690_881,8262,at,O
PMC39419690_881,8262,the,O
PMC39419690_881,8262,optic,O
PMC39419690_881,8262,nerve,O
PMC39419690_881,8262,head,O
PMC39419690_881,8262,0,O
PMC39430760_652,8263,Prophylaxis,O
PMC39430760_652,8263,of,O
PMC39430760_652,8263,childhood,O
PMC39430760_652,8263,migraine,O
PMC39430760_652,8263,:,O
PMC39430760_652,8263,topiramate,B-Drug
PMC39430760_652,8263,versus,O
PMC39430760_652,8263,propranolol,O
PMC39430760_652,8263,0,O
PMC39567980_869,8264,CONCLUSION,O
PMC39567980_869,8264,:,O
PMC39567980_869,8264,Antihistamines,O
PMC39567980_869,8264,seems,O
PMC39567980_869,8264,to,O
PMC39567980_869,8264,be,O
PMC39567980_869,8264,the,O
PMC39567980_869,8264,most,O
PMC39567980_869,8264,efficient,O
PMC39567980_869,8264,treatment,O
PMC39567980_869,8264,for,O
PMC39567980_869,8264,urticaria,B-Symptom
PMC39567980_869,8264,;,O
PMC39567980_869,8264,other,O
PMC39567980_869,8264,treatments,O
PMC39567980_869,8264,such,O
PMC39567980_869,8264,as,O
PMC39567980_869,8264,montelukast,B-Drug
PMC39567980_869,8264,",",O
PMC39567980_869,8264,azathioprine,O
PMC39567980_869,8264,",",O
PMC39567980_869,8264,and,O
PMC39567980_869,8264,mycophenolate,O
PMC39567980_869,8264,mofetil,O
PMC39567980_869,8264,may,O
PMC39567980_869,8264,also,O
PMC39567980_869,8264,be,O
PMC39567980_869,8264,used,O
PMC39567980_869,8264,",",O
PMC39567980_869,8264,but,O
PMC39567980_869,8264,only,O
PMC39567980_869,8264,in,O
PMC39567980_869,8264,combination,O
PMC39567980_869,8264,with,O
PMC39567980_869,8264,antihistamines,O
PMC39567980_869,8264,and,O
PMC39567980_869,8264,only,O
PMC39567980_869,8264,in,O
PMC39567980_869,8264,the,O
PMC39567980_869,8264,case,O
PMC39567980_869,8264,of,O
PMC39567980_869,8264,an,O
PMC39567980_869,8264,independent,O
PMC39567980_869,8264,antihistamines,O
PMC39567980_869,8264,treatment,O
PMC39567980_869,8264,failure,O
PMC39567980_869,8264,0,O
PMC39593820_419,8265,Antibiotics,O
PMC39593820_419,8265,are,O
PMC39593820_419,8265,the,O
PMC39593820_419,8265,mainstay,O
PMC39593820_419,8265,of,O
PMC39593820_419,8265,treatment,O
PMC39593820_419,8265,of,O
PMC39593820_419,8265,pouchitis,O
PMC39593820_419,8265,",",O
PMC39593820_419,8265,and,O
PMC39593820_419,8265,metronidazole,O
PMC39593820_419,8265,and,O
PMC39593820_419,8265,ciprofloxacin,B-Drug
PMC39593820_419,8265,are,O
PMC39593820_419,8265,the,O
PMC39593820_419,8265,most,O
PMC39593820_419,8265,common,O
PMC39593820_419,8265,initial,O
PMC39593820_419,8265,approaches,O
PMC39593820_419,8265,",",O
PMC39593820_419,8265,often,O
PMC39593820_419,8265,with,O
PMC39593820_419,8265,a,O
PMC39593820_419,8265,rapid,O
PMC39593820_419,8265,response,O
PMC39593820_419,8265,0,O
PMC39659290_226,8266,Pancreatitis,O
PMC39659290_226,8266,due,O
PMC39659290_226,8266,to,O
PMC39659290_226,8266,the,O
PMC39659290_226,8266,use,O
PMC39659290_226,8266,of,O
PMC39659290_226,8266,(,O
PMC39659290_226,8266,methylphenidate,B-Drug
PMC39659290_226,8266,),O
PMC39659290_226,8266,Ritalin,B-Drug
PMC39659290_226,8266,was,O
PMC39659290_226,8266,never,O
PMC39659290_226,8266,published,O
PMC39659290_226,8266,before,O
PMC39659290_226,8266,0,O
PMC39659290_325,8267,Severe,O
PMC39659290_325,8267,recurrent,O
PMC39659290_325,8267,pancreatitis,O
PMC39659290_325,8267,in,O
PMC39659290_325,8267,a,O
PMC39659290_325,8267,child,O
PMC39659290_325,8267,with,O
PMC39659290_325,8267,ADHD,B-Disease
PMC39659290_325,8267,after,O
PMC39659290_325,8267,starting,O
PMC39659290_325,8267,treatment,O
PMC39659290_325,8267,with,O
PMC39659290_325,8267,methylphenidate,B-Drug
PMC39659290_325,8267,(,O
PMC39659290_325,8267,Ritalin,B-Drug
PMC39659290_325,8267,),O
PMC39659290_325,8267,0,O
PMC39659290_420,8268,We,O
PMC39659290_420,8268,present,O
PMC39659290_420,8268,a,O
PMC39659290_420,8268,case,O
PMC39659290_420,8268,of,O
PMC39659290_420,8268,a,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,number,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,-,O
PMC39659290_420,8268,year,O
PMC39659290_420,8268,-,O
PMC39659290_420,8268,old,O
PMC39659290_420,8268,boy,O
PMC39659290_420,8268,",",O
PMC39659290_420,8268,who,O
PMC39659290_420,8268,had,O
PMC39659290_420,8268,severe,O
PMC39659290_420,8268,relapsing,O
PMC39659290_420,8268,pancreatitis,O
PMC39659290_420,8268,",",O
PMC39659290_420,8268,three,O
PMC39659290_420,8268,times,O
PMC39659290_420,8268,in,O
PMC39659290_420,8268,two,O
PMC39659290_420,8268,months,O
PMC39659290_420,8268,within,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,number,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,_,O
PMC39659290_420,8268,weeks,O
PMC39659290_420,8268,after,O
PMC39659290_420,8268,starting,O
PMC39659290_420,8268,treatment,O
PMC39659290_420,8268,with,O
PMC39659290_420,8268,methylphenidate,B-Drug
PMC39659290_420,8268,(,O
PMC39659290_420,8268,Ritalin,B-Drug
PMC39659290_420,8268,),O
PMC39659290_420,8268,due,O
PMC39659290_420,8268,to,O
PMC39659290_420,8268,attention,B-Disease
PMC39659290_420,8268,deficit,I-Disease
PMC39659290_420,8268,hyperactivity,I-Disease
PMC39659290_420,8268,disorder,I-Disease
PMC39659290_420,8268,(,O
PMC39659290_420,8268,ADHD,O
PMC39659290_420,8268,),O
PMC39659290_420,8268,0,O
PMC39659290_795,8269,Attention,O
PMC39659290_795,8269,must,O
PMC39659290_795,8269,be,O
PMC39659290_795,8269,made,O
PMC39659290_795,8269,by,O
PMC39659290_795,8269,the,O
PMC39659290_795,8269,physicians,O
PMC39659290_795,8269,regarding,O
PMC39659290_795,8269,this,O
PMC39659290_795,8269,possible,O
PMC39659290_795,8269,complication,O
PMC39659290_795,8269,",",O
PMC39659290_795,8269,and,O
PMC39659290_795,8269,this,O
PMC39659290_795,8269,complication,O
PMC39659290_795,8269,should,O
PMC39659290_795,8269,be,O
PMC39659290_795,8269,taken,O
PMC39659290_795,8269,into,O
PMC39659290_795,8269,consideration,O
PMC39659290_795,8269,in,O
PMC39659290_795,8269,every,O
PMC39659290_795,8269,patient,O
PMC39659290_795,8269,with,O
PMC39659290_795,8269,abdominal,B-Symptom
PMC39659290_795,8269,pain,I-Symptom
PMC39659290_795,8269,who,O
PMC39659290_795,8269,was,O
PMC39659290_795,8269,newly,O
PMC39659290_795,8269,treated,O
PMC39659290_795,8269,with,O
PMC39659290_795,8269,Ritalin,B-Drug
PMC39659290_795,8269,0,O
PMC39689120_328,8270,Daytime,B-Symptom
PMC39689120_328,8270,sleepiness,I-Symptom
PMC39689120_328,8270,associated,O
PMC39689120_328,8270,with,O
PMC39689120_328,8270,lurasidone,O
PMC39689120_328,8270,and,O
PMC39689120_328,8270,quetiapine,B-Drug
PMC39689120_328,8270,XR,O
PMC39689120_328,8270,:,O
PMC39689120_328,8270,results,O
PMC39689120_328,8270,from,O
PMC39689120_328,8270,a,O
PMC39689120_328,8270,randomized,O
PMC39689120_328,8270,double,O
PMC39689120_328,8270,-,O
PMC39689120_328,8270,blind,O
PMC39689120_328,8270,",",O
PMC39689120_328,8270,placebo,O
PMC39689120_328,8270,-,O
PMC39689120_328,8270,controlled,O
PMC39689120_328,8270,trial,O
PMC39689120_328,8270,in,O
PMC39689120_328,8270,patients,O
PMC39689120_328,8270,with,O
PMC39689120_328,8270,schizophrenia,B-Disease
PMC39689120_328,8270,0,O
PMC39689120_346,8271,Daytime,B-Symptom
PMC39689120_346,8271,sleepiness,I-Symptom
PMC39689120_346,8271,was,O
PMC39689120_346,8271,associated,O
PMC39689120_346,8271,with,O
PMC39689120_346,8271,improvement,O
PMC39689120_346,8271,in,O
PMC39689120_346,8271,agitation,B-Symptom
PMC39689120_346,8271,and,O
PMC39689120_346,8271,worsening,O
PMC39689120_346,8271,in,O
PMC39689120_346,8271,functional,O
PMC39689120_346,8271,capacity,O
PMC39689120_346,8271,for,O
PMC39689120_346,8271,quetiapine,B-Drug
PMC39689120_346,8271,XR,O
PMC39689120_346,8271,",",O
PMC39689120_346,8271,but,O
PMC39689120_346,8271,not,O
PMC39689120_346,8271,lurasidone,O
PMC39689120_346,8271,or,O
PMC39689120_346,8271,placebo,O
PMC39689120_346,8271,-,O
PMC39689120_346,8271,treated,O
PMC39689120_346,8271,patients,O
PMC39689120_346,8271,0,O
PMC39689120_471,8272,Sedation,B-Symptom
PMC39689120_471,8272,associated,O
PMC39689120_471,8272,with,O
PMC39689120_471,8272,quetiapine,B-Drug
PMC39689120_471,8272,XR,O
PMC39689120_471,8272,treatment,O
PMC39689120_471,8272,mediated,O
PMC39689120_471,8272,an,O
PMC39689120_471,8272,improvement,O
PMC39689120_471,8272,in,O
PMC39689120_471,8272,agitation,B-Symptom
PMC39689120_471,8272,[,O
PMC39689120_471,8272,assessed,O
PMC39689120_471,8272,by,O
PMC39689120_471,8272,the,O
PMC39689120_471,8272,Positive,O
PMC39689120_471,8272,and,O
PMC39689120_471,8272,Negative,O
PMC39689120_471,8272,Syndrome,O
PMC39689120_471,8272,Scale,O
PMC39689120_471,8272,-,O
PMC39689120_471,8272,Excitement,O
PMC39689120_471,8272,(,O
PMC39689120_471,8272,PANSS,O
PMC39689120_471,8272,-,O
PMC39689120_471,8272,EC,O
PMC39689120_471,8272,),O
PMC39689120_471,8272,subscale,O
PMC39689120_471,8272,],O
PMC39689120_471,8272,and,O
PMC39689120_471,8272,a,O
PMC39689120_471,8272,worsening,O
PMC39689120_471,8272,in,O
PMC39689120_471,8272,functional,O
PMC39689120_471,8272,capacity,O
PMC39689120_471,8272,[,O
PMC39689120_471,8272,assessed,O
PMC39689120_471,8272,by,O
PMC39689120_471,8272,the,O
PMC39689120_471,8272,University,O
PMC39689120_471,8272,of,O
PMC39689120_471,8272,California,O
PMC39689120_471,8272,-,O
PMC39689120_471,8272,San,O
PMC39689120_471,8272,Diego,O
PMC39689120_471,8272,(,O
PMC39689120_471,8272,UCSD,O
PMC39689120_471,8272,),O
PMC39689120_471,8272,Performance,O
PMC39689120_471,8272,-,O
PMC39689120_471,8272,Based,O
PMC39689120_471,8272,Skills,O
PMC39689120_471,8272,Assessment,O
PMC39689120_471,8272,-,O
PMC39689120_471,8272,Brief,O
PMC39689120_471,8272,Version,O
PMC39689120_471,8272,(,O
PMC39689120_471,8272,UPSA,O
PMC39689120_471,8272,-,O
PMC39689120_471,8272,B,O
PMC39689120_471,8272,),O
PMC39689120_471,8272,total,O
PMC39689120_471,8272,score,O
PMC39689120_471,8272,],O
PMC39689120_471,8272,;,O
PMC39689120_471,8272,these,O
PMC39689120_471,8272,mediating,O
PMC39689120_471,8272,relationships,O
PMC39689120_471,8272,were,O
PMC39689120_471,8272,not,O
PMC39689120_471,8272,observed,O
PMC39689120_471,8272,for,O
PMC39689120_471,8272,the,O
PMC39689120_471,8272,lurasidone,O
PMC39689120_471,8272,or,O
PMC39689120_471,8272,placebo,O
PMC39689120_471,8272,treatment,O
PMC39689120_471,8272,groups,O
PMC39689120_471,8272,0,O
PMC39703480_470,8273,Acute,O
PMC39703480_470,8273,Pancreatitis,O
PMC39703480_470,8273,and,O
PMC39703480_470,8273,Diabetic,O
PMC39703480_470,8273,Ketoacidosis,O
PMC39703480_470,8273,following,O
PMC39703480_470,8273,L,O
PMC39703480_470,8273,-,O
PMC39703480_470,8273,Asparaginase,O
PMC39703480_470,8273,/,O
PMC39703480_470,8273,Prednisone,B-Drug
PMC39703480_470,8273,Therapy,O
PMC39703480_470,8273,in,O
PMC39703480_470,8273,Acute,B-Disease
PMC39703480_470,8273,Lymphoblastic,I-Disease
PMC39703480_470,8273,Leukemia,I-Disease
PMC39703480_470,8273,0,O
PMC39763590_1010,8274,Moreover,O
PMC39763590_1010,8274,",",O
PMC39763590_1010,8274,metformin,O
PMC39763590_1010,8274,enhanced,O
PMC39763590_1010,8274,tamoxifen,B-Drug
PMC39763590_1010,8274,-,O
PMC39763590_1010,8274,mediated,O
PMC39763590_1010,8274,inhibition,O
PMC39763590_1010,8274,of,O
PMC39763590_1010,8274,proliferation,O
PMC39763590_1010,8274,",",O
PMC39763590_1010,8274,DNA,O
PMC39763590_1010,8274,replication,O
PMC39763590_1010,8274,activity,O
PMC39763590_1010,8274,",",O
PMC39763590_1010,8274,colony,O
PMC39763590_1010,8274,formation,O
PMC39763590_1010,8274,",",O
PMC39763590_1010,8274,soft,O
PMC39763590_1010,8274,-,O
PMC39763590_1010,8274,agar,O
PMC39763590_1010,8274,colony,O
PMC39763590_1010,8274,formation,O
PMC39763590_1010,8274,",",O
PMC39763590_1010,8274,and,O
PMC39763590_1010,8274,induction,O
PMC39763590_1010,8274,of,O
PMC39763590_1010,8274,apoptosis,O
PMC39763590_1010,8274,in,O
PMC39763590_1010,8274,ER,O
PMC39763590_1010,8274,-,O
PMC39763590_1010,8274,positive,O
PMC39763590_1010,8274,breast,B-Disease
PMC39763590_1010,8274,cancer,I-Disease
PMC39763590_1010,8274,cells,O
PMC39763590_1010,8274,0,O
PMC39775000_393,8275,Hypothalamus,O
PMC39775000_393,8275,-,O
PMC39775000_393,8275,anchored,O
PMC39775000_393,8275,resting,O
PMC39775000_393,8275,brain,O
PMC39775000_393,8275,network,O
PMC39775000_393,8275,changes,O
PMC39775000_393,8275,before,O
PMC39775000_393,8275,and,O
PMC39775000_393,8275,after,O
PMC39775000_393,8275,sertraline,B-Drug
PMC39775000_393,8275,treatment,O
PMC39775000_393,8275,in,O
PMC39775000_393,8275,major,B-Disease
PMC39775000_393,8275,depression,I-Disease
PMC39775000_393,8275,0,O
PMC39775000_847,8276,Sertraline,B-Drug
PMC39775000_847,8276,",",O
PMC39775000_847,8276,one,O
PMC39775000_847,8276,of,O
PMC39775000_847,8276,the,O
PMC39775000_847,8276,oldest,O
PMC39775000_847,8276,antidepressants,O
PMC39775000_847,8276,",",O
PMC39775000_847,8276,remains,O
PMC39775000_847,8276,to,O
PMC39775000_847,8276,be,O
PMC39775000_847,8276,the,O
PMC39775000_847,8276,most,O
PMC39775000_847,8276,efficacious,O
PMC39775000_847,8276,treatment,O
PMC39775000_847,8276,for,O
PMC39775000_847,8276,depression,B-Disease
PMC39775000_847,8276,0,O
PMC39809080_366,8277,Valproate,O
PMC39809080_366,8277,was,O
PMC39809080_366,8277,recommended,O
PMC39809080_366,8277,not,O
PMC39809080_366,8277,to,O
PMC39809080_366,8277,be,O
PMC39809080_366,8277,used,O
PMC39809080_366,8277,",",O
PMC39809080_366,8277,and,O
PMC39809080_366,8277,there,O
PMC39809080_366,8277,was,O
PMC39809080_366,8277,insufficient,O
PMC39809080_366,8277,evidence,O
PMC39809080_366,8277,to,O
PMC39809080_366,8277,recommend,O
PMC39809080_366,8277,for,O
PMC39809080_366,8277,or,O
PMC39809080_366,8277,against,O
PMC39809080_366,8277,the,O
PMC39809080_366,8277,use,O
PMC39809080_366,8277,of,O
PMC39809080_366,8277,selective,O
PMC39809080_366,8277,serotonin,O
PMC39809080_366,8277,reuptake,O
PMC39809080_366,8277,inhibitors,O
PMC39809080_366,8277,or,O
PMC39809080_366,8277,trazodone,B-Drug
PMC39809080_366,8277,for,O
PMC39809080_366,8277,the,O
PMC39809080_366,8277,treatment,O
PMC39809080_366,8277,of,O
PMC39809080_366,8277,agitation,B-Symptom
PMC39809080_366,8277,and,O
PMC39809080_366,8277,aggression,B-Symptom
PMC39809080_366,8277,0,O
PMC39840580_763,8278,OBJECTIVES,O
PMC39840580_763,8278,:,O
PMC39840580_763,8278,To,O
PMC39840580_763,8278,review,O
PMC39840580_763,8278,current,O
PMC39840580_763,8278,evidence,O
PMC39840580_763,8278,on,O
PMC39840580_763,8278,buprenorphine,B-Drug
PMC39840580_763,8278,-,O
PMC39840580_763,8278,naloxone,O
PMC39840580_763,8278,(,O
PMC39840580_763,8278,bup,O
PMC39840580_763,8278,/,O
PMC39840580_763,8278,nx,O
PMC39840580_763,8278,),O
PMC39840580_763,8278,for,O
PMC39840580_763,8278,the,O
PMC39840580_763,8278,treatment,O
PMC39840580_763,8278,of,O
PMC39840580_763,8278,opioid,O
PMC39840580_763,8278,-,O
PMC39840580_763,8278,use,O
PMC39840580_763,8278,disorders,O
PMC39840580_763,8278,",",O
PMC39840580_763,8278,with,O
PMC39840580_763,8278,a,O
PMC39840580_763,8278,focus,O
PMC39840580_763,8278,on,O
PMC39840580_763,8278,strategies,O
PMC39840580_763,8278,for,O
PMC39840580_763,8278,clinical,O
PMC39840580_763,8278,management,O
PMC39840580_763,8278,and,O
PMC39840580_763,8278,office,O
PMC39840580_763,8278,-,O
PMC39840580_763,8278,based,O
PMC39840580_763,8278,patient,O
PMC39840580_763,8278,care,O
PMC39840580_763,8278,0,O
PMC39862750_728,8279,Sex,O
PMC39862750_728,8279,differences,O
PMC39862750_728,8279,in,O
PMC39862750_728,8279,the,O
PMC39862750_728,8279,prediction,O
PMC39862750_728,8279,of,O
PMC39862750_728,8279,the,O
PMC39862750_728,8279,effectiveness,O
PMC39862750_728,8279,of,O
PMC39862750_728,8279,paroxetine,B-Drug
PMC39862750_728,8279,for,O
PMC39862750_728,8279,patients,O
PMC39862750_728,8279,with,O
PMC39862750_728,8279,major,B-Disease
PMC39862750_728,8279,depressive,I-Disease
PMC39862750_728,8279,disorder,I-Disease
PMC39862750_728,8279,identified,O
PMC39862750_728,8279,using,O
PMC39862750_728,8279,a,O
PMC39862750_728,8279,receiver,O
PMC39862750_728,8279,operating,O
PMC39862750_728,8279,characteristic,O
PMC39862750_728,8279,curve,O
PMC39862750_728,8279,analysis,O
PMC39862750_728,8279,for,O
PMC39862750_728,8279,early,O
PMC39862750_728,8279,response,O
PMC39862750_728,8279,0,O
PMC39882700_863,8280,Genetic,O
PMC39882700_863,8280,variation,O
PMC39882700_863,8280,in,O
PMC39882700_863,8280,OPRD,O
PMC39882700_863,8280,_,O
PMC39882700_863,8280,_,O
PMC39882700_863,8280,number,O
PMC39882700_863,8280,_,O
PMC39882700_863,8280,_,O
PMC39882700_863,8280,and,O
PMC39882700_863,8280,the,O
PMC39882700_863,8280,response,O
PMC39882700_863,8280,to,O
PMC39882700_863,8280,treatment,O
PMC39882700_863,8280,for,O
PMC39882700_863,8280,opioid,O
PMC39882700_863,8280,dependence,O
PMC39882700_863,8280,with,O
PMC39882700_863,8280,buprenorphine,B-Drug
PMC39882700_863,8280,in,O
PMC39882700_863,8280,European,O
PMC39882700_863,8280,-,O
PMC39882700_863,8280,American,O
PMC39882700_863,8280,females,O
PMC39882700_863,8280,0,O
PMC39892680_864,8281,Adriamycin,O
PMC39892680_864,8281,and,O
PMC39892680_864,8281,docetaxel,B-Drug
PMC39892680_864,8281,are,O
PMC39892680_864,8281,two,O
PMC39892680_864,8281,agents,O
PMC39892680_864,8281,commonly,O
PMC39892680_864,8281,used,O
PMC39892680_864,8281,in,O
PMC39892680_864,8281,treatment,O
PMC39892680_864,8281,of,O
PMC39892680_864,8281,breast,B-Disease
PMC39892680_864,8281,cancer,I-Disease
PMC39892680_864,8281,",",O
PMC39892680_864,8281,but,O
PMC39892680_864,8281,their,O
PMC39892680_864,8281,efficacy,O
PMC39892680_864,8281,is,O
PMC39892680_864,8281,often,O
PMC39892680_864,8281,limited,O
PMC39892680_864,8281,by,O
PMC39892680_864,8281,the,O
PMC39892680_864,8281,emergence,O
PMC39892680_864,8281,of,O
PMC39892680_864,8281,chemoresistance,O
PMC39892680_864,8281,0,O
PMC39900810_291,8282,Clinicians,O
PMC39900810_291,8282,should,O
PMC39900810_291,8282,be,O
PMC39900810_291,8282,aware,O
PMC39900810_291,8282,of,O
PMC39900810_291,8282,the,O
PMC39900810_291,8282,potentially,O
PMC39900810_291,8282,life,O
PMC39900810_291,8282,-,O
PMC39900810_291,8282,threatening,O
PMC39900810_291,8282,metabolic,O
PMC39900810_291,8282,disturbances,O
PMC39900810_291,8282,and,O
PMC39900810_291,8282,/,O
PMC39900810_291,8282,or,O
PMC39900810_291,8282,pancreatitis,O
PMC39900810_291,8282,associated,O
PMC39900810_291,8282,with,O
PMC39900810_291,8282,quetiapine,B-Drug
PMC39900810_291,8282,therapy,O
PMC39900810_291,8282,0,O
PMC399102135_876,8283,Effects,O
PMC399102135_876,8283,of,O
PMC399102135_876,8283,ebelactone,O
PMC399102135_876,8283,B,O
PMC399102135_876,8283,",",O
PMC399102135_876,8283,BP,O
PMC399102135_876,8283,_,O
PMC399102135_876,8283,_,O
PMC399102135_876,8283,number,O
PMC399102135_876,8283,_,O
PMC399102135_876,8283,_,O
PMC399102135_876,8283,",",O
PMC399102135_876,8283,and,O
PMC399102135_876,8283,lisinopril,B-Drug
PMC399102135_876,8283,on,O
PMC399102135_876,8283,the,O
PMC399102135_876,8283,development,O
PMC399102135_876,8283,of,O
PMC399102135_876,8283,deoxycorticosterone,O
PMC399102135_876,8283,acetate,O
PMC399102135_876,8283,(,O
PMC399102135_876,8283,DOCA,O
PMC399102135_876,8283,),O
PMC399102135_876,8283,-,O
PMC399102135_876,8283,salt,O
PMC399102135_876,8283,hypertension,O
PMC399102135_876,8283,0,O
PMC39919100_349,8284,Acute,O
PMC39919100_349,8284,myopia,B-Disease
PMC39919100_349,8284,and,O
PMC39919100_349,8284,angle,B-Disease
PMC39919100_349,8284,closure,I-Disease
PMC39919100_349,8284,glaucoma,I-Disease
PMC39919100_349,8284,from,O
PMC39919100_349,8284,topiramate,B-Drug
PMC39919100_349,8284,in,O
PMC39919100_349,8284,a,O
PMC39919100_349,8284,seven,O
PMC39919100_349,8284,-,O
PMC39919100_349,8284,year,O
PMC39919100_349,8284,-,O
PMC39919100_349,8284,old,O
PMC39919100_349,8284,:,O
PMC39919100_349,8284,a,O
PMC39919100_349,8284,case,O
PMC39919100_349,8284,report,O
PMC39919100_349,8284,and,O
PMC39919100_349,8284,review,O
PMC39919100_349,8284,of,O
PMC39919100_349,8284,the,O
PMC39919100_349,8284,literature,O
PMC39919100_349,8284,0,O
PMC39923570_872,8285,Buprenorphine,B-Drug
PMC39923570_872,8285,Outpatient,O
PMC39923570_872,8285,Outcomes,O
PMC39923570_872,8285,Project,O
PMC39923570_872,8285,:,O
PMC39923570_872,8285,can,O
PMC39923570_872,8285,Suboxone,B-Drug
PMC39923570_872,8285,be,O
PMC39923570_872,8285,a,O
PMC39923570_872,8285,viable,O
PMC39923570_872,8285,outpatient,O
PMC39923570_872,8285,option,O
PMC39923570_872,8285,for,O
PMC39923570_872,8285,heroin,O
PMC39923570_872,8285,addiction,O
PMC39923570_872,8285,?,O
PMC39945490_448,8285,Montelukast,B-Drug
PMC39945490_448,8285,is,O
PMC39945490_448,8285,a,O
PMC39945490_448,8285,selective,O
PMC39945490_448,8285,cysteinyl,O
PMC39945490_448,8285,-,O
PMC39945490_448,8285,leukotriene,O
PMC39945490_448,8285,receptor,O
PMC39945490_448,8285,antagonist,O
PMC39945490_448,8285,with,O
PMC39945490_448,8285,proven,O
PMC39945490_448,8285,effectiveness,O
PMC39945490_448,8285,in,O
PMC39945490_448,8285,patients,O
PMC39945490_448,8285,with,O
PMC39945490_448,8285,asthma,B-Disease
PMC39945490_448,8285,0,O
PMC40002490_275,8286,METHOD,O
PMC40002490_275,8286,:,O
PMC40002490_275,8286,Patients,O
PMC40002490_275,8286,were,O
PMC40002490_275,8286,asked,O
PMC40002490_275,8286,to,O
PMC40002490_275,8286,identify,O
PMC40002490_275,8286,the,O
PMC40002490_275,8286,"""",O
PMC40002490_275,8286,offending,O
PMC40002490_275,8286,"""",O
PMC40002490_275,8286,BD,O
PMC40002490_275,8286,medication,O
PMC40002490_275,8286,which,O
PMC40002490_275,8286,they,O
PMC40002490_275,8286,believed,O
PMC40002490_275,8286,was,O
PMC40002490_275,8286,causing,O
PMC40002490_275,8286,weight,B-Symptom
PMC40002490_275,8286,problems,I-Symptom
PMC40002490_275,8286,",",O
PMC40002490_275,8286,and,O
PMC40002490_275,8286,this,O
PMC40002490_275,8286,agent,O
PMC40002490_275,8286,was,O
PMC40002490_275,8286,replaced,O
PMC40002490_275,8286,with,O
PMC40002490_275,8286,ziprasidone,B-Drug
PMC40002490_275,8286,0,O
PMC40038290_616,8287,Ziprasidone,B-Drug
PMC40038290_616,8287,as,O
PMC40038290_616,8287,adjunctive,O
PMC40038290_616,8287,therapy,O
PMC40038290_616,8287,in,O
PMC40038290_616,8287,severe,O
PMC40038290_616,8287,bipolar,B-Disease
PMC40038290_616,8287,patients,O
PMC40038290_616,8287,treated,O
PMC40038290_616,8287,with,O
PMC40038290_616,8287,clozapine,O
PMC40038290_616,8287,0,O
PMC40038290_754,8288,To,O
PMC40038290_754,8288,confirm,O
PMC40038290_754,8288,the,O
PMC40038290_754,8288,efficacy,O
PMC40038290_754,8288,and,O
PMC40038290_754,8288,tolerability,O
PMC40038290_754,8288,of,O
PMC40038290_754,8288,ziprasidone,B-Drug
PMC40038290_754,8288,as,O
PMC40038290_754,8288,adjunctive,O
PMC40038290_754,8288,therapy,O
PMC40038290_754,8288,in,O
PMC40038290_754,8288,bipolar,B-Disease
PMC40038290_754,8288,patients,O
PMC40038290_754,8288,partially,O
PMC40038290_754,8288,responding,O
PMC40038290_754,8288,to,O
PMC40038290_754,8288,clozapine,O
PMC40038290_754,8288,or,O
PMC40038290_754,8288,with,O
PMC40038290_754,8288,persisting,O
PMC40038290_754,8288,negative,O
PMC40038290_754,8288,symptoms,O
PMC40038290_754,8288,",",O
PMC40038290_754,8288,overweight,O
PMC40038290_754,8288,",",O
PMC40038290_754,8288,or,O
PMC40038290_754,8288,with,O
PMC40038290_754,8288,metabolic,O
PMC40038290_754,8288,syndrome,O
PMC40038290_754,8288,0,O
PMC40049080_553,8289,Poor,O
PMC40049080_553,8289,response,O
PMC40049080_553,8289,to,O
PMC40049080_553,8289,substitution,O
PMC40049080_553,8289,therapy,O
PMC40049080_553,8289,with,O
PMC40049080_553,8289,cortisone,B-Drug
PMC40049080_553,8289,acetate,O
PMC40049080_553,8289,in,O
PMC40049080_553,8289,patients,O
PMC40049080_553,8289,with,O
PMC40049080_553,8289,congenital,B-Disease
PMC40049080_553,8289,adrenal,I-Disease
PMC40049080_553,8289,hyperplasia,I-Disease
PMC40049080_553,8289,0,O
PMC40075560_955,8290,CONCLUSIONS,O
PMC40075560_955,8290,:,O
PMC40075560_955,8290,This,O
PMC40075560_955,8290,analysis,O
PMC40075560_955,8290,suggests,O
PMC40075560_955,8290,no,O
PMC40075560_955,8290,difference,O
PMC40075560_955,8290,between,O
PMC40075560_955,8290,duloxetine,B-Drug
PMC40075560_955,8290,and,O
PMC40075560_955,8290,other,O
PMC40075560_955,8290,post,O
PMC40075560_955,8290,-,O
PMC40075560_955,8290,first,O
PMC40075560_955,8290,line,O
PMC40075560_955,8290,oral,O
PMC40075560_955,8290,treatments,O
PMC40075560_955,8290,for,O
PMC40075560_955,8290,osteoarthritis,B-Disease
PMC40075560_955,8290,(,O
PMC40075560_955,8290,OA,O
PMC40075560_955,8290,),O
PMC40075560_955,8290,in,O
PMC40075560_955,8290,total,O
PMC40075560_955,8290,WOMAC,O
PMC40075560_955,8290,score,O
PMC40075560_955,8290,after,O
PMC40075560_955,8290,approximately,O
PMC40075560_955,8290,_,O
PMC40075560_955,8290,_,O
PMC40075560_955,8290,number,O
PMC40075560_955,8290,_,O
PMC40075560_955,8290,_,O
PMC40075560_955,8290,weeks,O
PMC40075560_955,8290,of,O
PMC40075560_955,8290,treatment,O
PMC40075560_955,8290,0,O
PMC40106400_262,8291,The,O
PMC40106400_262,8291,effect,O
PMC40106400_262,8291,of,O
PMC40106400_262,8291,posterior,O
PMC40106400_262,8291,sub,O
PMC40106400_262,8291,-,O
PMC40106400_262,8291,Tenon,O
PMC40106400_262,8291,',O
PMC40106400_262,8291,s,O
PMC40106400_262,8291,capsule,O
PMC40106400_262,8291,triamcinolone,B-Drug
PMC40106400_262,8291,acetonide,O
PMC40106400_262,8291,injection,O
PMC40106400_262,8291,to,O
PMC40106400_262,8291,that,O
PMC40106400_262,8291,of,O
PMC40106400_262,8291,pars,O
PMC40106400_262,8291,plana,O
PMC40106400_262,8291,vitrectomy,O
PMC40106400_262,8291,for,O
PMC40106400_262,8291,diabetic,B-Disease
PMC40106400_262,8291,macular,I-Disease
PMC40106400_262,8291,edema,I-Disease
PMC40106400_262,8291,0,O
PMC40115670_288,8292,Cardiovascular,O
PMC40115670_288,8292,data,O
PMC40115670_288,8292,associated,O
PMC40115670_288,8292,with,O
PMC40115670_288,8292,long,O
PMC40115670_288,8292,-,O
PMC40115670_288,8292,term,O
PMC40115670_288,8292,use,O
PMC40115670_288,8292,of,O
PMC40115670_288,8292,phentermine,O
PMC40115670_288,8292,and,O
PMC40115670_288,8292,topiramate,B-Drug
PMC40115670_288,8292,extended,O
PMC40115670_288,8292,-,O
PMC40115670_288,8292,release,O
PMC40115670_288,8292,indicate,O
PMC40115670_288,8292,that,O
PMC40115670_288,8292,this,O
PMC40115670_288,8292,combination,O
PMC40115670_288,8292,may,O
PMC40115670_288,8292,be,O
PMC40115670_288,8292,a,O
PMC40115670_288,8292,safe,O
PMC40115670_288,8292,and,O
PMC40115670_288,8292,effective,O
PMC40115670_288,8292,option,O
PMC40115670_288,8292,for,O
PMC40115670_288,8292,reducing,B-Symptom
PMC40115670_288,8292,weight,I-Symptom
PMC40115670_288,8292,in,O
PMC40115670_288,8292,overweight,O
PMC40115670_288,8292,/,O
PMC40115670_288,8292,obese,O
PMC40115670_288,8292,patients,O
PMC40115670_288,8292,at,O
PMC40115670_288,8292,low,O
PMC40115670_288,8292,-,O
PMC40115670_288,8292,to,O
PMC40115670_288,8292,-,O
PMC40115670_288,8292,intermediate,O
PMC40115670_288,8292,cardiovascular,B-Disease
PMC40115670_288,8292,risk,O
PMC40115670_288,8292,0,O
PMC40123460_974,8293,Effects,O
PMC40123460_974,8293,of,O
PMC40123460_974,8293,EPHX,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,number,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,and,O
PMC40123460_974,8293,CYP,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,number,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,A,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,number,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,_,O
PMC40123460_974,8293,polymorphisms,O
PMC40123460_974,8293,on,O
PMC40123460_974,8293,carbamazepine,B-Drug
PMC40123460_974,8293,metabolism,O
PMC40123460_974,8293,in,O
PMC40123460_974,8293,epileptic,B-Disease
PMC40123460_974,8293,patients,O
PMC40123460_974,8293,0,O
PMC40176350_90,8294,Triamcinolone,B-Drug
PMC40176350_90,8294,acetonide,O
PMC40176350_90,8294,is,O
PMC40176350_90,8294,the,O
PMC40176350_90,8294,most,O
PMC40176350_90,8294,commonly,O
PMC40176350_90,8294,used,O
PMC40176350_90,8294,intravitreal,O
PMC40176350_90,8294,corticosteroid,O
PMC40176350_90,8294,for,O
PMC40176350_90,8294,treatment,O
PMC40176350_90,8294,of,O
PMC40176350_90,8294,uveitis,B-Symptom
PMC40176350_90,8294,and,O
PMC40176350_90,8294,uveitic,O
PMC40176350_90,8294,macular,O
PMC40176350_90,8294,oedema,O
PMC40176350_90,8294,0,O
PMC40196230_208,8295,METHODS,O
PMC40196230_208,8295,:,O
PMC40196230_208,8295,This,O
PMC40196230_208,8295,pilot,O
PMC40196230_208,8295,randomized,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,open,O
PMC40196230_208,8295,-,O
PMC40196230_208,8295,label,O
PMC40196230_208,8295,study,O
PMC40196230_208,8295,compared,O
PMC40196230_208,8295,the,O
PMC40196230_208,8295,efficacy,O
PMC40196230_208,8295,of,O
PMC40196230_208,8295,quetiapine,B-Drug
PMC40196230_208,8295,versus,O
PMC40196230_208,8295,olanzapine,B-Drug
PMC40196230_208,8295,in,O
PMC40196230_208,8295,reducing,O
PMC40196230_208,8295,impulsive,O
PMC40196230_208,8295,and,O
PMC40196230_208,8295,aggressive,B-Symptom
PMC40196230_208,8295,behaviors,I-Symptom
PMC40196230_208,8295,(,O
PMC40196230_208,8295,primary,O
PMC40196230_208,8295,endpoints,O
PMC40196230_208,8295,),O
PMC40196230_208,8295,and,O
PMC40196230_208,8295,psychotic,O
PMC40196230_208,8295,symptoms,O
PMC40196230_208,8295,(,O
PMC40196230_208,8295,secondary,O
PMC40196230_208,8295,endpoints,O
PMC40196230_208,8295,),O
PMC40196230_208,8295,from,O
PMC40196230_208,8295,baseline,O
PMC40196230_208,8295,to,O
PMC40196230_208,8295,days,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,and,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,",",O
PMC40196230_208,8295,in,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,number,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,_,O
PMC40196230_208,8295,violent,O
PMC40196230_208,8295,schizophrenic,B-Disease
PMC40196230_208,8295,patients,O
PMC40196230_208,8295,hospitalized,O
PMC40196230_208,8295,in,O
PMC40196230_208,8295,a,O
PMC40196230_208,8295,maximum,O
PMC40196230_208,8295,-,O
PMC40196230_208,8295,security,O
PMC40196230_208,8295,psychiatric,O
PMC40196230_208,8295,hospital,O
PMC40196230_208,8295,0,O
PMC40196230_885,8296,CONCLUSION,O
PMC40196230_885,8296,:,O
PMC40196230_885,8296,In,O
PMC40196230_885,8296,this,O
PMC40196230_885,8296,pilot,O
PMC40196230_885,8296,study,O
PMC40196230_885,8296,",",O
PMC40196230_885,8296,quetiapine,B-Drug
PMC40196230_885,8296,and,O
PMC40196230_885,8296,olanzapine,B-Drug
PMC40196230_885,8296,equally,O
PMC40196230_885,8296,decreased,O
PMC40196230_885,8296,impulsive,O
PMC40196230_885,8296,and,O
PMC40196230_885,8296,psychotic,B-Symptom
PMC40196230_885,8296,symptoms,I-Symptom
PMC40196230_885,8296,after,O
PMC40196230_885,8296,_,O
PMC40196230_885,8296,_,O
PMC40196230_885,8296,number,O
PMC40196230_885,8296,_,O
PMC40196230_885,8296,_,O
PMC40196230_885,8296,weeks,O
PMC40196230_885,8296,of,O
PMC40196230_885,8296,treatment,O
PMC40196230_885,8296,0,O
PMC40266430_454,8297,CONCLUSIONS,O
PMC40266430_454,8297,:,O
PMC40266430_454,8297,We,O
PMC40266430_454,8297,observed,O
PMC40266430_454,8297,that,O
PMC40266430_454,8297,ciprofloxacin,B-Drug
PMC40266430_454,8297,-,O
PMC40266430_454,8297,induced,O
PMC40266430_454,8297,pancreatitis,O
PMC40266430_454,8297,may,O
PMC40266430_454,8297,occur,O
PMC40266430_454,8297,with,O
PMC40266430_454,8297,an,O
PMC40266430_454,8297,incidence,O
PMC40266430_454,8297,of,O
PMC40266430_454,8297,approximately,O
PMC40266430_454,8297,_,O
PMC40266430_454,8297,_,O
PMC40266430_454,8297,number,O
PMC40266430_454,8297,_,O
PMC40266430_454,8297,_,O
PMC40266430_454,8297,%,O
PMC40266430_454,8297,0,O
PMC40293910_200,8298,S,O
PMC40293910_200,8298,_,O
PMC40293910_200,8298,_,O
PMC40293910_200,8298,number,O
PMC40293910_200,8298,_,O
PMC40293910_200,8298,_,O
PMC40293910_200,8298,combined,O
PMC40293910_200,8298,with,O
PMC40293910_200,8298,docetaxel,B-Drug
PMC40293910_200,8298,following,O
PMC40293910_200,8298,doxorubicin,O
PMC40293910_200,8298,plus,O
PMC40293910_200,8298,cyclophosphamide,O
PMC40293910_200,8298,as,O
PMC40293910_200,8298,neoadjuvant,O
PMC40293910_200,8298,therapy,O
PMC40293910_200,8298,in,O
PMC40293910_200,8298,breast,B-Disease
PMC40293910_200,8298,cancer,I-Disease
PMC40293910_200,8298,:,O
PMC40293910_200,8298,phase,O
PMC40293910_200,8298,II,O
PMC40293910_200,8298,trial,O
PMC40293910_200,8298,0,O
PMC40295260_135,8299,FINDINGS,O
PMC40295260_135,8299,:,O
PMC40295260_135,8299,Healthy,O
PMC40295260_135,8299,volunteers,O
PMC40295260_135,8299,(,O
PMC40295260_135,8299,HV,O
PMC40295260_135,8299,",",O
PMC40295260_135,8299,N,O
PMC40295260_135,8299,=,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,number,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,),O
PMC40295260_135,8299,and,O
PMC40295260_135,8299,seasonal,O
PMC40295260_135,8299,allergic,B-Disease
PMC40295260_135,8299,rhinitis,I-Disease
PMC40295260_135,8299,(,O
PMC40295260_135,8299,SAR,O
PMC40295260_135,8299,",",O
PMC40295260_135,8299,N,O
PMC40295260_135,8299,=,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,number,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,),O
PMC40295260_135,8299,asymptomatic,O
PMC40295260_135,8299,patients,O
PMC40295260_135,8299,were,O
PMC40295260_135,8299,treated,O
PMC40295260_135,8299,out,O
PMC40295260_135,8299,of,O
PMC40295260_135,8299,the,O
PMC40295260_135,8299,pollen,O
PMC40295260_135,8299,season,O
PMC40295260_135,8299,with,O
PMC40295260_135,8299,either,O
PMC40295260_135,8299,rupatadine,B-Drug
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,number,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,mg,O
PMC40295260_135,8299,",",O
PMC40295260_135,8299,levocetirizine,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,number,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,mg,O
PMC40295260_135,8299,",",O
PMC40295260_135,8299,or,O
PMC40295260_135,8299,placebo,O
PMC40295260_135,8299,once,O
PMC40295260_135,8299,a,O
PMC40295260_135,8299,day,O
PMC40295260_135,8299,during,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,number,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,_,O
PMC40295260_135,8299,days,O
PMC40295260_135,8299,prior,O
PMC40295260_135,8299,to,O
PMC40295260_135,8299,the,O
PMC40295260_135,8299,PAF,O
PMC40295260_135,8299,nasal,O
PMC40295260_135,8299,challenge,O
PMC40295260_135,8299,0,O
PMC40295260_33,8300,Evaluation,O
PMC40295260_33,8300,of,O
PMC40295260_33,8300,nasal,O
PMC40295260_33,8300,symptoms,O
PMC40295260_33,8300,induced,O
PMC40295260_33,8300,by,O
PMC40295260_33,8300,platelet,O
PMC40295260_33,8300,activating,O
PMC40295260_33,8300,factor,O
PMC40295260_33,8300,",",O
PMC40295260_33,8300,after,O
PMC40295260_33,8300,nasal,O
PMC40295260_33,8300,challenge,O
PMC40295260_33,8300,in,O
PMC40295260_33,8300,both,O
PMC40295260_33,8300,healthy,O
PMC40295260_33,8300,and,O
PMC40295260_33,8300,allergic,B-Disease
PMC40295260_33,8300,rhinitis,I-Disease
PMC40295260_33,8300,subjects,O
PMC40295260_33,8300,pretreated,O
PMC40295260_33,8300,with,O
PMC40295260_33,8300,rupatadine,B-Drug
PMC40295260_33,8300,",",O
PMC40295260_33,8300,levocetirizine,O
PMC40295260_33,8300,or,O
PMC40295260_33,8300,placebo,O
PMC40295260_33,8300,in,O
PMC40295260_33,8300,a,O
PMC40295260_33,8300,cross,O
PMC40295260_33,8300,-,O
PMC40295260_33,8300,over,O
PMC40295260_33,8300,study,O
PMC40295260_33,8300,design,O
PMC40295260_33,8300,0,O
PMC40315860_674,8301,MATERIALS,O
PMC40315860_674,8301,AND,O
PMC40315860_674,8301,METHODS,O
PMC40315860_674,8301,:,O
PMC40315860_674,8301,Thirteen,O
PMC40315860_674,8301,patients,O
PMC40315860_674,8301,of,O
PMC40315860_674,8301,bipolar,B-Disease
PMC40315860_674,8301,disorder,I-Disease
PMC40315860_674,8301,who,O
PMC40315860_674,8301,were,O
PMC40315860_674,8301,on,O
PMC40315860_674,8301,regular,O
PMC40315860_674,8301,treatment,O
PMC40315860_674,8301,with,O
PMC40315860_674,8301,mood,O
PMC40315860_674,8301,stabilizer,O
PMC40315860_674,8301,and,O
PMC40315860_674,8301,subsequently,O
PMC40315860_674,8301,relapsed,O
PMC40315860_674,8301,into,O
PMC40315860_674,8301,mania,O
PMC40315860_674,8301,or,O
PMC40315860_674,8301,depressive,O
PMC40315860_674,8301,episode,O
PMC40315860_674,8301,after,O
PMC40315860_674,8301,discontinuation,O
PMC40315860_674,8301,of,O
PMC40315860_674,8301,olanzapine,B-Drug
PMC40315860_674,8301,were,O
PMC40315860_674,8301,studied,O
PMC40315860_674,8301,for,O
PMC40315860_674,8301,various,O
PMC40315860_674,8301,socio,O
PMC40315860_674,8301,-,O
PMC40315860_674,8301,demographic,O
PMC40315860_674,8301,and,O
PMC40315860_674,8301,clinical,O
PMC40315860_674,8301,factors,O
PMC40315860_674,8301,using,O
PMC40315860_674,8301,retrospective,O
PMC40315860_674,8301,chart,O
PMC40315860_674,8301,review,O
PMC40315860_674,8301,0,O
PMC40322300_174,8302,CONCLUSION,O
PMC40322300_174,8302,:,O
PMC40322300_174,8302,Among,O
PMC40322300_174,8302,patients,O
PMC40322300_174,8302,with,O
PMC40322300_174,8302,MDD,B-Disease
PMC40322300_174,8302,who,O
PMC40322300_174,8302,do,O
PMC40322300_174,8302,not,O
PMC40322300_174,8302,respond,O
PMC40322300_174,8302,to,O
PMC40322300_174,8302,paroxetine,O
PMC40322300_174,8302,",",O
PMC40322300_174,8302,a,O
PMC40322300_174,8302,lower,O
PMC40322300_174,8302,plasma,O
PMC40322300_174,8302,concentration,O
PMC40322300_174,8302,or,O
PMC40322300_174,8302,a,O
PMC40322300_174,8302,lower,O
PMC40322300_174,8302,oral,O
PMC40322300_174,8302,dose,O
PMC40322300_174,8302,of,O
PMC40322300_174,8302,paroxetine,B-Drug
PMC40322300_174,8302,might,O
PMC40322300_174,8302,be,O
PMC40322300_174,8302,more,O
PMC40322300_174,8302,effective,O
PMC40322300_174,8302,in,O
PMC40322300_174,8302,those,O
PMC40322300_174,8302,with,O
PMC40322300_174,8302,the,O
PMC40322300_174,8302,SS,O
PMC40322300_174,8302,genotype,O
PMC40322300_174,8302,",",O
PMC40322300_174,8302,and,O
PMC40322300_174,8302,a,O
PMC40322300_174,8302,higher,O
PMC40322300_174,8302,plasma,O
PMC40322300_174,8302,concentration,O
PMC40322300_174,8302,might,O
PMC40322300_174,8302,be,O
PMC40322300_174,8302,more,O
PMC40322300_174,8302,effective,O
PMC40322300_174,8302,in,O
PMC40322300_174,8302,those,O
PMC40322300_174,8302,with,O
PMC40322300_174,8302,the,O
PMC40322300_174,8302,SL,O
PMC40322300_174,8302,or,O
PMC40322300_174,8302,LL,O
PMC40322300_174,8302,genotype,O
PMC40322300_174,8302,0,O
PMC40330330_52,8303,METHODS,O
PMC40330330_52,8303,:,O
PMC40330330_52,8303,We,O
PMC40330330_52,8303,analysed,O
PMC40330330_52,8303,data,O
PMC40330330_52,8303,from,O
PMC40330330_52,8303,the,O
PMC40330330_52,8303,Standard,O
PMC40330330_52,8303,and,O
PMC40330330_52,8303,New,O
PMC40330330_52,8303,Antiepileptic,O
PMC40330330_52,8303,Drug,O
PMC40330330_52,8303,(,O
PMC40330330_52,8303,arm,O
PMC40330330_52,8303,B,O
PMC40330330_52,8303,),O
PMC40330330_52,8303,study,O
PMC40330330_52,8303,",",O
PMC40330330_52,8303,a,O
PMC40330330_52,8303,randomised,O
PMC40330330_52,8303,trial,O
PMC40330330_52,8303,that,O
PMC40330330_52,8303,compared,O
PMC40330330_52,8303,initiating,O
PMC40330330_52,8303,treatment,O
PMC40330330_52,8303,with,O
PMC40330330_52,8303,lamotrigine,B-Drug
PMC40330330_52,8303,",",O
PMC40330330_52,8303,topiramate,B-Drug
PMC40330330_52,8303,and,O
PMC40330330_52,8303,valproate,O
PMC40330330_52,8303,in,O
PMC40330330_52,8303,patients,O
PMC40330330_52,8303,diagnosed,O
PMC40330330_52,8303,with,O
PMC40330330_52,8303,generalised,O
PMC40330330_52,8303,or,O
PMC40330330_52,8303,unclassified,O
PMC40330330_52,8303,epilepsy,B-Disease
PMC40330330_52,8303,0,O
PMC40339454_653,8304,Nabilone,O
PMC40339454_653,8304,was,O
PMC40339454_653,8304,used,O
PMC40339454_653,8304,in,O
PMC40339454_653,8304,a,O
PMC40339454_653,8304,patient,O
PMC40339454_653,8304,with,O
PMC40339454_653,8304,Alzheimers,B-Disease
PMC40339454_653,8304,disease,I-Disease
PMC40339454_653,8304,[,O
PMC40339454_653,8304,_,O
PMC40339454_653,8304,_,O
PMC40339454_653,8304,number,O
PMC40339454_653,8304,_,O
PMC40339454_653,8304,_,O
PMC40339454_653,8304,],O
PMC40339454_653,8304,who,O
PMC40339454_653,8304,had,O
PMC40339454_653,8304,been,O
PMC40339454_653,8304,subsequently,O
PMC40339454_653,8304,treated,O
PMC40339454_653,8304,with,O
PMC40339454_653,8304,donezepil,O
PMC40339454_653,8304,",",O
PMC40339454_653,8304,memantine,O
PMC40339454_653,8304,",",O
PMC40339454_653,8304,trazodone,B-Drug
PMC40339454_653,8304,",",O
PMC40339454_653,8304,quetiapine,B-Drug
PMC40339454_653,8304,",",O
PMC40339454_653,8304,and,O
PMC40339454_653,8304,olanzapine,B-Drug
PMC40339454_653,8304,without,O
PMC40339454_653,8304,any,O
PMC40339454_653,8304,impact,O
PMC40339454_653,8304,on,O
PMC40339454_653,8304,the,O
PMC40339454_653,8304,behavioral,O
PMC40339454_653,8304,symptoms,O
PMC40339454_653,8304,0,O
PMC40339468_339,8305,The,O
PMC40339468_339,8305,FDA,O
PMC40339468_339,8305,issued,O
PMC40339468_339,8305,an,O
PMC40339468_339,8305,alert,O
PMC40339468_339,8305,and,O
PMC40339468_339,8305,updated,O
PMC40339468_339,8305,product,O
PMC40339468_339,8305,labeling,O
PMC40339468_339,8305,recommending,O
PMC40339468_339,8305,genetic,O
PMC40339468_339,8305,testing,O
PMC40339468_339,8305,for,O
PMC40339468_339,8305,HLA,O
PMC40339468_339,8305,-,O
PMC40339468_339,8305,B,O
PMC40339468_339,8305,polymorphisms,O
PMC40339468_339,8305,to,O
PMC40339468_339,8305,predict,O
PMC40339468_339,8305,carbamazepine,B-Drug
PMC40339468_339,8305,-,O
PMC40339468_339,8305,induced,O
PMC40339468_339,8305,serious,O
PMC40339468_339,8305,skin,B-Symptom
PMC40339468_339,8305,reactions,I-Symptom
PMC40339468_339,8305,in,O
PMC40339468_339,8305,individuals,O
PMC40339468_339,8305,of,O
PMC40339468_339,8305,Asian,O
PMC40339468_339,8305,descent,O
PMC40339468_339,8305,[,O
PMC40339468_339,8305,_,O
PMC40339468_339,8305,_,O
PMC40339468_339,8305,number,O
PMC40339468_339,8305,_,O
PMC40339468_339,8305,_,O
PMC40339468_339,8305,],O
PMC40339468_339,8305,0,O
PMC40339531_989,8306,The,O
PMC40339531_989,8306,most,O
PMC40339531_989,8306,convincing,O
PMC40339531_989,8306,evidence,O
PMC40339531_989,8306,for,O
PMC40339531_989,8306,an,O
PMC40339531_989,8306,etiological,O
PMC40339531_989,8306,role,O
PMC40339531_989,8306,of,O
PMC40339531_989,8306,cysteinyl,O
PMC40339531_989,8306,-,O
PMC40339531_989,8306,LTs,O
PMC40339531_989,8306,in,O
PMC40339531_989,8306,asthma,B-Disease
PMC40339531_989,8306,comes,O
PMC40339531_989,8306,from,O
PMC40339531_989,8306,the,O
PMC40339531_989,8306,therapeutic,O
PMC40339531_989,8306,efficacy,O
PMC40339531_989,8306,of,O
PMC40339531_989,8306,CysLT,O
PMC40339531_989,8306,_,O
PMC40339531_989,8306,_,O
PMC40339531_989,8306,number,O
PMC40339531_989,8306,_,O
PMC40339531_989,8306,_,O
PMC40339531_989,8306,receptor,O
PMC40339531_989,8306,antagonists,O
PMC40339531_989,8306,(,O
PMC40339531_989,8306,e,O
PMC40339531_989,8306,0,O
PMC40339531_989,8307,g,O
PMC40339531_989,8307,0,O
PMC40339531_989,8308,",",O
PMC40339531_989,8308,montelukast,B-Drug
PMC40339531_989,8308,",",O
PMC40339531_989,8308,zafirlukast,O
PMC40339531_989,8308,",",O
PMC40339531_989,8308,pranlukast,O
PMC40339531_989,8308,),O
PMC40339531_989,8308,",",O
PMC40339531_989,8308,commonly,O
PMC40339531_989,8308,known,O
PMC40339531_989,8308,as,O
PMC40339531_989,8308,leukotriene,O
PMC40339531_989,8308,receptor,O
PMC40339531_989,8308,antagonists,O
PMC40339531_989,8308,(,O
PMC40339531_989,8308,LTRAs,O
PMC40339531_989,8308,),O
PMC40339531_989,8308,",",O
PMC40339531_989,8308,and,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,number,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,-,O
PMC40339531_989,8308,lipoxygenase,O
PMC40339531_989,8308,(,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,number,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,_,O
PMC40339531_989,8308,-,O
PMC40339531_989,8308,LO,O
PMC40339531_989,8308,),O
PMC40339531_989,8308,inhibitors,O
PMC40339531_989,8308,(,O
PMC40339531_989,8308,e,O
PMC40339531_989,8308,0,O
PMC40339531_989,8309,g,O
PMC40339531_989,8309,0,O
PMC40339531_989,8310,",",O
PMC40339531_989,8310,zileuton,O
PMC40339531_989,8310,),O
PMC40339531_989,8310,in,O
PMC40339531_989,8310,patients,O
PMC40339531_989,8310,with,O
PMC40339531_989,8310,asthma,B-Disease
PMC40339531_989,8310,[,O
PMC40339531_989,8310,_,O
PMC40339531_989,8310,_,O
PMC40339531_989,8310,number,O
PMC40339531_989,8310,_,O
PMC40339531_989,8310,_,O
PMC40339531_989,8310,],O
PMC40339531_989,8310,0,O
PMC40339536_834,8311,Selective,O
PMC40339536_834,8311,CysLT,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,number,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,receptor,O
PMC40339536_834,8311,antagonists,O
PMC40339536_834,8311,that,O
PMC40339536_834,8311,have,O
PMC40339536_834,8311,been,O
PMC40339536_834,8311,approved,O
PMC40339536_834,8311,for,O
PMC40339536_834,8311,clinical,O
PMC40339536_834,8311,use,O
PMC40339536_834,8311,in,O
PMC40339536_834,8311,asthma,B-Disease
PMC40339536_834,8311,include,O
PMC40339536_834,8311,montelukast,B-Drug
PMC40339536_834,8311,",",O
PMC40339536_834,8311,zafirlukast,O
PMC40339536_834,8311,and,O
PMC40339536_834,8311,pranlukast,O
PMC40339536_834,8311,(,O
PMC40339536_834,8311,Table,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,number,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,_,O
PMC40339536_834,8311,),O
PMC40339536_834,8311,0,O
PMC40339539_957,8312,(,O
PMC40339539_957,8312,A,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,Fractional,O
PMC40339539_957,8312,exhaled,O
PMC40339539_957,8312,nitric,O
PMC40339539_957,8312,oxide,O
PMC40339539_957,8312,(,O
PMC40339539_957,8312,FENO,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,in,O
PMC40339539_957,8312,children,O
PMC40339539_957,8312,with,O
PMC40339539_957,8312,asthma,B-Disease
PMC40339539_957,8312,(,O
PMC40339539_957,8312,n,O
PMC40339539_957,8312,=,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,number,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,at,O
PMC40339539_957,8312,baseline,O
PMC40339539_957,8312,(,O
PMC40339539_957,8312,day,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,number,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,",",O
PMC40339539_957,8312,before,O
PMC40339539_957,8312,treatment,O
PMC40339539_957,8312,with,O
PMC40339539_957,8312,montelukast,B-Drug
PMC40339539_957,8312,(,O
PMC40339539_957,8312,filled,O
PMC40339539_957,8312,squares,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,(,O
PMC40339539_957,8312,day,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,number,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,",",O
PMC40339539_957,8312,after,O
PMC40339539_957,8312,treatment,O
PMC40339539_957,8312,with,O
PMC40339539_957,8312,oral,O
PMC40339539_957,8312,montelukast,B-Drug
PMC40339539_957,8312,(,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,number,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,mg,O
PMC40339539_957,8312,qd,O
PMC40339539_957,8312,for,O
PMC40339539_957,8312,four,O
PMC40339539_957,8312,weeks,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,(,O
PMC40339539_957,8312,day,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,number,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,",",O
PMC40339539_957,8312,and,O
PMC40339539_957,8312,two,O
PMC40339539_957,8312,weeks,O
PMC40339539_957,8312,after,O
PMC40339539_957,8312,montelukast,B-Drug
PMC40339539_957,8312,withdrawal,O
PMC40339539_957,8312,(,O
PMC40339539_957,8312,day,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,number,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,_,O
PMC40339539_957,8312,),O
PMC40339539_957,8312,0,O
PMC403406417_1025,8313,Since,O
PMC403406417_1025,8313,depression,B-Disease
PMC403406417_1025,8313,may,O
PMC403406417_1025,8313,be,O
PMC403406417_1025,8313,associated,O
PMC403406417_1025,8313,with,O
PMC403406417_1025,8313,decreases,O
PMC403406417_1025,8313,in,O
PMC403406417_1025,8313,H,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,number,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,binding,O
PMC403406417_1025,8313,[,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,number,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,],O
PMC403406417_1025,8313,",",O
PMC403406417_1025,8313,the,O
PMC403406417_1025,8313,antagonism,O
PMC403406417_1025,8313,profile,O
PMC403406417_1025,8313,of,O
PMC403406417_1025,8313,quetiapine,B-Drug
PMC403406417_1025,8313,at,O
PMC403406417_1025,8313,H,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,number,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,receptors,O
PMC403406417_1025,8313,is,O
PMC403406417_1025,8313,likely,O
PMC403406417_1025,8313,to,O
PMC403406417_1025,8313,complementarily,O
PMC403406417_1025,8313,decrease,O
PMC403406417_1025,8313,the,O
PMC403406417_1025,8313,depressive,B-Symptom
PMC403406417_1025,8313,symptoms,I-Symptom
PMC403406417_1025,8313,via,O
PMC403406417_1025,8313,the,O
PMC403406417_1025,8313,inhibition,O
PMC403406417_1025,8313,of,O
PMC403406417_1025,8313,histamine,O
PMC403406417_1025,8313,synthesis,O
PMC403406417_1025,8313,[,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,number,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,_,O
PMC403406417_1025,8313,],O
PMC403406417_1025,8313,0,O
PMC403406419_452,8314,demonstrated,O
PMC403406419_452,8314,the,O
PMC403406419_452,8314,potential,O
PMC403406419_452,8314,efficacy,O
PMC403406419_452,8314,of,O
PMC403406419_452,8314,ziprasidone,B-Drug
PMC403406419_452,8314,augmentation,O
PMC403406419_452,8314,in,O
PMC403406419_452,8314,patients,O
PMC403406419_452,8314,with,O
PMC403406419_452,8314,treatment,O
PMC403406419_452,8314,resistant,O
PMC403406419_452,8314,major,B-Disease
PMC403406419_452,8314,depressive,I-Disease
PMC403406419_452,8314,disorder,I-Disease
PMC403406419_452,8314,[,O
PMC403406419_452,8314,_,O
PMC403406419_452,8314,_,O
PMC403406419_452,8314,number,O
PMC403406419_452,8314,_,O
PMC403406419_452,8314,_,O
PMC403406419_452,8314,],O
PMC403406419_452,8314,0,O
PMC403406419_565,8315,In,O
PMC403406419_565,8315,terms,O
PMC403406419_565,8315,of,O
PMC403406419_565,8315,common,O
PMC403406419_565,8315,adverse,O
PMC403406419_565,8315,effects,O
PMC403406419_565,8315,shared,O
PMC403406419_565,8315,among,O
PMC403406419_565,8315,atypical,O
PMC403406419_565,8315,antipsychotics,O
PMC403406419_565,8315,",",O
PMC403406419_565,8315,ziprasidone,B-Drug
PMC403406419_565,8315,is,O
PMC403406419_565,8315,less,O
PMC403406419_565,8315,likely,O
PMC403406419_565,8315,to,O
PMC403406419_565,8315,cause,O
PMC403406419_565,8315,weight,B-Symptom
PMC403406419_565,8315,gain,I-Symptom
PMC403406419_565,8315,",",O
PMC403406419_565,8315,elevation,O
PMC403406419_565,8315,in,O
PMC403406419_565,8315,prolactin,B-Symptom
PMC403406419_565,8315,levels,I-Symptom
PMC403406419_565,8315,",",O
PMC403406419_565,8315,and,O
PMC403406419_565,8315,EPS,B-Symptom
PMC403406419_565,8315,than,O
PMC403406419_565,8315,other,O
PMC403406419_565,8315,atypical,O
PMC403406419_565,8315,antipsychotics,O
PMC403406419_565,8315,0,O
PMC403406419_770,8316,Even,O
PMC403406419_770,8316,though,O
PMC403406419_770,8316,FDA,O
PMC403406419_770,8316,labels,O
PMC403406419_770,8316,the,O
PMC403406419_770,8316,use,O
PMC403406419_770,8316,of,O
PMC403406419_770,8316,ziprasidone,B-Drug
PMC403406419_770,8316,with,O
PMC403406419_770,8316,a,O
PMC403406419_770,8316,warning,O
PMC403406419_770,8316,due,O
PMC403406419_770,8316,to,O
PMC403406419_770,8316,possible,O
PMC403406419_770,8316,mortality,O
PMC403406419_770,8316,in,O
PMC403406419_770,8316,the,O
PMC403406419_770,8316,elderly,O
PMC403406419_770,8316,with,O
PMC403406419_770,8316,dementia,O
PMC403406419_770,8316,related,O
PMC403406419_770,8316,psychosis,O
PMC403406419_770,8316,and,O
PMC403406419_770,8316,potential,O
PMC403406419_770,8316,for,O
PMC403406419_770,8316,QTc,O
PMC403406419_770,8316,prologation,O
PMC403406419_770,8316,",",O
PMC403406419_770,8316,clinical,O
PMC403406419_770,8316,studies,O
PMC403406419_770,8316,showed,O
PMC403406419_770,8316,a,O
PMC403406419_770,8316,small,O
PMC403406419_770,8316,effect,O
PMC403406419_770,8316,of,O
PMC403406419_770,8316,ziprasidone,B-Drug
PMC403406419_770,8316,on,O
PMC403406419_770,8316,the,O
PMC403406419_770,8316,QTc,O
PMC403406419_770,8316,interval,O
PMC403406419_770,8316,between,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,number,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,to,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,number,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,ms,O
PMC403406419_770,8316,",",O
PMC403406419_770,8316,no,O
PMC403406419_770,8316,serious,O
PMC403406419_770,8316,electrocardiographic,O
PMC403406419_770,8316,changes,O
PMC403406419_770,8316,",",O
PMC403406419_770,8316,no,O
PMC403406419_770,8316,severe,O
PMC403406419_770,8316,cardiac,O
PMC403406419_770,8316,adverse,O
PMC403406419_770,8316,events,O
PMC403406419_770,8316,",",O
PMC403406419_770,8316,or,O
PMC403406419_770,8316,tardive,B-Symptom
PMC403406419_770,8316,dyskinesia,I-Symptom
PMC403406419_770,8316,[,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,number,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,_,O
PMC403406419_770,8316,],O
PMC403406419_770,8316,0,O
PMC40340697_829,8317,reported,O
PMC40340697_829,8317,that,O
PMC40340697_829,8317,the,O
PMC40340697_829,8317,BDNF,O
PMC40340697_829,8317,Met,O
PMC40340697_829,8317,genotype,O
PMC40340697_829,8317,was,O
PMC40340697_829,8317,associated,O
PMC40340697_829,8317,with,O
PMC40340697_829,8317,a,O
PMC40340697_829,8317,lower,O
PMC40340697_829,8317,risk,O
PMC40340697_829,8317,of,O
PMC40340697_829,8317,sexual,B-Symptom
PMC40340697_829,8317,side,I-Symptom
PMC40340697_829,8317,effects,I-Symptom
PMC40340697_829,8317,and,O
PMC40340697_829,8317,insomnia,B-Symptom
PMC40340697_829,8317,in,O
PMC40340697_829,8317,a,O
PMC40340697_829,8317,large,O
PMC40340697_829,8317,study,O
PMC40340697_829,8317,of,O
PMC40340697_829,8317,Chinese,O
PMC40340697_829,8317,subjects,O
PMC40340697_829,8317,prospectively,O
PMC40340697_829,8317,treated,O
PMC40340697_829,8317,with,O
PMC40340697_829,8317,fluoxetine,B-Drug
PMC40340697_829,8317,0,O
PMC403408210_302,8318,Olanzapine,B-Drug
PMC403408210_302,8318,is,O
PMC403408210_302,8318,a,O
PMC403408210_302,8318,second,O
PMC403408210_302,8318,-,O
PMC403408210_302,8318,generation,O
PMC403408210_302,8318,antipychotic,O
PMC403408210_302,8318,that,O
PMC403408210_302,8318,may,O
PMC403408210_302,8318,cause,O
PMC403408210_302,8318,weight,B-Symptom
PMC403408210_302,8318,gain,I-Symptom
PMC403408210_302,8318,and,O
PMC403408210_302,8318,metabolic,B-Disease
PMC403408210_302,8318,syndrome,I-Disease
PMC403408210_302,8318,in,O
PMC403408210_302,8318,some,O
PMC403408210_302,8318,cases,O
PMC403408210_302,8318,0,O
PMC40341016_786,8319,In,O
PMC40341016_786,8319,an,O
PMC40341016_786,8319,ecological,O
PMC40341016_786,8319,analysis,O
PMC40341016_786,8319,over,O
PMC40341016_786,8319,counties,O
PMC40341016_786,8319,in,O
PMC40341016_786,8319,the,O
PMC40341016_786,8319,USA,O
PMC40341016_786,8319,",",O
PMC40341016_786,8319,Gibbons,O
PMC40341016_786,8319,and,O
PMC40341016_786,8319,colleagues,O
PMC40341016_786,8319,[,O
PMC40341016_786,8319,_,O
PMC40341016_786,8319,_,O
PMC40341016_786,8319,number,O
PMC40341016_786,8319,_,O
PMC40341016_786,8319,_,O
PMC40341016_786,8319,],O
PMC40341016_786,8319,found,O
PMC40341016_786,8319,that,O
PMC40341016_786,8319,the,O
PMC40341016_786,8319,overall,O
PMC40341016_786,8319,association,O
PMC40341016_786,8319,between,O
PMC40341016_786,8319,antidepressant,O
PMC40341016_786,8319,prescriptions,O
PMC40341016_786,8319,and,O
PMC40341016_786,8319,the,O
PMC40341016_786,8319,suicide,O
PMC40341016_786,8319,rate,O
PMC40341016_786,8319,was,O
PMC40341016_786,8319,not,O
PMC40341016_786,8319,significant,O
PMC40341016_786,8319,for,O
PMC40341016_786,8319,prescriptions,O
PMC40341016_786,8319,for,O
PMC40341016_786,8319,SSRIs,O
PMC40341016_786,8319,",",O
PMC40341016_786,8319,but,O
PMC40341016_786,8319,the,O
PMC40341016_786,8319,prescription,O
PMC40341016_786,8319,of,O
PMC40341016_786,8319,other,O
PMC40341016_786,8319,new,O
PMC40341016_786,8319,-,O
PMC40341016_786,8319,generation,O
PMC40341016_786,8319,non,O
PMC40341016_786,8319,-,O
PMC40341016_786,8319,SSRI,O
PMC40341016_786,8319,antidepressants,O
PMC40341016_786,8319,(,O
PMC40341016_786,8319,nefazodone,O
PMC40341016_786,8319,hydrochloride,O
PMC40341016_786,8319,",",O
PMC40341016_786,8319,mirtazapine,O
PMC40341016_786,8319,",",O
PMC40341016_786,8319,bupropion,O
PMC40341016_786,8319,hydrochloride,O
PMC40341016_786,8319,",",O
PMC40341016_786,8319,and,O
PMC40341016_786,8319,venlafaxine,B-Drug
PMC40341016_786,8319,hydrochloride,O
PMC40341016_786,8319,),O
PMC40341016_786,8319,was,O
PMC40341016_786,8319,associated,O
PMC40341016_786,8319,with,O
PMC40341016_786,8319,lower,O
PMC40341016_786,8319,suicide,B-Symptom
PMC40341016_786,8319,rates,I-Symptom
PMC40341016_786,8319,(,O
PMC40341016_786,8319,both,O
PMC40341016_786,8319,within,O
PMC40341016_786,8319,and,O
PMC40341016_786,8319,between,O
PMC40341016_786,8319,counties,O
PMC40341016_786,8319,),O
PMC40341016_786,8319,0,O
PMC40341018_401,8320,[,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,],O
PMC40341018_401,8320,reported,O
PMC40341018_401,8320,no,O
PMC40341018_401,8320,increased,O
PMC40341018_401,8320,risk,O
PMC40341018_401,8320,of,O
PMC40341018_401,8320,suicidal,B-Symptom
PMC40341018_401,8320,behavior,I-Symptom
PMC40341018_401,8320,with,O
PMC40341018_401,8320,fluoxetine,B-Drug
PMC40341018_401,8320,compared,O
PMC40341018_401,8320,to,O
PMC40341018_401,8320,placebo,O
PMC40341018_401,8320,(,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,versus,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,),O
PMC40341018_401,8320,",",O
PMC40341018_401,8320,but,O
PMC40341018_401,8320,an,O
PMC40341018_401,8320,increased,O
PMC40341018_401,8320,risk,O
PMC40341018_401,8320,of,O
PMC40341018_401,8320,suicidal,B-Symptom
PMC40341018_401,8320,ideation,I-Symptom
PMC40341018_401,8320,or,O
PMC40341018_401,8320,attempting,B-Symptom
PMC40341018_401,8320,suicide,I-Symptom
PMC40341018_401,8320,was,O
PMC40341018_401,8320,observed,O
PMC40341018_401,8320,for,O
PMC40341018_401,8320,paroxetine,O
PMC40341018_401,8320,(,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,versus,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,),O
PMC40341018_401,8320,",",O
PMC40341018_401,8320,sertraline,B-Drug
PMC40341018_401,8320,(,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,versus,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,),O
PMC40341018_401,8320,",",O
PMC40341018_401,8320,citalopram,B-Drug
PMC40341018_401,8320,(,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,versus,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,",",O
PMC40341018_401,8320,),O
PMC40341018_401,8320,and,O
PMC40341018_401,8320,venlafaxine,B-Drug
PMC40341018_401,8320,(,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,versus,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,number,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,_,O
PMC40341018_401,8320,%,O
PMC40341018_401,8320,),O
PMC40341018_401,8320,0,O
PMC40341018_405,8321,A,O
PMC40341018_405,8321,borderline,O
PMC40341018_405,8321,value,O
PMC40341018_405,8321,for,O
PMC40341018_405,8321,paroxetine,B-Drug
PMC40341018_405,8321,in,O
PMC40341018_405,8321,comparison,O
PMC40341018_405,8321,with,O
PMC40341018_405,8321,amitriptyline,O
PMC40341018_405,8321,emerged,O
PMC40341018_405,8321,in,O
PMC40341018_405,8321,this,O
PMC40341018_405,8321,post,O
PMC40341018_405,8321,-,O
PMC40341018_405,8321,hoc,O
PMC40341018_405,8321,analysis,O
PMC40341018_405,8321,",",O
PMC40341018_405,8321,leaving,O
PMC40341018_405,8321,the,O
PMC40341018_405,8321,possibility,O
PMC40341018_405,8321,of,O
PMC40341018_405,8321,an,O
PMC40341018_405,8321,increased,O
PMC40341018_405,8321,risk,O
PMC40341018_405,8321,of,O
PMC40341018_405,8321,non,O
PMC40341018_405,8321,-,O
PMC40341018_405,8321,fatal,O
PMC40341018_405,8321,suicidal,B-Symptom
PMC40341018_405,8321,behaviors,I-Symptom
PMC40341018_405,8321,in,O
PMC40341018_405,8321,users,O
PMC40341018_405,8321,of,O
PMC40341018_405,8321,this,O
PMC40341018_405,8321,agent,O
PMC40341018_405,8321,0,O
PMC40341018_478,8322,They,O
PMC40341018_478,8322,found,O
PMC40341018_478,8322,that,O
PMC40341018_478,8322,the,O
PMC40341018_478,8322,risk,O
PMC40341018_478,8322,of,O
PMC40341018_478,8322,suicide,B-Symptom
PMC40341018_478,8322,was,O
PMC40341018_478,8322,higher,O
PMC40341018_478,8322,in,O
PMC40341018_478,8322,people,O
PMC40341018_478,8322,who,O
PMC40341018_478,8322,received,O
PMC40341018_478,8322,fluoxetine,B-Drug
PMC40341018_478,8322,(,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,number,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,per,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,number,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,",",O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,number,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,person,O
PMC40341018_478,8322,years,O
PMC40341018_478,8322,",",O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,number,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,%,O
PMC40341018_478,8322,CI,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,number,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,to,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,number,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,_,O
PMC40341018_478,8322,),O
PMC40341018_478,8322,than,O
PMC40341018_478,8322,in,O
PMC40341018_478,8322,those,O
PMC40341018_478,8322,receiving,O
PMC40341018_478,8322,dosulepine,O
PMC40341018_478,8322,(,O
PMC40341018_478,8322,dothiepin,O
PMC40341018_478,8322,),O
PMC40341018_478,8322,0,O
PMC40341018_510,8323,In,O
PMC40341018_510,8323,the,O
PMC40341018_510,8323,entire,O
PMC40341018_510,8323,cohort,O
PMC40341018_510,8323,",",O
PMC40341018_510,8323,fluoxetine,B-Drug
PMC40341018_510,8323,use,O
PMC40341018_510,8323,(,O
PMC40341018_510,8323,RR,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,number,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,),O
PMC40341018_510,8323,was,O
PMC40341018_510,8323,associated,O
PMC40341018_510,8323,with,O
PMC40341018_510,8323,a,O
PMC40341018_510,8323,lower,O
PMC40341018_510,8323,risk,O
PMC40341018_510,8323,of,O
PMC40341018_510,8323,suicide,B-Symptom
PMC40341018_510,8323,and,O
PMC40341018_510,8323,venlafaxine,B-Drug
PMC40341018_510,8323,(,O
PMC40341018_510,8323,RR,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,number,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,_,O
PMC40341018_510,8323,),O
PMC40341018_510,8323,with,O
PMC40341018_510,8323,a,O
PMC40341018_510,8323,higher,O
PMC40341018_510,8323,risk,O
PMC40341018_510,8323,0,O
PMC40341025_1005,8324,Carbamazepine,B-Drug
PMC40341025_1005,8324,(,O
PMC40341025_1005,8324,CBZ,O
PMC40341025_1005,8324,),O
PMC40341025_1005,8324,was,O
PMC40341025_1005,8324,first,O
PMC40341025_1005,8324,approved,O
PMC40341025_1005,8324,in,O
PMC40341025_1005,8324,_,O
PMC40341025_1005,8324,_,O
PMC40341025_1005,8324,number,O
PMC40341025_1005,8324,_,O
PMC40341025_1005,8324,_,O
PMC40341025_1005,8324,for,O
PMC40341025_1005,8324,use,O
PMC40341025_1005,8324,in,O
PMC40341025_1005,8324,partial,O
PMC40341025_1005,8324,-,O
PMC40341025_1005,8324,onset,O
PMC40341025_1005,8324,and,O
PMC40341025_1005,8324,generalized,B-Symptom
PMC40341025_1005,8324,tonic,I-Symptom
PMC40341025_1005,8324,-,I-Symptom
PMC40341025_1005,8324,clonic,I-Symptom
PMC40341025_1005,8324,seizures,I-Symptom
PMC40341025_1005,8324,0,O
PMC403410810_229,8325,The,O
PMC403410810_229,8325,authors,O
PMC403410810_229,8325,concluded,O
PMC403410810_229,8325,that,O
PMC403410810_229,8325,topiramate,B-Drug
PMC403410810_229,8325,should,O
PMC403410810_229,8325,be,O
PMC403410810_229,8325,used,O
PMC403410810_229,8325,with,O
PMC403410810_229,8325,caution,O
PMC403410810_229,8325,in,O
PMC403410810_229,8325,Autism,B-Disease
PMC403410810_229,8325,Spectrum,I-Disease
PMC403410810_229,8325,disorders,I-Disease
PMC403410810_229,8325,[,O
PMC403410810_229,8325,_,O
PMC403410810_229,8325,_,O
PMC403410810_229,8325,number,O
PMC403410810_229,8325,_,O
PMC403410810_229,8325,_,O
PMC403410810_229,8325,],O
PMC403410810_229,8325,0,O
PMC403410810_703,8326,However,O
PMC403410810_703,8326,",",O
PMC403410810_703,8326,a,O
PMC403410810_703,8326,pilot,O
PMC403410810_703,8326,double,O
PMC403410810_703,8326,blind,O
PMC403410810_703,8326,placebo,O
PMC403410810_703,8326,controlled,O
PMC403410810_703,8326,trial,O
PMC403410810_703,8326,examining,O
PMC403410810_703,8326,the,O
PMC403410810_703,8326,efficacy,O
PMC403410810_703,8326,of,O
PMC403410810_703,8326,topiramate,B-Drug
PMC403410810_703,8326,for,O
PMC403410810_703,8326,mania,O
PMC403410810_703,8326,in,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,number,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,children,O
PMC403410810_703,8326,and,O
PMC403410810_703,8326,adolescents,O
PMC403410810_703,8326,with,O
PMC403410810_703,8326,bipolar,B-Disease
PMC403410810_703,8326,disorder,I-Disease
PMC403410810_703,8326,was,O
PMC403410810_703,8326,discontinued,O
PMC403410810_703,8326,when,O
PMC403410810_703,8326,adult,O
PMC403410810_703,8326,mania,O
PMC403410810_703,8326,trials,O
PMC403410810_703,8326,failed,O
PMC403410810_703,8326,to,O
PMC403410810_703,8326,show,O
PMC403410810_703,8326,efficacy,O
PMC403410810_703,8326,[,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,number,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,_,O
PMC403410810_703,8326,],O
PMC403410810_703,8326,0,O
PMC403410815_256,8327,[,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,number,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,",",O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,number,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,],O
PMC403410815_256,8327,comparing,O
PMC403410815_256,8327,monotherapy,O
PMC403410815_256,8327,with,O
PMC403410815_256,8327,valproate,O
PMC403410815_256,8327,",",O
PMC403410815_256,8327,lithium,O
PMC403410815_256,8327,",",O
PMC403410815_256,8327,or,O
PMC403410815_256,8327,carbamazepine,B-Drug
PMC403410815_256,8327,in,O
PMC403410815_256,8327,children,O
PMC403410815_256,8327,and,O
PMC403410815_256,8327,adolescents,O
PMC403410815_256,8327,with,O
PMC403410815_256,8327,bipolar,B-Disease
PMC403410815_256,8327,disorder,I-Disease
PMC403410815_256,8327,",",O
PMC403410815_256,8327,response,O
PMC403410815_256,8327,rates,O
PMC403410815_256,8327,were,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,number,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,%,O
PMC403410815_256,8327,",",O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,number,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,%,O
PMC403410815_256,8327,",",O
PMC403410815_256,8327,and,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,number,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,_,O
PMC403410815_256,8327,%,O
PMC403410815_256,8327,respectively,O
PMC403410815_256,8327,0,O
PMC40341086_103,8328,In,O
PMC40341086_103,8328,a,O
PMC40341086_103,8328,pilot,O
PMC40341086_103,8328,study,O
PMC40341086_103,8328,of,O
PMC40341086_103,8328,carbamazepine,B-Drug
PMC40341086_103,8328,in,O
PMC40341086_103,8328,hospitalized,O
PMC40341086_103,8328,aggressive,O
PMC40341086_103,8328,and,O
PMC40341086_103,8328,explosive,O
PMC40341086_103,8328,children,O
PMC40341086_103,8328,with,O
PMC40341086_103,8328,a,O
PMC40341086_103,8328,diagnosis,O
PMC40341086_103,8328,of,O
PMC40341086_103,8328,conduct,B-Disease
PMC40341086_103,8328,disorder,I-Disease
PMC40341086_103,8328,",",O
PMC40341086_103,8328,significant,O
PMC40341086_103,8328,declines,O
PMC40341086_103,8328,in,O
PMC40341086_103,8328,aggressiveness,O
PMC40341086_103,8328,and,O
PMC40341086_103,8328,explosiveness,O
PMC40341086_103,8328,were,O
PMC40341086_103,8328,demonstrated,O
PMC40341086_103,8328,[,O
PMC40341086_103,8328,_,O
PMC40341086_103,8328,_,O
PMC40341086_103,8328,number,O
PMC40341086_103,8328,_,O
PMC40341086_103,8328,_,O
PMC40341086_103,8328,],O
PMC40341086_103,8328,0,O
PMC40341089_250,8329,A,O
PMC40341089_250,8329,double,O
PMC40341089_250,8329,-,O
PMC40341089_250,8329,blind,O
PMC40341089_250,8329,placebo,O
PMC40341089_250,8329,-,O
PMC40341089_250,8329,controlled,O
PMC40341089_250,8329,trial,O
PMC40341089_250,8329,is,O
PMC40341089_250,8329,currently,O
PMC40341089_250,8329,underway,O
PMC40341089_250,8329,to,O
PMC40341089_250,8329,assess,O
PMC40341089_250,8329,the,O
PMC40341089_250,8329,efficacy,O
PMC40341089_250,8329,of,O
PMC40341089_250,8329,lamotrigine,B-Drug
PMC40341089_250,8329,as,O
PMC40341089_250,8329,an,O
PMC40341089_250,8329,add,O
PMC40341089_250,8329,-,O
PMC40341089_250,8329,on,O
PMC40341089_250,8329,treatment,O
PMC40341089_250,8329,for,O
PMC40341089_250,8329,children,O
PMC40341089_250,8329,and,O
PMC40341089_250,8329,adolescents,O
PMC40341089_250,8329,with,O
PMC40341089_250,8329,bipolar,B-Disease
PMC40341089_250,8329,disorder,I-Disease
PMC40341089_250,8329,0,O
PMC40358220_131,8330,In,O
PMC40358220_131,8330,contrast,O
PMC40358220_131,8330,",",O
PMC40358220_131,8330,lamotrigine,B-Drug
PMC40358220_131,8330,",",O
PMC40358220_131,8330,a,O
PMC40358220_131,8330,mood,O
PMC40358220_131,8330,stabilizer,O
PMC40358220_131,8330,",",O
PMC40358220_131,8330,has,O
PMC40358220_131,8330,been,O
PMC40358220_131,8330,proven,O
PMC40358220_131,8330,to,O
PMC40358220_131,8330,be,O
PMC40358220_131,8330,effective,O
PMC40358220_131,8330,in,O
PMC40358220_131,8330,preventing,O
PMC40358220_131,8330,depression,B-Disease
PMC40358220_131,8330,in,O
PMC40358220_131,8330,patients,O
PMC40358220_131,8330,with,O
PMC40358220_131,8330,bipolar,B-Disease
PMC40358220_131,8330,disorder,I-Disease
PMC40358220_131,8330,0,O
PMC40358220_353,8331,RESULTS,O
PMC40358220_353,8331,:,O
PMC40358220_353,8331,Olanzapine,B-Drug
PMC40358220_353,8331,had,O
PMC40358220_353,8331,a,O
PMC40358220_353,8331,significantly,O
PMC40358220_353,8331,lower,O
PMC40358220_353,8331,recurrence,O
PMC40358220_353,8331,rate,O
PMC40358220_353,8331,of,O
PMC40358220_353,8331,depressive,O
PMC40358220_353,8331,episodes,O
PMC40358220_353,8331,than,O
PMC40358220_353,8331,lamotrigine,B-Drug
PMC40358220_353,8331,(,O
PMC40358220_353,8331,_,O
PMC40358220_353,8331,_,O
PMC40358220_353,8331,number,O
PMC40358220_353,8331,_,O
PMC40358220_353,8331,_,O
PMC40358220_353,8331,%,O
PMC40358220_353,8331,vs,O
PMC40358220_353,8331,0,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,number,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,%,O
PMC40358220_353,8332,",",O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,number,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,=,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,number,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,_,O
PMC40358220_353,8332,",",O
PMC40358220_353,8332,p,O
PMC40358220_353,8332,=,O
PMC40358220_353,8332,0,O
PMC40358220_353,8333,_,O
PMC40358220_353,8333,_,O
PMC40358220_353,8333,number,O
PMC40358220_353,8333,_,O
PMC40358220_353,8333,_,O
PMC40358220_353,8333,),O
PMC40358220_353,8333,0,O
PMC40358220_51,8334,CONCLUSIONS,O
PMC40358220_51,8334,:,O
PMC40358220_51,8334,This,O
PMC40358220_51,8334,prospective,O
PMC40358220_51,8334,naturalistic,O
PMC40358220_51,8334,study,O
PMC40358220_51,8334,suggests,O
PMC40358220_51,8334,that,O
PMC40358220_51,8334,olanzapine,B-Drug
PMC40358220_51,8334,is,O
PMC40358220_51,8334,more,O
PMC40358220_51,8334,effective,O
PMC40358220_51,8334,than,O
PMC40358220_51,8334,lamotrigine,B-Drug
PMC40358220_51,8334,in,O
PMC40358220_51,8334,the,O
PMC40358220_51,8334,prevention,O
PMC40358220_51,8334,of,O
PMC40358220_51,8334,depressive,O
PMC40358220_51,8334,episodes,O
PMC40358220_51,8334,in,O
PMC40358220_51,8334,patients,O
PMC40358220_51,8334,with,O
PMC40358220_51,8334,bipolar,B-Disease
PMC40358220_51,8334,disorder,I-Disease
PMC40358220_51,8334,0,O
PMC40358220_619,8335,METHODS,O
PMC40358220_619,8335,:,O
PMC40358220_619,8335,Patients,O
PMC40358220_619,8335,with,O
PMC40358220_619,8335,bipolar,B-Disease
PMC40358220_619,8335,disorder,I-Disease
PMC40358220_619,8335,in,O
PMC40358220_619,8335,a,O
PMC40358220_619,8335,euthymic,O
PMC40358220_619,8335,state,O
PMC40358220_619,8335,(,O
PMC40358220_619,8335,Young,O
PMC40358220_619,8335,',O
PMC40358220_619,8335,s,O
PMC40358220_619,8335,Mania,O
PMC40358220_619,8335,Rating,O
PMC40358220_619,8335,Scale,O
PMC40358220_619,8335,(,O
PMC40358220_619,8335,YMRS,O
PMC40358220_619,8335,),O
PMC40358220_619,8335,score,O
PMC40358220_619,8335,<,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,number,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,",",O
PMC40358220_619,8335,and,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,number,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,-,O
PMC40358220_619,8335,item,O
PMC40358220_619,8335,Hamilton,O
PMC40358220_619,8335,Depression,O
PMC40358220_619,8335,Rating,O
PMC40358220_619,8335,Scale,O
PMC40358220_619,8335,(,O
PMC40358220_619,8335,HAM,O
PMC40358220_619,8335,-,O
PMC40358220_619,8335,D,O
PMC40358220_619,8335,),O
PMC40358220_619,8335,score,O
PMC40358220_619,8335,<,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,number,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,_,O
PMC40358220_619,8335,),O
PMC40358220_619,8335,for,O
PMC40358220_619,8335,at,O
PMC40358220_619,8335,least,O
PMC40358220_619,8335,two,O
PMC40358220_619,8335,months,O
PMC40358220_619,8335,",",O
PMC40358220_619,8335,having,O
PMC40358220_619,8335,already,O
PMC40358220_619,8335,received,O
PMC40358220_619,8335,either,O
PMC40358220_619,8335,olanzapine,B-Drug
PMC40358220_619,8335,or,O
PMC40358220_619,8335,lamotrigine,B-Drug
PMC40358220_619,8335,as,O
PMC40358220_619,8335,the,O
PMC40358220_619,8335,maintenance,O
PMC40358220_619,8335,treatment,O
PMC40358220_619,8335,were,O
PMC40358220_619,8335,recruited,O
PMC40358220_619,8335,0,O
PMC40358220_681,8336,This,O
PMC40358220_681,8336,enriched,O
PMC40358220_681,8336,naturalistic,O
PMC40358220_681,8336,study,O
PMC40358220_681,8336,was,O
PMC40358220_681,8336,implemented,O
PMC40358220_681,8336,to,O
PMC40358220_681,8336,assess,O
PMC40358220_681,8336,the,O
PMC40358220_681,8336,effectiveness,O
PMC40358220_681,8336,of,O
PMC40358220_681,8336,olanzapine,B-Drug
PMC40358220_681,8336,and,O
PMC40358220_681,8336,lamotrigine,B-Drug
PMC40358220_681,8336,as,O
PMC40358220_681,8336,monotherapy,O
PMC40358220_681,8336,in,O
PMC40358220_681,8336,the,O
PMC40358220_681,8336,prevention,O
PMC40358220_681,8336,of,O
PMC40358220_681,8336,recurrence,O
PMC40358220_681,8336,of,O
PMC40358220_681,8336,bipolar,B-Disease
PMC40358220_681,8336,disorder,I-Disease
PMC40358220_681,8336,0,O
PMC40358220_765,8337,However,O
PMC40358220_765,8337,",",O
PMC40358220_765,8337,olanzapine,B-Drug
PMC40358220_765,8337,and,O
PMC40358220_765,8337,lamotrigine,B-Drug
PMC40358220_765,8337,had,O
PMC40358220_765,8337,similar,O
PMC40358220_765,8337,mania,O
PMC40358220_765,8337,(,O
PMC40358220_765,8337,_,O
PMC40358220_765,8337,_,O
PMC40358220_765,8337,number,O
PMC40358220_765,8337,_,O
PMC40358220_765,8337,_,O
PMC40358220_765,8337,%,O
PMC40358220_765,8337,vs,O
PMC40358220_765,8337,0,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,number,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,%,O
PMC40358220_765,8338,",",O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,number,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,=,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,number,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,_,O
PMC40358220_765,8338,",",O
PMC40358220_765,8338,p,O
PMC40358220_765,8338,=,O
PMC40358220_765,8338,0,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,number,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,",",O
PMC40358220_765,8339,Fisher,O
PMC40358220_765,8339,',O
PMC40358220_765,8339,s,O
PMC40358220_765,8339,exact,O
PMC40358220_765,8339,test,O
PMC40358220_765,8339,),O
PMC40358220_765,8339,and,O
PMC40358220_765,8339,any,O
PMC40358220_765,8339,mood,O
PMC40358220_765,8339,episode,O
PMC40358220_765,8339,(,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,number,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,_,O
PMC40358220_765,8339,%,O
PMC40358220_765,8339,vs,O
PMC40358220_765,8339,0,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,number,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,%,O
PMC40358220_765,8340,",",O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,number,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,=,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,number,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,_,O
PMC40358220_765,8340,",",O
PMC40358220_765,8340,p,O
PMC40358220_765,8340,=,O
PMC40358220_765,8340,0,O
PMC40358220_765,8341,_,O
PMC40358220_765,8341,_,O
PMC40358220_765,8341,number,O
PMC40358220_765,8341,_,O
PMC40358220_765,8341,_,O
PMC40358220_765,8341,),O
PMC40358220_765,8341,recurrence,O
PMC40358220_765,8341,rates,O
PMC40358220_765,8341,0,O
PMC40358220_805,8342,Olanzapine,B-Drug
PMC40358220_805,8342,is,O
PMC40358220_805,8342,superior,O
PMC40358220_805,8342,to,O
PMC40358220_805,8342,lamotrigine,B-Drug
PMC40358220_805,8342,in,O
PMC40358220_805,8342,the,O
PMC40358220_805,8342,prevention,O
PMC40358220_805,8342,of,O
PMC40358220_805,8342,bipolar,B-Disease
PMC40358220_805,8342,depression,I-Disease
PMC40358220_805,8342,:,O
PMC40358220_805,8342,a,O
PMC40358220_805,8342,naturalistic,O
PMC40358220_805,8342,observational,O
PMC40358220_805,8342,study,O
PMC40358220_805,8342,0,O
PMC40366555_686,8343,During,O
PMC40366555_686,8343,the,O
PMC40366555_686,8343,last,O
PMC40366555_686,8343,two,O
PMC40366555_686,8343,decades,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,several,O
PMC40366555_686,8343,new,O
PMC40366555_686,8343,drugs,O
PMC40366555_686,8343,have,O
PMC40366555_686,8343,been,O
PMC40366555_686,8343,licensed,O
PMC40366555_686,8343,for,O
PMC40366555_686,8343,the,O
PMC40366555_686,8343,treatment,O
PMC40366555_686,8343,of,O
PMC40366555_686,8343,epilepsy,B-Disease
PMC40366555_686,8343,including,O
PMC40366555_686,8343,felbamate,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,gabapentin,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,lamotrigine,B-Drug
PMC40366555_686,8343,",",O
PMC40366555_686,8343,topiramate,B-Drug
PMC40366555_686,8343,",",O
PMC40366555_686,8343,tiagabine,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,levetiracetam,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,oxcarbazepine,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,zonisamide,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,pregabalin,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,rufinamide,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,stiripentol,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,clobazam,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,vigabatrin,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,and,O
PMC40366555_686,8343,lacosamide,O
PMC40366555_686,8343,[,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,number,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,number,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,number,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,",",O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,number,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,_,O
PMC40366555_686,8343,],O
PMC40366555_686,8343,0,O
PMC40366556_268,8344,Phenobarbital,O
PMC40366556_268,8344,",",O
PMC40366556_268,8344,lamotrigine,B-Drug
PMC40366556_268,8344,",",O
PMC40366556_268,8344,and,O
PMC40366556_268,8344,phenytoin,O
PMC40366556_268,8344,have,O
PMC40366556_268,8344,been,O
PMC40366556_268,8344,reported,O
PMC40366556_268,8344,to,O
PMC40366556_268,8344,induce,O
PMC40366556_268,8344,absence,O
PMC40366556_268,8344,",",O
PMC40366556_268,8344,myoclonic,O
PMC40366556_268,8344,and,O
PMC40366556_268,8344,complex,O
PMC40366556_268,8344,partial,O
PMC40366556_268,8344,seizures,O
PMC40366556_268,8344,respectively,O
PMC40366556_268,8344,[,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,number,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,",",O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,number,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,",",O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,number,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,",",O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,number,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,_,O
PMC40366556_268,8344,],O
PMC40366556_268,8344,0,O
PMC40373000_313,8345,METHODS,O
PMC40373000_313,8345,:,O
PMC40373000_313,8345,A,O
PMC40373000_313,8345,post,O
PMC40373000_313,8345,hoc,O
PMC40373000_313,8345,analysis,O
PMC40373000_313,8345,of,O
PMC40373000_313,8345,a,O
PMC40373000_313,8345,multi,O
PMC40373000_313,8345,-,O
PMC40373000_313,8345,country,O
PMC40373000_313,8345,",",O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,number,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,-,O
PMC40373000_313,8345,month,O
PMC40373000_313,8345,",",O
PMC40373000_313,8345,prospective,O
PMC40373000_313,8345,",",O
PMC40373000_313,8345,observational,O
PMC40373000_313,8345,study,O
PMC40373000_313,8345,of,O
PMC40373000_313,8345,outpatients,O
PMC40373000_313,8345,with,O
PMC40373000_313,8345,schizophrenia,B-Disease
PMC40373000_313,8345,or,O
PMC40373000_313,8345,bipolar,B-Disease
PMC40373000_313,8345,mania,O
PMC40373000_313,8345,who,O
PMC40373000_313,8345,initiated,O
PMC40373000_313,8345,or,O
PMC40373000_313,8345,switched,O
PMC40373000_313,8345,to,O
PMC40373000_313,8345,treatment,O
PMC40373000_313,8345,with,O
PMC40373000_313,8345,oral,O
PMC40373000_313,8345,olanzapine,B-Drug
PMC40373000_313,8345,was,O
PMC40373000_313,8345,conducted,O
PMC40373000_313,8345,using,O
PMC40373000_313,8345,data,O
PMC40373000_313,8345,from,O
PMC40373000_313,8345,the,O
PMC40373000_313,8345,Chinese,O
PMC40373000_313,8345,schizophrenia,B-Disease
PMC40373000_313,8345,subgroup,O
PMC40373000_313,8345,(,O
PMC40373000_313,8345,n,O
PMC40373000_313,8345,=,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,number,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,_,O
PMC40373000_313,8345,),O
PMC40373000_313,8345,0,O
PMC40516600_340,8346,One,O
PMC40516600_340,8346,of,O
PMC40516600_340,8346,the,O
PMC40516600_340,8346,citalopram,B-Drug
PMC40516600_340,8346,participants,O
PMC40516600_340,8346,who,O
PMC40516600_340,8346,developed,O
PMC40516600_340,8346,prolonged,O
PMC40516600_340,8346,QTc,O
PMC40516600_340,8346,also,O
PMC40516600_340,8346,displayed,O
PMC40516600_340,8346,ventricular,B-Symptom
PMC40516600_340,8346,bigeminy,I-Symptom
PMC40516600_340,8346,0,O
PMC405395810_623,8347,Finally,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,as,O
PMC405395810_623,8347,observed,O
PMC405395810_623,8347,with,O
PMC405395810_623,8347,duloxetine,B-Drug
PMC405395810_623,8347,and,O
PMC405395810_623,8347,milnacipran,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,venlafaxine,B-Drug
PMC405395810_623,8347,attenuated,O
PMC405395810_623,8347,hyperalgesia,B-Symptom
PMC405395810_623,8347,and,O
PMC405395810_623,8347,/,O
PMC405395810_623,8347,or,O
PMC405395810_623,8347,allodynia,O
PMC405395810_623,8347,in,O
PMC405395810_623,8347,various,O
PMC405395810_623,8347,models,O
PMC405395810_623,8347,of,O
PMC405395810_623,8347,neuropathic,B-Disease
PMC405395810_623,8347,[,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,],O
PMC405395810_623,8347,or,O
PMC405395810_623,8347,inflammatory,O
PMC405395810_623,8347,pain,O
PMC405395810_623,8347,[,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,",",O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,],O
PMC405395810_623,8347,(,O
PMC405395810_623,8347,Table,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,number,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,_,O
PMC405395810_623,8347,),O
PMC405395810_623,8347,0,O
PMC405395814_223,8348,For,O
PMC405395814_223,8348,example,O
PMC405395814_223,8348,",",O
PMC405395814_223,8348,venlafaxine,B-Drug
PMC405395814_223,8348,was,O
PMC405395814_223,8348,shown,O
PMC405395814_223,8348,to,O
PMC405395814_223,8348,be,O
PMC405395814_223,8348,effective,O
PMC405395814_223,8348,in,O
PMC405395814_223,8348,several,O
PMC405395814_223,8348,chronic,O
PMC405395814_223,8348,neuropathic,O
PMC405395814_223,8348,pain,O
PMC405395814_223,8348,syndromes,O
PMC405395814_223,8348,",",O
PMC405395814_223,8348,whereas,O
PMC405395814_223,8348,SSRIs,O
PMC405395814_223,8348,such,O
PMC405395814_223,8348,as,O
PMC405395814_223,8348,fluoxetine,B-Drug
PMC405395814_223,8348,or,O
PMC405395814_223,8348,citalopram,B-Drug
PMC405395814_223,8348,",",O
PMC405395814_223,8348,did,O
PMC405395814_223,8348,not,O
PMC405395814_223,8348,show,O
PMC405395814_223,8348,any,O
PMC405395814_223,8348,activity,O
PMC405395814_223,8348,[,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,number,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,",",O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,number,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,_,O
PMC405395814_223,8348,],O
PMC405395814_223,8348,0,O
PMC40580040_287,8349,PURPOSE,O
PMC40580040_287,8349,:,O
PMC40580040_287,8349,To,O
PMC40580040_287,8349,overcome,O
PMC40580040_287,8349,cytochrome,O
PMC40580040_287,8349,P,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,D,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,(,O
PMC40580040_287,8349,CYP,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,D,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,),O
PMC40580040_287,8349,mediated,O
PMC40580040_287,8349,tamoxifen,B-Drug
PMC40580040_287,8349,resistance,O
PMC40580040_287,8349,in,O
PMC40580040_287,8349,postmenopausal,O
PMC40580040_287,8349,early,O
PMC40580040_287,8349,breast,B-Disease
PMC40580040_287,8349,cancer,I-Disease
PMC40580040_287,8349,",",O
PMC40580040_287,8349,CYP,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,D,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,phenotype,O
PMC40580040_287,8349,-,O
PMC40580040_287,8349,adjusted,O
PMC40580040_287,8349,tamoxifen,O
PMC40580040_287,8349,dosing,O
PMC40580040_287,8349,in,O
PMC40580040_287,8349,patients,O
PMC40580040_287,8349,with,O
PMC40580040_287,8349,impaired,O
PMC40580040_287,8349,CYP,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,D,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,number,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,_,O
PMC40580040_287,8349,metabolism,O
PMC40580040_287,8349,and,O
PMC40580040_287,8349,/,O
PMC40580040_287,8349,or,O
PMC40580040_287,8349,the,O
PMC40580040_287,8349,application,O
PMC40580040_287,8349,of,O
PMC40580040_287,8349,endoxifen,O
PMC40580040_287,8349,",",O
PMC40580040_287,8349,the,O
PMC40580040_287,8349,most,O
PMC40580040_287,8349,potent,O
PMC40580040_287,8349,tamoxifen,O
PMC40580040_287,8349,metabolite,O
PMC40580040_287,8349,",",O
PMC40580040_287,8349,are,O
PMC40580040_287,8349,alternative,O
PMC40580040_287,8349,treatment,O
PMC40580040_287,8349,options,O
PMC40580040_287,8349,0,O
PMC40611680_902,8350,The,O
PMC40611680_902,8350,effect,O
PMC40611680_902,8350,of,O
PMC40611680_902,8350,intravitreal,O
PMC40611680_902,8350,bevacizumab,B-Drug
PMC40611680_902,8350,on,O
PMC40611680_902,8350,ocular,O
PMC40611680_902,8350,blood,O
PMC40611680_902,8350,flow,O
PMC40611680_902,8350,in,O
PMC40611680_902,8350,diabetic,B-Disease
PMC40611680_902,8350,retinopathy,I-Disease
PMC40611680_902,8350,and,O
PMC40611680_902,8350,branch,O
PMC40611680_902,8350,retinal,O
PMC40611680_902,8350,vein,O
PMC40611680_902,8350,occlusion,O
PMC40611680_902,8350,as,O
PMC40611680_902,8350,measured,O
PMC40611680_902,8350,by,O
PMC40611680_902,8350,laser,O
PMC40611680_902,8350,speckle,O
PMC40611680_902,8350,flowgraphy,O
PMC40611680_902,8350,0,O
PMC40616620_491,8351,AIM,O
PMC40616620_491,8351,:,O
PMC40616620_491,8351,To,O
PMC40616620_491,8351,compare,O
PMC40616620_491,8351,the,O
PMC40616620_491,8351,effects,O
PMC40616620_491,8351,of,O
PMC40616620_491,8351,intravitrealbevacizumab,B-Drug
PMC40616620_491,8351,(,O
PMC40616620_491,8351,IVB,O
PMC40616620_491,8351,),O
PMC40616620_491,8351,and,O
PMC40616620_491,8351,intravitreal,O
PMC40616620_491,8351,triamcinolone,B-Drug
PMC40616620_491,8351,acetonide,I-Drug
PMC40616620_491,8351,(,O
PMC40616620_491,8351,IVT,O
PMC40616620_491,8351,),O
PMC40616620_491,8351,in,O
PMC40616620_491,8351,the,O
PMC40616620_491,8351,treatment,O
PMC40616620_491,8351,of,O
PMC40616620_491,8351,macular,O
PMC40616620_491,8351,edema,O
PMC40616620_491,8351,(,O
PMC40616620_491,8351,ME,O
PMC40616620_491,8351,),O
PMC40616620_491,8351,secondary,O
PMC40616620_491,8351,to,O
PMC40616620_491,8351,central,O
PMC40616620_491,8351,retinal,O
PMC40616620_491,8351,vein,O
PMC40616620_491,8351,occlusion,O
PMC40616620_491,8351,(,O
PMC40616620_491,8351,CRVO,O
PMC40616620_491,8351,),O
PMC40616620_491,8351,0,O
PMC40618020_76,8352,The,O
PMC40618020_76,8352,diagnosis,O
PMC40618020_76,8352,of,O
PMC40618020_76,8352,Attention,B-Disease
PMC40618020_76,8352,Deficit,I-Disease
PMC40618020_76,8352,Hyperactivity,I-Disease
PMC40618020_76,8352,Disorder,I-Disease
PMC40618020_76,8352,(,O
PMC40618020_76,8352,ADHD,O
PMC40618020_76,8352,),O
PMC40618020_76,8352,often,O
PMC40618020_76,8352,results,O
PMC40618020_76,8352,in,O
PMC40618020_76,8352,chronic,O
PMC40618020_76,8352,treatment,O
PMC40618020_76,8352,with,O
PMC40618020_76,8352,psychostimulants,O
PMC40618020_76,8352,such,O
PMC40618020_76,8352,as,O
PMC40618020_76,8352,methylphenidate,B-Drug
PMC40618020_76,8352,(,O
PMC40618020_76,8352,MPH,B-Drug
PMC40618020_76,8352,",",O
PMC40618020_76,8352,Ritalin,B-Drug
PMC40618020_76,8352,),O
PMC40618020_76,8352,0,O
PMC40645120_304,8353,BACKGROUND,O
PMC40645120_304,8353,:,O
PMC40645120_304,8353,Tamoxifen,B-Drug
PMC40645120_304,8353,",",O
PMC40645120_304,8353,an,O
PMC40645120_304,8353,agonist,O
PMC40645120_304,8353,of,O
PMC40645120_304,8353,estrogen,O
PMC40645120_304,8353,receptor,O
PMC40645120_304,8353,",",O
PMC40645120_304,8353,is,O
PMC40645120_304,8353,widely,O
PMC40645120_304,8353,prescribed,O
PMC40645120_304,8353,for,O
PMC40645120_304,8353,the,O
PMC40645120_304,8353,prevention,O
PMC40645120_304,8353,and,O
PMC40645120_304,8353,long,O
PMC40645120_304,8353,-,O
PMC40645120_304,8353,term,O
PMC40645120_304,8353,treatment,O
PMC40645120_304,8353,of,O
PMC40645120_304,8353,breast,B-Disease
PMC40645120_304,8353,cancer,I-Disease
PMC40645120_304,8353,0,O
PMC40651320_780,8354,Lisinopril,B-Drug
PMC40651320_780,8354,is,O
PMC40651320_780,8354,an,O
PMC40651320_780,8354,angiotensin,O
PMC40651320_780,8354,-,O
PMC40651320_780,8354,converting,O
PMC40651320_780,8354,enzyme,O
PMC40651320_780,8354,(,O
PMC40651320_780,8354,ACE,O
PMC40651320_780,8354,),O
PMC40651320_780,8354,inhibitor,O
PMC40651320_780,8354,",",O
PMC40651320_780,8354,primarily,O
PMC40651320_780,8354,used,O
PMC40651320_780,8354,for,O
PMC40651320_780,8354,the,O
PMC40651320_780,8354,treatment,O
PMC40651320_780,8354,of,O
PMC40651320_780,8354,hypertension,O
PMC40651320_780,8354,",",O
PMC40651320_780,8354,congestive,B-Symptom
PMC40651320_780,8354,heart,I-Symptom
PMC40651320_780,8354,failure,I-Symptom
PMC40651320_780,8354,",",O
PMC40651320_780,8354,and,O
PMC40651320_780,8354,heart,O
PMC40651320_780,8354,attack,O
PMC40651320_780,8354,0,O
PMC40671040_567,8355,BACKGROUND,O
PMC40671040_567,8355,:,O
PMC40671040_567,8355,The,O
PMC40671040_567,8355,guidelines,O
PMC40671040_567,8355,on,O
PMC40671040_567,8355,trigeminal,O
PMC40671040_567,8355,neuralgia,O
PMC40671040_567,8355,management,O
PMC40671040_567,8355,that,O
PMC40671040_567,8355,have,O
PMC40671040_567,8355,been,O
PMC40671040_567,8355,agreed,O
PMC40671040_567,8355,and,O
PMC40671040_567,8355,jointly,O
PMC40671040_567,8355,published,O
PMC40671040_567,8355,by,O
PMC40671040_567,8355,the,O
PMC40671040_567,8355,American,O
PMC40671040_567,8355,Academy,O
PMC40671040_567,8355,of,O
PMC40671040_567,8355,Neurology,O
PMC40671040_567,8355,and,O
PMC40671040_567,8355,the,O
PMC40671040_567,8355,European,O
PMC40671040_567,8355,Federation,O
PMC40671040_567,8355,of,O
PMC40671040_567,8355,Neurological,O
PMC40671040_567,8355,Societies,O
PMC40671040_567,8355,recommend,O
PMC40671040_567,8355,carbamazepine,B-Drug
PMC40671040_567,8355,(,O
PMC40671040_567,8355,CBZ,O
PMC40671040_567,8355,),O
PMC40671040_567,8355,and,O
PMC40671040_567,8355,oxcarbazepine,O
PMC40671040_567,8355,(,O
PMC40671040_567,8355,OXC,O
PMC40671040_567,8355,),O
PMC40671040_567,8355,as,O
PMC40671040_567,8355,the,O
PMC40671040_567,8355,first,O
PMC40671040_567,8355,-,O
PMC40671040_567,8355,choice,O
PMC40671040_567,8355,medical,O
PMC40671040_567,8355,treatments,O
PMC40671040_567,8355,in,O
PMC40671040_567,8355,patients,O
PMC40671040_567,8355,with,O
PMC40671040_567,8355,trigeminal,B-Disease
PMC40671040_567,8355,neuralgia,I-Disease
PMC40671040_567,8355,(,O
PMC40671040_567,8355,TN,O
PMC40671040_567,8355,),O
PMC40671040_567,8355,0,O
PMC40675050_903,8356,The,O
PMC40675050_903,8356,aim,O
PMC40675050_903,8356,of,O
PMC40675050_903,8356,the,O
PMC40675050_903,8356,Fluoxetine,O
PMC40675050_903,8356,for,O
PMC40675050_903,8356,Autistic,O
PMC40675050_903,8356,Behaviors,O
PMC40675050_903,8356,(,O
PMC40675050_903,8356,FAB,O
PMC40675050_903,8356,),O
PMC40675050_903,8356,study,O
PMC40675050_903,8356,is,O
PMC40675050_903,8356,to,O
PMC40675050_903,8356,determine,O
PMC40675050_903,8356,the,O
PMC40675050_903,8356,efficacy,O
PMC40675050_903,8356,and,O
PMC40675050_903,8356,safety,O
PMC40675050_903,8356,of,O
PMC40675050_903,8356,low,O
PMC40675050_903,8356,dose,O
PMC40675050_903,8356,fluoxetine,B-Drug
PMC40675050_903,8356,compared,O
PMC40675050_903,8356,with,O
PMC40675050_903,8356,placebo,O
PMC40675050_903,8356,",",O
PMC40675050_903,8356,for,O
PMC40675050_903,8356,reducing,O
PMC40675050_903,8356,the,O
PMC40675050_903,8356,frequency,O
PMC40675050_903,8356,and,O
PMC40675050_903,8356,severity,O
PMC40675050_903,8356,of,O
PMC40675050_903,8356,repetitive,O
PMC40675050_903,8356,stereotypic,O
PMC40675050_903,8356,behaviors,O
PMC40675050_903,8356,in,O
PMC40675050_903,8356,children,O
PMC40675050_903,8356,and,O
PMC40675050_903,8356,adolescents,O
PMC40675050_903,8356,with,O
PMC40675050_903,8356,an,O
PMC40675050_903,8356,autism,B-Disease
PMC40675050_903,8356,spectrum,I-Disease
PMC40675050_903,8356,disorder,I-Disease
PMC40675050_903,8356,(,O
PMC40675050_903,8356,ASD,O
PMC40675050_903,8356,),O
PMC40675050_903,8356,0,O
PMC40773900_13,8357,Quetiapine,B-Drug
PMC40773900_13,8357,for,O
PMC40773900_13,8357,acute,O
PMC40773900_13,8357,bipolar,B-Disease
PMC40773900_13,8357,depression,I-Disease
PMC40773900_13,8357,:,O
PMC40773900_13,8357,a,O
PMC40773900_13,8357,systematic,O
PMC40773900_13,8357,review,O
PMC40773900_13,8357,and,O
PMC40773900_13,8357,meta,O
PMC40773900_13,8357,-,O
PMC40773900_13,8357,analysis,O
PMC40773900_13,8357,0,O
PMC40773900_252,8358,The,O
PMC40773900_252,8358,lower,O
PMC40773900_252,8358,risk,O
PMC40773900_252,8358,of,O
PMC40773900_252,8358,headache,B-Symptom
PMC40773900_252,8358,in,O
PMC40773900_252,8358,quetiapine,B-Drug
PMC40773900_252,8358,-,O
PMC40773900_252,8358,treated,O
PMC40773900_252,8358,patients,O
PMC40773900_252,8358,with,O
PMC40773900_252,8358,acute,O
PMC40773900_252,8358,bipolar,B-Disease
PMC40773900_252,8358,depression,I-Disease
PMC40773900_252,8358,should,O
PMC40773900_252,8358,be,O
PMC40773900_252,8358,further,O
PMC40773900_252,8358,investigated,O
PMC40773900_252,8358,0,O
PMC40796310_164,8359,The,O
PMC40796310_164,8359,majority,O
PMC40796310_164,8359,of,O
PMC40796310_164,8359,studies,O
PMC40796310_164,8359,confirm,O
PMC40796310_164,8359,the,O
PMC40796310_164,8359,usefulness,O
PMC40796310_164,8359,of,O
PMC40796310_164,8359,montelukast,B-Drug
PMC40796310_164,8359,as,O
PMC40796310_164,8359,monotherapy,O
PMC40796310_164,8359,and,O
PMC40796310_164,8359,add,O
PMC40796310_164,8359,-,O
PMC40796310_164,8359,on,O
PMC40796310_164,8359,therapy,O
PMC40796310_164,8359,to,O
PMC40796310_164,8359,ICS,O
PMC40796310_164,8359,in,O
PMC40796310_164,8359,mild,O
PMC40796310_164,8359,to,O
PMC40796310_164,8359,moderate,O
PMC40796310_164,8359,childhood,O
PMC40796310_164,8359,asthma,B-Disease
PMC40796310_164,8359,across,O
PMC40796310_164,8359,all,O
PMC40796310_164,8359,age,O
PMC40796310_164,8359,groups,O
PMC40796310_164,8359,0,O
PMC40916740_540,8360,The,O
PMC40916740_540,8360,purpose,O
PMC40916740_540,8360,of,O
PMC40916740_540,8360,the,O
PMC40916740_540,8360,present,O
PMC40916740_540,8360,study,O
PMC40916740_540,8360,was,O
PMC40916740_540,8360,to,O
PMC40916740_540,8360,evaluate,O
PMC40916740_540,8360,TIMP,O
PMC40916740_540,8360,_,O
PMC40916740_540,8360,_,O
PMC40916740_540,8360,number,O
PMC40916740_540,8360,_,O
PMC40916740_540,8360,_,O
PMC40916740_540,8360,immunoreactivity,O
PMC40916740_540,8360,as,O
PMC40916740_540,8360,a,O
PMC40916740_540,8360,prognostic,O
PMC40916740_540,8360,and,O
PMC40916740_540,8360,predictive,O
PMC40916740_540,8360,marker,O
PMC40916740_540,8360,in,O
PMC40916740_540,8360,advanced,B-Disease
PMC40916740_540,8360,breast,I-Disease
PMC40916740_540,8360,cancer,I-Disease
PMC40916740_540,8360,patients,O
PMC40916740_540,8360,receiving,O
PMC40916740_540,8360,docetaxel,B-Drug
PMC40916740_540,8360,(,O
PMC40916740_540,8360,D,O
PMC40916740_540,8360,),O
PMC40916740_540,8360,or,O
PMC40916740_540,8360,gemcitabine,O
PMC40916740_540,8360,plus,O
PMC40916740_540,8360,docetaxel,O
PMC40916740_540,8360,(,O
PMC40916740_540,8360,GD,O
PMC40916740_540,8360,),O
PMC40916740_540,8360,0,O
PMC41025530_450,8361,Serum,O
PMC41025530_450,8361,metabolomic,O
PMC41025530_450,8361,response,O
PMC41025530_450,8361,of,O
PMC41025530_450,8361,myasthenia,B-Disease
PMC41025530_450,8361,gravis,I-Disease
PMC41025530_450,8361,patients,O
PMC41025530_450,8361,to,O
PMC41025530_450,8361,chronic,O
PMC41025530_450,8361,prednisone,B-Drug
PMC41025530_450,8361,treatment,O
PMC41025530_450,8361,0,O
PMC41027430_465,8362,For,O
PMC41027430_465,8362,cervical,O
PMC41027430_465,8362,cancer,O
PMC41027430_465,8362,",",O
PMC41027430_465,8362,bevacizumab,B-Drug
PMC41027430_465,8362,was,O
PMC41027430_465,8362,first,O
PMC41027430_465,8362,demonstrated,O
PMC41027430_465,8362,to,O
PMC41027430_465,8362,exhibit,O
PMC41027430_465,8362,outstanding,O
PMC41027430_465,8362,clinical,O
PMC41027430_465,8362,efficacy,O
PMC41027430_465,8362,in,O
PMC41027430_465,8362,a,O
PMC41027430_465,8362,recurrent,O
PMC41027430_465,8362,",",O
PMC41027430_465,8362,metastatic,O
PMC41027430_465,8362,setting,O
PMC41027430_465,8362,0,O
PMC41087560_548,8363,Hepatotoxicity,B-Symptom
PMC41087560_548,8363,caused,O
PMC41087560_548,8363,by,O
PMC41087560_548,8363,montelukast,B-Drug
PMC41087560_548,8363,in,O
PMC41087560_548,8363,a,O
PMC41087560_548,8363,paediatric,O
PMC41087560_548,8363,patient,O
PMC41087560_548,8363,0,O
PMC41087560_712,8364,Montelukast,B-Drug
PMC41087560_712,8364,is,O
PMC41087560_712,8364,a,O
PMC41087560_712,8364,selective,O
PMC41087560_712,8364,and,O
PMC41087560_712,8364,competitive,O
PMC41087560_712,8364,cysteinyl,O
PMC41087560_712,8364,leukotriene,O
PMC41087560_712,8364,receptor,O
PMC41087560_712,8364,antagonist,O
PMC41087560_712,8364,(,O
PMC41087560_712,8364,CystLTRA,O
PMC41087560_712,8364,),O
PMC41087560_712,8364,which,O
PMC41087560_712,8364,is,O
PMC41087560_712,8364,increasingly,O
PMC41087560_712,8364,used,O
PMC41087560_712,8364,for,O
PMC41087560_712,8364,the,O
PMC41087560_712,8364,treatment,O
PMC41087560_712,8364,of,O
PMC41087560_712,8364,allergic,B-Disease
PMC41087560_712,8364,asthma,B-Disease
PMC41087560_712,8364,0,O
PMC41121980_1023,8365,Changes,O
PMC41121980_1023,8365,in,O
PMC41121980_1023,8365,ovarian,O
PMC41121980_1023,8365,function,O
PMC41121980_1023,8365,in,O
PMC41121980_1023,8365,premenopausal,O
PMC41121980_1023,8365,women,O
PMC41121980_1023,8365,with,O
PMC41121980_1023,8365,breast,B-Disease
PMC41121980_1023,8365,cancer,I-Disease
PMC41121980_1023,8365,undergoing,O
PMC41121980_1023,8365,adjuvant,O
PMC41121980_1023,8365,TC,O
PMC41121980_1023,8365,(,O
PMC41121980_1023,8365,docetaxel,B-Drug
PMC41121980_1023,8365,and,O
PMC41121980_1023,8365,cyclophosphamide,O
PMC41121980_1023,8365,),O
PMC41121980_1023,8365,chemotherapy,O
PMC41121980_1023,8365,during,O
PMC41121980_1023,8365,a,O
PMC41121980_1023,8365,brief,O
PMC41121980_1023,8365,period,O
PMC41121980_1023,8365,of,O
PMC41121980_1023,8365,amenorrhea,B-Symptom
PMC41121980_1023,8365,around,O
PMC41121980_1023,8365,the,O
PMC41121980_1023,8365,last,O
PMC41121980_1023,8365,chemotherapy,O
PMC41121980_1023,8365,cycle,O
PMC41121980_1023,8365,0,O
PMC41135700_399,8366,This,O
PMC41135700_399,8366,study,O
PMC41135700_399,8366,investigated,O
PMC41135700_399,8366,the,O
PMC41135700_399,8366,feasibility,O
PMC41135700_399,8366,of,O
PMC41135700_399,8366,CA,O
PMC41135700_399,8366,IX,O
PMC41135700_399,8366,-,O
PMC41135700_399,8366,directed,O
PMC41135700_399,8366,immunoliposomes,O
PMC41135700_399,8366,for,O
PMC41135700_399,8366,targeted,O
PMC41135700_399,8366,delivery,O
PMC41135700_399,8366,of,O
PMC41135700_399,8366,docetaxel,B-Drug
PMC41135700_399,8366,to,O
PMC41135700_399,8366,human,O
PMC41135700_399,8366,lung,B-Disease
PMC41135700_399,8366,cancer,I-Disease
PMC41135700_399,8366,cells,O
PMC41135700_399,8366,in,O
PMC41135700_399,8366,vitro,O
PMC41135700_399,8366,0,O
PMC41146990_783,8367,The,O
PMC41146990_783,8367,antidepressant,O
PMC41146990_783,8367,sertraline,B-Drug
PMC41146990_783,8367,can,O
PMC41146990_783,8367,improve,O
PMC41146990_783,8367,the,O
PMC41146990_783,8367,executive,O
PMC41146990_783,8367,function,O
PMC41146990_783,8367,and,O
PMC41146990_783,8367,quality,O
PMC41146990_783,8367,of,O
PMC41146990_783,8367,life,O
PMC41146990_783,8367,",",O
PMC41146990_783,8367,which,O
PMC41146990_783,8367,may,O
PMC41146990_783,8367,be,O
PMC41146990_783,8367,helpful,O
PMC41146990_783,8367,in,O
PMC41146990_783,8367,the,O
PMC41146990_783,8367,clinical,O
PMC41146990_783,8367,practice,O
PMC41146990_783,8367,of,O
PMC41146990_783,8367,cancer,B-Disease
PMC41146990_783,8367,treatment,O
PMC41146990_783,8367,0,O
PMC41182420_601,8368,Fluoxetine,B-Drug
PMC41182420_601,8368,induces,O
PMC41182420_601,8368,vasodilatation,B-Symptom
PMC41182420_601,8368,of,O
PMC41182420_601,8368,cerebral,O
PMC41182420_601,8368,arterioles,O
PMC41182420_601,8368,by,O
PMC41182420_601,8368,co,O
PMC41182420_601,8368,-,O
PMC41182420_601,8368,modulating,O
PMC41182420_601,8368,NO,O
PMC41182420_601,8368,/,O
PMC41182420_601,8368,muscarinic,O
PMC41182420_601,8368,signalling,O
PMC41182420_601,8368,0,O
PMC41182730_996,8369,BACKGROUND,O
PMC41182730_996,8369,:,O
PMC41182730_996,8369,We,O
PMC41182730_996,8369,investigated,O
PMC41182730_996,8369,the,O
PMC41182730_996,8369,association,O
PMC41182730_996,8369,between,O
PMC41182730_996,8369,serum,O
PMC41182730_996,8369,proBDNF,O
PMC41182730_996,8369,",",O
PMC41182730_996,8369,a,O
PMC41182730_996,8369,precursor,O
PMC41182730_996,8369,of,O
PMC41182730_996,8369,brain,O
PMC41182730_996,8369,-,O
PMC41182730_996,8369,derived,O
PMC41182730_996,8369,neurotrophic,O
PMC41182730_996,8369,factor,O
PMC41182730_996,8369,(,O
PMC41182730_996,8369,BDNF,O
PMC41182730_996,8369,),O
PMC41182730_996,8369,",",O
PMC41182730_996,8369,and,O
PMC41182730_996,8369,response,O
PMC41182730_996,8369,to,O
PMC41182730_996,8369,fluvoxamine,B-Drug
PMC41182730_996,8369,in,O
PMC41182730_996,8369,patients,O
PMC41182730_996,8369,with,O
PMC41182730_996,8369,major,B-Disease
PMC41182730_996,8369,depressive,I-Disease
PMC41182730_996,8369,disorder,I-Disease
PMC41182730_996,8369,(,O
PMC41182730_996,8369,MDD,O
PMC41182730_996,8369,),O
PMC41182730_996,8369,using,O
PMC41182730_996,8369,the,O
PMC41182730_996,8369,Diagnostic,O
PMC41182730_996,8369,and,O
PMC41182730_996,8369,Statistical,O
PMC41182730_996,8369,Manual,O
PMC41182730_996,8369,of,O
PMC41182730_996,8369,Mental,O
PMC41182730_996,8369,Disorders,O
PMC41182730_996,8369,",",O
PMC41182730_996,8369,Fourth,O
PMC41182730_996,8369,Edition,O
PMC41182730_996,8369,",",O
PMC41182730_996,8369,Text,O
PMC41182730_996,8369,Revision,O
PMC41182730_996,8369,(,O
PMC41182730_996,8369,DSM,O
PMC41182730_996,8369,-,O
PMC41182730_996,8369,IV,O
PMC41182730_996,8369,-,O
PMC41182730_996,8369,TR,O
PMC41182730_996,8369,),O
PMC41182730_996,8369,:,O
PMC41182730_996,8369,physically,O
PMC41182730_996,8369,healthy,O
PMC41182730_996,8369,and,O
PMC41182730_996,8369,free,O
PMC41182730_996,8369,of,O
PMC41182730_996,8369,current,O
PMC41182730_996,8369,alcohol,O
PMC41182730_996,8369,or,O
PMC41182730_996,8369,drug,O
PMC41182730_996,8369,abuse,O
PMC41182730_996,8369,",",O
PMC41182730_996,8369,comorbid,O
PMC41182730_996,8369,anxiety,B-Symptom
PMC41182730_996,8369,",",O
PMC41182730_996,8369,or,O
PMC41182730_996,8369,personality,B-Disease
PMC41182730_996,8369,disorders,I-Disease
PMC41182730_996,8369,0,O
PMC41189670_375,8370,significantly,O
PMC41189670_375,8370,reduced,O
PMC41189670_375,8370,(,O
PMC41189670_375,8370,_,O
PMC41189670_375,8370,_,O
PMC41189670_375,8370,number,O
PMC41189670_375,8370,_,O
PMC41189670_375,8370,_,O
PMC41189670_375,8370,%,O
PMC41189670_375,8370,),O
PMC41189670_375,8370,weight,B-Symptom
PMC41189670_375,8370,gain,I-Symptom
PMC41189670_375,8370,induced,O
PMC41189670_375,8370,by,O
PMC41189670_375,8370,olanzapine,B-Drug
PMC41189670_375,8370,0,O
PMC41202890_966,8371,In,O
PMC41202890_966,8371,the,O
PMC41202890_966,8371,quetiapine,B-Drug
PMC41202890_966,8371,group,O
PMC41202890_966,8371,serum,B-Symptom
PMC41202890_966,8371,prolactin,I-Symptom
PMC41202890_966,8371,remained,O
PMC41202890_966,8371,stable,O
PMC41202890_966,8371,throughout,O
PMC41202890_966,8371,the,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,number,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,months,O
PMC41202890_966,8371,but,O
PMC41202890_966,8371,in,O
PMC41202890_966,8371,the,O
PMC41202890_966,8371,risperidone,O
PMC41202890_966,8371,group,O
PMC41202890_966,8371,the,O
PMC41202890_966,8371,serum,B-Symptom
PMC41202890_966,8371,prolactin,I-Symptom
PMC41202890_966,8371,level,I-Symptom
PMC41202890_966,8371,increased,I-Symptom
PMC41202890_966,8371,_,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,number,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,-,O
PMC41202890_966,8371,to,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,number,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,_,O
PMC41202890_966,8371,-,O
PMC41202890_966,8371,fold,O
PMC41202890_966,8371,over,O
PMC41202890_966,8371,the,O
PMC41202890_966,8371,one,O
PMC41202890_966,8371,-,O
PMC41202890_966,8371,year,O
PMC41202890_966,8371,follow,O
PMC41202890_966,8371,-,O
PMC41202890_966,8371,up,O
PMC41202890_966,8371,0,O
PMC41202890_967,8372,Randomized,O
PMC41202890_967,8372,controlled,O
PMC41202890_967,8372,trial,O
PMC41202890_967,8372,comparing,O
PMC41202890_967,8372,changes,O
PMC41202890_967,8372,in,O
PMC41202890_967,8372,serum,O
PMC41202890_967,8372,prolactin,O
PMC41202890_967,8372,and,O
PMC41202890_967,8372,weight,O
PMC41202890_967,8372,among,O
PMC41202890_967,8372,female,O
PMC41202890_967,8372,patients,O
PMC41202890_967,8372,with,O
PMC41202890_967,8372,first,O
PMC41202890_967,8372,-,O
PMC41202890_967,8372,episode,O
PMC41202890_967,8372,schizophrenia,B-Disease
PMC41202890_967,8372,over,O
PMC41202890_967,8372,_,O
PMC41202890_967,8372,_,O
PMC41202890_967,8372,number,O
PMC41202890_967,8372,_,O
PMC41202890_967,8372,_,O
PMC41202890_967,8372,months,O
PMC41202890_967,8372,of,O
PMC41202890_967,8372,treatment,O
PMC41202890_967,8372,with,O
PMC41202890_967,8372,risperidone,O
PMC41202890_967,8372,or,O
PMC41202890_967,8372,quetiapine,B-Drug
PMC41202890_967,8372,0,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,number,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,eyes,O
PMC41212530_93,8373,of,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,number,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,_,O
PMC41212530_93,8373,patients,O
PMC41212530_93,8373,with,O
PMC41212530_93,8373,exudative,O
PMC41212530_93,8373,AMD,B-Disease
PMC41212530_93,8373,underwent,O
PMC41212530_93,8373,intravitreal,O
PMC41212530_93,8373,injection,O
PMC41212530_93,8373,of,O
PMC41212530_93,8373,bevacizumab,B-Drug
PMC41212530_93,8373,three,O
PMC41212530_93,8373,times,O
PMC41212530_93,8373,at,O
PMC41212530_93,8373,monthly,O
PMC41212530_93,8373,intervals,O
PMC41212530_93,8373,0,O
PMC41280290_201,8374,Chronic,O
PMC41280290_201,8374,treatment,O
PMC41280290_201,8374,with,O
PMC41280290_201,8374,prazosin,O
PMC41280290_201,8374,or,O
PMC41280290_201,8374,duloxetine,B-Drug
PMC41280290_201,8374,lessens,O
PMC41280290_201,8374,concurrent,O
PMC41280290_201,8374,anxiety,B-Symptom
PMC41280290_201,8374,-,O
PMC41280290_201,8374,like,O
PMC41280290_201,8374,behavior,O
PMC41280290_201,8374,and,O
PMC41280290_201,8374,alcohol,O
PMC41280290_201,8374,intake,O
PMC41280290_201,8374,:,O
PMC41280290_201,8374,evidence,O
PMC41280290_201,8374,of,O
PMC41280290_201,8374,disrupted,O
PMC41280290_201,8374,noradrenergic,O
PMC41280290_201,8374,signaling,O
PMC41280290_201,8374,in,O
PMC41280290_201,8374,anxiety,B-Symptom
PMC41280290_201,8374,-,O
PMC41280290_201,8374,related,O
PMC41280290_201,8374,alcohol,O
PMC41280290_201,8374,use,O
PMC41280290_201,8374,0,O
PMC41296740_846,8375,We,O
PMC41296740_846,8375,report,O
PMC41296740_846,8375,a,O
PMC41296740_846,8375,rare,O
PMC41296740_846,8375,case,O
PMC41296740_846,8375,of,O
PMC41296740_846,8375,severe,O
PMC41296740_846,8375,acute,O
PMC41296740_846,8375,rhabdomyolysis,O
PMC41296740_846,8375,in,O
PMC41296740_846,8375,association,O
PMC41296740_846,8375,with,O
PMC41296740_846,8375,coadministration,O
PMC41296740_846,8375,of,O
PMC41296740_846,8375,levofloxacin,B-Drug
PMC41296740_846,8375,and,O
PMC41296740_846,8375,simvastatin,O
PMC41296740_846,8375,in,O
PMC41296740_846,8375,a,O
PMC41296740_846,8375,patient,O
PMC41296740_846,8375,with,O
PMC41296740_846,8375,normal,O
PMC41296740_846,8375,renal,O
PMC41296740_846,8375,function,O
PMC41296740_846,8375,0,O
PMC41340040_546,8376,Neurological,O
PMC41340040_546,8376,Toxicity,O
PMC41340040_546,8376,in,O
PMC41340040_546,8376,Metastatic,B-Disease
PMC41340040_546,8376,Colorectal,I-Disease
PMC41340040_546,8376,Cancer,I-Disease
PMC41340040_546,8376,Patients,O
PMC41340040_546,8376,Treated,O
PMC41340040_546,8376,with,O
PMC41340040_546,8376,Modified,O
PMC41340040_546,8376,FOLFOX,O
PMC41340040_546,8376,_,O
PMC41340040_546,8376,_,O
PMC41340040_546,8376,number,O
PMC41340040_546,8376,_,O
PMC41340040_546,8376,_,O
PMC41340040_546,8376,Plus,O
PMC41340040_546,8376,Bevacizumab,B-Drug
PMC41340040_546,8376,0,O
PMC41436040_488,8377,Tamoxifen,B-Drug
PMC41436040_488,8377,plus,O
PMC41436040_488,8377,tegafur,O
PMC41436040_488,8377,-,O
PMC41436040_488,8377,uracil,O
PMC41436040_488,8377,(,O
PMC41436040_488,8377,TUFT,O
PMC41436040_488,8377,),O
PMC41436040_488,8377,versus,O
PMC41436040_488,8377,tamoxifen,B-Drug
PMC41436040_488,8377,plus,O
PMC41436040_488,8377,Adriamycin,O
PMC41436040_488,8377,(,O
PMC41436040_488,8377,doxorubicin,O
PMC41436040_488,8377,),O
PMC41436040_488,8377,and,O
PMC41436040_488,8377,cyclophosphamide,O
PMC41436040_488,8377,(,O
PMC41436040_488,8377,ACT,O
PMC41436040_488,8377,),O
PMC41436040_488,8377,as,O
PMC41436040_488,8377,adjuvant,O
PMC41436040_488,8377,therapy,O
PMC41436040_488,8377,to,O
PMC41436040_488,8377,treat,O
PMC41436040_488,8377,node,O
PMC41436040_488,8377,-,O
PMC41436040_488,8377,positive,O
PMC41436040_488,8377,premenopausal,B-Disease
PMC41436040_488,8377,breast,I-Disease
PMC41436040_488,8377,cancer,I-Disease
PMC41436040_488,8377,(,O
PMC41436040_488,8377,PreMBC,O
PMC41436040_488,8377,),O
PMC41436040_488,8377,:,O
PMC41436040_488,8377,results,O
PMC41436040_488,8377,of,O
PMC41436040_488,8377,Japan,O
PMC41436040_488,8377,Clinical,O
PMC41436040_488,8377,Oncology,O
PMC41436040_488,8377,Group,O
PMC41436040_488,8377,Study,O
PMC41436040_488,8377,_,O
PMC41436040_488,8377,_,O
PMC41436040_488,8377,number,O
PMC41436040_488,8377,_,O
PMC41436040_488,8377,_,O
PMC41436040_488,8377,0,O
PMC41437350_320,8378,CONCLUSION,O
PMC41437350_320,8378,:,O
PMC41437350_320,8378,The,O
PMC41437350_320,8378,results,O
PMC41437350_320,8378,show,O
PMC41437350_320,8378,that,O
PMC41437350_320,8378,prescription,O
PMC41437350_320,8378,of,O
PMC41437350_320,8378,intratechal,O
PMC41437350_320,8378,buprenorphine,B-Drug
PMC41437350_320,8378,prolongs,O
PMC41437350_320,8378,the,O
PMC41437350_320,8378,duration,O
PMC41437350_320,8378,of,O
PMC41437350_320,8378,analgesia,B-Symptom
PMC41437350_320,8378,without,O
PMC41437350_320,8378,any,O
PMC41437350_320,8378,significant,O
PMC41437350_320,8378,considerable,O
PMC41437350_320,8378,side,O
PMC41437350_320,8378,effects,O
PMC41437350_320,8378,0,O
PMC41459640_166,8379,Topiramate,B-Drug
PMC41459640_166,8379,",",O
PMC41459640_166,8379,vitamin,O
PMC41459640_166,8379,B,O
PMC41459640_166,8379,_,O
PMC41459640_166,8379,_,O
PMC41459640_166,8379,number,O
PMC41459640_166,8379,_,O
PMC41459640_166,8379,_,O
PMC41459640_166,8379,",",O
PMC41459640_166,8379,and,O
PMC41459640_166,8379,immunoglobulin,O
PMC41459640_166,8379,are,O
PMC41459640_166,8379,effective,O
PMC41459640_166,8379,in,O
PMC41459640_166,8379,some,O
PMC41459640_166,8379,children,O
PMC41459640_166,8379,with,O
PMC41459640_166,8379,infantile,O
PMC41459640_166,8379,spasms,B-Symptom
PMC41459640_166,8379,0,O
PMC41459640_508,8380,These,O
PMC41459640_508,8380,findings,O
PMC41459640_508,8380,indicate,O
PMC41459640_508,8380,that,O
PMC41459640_508,8380,initial,O
PMC41459640_508,8380,polytherapy,O
PMC41459640_508,8380,with,O
PMC41459640_508,8380,adrenocorticotropic,O
PMC41459640_508,8380,hormone,O
PMC41459640_508,8380,",",O
PMC41459640_508,8380,topiramate,B-Drug
PMC41459640_508,8380,",",O
PMC41459640_508,8380,vitamin,O
PMC41459640_508,8380,B,O
PMC41459640_508,8380,_,O
PMC41459640_508,8380,_,O
PMC41459640_508,8380,number,O
PMC41459640_508,8380,_,O
PMC41459640_508,8380,_,O
PMC41459640_508,8380,",",O
PMC41459640_508,8380,and,O
PMC41459640_508,8380,immunoglobulin,O
PMC41459640_508,8380,effectively,O
PMC41459640_508,8380,improves,O
PMC41459640_508,8380,the,O
PMC41459640_508,8380,prognosis,O
PMC41459640_508,8380,of,O
PMC41459640_508,8380,infantile,O
PMC41459640_508,8380,spasms,B-Symptom
PMC41459640_508,8380,",",O
PMC41459640_508,8380,and,O
PMC41459640_508,8380,its,O
PMC41459640_508,8380,effects,O
PMC41459640_508,8380,were,O
PMC41459640_508,8380,superior,O
PMC41459640_508,8380,in,O
PMC41459640_508,8380,cryptogenic,O
PMC41459640_508,8380,children,O
PMC41459640_508,8380,to,O
PMC41459640_508,8380,symptomatic,O
PMC41459640_508,8380,children,O
PMC41459640_508,8380,0,O
PMC41466100_713,8381,The,O
PMC41466100_713,8381,efficacy,O
PMC41466100_713,8381,of,O
PMC41466100_713,8381,paroxetine,B-Drug
PMC41466100_713,8381,and,O
PMC41466100_713,8381,placebo,O
PMC41466100_713,8381,in,O
PMC41466100_713,8381,treating,O
PMC41466100_713,8381,anxiety,B-Symptom
PMC41466100_713,8381,and,O
PMC41466100_713,8381,depression,B-Disease
PMC41466100_713,8381,:,O
PMC41466100_713,8381,a,O
PMC41466100_713,8381,meta,O
PMC41466100_713,8381,-,O
PMC41466100_713,8381,analysis,O
PMC41466100_713,8381,of,O
PMC41466100_713,8381,change,O
PMC41466100_713,8381,on,O
PMC41466100_713,8381,the,O
PMC41466100_713,8381,Hamilton,O
PMC41466100_713,8381,Rating,O
PMC41466100_713,8381,Scales,O
PMC41466100_713,8381,0,O
PMC41466100_908,8382,CONCLUSIONS,O
PMC41466100_908,8382,:,O
PMC41466100_908,8382,The,O
PMC41466100_908,8382,available,O
PMC41466100_908,8382,empirical,O
PMC41466100_908,8382,evidence,O
PMC41466100_908,8382,indicates,O
PMC41466100_908,8382,that,O
PMC41466100_908,8382,paroxetine,B-Drug
PMC41466100_908,8382,provides,O
PMC41466100_908,8382,only,O
PMC41466100_908,8382,a,O
PMC41466100_908,8382,modest,O
PMC41466100_908,8382,advantage,O
PMC41466100_908,8382,over,O
PMC41466100_908,8382,placebo,O
PMC41466100_908,8382,in,O
PMC41466100_908,8382,treatment,O
PMC41466100_908,8382,of,O
PMC41466100_908,8382,anxiety,B-Symptom
PMC41466100_908,8382,and,O
PMC41466100_908,8382,depression,B-Disease
PMC41466100_908,8382,0,O
PMC41498970_697,8383,Carbamazepine,B-Drug
PMC41498970_697,8383,was,O
PMC41498970_697,8383,the,O
PMC41498970_697,8383,most,O
PMC41498970_697,8383,consumed,O
PMC41498970_697,8383,medication,O
PMC41498970_697,8383,for,O
PMC41498970_697,8383,pain,B-Symptom
PMC41498970_697,8383,control,O
PMC41498970_697,8383,and,O
PMC41498970_697,8383,the,O
PMC41498970_697,8383,microvascular,O
PMC41498970_697,8383,decompression,O
PMC41498970_697,8383,was,O
PMC41498970_697,8383,the,O
PMC41498970_697,8383,most,O
PMC41498970_697,8383,performed,O
PMC41498970_697,8383,surgical,O
PMC41498970_697,8383,method,O
PMC41498970_697,8383,in,O
PMC41498970_697,8383,patients,O
PMC41498970_697,8383,0,O
PMC41506570_635,8384,A,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,number,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,-,O
PMC41506570_635,8384,year,O
PMC41506570_635,8384,-,O
PMC41506570_635,8384,old,O
PMC41506570_635,8384,male,O
PMC41506570_635,8384,with,O
PMC41506570_635,8384,intractable,O
PMC41506570_635,8384,frontal,O
PMC41506570_635,8384,lobe,O
PMC41506570_635,8384,seizures,B-Symptom
PMC41506570_635,8384,experienced,O
PMC41506570_635,8384,severe,O
PMC41506570_635,8384,ventricular,O
PMC41506570_635,8384,tachycardia,O
PMC41506570_635,8384,following,O
PMC41506570_635,8384,the,O
PMC41506570_635,8384,addition,O
PMC41506570_635,8384,of,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,number,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,_,O
PMC41506570_635,8384,mg,O
PMC41506570_635,8384,lacosamide,O
PMC41506570_635,8384,to,O
PMC41506570_635,8384,his,O
PMC41506570_635,8384,existing,O
PMC41506570_635,8384,regimen,O
PMC41506570_635,8384,of,O
PMC41506570_635,8384,carbamazepine,B-Drug
PMC41506570_635,8384,",",O
PMC41506570_635,8384,lamotrigine,B-Drug
PMC41506570_635,8384,",",O
PMC41506570_635,8384,clonazepam,O
PMC41506570_635,8384,",",O
PMC41506570_635,8384,and,O
PMC41506570_635,8384,valproate,O
PMC41506570_635,8384,0,O
PMC41577410_215,8385,To,O
PMC41577410_215,8385,identify,O
PMC41577410_215,8385,molecular,O
PMC41577410_215,8385,alterations,O
PMC41577410_215,8385,in,O
PMC41577410_215,8385,prostate,B-Disease
PMC41577410_215,8385,cancers,I-Disease
PMC41577410_215,8385,associating,O
PMC41577410_215,8385,with,O
PMC41577410_215,8385,relapse,O
PMC41577410_215,8385,following,O
PMC41577410_215,8385,neoadjuvant,O
PMC41577410_215,8385,chemotherapy,O
PMC41577410_215,8385,and,O
PMC41577410_215,8385,radical,O
PMC41577410_215,8385,prostatectomy,O
PMC41577410_215,8385,patients,O
PMC41577410_215,8385,with,O
PMC41577410_215,8385,high,O
PMC41577410_215,8385,-,O
PMC41577410_215,8385,risk,O
PMC41577410_215,8385,localized,O
PMC41577410_215,8385,prostate,B-Disease
PMC41577410_215,8385,cancer,I-Disease
PMC41577410_215,8385,were,O
PMC41577410_215,8385,enrolled,O
PMC41577410_215,8385,into,O
PMC41577410_215,8385,a,O
PMC41577410_215,8385,phase,O
PMC41577410_215,8385,I,O
PMC41577410_215,8385,-,O
PMC41577410_215,8385,II,O
PMC41577410_215,8385,clinical,O
PMC41577410_215,8385,trial,O
PMC41577410_215,8385,of,O
PMC41577410_215,8385,neoadjuvant,O
PMC41577410_215,8385,chemotherapy,O
PMC41577410_215,8385,with,O
PMC41577410_215,8385,docetaxel,B-Drug
PMC41577410_215,8385,and,O
PMC41577410_215,8385,mitoxantrone,O
PMC41577410_215,8385,followed,O
PMC41577410_215,8385,by,O
PMC41577410_215,8385,prostatectomy,O
PMC41577410_215,8385,0,O
PMC41595080_392,8386,METHODS,O
PMC41595080_392,8386,:,O
PMC41595080_392,8386,We,O
PMC41595080_392,8386,conducted,O
PMC41595080_392,8386,a,O
PMC41595080_392,8386,multinational,O
PMC41595080_392,8386,",",O
PMC41595080_392,8386,observational,O
PMC41595080_392,8386,",",O
PMC41595080_392,8386,retrospective,O
PMC41595080_392,8386,cohort,O
PMC41595080_392,8386,study,O
PMC41595080_392,8386,to,O
PMC41595080_392,8386,describe,O
PMC41595080_392,8386,and,O
PMC41595080_392,8386,compare,O
PMC41595080_392,8386,hospital,O
PMC41595080_392,8386,stay,O
PMC41595080_392,8386,in,O
PMC41595080_392,8386,patients,O
PMC41595080_392,8386,admitted,O
PMC41595080_392,8386,for,O
PMC41595080_392,8386,an,O
PMC41595080_392,8386,acute,O
PMC41595080_392,8386,bipolar,B-Disease
PMC41595080_392,8386,manic,O
PMC41595080_392,8386,episode,O
PMC41595080_392,8386,treated,O
PMC41595080_392,8386,with,O
PMC41595080_392,8386,quetiapine,B-Drug
PMC41595080_392,8386,IR,O
PMC41595080_392,8386,or,O
PMC41595080_392,8386,XR,O
PMC41595080_392,8386,from,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,number,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,October,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,number,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,October,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,number,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,_,O
PMC41595080_392,8386,0,O
PMC41643380_40,8387,Results,O
PMC41643380_40,8387,revealed,O
PMC41643380_40,8387,that,O
PMC41643380_40,8387,both,O
PMC41643380_40,8387,prostimulant,O
PMC41643380_40,8387,and,O
PMC41643380_40,8387,stimulant,O
PMC41643380_40,8387,medications,O
PMC41643380_40,8387,",",O
PMC41643380_40,8387,including,O
PMC41643380_40,8387,lisdexamfetamine,B-Drug
PMC41643380_40,8387,dimesylate,I-Drug
PMC41643380_40,8387,",",O
PMC41643380_40,8387,methylphenidate,B-Drug
PMC41643380_40,8387,",",O
PMC41643380_40,8387,amphetamines,B-Drug
PMC41643380_40,8387,",",O
PMC41643380_40,8387,and,O
PMC41643380_40,8387,mixed,O
PMC41643380_40,8387,-,O
PMC41643380_40,8387,amphetamine,O
PMC41643380_40,8387,salts,O
PMC41643380_40,8387,",",O
PMC41643380_40,8387,are,O
PMC41643380_40,8387,effective,O
PMC41643380_40,8387,at,O
PMC41643380_40,8387,reducing,O
PMC41643380_40,8387,ADHD,O
PMC41643380_40,8387,symptoms,O
PMC41643380_40,8387,in,O
PMC41643380_40,8387,adolescents,O
PMC41643380_40,8387,and,O
PMC41643380_40,8387,adults,O
PMC41643380_40,8387,with,O
PMC41643380_40,8387,ADHD,B-Disease
PMC41643380_40,8387,0,O
PMC41652770_997,8388,Using,O
PMC41652770_997,8388,a,O
PMC41652770_997,8388,case,O
PMC41652770_997,8388,-,O
PMC41652770_997,8388,only,O
PMC41652770_997,8388,design,O
PMC41652770_997,8388,with,O
PMC41652770_997,8388,_,O
PMC41652770_997,8388,_,O
PMC41652770_997,8388,number,O
PMC41652770_997,8388,_,O
PMC41652770_997,8388,_,O
PMC41652770_997,8388,high,O
PMC41652770_997,8388,-,O
PMC41652770_997,8388,risk,O
PMC41652770_997,8388,hypertensive,O
PMC41652770_997,8388,individuals,O
PMC41652770_997,8388,from,O
PMC41652770_997,8388,the,O
PMC41652770_997,8388,Genetics,O
PMC41652770_997,8388,of,O
PMC41652770_997,8388,Hypertension,O
PMC41652770_997,8388,Associated,O
PMC41652770_997,8388,Treatment,O
PMC41652770_997,8388,(,O
PMC41652770_997,8388,GenHAT,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,study,O
PMC41652770_997,8388,",",O
PMC41652770_997,8388,we,O
PMC41652770_997,8388,examined,O
PMC41652770_997,8388,whether,O
PMC41652770_997,8388,seven,O
PMC41652770_997,8388,single,O
PMC41652770_997,8388,nucleotide,O
PMC41652770_997,8388,polymorphisms,O
PMC41652770_997,8388,(,O
PMC41652770_997,8388,SNPs,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,in,O
PMC41652770_997,8388,the,O
PMC41652770_997,8388,angiotensinogen,O
PMC41652770_997,8388,gene,O
PMC41652770_997,8388,(,O
PMC41652770_997,8388,AGT,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,interact,O
PMC41652770_997,8388,with,O
PMC41652770_997,8388,three,O
PMC41652770_997,8388,classes,O
PMC41652770_997,8388,of,O
PMC41652770_997,8388,antihypertensive,O
PMC41652770_997,8388,drugs,O
PMC41652770_997,8388,including,O
PMC41652770_997,8388,chlorthalidone,O
PMC41652770_997,8388,(,O
PMC41652770_997,8388,a,O
PMC41652770_997,8388,thiazide,O
PMC41652770_997,8388,diuretic,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,",",O
PMC41652770_997,8388,lisinopril,B-Drug
PMC41652770_997,8388,(,O
PMC41652770_997,8388,an,O
PMC41652770_997,8388,ACE,O
PMC41652770_997,8388,inhibitor,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,",",O
PMC41652770_997,8388,and,O
PMC41652770_997,8388,amlodipine,O
PMC41652770_997,8388,(,O
PMC41652770_997,8388,a,O
PMC41652770_997,8388,calcium,O
PMC41652770_997,8388,channel,O
PMC41652770_997,8388,blocker,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,to,O
PMC41652770_997,8388,modify,O
PMC41652770_997,8388,the,O
PMC41652770_997,8388,risk,O
PMC41652770_997,8388,of,O
PMC41652770_997,8388,incident,O
PMC41652770_997,8388,coronary,B-Disease
PMC41652770_997,8388,heart,I-Disease
PMC41652770_997,8388,disease,I-Disease
PMC41652770_997,8388,(,O
PMC41652770_997,8388,CHD,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,and,O
PMC41652770_997,8388,heart,B-Symptom
PMC41652770_997,8388,failure,I-Symptom
PMC41652770_997,8388,(,O
PMC41652770_997,8388,HF,O
PMC41652770_997,8388,),O
PMC41652770_997,8388,among,O
PMC41652770_997,8388,Caucasian,O
PMC41652770_997,8388,and,O
PMC41652770_997,8388,African,O
PMC41652770_997,8388,American,O
PMC41652770_997,8388,participants,O
PMC41652770_997,8388,",",O
PMC41652770_997,8388,separately,O
PMC41652770_997,8388,0,O
PMC41655860_926,8389,CONCLUSIONS,O
PMC41655860_926,8389,:,O
PMC41655860_926,8389,The,O
PMC41655860_926,8389,combination,O
PMC41655860_926,8389,of,O
PMC41655860_926,8389,AIGIV,O
PMC41655860_926,8389,with,O
PMC41655860_926,8389,antibiotics,O
PMC41655860_926,8389,provided,O
PMC41655860_926,8389,an,O
PMC41655860_926,8389,improvement,O
PMC41655860_926,8389,in,O
PMC41655860_926,8389,survival,O
PMC41655860_926,8389,compared,O
PMC41655860_926,8389,to,O
PMC41655860_926,8389,levofloxacin,B-Drug
PMC41655860_926,8389,treatment,O
PMC41655860_926,8389,alone,O
PMC41655860_926,8389,when,O
PMC41655860_926,8389,treatment,O
PMC41655860_926,8389,was,O
PMC41655860_926,8389,delayed,O
PMC41655860_926,8389,up,O
PMC41655860_926,8389,to,O
PMC41655860_926,8389,_,O
PMC41655860_926,8389,_,O
PMC41655860_926,8389,number,O
PMC41655860_926,8389,_,O
PMC41655860_926,8389,_,O
PMC41655860_926,8389,hours,O
PMC41655860_926,8389,post,O
PMC41655860_926,8389,-,O
PMC41655860_926,8389,anthrax,B-Disease
PMC41655860_926,8389,exposure,O
PMC41655860_926,8389,0,O
PMC41774150_118,8390,BACKGROUND,O
PMC41774150_118,8390,:,O
PMC41774150_118,8390,Topiramate,B-Drug
PMC41774150_118,8390,is,O
PMC41774150_118,8390,a,O
PMC41774150_118,8390,drug,O
PMC41774150_118,8390,which,O
PMC41774150_118,8390,emerged,O
PMC41774150_118,8390,from,O
PMC41774150_118,8390,its,O
PMC41774150_118,8390,anticonvulsant,O
PMC41774150_118,8390,properties,O
PMC41774150_118,8390,and,O
PMC41774150_118,8390,now,O
PMC41774150_118,8390,over,O
PMC41774150_118,8390,the,O
PMC41774150_118,8390,years,O
PMC41774150_118,8390,is,O
PMC41774150_118,8390,used,O
PMC41774150_118,8390,for,O
PMC41774150_118,8390,a,O
PMC41774150_118,8390,wider,O
PMC41774150_118,8390,range,O
PMC41774150_118,8390,of,O
PMC41774150_118,8390,indications,O
PMC41774150_118,8390,",",O
PMC41774150_118,8390,including,O
PMC41774150_118,8390,migraine,O
PMC41774150_118,8390,prophylaxis,O
PMC41774150_118,8390,0,O
PMC41774150_815,8391,We,O
PMC41774150_815,8391,described,O
PMC41774150_815,8391,a,O
PMC41774150_815,8391,very,O
PMC41774150_815,8391,rare,O
PMC41774150_815,8391,case,O
PMC41774150_815,8391,of,O
PMC41774150_815,8391,topiramate,B-Drug
PMC41774150_815,8391,induced,O
PMC41774150_815,8391,acute,O
PMC41774150_815,8391,onset,O
PMC41774150_815,8391,myopia,O
PMC41774150_815,8391,during,O
PMC41774150_815,8391,use,O
PMC41774150_815,8391,for,O
PMC41774150_815,8391,migraine,O
PMC41774150_815,8391,0,O
PMC41891040_692,8392,Intermittent,O
PMC41891040_692,8392,montelukast,B-Drug
PMC41891040_692,8392,in,O
PMC41891040_692,8392,children,O
PMC41891040_692,8392,aged,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,number,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,months,O
PMC41891040_692,8392,to,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,number,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,_,O
PMC41891040_692,8392,years,O
PMC41891040_692,8392,with,O
PMC41891040_692,8392,wheeze,B-Symptom
PMC41891040_692,8392,(,O
PMC41891040_692,8392,WAIT,O
PMC41891040_692,8392,trial,O
PMC41891040_692,8392,),O
PMC41891040_692,8392,:,O
PMC41891040_692,8392,a,O
PMC41891040_692,8392,multicentre,O
PMC41891040_692,8392,",",O
PMC41891040_692,8392,randomised,O
PMC41891040_692,8392,",",O
PMC41891040_692,8392,placebo,O
PMC41891040_692,8392,-,O
PMC41891040_692,8392,controlled,O
PMC41891040_692,8392,trial,O
PMC41891040_692,8392,0,O
PMC41891040_759,8393,There,O
PMC41891040_759,8393,was,O
PMC41891040_759,8393,no,O
PMC41891040_759,8393,difference,O
PMC41891040_759,8393,in,O
PMC41891040_759,8393,unscheduled,O
PMC41891040_759,8393,medical,O
PMC41891040_759,8393,attendances,O
PMC41891040_759,8393,for,O
PMC41891040_759,8393,wheezing,B-Symptom
PMC41891040_759,8393,episodes,O
PMC41891040_759,8393,between,O
PMC41891040_759,8393,children,O
PMC41891040_759,8393,in,O
PMC41891040_759,8393,the,O
PMC41891040_759,8393,montelukast,B-Drug
PMC41891040_759,8393,and,O
PMC41891040_759,8393,placebo,O
PMC41891040_759,8393,groups,O
PMC41891040_759,8393,(,O
PMC41891040_759,8393,mean,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,[,O
PMC41891040_759,8393,SD,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,],O
PMC41891040_759,8393,vs,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,[,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,],O
PMC41891040_759,8393,;,O
PMC41891040_759,8393,incidence,O
PMC41891040_759,8393,rate,O
PMC41891040_759,8393,ratio,O
PMC41891040_759,8393,[,O
PMC41891040_759,8393,IRR,O
PMC41891040_759,8393,],O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,",",O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,%,O
PMC41891040_759,8393,CI,O
PMC41891040_759,8393,:,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,;,O
PMC41891040_759,8393,p,O
PMC41891040_759,8393,=,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,number,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,_,O
PMC41891040_759,8393,),O
PMC41891040_759,8393,0,O
PMC41905660_667,8394,Circulating,O
PMC41905660_667,8394,biomarkers,O
PMC41905660_667,8394,in,O
PMC41905660_667,8394,advanced,O
PMC41905660_667,8394,colorectal,B-Disease
PMC41905660_667,8394,cancer,I-Disease
PMC41905660_667,8394,patients,O
PMC41905660_667,8394,randomly,O
PMC41905660_667,8394,assigned,O
PMC41905660_667,8394,to,O
PMC41905660_667,8394,three,O
PMC41905660_667,8394,bevacizumab,B-Drug
PMC41905660_667,8394,-,O
PMC41905660_667,8394,based,O
PMC41905660_667,8394,regimens,O
PMC41905660_667,8394,0,O
PMC41909790_263,8395,While,O
PMC41909790_263,8395,mild,O
PMC41909790_263,8395,elevation,O
PMC41909790_263,8395,of,O
PMC41909790_263,8395,blood,O
PMC41909790_263,8395,pressure,O
PMC41909790_263,8395,could,O
PMC41909790_263,8395,be,O
PMC41909790_263,8395,observed,O
PMC41909790_263,8395,after,O
PMC41909790_263,8395,venlafaxine,B-Drug
PMC41909790_263,8395,treatment,O
PMC41909790_263,8395,",",O
PMC41909790_263,8395,this,O
PMC41909790_263,8395,case,O
PMC41909790_263,8395,shows,O
PMC41909790_263,8395,that,O
PMC41909790_263,8395,accelerated,O
PMC41909790_263,8395,hypertension,B-Disease
PMC41909790_263,8395,with,O
PMC41909790_263,8395,a,O
PMC41909790_263,8395,diastolic,B-Symptom
PMC41909790_263,8395,blood,I-Symptom
PMC41909790_263,8395,pressure,I-Symptom
PMC41909790_263,8395,rise,O
PMC41909790_263,8395,above,O
PMC41909790_263,8395,_,O
PMC41909790_263,8395,_,O
PMC41909790_263,8395,number,O
PMC41909790_263,8395,_,O
PMC41909790_263,8395,_,O
PMC41909790_263,8395,mmHg,O
PMC41909790_263,8395,could,O
PMC41909790_263,8395,be,O
PMC41909790_263,8395,observed,O
PMC41909790_263,8395,at,O
PMC41909790_263,8395,relatively,O
PMC41909790_263,8395,low,O
PMC41909790_263,8395,doses,O
PMC41909790_263,8395,of,O
PMC41909790_263,8395,venlafaxine,B-Drug
PMC41909790_263,8395,0,O
PMC41999840_422,8396,Exploratory,O
PMC41999840_422,8396,meta,O
PMC41999840_422,8396,-,O
PMC41999840_422,8396,analysis,O
PMC41999840_422,8396,on,O
PMC41999840_422,8396,lisdexamfetamine,B-Drug
PMC41999840_422,8396,versus,O
PMC41999840_422,8396,placebo,O
PMC41999840_422,8396,in,O
PMC41999840_422,8396,adult,O
PMC41999840_422,8396,ADHD,B-Disease
PMC41999840_422,8396,0,O
PMC41999840_485,8397,BACKGROUND,O
PMC41999840_485,8397,:,O
PMC41999840_485,8397,Recent,O
PMC41999840_485,8397,studies,O
PMC41999840_485,8397,have,O
PMC41999840_485,8397,promised,O
PMC41999840_485,8397,that,O
PMC41999840_485,8397,lisdexamfetamine,B-Drug
PMC41999840_485,8397,(,O
PMC41999840_485,8397,LDX,O
PMC41999840_485,8397,),O
PMC41999840_485,8397,is,O
PMC41999840_485,8397,effective,O
PMC41999840_485,8397,in,O
PMC41999840_485,8397,the,O
PMC41999840_485,8397,treatment,O
PMC41999840_485,8397,of,O
PMC41999840_485,8397,adults,O
PMC41999840_485,8397,with,O
PMC41999840_485,8397,attention,B-Disease
PMC41999840_485,8397,-,I-Disease
PMC41999840_485,8397,deficit,I-Disease
PMC41999840_485,8397,hyperactivity,I-Disease
PMC41999840_485,8397,disorder,I-Disease
PMC41999840_485,8397,(,O
PMC41999840_485,8397,ADHD,O
PMC41999840_485,8397,),O
PMC41999840_485,8397,0,O
PMC42049110_549,8398,PURPOSE,O
PMC42049110_549,8398,:,O
PMC42049110_549,8398,To,O
PMC42049110_549,8398,examine,O
PMC42049110_549,8398,the,O
PMC42049110_549,8398,impact,O
PMC42049110_549,8398,of,O
PMC42049110_549,8398,newly,O
PMC42049110_549,8398,initiated,O
PMC42049110_549,8398,pregabalin,O
PMC42049110_549,8398,or,O
PMC42049110_549,8398,duloxetine,B-Drug
PMC42049110_549,8398,treatment,O
PMC42049110_549,8398,on,O
PMC42049110_549,8398,fibromyalgia,B-Disease
PMC42049110_549,8398,(,O
PMC42049110_549,8398,FM,O
PMC42049110_549,8398,),O
PMC42049110_549,8398,patients,O
PMC42049110_549,8398,',O
PMC42049110_549,8398,encounters,O
PMC42049110_549,8398,with,O
PMC42049110_549,8398,potential,O
PMC42049110_549,8398,drug,O
PMC42049110_549,8398,-,O
PMC42049110_549,8398,drug,O
PMC42049110_549,8398,interactions,O
PMC42049110_549,8398,(,O
PMC42049110_549,8398,DDIs,O
PMC42049110_549,8398,),O
PMC42049110_549,8398,",",O
PMC42049110_549,8398,the,O
PMC42049110_549,8398,health,O
PMC42049110_549,8398,care,O
PMC42049110_549,8398,cost,O
PMC42049110_549,8398,and,O
PMC42049110_549,8398,utilization,O
PMC42049110_549,8398,consequences,O
PMC42049110_549,8398,of,O
PMC42049110_549,8398,those,O
PMC42049110_549,8398,interactions,O
PMC42049110_549,8398,",",O
PMC42049110_549,8398,and,O
PMC42049110_549,8398,the,O
PMC42049110_549,8398,impact,O
PMC42049110_549,8398,of,O
PMC42049110_549,8398,treatment,O
PMC42049110_549,8398,on,O
PMC42049110_549,8398,opioid,O
PMC42049110_549,8398,utilization,O
PMC42049110_549,8398,0,O
PMC42135550_1034,8399,_,O
PMC42135550_1034,8399,_,O
PMC42135550_1034,8399,number,O
PMC42135550_1034,8399,_,O
PMC42135550_1034,8399,_,O
PMC42135550_1034,8399,%,O
PMC42135550_1034,8399,Of,O
PMC42135550_1034,8399,the,O
PMC42135550_1034,8399,paper,O
PMC42135550_1034,8399,and,O
PMC42135550_1034,8399,pencil,O
PMC42135550_1034,8399,pain,O
PMC42135550_1034,8399,diaries,O
PMC42135550_1034,8399,were,O
PMC42135550_1034,8399,returned,O
PMC42135550_1034,8399,for,O
PMC42135550_1034,8399,data,O
PMC42135550_1034,8399,analysis,O
PMC42135550_1034,8399,0,O
PMC42135550_1034,8400,The,O
PMC42135550_1034,8400,triamcinolone,B-Drug
PMC42135550_1034,8400,acetonide,I-Drug
PMC42135550_1034,8400,group,O
PMC42135550_1034,8400,showed,O
PMC42135550_1034,8400,the,O
PMC42135550_1034,8400,largest,O
PMC42135550_1034,8400,decrease,O
PMC42135550_1034,8400,in,O
PMC42135550_1034,8400,pain,B-Symptom
PMC42135550_1034,8400,on,O
PMC42135550_1034,8400,the,O
PMC42135550_1034,8400,VAS,O
PMC42135550_1034,8400,scores,O
PMC42135550_1034,8400,after,O
PMC42135550_1034,8400,injection,O
PMC42135550_1034,8400,compared,O
PMC42135550_1034,8400,to,O
PMC42135550_1034,8400,the,O
PMC42135550_1034,8400,hyaluronic,O
PMC42135550_1034,8400,acid,O
PMC42135550_1034,8400,and,O
PMC42135550_1034,8400,NaCl,O
PMC42135550_1034,8400,group,O
PMC42135550_1034,8400,in,O
PMC42135550_1034,8400,the,O
PMC42135550_1034,8400,first,O
PMC42135550_1034,8400,week,O
PMC42135550_1034,8400,after,O
PMC42135550_1034,8400,injection,O
PMC42135550_1034,8400,0,O
PMC42135550_654,8401,The,O
PMC42135550_654,8401,third,O
PMC42135550_654,8401,triamcinolone,B-Drug
PMC42135550_654,8401,acetonide,O
PMC42135550_654,8401,injection,O
PMC42135550_654,8401,only,O
PMC42135550_654,8401,showed,O
PMC42135550_654,8401,a,O
PMC42135550_654,8401,slight,O
PMC42135550_654,8401,improvement,O
PMC42135550_654,8401,in,O
PMC42135550_654,8401,pain,B-Symptom
PMC42135550_654,8401,reduction,O
PMC42135550_654,8401,0,O
PMC42187970_761,8402,Therefore,O
PMC42187970_761,8402,",",O
PMC42187970_761,8402,the,O
PMC42187970_761,8402,possibility,O
PMC42187970_761,8402,that,O
PMC42187970_761,8402,sertraline,B-Drug
PMC42187970_761,8402,could,O
PMC42187970_761,8402,overcome,O
PMC42187970_761,8402,the,O
PMC42187970_761,8402,rise,O
PMC42187970_761,8402,in,O
PMC42187970_761,8402,pro,O
PMC42187970_761,8402,-,O
PMC42187970_761,8402,inflammatory,O
PMC42187970_761,8402,cytokine,O
PMC42187970_761,8402,expression,O
PMC42187970_761,8402,induced,O
PMC42187970_761,8402,by,O
PMC42187970_761,8402,seizures,B-Symptom
PMC42187970_761,8402,has,O
PMC42187970_761,8402,been,O
PMC42187970_761,8402,investigated,O
PMC42187970_761,8402,0,O
PMC42195570_361,8403,BACKGROUND,O
PMC42195570_361,8403,:,O
PMC42195570_361,8403,Following,O
PMC42195570_361,8403,the,O
PMC42195570_361,8403,approval,O
PMC42195570_361,8403,of,O
PMC42195570_361,8403,lisdexamfetamine,B-Drug
PMC42195570_361,8403,dimesylate,I-Drug
PMC42195570_361,8403,(,O
PMC42195570_361,8403,LDX,O
PMC42195570_361,8403,),O
PMC42195570_361,8403,in,O
PMC42195570_361,8403,several,O
PMC42195570_361,8403,European,O
PMC42195570_361,8403,countries,O
PMC42195570_361,8403,for,O
PMC42195570_361,8403,the,O
PMC42195570_361,8403,treatment,O
PMC42195570_361,8403,of,O
PMC42195570_361,8403,attention,B-Disease
PMC42195570_361,8403,-,I-Disease
PMC42195570_361,8403,deficit,I-Disease
PMC42195570_361,8403,/,I-Disease
PMC42195570_361,8403,hyperactivity,I-Disease
PMC42195570_361,8403,disorder,I-Disease
PMC42195570_361,8403,(,O
PMC42195570_361,8403,ADHD,O
PMC42195570_361,8403,),O
PMC42195570_361,8403,in,O
PMC42195570_361,8403,children,O
PMC42195570_361,8403,and,O
PMC42195570_361,8403,adolescents,O
PMC42195570_361,8403,with,O
PMC42195570_361,8403,an,O
PMC42195570_361,8403,inadequate,O
PMC42195570_361,8403,response,O
PMC42195570_361,8403,to,O
PMC42195570_361,8403,methylphenidate,B-Drug
PMC42195570_361,8403,(,O
PMC42195570_361,8403,MPH,O
PMC42195570_361,8403,),O
PMC42195570_361,8403,treatment,O
PMC42195570_361,8403,",",O
PMC42195570_361,8403,the,O
PMC42195570_361,8403,aim,O
PMC42195570_361,8403,of,O
PMC42195570_361,8403,the,O
PMC42195570_361,8403,present,O
PMC42195570_361,8403,analysis,O
PMC42195570_361,8403,was,O
PMC42195570_361,8403,to,O
PMC42195570_361,8403,establish,O
PMC42195570_361,8403,the,O
PMC42195570_361,8403,response,O
PMC42195570_361,8403,to,O
PMC42195570_361,8403,LDX,B-Drug
PMC42195570_361,8403,in,O
PMC42195570_361,8403,subgroups,O
PMC42195570_361,8403,of,O
PMC42195570_361,8403,patients,O
PMC42195570_361,8403,with,O
PMC42195570_361,8403,different,O
PMC42195570_361,8403,ADHD,B-Disease
PMC42195570_361,8403,medication,O
PMC42195570_361,8403,histories,O
PMC42195570_361,8403,0,O
PMC42196650_888,8404,OBJECTIVE,O
PMC42196650_888,8404,:,O
PMC42196650_888,8404,to,O
PMC42196650_888,8404,evaluate,O
PMC42196650_888,8404,the,O
PMC42196650_888,8404,impact,O
PMC42196650_888,8404,of,O
PMC42196650_888,8404,concomitant,O
PMC42196650_888,8404,administration,O
PMC42196650_888,8404,of,O
PMC42196650_888,8404,CYP,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,number,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,D,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,number,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,_,O
PMC42196650_888,8404,inhibitors,O
PMC42196650_888,8404,or,O
PMC42196650_888,8404,substrates,O
PMC42196650_888,8404,on,O
PMC42196650_888,8404,the,O
PMC42196650_888,8404,efficacy,O
PMC42196650_888,8404,",",O
PMC42196650_888,8404,tolerability,O
PMC42196650_888,8404,and,O
PMC42196650_888,8404,costs,O
PMC42196650_888,8404,of,O
PMC42196650_888,8404,patients,O
PMC42196650_888,8404,treated,O
PMC42196650_888,8404,with,O
PMC42196650_888,8404,venlafaxine,B-Drug
PMC42196650_888,8404,for,O
PMC42196650_888,8404,major,B-Disease
PMC42196650_888,8404,depressive,I-Disease
PMC42196650_888,8404,disorder,I-Disease
PMC42196650_888,8404,in,O
PMC42196650_888,8404,clinical,O
PMC42196650_888,8404,practice,O
PMC42196650_888,8404,0,O
PMC42216030_301,8405,OBJECTIVES,O
PMC42216030_301,8405,:,O
PMC42216030_301,8405,A,O
PMC42216030_301,8405,secondary,O
PMC42216030_301,8405,objective,O
PMC42216030_301,8405,of,O
PMC42216030_301,8405,this,O
PMC42216030_301,8405,head,O
PMC42216030_301,8405,-,O
PMC42216030_301,8405,to,O
PMC42216030_301,8405,-,O
PMC42216030_301,8405,head,O
PMC42216030_301,8405,study,O
PMC42216030_301,8405,of,O
PMC42216030_301,8405,lisdexamfetamine,B-Drug
PMC42216030_301,8405,dimesylate,I-Drug
PMC42216030_301,8405,(,O
PMC42216030_301,8405,LDX,O
PMC42216030_301,8405,),O
PMC42216030_301,8405,and,O
PMC42216030_301,8405,atomoxetine,O
PMC42216030_301,8405,(,O
PMC42216030_301,8405,ATX,O
PMC42216030_301,8405,),O
PMC42216030_301,8405,was,O
PMC42216030_301,8405,to,O
PMC42216030_301,8405,assess,O
PMC42216030_301,8405,treatment,O
PMC42216030_301,8405,response,O
PMC42216030_301,8405,rates,O
PMC42216030_301,8405,in,O
PMC42216030_301,8405,children,O
PMC42216030_301,8405,and,O
PMC42216030_301,8405,adolescents,O
PMC42216030_301,8405,with,O
PMC42216030_301,8405,attention,B-Disease
PMC42216030_301,8405,-,I-Disease
PMC42216030_301,8405,deficit,I-Disease
PMC42216030_301,8405,hyperactivity,I-Disease
PMC42216030_301,8405,disorder,I-Disease
PMC42216030_301,8405,(,O
PMC42216030_301,8405,ADHD,O
PMC42216030_301,8405,),O
PMC42216030_301,8405,and,O
PMC42216030_301,8405,an,O
PMC42216030_301,8405,inadequate,O
PMC42216030_301,8405,response,O
PMC42216030_301,8405,to,O
PMC42216030_301,8405,methylphenidate,B-Drug
PMC42216030_301,8405,(,O
PMC42216030_301,8405,MPH,O
PMC42216030_301,8405,),O
PMC42216030_301,8405,0,O
PMC42216030_97,8406,Treatment,O
PMC42216030_97,8406,response,O
PMC42216030_97,8406,and,O
PMC42216030_97,8406,remission,O
PMC42216030_97,8406,in,O
PMC42216030_97,8406,a,O
PMC42216030_97,8406,double,O
PMC42216030_97,8406,-,O
PMC42216030_97,8406,blind,O
PMC42216030_97,8406,",",O
PMC42216030_97,8406,randomized,O
PMC42216030_97,8406,",",O
PMC42216030_97,8406,head,O
PMC42216030_97,8406,-,O
PMC42216030_97,8406,to,O
PMC42216030_97,8406,-,O
PMC42216030_97,8406,head,O
PMC42216030_97,8406,study,O
PMC42216030_97,8406,of,O
PMC42216030_97,8406,lisdexamfetamine,B-Drug
PMC42216030_97,8406,dimesylate,I-Drug
PMC42216030_97,8406,and,O
PMC42216030_97,8406,atomoxetine,O
PMC42216030_97,8406,in,O
PMC42216030_97,8406,children,O
PMC42216030_97,8406,and,O
PMC42216030_97,8406,adolescents,O
PMC42216030_97,8406,with,O
PMC42216030_97,8406,attention,B-Disease
PMC42216030_97,8406,-,I-Disease
PMC42216030_97,8406,deficit,I-Disease
PMC42216030_97,8406,hyperactivity,I-Disease
PMC42216030_97,8406,disorder,I-Disease
PMC42216030_97,8406,0,O
PMC42235230_259,8407,RESULTS,O
PMC42235230_259,8407,:,O
PMC42235230_259,8407,The,O
PMC42235230_259,8407,primary,O
PMC42235230_259,8407,objective,O
PMC42235230_259,8407,of,O
PMC42235230_259,8407,the,O
PMC42235230_259,8407,study,O
PMC42235230_259,8407,was,O
PMC42235230_259,8407,to,O
PMC42235230_259,8407,assess,O
PMC42235230_259,8407,the,O
PMC42235230_259,8407,objective,O
PMC42235230_259,8407,(,O
PMC42235230_259,8407,polysomnographic,O
PMC42235230_259,8407,),O
PMC42235230_259,8407,changes,B-Symptom
PMC42235230_259,8407,in,I-Symptom
PMC42235230_259,8407,sleep,I-Symptom
PMC42235230_259,8407,quality,I-Symptom
PMC42235230_259,8407,",",O
PMC42235230_259,8407,defined,O
PMC42235230_259,8407,as,O
PMC42235230_259,8407,changes,O
PMC42235230_259,8407,in,O
PMC42235230_259,8407,SWS,B-Symptom
PMC42235230_259,8407,",",O
PMC42235230_259,8407,following,O
PMC42235230_259,8407,olanzapine,B-Drug
PMC42235230_259,8407,treatment,O
PMC42235230_259,8407,for,O
PMC42235230_259,8407,depression,B-Disease
PMC42235230_259,8407,0,O
PMC42235230_463,8408,CONCLUSIONS,O
PMC42235230_463,8408,:,O
PMC42235230_463,8408,Olanzapine,B-Drug
PMC42235230_463,8408,augmentation,O
PMC42235230_463,8408,treatment,O
PMC42235230_463,8408,generally,O
PMC42235230_463,8408,did,O
PMC42235230_463,8408,not,O
PMC42235230_463,8408,improve,O
PMC42235230_463,8408,SWS,B-Symptom
PMC42235230_463,8408,but,O
PMC42235230_463,8408,did,O
PMC42235230_463,8408,improve,O
PMC42235230_463,8408,sleep,B-Symptom
PMC42235230_463,8408,continuity,I-Symptom
PMC42235230_463,8408,and,O
PMC42235230_463,8408,depression,B-Disease
PMC42235230_463,8408,0,O
PMC42235230_605,8409,The,O
PMC42235230_605,8409,effect,O
PMC42235230_605,8409,of,O
PMC42235230_605,8409,olanzapine,B-Drug
PMC42235230_605,8409,augmentation,O
PMC42235230_605,8409,therapy,O
PMC42235230_605,8409,on,O
PMC42235230_605,8409,other,O
PMC42235230_605,8409,features,O
PMC42235230_605,8409,of,O
PMC42235230_605,8409,sleep,O
PMC42235230_605,8409,(,O
PMC42235230_605,8409,e,O
PMC42235230_605,8409,0,O
PMC42235230_605,8410,g,O
PMC42235230_605,8410,0,O
PMC42235230_605,8411,",",O
PMC42235230_605,8411,sleep,B-Symptom
PMC42235230_605,8411,continuity,I-Symptom
PMC42235230_605,8411,),O
PMC42235230_605,8411,and,O
PMC42235230_605,8411,depression,B-Disease
PMC42235230_605,8411,(,O
PMC42235230_605,8411,e,O
PMC42235230_605,8411,0,O
PMC42235230_605,8412,g,O
PMC42235230_605,8412,0,O
PMC42235230_605,8413,",",O
PMC42235230_605,8413,illness,O
PMC42235230_605,8413,severity,O
PMC42235230_605,8413,and,O
PMC42235230_605,8413,cognitive,O
PMC42235230_605,8413,function,O
PMC42235230_605,8413,),O
PMC42235230_605,8413,were,O
PMC42235230_605,8413,also,O
PMC42235230_605,8413,determined,O
PMC42235230_605,8413,0,O
PMC42256180_684,8414,Acute,O
PMC42256180_684,8414,dyskinesia,B-Symptom
PMC42256180_684,8414,",",O
PMC42256180_684,8414,myoclonus,B-Symptom
PMC42256180_684,8414,",",O
PMC42256180_684,8414,and,O
PMC42256180_684,8414,akathisa,B-Symptom
PMC42256180_684,8414,in,O
PMC42256180_684,8414,an,O
PMC42256180_684,8414,adolescent,O
PMC42256180_684,8414,male,O
PMC42256180_684,8414,abusing,O
PMC42256180_684,8414,quetiapine,B-Drug
PMC42256180_684,8414,via,O
PMC42256180_684,8414,nasal,O
PMC42256180_684,8414,insufflation,O
PMC42256180_684,8414,:,O
PMC42256180_684,8414,a,O
PMC42256180_684,8414,case,O
PMC42256180_684,8414,study,O
PMC42256180_684,8414,0,O
PMC42266670_243,8415,CUSP,O
PMC42266670_243,8415,_,O
PMC42266670_243,8415,_,O
PMC42266670_243,8415,number,O
PMC42266670_243,8415,_,O
PMC42266670_243,8415,_,O
PMC42266670_243,8415,*,O
PMC42266670_243,8415,treatment,O
PMC42266670_243,8415,protocol,O
PMC42266670_243,8415,for,O
PMC42266670_243,8415,recurrent,O
PMC42266670_243,8415,glioblastoma,B-Disease
PMC42266670_243,8415,:,O
PMC42266670_243,8415,aprepitant,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,artesunate,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,auranofin,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,captopril,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,celecoxib,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,disulfiram,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,itraconazole,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,ritonavir,O
PMC42266670_243,8415,",",O
PMC42266670_243,8415,sertraline,B-Drug
PMC42266670_243,8415,augmenting,O
PMC42266670_243,8415,continuous,O
PMC42266670_243,8415,low,O
PMC42266670_243,8415,dose,O
PMC42266670_243,8415,temozolomide,O
PMC42266670_243,8415,0,O
PMC42271150_184,8416,Based,O
PMC42271150_184,8416,on,O
PMC42271150_184,8416,sample,O
PMC42271150_184,8416,size,O
PMC42271150_184,8416,estimation,O
PMC42271150_184,8416,",",O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,number,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,patients,O
PMC42271150_184,8416,aged,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,number,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,years,O
PMC42271150_184,8416,with,O
PMC42271150_184,8416,psychosis,O
PMC42271150_184,8416,",",O
PMC42271150_184,8416,antipsychotic,O
PMC42271150_184,8416,-,O
PMC42271150_184,8416,nave,O
PMC42271150_184,8416,or,O
PMC42271150_184,8416,treated,O
PMC42271150_184,8416,for,O
PMC42271150_184,8416,a,O
PMC42271150_184,8416,limited,O
PMC42271150_184,8416,period,O
PMC42271150_184,8416,are,O
PMC42271150_184,8416,",",O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,number,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,:,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,number,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,randomised,O
PMC42271150_184,8416,to,O
PMC42271150_184,8416,a,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,number,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,_,O
PMC42271150_184,8416,-,O
PMC42271150_184,8416,week,O
PMC42271150_184,8416,",",O
PMC42271150_184,8416,double,O
PMC42271150_184,8416,-,O
PMC42271150_184,8416,blind,O
PMC42271150_184,8416,intervention,O
PMC42271150_184,8416,with,O
PMC42271150_184,8416,quetiapine,B-Drug
PMC42271150_184,8416,versus,O
PMC42271150_184,8416,aripiprazole,O
PMC42271150_184,8416,0,O
PMC42273480_482,8417,The,O
PMC42273480_482,8417,child,O
PMC42273480_482,8417,was,O
PMC42273480_482,8417,diagnosed,O
PMC42273480_482,8417,by,O
PMC42273480_482,8417,the,O
PMC42273480_482,8417,healthcare,O
PMC42273480_482,8417,center,O
PMC42273480_482,8417,with,O
PMC42273480_482,8417,depressive,B-Disease
PMC42273480_482,8417,disorder,I-Disease
PMC42273480_482,8417,and,O
PMC42273480_482,8417,behavioral,O
PMC42273480_482,8417,disorder,O
PMC42273480_482,8417,",",O
PMC42273480_482,8417,and,O
PMC42273480_482,8417,was,O
PMC42273480_482,8417,medicated,O
PMC42273480_482,8417,with,O
PMC42273480_482,8417,sertraline,B-Drug
PMC42273480_482,8417,and,O
PMC42273480_482,8417,risperidone,O
PMC42273480_482,8417,0,O
PMC42279080_656,8418,In,O
PMC42279080_656,8418,this,O
PMC42279080_656,8418,case,O
PMC42279080_656,8418,",",O
PMC42279080_656,8418,a,O
PMC42279080_656,8418,primary,O
PMC42279080_656,8418,care,O
PMC42279080_656,8418,patient,O
PMC42279080_656,8418,on,O
PMC42279080_656,8418,buprenorphine,B-Drug
PMC42279080_656,8418,/,O
PMC42279080_656,8418,naloxone,O
PMC42279080_656,8418,maintenance,O
PMC42279080_656,8418,therapy,O
PMC42279080_656,8418,demonstrating,O
PMC42279080_656,8418,altered,O
PMC42279080_656,8418,mental,O
PMC42279080_656,8418,status,O
PMC42279080_656,8418,",",O
PMC42279080_656,8418,hallucinations,B-Symptom
PMC42279080_656,8418,",",O
PMC42279080_656,8418,falls,B-Symptom
PMC42279080_656,8418,",",O
PMC42279080_656,8418,and,O
PMC42279080_656,8418,rebound,O
PMC42279080_656,8418,hypertension,O
PMC42279080_656,8418,was,O
PMC42279080_656,8418,found,O
PMC42279080_656,8418,to,O
PMC42279080_656,8418,be,O
PMC42279080_656,8418,concomitantly,O
PMC42279080_656,8418,abusing,O
PMC42279080_656,8418,clonidine,O
PMC42279080_656,8418,and,O
PMC42279080_656,8418,amitryptyline,O
PMC42279080_656,8418,",",O
PMC42279080_656,8418,which,O
PMC42279080_656,8418,share,O
PMC42279080_656,8418,metabolic,O
PMC42279080_656,8418,pathways,O
PMC42279080_656,8418,with,O
PMC42279080_656,8418,buprenorphine,O
PMC42279080_656,8418,0,O
PMC42290630_714,8419,RESULTS,O
PMC42290630_714,8419,:,O
PMC42290630_714,8419,Among,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,number,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,patients,O
PMC42290630_714,8419,who,O
PMC42290630_714,8419,developed,O
PMC42290630_714,8419,delirium,B-Symptom
PMC42290630_714,8419,",",O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,number,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,patients,O
PMC42290630_714,8419,received,O
PMC42290630_714,8419,antipsychotics,O
PMC42290630_714,8419,",",O
PMC42290630_714,8419,such,O
PMC42290630_714,8419,as,O
PMC42290630_714,8419,risperidone,O
PMC42290630_714,8419,(,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,number,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,%,O
PMC42290630_714,8419,),O
PMC42290630_714,8419,",",O
PMC42290630_714,8419,quetiapine,B-Drug
PMC42290630_714,8419,(,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,number,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,%,O
PMC42290630_714,8419,),O
PMC42290630_714,8419,",",O
PMC42290630_714,8419,and,O
PMC42290630_714,8419,parenteral,O
PMC42290630_714,8419,haloperidol,O
PMC42290630_714,8419,(,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,number,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,_,O
PMC42290630_714,8419,%,O
PMC42290630_714,8419,),O
PMC42290630_714,8419,",",O
PMC42290630_714,8419,for,O
PMC42290630_714,8419,delirium,B-Symptom
PMC42290630_714,8419,0,O
PMC42327330_814,8420,The,O
PMC42327330_814,8420,aim,O
PMC42327330_814,8420,of,O
PMC42327330_814,8420,the,O
PMC42327330_814,8420,present,O
PMC42327330_814,8420,study,O
PMC42327330_814,8420,was,O
PMC42327330_814,8420,to,O
PMC42327330_814,8420,investigate,O
PMC42327330_814,8420,if,O
PMC42327330_814,8420,the,O
PMC42327330_814,8420,insulin,O
PMC42327330_814,8420,-,O
PMC42327330_814,8420,like,O
PMC42327330_814,8420,growth,O
PMC42327330_814,8420,factor,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,number,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,receptor,O
PMC42327330_814,8420,(,O
PMC42327330_814,8420,IGF,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,number,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,_,O
PMC42327330_814,8420,R,O
PMC42327330_814,8420,),O
PMC42327330_814,8420,signaling,O
PMC42327330_814,8420,pathway,O
PMC42327330_814,8420,was,O
PMC42327330_814,8420,activated,O
PMC42327330_814,8420,or,O
PMC42327330_814,8420,deregulated,O
PMC42327330_814,8420,in,O
PMC42327330_814,8420,breast,B-Disease
PMC42327330_814,8420,cancer,I-Disease
PMC42327330_814,8420,patients,O
PMC42327330_814,8420,and,O
PMC42327330_814,8420,to,O
PMC42327330_814,8420,explore,O
PMC42327330_814,8420,if,O
PMC42327330_814,8420,any,O
PMC42327330_814,8420,of,O
PMC42327330_814,8420,the,O
PMC42327330_814,8420,markers,O
PMC42327330_814,8420,were,O
PMC42327330_814,8420,prognostic,O
PMC42327330_814,8420,",",O
PMC42327330_814,8420,with,O
PMC42327330_814,8420,or,O
PMC42327330_814,8420,without,O
PMC42327330_814,8420,adjuvant,O
PMC42327330_814,8420,tamoxifen,B-Drug
PMC42327330_814,8420,0,O
PMC42397300_1031,8421,A,O
PMC42397300_1031,8421,total,O
PMC42397300_1031,8421,of,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,number,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,unmedicated,O
PMC42397300_1031,8421,patients,O
PMC42397300_1031,8421,with,O
PMC42397300_1031,8421,major,B-Disease
PMC42397300_1031,8421,depression,I-Disease
PMC42397300_1031,8421,all,O
PMC42397300_1031,8421,met,O
PMC42397300_1031,8421,the,O
PMC42397300_1031,8421,diagnostic,O
PMC42397300_1031,8421,criteria,O
PMC42397300_1031,8421,of,O
PMC42397300_1031,8421,stagnation,O
PMC42397300_1031,8421,of,O
PMC42397300_1031,8421,liver,O
PMC42397300_1031,8421,qi,O
PMC42397300_1031,8421,of,O
PMC42397300_1031,8421,traditional,O
PMC42397300_1031,8421,Chinese,O
PMC42397300_1031,8421,medicine,O
PMC42397300_1031,8421,and,O
PMC42397300_1031,8421,were,O
PMC42397300_1031,8421,divided,O
PMC42397300_1031,8421,into,O
PMC42397300_1031,8421,two,O
PMC42397300_1031,8421,groups,O
PMC42397300_1031,8421,:,O
PMC42397300_1031,8421,CHSGS,O
PMC42397300_1031,8421,group,O
PMC42397300_1031,8421,(,O
PMC42397300_1031,8421,n,O
PMC42397300_1031,8421,=,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,number,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,),O
PMC42397300_1031,8421,and,O
PMC42397300_1031,8421,fluoxetine,B-Drug
PMC42397300_1031,8421,group,O
PMC42397300_1031,8421,(,O
PMC42397300_1031,8421,n,O
PMC42397300_1031,8421,=,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,number,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,_,O
PMC42397300_1031,8421,),O
PMC42397300_1031,8421,0,O
PMC42410920_277,8422,Flesinoxan,O
PMC42410920_277,8422,",",O
PMC42410920_277,8422,duloxetine,B-Drug
PMC42410920_277,8422,",",O
PMC42410920_277,8422,ondansetron,O
PMC42410920_277,8422,",",O
PMC42410920_277,8422,but,O
PMC42410920_277,8422,not,O
PMC42410920_277,8422,escitalopram,O
PMC42410920_277,8422,or,O
PMC42410920_277,8422,SB,O
PMC42410920_277,8422,_,O
PMC42410920_277,8422,_,O
PMC42410920_277,8422,number,O
PMC42410920_277,8422,_,O
PMC42410920_277,8422,_,O
PMC42410920_277,8422,-,O
PMC42410920_277,8422,A,O
PMC42410920_277,8422,increased,O
PMC42410920_277,8422,wakefulness,B-Symptom
PMC42410920_277,8422,0,O
PMC42437242_126,8423,Similarly,O
PMC42437242_126,8423,",",O
PMC42437242_126,8423,in,O
PMC42437242_126,8423,unipolar,O
PMC42437242_126,8423,depression,B-Disease
PMC42437242_126,8423,",",O
PMC42437242_126,8423,only,O
PMC42437242_126,8423,quetiapine,B-Drug
PMC42437242_126,8423,has,O
PMC42437242_126,8423,been,O
PMC42437242_126,8423,shown,O
PMC42437242_126,8423,to,O
PMC42437242_126,8423,be,O
PMC42437242_126,8423,effective,O
PMC42437242_126,8423,in,O
PMC42437242_126,8423,monotherapy,O
PMC42437242_126,8423,0,O
PMC42461270_542,8424,BACKGROUND,O
PMC42461270_542,8424,:,O
PMC42461270_542,8424,The,O
PMC42461270_542,8424,stimulant,O
PMC42461270_542,8424,prodrug,O
PMC42461270_542,8424,lisdexamfetamine,B-Drug
PMC42461270_542,8424,dimesylate,I-Drug
PMC42461270_542,8424,(,O
PMC42461270_542,8424,LDX,O
PMC42461270_542,8424,),O
PMC42461270_542,8424,is,O
PMC42461270_542,8424,an,O
PMC42461270_542,8424,effective,O
PMC42461270_542,8424,and,O
PMC42461270_542,8424,generally,O
PMC42461270_542,8424,well,O
PMC42461270_542,8424,tolerated,O
PMC42461270_542,8424,treatment,O
PMC42461270_542,8424,for,O
PMC42461270_542,8424,the,O
PMC42461270_542,8424,symptoms,O
PMC42461270_542,8424,of,O
PMC42461270_542,8424,attention,B-Disease
PMC42461270_542,8424,-,I-Disease
PMC42461270_542,8424,deficit,I-Disease
PMC42461270_542,8424,/,I-Disease
PMC42461270_542,8424,hyperactivity,I-Disease
PMC42461270_542,8424,disorder,I-Disease
PMC42461270_542,8424,(,O
PMC42461270_542,8424,ADHD,O
PMC42461270_542,8424,),O
PMC42461270_542,8424,0,O
PMC42470010_69,8425,Tamoxifen,B-Drug
PMC42470010_69,8425,(,O
PMC42470010_69,8425,TAM,O
PMC42470010_69,8425,),O
PMC42470010_69,8425,is,O
PMC42470010_69,8425,the,O
PMC42470010_69,8425,mainline,O
PMC42470010_69,8425,drug,O
PMC42470010_69,8425,treatment,O
PMC42470010_69,8425,for,O
PMC42470010_69,8425,breast,B-Disease
PMC42470010_69,8425,cancer,I-Disease
PMC42470010_69,8425,",",O
PMC42470010_69,8425,despite,O
PMC42470010_69,8425,its,O
PMC42470010_69,8425,side,O
PMC42470010_69,8425,effects,O
PMC42470010_69,8425,and,O
PMC42470010_69,8425,the,O
PMC42470010_69,8425,development,O
PMC42470010_69,8425,of,O
PMC42470010_69,8425,resistance,O
PMC42470010_69,8425,0,O
PMC42511690_532,8426,Paramedics,O
PMC42511690_532,8426,were,O
PMC42511690_532,8426,trained,O
PMC42511690_532,8426,to,O
PMC42511690_532,8426,identify,O
PMC42511690_532,8426,",",O
PMC42511690_532,8426,consent,O
PMC42511690_532,8426,and,O
PMC42511690_532,8426,deliver,O
PMC42511690_532,8426,a,O
PMC42511690_532,8426,first,O
PMC42511690_532,8426,dose,O
PMC42511690_532,8426,of,O
PMC42511690_532,8426,lisinopril,B-Drug
PMC42511690_532,8426,or,O
PMC42511690_532,8426,placebo,O
PMC42511690_532,8426,to,O
PMC42511690_532,8426,adults,O
PMC42511690_532,8426,with,O
PMC42511690_532,8426,suspected,O
PMC42511690_532,8426,stroke,B-Symptom
PMC42511690_532,8426,and,O
PMC42511690_532,8426,hypertension,O
PMC42511690_532,8426,while,O
PMC42511690_532,8426,responding,O
PMC42511690_532,8426,to,O
PMC42511690_532,8426,the,O
PMC42511690_532,8426,emergency,O
PMC42511690_532,8426,call,O
PMC42511690_532,8426,0,O
PMC42571050_700,8427,Lisdexamfetamine,B-Drug
PMC42571050_700,8427,dimesylate,I-Drug
PMC42571050_700,8427,(,O
PMC42571050_700,8427,LDX,O
PMC42571050_700,8427,),O
PMC42571050_700,8427,is,O
PMC42571050_700,8427,approved,O
PMC42571050_700,8427,as,O
PMC42571050_700,8427,a,O
PMC42571050_700,8427,once,O
PMC42571050_700,8427,-,O
PMC42571050_700,8427,daily,O
PMC42571050_700,8427,treatment,O
PMC42571050_700,8427,for,O
PMC42571050_700,8427,attention,B-Disease
PMC42571050_700,8427,-,I-Disease
PMC42571050_700,8427,deficit,I-Disease
PMC42571050_700,8427,/,I-Disease
PMC42571050_700,8427,hyperactivity,I-Disease
PMC42571050_700,8427,disorder,I-Disease
PMC42571050_700,8427,in,O
PMC42571050_700,8427,children,O
PMC42571050_700,8427,",",O
PMC42571050_700,8427,adolescents,O
PMC42571050_700,8427,",",O
PMC42571050_700,8427,and,O
PMC42571050_700,8427,adults,O
PMC42571050_700,8427,in,O
PMC42571050_700,8427,some,O
PMC42571050_700,8427,countries,O
PMC42571050_700,8427,0,O
PMC42599880_1029,8428,Fluoxetine,B-Drug
PMC42599880_1029,8428,is,O
PMC42599880_1029,8428,the,O
PMC42599880_1029,8428,only,O
PMC42599880_1029,8428,psychopharmacological,O
PMC42599880_1029,8428,agent,O
PMC42599880_1029,8428,approved,O
PMC42599880_1029,8428,for,O
PMC42599880_1029,8428,depression,B-Disease
PMC42599880_1029,8428,by,O
PMC42599880_1029,8428,the,O
PMC42599880_1029,8428,US,O
PMC42599880_1029,8428,Food,O
PMC42599880_1029,8428,and,O
PMC42599880_1029,8428,Drug,O
PMC42599880_1029,8428,Administration,O
PMC42599880_1029,8428,for,O
PMC42599880_1029,8428,children,O
PMC42599880_1029,8428,and,O
PMC42599880_1029,8428,is,O
PMC42599880_1029,8428,commonly,O
PMC42599880_1029,8428,used,O
PMC42599880_1029,8428,therapeutically,O
PMC42599880_1029,8428,in,O
PMC42599880_1029,8428,a,O
PMC42599880_1029,8428,variety,O
PMC42599880_1029,8428,of,O
PMC42599880_1029,8428,neurodevelopmental,O
PMC42599880_1029,8428,disorders,O
PMC42599880_1029,8428,0,O
PMC42640870_113,8429,Hyponatremia,B-Symptom
PMC42640870_113,8429,is,O
PMC42640870_113,8429,a,O
PMC42640870_113,8429,known,O
PMC42640870_113,8429,adverse,O
PMC42640870_113,8429,effect,O
PMC42640870_113,8429,of,O
PMC42640870_113,8429,duloxetine,B-Drug
PMC42640870_113,8429,",",O
PMC42640870_113,8429,and,O
PMC42640870_113,8429,it,O
PMC42640870_113,8429,can,O
PMC42640870_113,8429,lead,O
PMC42640870_113,8429,to,O
PMC42640870_113,8429,potentially,O
PMC42640870_113,8429,life,O
PMC42640870_113,8429,-,O
PMC42640870_113,8429,threatening,O
PMC42640870_113,8429,complications,O
PMC42640870_113,8429,0,O
PMC42640880_790,8430,She,O
PMC42640880_790,8430,was,O
PMC42640880_790,8430,earlier,O
PMC42640880_790,8430,treated,O
PMC42640880_790,8430,with,O
PMC42640880_790,8430,Cap,O
PMC42640880_790,8430,venlafaxine,B-Drug
PMC42640880_790,8430,up,O
PMC42640880_790,8430,to,O
PMC42640880_790,8430,_,O
PMC42640880_790,8430,_,O
PMC42640880_790,8430,number,O
PMC42640880_790,8430,_,O
PMC42640880_790,8430,_,O
PMC42640880_790,8430,mg,O
PMC42640880_790,8430,/,O
PMC42640880_790,8430,day,O
PMC42640880_790,8430,",",O
PMC42640880_790,8430,but,O
PMC42640880_790,8430,had,O
PMC42640880_790,8430,a,O
PMC42640880_790,8430,relapse,O
PMC42640880_790,8430,of,O
PMC42640880_790,8430,depressive,B-Symptom
PMC42640880_790,8430,symptoms,I-Symptom
PMC42640880_790,8430,when,O
PMC42640880_790,8430,an,O
PMC42640880_790,8430,attempt,O
PMC42640880_790,8430,was,O
PMC42640880_790,8430,made,O
PMC42640880_790,8430,to,O
PMC42640880_790,8430,taper,O
PMC42640880_790,8430,off,O
PMC42640880_790,8430,venlafaxine,O
PMC42640880_790,8430,0,O
PMC42655400_506,8431,Persistent,O
PMC42655400_506,8431,genital,O
PMC42655400_506,8431,arousal,O
PMC42655400_506,8431,disorder,O
PMC42655400_506,8431,:,O
PMC42655400_506,8431,confluent,O
PMC42655400_506,8431,patient,O
PMC42655400_506,8431,history,O
PMC42655400_506,8431,of,O
PMC42655400_506,8431,agitated,B-Symptom
PMC42655400_506,8431,depression,B-Disease
PMC42655400_506,8431,",",O
PMC42655400_506,8431,paroxetine,B-Drug
PMC42655400_506,8431,cessation,O
PMC42655400_506,8431,",",O
PMC42655400_506,8431,and,O
PMC42655400_506,8431,a,O
PMC42655400_506,8431,tarlov,O
PMC42655400_506,8431,cyst,O
PMC42655400_506,8431,0,O
PMC42669510_687,8432,Case,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,number,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,is,O
PMC42669510_687,8432,that,O
PMC42669510_687,8432,of,O
PMC42669510_687,8432,an,O
PMC42669510_687,8432,immunocompetent,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,number,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,_,O
PMC42669510_687,8432,-,O
PMC42669510_687,8432,year,O
PMC42669510_687,8432,-,O
PMC42669510_687,8432,old,O
PMC42669510_687,8432,Japanese,O
PMC42669510_687,8432,woman,O
PMC42669510_687,8432,with,O
PMC42669510_687,8432,MAC,O
PMC42669510_687,8432,lung,O
PMC42669510_687,8432,disease,O
PMC42669510_687,8432,",",O
PMC42669510_687,8432,who,O
PMC42669510_687,8432,was,O
PMC42669510_687,8432,treated,O
PMC42669510_687,8432,with,O
PMC42669510_687,8432,a,O
PMC42669510_687,8432,combined,O
PMC42669510_687,8432,therapy,O
PMC42669510_687,8432,of,O
PMC42669510_687,8432,clarithromycin,O
PMC42669510_687,8432,",",O
PMC42669510_687,8432,rifampicin,O
PMC42669510_687,8432,",",O
PMC42669510_687,8432,ethambutol,O
PMC42669510_687,8432,",",O
PMC42669510_687,8432,and,O
PMC42669510_687,8432,levofloxacin,B-Drug
PMC42669510_687,8432,0,O
PMC42717880_880,8433,In,O
PMC42717880_880,8433,patients,O
PMC42717880_880,8433,with,O
PMC42717880_880,8433,nonsquamous,O
PMC42717880_880,8433,NSCLC,B-Disease
PMC42717880_880,8433,",",O
PMC42717880_880,8433,the,O
PMC42717880_880,8433,incremental,O
PMC42717880_880,8433,cost,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,effectiveness,O
PMC42717880_880,8433,ratios,O
PMC42717880_880,8433,(,O
PMC42717880_880,8433,ICERs,O
PMC42717880_880,8433,),O
PMC42717880_880,8433,per,O
PMC42717880_880,8433,life,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,year,O
PMC42717880_880,8433,gained,O
PMC42717880_880,8433,(,O
PMC42717880_880,8433,LYG,O
PMC42717880_880,8433,),O
PMC42717880_880,8433,were,O
PMC42717880_880,8433,$,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,number,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,number,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,$,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,number,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,number,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,and,O
PMC42717880_880,8433,more,O
PMC42717880_880,8433,than,O
PMC42717880_880,8433,$,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,number,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,number,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,_,O
PMC42717880_880,8433,for,O
PMC42717880_880,8433,cisplatin,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,pemetrexed,O
PMC42717880_880,8433,compared,O
PMC42717880_880,8433,with,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,respectively,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,cisplatin,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,gemcitabine,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,cisplatin,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,carboplatin,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,paclitaxel,O
PMC42717880_880,8433,",",O
PMC42717880_880,8433,and,O
PMC42717880_880,8433,carboplatin,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,paclitaxel,O
PMC42717880_880,8433,-,O
PMC42717880_880,8433,bevacizumab,B-Drug
PMC42717880_880,8433,0,O
PMC42743370_575,8434,Low,O
PMC42743370_575,8434,-,O
PMC42743370_575,8434,dose,O
PMC42743370_575,8434,paroxetine,B-Drug
PMC42743370_575,8434,(,O
PMC42743370_575,8434,_,O
PMC42743370_575,8434,_,O
PMC42743370_575,8434,number,O
PMC42743370_575,8434,_,O
PMC42743370_575,8434,_,O
PMC42743370_575,8434,mg,O
PMC42743370_575,8434,),O
PMC42743370_575,8434,improves,O
PMC42743370_575,8434,sleep,O
PMC42743370_575,8434,in,O
PMC42743370_575,8434,women,O
PMC42743370_575,8434,with,O
PMC42743370_575,8434,vasomotor,O
PMC42743370_575,8434,symptoms,O
PMC42743370_575,8434,associated,O
PMC42743370_575,8434,with,O
PMC42743370_575,8434,menopause,B-Symptom
PMC42743370_575,8434,0,O
PMC42743370_990,8435,Paroxetine,B-Drug
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,number,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,mg,O
PMC42743370_990,8435,treatment,O
PMC42743370_990,8435,also,O
PMC42743370_990,8435,significantly,O
PMC42743370_990,8435,increased,O
PMC42743370_990,8435,nighttime,O
PMC42743370_990,8435,sleep,O
PMC42743370_990,8435,duration,O
PMC42743370_990,8435,(,O
PMC42743370_990,8435,week,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,number,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,",",O
PMC42743370_990,8435,+,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,number,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,vs,O
PMC42743370_990,8435,+,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,number,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,min,O
PMC42743370_990,8435,for,O
PMC42743370_990,8435,placebo,O
PMC42743370_990,8435,;,O
PMC42743370_990,8435,P,O
PMC42743370_990,8435,=,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,number,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,_,O
PMC42743370_990,8435,),O
PMC42743370_990,8435,",",O
PMC42743370_990,8435,but,O
PMC42743370_990,8435,no,O
PMC42743370_990,8435,significant,O
PMC42743370_990,8435,between,O
PMC42743370_990,8435,-,O
PMC42743370_990,8435,group,O
PMC42743370_990,8435,differences,O
PMC42743370_990,8435,in,O
PMC42743370_990,8435,sleep,O
PMC42743370_990,8435,-,O
PMC42743370_990,8435,onset,O
PMC42743370_990,8435,latency,O
PMC42743370_990,8435,or,O
PMC42743370_990,8435,sleep,O
PMC42743370_990,8435,-,O
PMC42743370_990,8435,related,O
PMC42743370_990,8435,adverse,O
PMC42743370_990,8435,events,O
PMC42743370_990,8435,such,O
PMC42743370_990,8435,as,O
PMC42743370_990,8435,sedation,B-Symptom
PMC42743370_990,8435,were,O
PMC42743370_990,8435,observed,O
PMC42743370_990,8435,0,O
PMC42745490_696,8436,The,O
PMC42745490_696,8436,aim,O
PMC42745490_696,8436,of,O
PMC42745490_696,8436,this,O
PMC42745490_696,8436,study,O
PMC42745490_696,8436,was,O
PMC42745490_696,8436,to,O
PMC42745490_696,8436,evaluate,O
PMC42745490_696,8436,the,O
PMC42745490_696,8436,effects,O
PMC42745490_696,8436,of,O
PMC42745490_696,8436,intracerebroventricular,O
PMC42745490_696,8436,of,O
PMC42745490_696,8436,venlafaxine,B-Drug
PMC42745490_696,8436,on,O
PMC42745490_696,8436,the,O
PMC42745490_696,8436,morphine,O
PMC42745490_696,8436,dependence,O
PMC42745490_696,8436,and,O
PMC42745490_696,8436,pain,B-Symptom
PMC42745490_696,8436,perception,O
PMC42745490_696,8436,0,O
PMC42764850_934,8437,Zonisamide,O
PMC42764850_934,8437,",",O
PMC42764850_934,8437,topiramate,B-Drug
PMC42764850_934,8437,",",O
PMC42764850_934,8437,and,O
PMC42764850_934,8437,levetiracetam,O
PMC42764850_934,8437,:,O
PMC42764850_934,8437,efficacy,O
PMC42764850_934,8437,and,O
PMC42764850_934,8437,neuropsychological,O
PMC42764850_934,8437,effects,O
PMC42764850_934,8437,in,O
PMC42764850_934,8437,alcohol,B-Disease
PMC42764850_934,8437,use,I-Disease
PMC42764850_934,8437,disorders,I-Disease
PMC42764850_934,8437,0,O
PMC42776080_923,8438,A,O
PMC42776080_923,8438,case,O
PMC42776080_923,8438,of,O
PMC42776080_923,8438,Ventricular,B-Symptom
PMC42776080_923,8438,Tachycardia,I-Symptom
PMC42776080_923,8438,and,O
PMC42776080_923,8438,Cardiac,B-Symptom
PMC42776080_923,8438,Arrest,I-Symptom
PMC42776080_923,8438,Associated,O
PMC42776080_923,8438,with,O
PMC42776080_923,8438,Sertraline,B-Drug
PMC42776080_923,8438,and,O
PMC42776080_923,8438,Mirtazapine,O
PMC42776080_923,8438,Combination,O
PMC42776080_923,8438,0,O
PMC42804630_239,8439,Because,O
PMC42804630_239,8439,of,O
PMC42804630_239,8439,an,O
PMC42804630_239,8439,incomplete,O
PMC42804630_239,8439,recovery,O
PMC42804630_239,8439,of,O
PMC42804630_239,8439,her,O
PMC42804630_239,8439,visual,B-Symptom
PMC42804630_239,8439,functions,I-Symptom
PMC42804630_239,8439,",",O
PMC42804630_239,8439,diarrhoea,B-Symptom
PMC42804630_239,8439,and,O
PMC42804630_239,8439,general,O
PMC42804630_239,8439,malaise,O
PMC42804630_239,8439,",",O
PMC42804630_239,8439,melphalan,B-Drug
PMC42804630_239,8439,",",O
PMC42804630_239,8439,followed,O
PMC42804630_239,8439,by,O
PMC42804630_239,8439,autologous,O
PMC42804630_239,8439,peripheral,O
PMC42804630_239,8439,blood,O
PMC42804630_239,8439,stem,O
PMC42804630_239,8439,cell,O
PMC42804630_239,8439,transplantation,O
PMC42804630_239,8439,",",O
PMC42804630_239,8439,was,O
PMC42804630_239,8439,initiated,O
PMC42804630_239,8439,0,O
PMC42852740_155,8440,Endophthalmitis,B-Symptom
PMC42852740_155,8440,outbreak,O
PMC42852740_155,8440,associated,O
PMC42852740_155,8440,with,O
PMC42852740_155,8440,repackaged,O
PMC42852740_155,8440,bevacizumab,B-Drug
PMC42852740_155,8440,0,O
PMC42866990_186,8441,OBJECTIVES,O
PMC42866990_186,8441,:,O
PMC42866990_186,8441,To,O
PMC42866990_186,8441,investigate,O
PMC42866990_186,8441,the,O
PMC42866990_186,8441,appropriate,O
PMC42866990_186,8441,dose,O
PMC42866990_186,8441,and,O
PMC42866990_186,8441,interval,O
PMC42866990_186,8441,for,O
PMC42866990_186,8441,the,O
PMC42866990_186,8441,administration,O
PMC42866990_186,8441,of,O
PMC42866990_186,8441,triamcinolone,B-Drug
PMC42866990_186,8441,acetonide,O
PMC42866990_186,8441,(,O
PMC42866990_186,8441,TA,O
PMC42866990_186,8441,),O
PMC42866990_186,8441,in,O
PMC42866990_186,8441,treating,O
PMC42866990_186,8441,tendinopathy,B-Disease
PMC42866990_186,8441,to,O
PMC42866990_186,8441,avoid,O
PMC42866990_186,8441,adverse,O
PMC42866990_186,8441,effects,O
PMC42866990_186,8441,such,O
PMC42866990_186,8441,as,O
PMC42866990_186,8441,tendon,O
PMC42866990_186,8441,degeneration,O
PMC42866990_186,8441,and,O
PMC42866990_186,8441,rupture,O
PMC42866990_186,8441,0,O
PMC42931720_720,8442,Several,O
PMC42931720_720,8442,studies,O
PMC42931720_720,8442,have,O
PMC42931720_720,8442,suggested,O
PMC42931720_720,8442,that,O
PMC42931720_720,8442,antiepileptic,O
PMC42931720_720,8442,drugs,O
PMC42931720_720,8442,",",O
PMC42931720_720,8442,such,O
PMC42931720_720,8442,as,O
PMC42931720_720,8442,gabapentin,O
PMC42931720_720,8442,and,O
PMC42931720_720,8442,lamotrigine,B-Drug
PMC42931720_720,8442,",",O
PMC42931720_720,8442,may,O
PMC42931720_720,8442,be,O
PMC42931720_720,8442,effective,O
PMC42931720_720,8442,in,O
PMC42931720_720,8442,the,O
PMC42931720_720,8442,treatment,O
PMC42931720_720,8442,of,O
PMC42931720_720,8442,PTSD,O
PMC42931720_720,8442,symptoms,O
PMC42931720_720,8442,0,O
PMC42939180_396,8443,Progression,O
PMC42939180_396,8443,to,O
PMC42939180_396,8443,macula,O
PMC42939180_396,8443,-,O
PMC42939180_396,8443,off,O
PMC42939180_396,8443,tractional,O
PMC42939180_396,8443,retinal,B-Symptom
PMC42939180_396,8443,detachment,I-Symptom
PMC42939180_396,8443,after,O
PMC42939180_396,8443,a,O
PMC42939180_396,8443,contralateral,O
PMC42939180_396,8443,intraoperative,O
PMC42939180_396,8443,intravitreal,O
PMC42939180_396,8443,bevacizumab,B-Drug
PMC42939180_396,8443,injection,O
PMC42939180_396,8443,for,O
PMC42939180_396,8443,proliferative,O
PMC42939180_396,8443,diabetic,O
PMC42939180_396,8443,retinopathy,O
PMC42939180_396,8443,0,O
PMC42950550_744,8444,We,O
PMC42950550_744,8444,evaluated,O
PMC42950550_744,8444,demographic,O
PMC42950550_744,8444,data,O
PMC42950550_744,8444,",",O
PMC42950550_744,8444,disease,O
PMC42950550_744,8444,entities,O
PMC42950550_744,8444,",",O
PMC42950550_744,8444,duration,O
PMC42950550_744,8444,of,O
PMC42950550_744,8444,topiramate,B-Drug
PMC42950550_744,8444,administration,O
PMC42950550_744,8444,",",O
PMC42950550_744,8444,initial,O
PMC42950550_744,8444,and,O
PMC42950550_744,8444,subsequent,O
PMC42950550_744,8444,dosage,O
PMC42950550_744,8444,adjustment,O
PMC42950550_744,8444,",",O
PMC42950550_744,8444,concomitant,O
PMC42950550_744,8444,AEDs,O
PMC42950550_744,8444,",",O
PMC42950550_744,8444,the,O
PMC42950550_744,8444,frequency,O
PMC42950550_744,8444,of,O
PMC42950550_744,8444,seizure,B-Symptom
PMC42950550_744,8444,reduction,O
PMC42950550_744,8444,",",O
PMC42950550_744,8444,and,O
PMC42950550_744,8444,adverse,O
PMC42950550_744,8444,events,O
PMC42950550_744,8444,0,O
PMC42969600_73,8445,METHODS,O
PMC42969600_73,8445,:,O
PMC42969600_73,8445,Pooled,O
PMC42969600_73,8445,data,O
PMC42969600_73,8445,were,O
PMC42969600_73,8445,analyzed,O
PMC42969600_73,8445,from,O
PMC42969600_73,8445,four,O
PMC42969600_73,8445,randomized,O
PMC42969600_73,8445,",",O
PMC42969600_73,8445,double,O
PMC42969600_73,8445,-,O
PMC42969600_73,8445,blind,O
PMC42969600_73,8445,",",O
PMC42969600_73,8445,placebo,O
PMC42969600_73,8445,-,O
PMC42969600_73,8445,controlled,O
PMC42969600_73,8445,studies,O
PMC42969600_73,8445,that,O
PMC42969600_73,8445,compared,O
PMC42969600_73,8445,duloxetine,B-Drug
PMC42969600_73,8445,at,O
PMC42969600_73,8445,the,O
PMC42969600_73,8445,dose,O
PMC42969600_73,8445,range,O
PMC42969600_73,8445,approved,O
PMC42969600_73,8445,in,O
PMC42969600_73,8445,Japan,O
PMC42969600_73,8445,(,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,number,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,mg,O
PMC42969600_73,8445,/,O
PMC42969600_73,8445,day,O
PMC42969600_73,8445,),O
PMC42969600_73,8445,with,O
PMC42969600_73,8445,other,O
PMC42969600_73,8445,SSRIs,O
PMC42969600_73,8445,(,O
PMC42969600_73,8445,paroxetine,B-Drug
PMC42969600_73,8445,_,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,number,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,mg,O
PMC42969600_73,8445,/,O
PMC42969600_73,8445,day,O
PMC42969600_73,8445,or,O
PMC42969600_73,8445,escitalopram,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,number,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,_,O
PMC42969600_73,8445,mg,O
PMC42969600_73,8445,/,O
PMC42969600_73,8445,day,O
PMC42969600_73,8445,),O
PMC42969600_73,8445,and,O
PMC42969600_73,8445,placebo,O
PMC42969600_73,8445,in,O
PMC42969600_73,8445,patients,O
PMC42969600_73,8445,with,O
PMC42969600_73,8445,major,B-Disease
PMC42969600_73,8445,depressive,I-Disease
PMC42969600_73,8445,disorder,I-Disease
PMC42969600_73,8445,0,O
PMC43004320_648,8446,RESULTS,O
PMC43004320_648,8446,:,O
PMC43004320_648,8446,These,O
PMC43004320_648,8446,adjustments,O
PMC43004320_648,8446,were,O
PMC43004320_648,8446,applied,O
PMC43004320_648,8446,to,O
PMC43004320_648,8446,data,O
PMC43004320_648,8446,from,O
PMC43004320_648,8446,a,O
PMC43004320_648,8446,randomized,O
PMC43004320_648,8446,double,O
PMC43004320_648,8446,-,O
PMC43004320_648,8446,blind,O
PMC43004320_648,8446,concurrent,O
PMC43004320_648,8446,trial,O
PMC43004320_648,8446,(,O
PMC43004320_648,8446,SPD,O
PMC43004320_648,8446,_,O
PMC43004320_648,8446,_,O
PMC43004320_648,8446,number,O
PMC43004320_648,8446,_,O
PMC43004320_648,8446,_,O
PMC43004320_648,8446,),O
PMC43004320_648,8446,that,O
PMC43004320_648,8446,established,O
PMC43004320_648,8446,the,O
PMC43004320_648,8446,efficacy,O
PMC43004320_648,8446,and,O
PMC43004320_648,8446,safety,O
PMC43004320_648,8446,of,O
PMC43004320_648,8446,lisdexamfetamine,B-Drug
PMC43004320_648,8446,dimesylate,I-Drug
PMC43004320_648,8446,(,O
PMC43004320_648,8446,LDX,O
PMC43004320_648,8446,),O
PMC43004320_648,8446,in,O
PMC43004320_648,8446,children,O
PMC43004320_648,8446,and,O
PMC43004320_648,8446,adolescents,O
PMC43004320_648,8446,with,O
PMC43004320_648,8446,attention,B-Disease
PMC43004320_648,8446,-,I-Disease
PMC43004320_648,8446,deficit,I-Disease
PMC43004320_648,8446,/,I-Disease
PMC43004320_648,8446,hyperactivity,I-Disease
PMC43004320_648,8446,disorder,I-Disease
PMC43004320_648,8446,(,O
PMC43004320_648,8446,ADHD,O
PMC43004320_648,8446,),O
PMC43004320_648,8446,0,O
PMC43015270_151,8447,The,O
PMC43015270_151,8447,findings,O
PMC43015270_151,8447,reveal,O
PMC43015270_151,8447,a,O
PMC43015270_151,8447,novel,O
PMC43015270_151,8447,potential,O
PMC43015270_151,8447,strategy,O
PMC43015270_151,8447,against,O
PMC43015270_151,8447,pancreatic,B-Disease
PMC43015270_151,8447,cancer,I-Disease
PMC43015270_151,8447,using,O
PMC43015270_151,8447,co,O
PMC43015270_151,8447,-,O
PMC43015270_151,8447,treatment,O
PMC43015270_151,8447,with,O
PMC43015270_151,8447,tamoxifen,B-Drug
PMC43015270_151,8447,plus,O
PMC43015270_151,8447,cantharidin,O
PMC43015270_151,8447,or,O
PMC43015270_151,8447,cantharidin,O
PMC43015270_151,8447,derivatives,O
PMC43015270_151,8447,0,O
PMC43024690_137,8448,Conjunctival,O
PMC43024690_137,8448,necrosis,B-Symptom
PMC43024690_137,8448,following,O
PMC43024690_137,8448,a,O
PMC43024690_137,8448,subconjunctival,O
PMC43024690_137,8448,injection,O
PMC43024690_137,8448,of,O
PMC43024690_137,8448,triamcinolone,B-Drug
PMC43024690_137,8448,acetonide,O
PMC43024690_137,8448,in,O
PMC43024690_137,8448,a,O
PMC43024690_137,8448,child,O
PMC43024690_137,8448,0,O
PMC43025310_725,8449,Topiramate,B-Drug
PMC43025310_725,8449,(,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,number,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,mg,O
PMC43025310_725,8449,/,O
PMC43025310_725,8449,d,O
PMC43025310_725,8449,),O
PMC43025310_725,8449,was,O
PMC43025310_725,8449,more,O
PMC43025310_725,8449,effective,O
PMC43025310_725,8449,than,O
PMC43025310_725,8449,placebo,O
PMC43025310_725,8449,in,O
PMC43025310_725,8449,terms,O
PMC43025310_725,8449,of,O
PMC43025310_725,8449,the,O
PMC43025310_725,8449,change,O
PMC43025310_725,8449,in,O
PMC43025310_725,8449,mean,O
PMC43025310_725,8449,monthly,O
PMC43025310_725,8449,migraine,O
PMC43025310_725,8449,days,O
PMC43025310_725,8449,(,O
PMC43025310_725,8449,MD,O
PMC43025310_725,8449,:,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,number,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,",",O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,number,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,%,O
PMC43025310_725,8449,CI,O
PMC43025310_725,8449,:,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,number,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,to,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,number,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,",",O
PMC43025310_725,8449,P,O
PMC43025310_725,8449,<,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,number,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,_,O
PMC43025310_725,8449,),O
PMC43025310_725,8449,0,O
PMC43073640_244,8450,CONCLUSION,O
PMC43073640_244,8450,:,O
PMC43073640_244,8450,No,O
PMC43073640_244,8450,significant,O
PMC43073640_244,8450,difference,O
PMC43073640_244,8450,between,O
PMC43073640_244,8450,cinnarizine,O
PMC43073640_244,8450,and,O
PMC43073640_244,8450,topiramate,B-Drug
PMC43073640_244,8450,was,O
PMC43073640_244,8450,found,O
PMC43073640_244,8450,for,O
PMC43073640_244,8450,the,O
PMC43073640_244,8450,prevention,O
PMC43073640_244,8450,of,O
PMC43073640_244,8450,pediatric,O
PMC43073640_244,8450,migraines,O
PMC43073640_244,8450,0,O
PMC43078850_71,8451,BACKGROUND,O
PMC43078850_71,8451,:,O
PMC43078850_71,8451,The,O
PMC43078850_71,8451,aim,O
PMC43078850_71,8451,of,O
PMC43078850_71,8451,the,O
PMC43078850_71,8451,present,O
PMC43078850_71,8451,analysis,O
PMC43078850_71,8451,was,O
PMC43078850_71,8451,to,O
PMC43078850_71,8451,evaluate,O
PMC43078850_71,8451,the,O
PMC43078850_71,8451,recurrence,O
PMC43078850_71,8451,pattern,O
PMC43078850_71,8451,in,O
PMC43078850_71,8451,patients,O
PMC43078850_71,8451,with,O
PMC43078850_71,8451,recurrent,O
PMC43078850_71,8451,malignant,O
PMC43078850_71,8451,glioma,B-Disease
PMC43078850_71,8451,after,O
PMC43078850_71,8451,re,O
PMC43078850_71,8451,-,O
PMC43078850_71,8451,irradiation,O
PMC43078850_71,8451,in,O
PMC43078850_71,8451,combination,O
PMC43078850_71,8451,with,O
PMC43078850_71,8451,bevacizumab,B-Drug
PMC43078850_71,8451,as,O
PMC43078850_71,8451,there,O
PMC43078850_71,8451,is,O
PMC43078850_71,8451,limited,O
PMC43078850_71,8451,data,O
PMC43078850_71,8451,on,O
PMC43078850_71,8451,how,O
PMC43078850_71,8451,to,O
PMC43078850_71,8451,optimally,O
PMC43078850_71,8451,choose,O
PMC43078850_71,8451,dose,O
PMC43078850_71,8451,",",O
PMC43078850_71,8451,fractionation,O
PMC43078850_71,8451,and,O
PMC43078850_71,8451,delineation,O
PMC43078850_71,8451,margins,O
PMC43078850_71,8451,0,O
PMC43079660_365,8452,Probable,O
PMC43079660_365,8452,topiramate,B-Drug
PMC43079660_365,8452,-,O
PMC43079660_365,8452,induced,O
PMC43079660_365,8452,diarrhea,B-Symptom
PMC43079660_365,8452,in,O
PMC43079660_365,8452,a,O
PMC43079660_365,8452,_,O
PMC43079660_365,8452,_,O
PMC43079660_365,8452,number,O
PMC43079660_365,8452,_,O
PMC43079660_365,8452,_,O
PMC43079660_365,8452,-,O
PMC43079660_365,8452,month,O
PMC43079660_365,8452,-,O
PMC43079660_365,8452,old,O
PMC43079660_365,8452,breast,O
PMC43079660_365,8452,-,O
PMC43079660_365,8452,fed,O
PMC43079660_365,8452,child,O
PMC43079660_365,8452,-,O
PMC43079660_365,8452,A,O
PMC43079660_365,8452,case,O
PMC43079660_365,8452,report,O
PMC43079660_365,8452,0,O
PMC43079660_808,8453,Diarrhea,B-Symptom
PMC43079660_808,8453,is,O
PMC43079660_808,8453,a,O
PMC43079660_808,8453,well,O
PMC43079660_808,8453,-,O
PMC43079660_808,8453,known,O
PMC43079660_808,8453,adverse,O
PMC43079660_808,8453,reaction,O
PMC43079660_808,8453,to,O
PMC43079660_808,8453,topiramate,B-Drug
PMC43079660_808,8453,and,O
PMC43079660_808,8453,has,O
PMC43079660_808,8453,the,O
PMC43079660_808,8453,potential,O
PMC43079660_808,8453,to,O
PMC43079660_808,8453,cause,O
PMC43079660_808,8453,serious,O
PMC43079660_808,8453,electrolyte,O
PMC43079660_808,8453,disturbances,O
PMC43079660_808,8453,in,O
PMC43079660_808,8453,neonates,O
PMC43079660_808,8453,and,O
PMC43079660_808,8453,infants,O
PMC43079660_808,8453,0,O
PMC43079810_642,8454,A,O
PMC43079810_642,8454,multicenter,O
PMC43079810_642,8454,",",O
PMC43079810_642,8454,randomized,O
PMC43079810_642,8454,clinical,O
PMC43079810_642,8454,trial,O
PMC43079810_642,8454,comparing,O
PMC43079810_642,8454,the,O
PMC43079810_642,8454,three,O
PMC43079810_642,8454,-,O
PMC43079810_642,8454,weekly,O
PMC43079810_642,8454,docetaxel,B-Drug
PMC43079810_642,8454,regimen,O
PMC43079810_642,8454,plus,O
PMC43079810_642,8454,prednisone,O
PMC43079810_642,8454,versus,O
PMC43079810_642,8454,mitoxantone,O
PMC43079810_642,8454,plus,O
PMC43079810_642,8454,prednisone,O
PMC43079810_642,8454,for,O
PMC43079810_642,8454,Chinese,O
PMC43079810_642,8454,patients,O
PMC43079810_642,8454,with,O
PMC43079810_642,8454,metastatic,B-Disease
PMC43079810_642,8454,castration,I-Disease
PMC43079810_642,8454,refractory,I-Disease
PMC43079810_642,8454,prostate,I-Disease
PMC43079810_642,8454,cancer,I-Disease
PMC43079810_642,8454,0,O
PMC43079810_797,8455,PURPOSE,O
PMC43079810_797,8455,:,O
PMC43079810_797,8455,To,O
PMC43079810_797,8455,explore,O
PMC43079810_797,8455,the,O
PMC43079810_797,8455,feasibility,O
PMC43079810_797,8455,and,O
PMC43079810_797,8455,efficacy,O
PMC43079810_797,8455,of,O
PMC43079810_797,8455,docetaxel,B-Drug
PMC43079810_797,8455,plus,O
PMC43079810_797,8455,prednisone,B-Drug
PMC43079810_797,8455,for,O
PMC43079810_797,8455,Chinese,O
PMC43079810_797,8455,population,O
PMC43079810_797,8455,with,O
PMC43079810_797,8455,metastatic,B-Disease
PMC43079810_797,8455,castration,I-Disease
PMC43079810_797,8455,refractory,I-Disease
PMC43079810_797,8455,prostate,I-Disease
PMC43079810_797,8455,cancer,I-Disease
PMC43079810_797,8455,(,O
PMC43079810_797,8455,mCRPC,O
PMC43079810_797,8455,),O
PMC43079810_797,8455,0,O
PMC43080210_591,8456,Docetaxel,B-Drug
PMC43080210_591,8456,",",O
PMC43080210_591,8456,the,O
PMC43080210_591,8456,chemotherapeutic,O
PMC43080210_591,8456,used,O
PMC43080210_591,8456,for,O
PMC43080210_591,8456,this,O
PMC43080210_591,8456,experiment,O
PMC43080210_591,8456,",",O
PMC43080210_591,8456,caused,O
PMC43080210_591,8456,significant,O
PMC43080210_591,8456,metabolic,O
PMC43080210_591,8456,changes,O
PMC43080210_591,8456,in,O
PMC43080210_591,8456,amino,O
PMC43080210_591,8456,acid,O
PMC43080210_591,8456,and,O
PMC43080210_591,8456,carbohydrate,O
PMC43080210_591,8456,metabolism,O
PMC43080210_591,8456,in,O
PMC43080210_591,8456,ovarian,B-Disease
PMC43080210_591,8456,cancer,I-Disease
PMC43080210_591,8456,cells,O
PMC43080210_591,8456,",",O
PMC43080210_591,8456,but,O
PMC43080210_591,8456,had,O
PMC43080210_591,8456,virtually,O
PMC43080210_591,8456,no,O
PMC43080210_591,8456,metabolic,O
PMC43080210_591,8456,effect,O
PMC43080210_591,8456,on,O
PMC43080210_591,8456,isogenic,O
PMC43080210_591,8456,ovarian,O
PMC43080210_591,8456,cancer,O
PMC43080210_591,8456,stem,O
PMC43080210_591,8456,cells,O
PMC43080210_591,8456,0,O
PMC43097850_602,8457,They,O
PMC43097850_602,8457,also,O
PMC43097850_602,8457,highlight,O
PMC43097850_602,8457,the,O
PMC43097850_602,8457,potential,O
PMC43097850_602,8457,mediating,O
PMC43097850_602,8457,role,O
PMC43097850_602,8457,of,O
PMC43097850_602,8457,treatment,O
PMC43097850_602,8457,with,O
PMC43097850_602,8457,duloxetine,B-Drug
PMC43097850_602,8457,on,O
PMC43097850_602,8457,the,O
PMC43097850_602,8457,negative,O
PMC43097850_602,8457,relationship,O
PMC43097850_602,8457,between,O
PMC43097850_602,8457,depression,B-Disease
PMC43097850_602,8457,-,O
PMC43097850_602,8457,related,O
PMC43097850_602,8457,pain,B-Symptom
PMC43097850_602,8457,and,O
PMC43097850_602,8457,outcomes,O
PMC43097850_602,8457,of,O
PMC43097850_602,8457,depression,B-Disease
PMC43097850_602,8457,0,O
PMC43102650_958,8458,Efficacy,O
PMC43102650_958,8458,of,O
PMC43102650_958,8458,adjunctive,O
PMC43102650_958,8458,treatments,O
PMC43102650_958,8458,added,O
PMC43102650_958,8458,to,O
PMC43102650_958,8458,olanzapine,B-Drug
PMC43102650_958,8458,or,O
PMC43102650_958,8458,clozapine,O
PMC43102650_958,8458,for,O
PMC43102650_958,8458,weight,O
PMC43102650_958,8458,control,O
PMC43102650_958,8458,in,O
PMC43102650_958,8458,patients,O
PMC43102650_958,8458,with,O
PMC43102650_958,8458,schizophrenia,B-Disease
PMC43102650_958,8458,:,O
PMC43102650_958,8458,a,O
PMC43102650_958,8458,systematic,O
PMC43102650_958,8458,review,O
PMC43102650_958,8458,and,O
PMC43102650_958,8458,meta,O
PMC43102650_958,8458,-,O
PMC43102650_958,8458,analysis,O
PMC43102650_958,8458,0,O
PMC43109200_486,8459,Clozapine,O
PMC43109200_486,8459,and,O
PMC43109200_486,8459,olanzapine,B-Drug
PMC43109200_486,8459,were,O
PMC43109200_486,8459,superior,O
PMC43109200_486,8459,in,O
PMC43109200_486,8459,terms,O
PMC43109200_486,8459,of,O
PMC43109200_486,8459,akathisia,B-Symptom
PMC43109200_486,8459,and,O
PMC43109200_486,8459,extrapyramidal,B-Symptom
PMC43109200_486,8459,symptom,I-Symptom
PMC43109200_486,8459,risk,O
PMC43109200_486,8459,",",O
PMC43109200_486,8459,but,O
PMC43109200_486,8459,",",O
PMC43109200_486,8459,far,O
PMC43109200_486,8459,more,O
PMC43109200_486,8459,prone,O
PMC43109200_486,8459,to,O
PMC43109200_486,8459,induce,O
PMC43109200_486,8459,clinically,O
PMC43109200_486,8459,important,O
PMC43109200_486,8459,weight,B-Symptom
PMC43109200_486,8459,gain,I-Symptom
PMC43109200_486,8459,0,O
PMC43137590_225,8460,However,O
PMC43137590_225,8460,",",O
PMC43137590_225,8460,allergology,O
PMC43137590_225,8460,workup,O
PMC43137590_225,8460,ruled,O
PMC43137590_225,8460,out,O
PMC43137590_225,8460,an,O
PMC43137590_225,8460,allergic,O
PMC43137590_225,8460,etiology,O
PMC43137590_225,8460,as,O
PMC43137590_225,8460,well,O
PMC43137590_225,8460,as,O
PMC43137590_225,8460,mastocytosis,O
PMC43137590_225,8460,",",O
PMC43137590_225,8460,and,O
PMC43137590_225,8460,hypotension,B-Symptom
PMC43137590_225,8460,recalcitrant,O
PMC43137590_225,8460,to,O
PMC43137590_225,8460,treatment,O
PMC43137590_225,8460,was,O
PMC43137590_225,8460,attributed,O
PMC43137590_225,8460,to,O
PMC43137590_225,8460,uninterrupted,O
PMC43137590_225,8460,lisinopril,B-Drug
PMC43137590_225,8460,therapy,O
PMC43137590_225,8460,0,O
PMC43195270_279,8461,For,O
PMC43195270_279,8461,prostate,B-Disease
PMC43195270_279,8461,cancer,I-Disease
PMC43195270_279,8461,patients,O
PMC43195270_279,8461,",",O
PMC43195270_279,8461,several,O
PMC43195270_279,8461,phase,O
PMC43195270_279,8461,I,O
PMC43195270_279,8461,and,O
PMC43195270_279,8461,II,O
PMC43195270_279,8461,clinical,O
PMC43195270_279,8461,trials,O
PMC43195270_279,8461,have,O
PMC43195270_279,8461,shown,O
PMC43195270_279,8461,that,O
PMC43195270_279,8461,combined,O
PMC43195270_279,8461,(,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,number,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,),O
PMC43195270_279,8461,Sm,O
PMC43195270_279,8461,-,O
PMC43195270_279,8461,EDTMP,O
PMC43195270_279,8461,and,O
PMC43195270_279,8461,docetaxel,B-Drug
PMC43195270_279,8461,-,O
PMC43195270_279,8461,based,O
PMC43195270_279,8461,chemotherapy,O
PMC43195270_279,8461,can,O
PMC43195270_279,8461,result,O
PMC43195270_279,8461,in,O
PMC43195270_279,8461,>,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,number,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,_,O
PMC43195270_279,8461,%,O
PMC43195270_279,8461,decrease,O
PMC43195270_279,8461,in,O
PMC43195270_279,8461,prostate,O
PMC43195270_279,8461,-,O
PMC43195270_279,8461,specific,O
PMC43195270_279,8461,antigen,O
PMC43195270_279,8461,with,O
PMC43195270_279,8461,manageable,O
PMC43195270_279,8461,myelosuppression,B-Symptom
PMC43195270_279,8461,0,O
PMC43239600_378,8462,Sertraline,B-Drug
PMC43239600_378,8462,has,O
PMC43239600_378,8462,been,O
PMC43239600_378,8462,found,O
PMC43239600_378,8462,to,O
PMC43239600_378,8462,be,O
PMC43239600_378,8462,effective,O
PMC43239600_378,8462,in,O
PMC43239600_378,8462,the,O
PMC43239600_378,8462,treatment,O
PMC43239600_378,8462,of,O
PMC43239600_378,8462,depression,B-Disease
PMC43239600_378,8462,with,O
PMC43239600_378,8462,significant,O
PMC43239600_378,8462,improvement,O
PMC43239600_378,8462,in,O
PMC43239600_378,8462,QOL,O
PMC43239600_378,8462,in,O
PMC43239600_378,8462,TBI,O
PMC43239600_378,8462,patients,O
PMC43239600_378,8462,0,O
PMC43239600_913,8463,Role,O
PMC43239600_913,8463,of,O
PMC43239600_913,8463,sertraline,B-Drug
PMC43239600_913,8463,in,O
PMC43239600_913,8463,posttraumatic,O
PMC43239600_913,8463,brain,O
PMC43239600_913,8463,injury,O
PMC43239600_913,8463,depression,B-Disease
PMC43239600_913,8463,and,O
PMC43239600_913,8463,quality,O
PMC43239600_913,8463,-,O
PMC43239600_913,8463,of,O
PMC43239600_913,8463,-,O
PMC43239600_913,8463,life,O
PMC43239600_913,8463,in,O
PMC43239600_913,8463,TBI,O
PMC43239600_913,8463,0,O
PMC43449820_543,8464,In,O
PMC43449820_543,8464,view,O
PMC43449820_543,8464,of,O
PMC43449820_543,8464,this,O
PMC43449820_543,8464,clinical,O
PMC43449820_543,8464,picture,O
PMC43449820_543,8464,a,O
PMC43449820_543,8464,provisional,O
PMC43449820_543,8464,diagnosis,O
PMC43449820_543,8464,of,O
PMC43449820_543,8464,angioedema,B-Symptom
PMC43449820_543,8464,secondary,O
PMC43449820_543,8464,to,O
PMC43449820_543,8464,Lisinopril,B-Drug
PMC43449820_543,8464,was,O
PMC43449820_543,8464,made,O
PMC43449820_543,8464,and,O
PMC43449820_543,8464,it,O
PMC43449820_543,8464,was,O
PMC43449820_543,8464,discontinued,O
PMC43449820_543,8464,0,O
PMC43459900_621,8465,This,O
PMC43459900_621,8465,study,O
PMC43459900_621,8465,evaluated,O
PMC43459900_621,8465,the,O
PMC43459900_621,8465,safety,O
PMC43459900_621,8465,and,O
PMC43459900_621,8465,effectiveness,O
PMC43459900_621,8465,of,O
PMC43459900_621,8465,paroxetine,B-Drug
PMC43459900_621,8465,controlled,O
PMC43459900_621,8465,-,O
PMC43459900_621,8465,release,O
PMC43459900_621,8465,(,O
PMC43459900_621,8465,CR,O
PMC43459900_621,8465,),O
PMC43459900_621,8465,tablets,O
PMC43459900_621,8465,in,O
PMC43459900_621,8465,Japanese,O
PMC43459900_621,8465,patients,O
PMC43459900_621,8465,with,O
PMC43459900_621,8465,depression,B-Disease
PMC43459900_621,8465,/,O
PMC43459900_621,8465,depressive,O
PMC43459900_621,8465,state,O
PMC43459900_621,8465,(,O
PMC43459900_621,8465,hereafter,O
PMC43459900_621,8465,referred,O
PMC43459900_621,8465,to,O
PMC43459900_621,8465,as,O
PMC43459900_621,8465,depression,B-Disease
PMC43459900_621,8465,),O
PMC43459900_621,8465,in,O
PMC43459900_621,8465,routine,O
PMC43459900_621,8465,clinical,O
PMC43459900_621,8465,practice,O
PMC43459900_621,8465,in,O
PMC43459900_621,8465,Japan,O
PMC43459900_621,8465,0,O
PMC43481430_756,8466,The,O
PMC43481430_756,8466,first,O
PMC43481430_756,8466,-,O
PMC43481430_756,8466,line,O
PMC43481430_756,8466,maintenance,O
PMC43481430_756,8466,treatment,O
PMC43481430_756,8466,following,O
PMC43481430_756,8466,mania,O
PMC43481430_756,8466,or,O
PMC43481430_756,8466,depression,B-Disease
PMC43481430_756,8466,was,O
PMC43481430_756,8466,MS,O
PMC43481430_756,8466,monotherapy,O
PMC43481430_756,8466,or,O
PMC43481430_756,8466,MS,O
PMC43481430_756,8466,plus,O
PMC43481430_756,8466,AAP,O
PMC43481430_756,8466,;,O
PMC43481430_756,8466,the,O
PMC43481430_756,8466,first,O
PMC43481430_756,8466,-,O
PMC43481430_756,8466,line,O
PMC43481430_756,8466,treatment,O
PMC43481430_756,8466,after,O
PMC43481430_756,8466,mania,O
PMC43481430_756,8466,was,O
PMC43481430_756,8466,AAP,O
PMC43481430_756,8466,monotherapy,O
PMC43481430_756,8466,;,O
PMC43481430_756,8466,and,O
PMC43481430_756,8466,the,O
PMC43481430_756,8466,first,O
PMC43481430_756,8466,-,O
PMC43481430_756,8466,line,O
PMC43481430_756,8466,treatment,O
PMC43481430_756,8466,after,O
PMC43481430_756,8466,depression,B-Disease
PMC43481430_756,8466,was,O
PMC43481430_756,8466,lamotrigine,B-Drug
PMC43481430_756,8466,(,O
PMC43481430_756,8466,LTG,O
PMC43481430_756,8466,),O
PMC43481430_756,8466,monotherapy,O
PMC43481430_756,8466,",",O
PMC43481430_756,8466,LTG,B-Drug
PMC43481430_756,8466,plus,O
PMC43481430_756,8466,MS,O
PMC43481430_756,8466,/,O
PMC43481430_756,8466,AAP,O
PMC43481430_756,8466,",",O
PMC43481430_756,8466,or,O
PMC43481430_756,8466,MS,O
PMC43481430_756,8466,plus,O
PMC43481430_756,8466,AAP,O
PMC43481430_756,8466,plus,O
PMC43481430_756,8466,LTG,B-Drug
PMC43481430_756,8466,0,O
PMC43483550_545,8467,Venlafaxine,B-Drug
PMC43483550_545,8467,may,O
PMC43483550_545,8467,infrequently,O
PMC43483550_545,8467,induce,O
PMC43483550_545,8467,hypertensive,B-Symptom
PMC43483550_545,8467,crisis,I-Symptom
PMC43483550_545,8467,0,O
PMC43532760_509,8468,The,O
PMC43532760_509,8468,adjusted,O
PMC43532760_509,8468,hazard,O
PMC43532760_509,8468,ratios,O
PMC43532760_509,8468,for,O
PMC43532760_509,8468,attempted,B-Symptom
PMC43532760_509,8468,suicide,I-Symptom
PMC43532760_509,8468,or,O
PMC43532760_509,8468,self,O
PMC43532760_509,8468,harm,O
PMC43532760_509,8468,were,O
PMC43532760_509,8468,significantly,O
PMC43532760_509,8468,increased,O
PMC43532760_509,8468,for,O
PMC43532760_509,8468,three,O
PMC43532760_509,8468,of,O
PMC43532760_509,8468,the,O
PMC43532760_509,8468,most,O
PMC43532760_509,8468,commonly,O
PMC43532760_509,8468,prescribed,O
PMC43532760_509,8468,drugs,O
PMC43532760_509,8468,compared,O
PMC43532760_509,8468,with,O
PMC43532760_509,8468,citalopram,B-Drug
PMC43532760_509,8468,:,O
PMC43532760_509,8468,venlafaxine,B-Drug
PMC43532760_509,8468,(,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,to,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,),O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,trazodone,B-Drug
PMC43532760_509,8468,(,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,to,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,),O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,and,O
PMC43532760_509,8468,mirtazapine,O
PMC43532760_509,8468,(,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,to,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,),O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,and,O
PMC43532760_509,8468,significantly,O
PMC43532760_509,8468,reduced,O
PMC43532760_509,8468,for,O
PMC43532760_509,8468,amitriptyline,O
PMC43532760_509,8468,(,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,",",O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,to,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,number,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,_,O
PMC43532760_509,8468,),O
PMC43532760_509,8468,0,O
PMC43532760_644,8469,Mirtazapine,O
PMC43532760_644,8469,",",O
PMC43532760_644,8469,venlafaxine,B-Drug
PMC43532760_644,8469,",",O
PMC43532760_644,8469,and,O
PMC43532760_644,8469,trazodone,O
PMC43532760_644,8469,were,O
PMC43532760_644,8469,associated,O
PMC43532760_644,8469,with,O
PMC43532760_644,8469,the,O
PMC43532760_644,8469,highest,O
PMC43532760_644,8469,rates,O
PMC43532760_644,8469,of,O
PMC43532760_644,8469,suicide,B-Symptom
PMC43532760_644,8469,and,O
PMC43532760_644,8469,attempted,B-Symptom
PMC43532760_644,8469,suicide,I-Symptom
PMC43532760_644,8469,or,O
PMC43532760_644,8469,self,O
PMC43532760_644,8469,harm,O
PMC43532760_644,8469,",",O
PMC43532760_644,8469,but,O
PMC43532760_644,8469,the,O
PMC43532760_644,8469,number,O
PMC43532760_644,8469,of,O
PMC43532760_644,8469,suicide,O
PMC43532760_644,8469,events,O
PMC43532760_644,8469,was,O
PMC43532760_644,8469,small,O
PMC43532760_644,8469,leading,O
PMC43532760_644,8469,to,O
PMC43532760_644,8469,imprecise,O
PMC43532760_644,8469,estimates,O
PMC43532760_644,8469,0,O
PMC43560470_432,8470,This,O
PMC43560470_432,8470,is,O
PMC43560470_432,8470,the,O
PMC43560470_432,8470,second,O
PMC43560470_432,8470,case,O
PMC43560470_432,8470,report,O
PMC43560470_432,8470,to,O
PMC43560470_432,8470,identify,O
PMC43560470_432,8470,olanzapine,B-Drug
PMC43560470_432,8470,as,O
PMC43560470_432,8470,a,O
PMC43560470_432,8470,causative,O
PMC43560470_432,8470,agent,O
PMC43560470_432,8470,in,O
PMC43560470_432,8470,eosinophilic,O
PMC43560470_432,8470,pleural,O
PMC43560470_432,8470,effusion,O
PMC43560470_432,8470,0,O
PMC43562690_336,8471,Tamoxifen,B-Drug
PMC43562690_336,8471,has,O
PMC43562690_336,8471,been,O
PMC43562690_336,8471,prescribed,O
PMC43562690_336,8471,to,O
PMC43562690_336,8471,millions,O
PMC43562690_336,8471,of,O
PMC43562690_336,8471,females,O
PMC43562690_336,8471,for,O
PMC43562690_336,8471,breast,B-Disease
PMC43562690_336,8471,cancer,I-Disease
PMC43562690_336,8471,prevention,O
PMC43562690_336,8471,or,O
PMC43562690_336,8471,treatment,O
PMC43562690_336,8471,0,O
PMC43570720_972,8472,Relative,O
PMC43570720_972,8472,efficacy,O
PMC43570720_972,8472,of,O
PMC43570720_972,8472,pimecrolimus,O
PMC43570720_972,8472,cream,O
PMC43570720_972,8472,and,O
PMC43570720_972,8472,triamcinolone,B-Drug
PMC43570720_972,8472,acetonide,O
PMC43570720_972,8472,paste,O
PMC43570720_972,8472,in,O
PMC43570720_972,8472,the,O
PMC43570720_972,8472,treatment,O
PMC43570720_972,8472,of,O
PMC43570720_972,8472,symptomatic,O
PMC43570720_972,8472,oral,O
PMC43570720_972,8472,lichen,B-Disease
PMC43570720_972,8472,planus,I-Disease
PMC43570720_972,8472,0,O
PMC43644710_661,8473,Comparison,O
PMC43644710_661,8473,of,O
PMC43644710_661,8473,therapeutic,O
PMC43644710_661,8473,effects,O
PMC43644710_661,8473,of,O
PMC43644710_661,8473,omega,O
PMC43644710_661,8473,_,O
PMC43644710_661,8473,_,O
PMC43644710_661,8473,number,O
PMC43644710_661,8473,_,O
PMC43644710_661,8473,_,O
PMC43644710_661,8473,and,O
PMC43644710_661,8473,methylphenidate,B-Drug
PMC43644710_661,8473,(,O
PMC43644710_661,8473,ritalin,B-Drug
PMC43644710_661,8473,(,O
PMC43644710_661,8473,),O
PMC43644710_661,8473,),O
PMC43644710_661,8473,in,O
PMC43644710_661,8473,treating,O
PMC43644710_661,8473,children,O
PMC43644710_661,8473,with,O
PMC43644710_661,8473,attention,B-Disease
PMC43644710_661,8473,deficit,I-Disease
PMC43644710_661,8473,hyperactivity,I-Disease
PMC43644710_661,8473,disorder,I-Disease
PMC43644710_661,8473,0,O
PMC43644710_893,8474,This,O
PMC43644710_893,8474,study,O
PMC43644710_893,8474,was,O
PMC43644710_893,8474,designed,O
PMC43644710_893,8474,to,O
PMC43644710_893,8474,evaluate,O
PMC43644710_893,8474,and,O
PMC43644710_893,8474,compare,O
PMC43644710_893,8474,the,O
PMC43644710_893,8474,therapeutic,O
PMC43644710_893,8474,effects,O
PMC43644710_893,8474,of,O
PMC43644710_893,8474,two,O
PMC43644710_893,8474,drugs,O
PMC43644710_893,8474,",",O
PMC43644710_893,8474,that,O
PMC43644710_893,8474,is,O
PMC43644710_893,8474,",",O
PMC43644710_893,8474,omega,O
PMC43644710_893,8474,_,O
PMC43644710_893,8474,_,O
PMC43644710_893,8474,number,O
PMC43644710_893,8474,_,O
PMC43644710_893,8474,_,O
PMC43644710_893,8474,and,O
PMC43644710_893,8474,methylphenidate,B-Drug
PMC43644710_893,8474,hydrochloride,O
PMC43644710_893,8474,(,O
PMC43644710_893,8474,Ritalin,B-Drug
PMC43644710_893,8474,(,O
PMC43644710_893,8474,),O
PMC43644710_893,8474,),O
PMC43644710_893,8474,",",O
PMC43644710_893,8474,used,O
PMC43644710_893,8474,to,O
PMC43644710_893,8474,treat,O
PMC43644710_893,8474,patients,O
PMC43644710_893,8474,with,O
PMC43644710_893,8474,ADHD,B-Disease
PMC43644710_893,8474,0,O
PMC43646430_105,8475,Typology,O
PMC43646430_105,8475,of,O
PMC43646430_105,8475,patients,O
PMC43646430_105,8475,with,O
PMC43646430_105,8475,fibromyalgia,B-Disease
PMC43646430_105,8475,:,O
PMC43646430_105,8475,cluster,O
PMC43646430_105,8475,analysis,O
PMC43646430_105,8475,of,O
PMC43646430_105,8475,duloxetine,B-Drug
PMC43646430_105,8475,study,O
PMC43646430_105,8475,patients,O
PMC43646430_105,8475,0,O
PMC43649760_357,8476,GPU,O
PMC43649760_357,8476,-,O
PMC43649760_357,8476,accelerated,O
PMC43649760_357,8476,compartmental,O
PMC43649760_357,8476,modeling,O
PMC43649760_357,8476,analysis,O
PMC43649760_357,8476,of,O
PMC43649760_357,8476,DCE,O
PMC43649760_357,8476,-,O
PMC43649760_357,8476,MRI,O
PMC43649760_357,8476,data,O
PMC43649760_357,8476,from,O
PMC43649760_357,8476,glioblastoma,B-Disease
PMC43649760_357,8476,patients,O
PMC43649760_357,8476,treated,O
PMC43649760_357,8476,with,O
PMC43649760_357,8476,bevacizumab,B-Drug
PMC43649760_357,8476,0,O
PMC43688950_699,8477,CONCLUSION,O
PMC43688950_699,8477,:,O
PMC43688950_699,8477,The,O
PMC43688950_699,8477,results,O
PMC43688950_699,8477,of,O
PMC43688950_699,8477,this,O
PMC43688950_699,8477,study,O
PMC43688950_699,8477,suggest,O
PMC43688950_699,8477,that,O
PMC43688950_699,8477,duloxetine,B-Drug
PMC43688950_699,8477,may,O
PMC43688950_699,8477,provide,O
PMC43688950_699,8477,a,O
PMC43688950_699,8477,significant,O
PMC43688950_699,8477,reduction,O
PMC43688950_699,8477,in,O
PMC43688950_699,8477,symptoms,O
PMC43688950_699,8477,for,O
PMC43688950_699,8477,patients,O
PMC43688950_699,8477,with,O
PMC43688950_699,8477,obsessive,B-Disease
PMC43688950_699,8477,-,I-Disease
PMC43688950_699,8477,compulsive,I-Disease
PMC43688950_699,8477,disorder,I-Disease
PMC43688950_699,8477,0,O
PMC43765130_818,8478,CONCLUSION,O
PMC43765130_818,8478,:,O
PMC43765130_818,8478,Adding,O
PMC43765130_818,8478,vitamin,O
PMC43765130_818,8478,C,O
PMC43765130_818,8478,to,O
PMC43765130_818,8478,citalopram,B-Drug
PMC43765130_818,8478,did,O
PMC43765130_818,8478,not,O
PMC43765130_818,8478,increase,O
PMC43765130_818,8478,the,O
PMC43765130_818,8478,efficacy,O
PMC43765130_818,8478,of,O
PMC43765130_818,8478,citalopram,B-Drug
PMC43765130_818,8478,in,O
PMC43765130_818,8478,MDD,B-Disease
PMC43765130_818,8478,patients,O
PMC43765130_818,8478,0,O
PMC43790690_341,8479,Association,O
PMC43790690_341,8479,of,O
PMC43790690_341,8479,body,O
PMC43790690_341,8479,composition,O
PMC43790690_341,8479,with,O
PMC43790690_341,8479,outcome,O
PMC43790690_341,8479,of,O
PMC43790690_341,8479,docetaxel,B-Drug
PMC43790690_341,8479,chemotherapy,O
PMC43790690_341,8479,in,O
PMC43790690_341,8479,metastatic,B-Disease
PMC43790690_341,8479,prostate,I-Disease
PMC43790690_341,8479,cancer,I-Disease
PMC43790690_341,8479,:,O
PMC43790690_341,8479,a,O
PMC43790690_341,8479,retrospective,O
PMC43790690_341,8479,review,O
PMC43790690_341,8479,0,O
PMC43861250_1028,8480,Duloxetine,B-Drug
PMC43861250_1028,8480,",",O
PMC43861250_1028,8480,an,O
PMC43861250_1028,8480,antidepressant,O
PMC43861250_1028,8480,agent,O
PMC43861250_1028,8480,",",O
PMC43861250_1028,8480,is,O
PMC43861250_1028,8480,also,O
PMC43861250_1028,8480,used,O
PMC43861250_1028,8480,in,O
PMC43861250_1028,8480,the,O
PMC43861250_1028,8480,treatment,O
PMC43861250_1028,8480,of,O
PMC43861250_1028,8480,anxiety,B-Symptom
PMC43861250_1028,8480,0,O
PMC43898150_390,8481,BACKGROUND,O
PMC43898150_390,8481,:,O
PMC43898150_390,8481,Several,O
PMC43898150_390,8481,studies,O
PMC43898150_390,8481,have,O
PMC43898150_390,8481,shown,O
PMC43898150_390,8481,that,O
PMC43898150_390,8481,lisdexamfetamine,B-Drug
PMC43898150_390,8481,(,O
PMC43898150_390,8481,LDX,O
PMC43898150_390,8481,),O
PMC43898150_390,8481,is,O
PMC43898150_390,8481,efficacious,O
PMC43898150_390,8481,in,O
PMC43898150_390,8481,children,O
PMC43898150_390,8481,and,O
PMC43898150_390,8481,adolescents,O
PMC43898150_390,8481,with,O
PMC43898150_390,8481,attention,B-Disease
PMC43898150_390,8481,-,I-Disease
PMC43898150_390,8481,deficit,I-Disease
PMC43898150_390,8481,/,I-Disease
PMC43898150_390,8481,hyperactivity,I-Disease
PMC43898150_390,8481,disorder,I-Disease
PMC43898150_390,8481,(,O
PMC43898150_390,8481,ADHD,O
PMC43898150_390,8481,),O
PMC43898150_390,8481,0,O
PMC43898150_444,8482,Comparative,O
PMC43898150_444,8482,efficacy,O
PMC43898150_444,8482,",",O
PMC43898150_444,8482,acceptability,O
PMC43898150_444,8482,",",O
PMC43898150_444,8482,and,O
PMC43898150_444,8482,tolerability,O
PMC43898150_444,8482,of,O
PMC43898150_444,8482,lisdexamfetamine,B-Drug
PMC43898150_444,8482,in,O
PMC43898150_444,8482,child,O
PMC43898150_444,8482,and,O
PMC43898150_444,8482,adolescent,O
PMC43898150_444,8482,ADHD,B-Disease
PMC43898150_444,8482,:,O
PMC43898150_444,8482,a,O
PMC43898150_444,8482,meta,O
PMC43898150_444,8482,-,O
PMC43898150_444,8482,analysis,O
PMC43898150_444,8482,of,O
PMC43898150_444,8482,randomized,O
PMC43898150_444,8482,",",O
PMC43898150_444,8482,controlled,O
PMC43898150_444,8482,trials,O
PMC43898150_444,8482,0,O
PMC43905960_235,8483,METHODS,O
PMC43905960_235,8483,:,O
PMC43905960_235,8483,This,O
PMC43905960_235,8483,cross,O
PMC43905960_235,8483,-,O
PMC43905960_235,8483,sectional,O
PMC43905960_235,8483,study,O
PMC43905960_235,8483,included,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,subjects,O
PMC43905960_235,8483,with,O
PMC43905960_235,8483,schizophrenia,B-Disease
PMC43905960_235,8483,who,O
PMC43905960_235,8483,were,O
PMC43905960_235,8483,on,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,monotherapy,O
PMC43905960_235,8483,with,O
PMC43905960_235,8483,clozapine,O
PMC43905960_235,8483,(,O
PMC43905960_235,8483,CL,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,",",O
PMC43905960_235,8483,olanzapine,B-Drug
PMC43905960_235,8483,(,O
PMC43905960_235,8483,OL,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,",",O
PMC43905960_235,8483,or,O
PMC43905960_235,8483,quetiapine,B-Drug
PMC43905960_235,8483,(,O
PMC43905960_235,8483,QT,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,(,O
PMC43905960_235,8483,n,O
PMC43905960_235,8483,=,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,",",O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,monotherapy,O
PMC43905960_235,8483,with,O
PMC43905960_235,8483,risperidone,O
PMC43905960_235,8483,(,O
PMC43905960_235,8483,RSP,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,(,O
PMC43905960_235,8483,n,O
PMC43905960_235,8483,=,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,",",O
PMC43905960_235,8483,or,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,monotherapy,O
PMC43905960_235,8483,with,O
PMC43905960_235,8483,aripiprizole,O
PMC43905960_235,8483,(,O
PMC43905960_235,8483,ARP,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,",",O
PMC43905960_235,8483,or,O
PMC43905960_235,8483,ziprasidone,B-Drug
PMC43905960_235,8483,(,O
PMC43905960_235,8483,ZPS,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,(,O
PMC43905960_235,8483,n,O
PMC43905960_235,8483,=,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,),O
PMC43905960_235,8483,more,O
PMC43905960_235,8483,than,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,number,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,_,O
PMC43905960_235,8483,year,O
PMC43905960_235,8483,0,O
PMC43926160_606,8484,To,O
PMC43926160_606,8484,evaluate,O
PMC43926160_606,8484,Aurora,O
PMC43926160_606,8484,kinase,O
PMC43926160_606,8484,B,O
PMC43926160_606,8484,as,O
PMC43926160_606,8484,a,O
PMC43926160_606,8484,biomarker,O
PMC43926160_606,8484,for,O
PMC43926160_606,8484,endocrine,O
PMC43926160_606,8484,resistance,O
PMC43926160_606,8484,",",O
PMC43926160_606,8484,immunohistochemistry,O
PMC43926160_606,8484,was,O
PMC43926160_606,8484,performed,O
PMC43926160_606,8484,on,O
PMC43926160_606,8484,archival,O
PMC43926160_606,8484,primary,O
PMC43926160_606,8484,tumor,O
PMC43926160_606,8484,tissue,O
PMC43926160_606,8484,from,O
PMC43926160_606,8484,breast,B-Disease
PMC43926160_606,8484,cancer,I-Disease
PMC43926160_606,8484,patients,O
PMC43926160_606,8484,who,O
PMC43926160_606,8484,have,O
PMC43926160_606,8484,received,O
PMC43926160_606,8484,adjuvant,O
PMC43926160_606,8484,endocrine,O
PMC43926160_606,8484,treatment,O
PMC43926160_606,8484,with,O
PMC43926160_606,8484,tamoxifen,B-Drug
PMC43926160_606,8484,0,O
PMC43928640_7,8485,Bilateral,O
PMC43928640_7,8485,cystoid,O
PMC43928640_7,8485,macular,O
PMC43928640_7,8485,edema,O
PMC43928640_7,8485,following,O
PMC43928640_7,8485,docetaxel,B-Drug
PMC43928640_7,8485,chemotherapy,O
PMC43928640_7,8485,in,O
PMC43928640_7,8485,a,O
PMC43928640_7,8485,patient,O
PMC43928640_7,8485,with,O
PMC43928640_7,8485,retinitis,O
PMC43928640_7,8485,pigmentosa,O
PMC43928640_7,8485,:,O
PMC43928640_7,8485,a,O
PMC43928640_7,8485,case,O
PMC43928640_7,8485,report,O
PMC43928640_7,8485,0,O
PMC43995490_376,8486,The,O
PMC43995490_376,8486,results,O
PMC43995490_376,8486,showed,O
PMC43995490_376,8486,that,O
PMC43995490_376,8486,As,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,number,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,O,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,number,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,_,O
PMC43995490_376,8486,combined,O
PMC43995490_376,8486,with,O
PMC43995490_376,8486,ascorbic,O
PMC43995490_376,8486,acid,O
PMC43995490_376,8486,",",O
PMC43995490_376,8486,ifosfamide,O
PMC43995490_376,8486,",",O
PMC43995490_376,8486,and,O
PMC43995490_376,8486,prednisone,B-Drug
PMC43995490_376,8486,chemotherapy,O
PMC43995490_376,8486,may,O
PMC43995490_376,8486,be,O
PMC43995490_376,8486,a,O
PMC43995490_376,8486,choice,O
PMC43995490_376,8486,treatment,O
PMC43995490_376,8486,for,O
PMC43995490_376,8486,repeatedly,O
PMC43995490_376,8486,relapsed,O
PMC43995490_376,8486,and,O
PMC43995490_376,8486,refractory,O
PMC43995490_376,8486,MM,B-Disease
PMC43995490_376,8486,patients,O
PMC43995490_376,8486,0,O
PMC44030340_333,8487,UNLABELLED,O
PMC44030340_333,8487,:,O
PMC44030340_333,8487,Phenytoin,O
PMC44030340_333,8487,(,O
PMC44030340_333,8487,PHT,O
PMC44030340_333,8487,),O
PMC44030340_333,8487,and,O
PMC44030340_333,8487,Carbamazepine,B-Drug
PMC44030340_333,8487,(,O
PMC44030340_333,8487,CBZ,O
PMC44030340_333,8487,),O
PMC44030340_333,8487,are,O
PMC44030340_333,8487,excellent,O
PMC44030340_333,8487,sodium,O
PMC44030340_333,8487,channel,O
PMC44030340_333,8487,blockers,O
PMC44030340_333,8487,administered,O
PMC44030340_333,8487,in,O
PMC44030340_333,8487,clinical,O
PMC44030340_333,8487,treatment,O
PMC44030340_333,8487,of,O
PMC44030340_333,8487,epileptic,O
PMC44030340_333,8487,seizures,B-Symptom
PMC44030340_333,8487,0,O
PMC44038890_585,8488,The,O
PMC44038890_585,8488,rapid,O
PMC44038890_585,8488,onset,O
PMC44038890_585,8488,of,O
PMC44038890_585,8488,sertraline,B-Drug
PMC44038890_585,8488,plus,O
PMC44038890_585,8488,short,O
PMC44038890_585,8488,-,O
PMC44038890_585,8488,term,O
PMC44038890_585,8488,deanxit,O
PMC44038890_585,8488,indicated,O
PMC44038890_585,8488,that,O
PMC44038890_585,8488,it,O
PMC44038890_585,8488,might,O
PMC44038890_585,8488,be,O
PMC44038890_585,8488,an,O
PMC44038890_585,8488,inspiring,O
PMC44038890_585,8488,strategy,O
PMC44038890_585,8488,to,O
PMC44038890_585,8488,manage,O
PMC44038890_585,8488,depression,B-Disease
PMC44038890_585,8488,and,O
PMC44038890_585,8488,anxiety,O
PMC44038890_585,8488,within,O
PMC44038890_585,8488,the,O
PMC44038890_585,8488,first,O
PMC44038890_585,8488,two,O
PMC44038890_585,8488,weeks,O
PMC44038890_585,8488,in,O
PMC44038890_585,8488,chronic,O
PMC44038890_585,8488,somatic,O
PMC44038890_585,8488,diseases,O
PMC44038890_585,8488,0,O
PMC44042650_306,8489,INTRODUCTION,O
PMC44042650_306,8489,:,O
PMC44042650_306,8489,A,O
PMC44042650_306,8489,wide,O
PMC44042650_306,8489,variety,O
PMC44042650_306,8489,of,O
PMC44042650_306,8489,atypical,O
PMC44042650_306,8489,antipsychotic,O
PMC44042650_306,8489,drugs,O
PMC44042650_306,8489,(,O
PMC44042650_306,8489,risperidone,O
PMC44042650_306,8489,",",O
PMC44042650_306,8489,olanzapine,B-Drug
PMC44042650_306,8489,",",O
PMC44042650_306,8489,quetiapine,O
PMC44042650_306,8489,",",O
PMC44042650_306,8489,aripiprazole,O
PMC44042650_306,8489,",",O
PMC44042650_306,8489,ziprasidone,B-Drug
PMC44042650_306,8489,and,O
PMC44042650_306,8489,clozapine,O
PMC44042650_306,8489,),O
PMC44042650_306,8489,are,O
PMC44042650_306,8489,widely,O
PMC44042650_306,8489,used,O
PMC44042650_306,8489,in,O
PMC44042650_306,8489,the,O
PMC44042650_306,8489,management,O
PMC44042650_306,8489,of,O
PMC44042650_306,8489,neuropsychiatric,B-Symptom
PMC44042650_306,8489,symptoms,I-Symptom
PMC44042650_306,8489,",",O
PMC44042650_306,8489,which,O
PMC44042650_306,8489,are,O
PMC44042650_306,8489,commonly,O
PMC44042650_306,8489,seen,O
PMC44042650_306,8489,in,O
PMC44042650_306,8489,dementia,B-Symptom
PMC44042650_306,8489,",",O
PMC44042650_306,8489,but,O
PMC44042650_306,8489,results,O
PMC44042650_306,8489,from,O
PMC44042650_306,8489,randomised,O
PMC44042650_306,8489,controlled,O
PMC44042650_306,8489,trials,O
PMC44042650_306,8489,(,O
PMC44042650_306,8489,RCTs,O
PMC44042650_306,8489,),O
PMC44042650_306,8489,on,O
PMC44042650_306,8489,the,O
PMC44042650_306,8489,efficacy,O
PMC44042650_306,8489,and,O
PMC44042650_306,8489,safety,O
PMC44042650_306,8489,of,O
PMC44042650_306,8489,these,O
PMC44042650_306,8489,agents,O
PMC44042650_306,8489,are,O
PMC44042650_306,8489,conflicting,O
PMC44042650_306,8489,0,O
PMC44099560_577,8490,The,O
PMC44099560_577,8490,effect,O
PMC44099560_577,8490,of,O
PMC44099560_577,8490,pimecrolimus,O
PMC44099560_577,8490,cream,O
PMC44099560_577,8490,_,O
PMC44099560_577,8490,_,O
PMC44099560_577,8490,number,O
PMC44099560_577,8490,_,O
PMC44099560_577,8490,_,O
PMC44099560_577,8490,%,O
PMC44099560_577,8490,compared,O
PMC44099560_577,8490,with,O
PMC44099560_577,8490,triamcinolone,O
PMC44099560_577,8490,acetonide,O
PMC44099560_577,8490,paste,O
PMC44099560_577,8490,in,O
PMC44099560_577,8490,treatment,O
PMC44099560_577,8490,of,O
PMC44099560_577,8490,atrophic,O
PMC44099560_577,8490,-,O
PMC44099560_577,8490,erosive,O
PMC44099560_577,8490,oral,O
PMC44099560_577,8490,lichen,B-Disease
PMC44099560_577,8490,planus,I-Disease
PMC44099560_577,8490,0,O
PMC4413840_1033,8491,Three,O
PMC4413840_1033,8491,year,O
PMC4413840_1033,8491,naturalistic,O
PMC4413840_1033,8491,outcome,O
PMC4413840_1033,8491,study,O
PMC4413840_1033,8491,of,O
PMC4413840_1033,8491,panic,B-Disease
PMC4413840_1033,8491,disorder,I-Disease
PMC4413840_1033,8491,patients,O
PMC4413840_1033,8491,treated,O
PMC4413840_1033,8491,with,O
PMC4413840_1033,8491,paroxetine,B-Drug
PMC4413840_1033,8491,0,O
PMC4413840_125,8492,METHODS,O
PMC4413840_125,8492,:,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,number,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,patients,O
PMC4413840_125,8492,with,O
PMC4413840_125,8492,panic,B-Disease
PMC4413840_125,8492,disorder,I-Disease
PMC4413840_125,8492,(,O
PMC4413840_125,8492,PD,O
PMC4413840_125,8492,),O
PMC4413840_125,8492,",",O
PMC4413840_125,8492,with,O
PMC4413840_125,8492,or,O
PMC4413840_125,8492,without,O
PMC4413840_125,8492,agoraphobia,O
PMC4413840_125,8492,",",O
PMC4413840_125,8492,successfully,O
PMC4413840_125,8492,finished,O
PMC4413840_125,8492,a,O
PMC4413840_125,8492,short,O
PMC4413840_125,8492,-,O
PMC4413840_125,8492,term,O
PMC4413840_125,8492,(,O
PMC4413840_125,8492,ie,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,number,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,_,O
PMC4413840_125,8492,week,O
PMC4413840_125,8492,),O
PMC4413840_125,8492,trial,O
PMC4413840_125,8492,of,O
PMC4413840_125,8492,paroxetine,B-Drug
PMC4413840_125,8492,treatment,O
PMC4413840_125,8492,0,O
PMC4413840_480,8493,BACKGROUND,O
PMC4413840_480,8493,:,O
PMC4413840_480,8493,This,O
PMC4413840_480,8493,naturalistic,O
PMC4413840_480,8493,open,O
PMC4413840_480,8493,label,O
PMC4413840_480,8493,follow,O
PMC4413840_480,8493,-,O
PMC4413840_480,8493,up,O
PMC4413840_480,8493,study,O
PMC4413840_480,8493,had,O
PMC4413840_480,8493,three,O
PMC4413840_480,8493,objectives,O
PMC4413840_480,8493,:,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,number,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,),O
PMC4413840_480,8493,To,O
PMC4413840_480,8493,observe,O
PMC4413840_480,8493,the,O
PMC4413840_480,8493,course,O
PMC4413840_480,8493,of,O
PMC4413840_480,8493,illness,O
PMC4413840_480,8493,in,O
PMC4413840_480,8493,Panic,B-Disease
PMC4413840_480,8493,Disorder,I-Disease
PMC4413840_480,8493,patients,O
PMC4413840_480,8493,receiving,O
PMC4413840_480,8493,long,O
PMC4413840_480,8493,-,O
PMC4413840_480,8493,term,O
PMC4413840_480,8493,versus,O
PMC4413840_480,8493,intermediate,O
PMC4413840_480,8493,-,O
PMC4413840_480,8493,term,O
PMC4413840_480,8493,paroxetine,B-Drug
PMC4413840_480,8493,treatment,O
PMC4413840_480,8493,",",O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,number,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,),O
PMC4413840_480,8493,To,O
PMC4413840_480,8493,compare,O
PMC4413840_480,8493,the,O
PMC4413840_480,8493,relapse,O
PMC4413840_480,8493,rates,O
PMC4413840_480,8493,and,O
PMC4413840_480,8493,side,O
PMC4413840_480,8493,-,O
PMC4413840_480,8493,effect,O
PMC4413840_480,8493,profile,O
PMC4413840_480,8493,after,O
PMC4413840_480,8493,long,O
PMC4413840_480,8493,-,O
PMC4413840_480,8493,term,O
PMC4413840_480,8493,paroxetine,B-Drug
PMC4413840_480,8493,treatment,O
PMC4413840_480,8493,between,O
PMC4413840_480,8493,patients,O
PMC4413840_480,8493,with,O
PMC4413840_480,8493,Panic,B-Disease
PMC4413840_480,8493,Disorder,I-Disease
PMC4413840_480,8493,and,O
PMC4413840_480,8493,Panic,B-Disease
PMC4413840_480,8493,Disorder,I-Disease
PMC4413840_480,8493,with,O
PMC4413840_480,8493,Agoraphobia,O
PMC4413840_480,8493,",",O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,number,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,),O
PMC4413840_480,8493,To,O
PMC4413840_480,8493,observe,O
PMC4413840_480,8493,paroxetine,O
PMC4413840_480,8493,',O
PMC4413840_480,8493,s,O
PMC4413840_480,8493,tolerability,O
PMC4413840_480,8493,over,O
PMC4413840_480,8493,a,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,number,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,_,O
PMC4413840_480,8493,month,O
PMC4413840_480,8493,period,O
PMC4413840_480,8493,0,O
PMC44141670_42,8494,Our,O
PMC44141670_42,8494,preliminary,O
PMC44141670_42,8494,data,O
PMC44141670_42,8494,suggest,O
PMC44141670_42,8494,that,O
PMC44141670_42,8494,tamoxifen,B-Drug
PMC44141670_42,8494,sensitizes,O
PMC44141670_42,8494,glioblastoma,B-Disease
PMC44141670_42,8494,cells,O
PMC44141670_42,8494,towards,O
PMC44141670_42,8494,oncolytic,O
PMC44141670_42,8494,treatment,O
PMC44141670_42,8494,with,O
PMC44141670_42,8494,CRAd,O
PMC44141670_42,8494,-,O
PMC44141670_42,8494,S,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,number,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,/,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,number,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,_,O
PMC44141670_42,8494,",",O
PMC44141670_42,8494,which,O
PMC44141670_42,8494,may,O
PMC44141670_42,8494,prove,O
PMC44141670_42,8494,useful,O
PMC44141670_42,8494,for,O
PMC44141670_42,8494,GBM,B-Disease
PMC44141670_42,8494,in,O
PMC44141670_42,8494,future,O
PMC44141670_42,8494,experimental,O
PMC44141670_42,8494,therapy,O
PMC44141670_42,8494,0,O
PMC44172670_231,8495,MDD,B-Disease
PMC44172670_231,8495,patients,O
PMC44172670_231,8495,received,O
PMC44172670_231,8495,treatment,O
PMC44172670_231,8495,with,O
PMC44172670_231,8495,duloxetine,B-Drug
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,number,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,mg,O
PMC44172670_231,8495,daily,O
PMC44172670_231,8495,for,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,number,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,weeks,O
PMC44172670_231,8495,with,O
PMC44172670_231,8495,an,O
PMC44172670_231,8495,optional,O
PMC44172670_231,8495,dose,O
PMC44172670_231,8495,increase,O
PMC44172670_231,8495,to,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,number,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,mg,O
PMC44172670_231,8495,daily,O
PMC44172670_231,8495,after,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,number,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,_,O
PMC44172670_231,8495,weeks,O
PMC44172670_231,8495,0,O
PMC44173460_100,8496,Single,O
PMC44173460_100,8496,RCT,O
PMC44173460_100,8496,evidence,O
PMC44173460_100,8496,indicates,O
PMC44173460_100,8496,that,O
PMC44173460_100,8496,tramadol,O
PMC44173460_100,8496,is,O
PMC44173460_100,8496,significantly,O
PMC44173460_100,8496,more,O
PMC44173460_100,8496,effective,O
PMC44173460_100,8496,than,O
PMC44173460_100,8496,paroxetine,B-Drug
PMC44173460_100,8496,taken,O
PMC44173460_100,8496,on,O
PMC44173460_100,8496,-,O
PMC44173460_100,8496,demand,O
PMC44173460_100,8496,",",O
PMC44173460_100,8496,sildenafil,O
PMC44173460_100,8496,",",O
PMC44173460_100,8496,lidocaine,O
PMC44173460_100,8496,gel,O
PMC44173460_100,8496,",",O
PMC44173460_100,8496,or,O
PMC44173460_100,8496,behavioural,O
PMC44173460_100,8496,therapy,O
PMC44173460_100,8496,on,O
PMC44173460_100,8496,IELT,O
PMC44173460_100,8496,in,O
PMC44173460_100,8496,men,O
PMC44173460_100,8496,with,O
PMC44173460_100,8496,PE,B-Symptom
PMC44173460_100,8496,0,O
PMC44214060_171,8497,In,O
PMC44214060_171,8497,this,O
PMC44214060_171,8497,case,O
PMC44214060_171,8497,report,O
PMC44214060_171,8497,",",O
PMC44214060_171,8497,we,O
PMC44214060_171,8497,describe,O
PMC44214060_171,8497,a,O
PMC44214060_171,8497,research,O
PMC44214060_171,8497,subject,O
PMC44214060_171,8497,taking,O
PMC44214060_171,8497,duloxetine,B-Drug
PMC44214060_171,8497,who,O
PMC44214060_171,8497,developed,O
PMC44214060_171,8497,severe,O
PMC44214060_171,8497,symptomatic,O
PMC44214060_171,8497,hyponatremia,B-Symptom
PMC44214060_171,8497,during,O
PMC44214060_171,8497,glomerular,O
PMC44214060_171,8497,filtration,O
PMC44214060_171,8497,rate,O
PMC44214060_171,8497,testing,O
PMC44214060_171,8497,despite,O
PMC44214060_171,8497,having,O
PMC44214060_171,8497,undergone,O
PMC44214060_171,8497,such,O
PMC44214060_171,8497,testing,O
PMC44214060_171,8497,uneventfully,O
PMC44214060_171,8497,in,O
PMC44214060_171,8497,the,O
PMC44214060_171,8497,past,O
PMC44214060_171,8497,0,O
PMC44214060_224,8498,Prior,O
PMC44214060_224,8498,reports,O
PMC44214060_224,8498,have,O
PMC44214060_224,8498,linked,O
PMC44214060_224,8498,duloxetine,B-Drug
PMC44214060_224,8498,with,O
PMC44214060_224,8498,hyponatremia,B-Symptom
PMC44214060_224,8498,",",O
PMC44214060_224,8498,but,O
PMC44214060_224,8498,it,O
PMC44214060_224,8498,is,O
PMC44214060_224,8498,uncommon,O
PMC44214060_224,8498,0,O
PMC44231580_1024,8499,Olanzapine,B-Drug
PMC44231580_1024,8499,-,O
PMC44231580_1024,8499,induced,O
PMC44231580_1024,8499,Orthostatic,B-Symptom
PMC44231580_1024,8499,Hypotension,I-Symptom
PMC44231580_1024,8499,0,O
PMC44258050_811,8500,Efficacy,O
PMC44258050_811,8500,of,O
PMC44258050_811,8500,Methylphenidate,B-Drug
PMC44258050_811,8500,Hydrochloride,O
PMC44258050_811,8500,Extended,O
PMC44258050_811,8500,-,O
PMC44258050_811,8500,Release,O
PMC44258050_811,8500,Capsules,O
PMC44258050_811,8500,(,O
PMC44258050_811,8500,Aptensio,O
PMC44258050_811,8500,XR,O
PMC44258050_811,8500,),O
PMC44258050_811,8500,in,O
PMC44258050_811,8500,Children,O
PMC44258050_811,8500,and,O
PMC44258050_811,8500,Adolescents,O
PMC44258050_811,8500,with,O
PMC44258050_811,8500,Attention,B-Disease
PMC44258050_811,8500,-,I-Disease
PMC44258050_811,8500,Deficit,I-Disease
PMC44258050_811,8500,/,I-Disease
PMC44258050_811,8500,Hyperactivity,I-Disease
PMC44258050_811,8500,Disorder,I-Disease
PMC44258050_811,8500,:,O
PMC44258050_811,8500,A,O
PMC44258050_811,8500,Phase,O
PMC44258050_811,8500,II,O
PMC44258050_811,8500,",",O
PMC44258050_811,8500,Randomized,O
PMC44258050_811,8500,",",O
PMC44258050_811,8500,Double,O
PMC44258050_811,8500,-,O
PMC44258050_811,8500,Blind,O
PMC44258050_811,8500,Study,O
PMC44258050_811,8500,0,O
PMC44265460_812,8501,CONCLUSION,O
PMC44265460_812,8501,:,O
PMC44265460_812,8501,Quetiapine,B-Drug
PMC44265460_812,8501,-,O
PMC44265460_812,8501,associated,O
PMC44265460_812,8501,leucopenia,B-Symptom
PMC44265460_812,8501,and,O
PMC44265460_812,8501,thrombocytopenia,B-Symptom
PMC44265460_812,8501,seems,O
PMC44265460_812,8501,reversible,O
PMC44265460_812,8501,but,O
PMC44265460_812,8501,possibly,O
PMC44265460_812,8501,fatal,O
PMC44265460_812,8501,0,O
PMC44344510_260,8502,Sertraline,B-Drug
PMC44344510_260,8502,(,O
PMC44344510_260,8502,_,O
PMC44344510_260,8502,_,O
PMC44344510_260,8502,number,O
PMC44344510_260,8502,_,O
PMC44344510_260,8502,_,O
PMC44344510_260,8502,mg,O
PMC44344510_260,8502,/,O
PMC44344510_260,8502,day,O
PMC44344510_260,8502,),O
PMC44344510_260,8502,was,O
PMC44344510_260,8502,prescribed,O
PMC44344510_260,8502,for,O
PMC44344510_260,8502,her,O
PMC44344510_260,8502,phobia,O
PMC44344510_260,8502,0,O
PMC44390180_409,8503,CONCLUSIONS,O
PMC44390180_409,8503,:,O
PMC44390180_409,8503,Overall,O
PMC44390180_409,8503,",",O
PMC44390180_409,8503,the,O
PMC44390180_409,8503,regimen,O
PMC44390180_409,8503,of,O
PMC44390180_409,8503,T,O
PMC44390180_409,8503,-,O
PMC44390180_409,8503,DM,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,number,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,as,O
PMC44390180_409,8503,well,O
PMC44390180_409,8503,as,O
PMC44390180_409,8503,pertuzumab,O
PMC44390180_409,8503,in,O
PMC44390180_409,8503,combination,O
PMC44390180_409,8503,with,O
PMC44390180_409,8503,trastuzumab,O
PMC44390180_409,8503,and,O
PMC44390180_409,8503,docetaxel,B-Drug
PMC44390180_409,8503,is,O
PMC44390180_409,8503,efficacious,O
PMC44390180_409,8503,with,O
PMC44390180_409,8503,fewer,O
PMC44390180_409,8503,side,O
PMC44390180_409,8503,effects,O
PMC44390180_409,8503,as,O
PMC44390180_409,8503,compared,O
PMC44390180_409,8503,with,O
PMC44390180_409,8503,other,O
PMC44390180_409,8503,regimens,O
PMC44390180_409,8503,",",O
PMC44390180_409,8503,especially,O
PMC44390180_409,8503,for,O
PMC44390180_409,8503,advanced,O
PMC44390180_409,8503,HER,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,number,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,_,O
PMC44390180_409,8503,+,O
PMC44390180_409,8503,breast,B-Disease
PMC44390180_409,8503,cancer,I-Disease
PMC44390180_409,8503,0,O
PMC44464930_467,8504,Thus,O
PMC44464930_467,8504,",",O
PMC44464930_467,8504,we,O
PMC44464930_467,8504,hypothesized,O
PMC44464930_467,8504,that,O
PMC44464930_467,8504,CVD,O
PMC44464930_467,8504,would,O
PMC44464930_467,8504,prevent,O
PMC44464930_467,8504,and,O
PMC44464930_467,8504,/,O
PMC44464930_467,8504,or,O
PMC44464930_467,8504,reverse,O
PMC44464930_467,8504,mania,O
PMC44464930_467,8504,-,O
PMC44464930_467,8504,like,O
PMC44464930_467,8504,behavioral,O
PMC44464930_467,8504,and,O
PMC44464930_467,8504,neurochemical,O
PMC44464930_467,8504,alterations,O
PMC44464930_467,8504,induced,O
PMC44464930_467,8504,by,O
PMC44464930_467,8504,lisdexamfetamine,B-Drug
PMC44464930_467,8504,dimesylate,I-Drug
PMC44464930_467,8504,(,O
PMC44464930_467,8504,LDX,O
PMC44464930_467,8504,),O
PMC44464930_467,8504,0,O
PMC44493850_258,8505,In,O
PMC44493850_258,8505,_,O
PMC44493850_258,8505,_,O
PMC44493850_258,8505,number,O
PMC44493850_258,8505,_,O
PMC44493850_258,8505,_,O
PMC44493850_258,8505,insufficient,O
PMC44493850_258,8505,responders,O
PMC44493850_258,8505,to,O
PMC44493850_258,8505,previous,O
PMC44493850_258,8505,ADHD,B-Disease
PMC44493850_258,8505,medications,O
PMC44493850_258,8505,",",O
PMC44493850_258,8505,benefit,O
PMC44493850_258,8505,from,O
PMC44493850_258,8505,Ritalin,B-Drug
PMC44493850_258,8505,(,O
PMC44493850_258,8505,),O
PMC44493850_258,8505,LA,O
PMC44493850_258,8505,was,O
PMC44493850_258,8505,above,O
PMC44493850_258,8505,average,O
PMC44493850_258,8505,and,O
PMC44493850_258,8505,effect,O
PMC44493850_258,8505,duration,O
PMC44493850_258,8505,was,O
PMC44493850_258,8505,significantly,O
PMC44493850_258,8505,prolonged,O
PMC44493850_258,8505,as,O
PMC44493850_258,8505,compared,O
PMC44493850_258,8505,to,O
PMC44493850_258,8505,pretreatment,O
PMC44493850_258,8505,0,O
PMC44503700_169,8506,Buprenorphine,B-Drug
PMC44503700_169,8506,is,O
PMC44503700_169,8506,a,O
PMC44503700_169,8506,successful,O
PMC44503700_169,8506,analgesic,O
PMC44503700_169,8506,and,O
PMC44503700_169,8506,treatment,O
PMC44503700_169,8506,for,O
PMC44503700_169,8506,opioid,O
PMC44503700_169,8506,abuse,O
PMC44503700_169,8506,",",O
PMC44503700_169,8506,with,O
PMC44503700_169,8506,both,O
PMC44503700_169,8506,activities,O
PMC44503700_169,8506,relying,O
PMC44503700_169,8506,on,O
PMC44503700_169,8506,its,O
PMC44503700_169,8506,partial,O
PMC44503700_169,8506,agonist,O
PMC44503700_169,8506,activity,O
PMC44503700_169,8506,at,O
PMC44503700_169,8506,mu,O
PMC44503700_169,8506,opioid,O
PMC44503700_169,8506,receptors,O
PMC44503700_169,8506,0,O
PMC44505090_939,8507,BACKGROUND,O
PMC44505090_939,8507,:,O
PMC44505090_939,8507,This,O
PMC44505090_939,8507,pilot,O
PMC44505090_939,8507,study,O
PMC44505090_939,8507,",",O
PMC44505090_939,8507,conducted,O
PMC44505090_939,8507,on,O
PMC44505090_939,8507,a,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,number,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,/,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,number,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,th,O
PMC44505090_939,8507,representative,O
PMC44505090_939,8507,sample,O
PMC44505090_939,8507,of,O
PMC44505090_939,8507,French,O
PMC44505090_939,8507,claims,O
PMC44505090_939,8507,data,O
PMC44505090_939,8507,",",O
PMC44505090_939,8507,prepared,O
PMC44505090_939,8507,a,O
PMC44505090_939,8507,project,O
PMC44505090_939,8507,to,O
PMC44505090_939,8507,assess,O
PMC44505090_939,8507,the,O
PMC44505090_939,8507,effectiveness,O
PMC44505090_939,8507,of,O
PMC44505090_939,8507,Montelukast,B-Drug
PMC44505090_939,8507,(,O
PMC44505090_939,8507,MTL,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,number,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,),O
PMC44505090_939,8507,as,O
PMC44505090_939,8507,add,O
PMC44505090_939,8507,-,O
PMC44505090_939,8507,on,O
PMC44505090_939,8507,therapy,O
PMC44505090_939,8507,for,O
PMC44505090_939,8507,asthma,B-Disease
PMC44505090_939,8507,in,O
PMC44505090_939,8507,infants,O
PMC44505090_939,8507,(,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,number,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,_,O
PMC44505090_939,8507,months,O
PMC44505090_939,8507,),O
PMC44505090_939,8507,compared,O
PMC44505090_939,8507,to,O
PMC44505090_939,8507,inhaled,O
PMC44505090_939,8507,corticosteroids,O
PMC44505090_939,8507,(,O
PMC44505090_939,8507,ICS,O
PMC44505090_939,8507,),O
PMC44505090_939,8507,",",O
PMC44505090_939,8507,based,O
PMC44505090_939,8507,on,O
PMC44505090_939,8507,real,O
PMC44505090_939,8507,-,O
PMC44505090_939,8507,world,O
PMC44505090_939,8507,data,O
PMC44505090_939,8507,0,O
PMC44505620_859,8508,A,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,number,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,-,O
PMC44505620_859,8508,year,O
PMC44505620_859,8508,-,O
PMC44505620_859,8508,old,O
PMC44505620_859,8508,multidrug,O
PMC44505620_859,8508,-,O
PMC44505620_859,8508,resistant,O
PMC44505620_859,8508,tuberculosis,B-Disease
PMC44505620_859,8508,female,O
PMC44505620_859,8508,patient,O
PMC44505620_859,8508,diagnosed,O
PMC44505620_859,8508,as,O
PMC44505620_859,8508,cycloserine,O
PMC44505620_859,8508,-,O
PMC44505620_859,8508,induced,O
PMC44505620_859,8508,psychosis,O
PMC44505620_859,8508,developed,O
PMC44505620_859,8508,several,O
PMC44505620_859,8508,neuroleptic,O
PMC44505620_859,8508,side,O
PMC44505620_859,8508,effects,O
PMC44505620_859,8508,such,O
PMC44505620_859,8508,as,O
PMC44505620_859,8508,extrapyramidal,B-Symptom
PMC44505620_859,8508,reaction,I-Symptom
PMC44505620_859,8508,",",O
PMC44505620_859,8508,neuroleptic,O
PMC44505620_859,8508,malignant,O
PMC44505620_859,8508,syndrome,O
PMC44505620_859,8508,",",O
PMC44505620_859,8508,and,O
PMC44505620_859,8508,drug,O
PMC44505620_859,8508,-,O
PMC44505620_859,8508,induced,O
PMC44505620_859,8508,parkinsonism,B-Disease
PMC44505620_859,8508,while,O
PMC44505620_859,8508,she,O
PMC44505620_859,8508,was,O
PMC44505620_859,8508,being,O
PMC44505620_859,8508,treated,O
PMC44505620_859,8508,with,O
PMC44505620_859,8508,initially,O
PMC44505620_859,8508,haloperidol,O
PMC44505620_859,8508,and,O
PMC44505620_859,8508,then,O
PMC44505620_859,8508,olanzapine,B-Drug
PMC44505620_859,8508,over,O
PMC44505620_859,8508,a,O
PMC44505620_859,8508,period,O
PMC44505620_859,8508,of,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,number,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,_,O
PMC44505620_859,8508,months,O
PMC44505620_859,8508,0,O
PMC44538570_529,8509,No,O
PMC44538570_529,8509,reliable,O
PMC44538570_529,8509,markers,O
PMC44538570_529,8509,are,O
PMC44538570_529,8509,available,O
PMC44538570_529,8509,for,O
PMC44538570_529,8509,predicting,O
PMC44538570_529,8509,bevacizumab,B-Drug
PMC44538570_529,8509,-,O
PMC44538570_529,8509,induced,O
PMC44538570_529,8509,hypertension,O
PMC44538570_529,8509,0,O
PMC44542200_672,8510,Population,O
PMC44542200_672,8510,pharmacokinetics,O
PMC44542200_672,8510,of,O
PMC44542200_672,8510,methylphenidate,B-Drug
PMC44542200_672,8510,hydrochloride,O
PMC44542200_672,8510,extended,O
PMC44542200_672,8510,-,O
PMC44542200_672,8510,release,O
PMC44542200_672,8510,multiple,O
PMC44542200_672,8510,-,O
PMC44542200_672,8510,layer,O
PMC44542200_672,8510,beads,O
PMC44542200_672,8510,in,O
PMC44542200_672,8510,pediatric,O
PMC44542200_672,8510,subjects,O
PMC44542200_672,8510,with,O
PMC44542200_672,8510,attention,B-Disease
PMC44542200_672,8510,deficit,I-Disease
PMC44542200_672,8510,hyperactivity,I-Disease
PMC44542200_672,8510,disorder,I-Disease
PMC44542200_672,8510,0,O
PMC44542200_682,8511,A,O
PMC44542200_682,8511,new,O
PMC44542200_682,8511,multilayer,O
PMC44542200_682,8511,-,O
PMC44542200_682,8511,bead,O
PMC44542200_682,8511,formulation,O
PMC44542200_682,8511,of,O
PMC44542200_682,8511,extended,O
PMC44542200_682,8511,-,O
PMC44542200_682,8511,release,O
PMC44542200_682,8511,methylphenidate,B-Drug
PMC44542200_682,8511,hydrochloride,O
PMC44542200_682,8511,(,O
PMC44542200_682,8511,MPH,O
PMC44542200_682,8511,-,O
PMC44542200_682,8511,MLR,O
PMC44542200_682,8511,),O
PMC44542200_682,8511,has,O
PMC44542200_682,8511,been,O
PMC44542200_682,8511,evaluated,O
PMC44542200_682,8511,in,O
PMC44542200_682,8511,pharmacokinetic,O
PMC44542200_682,8511,studies,O
PMC44542200_682,8511,in,O
PMC44542200_682,8511,healthy,O
PMC44542200_682,8511,adults,O
PMC44542200_682,8511,and,O
PMC44542200_682,8511,in,O
PMC44542200_682,8511,Phase,O
PMC44542200_682,8511,II,O
PMC44542200_682,8511,efficacy,O
PMC44542200_682,8511,/,O
PMC44542200_682,8511,safety,O
PMC44542200_682,8511,studies,O
PMC44542200_682,8511,in,O
PMC44542200_682,8511,children,O
PMC44542200_682,8511,and,O
PMC44542200_682,8511,adolescents,O
PMC44542200_682,8511,with,O
PMC44542200_682,8511,attention,B-Disease
PMC44542200_682,8511,deficit,I-Disease
PMC44542200_682,8511,hyperactivity,I-Disease
PMC44542200_682,8511,disorder,I-Disease
PMC44542200_682,8511,(,O
PMC44542200_682,8511,ADHD,O
PMC44542200_682,8511,),O
PMC44542200_682,8511,0,O
PMC44568960_768,8512,Phentermine,O
PMC44568960_768,8512,-,O
PMC44568960_768,8512,topiramate,B-Drug
PMC44568960_768,8512,:,O
PMC44568960_768,8512,First,O
PMC44568960_768,8512,combination,O
PMC44568960_768,8512,drug,O
PMC44568960_768,8512,for,O
PMC44568960_768,8512,obesity,B-Disease
PMC44568960_768,8512,0,O
PMC44568960_920,8513,The,O
PMC44568960_920,8513,US,O
PMC44568960_920,8513,Food,O
PMC44568960_920,8513,and,O
PMC44568960_920,8513,Drug,O
PMC44568960_920,8513,Administration,O
PMC44568960_920,8513,granted,O
PMC44568960_920,8513,approval,O
PMC44568960_920,8513,to,O
PMC44568960_920,8513,a,O
PMC44568960_920,8513,fixed,O
PMC44568960_920,8513,dose,O
PMC44568960_920,8513,mid,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,number,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,combination,O
PMC44568960_920,8513,of,O
PMC44568960_920,8513,phentermine,O
PMC44568960_920,8513,immediate,O
PMC44568960_920,8513,release,O
PMC44568960_920,8513,and,O
PMC44568960_920,8513,topiramate,B-Drug
PMC44568960_920,8513,extended,O
PMC44568960_920,8513,release,O
PMC44568960_920,8513,in,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,number,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,_,O
PMC44568960_920,8513,for,O
PMC44568960_920,8513,treatment,O
PMC44568960_920,8513,of,O
PMC44568960_920,8513,obese,B-Disease
PMC44568960_920,8513,patients,O
PMC44568960_920,8513,or,O
PMC44568960_920,8513,overweight,O
PMC44568960_920,8513,patients,O
PMC44568960_920,8513,with,O
PMC44568960_920,8513,comorbid,O
PMC44568960_920,8513,conditions,O
PMC44568960_920,8513,0,O
PMC44569840_119,8514,He,O
PMC44569840_119,8514,doubled,O
PMC44569840_119,8514,the,O
PMC44569840_119,8514,dose,O
PMC44569840_119,8514,of,O
PMC44569840_119,8514,trazodone,B-Drug
PMC44569840_119,8514,_,O
PMC44569840_119,8514,_,O
PMC44569840_119,8514,number,O
PMC44569840_119,8514,_,O
PMC44569840_119,8514,_,O
PMC44569840_119,8514,mg,O
PMC44569840_119,8514,on,O
PMC44569840_119,8514,the,O
PMC44569840_119,8514,night,O
PMC44569840_119,8514,prior,O
PMC44569840_119,8514,to,O
PMC44569840_119,8514,presentation,O
PMC44569840_119,8514,to,O
PMC44569840_119,8514,calm,O
PMC44569840_119,8514,his,O
PMC44569840_119,8514,anxiety,B-Symptom
PMC44569840_119,8514,0,O
PMC44569840_153,8515,BACKGROUND,O
PMC44569840_153,8515,:,O
PMC44569840_153,8515,This,O
PMC44569840_153,8515,case,O
PMC44569840_153,8515,report,O
PMC44569840_153,8515,highlights,O
PMC44569840_153,8515,serious,O
PMC44569840_153,8515,cardiovascular,O
PMC44569840_153,8515,adverse,O
PMC44569840_153,8515,effects,O
PMC44569840_153,8515,with,O
PMC44569840_153,8515,a,O
PMC44569840_153,8515,conventional,O
PMC44569840_153,8515,dose,O
PMC44569840_153,8515,of,O
PMC44569840_153,8515,trazodone,B-Drug
PMC44569840_153,8515,as,O
PMC44569840_153,8515,a,O
PMC44569840_153,8515,result,O
PMC44569840_153,8515,of,O
PMC44569840_153,8515,its,O
PMC44569840_153,8515,potential,O
PMC44569840_153,8515,interaction,O
PMC44569840_153,8515,with,O
PMC44569840_153,8515,omeprazole,O
PMC44569840_153,8515,0,O
PMC44584390_281,8516,These,O
PMC44584390_281,8516,results,O
PMC44584390_281,8516,support,O
PMC44584390_281,8516,further,O
PMC44584390_281,8516,consideration,O
PMC44584390_281,8516,of,O
PMC44584390_281,8516,lisdexamfetamine,B-Drug
PMC44584390_281,8516,as,O
PMC44584390_281,8516,an,O
PMC44584390_281,8516,agonist,O
PMC44584390_281,8516,-,O
PMC44584390_281,8516,based,O
PMC44584390_281,8516,medication,O
PMC44584390_281,8516,candidate,O
PMC44584390_281,8516,for,O
PMC44584390_281,8516,cocaine,O
PMC44584390_281,8516,addiction,O
PMC44584390_281,8516,0,O
PMC44623970_694,8517,Phase,O
PMC44623970_694,8517,I,O
PMC44623970_694,8517,/,O
PMC44623970_694,8517,II,O
PMC44623970_694,8517,trial,O
PMC44623970_694,8517,of,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,number,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,-,O
PMC44623970_694,8517,weekly,O
PMC44623970_694,8517,docetaxel,B-Drug
PMC44623970_694,8517,combined,O
PMC44623970_694,8517,with,O
PMC44623970_694,8517,cisplatin,O
PMC44623970_694,8517,plus,O
PMC44623970_694,8517,fluorouracil,O
PMC44623970_694,8517,in,O
PMC44623970_694,8517,metastatic,B-Disease
PMC44623970_694,8517,esophageal,I-Disease
PMC44623970_694,8517,cancer,I-Disease
PMC44623970_694,8517,(,O
PMC44623970_694,8517,JCOG,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,number,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,_,O
PMC44623970_694,8517,),O
PMC44623970_694,8517,0,O
PMC44640140_330,8518,Serotonin,B-Disease
PMC44640140_330,8518,Syndrome,I-Disease
PMC44640140_330,8518,in,O
PMC44640140_330,8518,a,O
PMC44640140_330,8518,Patient,O
PMC44640140_330,8518,on,O
PMC44640140_330,8518,Trazodone,B-Drug
PMC44640140_330,8518,and,O
PMC44640140_330,8518,Duloxetine,B-Drug
PMC44640140_330,8518,Who,O
PMC44640140_330,8518,Received,O
PMC44640140_330,8518,Fentanyl,O
PMC44640140_330,8518,following,O
PMC44640140_330,8518,a,O
PMC44640140_330,8518,Percutaneous,O
PMC44640140_330,8518,Liver,O
PMC44640140_330,8518,Biopsy,O
PMC44640140_330,8518,0,O
PMC44641860_72,8519,The,O
PMC44641860_72,8519,above,O
PMC44641860_72,8519,study,O
PMC44641860_72,8519,revealed,O
PMC44641860_72,8519,that,O
PMC44641860_72,8519,the,O
PMC44641860_72,8519,compounds,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,chloro,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,H,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,[,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,],O
PMC44641860_72,8519,triazino,O
PMC44641860_72,8519,[,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,b,O
PMC44641860_72,8519,],O
PMC44641860_72,8519,indol,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,(,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,H,O
PMC44641860_72,8519,),O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,one,O
PMC44641860_72,8519,(,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,e,O
PMC44641860_72,8519,),O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,dibromo,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,H,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,[,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,],O
PMC44641860_72,8519,triazino,O
PMC44641860_72,8519,[,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,b,O
PMC44641860_72,8519,],O
PMC44641860_72,8519,indol,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,(,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,H,O
PMC44641860_72,8519,),O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,one,O
PMC44641860_72,8519,(,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,i,O
PMC44641860_72,8519,),O
PMC44641860_72,8519,and,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,dibromo,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,methyl,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,H,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,[,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,],O
PMC44641860_72,8519,triazino,O
PMC44641860_72,8519,[,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,",",O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,b,O
PMC44641860_72,8519,],O
PMC44641860_72,8519,indol,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,(,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,H,O
PMC44641860_72,8519,),O
PMC44641860_72,8519,-,O
PMC44641860_72,8519,one,O
PMC44641860_72,8519,(,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,number,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,_,O
PMC44641860_72,8519,k,O
PMC44641860_72,8519,),O
PMC44641860_72,8519,possess,O
PMC44641860_72,8519,excellent,O
PMC44641860_72,8519,anticonvulsant,O
PMC44641860_72,8519,activity,O
PMC44641860_72,8519,in,O
PMC44641860_72,8519,the,O
PMC44641860_72,8519,series,O
PMC44641860_72,8519,with,O
PMC44641860_72,8519,little,O
PMC44641860_72,8519,CNS,O
PMC44641860_72,8519,depressant,O
PMC44641860_72,8519,effect,O
PMC44641860_72,8519,and,O
PMC44641860_72,8519,no,O
PMC44641860_72,8519,neurotoxicity,O
PMC44641860_72,8519,as,O
PMC44641860_72,8519,compared,O
PMC44641860_72,8519,to,O
PMC44641860_72,8519,standard,O
PMC44641860_72,8519,drugs,O
PMC44641860_72,8519,phenytoin,O
PMC44641860_72,8519,and,O
PMC44641860_72,8519,carbamazepine,B-Drug
PMC44641860_72,8519,0,O
PMC44643580_801,8520,Similar,O
PMC44643580_801,8520,to,O
PMC44643580_801,8520,ziprasidone,B-Drug
PMC44643580_801,8520,and,O
PMC44643580_801,8520,aripiprazole,O
PMC44643580_801,8520,",",O
PMC44643580_801,8520,these,O
PMC44643580_801,8520,new,O
PMC44643580_801,8520,agents,O
PMC44643580_801,8520,are,O
PMC44643580_801,8520,advisable,O
PMC44643580_801,8520,for,O
PMC44643580_801,8520,the,O
PMC44643580_801,8520,lower,O
PMC44643580_801,8520,propensity,O
PMC44643580_801,8520,to,O
PMC44643580_801,8520,give,O
PMC44643580_801,8520,weight,B-Symptom
PMC44643580_801,8520,gain,I-Symptom
PMC44643580_801,8520,and,O
PMC44643580_801,8520,metabolic,O
PMC44643580_801,8520,abnormalities,O
PMC44643580_801,8520,in,O
PMC44643580_801,8520,comparison,O
PMC44643580_801,8520,with,O
PMC44643580_801,8520,older,O
PMC44643580_801,8520,second,O
PMC44643580_801,8520,-,O
PMC44643580_801,8520,generation,O
PMC44643580_801,8520,antipsychotics,O
PMC44643580_801,8520,such,O
PMC44643580_801,8520,as,O
PMC44643580_801,8520,olanzapine,B-Drug
PMC44643580_801,8520,or,O
PMC44643580_801,8520,clozapine,O
PMC44643580_801,8520,0,O
PMC44684540_583,8521,The,O
PMC44684540_583,8521,mean,O
PMC44684540_583,8521,acne,O
PMC44684540_583,8521,severity,O
PMC44684540_583,8521,index,O
PMC44684540_583,8521,after,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,number,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,-,O
PMC44684540_583,8521,month,O
PMC44684540_583,8521,was,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,number,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,_,O
PMC44684540_583,8521,0,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,number,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,and,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,number,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,_,O
PMC44684540_583,8522,0,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,number,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,in,O
PMC44684540_583,8523,Montelukast,B-Drug
PMC44684540_583,8523,and,O
PMC44684540_583,8523,doxycycline,O
PMC44684540_583,8523,group,O
PMC44684540_583,8523,",",O
PMC44684540_583,8523,respectively,O
PMC44684540_583,8523,(,O
PMC44684540_583,8523,P,O
PMC44684540_583,8523,=,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,number,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,_,O
PMC44684540_583,8523,),O
PMC44684540_583,8523,0,O
PMC44706850_362,8524,We,O
PMC44706850_362,8524,used,O
PMC44706850_362,8524,GWAS,O
PMC44706850_362,8524,to,O
PMC44706850_362,8524,identify,O
PMC44706850_362,8524,novel,O
PMC44706850_362,8524,SNPs,O
PMC44706850_362,8524,associated,O
PMC44706850_362,8524,with,O
PMC44706850_362,8524,the,O
PMC44706850_362,8524,response,O
PMC44706850_362,8524,to,O
PMC44706850_362,8524,the,O
PMC44706850_362,8524,LTRA,O
PMC44706850_362,8524,",",O
PMC44706850_362,8524,montelukast,B-Drug
PMC44706850_362,8524,",",O
PMC44706850_362,8524,in,O
PMC44706850_362,8524,asthmatics,B-Disease
PMC44706850_362,8524,0,O
PMC44744540_285,8525,Quetiapine,B-Drug
PMC44744540_285,8525,",",O
PMC44744540_285,8525,an,O
PMC44744540_285,8525,atypical,O
PMC44744540_285,8525,antipsychotic,O
PMC44744540_285,8525,",",O
PMC44744540_285,8525,has,O
PMC44744540_285,8525,been,O
PMC44744540_285,8525,employed,O
PMC44744540_285,8525,to,O
PMC44744540_285,8525,treat,O
PMC44744540_285,8525,alcoholic,O
PMC44744540_285,8525,patients,O
PMC44744540_285,8525,with,O
PMC44744540_285,8525,comorbid,O
PMC44744540_285,8525,psychopathology,O
PMC44744540_285,8525,0,O
PMC44758220_579,8526,In,O
PMC44758220_579,8526,combination,O
PMC44758220_579,8526,with,O
PMC44758220_579,8526,Tat,O
PMC44758220_579,8526,",",O
PMC44758220_579,8526,buprenorphine,B-Drug
PMC44758220_579,8526,displayed,O
PMC44758220_579,8526,paradoxical,O
PMC44758220_579,8526,",",O
PMC44758220_579,8526,concentration,O
PMC44758220_579,8526,-,O
PMC44758220_579,8526,dependent,O
PMC44758220_579,8526,",",O
PMC44758220_579,8526,neurotoxic,O
PMC44758220_579,8526,and,O
PMC44758220_579,8526,neuroprotective,B-Symptom
PMC44758220_579,8526,actions,I-Symptom
PMC44758220_579,8526,0,O
PMC44794280_165,8527,Under,O
PMC44794280_165,8527,the,O
PMC44794280_165,8527,tradenames,O
PMC44794280_165,8527,Rupafin,O
PMC44794280_165,8527,and,O
PMC44794280_165,8527,Urtimed,O
PMC44794280_165,8527,",",O
PMC44794280_165,8527,Rrupatadine,B-Drug
PMC44794280_165,8527,is,O
PMC44794280_165,8527,approvedregistered,O
PMC44794280_165,8527,in,O
PMC44794280_165,8527,Germany,O
PMC44794280_165,8527,for,O
PMC44794280_165,8527,the,O
PMC44794280_165,8527,treatment,O
PMC44794280_165,8527,of,O
PMC44794280_165,8527,allergic,B-Disease
PMC44794280_165,8527,rhinitis,I-Disease
PMC44794280_165,8527,and,O
PMC44794280_165,8527,urticaria,B-Symptom
PMC44794280_165,8527,infor,O
PMC44794280_165,8527,adults,O
PMC44794280_165,8527,and,O
PMC44794280_165,8527,children,O
PMC44794280_165,8527,aged,O
PMC44794280_165,8527,over,O
PMC44794280_165,8527,_,O
PMC44794280_165,8527,_,O
PMC44794280_165,8527,number,O
PMC44794280_165,8527,_,O
PMC44794280_165,8527,_,O
PMC44794280_165,8527,years,O
PMC44794280_165,8527,0,O
PMC44794280_195,8528,Rupatadine,B-Drug
PMC44794280_195,8528,has,O
PMC44794280_195,8528,been,O
PMC44794280_195,8528,found,O
PMC44794280_195,8528,to,O
PMC44794280_195,8528,be,O
PMC44794280_195,8528,effective,O
PMC44794280_195,8528,and,O
PMC44794280_195,8528,safe,O
PMC44794280_195,8528,Iin,O
PMC44794280_195,8528,a,O
PMC44794280_195,8528,variety,O
PMC44794280_195,8528,of,O
PMC44794280_195,8528,randomized,O
PMC44794280_195,8528,clinical,O
PMC44794280_195,8528,trials,O
PMC44794280_195,8528,both,O
PMC44794280_195,8528,in,O
PMC44794280_195,8528,both,O
PMC44794280_195,8528,seasonal,O
PMC44794280_195,8528,and,O
PMC44794280_195,8528,perennial,O
PMC44794280_195,8528,allergic,B-Disease
PMC44794280_195,8528,rhinitis,I-Disease
PMC44794280_195,8528,",",O
PMC44794280_195,8528,as,O
PMC44794280_195,8528,well,O
PMC44794280_195,8528,as,O
PMC44794280_195,8528,inbut,O
PMC44794280_195,8528,also,O
PMC44794280_195,8528,chronic,O
PMC44794280_195,8528,urticaria,B-Symptom
PMC44794280_195,8528,Rupatadine,B-Drug
PMC44794280_195,8528,has,O
PMC44794280_195,8528,been,O
PMC44794280_195,8528,found,O
PMC44794280_195,8528,as,O
PMC44794280_195,8528,effective,O
PMC44794280_195,8528,and,O
PMC44794280_195,8528,safe,O
PMC44794280_195,8528,0,O
PMC44808200_84,8529,OBJECTIVES,O
PMC44808200_84,8529,:,O
PMC44808200_84,8529,The,O
PMC44808200_84,8529,aim,O
PMC44808200_84,8529,of,O
PMC44808200_84,8529,this,O
PMC44808200_84,8529,study,O
PMC44808200_84,8529,was,O
PMC44808200_84,8529,to,O
PMC44808200_84,8529,determine,O
PMC44808200_84,8529,the,O
PMC44808200_84,8529,effects,O
PMC44808200_84,8529,of,O
PMC44808200_84,8529,modafinil,B-Drug
PMC44808200_84,8529,and,O
PMC44808200_84,8529,its,O
PMC44808200_84,8529,metabolites,O
PMC44808200_84,8529,(,O
PMC44808200_84,8529,sulfone,O
PMC44808200_84,8529,and,O
PMC44808200_84,8529,carboxylic,O
PMC44808200_84,8529,acid,O
PMC44808200_84,8529,),O
PMC44808200_84,8529,on,O
PMC44808200_84,8529,the,O
PMC44808200_84,8529,anticonvulsant,B-Symptom
PMC44808200_84,8529,action,I-Symptom
PMC44808200_84,8529,of,O
PMC44808200_84,8529,four,O
PMC44808200_84,8529,classical,O
PMC44808200_84,8529,antiepileptic,B-Disease
PMC44808200_84,8529,drugs,O
PMC44808200_84,8529,(,O
PMC44808200_84,8529,AEDs,O
PMC44808200_84,8529,),O
PMC44808200_84,8529,-,O
PMC44808200_84,8529,carbamazepine,B-Drug
PMC44808200_84,8529,(,O
PMC44808200_84,8529,CBZ,O
PMC44808200_84,8529,),O
PMC44808200_84,8529,",",O
PMC44808200_84,8529,phenobarbital,O
PMC44808200_84,8529,(,O
PMC44808200_84,8529,PB,O
PMC44808200_84,8529,),O
PMC44808200_84,8529,",",O
PMC44808200_84,8529,phenytoin,O
PMC44808200_84,8529,(,O
PMC44808200_84,8529,PHT,O
PMC44808200_84,8529,),O
PMC44808200_84,8529,",",O
PMC44808200_84,8529,and,O
PMC44808200_84,8529,valproate,O
PMC44808200_84,8529,(,O
PMC44808200_84,8529,VPA,O
PMC44808200_84,8529,),O
PMC44808200_84,8529,0,O
PMC44930910_1030,8530,METHODS,O
PMC44930910_1030,8530,:,O
PMC44930910_1030,8530,Adult,O
PMC44930910_1030,8530,patients,O
PMC44930910_1030,8530,with,O
PMC44930910_1030,8530,focal,O
PMC44930910_1030,8530,epilepsy,B-Disease
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,who,O
PMC44930910_1030,8530,were,O
PMC44930910_1030,8530,prescribed,O
PMC44930910_1030,8530,with,O
PMC44930910_1030,8530,carbamazepine,B-Drug
PMC44930910_1030,8530,(,O
PMC44930910_1030,8530,CBZ,O
PMC44930910_1030,8530,),O
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,valproate,O
PMC44930910_1030,8530,(,O
PMC44930910_1030,8530,VPA,O
PMC44930910_1030,8530,),O
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,lamotrigine,B-Drug
PMC44930910_1030,8530,(,O
PMC44930910_1030,8530,LTG,O
PMC44930910_1030,8530,),O
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,topiramate,B-Drug
PMC44930910_1030,8530,(,O
PMC44930910_1030,8530,TPM,O
PMC44930910_1030,8530,),O
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,or,O
PMC44930910_1030,8530,oxcarbazepine,O
PMC44930910_1030,8530,(,O
PMC44930910_1030,8530,OXC,O
PMC44930910_1030,8530,),O
PMC44930910_1030,8530,as,O
PMC44930910_1030,8530,monotherapy,O
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,during,O
PMC44930910_1030,8530,the,O
PMC44930910_1030,8530,period,O
PMC44930910_1030,8530,from,O
PMC44930910_1030,8530,January,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,number,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,to,O
PMC44930910_1030,8530,June,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,number,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,_,O
PMC44930910_1030,8530,registered,O
PMC44930910_1030,8530,in,O
PMC44930910_1030,8530,Wenzhou,O
PMC44930910_1030,8530,Epilepsy,O
PMC44930910_1030,8530,Follow,O
PMC44930910_1030,8530,Up,O
PMC44930910_1030,8530,Registry,O
PMC44930910_1030,8530,Database,O
PMC44930910_1030,8530,(,O
PMC44930910_1030,8530,WEFURD,O
PMC44930910_1030,8530,),O
PMC44930910_1030,8530,",",O
PMC44930910_1030,8530,were,O
PMC44930910_1030,8530,included,O
PMC44930910_1030,8530,in,O
PMC44930910_1030,8530,the,O
PMC44930910_1030,8530,study,O
PMC44930910_1030,8530,0,O
PMC44933620_141,8531,However,O
PMC44933620_141,8531,",",O
PMC44933620_141,8531,a,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,number,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,-,O
PMC44933620_141,8531,year,O
PMC44933620_141,8531,-,O
PMC44933620_141,8531,old,O
PMC44933620_141,8531,male,O
PMC44933620_141,8531,patient,O
PMC44933620_141,8531,who,O
PMC44933620_141,8531,was,O
PMC44933620_141,8531,admitted,O
PMC44933620_141,8531,with,O
PMC44933620_141,8531,Stevens,B-Disease
PMC44933620_141,8531,-,I-Disease
PMC44933620_141,8531,Johnson,I-Disease
PMC44933620_141,8531,syndrome,I-Disease
PMC44933620_141,8531,after,O
PMC44933620_141,8531,taking,O
PMC44933620_141,8531,lamotrigine,B-Drug
PMC44933620_141,8531,for,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,number,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,days,O
PMC44933620_141,8531,experienced,O
PMC44933620_141,8531,hepatic,B-Symptom
PMC44933620_141,8531,failure,I-Symptom
PMC44933620_141,8531,and,O
PMC44933620_141,8531,died,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,number,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,_,O
PMC44933620_141,8531,days,O
PMC44933620_141,8531,after,O
PMC44933620_141,8531,admission,O
PMC44933620_141,8531,0,O
PMC44988740_210,8532,Nephrolithiasis,O
PMC44988740_210,8532,is,O
PMC44988740_210,8532,a,O
PMC44988740_210,8532,less,O
PMC44988740_210,8532,common,O
PMC44988740_210,8532,side,O
PMC44988740_210,8532,effect,O
PMC44988740_210,8532,of,O
PMC44988740_210,8532,the,O
PMC44988740_210,8532,antiepileptic,O
PMC44988740_210,8532,drug,O
PMC44988740_210,8532,topiramate,B-Drug
PMC44988740_210,8532,0,O
PMC44990820_646,8533,However,O
PMC44990820_646,8533,",",O
PMC44990820_646,8533,leviteracetam,O
PMC44990820_646,8533,led,O
PMC44990820_646,8533,to,O
PMC44990820_646,8533,depression,B-Disease
PMC44990820_646,8533,more,O
PMC44990820_646,8533,frequently,O
PMC44990820_646,8533,than,O
PMC44990820_646,8533,carbamazepine,B-Drug
PMC44990820_646,8533,",",O
PMC44990820_646,8533,while,O
PMC44990820_646,8533,carbamazepine,O
PMC44990820_646,8533,caused,O
PMC44990820_646,8533,rash,B-Symptom
PMC44990820_646,8533,more,O
PMC44990820_646,8533,frequently,O
PMC44990820_646,8533,0,O
PMC45008910_46,8534,Her,O
PMC45008910_46,8534,vivid,B-Symptom
PMC45008910_46,8534,"""",I-Symptom
PMC45008910_46,8534,bad,I-Symptom
PMC45008910_46,8534,dreams,I-Symptom
PMC45008910_46,8534,"""",I-Symptom
PMC45008910_46,8534,remained,O
PMC45008910_46,8534,refractory,O
PMC45008910_46,8534,in,O
PMC45008910_46,8534,spite,O
PMC45008910_46,8534,of,O
PMC45008910_46,8534,_,O
PMC45008910_46,8534,_,O
PMC45008910_46,8534,number,O
PMC45008910_46,8534,_,O
PMC45008910_46,8534,_,O
PMC45008910_46,8534,months,O
PMC45008910_46,8534,of,O
PMC45008910_46,8534,treatment,O
PMC45008910_46,8534,with,O
PMC45008910_46,8534,Dialectical,O
PMC45008910_46,8534,Behavioral,O
PMC45008910_46,8534,Therapy,O
PMC45008910_46,8534,(,O
PMC45008910_46,8534,DBT,O
PMC45008910_46,8534,),O
PMC45008910_46,8534,and,O
PMC45008910_46,8534,standard,O
PMC45008910_46,8534,pharmaceutical,O
PMC45008910_46,8534,agents,O
PMC45008910_46,8534,which,O
PMC45008910_46,8534,included,O
PMC45008910_46,8534,prazosin,O
PMC45008910_46,8534,",",O
PMC45008910_46,8534,clonidie,O
PMC45008910_46,8534,and,O
PMC45008910_46,8534,Adderall,B-Drug
PMC45008910_46,8534,0,O
PMC45065960_96,8535,METHODS,O
PMC45065960_96,8535,/,O
PMC45065960_96,8535,DESIGN,O
PMC45065960_96,8535,:,O
PMC45065960_96,8535,A,O
PMC45065960_96,8535,two,O
PMC45065960_96,8535,parallel,O
PMC45065960_96,8535,-,O
PMC45065960_96,8535,arm,O
PMC45065960_96,8535,",",O
PMC45065960_96,8535,placebo,O
PMC45065960_96,8535,controlled,O
PMC45065960_96,8535,randomized,O
PMC45065960_96,8535,trial,O
PMC45065960_96,8535,of,O
PMC45065960_96,8535,usual,O
PMC45065960_96,8535,care,O
PMC45065960_96,8535,plus,O
PMC45065960_96,8535,either,O
PMC45065960_96,8535,lamotrigine,B-Drug
PMC45065960_96,8535,or,O
PMC45065960_96,8535,an,O
PMC45065960_96,8535,inert,O
PMC45065960_96,8535,placebo,O
PMC45065960_96,8535,for,O
PMC45065960_96,8535,people,O
PMC45065960_96,8535,aged,O
PMC45065960_96,8535,over,O
PMC45065960_96,8535,_,O
PMC45065960_96,8535,_,O
PMC45065960_96,8535,number,O
PMC45065960_96,8535,_,O
PMC45065960_96,8535,_,O
PMC45065960_96,8535,who,O
PMC45065960_96,8535,are,O
PMC45065960_96,8535,using,O
PMC45065960_96,8535,mental,O
PMC45065960_96,8535,health,O
PMC45065960_96,8535,services,O
PMC45065960_96,8535,and,O
PMC45065960_96,8535,meet,O
PMC45065960_96,8535,diagnostic,O
PMC45065960_96,8535,criteria,O
PMC45065960_96,8535,for,O
PMC45065960_96,8535,BPD,B-Disease
PMC45065960_96,8535,0,O
PMC45096560_824,8536,To,O
PMC45096560_824,8536,compare,O
PMC45096560_824,8536,the,O
PMC45096560_824,8536,efficacy,O
PMC45096560_824,8536,of,O
PMC45096560_824,8536,the,O
PMC45096560_824,8536,addition,O
PMC45096560_824,8536,of,O
PMC45096560_824,8536,montelukast,B-Drug
PMC45096560_824,8536,to,O
PMC45096560_824,8536,low,O
PMC45096560_824,8536,-,O
PMC45096560_824,8536,dose,O
PMC45096560_824,8536,inhaled,O
PMC45096560_824,8536,budesonide,O
PMC45096560_824,8536,(,O
PMC45096560_824,8536,MON,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,number,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,BUD,O
PMC45096560_824,8536,),O
PMC45096560_824,8536,versus,O
PMC45096560_824,8536,increasing,O
PMC45096560_824,8536,the,O
PMC45096560_824,8536,dose,O
PMC45096560_824,8536,of,O
PMC45096560_824,8536,inhaled,O
PMC45096560_824,8536,steroid,O
PMC45096560_824,8536,(,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,number,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,_,O
PMC45096560_824,8536,BUD,O
PMC45096560_824,8536,),O
PMC45096560_824,8536,on,O
PMC45096560_824,8536,asthma,B-Disease
PMC45096560_824,8536,control,O
PMC45096560_824,8536,in,O
PMC45096560_824,8536,older,O
PMC45096560_824,8536,asthmatics,O
PMC45096560_824,8536,0,O
PMC45154850_473,8537,Tamoxifen,B-Drug
PMC45154850_473,8537,-,O
PMC45154850_473,8537,associated,O
PMC45154850_473,8537,polypoid,O
PMC45154850_473,8537,endometriosis,O
PMC45154850_473,8537,mimicking,O
PMC45154850_473,8537,an,O
PMC45154850_473,8537,ovarian,O
PMC45154850_473,8537,neoplasm,O
PMC45154850_473,8537,0,O
PMC45181120_971,8538,This,O
PMC45181120_971,8538,study,O
PMC45181120_971,8538,was,O
PMC45181120_971,8538,designed,O
PMC45181120_971,8538,to,O
PMC45181120_971,8538,determine,O
PMC45181120_971,8538,the,O
PMC45181120_971,8538,efficacy,O
PMC45181120_971,8538,of,O
PMC45181120_971,8538,acute,O
PMC45181120_971,8538,venlafaxine,B-Drug
PMC45181120_971,8538,administration,O
PMC45181120_971,8538,in,O
PMC45181120_971,8538,alleviating,O
PMC45181120_971,8538,symptoms,O
PMC45181120_971,8538,of,O
PMC45181120_971,8538,neuropathic,O
PMC45181120_971,8538,pain,O
PMC45181120_971,8538,and,O
PMC45181120_971,8538,the,O
PMC45181120_971,8538,role,O
PMC45181120_971,8538,of,O
PMC45181120_971,8538,endogenous,O
PMC45181120_971,8538,adenosine,O
PMC45181120_971,8538,and,O
PMC45181120_971,8538,opioid,O
PMC45181120_971,8538,systems,O
PMC45181120_971,8538,in,O
PMC45181120_971,8538,this,O
PMC45181120_971,8538,effect,O
PMC45181120_971,8538,of,O
PMC45181120_971,8538,venlafaxine,B-Drug
PMC45181120_971,8538,0,O
PMC45181180_500,8539,The,O
PMC45181180_500,8539,results,O
PMC45181180_500,8539,suggested,O
PMC45181180_500,8539,that,O
PMC45181180_500,8539,celecoxib,O
PMC45181180_500,8539,may,O
PMC45181180_500,8539,hasten,O
PMC45181180_500,8539,the,O
PMC45181180_500,8539,onset,O
PMC45181180_500,8539,of,O
PMC45181180_500,8539,therapeutic,O
PMC45181180_500,8539,action,O
PMC45181180_500,8539,of,O
PMC45181180_500,8539,sertraline,B-Drug
PMC45181180_500,8539,and,O
PMC45181180_500,8539,increase,O
PMC45181180_500,8539,response,O
PMC45181180_500,8539,and,O
PMC45181180_500,8539,remission,O
PMC45181180_500,8539,rate,O
PMC45181180_500,8539,in,O
PMC45181180_500,8539,depressive,B-Disease
PMC45181180_500,8539,disorders,I-Disease
PMC45181180_500,8539,0,O
PMC45254280_245,8540,Co,O
PMC45254280_245,8540,-,O
PMC45254280_245,8540,relationship,O
PMC45254280_245,8540,between,O
PMC45254280_245,8540,sexual,B-Symptom
PMC45254280_245,8540,dysfunction,I-Symptom
PMC45254280_245,8540,and,O
PMC45254280_245,8540,high,O
PMC45254280_245,8540,-,O
PMC45254280_245,8540,risk,O
PMC45254280_245,8540,sexual,B-Symptom
PMC45254280_245,8540,behavior,I-Symptom
PMC45254280_245,8540,in,O
PMC45254280_245,8540,patients,O
PMC45254280_245,8540,receiving,O
PMC45254280_245,8540,buprenorphine,B-Drug
PMC45254280_245,8540,and,O
PMC45254280_245,8540,naltrexone,O
PMC45254280_245,8540,maintenance,O
PMC45254280_245,8540,therapy,O
PMC45254280_245,8540,for,O
PMC45254280_245,8540,opioid,O
PMC45254280_245,8540,dependence,O
PMC45254280_245,8540,0,O
PMC45268340_875,8541,It,O
PMC45268340_875,8541,illustrates,O
PMC45268340_875,8541,the,O
PMC45268340_875,8541,application,O
PMC45268340_875,8541,of,O
PMC45268340_875,8541,MA,O
PMC45268340_875,8541,models,O
PMC45268340_875,8541,with,O
PMC45268340_875,8541,the,O
PMC45268340_875,8541,open,O
PMC45268340_875,8541,-,O
PMC45268340_875,8541,source,O
PMC45268340_875,8541,software,O
PMC45268340_875,8541,R,O
PMC45268340_875,8541,using,O
PMC45268340_875,8541,publicly,O
PMC45268340_875,8541,available,O
PMC45268340_875,8541,data,O
PMC45268340_875,8541,from,O
PMC45268340_875,8541,five,O
PMC45268340_875,8541,studies,O
PMC45268340_875,8541,on,O
PMC45268340_875,8541,lamotrigine,B-Drug
PMC45268340_875,8541,to,O
PMC45268340_875,8541,treat,O
PMC45268340_875,8541,bipolar,B-Disease
PMC45268340_875,8541,depression,I-Disease
PMC45268340_875,8541,and,O
PMC45268340_875,8541,finds,O
PMC45268340_875,8541,that,O
PMC45268340_875,8541,meta,O
PMC45268340_875,8541,-,O
PMC45268340_875,8541,analysis,O
PMC45268340_875,8541,identifies,O
PMC45268340_875,8541,a,O
PMC45268340_875,8541,statistically,O
PMC45268340_875,8541,significant,O
PMC45268340_875,8541,advantage,O
PMC45268340_875,8541,of,O
PMC45268340_875,8541,lamotrigine,B-Drug
PMC45268340_875,8541,over,O
PMC45268340_875,8541,placebo,O
PMC45268340_875,8541,that,O
PMC45268340_875,8541,was,O
PMC45268340_875,8541,not,O
PMC45268340_875,8541,evident,O
PMC45268340_875,8541,in,O
PMC45268340_875,8541,the,O
PMC45268340_875,8541,individual,O
PMC45268340_875,8541,studies,O
PMC45268340_875,8541,0,O
PMC45301890_86,8542,This,O
PMC45301890_86,8542,study,O
PMC45301890_86,8542,aimed,O
PMC45301890_86,8542,to,O
PMC45301890_86,8542,evaluate,O
PMC45301890_86,8542,the,O
PMC45301890_86,8542,effectiveness,O
PMC45301890_86,8542,of,O
PMC45301890_86,8542,electroconvulsive,O
PMC45301890_86,8542,therapy,O
PMC45301890_86,8542,(,O
PMC45301890_86,8542,ECT,O
PMC45301890_86,8542,),O
PMC45301890_86,8542,in,O
PMC45301890_86,8542,persistent,O
PMC45301890_86,8542,METH,O
PMC45301890_86,8542,psychosis,B-Disease
PMC45301890_86,8542,patients,O
PMC45301890_86,8542,hospitalized,O
PMC45301890_86,8542,at,O
PMC45301890_86,8542,Shahid,O
PMC45301890_86,8542,Beheshti,O
PMC45301890_86,8542,Hospital,O
PMC45301890_86,8542,",",O
PMC45301890_86,8542,Kerman,O
PMC45301890_86,8542,",",O
PMC45301890_86,8542,Iran,O
PMC45301890_86,8542,",",O
PMC45301890_86,8542,from,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,number,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,September,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,number,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,until,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,number,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,September,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,number,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,_,O
PMC45301890_86,8542,",",O
PMC45301890_86,8542,who,O
PMC45301890_86,8542,were,O
PMC45301890_86,8542,not,O
PMC45301890_86,8542,remitted,O
PMC45301890_86,8542,after,O
PMC45301890_86,8542,treatment,O
PMC45301890_86,8542,with,O
PMC45301890_86,8542,olanzapine,B-Drug
PMC45301890_86,8542,0,O
PMC45301950_350,8543,Result,O
PMC45301950_350,8543,of,O
PMC45301950_350,8543,this,O
PMC45301950_350,8543,study,O
PMC45301950_350,8543,showed,O
PMC45301950_350,8543,that,O
PMC45301950_350,8543,physicians,O
PMC45301950_350,8543,can,O
PMC45301950_350,8543,rely,O
PMC45301950_350,8543,on,O
PMC45301950_350,8543,SL,O
PMC45301950_350,8543,buprenorphine,B-Drug
PMC45301950_350,8543,for,O
PMC45301950_350,8543,post,B-Symptom
PMC45301950_350,8543,-,I-Symptom
PMC45301950_350,8543,operative,I-Symptom
PMC45301950_350,8543,analgesia,I-Symptom
PMC45301950_350,8543,0,O
PMC45301950_397,8544,At,O
PMC45301950_397,8544,the,O
PMC45301950_397,8544,same,O
PMC45301950_397,8544,time,O
PMC45301950_397,8544,",",O
PMC45301950_397,8544,patients,O
PMC45301950_397,8544,in,O
PMC45301950_397,8544,buprenorphine,B-Drug
PMC45301950_397,8544,experienced,O
PMC45301950_397,8544,less,O
PMC45301950_397,8544,severe,O
PMC45301950_397,8544,withdrawal,O
PMC45301950_397,8544,syndrome,O
PMC45301950_397,8544,0,O
PMC45303470_329,8545,Additionally,O
PMC45303470_329,8545,",",O
PMC45303470_329,8545,lower,O
PMC45303470_329,8545,expression,O
PMC45303470_329,8545,levels,O
PMC45303470_329,8545,of,O
PMC45303470_329,8545,miR,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,number,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,a,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,number,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,_,O
PMC45303470_329,8545,p,O
PMC45303470_329,8545,were,O
PMC45303470_329,8545,associated,O
PMC45303470_329,8545,with,O
PMC45303470_329,8545,poor,O
PMC45303470_329,8545,prognosis,O
PMC45303470_329,8545,for,O
PMC45303470_329,8545,tamoxifen,B-Drug
PMC45303470_329,8545,-,O
PMC45303470_329,8545,treated,O
PMC45303470_329,8545,patients,O
PMC45303470_329,8545,with,O
PMC45303470_329,8545,breast,B-Disease
PMC45303470_329,8545,cancer,I-Disease
PMC45303470_329,8545,0,O
PMC45310080_791,8546,CONCLUSION,O
PMC45310080_791,8546,:,O
PMC45310080_791,8546,Docetaxel,B-Drug
PMC45310080_791,8546,leads,O
PMC45310080_791,8546,to,O
PMC45310080_791,8546,a,O
PMC45310080_791,8546,better,O
PMC45310080_791,8546,result,O
PMC45310080_791,8546,than,O
PMC45310080_791,8546,vinca,O
PMC45310080_791,8546,alkaloid,O
PMC45310080_791,8546,in,O
PMC45310080_791,8546,effectiveness,O
PMC45310080_791,8546,and,O
PMC45310080_791,8546,safety,O
PMC45310080_791,8546,on,O
PMC45310080_791,8546,patients,O
PMC45310080_791,8546,with,O
PMC45310080_791,8546,advanced,O
PMC45310080_791,8546,non,B-Disease
PMC45310080_791,8546,-,I-Disease
PMC45310080_791,8546,small,I-Disease
PMC45310080_791,8546,-,I-Disease
PMC45310080_791,8546,cell,I-Disease
PMC45310080_791,8546,lung,I-Disease
PMC45310080_791,8546,cancer,I-Disease
PMC45310080_791,8546,as,O
PMC45310080_791,8546,first,O
PMC45310080_791,8546,-,O
PMC45310080_791,8546,line,O
PMC45310080_791,8546,therapy,O
PMC45310080_791,8546,0,O
PMC45354090_298,8547,Recently,O
PMC45354090_298,8547,",",O
PMC45354090_298,8547,two,O
PMC45354090_298,8547,phase,O
PMC45354090_298,8547,II,O
PMC45354090_298,8547,studies,O
PMC45354090_298,8547,of,O
PMC45354090_298,8547,bevacizumab,B-Drug
PMC45354090_298,8547,",",O
PMC45354090_298,8547,an,O
PMC45354090_298,8547,anti,O
PMC45354090_298,8547,-,O
PMC45354090_298,8547,angiogenic,O
PMC45354090_298,8547,",",O
PMC45354090_298,8547,for,O
PMC45354090_298,8547,newly,O
PMC45354090_298,8547,diagnosed,O
PMC45354090_298,8547,glioblastoma,B-Disease
PMC45354090_298,8547,(,O
PMC45354090_298,8547,GBM,O
PMC45354090_298,8547,),O
PMC45354090_298,8547,patients,O
PMC45354090_298,8547,were,O
PMC45354090_298,8547,released,O
PMC45354090_298,8547,0,O
PMC45393960_451,8548,OBJECTIVES,O
PMC45393960_451,8548,:,O
PMC45393960_451,8548,In,O
PMC45393960_451,8548,this,O
PMC45393960_451,8548,study,O
PMC45393960_451,8548,",",O
PMC45393960_451,8548,the,O
PMC45393960_451,8548,effectiveness,O
PMC45393960_451,8548,of,O
PMC45393960_451,8548,short,O
PMC45393960_451,8548,-,O
PMC45393960_451,8548,term,O
PMC45393960_451,8548,psychodynamic,O
PMC45393960_451,8548,psychotherapy,O
PMC45393960_451,8548,on,O
PMC45393960_451,8548,the,O
PMC45393960_451,8548,treatment,O
PMC45393960_451,8548,of,O
PMC45393960_451,8548,social,O
PMC45393960_451,8548,phobia,O
PMC45393960_451,8548,has,O
PMC45393960_451,8548,been,O
PMC45393960_451,8548,compared,O
PMC45393960_451,8548,to,O
PMC45393960_451,8548,the,O
PMC45393960_451,8548,effectiveness,O
PMC45393960_451,8548,of,O
PMC45393960_451,8548,sertraline,B-Drug
PMC45393960_451,8548,and,O
PMC45393960_451,8548,waiting,O
PMC45393960_451,8548,list,O
PMC45393960_451,8548,0,O
PMC45393970_599,8549,CONCLUSIONS,O
PMC45393970_599,8549,:,O
PMC45393970_599,8549,This,O
PMC45393970_599,8549,study,O
PMC45393970_599,8549,suggests,O
PMC45393970_599,8549,that,O
PMC45393970_599,8549,the,O
PMC45393970_599,8549,efficacy,O
PMC45393970_599,8549,of,O
PMC45393970_599,8549,citalopram,B-Drug
PMC45393970_599,8549,is,O
PMC45393970_599,8549,similar,O
PMC45393970_599,8549,to,O
PMC45393970_599,8549,that,O
PMC45393970_599,8549,of,O
PMC45393970_599,8549,Cipram,O
PMC45393970_599,8549,in,O
PMC45393970_599,8549,the,O
PMC45393970_599,8549,treatment,O
PMC45393970_599,8549,of,O
PMC45393970_599,8549,MADD,O
PMC45393970_599,8549,after,O
PMC45393970_599,8549,_,O
PMC45393970_599,8549,_,O
PMC45393970_599,8549,number,O
PMC45393970_599,8549,_,O
PMC45393970_599,8549,_,O
PMC45393970_599,8549,weeks,O
PMC45393970_599,8549,0,O
PMC45395820_948,8550,OBJECTIVES,O
PMC45395820_948,8550,:,O
PMC45395820_948,8550,In,O
PMC45395820_948,8550,this,O
PMC45395820_948,8550,study,O
PMC45395820_948,8550,",",O
PMC45395820_948,8550,we,O
PMC45395820_948,8550,compared,O
PMC45395820_948,8550,the,O
PMC45395820_948,8550,efficacy,O
PMC45395820_948,8550,of,O
PMC45395820_948,8550,citalopram,B-Drug
PMC45395820_948,8550,and,O
PMC45395820_948,8550,venlafaxine,B-Drug
PMC45395820_948,8550,in,O
PMC45395820_948,8550,major,B-Disease
PMC45395820_948,8550,depression,I-Disease
PMC45395820_948,8550,",",O
PMC45395820_948,8550,which,O
PMC45395820_948,8550,has,O
PMC45395820_948,8550,not,O
PMC45395820_948,8550,yet,O
PMC45395820_948,8550,been,O
PMC45395820_948,8550,studied,O
PMC45395820_948,8550,in,O
PMC45395820_948,8550,Iran,O
PMC45395820_948,8550,0,O
PMC45411680_178,8551,CONCLUSION,O
PMC45411680_178,8551,:,O
PMC45411680_178,8551,Comparison,O
PMC45411680_178,8551,of,O
PMC45411680_178,8551,different,O
PMC45411680_178,8551,eradication,O
PMC45411680_178,8551,treatments,O
PMC45411680_178,8551,for,O
PMC45411680_178,8551,H,O
PMC45411680_178,8551,pylori,O
PMC45411680_178,8551,showed,O
PMC45411680_178,8551,that,O
PMC45411680_178,8551,concomitant,O
PMC45411680_178,8551,treatments,O
PMC45411680_178,8551,",",O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,or,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,days,O
PMC45411680_178,8551,of,O
PMC45411680_178,8551,probiotic,O
PMC45411680_178,8551,supplemented,O
PMC45411680_178,8551,triple,O
PMC45411680_178,8551,treatment,O
PMC45411680_178,8551,",",O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,or,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,days,O
PMC45411680_178,8551,of,O
PMC45411680_178,8551,levofloxacin,B-Drug
PMC45411680_178,8551,based,O
PMC45411680_178,8551,triple,O
PMC45411680_178,8551,treatment,O
PMC45411680_178,8551,",",O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,days,O
PMC45411680_178,8551,of,O
PMC45411680_178,8551,hybrid,O
PMC45411680_178,8551,treatment,O
PMC45411680_178,8551,",",O
PMC45411680_178,8551,and,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,or,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,number,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,_,O
PMC45411680_178,8551,days,O
PMC45411680_178,8551,of,O
PMC45411680_178,8551,sequential,O
PMC45411680_178,8551,treatment,O
PMC45411680_178,8551,might,O
PMC45411680_178,8551,be,O
PMC45411680_178,8551,better,O
PMC45411680_178,8551,alternatives,O
PMC45411680_178,8551,for,O
PMC45411680_178,8551,the,O
PMC45411680_178,8551,eradication,O
PMC45411680_178,8551,of,O
PMC45411680_178,8551,H,O
PMC45411680_178,8551,pylori,O
PMC45411680_178,8551,0,O
PMC45411840_598,8552,CONCLUSION,O
PMC45411840_598,8552,:,O
PMC45411840_598,8552,Buprenorphine,B-Drug
PMC45411840_598,8552,_,O
PMC45411840_598,8552,_,O
PMC45411840_598,8552,number,O
PMC45411840_598,8552,_,O
PMC45411840_598,8552,_,O
PMC45411840_598,8552,g,O
PMC45411840_598,8552,/,O
PMC45411840_598,8552,kg,O
PMC45411840_598,8552,in,O
PMC45411840_598,8552,axillary,O
PMC45411840_598,8552,plexus,O
PMC45411840_598,8552,block,O
PMC45411840_598,8552,provides,O
PMC45411840_598,8552,significantly,O
PMC45411840_598,8552,prolonged,B-Symptom
PMC45411840_598,8552,analgesia,I-Symptom
PMC45411840_598,8552,with,O
PMC45411840_598,8552,less,O
PMC45411840_598,8552,RA,O
PMC45411840_598,8552,requirement,O
PMC45411840_598,8552,and,O
PMC45411840_598,8552,greater,O
PMC45411840_598,8552,patient,O
PMC45411840_598,8552,satisfaction,O
PMC45411840_598,8552,compared,O
PMC45411840_598,8552,to,O
PMC45411840_598,8552,IM,O
PMC45411840_598,8552,administration,O
PMC45411840_598,8552,0,O
PMC45467950_78,8553,Prednisone,B-Drug
PMC45467950_78,8553,was,O
PMC45467950_78,8553,started,O
PMC45467950_78,8553,with,O
PMC45467950_78,8553,improvement,O
PMC45467950_78,8553,of,O
PMC45467950_78,8553,the,O
PMC45467950_78,8553,skin,B-Symptom
PMC45467950_78,8553,lesions,I-Symptom
PMC45467950_78,8553,and,O
PMC45467950_78,8553,a,O
PMC45467950_78,8553,recovery,O
PMC45467950_78,8553,condition,O
PMC45467950_78,8553,0,O
PMC45513300_213,8554,A,O
PMC45513300_213,8554,_,O
PMC45513300_213,8554,_,O
PMC45513300_213,8554,number,O
PMC45513300_213,8554,_,O
PMC45513300_213,8554,_,O
PMC45513300_213,8554,-,O
PMC45513300_213,8554,year,O
PMC45513300_213,8554,-,O
PMC45513300_213,8554,old,O
PMC45513300_213,8554,indigenous,O
PMC45513300_213,8554,Australian,O
PMC45513300_213,8554,male,O
PMC45513300_213,8554,was,O
PMC45513300_213,8554,admitted,O
PMC45513300_213,8554,to,O
PMC45513300_213,8554,the,O
PMC45513300_213,8554,intensive,O
PMC45513300_213,8554,care,O
PMC45513300_213,8554,unit,O
PMC45513300_213,8554,with,O
PMC45513300_213,8554,fulminant,O
PMC45513300_213,8554,hepatic,B-Symptom
PMC45513300_213,8554,failure,I-Symptom
PMC45513300_213,8554,secondary,O
PMC45513300_213,8554,to,O
PMC45513300_213,8554,intravenous,O
PMC45513300_213,8554,use,O
PMC45513300_213,8554,of,O
PMC45513300_213,8554,buprenorphine,B-Drug
PMC45513300_213,8554,",",O
PMC45513300_213,8554,which,O
PMC45513300_213,8554,had,O
PMC45513300_213,8554,been,O
PMC45513300_213,8554,prescribed,O
PMC45513300_213,8554,sublingually,O
PMC45513300_213,8554,for,O
PMC45513300_213,8554,opioid,O
PMC45513300_213,8554,dependence,O
PMC45513300_213,8554,0,O
PMC45610480_360,8555,Melphalan,B-Drug
PMC45610480_360,8555,is,O
PMC45610480_360,8555,an,O
PMC45610480_360,8555,alkylating,O
PMC45610480_360,8555,agent,O
PMC45610480_360,8555,frequently,O
PMC45610480_360,8555,used,O
PMC45610480_360,8555,in,O
PMC45610480_360,8555,an,O
PMC45610480_360,8555,intravenous,O
PMC45610480_360,8555,formulation,O
PMC45610480_360,8555,to,O
PMC45610480_360,8555,treat,O
PMC45610480_360,8555,hematologic,B-Disease
PMC45610480_360,8555,malignancies,I-Disease
PMC45610480_360,8555,and,O
PMC45610480_360,8555,solid,O
PMC45610480_360,8555,tumors,O
PMC45610480_360,8555,in,O
PMC45610480_360,8555,both,O
PMC45610480_360,8555,adults,O
PMC45610480_360,8555,and,O
PMC45610480_360,8555,children,O
PMC45610480_360,8555,0,O
